Clustering O 0 5.884530764888041e-05
of O 0 1.0522990123718046e-06
missense O 0 0.0002979053242597729
mutations O 0 0.0002664898056536913
in O 0 9.937840559359756e-07
the O 0 3.001823824888561e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999865293502808
telangiectasia I-Disease 1 1.0
gene O 0 0.00015876165707595646
in O 0 6.922598316805306e-08
a O 0 2.638938951804448e-07
sporadic B-Disease 0 2.2148384232423268e-05
T I-Disease 0 0.4967480003833771
- I-Disease 0 0.03749668225646019
cell I-Disease 1 0.6532473564147949
leukaemia I-Disease 1 0.8805923461914062
. O 0 3.562899109965656e-06

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999994039535522
telangiectasia I-Disease 1 1.0
( O 0 0.015797870233654976
A B-Disease 1 0.9999973773956299
- I-Disease 1 0.9999947547912598
T I-Disease 1 1.0
) O 0 3.355330306931137e-07
is O 0 9.397282063616785e-09
a O 0 3.612667498487099e-08
recessive B-Disease 0 7.407130033243448e-05
multi I-Disease 0 0.00046625302638858557
- I-Disease 1 0.6856420040130615
system I-Disease 0 0.0065634651109576225
disorder I-Disease 0 0.4240478277206421
caused O 0 7.703252435931063e-07
by O 0 1.569506835608081e-08
mutations O 0 4.3994955944981484e-07
in O 0 4.6483554783094405e-09
the O 0 5.643896905382917e-09
ATM O 0 2.93559623969486e-05
gene O 0 8.531260959898646e-07
at O 0 1.3016192212944588e-07
11q22 O 0 1.8111493318428984e-06
- O 0 4.555312261800282e-05
q23 O 0 1.2710596820397768e-05
( O 0 9.091499464375374e-08
ref O 0 8.229971172113437e-06
. O 0 3.48821878048966e-08
3 O 0 1.0018060692118524e-07
) O 0 7.33885485715291e-08
. O 0 2.94188367888637e-07

The O 0 3.6061696846445557e-06
risk O 0 1.630806946195662e-05
of O 0 2.0740864670187875e-07
cancer B-Disease 0 0.00010200079850619659
, O 0 7.479975749902223e-08
especially O 0 7.708486293722672e-08
lymphoid B-Disease 0 2.556251456553582e-05
neoplasias I-Disease 0 0.00014622253365814686
, O 0 1.4964210492962593e-07
is O 0 3.060323194858938e-08
substantially O 0 4.73070855377955e-07
elevated O 0 3.627555315688369e-06
in O 0 7.599107902933611e-07
A B-Disease 1 0.9999992847442627
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
patients O 0 0.0005475525977090001
and O 0 1.3368291718052205e-07
has O 0 3.3151738421111077e-07
long O 0 3.1303343916988524e-07
been O 0 7.21568312656018e-07
associated O 0 5.650086905006901e-07
with O 0 2.7123103336634813e-06
chromosomal O 1 1.0
instability O 1 0.999984860420227
. O 0 1.0409352398710325e-05

By O 0 4.891324351774529e-06
analysing O 0 0.00036039482802152634
tumour B-Disease 1 0.999998927116394
DNA O 0 0.000584921333938837
from O 0 6.089766770855931e-07
patients O 0 4.5130832404538523e-07
with O 0 2.2020197221195303e-08
sporadic B-Disease 0 1.270204120373819e-05
T I-Disease 0 0.2609613835811615
- I-Disease 0 0.02248021960258484
cell I-Disease 0 0.27307766675949097
prolymphocytic I-Disease 0 0.20887568593025208
leukaemia I-Disease 1 0.9914051294326782
( O 0 2.8557358291436685e-06
T B-Disease 0 0.02651008777320385
- I-Disease 0 0.0002626401837915182
PLL I-Disease 0 8.641374006401747e-05
) O 0 3.3901255136470354e-08
, O 0 3.2573037600514e-09
a O 0 1.1235302466161556e-08
rare O 0 5.4366999791000126e-08
clonal B-Disease 0 1.4756483324163128e-06
malignancy I-Disease 0 2.0879757357761264e-05
with O 0 1.0684321871679003e-08
similarities O 0 1.1870969984784097e-07
to O 0 2.3418392558482992e-08
a O 0 1.3537201937197096e-07
mature B-Disease 0 2.9337468276935397e-06
T I-Disease 0 0.0004942099330946803
- I-Disease 0 6.006459807395004e-05
cell I-Disease 0 0.000853208708576858
leukaemia I-Disease 0 0.0042454940266907215
seen O 0 4.123119651922025e-06
in O 0 3.652479279026011e-07
A B-Disease 1 0.9999463558197021
- I-Disease 1 0.9998483657836914
T I-Disease 1 1.0
, O 0 3.4122996339647216e-07
we O 0 1.2164187879193378e-08
demonstrate O 0 5.067316788398557e-09
a O 0 5.048033102639238e-09
high O 0 1.3269871423915447e-08
frequency O 0 7.095581366911574e-08
of O 0 7.517646949395385e-09
ATM O 0 0.0001272265799343586
mutations O 0 7.773383913445286e-06
in O 0 1.3596304881957622e-07
T B-Disease 0 0.005863826721906662
- I-Disease 0 0.0002826588461175561
PLL I-Disease 0 0.000658260250929743
. O 0 3.6586188798537478e-06

In O 0 2.4163330181181664e-06
marked O 0 8.021902431210037e-07
contrast O 0 1.778184923750814e-07
to O 0 1.9265502970711168e-08
the O 0 8.281880958804777e-09
ATM O 0 4.079750942764804e-05
mutation O 0 1.5019901411505998e-06
pattern O 0 1.9535830233508023e-06
in O 0 9.698570693217334e-07
A B-Disease 1 0.999995231628418
- I-Disease 1 0.9999933242797852
T I-Disease 1 1.0
, O 0 8.216634483915186e-08
the O 0 2.3323967202060203e-09
most O 0 1.6710333117231357e-09
frequent O 0 3.1437068059858575e-08
nucleotide O 0 2.8079253411306127e-07
changes O 0 4.17676275787926e-08
in O 0 2.2603787286357147e-08
this O 0 5.664984215059121e-08
leukaemia B-Disease 0 0.0006574512226507068
were O 0 5.56323300315853e-07
missense O 0 0.00010032674617832527
mutations O 0 5.871548637514934e-05
. O 0 1.4266115613281727e-06

These O 0 4.116427021472191e-07
clustered O 0 1.787819087439857e-06
in O 0 1.1564019075649412e-07
the O 0 2.35390356095877e-08
region O 0 2.8643637506320374e-07
corresponding O 0 7.161975190683734e-08
to O 0 2.181294256331512e-08
the O 0 6.422975928899177e-09
kinase O 0 9.368165478917945e-07
domain O 0 9.008144985500621e-08
, O 0 1.0600206046262883e-08
which O 0 5.268301794814079e-09
is O 0 1.8678738555877317e-09
highly O 0 2.9340920804088455e-09
conserved O 0 1.4695161532074508e-08
in O 0 1.1154951629066545e-08
ATM O 0 2.2549273126060143e-05
- O 0 3.6052722407475812e-06
related O 0 6.97105306812773e-08
proteins O 0 1.3537868603918923e-08
in O 0 1.0533211636243323e-08
mouse O 0 1.7380219787810347e-06
, O 0 9.608839235397681e-08
yeast O 0 1.888817109829688e-06
and O 0 1.5719822954451956e-07
Drosophila O 0 1.262644218513742e-06
. O 0 5.500092470356321e-07

The O 0 1.0114343922396074e-06
resulting O 0 5.544160899262351e-07
amino O 0 5.822761863782944e-07
- O 0 5.301647433952894e-06
acid O 0 9.275833008359768e-07
substitutions O 0 1.5554145704754774e-07
are O 0 6.878385416797528e-09
predicted O 0 3.141867352951522e-07
to O 0 2.048870406667902e-08
interfere O 0 2.0844058212787786e-07
with O 0 2.6257687579800404e-08
ATP O 0 0.00010350866796215996
binding O 0 1.4143195130600361e-06
or O 0 1.691974631512494e-07
substrate O 0 5.240221526037203e-06
recognition O 0 6.769629976588476e-07
. O 0 1.0113399184774607e-06

Two O 0 8.519147058905219e-07
of O 0 1.6277334680125932e-07
seventeen O 0 2.1544506125792395e-06
mutated O 0 2.6377356334705837e-05
T B-Disease 0 0.0005454499623738229
- I-Disease 0 2.7682874133461155e-05
PLL I-Disease 0 4.5200107706477866e-05
samples O 0 1.9160311239829753e-06
had O 0 1.3975379431485635e-07
a O 0 5.8935178515184816e-08
previously O 0 1.8612903431858285e-06
reported O 0 3.4471446269890293e-05
A B-Disease 1 0.9968677163124084
- I-Disease 1 0.997878909111023
T I-Disease 1 0.9999996423721313
allele O 0 0.00015430273197125643
. O 0 1.50805124121689e-06

In O 0 4.02164778279257e-06
contrast O 0 1.8185274939241935e-06
, O 0 8.608283508237946e-08
no O 0 3.6607922027087625e-08
mutations O 0 5.945623229308694e-07
were O 0 3.986293251045936e-08
detected O 0 1.6713806871848647e-07
in O 0 1.4261843928053963e-09
the O 0 3.542344417795107e-09
p53 O 0 5.144291392866762e-08
gene O 0 3.19005096116598e-07
, O 0 1.6388604251460492e-08
suggesting O 0 1.0983334419734092e-07
that O 0 1.332015564514677e-08
this O 0 2.5085009269787406e-07
tumour B-Disease 1 0.9999997615814209
suppressor O 0 0.00013145692355465144
is O 0 2.508912473331293e-07
not O 0 1.964075835303447e-08
frequently O 0 1.2179167185877304e-07
altered O 0 2.809724946928327e-06
in O 0 6.893387904938209e-08
this O 0 2.779134717911802e-07
leukaemia B-Disease 0 0.010314632207155228
. O 0 1.4553040728060296e-06

Occasional O 0 8.690932736499235e-05
missense O 0 0.0006208259728737175
mutations O 0 0.00014941522385925055
in O 0 2.5005996917570883e-07
ATM O 0 0.00014077191008254886
were O 0 1.2410184808686608e-06
also O 0 2.146252597867715e-07
found O 0 1.7314876288310188e-07
in O 0 6.403620886885619e-07
tumour B-Disease 1 0.9999991655349731
DNA O 0 3.8148591556819156e-05
from O 0 9.532353573149521e-08
patients O 0 3.998957609496756e-08
with O 0 3.477243382121742e-09
B B-Disease 0 1.988509211514611e-06
- I-Disease 0 1.39065987241338e-05
cell I-Disease 0 0.004525294993072748
non I-Disease 0 8.736825839150697e-05
- I-Disease 1 0.950846254825592
Hodgkins I-Disease 1 0.9999984502792358
lymphomas I-Disease 1 0.9398931860923767
( O 0 3.1844007253312157e-07
B B-Disease 0 1.87829800779582e-06
- I-Disease 0 8.495898327964824e-06
NHL I-Disease 0 1.9873318706231657e-06
) O 0 1.2443535979400622e-08
and O 0 5.4903535051664676e-09
a O 0 5.0731799206005235e-08
B B-Disease 0 1.689827968220925e-06
- I-Disease 0 3.184098432029714e-06
NHL I-Disease 0 1.1354618436598685e-06
cell O 0 2.5410388843738474e-05
line O 0 1.4496314179268666e-05
. O 0 9.641330507292878e-07

The O 0 8.691663424542639e-07
evidence O 0 1.0147853402031615e-07
of O 0 3.3376155172959443e-09
a O 0 3.3694515622073595e-08
significant O 0 3.501784462400792e-08
proportion O 0 1.0366927938321169e-07
of O 0 2.3102732171764728e-08
loss O 0 3.911208295903634e-06
- O 0 2.158034703825251e-06
of O 0 3.1635988051448294e-08
- O 0 6.481659966084408e-06
function O 0 6.521687510030461e-07
mutations O 0 2.2586177692573983e-06
and O 0 1.3416896926798927e-08
a O 0 5.080849518890318e-08
complete O 0 1.7044938260823983e-07
absence O 0 2.133806731308141e-08
of O 0 9.26838272796715e-10
the O 0 4.580795742725741e-09
normal O 0 5.7653124940770795e-08
copy O 0 3.262205439114041e-07
of O 0 3.3038061175716393e-09
ATM O 0 9.335309187008534e-06
in O 0 1.5341058201556734e-08
the O 0 7.2004202600339795e-09
majority O 0 3.049781938102569e-08
of O 0 2.7571671168402645e-08
mutated O 0 0.0002898263046517968
tumours B-Disease 1 0.9999990463256836
establishes O 0 4.188229468127247e-06
somatic O 0 6.9163816078798845e-06
inactivation O 0 1.4146717148832977e-05
of O 0 2.8277176156166206e-09
this O 0 7.572619864504304e-09
gene O 0 1.2041684271935083e-07
in O 0 9.38112787451928e-09
the O 0 2.9377615007319946e-08
pathogenesis O 0 8.668760528962594e-06
of O 0 2.2380792330523036e-08
sporadic B-Disease 0 1.2302420145715587e-05
T I-Disease 0 0.05174798518419266
- I-Disease 0 6.308506999630481e-05
PLL I-Disease 0 3.325742727611214e-05
and O 0 1.4381048174527677e-07
suggests O 0 5.08386399644678e-08
that O 0 3.5402507592152688e-09
ATM O 0 5.482096639752854e-06
acts O 0 1.451739990443457e-07
as O 0 3.154993777343407e-08
a O 0 1.9427329789323267e-06
tumour B-Disease 1 0.9999992847442627
suppressor O 0 0.00045814079931005836
. O 0 2.3852478534536203e-06

As O 0 2.3907637114461977e-06
constitutional O 0 2.888528172206861e-07
DNA O 0 4.269861165084876e-06
was O 0 2.385093239354319e-06
not O 0 1.0194720623246667e-08
available O 0 5.284725990151173e-09
, O 0 3.47878881257202e-09
a O 0 1.0467904587585508e-07
putative O 0 4.364699998404831e-05
hereditary O 0 0.44449755549430847
predisposition O 0 0.00015547718794550747
to O 0 4.743222234537825e-06
T B-Disease 0 0.30023062229156494
- I-Disease 0 0.0001421102206222713
PLL I-Disease 0 6.567385571543127e-05
will O 0 2.5348677468173264e-07
require O 0 2.2302723223788234e-08
further O 0 4.155474897515887e-08
investigation O 0 2.0933539701672998e-07
. O 0 6.779231398468255e-08
. O 0 3.8370853872038424e-07

Myotonic B-Disease 1 0.9999995231628418
dystrophy I-Disease 1 0.9999998807907104
protein O 0 0.0019370827358216047
kinase O 0 0.00036907431785948575
is O 0 3.3599766879888193e-07
involved O 0 3.7105277073123943e-08
in O 0 6.778556382869283e-09
the O 0 7.304330473800746e-09
modulation O 0 1.2663412007896113e-07
of O 0 3.130379955251783e-09
the O 0 2.0683614820882212e-08
Ca2 O 0 1.9589560906752013e-06
+ O 0 1.2062159839842934e-05
homeostasis O 0 1.9893775970558636e-05
in O 0 2.892382156005624e-07
skeletal O 0 0.00024174140708055347
muscle O 0 4.4697735575027764e-05
cells O 0 2.0399820641614497e-05
. O 0 8.863683547133405e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9979520440101624
DM B-Disease 1 1.0
) O 0 9.697853784018662e-06
, O 0 5.894731813782528e-08
the O 0 6.6738339299377e-09
most O 0 3.286480421138549e-08
prevalent O 0 1.4758039469597861e-05
muscular B-Disease 0 0.04772109165787697
disorder I-Disease 0 0.03983958810567856
in O 0 5.564193656937277e-07
adults O 0 9.811033123696689e-07
, O 0 4.257209340607915e-08
is O 0 6.14748785210395e-08
caused O 0 4.4860152570436185e-07
by O 0 3.304192475184209e-08
( O 0 1.1999063076473249e-07
CTG O 0 1.2456817785277963e-05
) O 0 2.7559210025174252e-08
n O 0 2.1076859866298037e-06
- O 0 2.0041777588630794e-06
repeat O 0 1.5751202226965688e-06
expansion O 0 3.5184285707146046e-08
in O 0 5.314606532635935e-09
a O 0 5.896662713666956e-09
gene O 0 1.70804685950543e-08
encoding O 0 2.0421754953758864e-08
a O 0 3.9948336194584044e-08
protein O 0 5.651212973134534e-07
kinase O 0 7.00143791618757e-05
( O 0 2.2037652342987712e-06
DM B-Disease 1 0.9999980926513672
protein O 0 3.6627241115638753e-06
kinase O 0 5.874948783457512e-06
; O 0 1.369983237964334e-07
DMPK O 0 1.3372106877795886e-05
) O 0 2.0110897835934338e-08
and O 0 3.8895104914615786e-09
involves O 0 7.668053747522663e-09
changes O 0 1.106157920816031e-08
in O 0 2.4003115939308373e-08
cytoarchitecture O 0 1.551314016978722e-05
and O 0 4.5308419771572517e-07
ion O 0 2.524669253034517e-05
homeostasis O 0 7.026024104561657e-05
. O 0 1.5901269989626599e-06

To O 0 4.201967840344878e-06
obtain O 0 1.5279289300451637e-06
clues O 0 6.967816261749249e-06
to O 0 7.565419934962847e-08
the O 0 2.055650227816841e-08
normal O 0 1.5135522346554353e-07
biological O 0 1.0520125215407461e-07
role O 0 1.886546918683507e-08
of O 0 6.145023156989282e-09
DMPK O 0 1.1052489753637929e-05
in O 0 9.898042918621286e-08
cellular O 0 8.213755791075528e-06
ion O 0 7.841017577447928e-06
homeostasis O 0 1.563088699185755e-05
, O 0 7.419104974815127e-08
we O 0 1.3757880168441261e-08
have O 0 4.514338236560889e-09
compared O 0 3.465783393608035e-08
the O 0 1.0183351939474505e-08
resting O 0 5.742638222727692e-07
[ O 0 6.961486320733457e-08
Ca2 O 0 2.909440581788658e-07
+ O 0 1.1037637932531652e-06
] O 0 2.593550334495376e-07
i O 0 5.16112734771923e-08
, O 0 2.4659463360166e-09
the O 0 1.134895177834494e-09
amplitude O 0 1.0936024530394661e-08
and O 0 9.153787949855996e-09
shape O 0 1.1622904594332795e-07
of O 0 1.1200149252488245e-08
depolarization O 0 6.346568284243403e-07
- O 0 1.482839525124291e-05
induced O 0 1.0236114576400723e-05
Ca2 O 0 7.890126312304346e-07
+ O 0 1.7428237697458826e-06
transients O 0 9.484349902777467e-06
, O 0 2.9392523970273032e-08
and O 0 7.2890351532350905e-09
the O 0 2.1070483136043094e-09
content O 0 2.0476514706047055e-08
of O 0 3.0025724129245646e-09
ATP O 0 6.32100272923708e-05
- O 0 4.033419827464968e-06
driven O 0 1.0182951655224315e-06
ion O 0 6.938883529983286e-07
pumps O 0 6.288321969805111e-07
in O 0 1.647903324908384e-08
cultured O 0 3.540209490893176e-06
skeletal O 0 4.36892660218291e-05
muscle O 0 2.5167564672301523e-06
cells O 0 3.220751523258514e-07
of O 0 2.4166550982585022e-09
wild O 0 1.557385616024476e-07
- O 0 7.028929758234881e-06
type O 0 1.2691959909716388e-06
and O 0 2.213402297002176e-07
DMPK O 0 5.493236312759109e-05
[ O 0 7.447261509696546e-07
- O 0 2.1775587811134756e-05
/ O 0 5.9306807088432834e-05
- O 0 2.1208092221058905e-05
] O 0 2.9621044177474687e-06
knockout O 0 7.137053762562573e-05
mice O 0 7.626906153745949e-05
. O 0 7.33087915705255e-07

In O 0 1.0447759450471494e-05
vitro O 0 8.390341099584475e-05
- O 0 5.254457937553525e-05
differentiated O 0 2.102732651110273e-05
DMPK O 0 0.00011859556252602488
[ O 0 1.3442455610856996e-06
- O 0 2.3194375899038278e-05
/ O 0 5.4258467571344227e-05
- O 0 9.47931403061375e-06
] O 0 2.638239493535366e-07
myotubes O 0 7.884033834670845e-07
exhibit O 0 5.031981586967049e-08
a O 0 3.47522934873723e-08
higher O 0 1.260060003005492e-07
resting O 0 9.212254212798143e-07
[ O 0 1.3742149462814268e-07
Ca2 O 0 5.082245593257539e-07
+ O 0 1.6352997818103177e-06
] O 0 2.6693408017308684e-07
i O 0 6.991226086938696e-08
than O 0 5.712974537885884e-09
do O 0 5.5152598044116985e-09
wild O 0 2.1253054427461393e-08
- O 0 1.4694846868223976e-06
type O 0 8.164018936440698e-07
myotubes O 0 5.1317560973984655e-06
because O 0 1.025999107895359e-08
of O 0 6.014062026160616e-10
an O 0 1.137769700676472e-08
altered O 0 2.2948704554437427e-06
open O 0 6.598008894798113e-07
probability O 0 1.5681216325447167e-08
of O 0 2.8560773746022505e-09
voltage O 0 4.858710326516302e-06
- O 0 2.0811945432797074e-05
dependent O 0 3.786386287174537e-06
l O 0 5.319255706126569e-06
- O 0 5.509452876140131e-07
type O 0 2.032004005059207e-07
Ca2 O 0 4.3854288378497586e-07
+ O 0 2.866470651952113e-07
and O 0 4.578448198344631e-08
Na O 0 3.169087449350627e-06
+ O 0 1.5211912796075922e-06
channels O 0 3.0685403089592e-06
. O 0 9.564842002873775e-07

The O 0 1.3703167951462092e-06
mutant O 0 3.997949988843175e-06
myotubes O 0 1.6109748685266823e-05
exhibit O 0 5.585613962466596e-07
smaller O 0 1.1132765820320856e-07
and O 0 5.871246600008817e-08
slower O 0 1.9307105958432658e-06
Ca2 O 0 2.1335010842449265e-06
+ O 0 1.1754008255593362e-06
responses O 0 6.927419349267439e-08
upon O 0 1.3319775504783138e-08
triggering O 0 2.847819473572599e-07
by O 0 1.4074524656848553e-08
acetylcholine O 0 4.128725777263753e-05
or O 0 9.163204595097341e-07
high O 0 5.380389325182477e-07
external O 0 3.339191835038946e-06
K O 0 8.354209057870321e-06
+ O 0 5.437852450995706e-06
. O 0 6.964174872337026e-07

In O 0 2.433081363051315e-06
addition O 0 2.473334177466313e-07
, O 0 1.1231322361027196e-07
we O 0 2.1911853664846603e-08
observed O 0 2.4675143706076597e-08
that O 0 1.2249629088856295e-09
these O 0 1.5943104614279946e-09
Ca2 O 0 5.841015422447526e-07
+ O 0 6.23020878265379e-06
transients O 0 3.3730822906363755e-05
partially O 0 9.655771464167628e-06
result O 0 8.289106290249038e-08
from O 0 2.12201922700217e-09
an O 0 1.904602031643776e-09
influx O 0 6.604931268583414e-09
of O 0 9.322155269941845e-10
extracellular O 0 3.179011187626202e-08
Ca2 O 0 1.7333114499251678e-07
+ O 0 1.1350240214369478e-07
through O 0 5.6096181033638e-09
the O 0 1.552799488990786e-08
l O 0 3.398280568944756e-06
- O 0 1.468470486543083e-06
type O 0 4.282006784706027e-07
Ca2 O 0 1.1610491128521971e-06
+ O 0 1.357344217467471e-06
channel O 0 9.41141479415819e-06
. O 0 7.370381354121491e-07

Neither O 0 1.3400038369582035e-05
the O 0 1.7022617271322815e-07
content O 0 2.941179673143779e-07
nor O 0 1.8147007097013557e-07
the O 0 6.316453582400072e-09
activity O 0 2.3801609572160487e-08
of O 0 8.226746395223472e-09
Na O 0 9.41802227316657e-06
+ O 0 3.797079216383281e-06
/ O 0 3.4263157431269065e-06
K O 0 9.887189662549645e-07
+ O 0 9.183220299746608e-07
ATPase O 0 6.7729511101788376e-06
and O 0 1.420842181687476e-07
sarcoplasmic O 0 4.993397851649206e-06
reticulum O 0 4.550477115117246e-06
Ca2 O 0 2.041655534412712e-06
+ O 0 1.64003199643048e-06
- O 0 4.4053958845324814e-06
ATPase O 0 1.9473574866424315e-05
are O 0 3.612963794807911e-08
affected O 0 5.786597156998141e-08
by O 0 2.8270610741287783e-08
DMPK O 0 0.00010925522656179965
absence O 0 1.3784443808617652e-06
. O 0 6.77062473641854e-07

In O 0 4.928061116515892e-06
conclusion O 0 1.0705047088777064e-06
, O 0 7.2530632166945e-08
our O 0 4.432888900396392e-08
data O 0 3.4250930980306293e-07
suggest O 0 3.176338125854272e-08
that O 0 8.298293607822416e-09
DMPK O 0 1.8929154975921847e-05
is O 0 3.002373460958552e-08
involved O 0 1.0880722101092033e-08
in O 0 8.700087761326358e-09
modulating O 0 5.752416427640128e-07
the O 0 2.499044704507014e-08
initial O 0 7.880908725610425e-08
events O 0 1.0597678290480417e-08
of O 0 5.198211638912653e-09
excitation O 0 1.341178858638159e-06
- O 0 3.614989691413939e-05
contraction O 0 2.8261552870390005e-05
coupling O 0 8.897857242118334e-07
in O 0 1.8885492636400159e-07
skeletal O 0 0.0002588337520137429
muscle O 0 1.2274962500669062e-05
. O 0 1.7286430420426768e-07
. O 0 6.488429562523379e-07

Constitutional O 0 9.49504756135866e-05
RB1 O 0 0.004007928539067507
- O 0 0.0005168192437849939
gene O 0 5.377549314289354e-05
mutations O 0 0.0001020157869788818
in O 0 2.593214105672814e-07
patients O 0 1.872410393843893e-06
with O 0 8.601225687243641e-08
isolated O 0 8.880595123628154e-05
unilateral B-Disease 0 0.0004038295883219689
retinoblastoma I-Disease 0 0.004961369559168816
. O 0 4.225282737024827e-06

In O 0 5.812309154862305e-06
most O 0 1.8301550142041378e-07
patients O 0 4.0762364506008453e-07
with O 0 1.7377198346935074e-08
isolated O 0 6.924856279511005e-06
unilateral B-Disease 0 4.518614150583744e-05
retinoblastoma I-Disease 0 0.0005973675288259983
, O 0 7.167441253841389e-07
tumor B-Disease 0 5.388608315115562e-06
development O 0 2.0937049427516286e-08
is O 0 2.5225583399901552e-08
initiated O 0 2.7766089871761324e-08
by O 0 5.305916594977589e-09
somatic O 0 1.1666787713693338e-06
inactivation O 0 7.635206202394329e-06
of O 0 2.1798292060282165e-09
both O 0 1.0581016063326842e-08
alleles O 0 7.660469947268211e-08
of O 0 1.3671921372804263e-08
the O 0 2.93011822805056e-07
RB1 O 0 0.00043879557051695883
gene O 0 1.3352176210901234e-05
. O 0 1.3995335166328005e-06

However O 0 3.763723498195759e-06
, O 0 4.55295037227188e-08
some O 0 1.992966014441322e-09
of O 0 1.620869549689985e-09
these O 0 5.562440286155379e-09
patients O 0 9.862124272785877e-08
can O 0 4.614894422161342e-08
transmit O 0 5.270356632536277e-05
retinoblastoma B-Disease 0 0.0004468259576242417
predisposition O 0 5.86313362873625e-05
to O 0 1.8535993717705423e-07
their O 0 6.457009362748067e-07
offspring O 0 2.5979023121180944e-05
. O 0 1.295100332754373e-06

To O 0 2.3590735054312972e-06
determine O 0 3.789255060837604e-07
the O 0 3.092625533440696e-08
frequency O 0 8.884891826710373e-07
and O 0 8.739791468315161e-08
nature O 0 3.431415152022055e-08
of O 0 1.1667300903184241e-08
constitutional O 0 1.7076665415061143e-07
RB1 O 0 0.00011536708916537464
- O 0 2.3651586161577143e-05
gene O 0 3.137045496259816e-06
mutations O 0 3.7866604998271214e-06
in O 0 5.101047051425667e-08
patients O 0 4.0686555280444736e-07
with O 0 2.543487553907653e-08
isolated O 0 1.1184787581441924e-05
unilateral B-Disease 0 2.216368193330709e-05
retinoblastoma I-Disease 0 7.639791147084907e-05
, O 0 1.792597714711519e-07
we O 0 1.3672964982447411e-08
analyzed O 0 8.11974629755241e-08
DNA O 0 9.266283882425341e-07
from O 0 5.346054976484993e-08
peripheral O 0 3.17609119520057e-05
blood O 0 1.0371045391366351e-05
and O 0 4.151855250711378e-07
from O 0 8.042385388762341e-07
tumor B-Disease 0 0.0004243756120558828
tissue O 0 0.0001441383210476488
. O 0 1.3330052297533257e-06

The O 0 1.614300686014758e-06
analysis O 0 1.2654336387640797e-06
of O 0 3.6963231764275406e-07
tumors B-Disease 1 0.9999995231628418
from O 0 4.822789492209267e-07
54 O 0 9.504699960416474e-07
( O 0 3.863795328129527e-08
71 O 0 1.6185200024665392e-07
% O 0 1.4690398231209656e-08
) O 0 3.0307716336608337e-09
of O 0 2.825038425413595e-09
76 O 0 7.140294542296033e-07
informative O 0 1.9356516531843226e-06
patients O 0 3.109743147433619e-06
showed O 0 2.7089599825558253e-06
loss O 0 1.2259778259249288e-06
of O 0 4.58544846537734e-08
constitutional O 0 1.570754989188572e-06
heterozygosity O 0 0.00041306737693957984
( O 0 1.1649360203591641e-05
LOH O 1 0.9999517202377319
) O 0 2.692286216188222e-07
at O 0 4.5599244913319126e-07
intragenic O 0 4.4847343815490603e-05
loci O 0 1.1673058907035738e-05
. O 0 1.5285891095118131e-06

Three O 0 1.771789243321109e-06
of O 0 1.5314694223889092e-07
13 O 0 1.524028789390286e-06
uninformative O 0 0.0006923754117451608
patients O 0 4.050177085446194e-05
had O 0 1.636657088965876e-06
constitutional O 0 1.1509265505083022e-06
deletions O 0 4.556633211905137e-05
. O 0 3.509452199068619e-06

For O 0 1.6655633316986496e-06
39 O 0 1.2960938420292223e-06
randomly O 0 7.99445388111053e-07
selected O 0 1.6546345023016329e-06
tumors B-Disease 1 0.9999957084655762
, O 0 1.880535336340472e-07
SSCP O 0 4.397223892738111e-05
, O 0 8.244845872695805e-08
hetero O 0 3.0373585104825906e-06
- O 0 1.907833393488545e-06
duplex O 0 0.0001440599880879745
analysis O 0 3.2070357747215894e-07
, O 0 8.2779640919739e-09
sequencing O 0 6.774759242489381e-08
, O 0 9.955654967086502e-09
and O 0 1.1639428088017212e-08
Southern O 0 1.385352419447372e-07
blot O 0 5.3725259931525216e-05
analysis O 0 1.2367409851776756e-07
were O 0 7.670482027322123e-09
used O 0 2.8702228149768416e-08
to O 0 8.75798136235062e-08
identify O 0 3.951418420911068e-06
mutations O 0 2.0351224520709366e-05
. O 0 8.288464528050099e-07

Mutations O 0 0.0006617475883103907
were O 0 2.514892003091518e-06
detected O 0 4.58099157185643e-06
in O 0 5.972173511281653e-08
21 O 0 2.622771262394963e-07
( O 0 2.435457346905423e-08
91 O 0 7.883178909651178e-08
% O 0 1.599510568439655e-08
) O 0 6.180427281066159e-09
of O 0 1.9798427786099637e-08
23 O 0 0.00020371307618916035
tumors B-Disease 1 0.9999998807907104
with O 0 3.078578447457403e-05
LOH O 1 0.9999953508377075
. O 0 1.694418278930243e-05

In O 0 7.295349860214628e-06
6 O 0 2.838212822098285e-06
( O 0 6.892585702189535e-08
38 O 0 1.409346879199802e-07
% O 0 1.719067732608437e-08
) O 0 7.483996533608206e-09
of O 0 1.227601842401782e-08
16 O 0 0.00014665542403236032
tumors B-Disease 1 1.0
without O 0 1.4659904991276562e-05
LOH O 1 0.9999520778656006
, O 0 1.360600663247169e-07
one O 0 2.983017211022343e-08
mutation O 0 2.593500880720967e-07
was O 0 5.376865601647296e-07
detected O 0 9.59843305281538e-07
, O 0 8.627708325548156e-09
and O 0 1.6867119256858132e-08
in O 0 1.9971528431028673e-08
9 O 0 8.06038315204205e-07
( O 0 1.5089684168856365e-08
56 O 0 7.110931932174935e-08
% O 0 7.481542496634574e-09
) O 0 2.0394652633370924e-09
of O 0 5.906343414352477e-09
the O 0 9.694219443190377e-06
tumors B-Disease 1 1.0
without O 0 4.30722939199768e-05
LOH O 1 0.9999366998672485
, O 0 3.3311624747511814e-07
both O 0 4.420705224106314e-08
mutations O 0 3.4104166388715385e-06
were O 0 6.109812034083006e-08
found O 0 2.1469548983077402e-07
. O 0 4.3241928437964816e-07

Thus O 0 4.93787911182153e-06
, O 0 8.982323862483099e-08
a O 0 1.9554114771835884e-08
total O 0 1.3399302112304667e-08
of O 0 3.667248060779116e-09
45 O 0 6.644711447734153e-08
mutations O 0 5.564246521316818e-07
were O 0 6.54708713909713e-08
identified O 0 2.4246476186817745e-06
in O 0 1.4802841405980871e-06
tumors B-Disease 1 0.9999996423721313
of O 0 2.1235797476037988e-07
36 O 0 4.953801635565469e-06
patients O 0 1.2621204632523586e-06
. O 0 3.396368413177697e-07

Thirty O 0 3.255816409364343e-05
- O 0 9.342325938632712e-06
nine O 0 1.4826815686319605e-07
of O 0 3.021686456605721e-09
the O 0 7.964348291977785e-09
mutations O 0 7.787182880747423e-07
- O 0 4.3744225308728346e-07
including O 0 1.0767545077783325e-08
34 O 0 2.4018504518608097e-08
small O 0 9.688706725796692e-09
mutations O 0 5.633402224702877e-07
, O 0 4.844268097770055e-09
2 O 0 1.654997028310845e-08
large O 0 2.6676374886847043e-08
structural O 0 7.540901606262196e-06
alterations O 0 4.35014590038918e-06
, O 0 6.103302041537972e-08
and O 0 9.660072208816928e-08
hypermethylation O 0 2.1136536815902218e-05
in O 0 7.583035994684906e-07
3 O 0 0.0007409362006001174
tumors O 1 1.0
- O 0 0.00023512325424235314
were O 0 8.444277455055271e-07
not O 0 1.8002413781914584e-08
detected O 0 1.7391315054737788e-07
in O 0 2.409760391230975e-09
the O 0 8.265972795129528e-09
corresponding O 0 3.881882548739668e-07
peripheral O 0 4.0837716369424015e-05
blood O 0 7.36772835807642e-06
DNA O 0 5.220355524215847e-05
. O 0 1.4092045148572652e-06

In O 0 2.115404095093254e-05
6 O 0 1.1751345482480247e-05
( O 0 2.2515756370466988e-07
17 O 0 2.581274429758196e-07
% O 0 1.6004657155122004e-08
) O 0 2.5835353856251686e-09
of O 0 8.759760139476214e-10
the O 0 3.570415429976492e-08
36 O 0 1.1722328281393857e-06
patients O 0 1.2526649584287952e-07
, O 0 3.661823955170007e-09
a O 0 3.5786104746193814e-08
mutation O 0 9.845836075328407e-07
was O 0 1.3507377616406302e-06
detected O 0 7.285520950972568e-07
in O 0 1.0905362834989774e-08
constitutional O 0 1.4784112600807475e-08
DNA O 0 1.4825150174146984e-06
, O 0 4.891063554168795e-08
and O 0 1.7560655152237814e-08
1 O 0 4.079051407757106e-08
of O 0 3.1438671665995344e-09
these O 0 1.506052882405129e-08
mutations O 0 1.4658568261438631e-06
is O 0 3.377977719765113e-08
known O 0 1.1059347571062972e-07
to O 0 7.807492607980748e-08
be O 0 6.64430643837477e-08
associated O 0 2.1978321385063282e-08
with O 0 2.3140218630146592e-08
reduced O 0 1.4310375263448805e-05
expressivity O 0 0.00019400844757910818
. O 0 3.2474411000293912e-06

The O 0 1.123063157137949e-06
presence O 0 3.5360420724828145e-07
of O 0 1.341751154626536e-08
a O 0 8.6326011228266e-08
constitutional O 0 9.188215699396096e-08
mutation O 0 1.4596406572309206e-06
was O 0 1.3466939208228723e-06
not O 0 2.2518928943782157e-08
associated O 0 1.0257388716183868e-08
with O 0 3.6068275033329655e-09
an O 0 3.550057314782862e-08
early O 0 4.2179766523986473e-07
age O 0 1.083322231920647e-07
at O 0 3.996609621026437e-07
treatment O 0 1.7516483694635099e-06
. O 0 4.498499208693829e-07

In O 0 5.19632340001408e-06
1 O 0 8.8077840700862e-06
patient O 0 6.381992989190621e-06
, O 0 5.611001796523851e-08
somatic O 0 3.3875028293550713e-06
mosaicism O 0 9.310791938332841e-05
was O 0 2.4264334115287056e-06
demonstrated O 0 1.1631110652388088e-07
by O 0 6.447672173948149e-09
molecular O 0 1.6899588217711425e-07
analysis O 0 2.4420344857389864e-08
of O 0 2.8482165514986946e-09
DNA O 0 1.5589965869367006e-06
and O 0 4.928230268319567e-08
RNA O 0 1.838856974245573e-06
from O 0 1.5336588887748803e-07
peripheral O 0 5.7860888773575425e-05
blood O 0 3.378120527486317e-05
. O 0 1.7191830465890234e-06

In O 0 8.239167073043063e-06
2 O 0 1.2163327482994646e-05
patients O 0 7.738758540654089e-07
without O 0 1.3346910243683396e-08
a O 0 1.0019684992812472e-07
detectable O 0 6.8140261646476574e-06
mutation O 0 3.347507345097256e-06
in O 0 1.4023297012499825e-07
peripheral O 0 0.00010543438111199066
blood O 0 3.7487578083528206e-05
, O 0 3.06351807921601e-07
mosaicism O 0 2.6002026061178185e-05
was O 0 2.790698090393562e-06
suggested O 0 2.1026377794441942e-07
because O 0 1.2326557552455597e-08
1 O 0 2.9366859166657378e-08
of O 0 1.7950906316954729e-09
the O 0 1.1105851882575735e-07
patients O 0 1.8084655266648042e-06
showed O 0 7.655219633306842e-06
multifocal O 1 0.9342154264450073
tumors B-Disease 1 1.0
and O 0 2.2944014688164316e-07
the O 0 9.709777870625658e-09
other O 0 8.966128284271235e-09
later O 0 1.1101404595592612e-07
developed O 0 1.4500380984827643e-07
bilateral B-Disease 0 5.028317104915914e-07
retinoblastoma I-Disease 0 0.0001842987403506413
. O 0 2.7240271265327465e-06

In O 0 2.784809112199582e-06
conclusion O 0 4.901298780168872e-07
, O 0 5.187220608604548e-08
our O 0 2.9645434551639482e-08
results O 0 1.1218990181305344e-07
emphasize O 0 7.025540327276758e-08
that O 0 5.121917112660412e-09
the O 0 3.854254249091582e-09
manifestation O 0 1.5021318233721104e-07
and O 0 4.3310933506290894e-08
transmissibility O 0 5.036840775574092e-07
of O 0 7.820276870518228e-09
retinoblastoma B-Disease 0 2.132813506250386e-06
depend O 0 1.031668759310378e-07
on O 0 3.2062769150797976e-07
the O 0 1.9297202058510265e-08
nature O 0 3.8197715213073025e-08
of O 0 1.3395105025182374e-09
the O 0 7.05167657599759e-09
first O 0 1.3724338998599706e-07
mutation O 0 1.468239219093448e-07
, O 0 3.590299391120766e-09
its O 0 1.716413855490373e-08
time O 0 1.8445788896315207e-08
in O 0 5.90467585936949e-09
development O 0 8.73977068494014e-09
, O 0 1.3671713539054053e-08
and O 0 6.86895962331846e-09
the O 0 3.105723234142488e-09
number O 0 7.0648424888020145e-09
and O 0 1.3754888783523711e-08
types O 0 5.286802995385642e-09
of O 0 3.720397767636996e-09
cells O 0 3.3642217545093445e-07
that O 0 2.9313525828911224e-08
are O 0 1.8335576612571458e-08
affected O 0 7.452619144032724e-08
. O 0 4.742552661696209e-08
. O 0 3.72810376347843e-07

Hereditary B-Disease 1 0.9999983310699463
deficiency I-Disease 1 0.9998441934585571
of I-Disease 0 1.5462772751106968e-07
the I-Disease 0 6.725282020170198e-08
fifth I-Disease 0 1.7591648884263122e-06
component I-Disease 0 1.305898820191942e-07
of I-Disease 0 5.2198112499013405e-09
complement I-Disease 0 9.85776154038831e-08
in O 0 1.4994095920428663e-07
man O 0 1.3919403500040062e-05
. O 0 1.4486214467979153e-06

I O 0 0.001181446248665452
. O 0 2.168746868846938e-05

Clinical O 0 0.003262652549892664
, O 0 3.0608421184297185e-06
immunochemical O 0 0.00014167763583827764
, O 0 5.672693532687845e-07
and O 0 1.5359158567207487e-07
family O 0 1.3888807188777719e-06
studies O 0 5.036716288486787e-07
. O 0 7.00108671480848e-07

The O 0 1.1420756891311612e-06
first O 0 4.4582080249711e-07
recognized O 0 2.7464395202514424e-07
human O 0 3.4508173030189937e-07
kindred O 0 9.166874951915815e-05
with O 0 1.6148142094607465e-05
hereditary B-Disease 1 0.9999977350234985
deficiency I-Disease 1 0.8284779787063599
of I-Disease 0 1.3599255943574917e-08
the I-Disease 0 5.2631218494525456e-08
fifth I-Disease 0 2.718468067541835e-06
component I-Disease 0 2.2282638667547872e-07
of I-Disease 0 9.587526328402873e-09
complement I-Disease 0 2.9255502909109055e-07
( O 0 2.0448226223379606e-07
C5 O 0 0.00010390987154096365
) O 0 1.1280152278914102e-07
is O 0 1.0038641562459816e-07
described O 0 4.949925369146513e-06
. O 0 1.5316870758397272e-06

The O 0 1.1437182365625631e-06
proband O 0 1.799419078452047e-05
, O 0 3.8251446454751203e-08
a O 0 2.059861614611691e-08
20 O 0 2.6594735302865047e-08
- O 0 1.0291250873706304e-06
year O 0 2.4855449964888976e-07
- O 0 1.196339439957228e-06
old O 0 9.373527518619085e-07
black O 0 9.566410881234333e-07
female O 0 1.4666105698779575e-06
with O 0 2.590186704765074e-05
systemic B-Disease 1 1.0
lupus I-Disease 1 0.999998927116394
erythematosus I-Disease 1 0.9999995231628418
since O 0 9.596522431820631e-06
age O 0 3.046604888368165e-07
11 O 0 9.976473336337222e-08
, O 0 4.478893345094548e-08
lacked O 0 5.617126248580462e-07
serum O 0 9.742317388372612e-07
hemolytic O 0 2.435740861983504e-05
complement O 0 2.092424011834737e-07
activity O 0 1.9878538637385645e-07
, O 0 2.1879944966940457e-08
even O 0 3.3912119334900126e-08
during O 0 2.0542437084714038e-07
remission O 0 8.066665031947196e-06
. O 0 3.679132589695655e-07

C5 O 0 0.005067870952188969
was O 0 3.707771247718483e-05
undetectable O 0 1.6412979675806127e-05
in O 0 1.4021904348737735e-07
her O 0 1.4551028471032623e-06
serum O 0 7.425051080645062e-07
by O 0 1.2452558095787936e-08
both O 0 3.553729044369902e-08
immunodiffusion O 0 5.5158081522677094e-05
and O 0 2.6904278911388246e-06
hemolytic O 0 0.0071726529859006405
assays O 0 9.307036816608161e-05
. O 0 2.6147868084080983e-06

Other O 0 4.431240938629344e-07
complement O 0 3.252848159718269e-07
components O 0 7.377533393082558e-07
were O 0 7.350482178480888e-08
normal O 0 1.0636868097435581e-07
during O 0 9.010842916268302e-08
remission O 0 1.3522895869755303e-06
of O 0 7.087817976980659e-08
lupus O 0 0.017946844920516014
, O 0 5.404462655178577e-08
but O 0 3.1661102184443735e-08
C1 O 0 3.831077719951281e-06
, O 0 6.977983701972335e-08
C4 O 0 3.9336548070423305e-05
, O 0 8.672324725012004e-08
C2 O 0 3.577871211746242e-06
, O 0 3.014204708051693e-08
and O 0 3.938198744890542e-08
C3 O 0 0.00017454917542636395
levels O 0 9.118118668993702e-07
fell O 0 3.6251462006475776e-05
during O 0 9.905112392516457e-07
exacerbations O 0 0.000404954917030409
. O 0 1.4901507938702707e-06

A O 0 1.0519887837290298e-05
younger O 0 5.957013399893185e-06
half O 0 2.09975337384094e-06
- O 0 7.837187149561942e-05
sister O 0 0.0001170082250609994
, O 0 2.1649597670148069e-07
who O 0 3.6714425277750706e-07
had O 0 7.97533346030832e-07
no O 0 3.161801487294724e-07
underlying O 0 0.0004811118997167796
disease O 0 0.003365115262567997
, O 0 1.9423683284003346e-07
was O 0 2.3913064524094807e-06
also O 0 2.8625203185583814e-07
found O 0 1.374359186456786e-07
to O 0 6.62967281073179e-08
lack O 0 5.249647188065865e-07
immunochemically O 0 0.00025427393848076463
detectable O 0 0.00011854061449412256
C5 O 0 0.0002444454876240343
. O 0 2.356063077968429e-06

By O 0 8.105802407953888e-06
hemolytic O 0 0.02998930960893631
assay O 0 0.000718403491191566
, O 0 3.392491407794296e-06
she O 0 2.1623650354740676e-06
exhibited O 0 2.456512504522834e-07
1 O 0 9.821540203347467e-08
- O 0 1.2368606121526682e-06
2 O 0 5.147874730937474e-07
% O 0 7.515122746326597e-09
of O 0 7.250304245864925e-10
the O 0 1.2844340702145018e-08
normal O 0 4.103950175249338e-07
serum O 0 4.089787069005979e-07
C5 O 0 5.059022896602983e-06
level O 0 3.727793895791365e-08
and O 0 1.4635748613045507e-08
normal O 0 4.6265451913996e-08
concentrations O 0 8.924654792963338e-08
of O 0 1.0817540196939035e-09
other O 0 3.842949958254849e-09
complement O 0 9.689265567658367e-08
components O 0 1.962020633072825e-06
. O 0 8.963718300947221e-07

C5 O 0 0.001638538553379476
levels O 0 8.312684258271474e-06
of O 0 3.7987014422924403e-08
other O 0 1.7095233673103394e-08
family O 0 9.31604873244396e-08
members O 0 1.521395276427029e-08
were O 0 1.1353980866601887e-08
either O 0 4.0093728337353696e-09
normal O 0 4.1846330844919066e-08
or O 0 2.1661778148995836e-08
approximately O 0 2.6854850787572104e-08
half O 0 1.117113868076558e-07
- O 0 4.991365130990744e-06
normal O 0 9.70744622463826e-07
, O 0 1.6998697560666187e-08
consistent O 0 3.8698946269732915e-08
with O 0 2.0284291579741875e-08
autosomal O 0 0.00013514937018044293
codominant O 0 2.441457036184147e-05
inheritance O 0 2.39333235185768e-06
of O 0 2.6032139999188075e-08
the O 0 1.644688722990395e-07
gene O 0 5.416892236098647e-05
determining O 0 0.00014705589273944497
C5 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
. O 0 5.161155513633275e-06

Normal O 0 0.0015173661522567272
hemolytic O 1 0.9593436121940613
titers O 0 0.001489776186645031
were O 0 4.268415523256408e-06
restored O 0 2.3314207737712422e-06
to O 0 1.4729599229212909e-07
both O 0 4.1554758922757173e-07
homozygous O 0 0.0003764582215808332
C5 B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999986886978149
deficient I-Disease 1 1.0
( O 0 3.5949396988144144e-05
C5D B-Disease 1 0.9999996423721313
) O 0 7.2961177011166e-07
sera O 0 2.552742444095202e-06
by O 0 3.1541860234796104e-09
addition O 0 6.017805809221954e-09
of O 0 5.371277200794111e-09
highly O 0 3.1635508435101656e-07
purified O 0 6.009016487951158e-06
human O 0 1.0914457106991904e-06
C5 O 0 0.000379729550331831
. O 0 4.638333393813809e-06

In O 0 4.4524822442326695e-06
specific O 0 1.1725078365998343e-06
C5 O 0 0.00011050090688513592
titrations O 0 0.0001875250891316682
, O 0 7.095283081071102e-07
however O 0 4.7726430807415454e-08
, O 0 1.4493074296240138e-08
it O 0 2.317511160754293e-08
was O 0 6.11783548265521e-07
noted O 0 6.641582217525865e-08
that O 0 5.832679672579388e-09
when O 0 9.030626912931439e-09
limited O 0 4.9921440314903975e-09
amounts O 0 4.218352334106612e-09
of O 0 4.0303813619857465e-09
C5 O 0 1.1330139386700466e-05
were O 0 7.723188133468284e-08
assayed O 0 1.3751301253250858e-07
in O 0 1.7138220842483065e-09
the O 0 1.9709573972903627e-09
presence O 0 4.065177527934338e-09
of O 0 3.336520837393664e-09
low O 0 1.7232804339073482e-07
dilutions O 0 2.8692982141365064e-06
of O 0 2.432045320688303e-08
either O 0 8.613322961537051e-07
C5D B-Disease 1 0.9999972581863403
serum O 0 8.011420504772104e-06
, O 0 1.4769681477844188e-08
curving O 0 1.5604661030010902e-07
rather O 0 1.2262376003491227e-08
than O 0 3.771611467584535e-09
linear O 0 6.549348086082318e-08
dose O 0 1.0415470796942827e-06
- O 0 2.2149804408400087e-06
response O 0 1.0209006973127543e-07
plots O 0 1.1664207022477058e-06
were O 0 2.270620456101824e-07
consistently O 0 5.031344016970252e-07
obtained O 0 1.4060485398204037e-07
, O 0 1.6137722269604637e-08
suggesting O 0 7.61570149165891e-08
some O 0 8.6881151162288e-09
inhibitory O 0 8.712427188584115e-07
effect O 0 8.751900395509438e-07
. O 0 5.070355655334424e-07

Further O 0 9.692583262221888e-06
studies O 0 1.250753030035412e-06
suggested O 0 2.942189496479841e-07
that O 0 2.2090956619535973e-08
low O 0 3.047694576707727e-07
dilutions O 0 1.5719113434897736e-05
of O 0 2.466103410370124e-07
C5D B-Disease 1 0.9999990463256836
serum O 0 4.391406946524512e-06
contain O 0 3.6753025511870874e-08
a O 0 5.947495296254601e-08
factor O 0 7.316464234463638e-08
( O 0 1.713339159437055e-08
or O 0 9.979403614579496e-08
factors O 0 2.937111531764458e-08
) O 0 1.3016634881068967e-08
interfering O 0 2.6010010856225563e-07
at O 0 1.1377290576319865e-07
some O 0 1.9491472880162064e-09
step O 0 4.5828429051653075e-08
in O 0 9.017012025935855e-09
the O 0 7.010093128201333e-08
hemolytic O 0 6.821654096711427e-05
assay O 0 1.3394173038250301e-05
of O 0 2.8047612232739993e-08
C5 O 0 0.00017512732301838696
, O 0 4.8873513236458166e-08
rather O 0 6.159409871031585e-09
than O 0 6.0197575812992454e-09
a O 0 4.980971013424096e-08
true O 0 4.361825460819091e-07
C5 O 0 8.28394404379651e-05
inhibitor O 0 3.3611988783377456e-06
or O 0 2.8303801968831976e-07
inactivator O 0 5.1753089792327955e-05
. O 0 1.0379318382547353e-06

Of O 0 3.269872422606568e-06
clinical O 0 5.5571854318259284e-05
interest O 0 3.632428899891238e-07
are O 0 8.2947366308872e-08
( O 0 6.141299735418215e-08
a O 0 2.564190424436674e-07
) O 0 4.100557760011725e-08
the O 0 9.30074062210906e-09
documentation O 0 2.5415852178412024e-07
of O 0 9.2263775286483e-08
membranous O 0 0.0025736696552485228
glomerulonephritis B-Disease 1 0.9999998807907104
, O 0 8.7436601461377e-05
vasculitis B-Disease 1 0.9999996423721313
, O 0 1.3414126442512497e-05
and O 0 0.0006364562432281673
arthritis B-Disease 1 1.0
in O 0 2.5795588953769766e-07
an O 0 1.7203508662078093e-07
individual O 0 1.8225348696887522e-07
lacking O 0 1.7311421061094734e-06
C5 O 0 0.00018083986651618034
( O 0 6.784509309909481e-08
and O 0 2.5632116873453015e-08
its O 0 1.267817850703068e-07
biologic O 0 3.5231169022154063e-06
functions O 0 4.982918966334182e-08
) O 0 2.7401547697536444e-08
, O 0 4.2752006379487284e-08
and O 0 2.000617200792476e-07
( O 0 6.715079337027419e-08
b O 0 2.0663550515109819e-07
) O 0 5.057342544745325e-09
a O 0 1.1073971073471967e-08
remarkable O 0 7.622386277716942e-08
propensity O 0 3.089423671553959e-06
to O 0 6.650881914538331e-06
bacterial B-Disease 1 0.9999983310699463
infections I-Disease 1 1.0
in O 0 9.121860955474403e-08
the O 0 6.667843877039559e-08
proband O 0 3.307578663225286e-05
, O 0 3.8903429810943635e-08
even O 0 8.005408780320522e-09
during O 0 6.546410968866212e-09
periods O 0 5.014513249079755e-09
of O 0 1.551578865388592e-09
low O 0 2.830579717283399e-07
- O 0 3.3414439712942112e-06
dose O 0 5.71715190744726e-07
or O 0 9.024152980430244e-09
alternate O 0 1.4892799526933231e-07
- O 0 5.075085482530994e-06
day O 0 2.1150494831090327e-06
corticosteroid O 0 0.00017959473188966513
therapy O 0 5.607734237855766e-06
. O 0 3.666110615085927e-07

Other O 0 1.5268188917616499e-06
observations O 0 3.4170936942246044e-06
indicate O 0 1.3730153796132072e-06
that O 0 2.8932364060096916e-08
the O 0 7.74439996575893e-08
C5D B-Disease 1 0.9999980926513672
state O 0 1.1556124945855117e-07
is O 0 6.1296647757558276e-09
compatible O 0 3.1422022317428855e-08
with O 0 8.595415934564699e-09
normal O 0 1.650722794011017e-07
coagulation O 0 2.6058873459078313e-07
function O 0 5.1199176454019835e-08
and O 0 2.1989558618429328e-08
the O 0 6.587494105758651e-09
capacity O 0 7.816906233415466e-09
to O 0 1.1591219539752728e-08
mount O 0 2.3697700157754298e-07
a O 0 1.5602162193317781e-06
neutrophilic O 0 0.0017222088063135743
leukocytosis O 0 0.0009345555445179343
during O 0 3.912536612915574e-06
pyogenic B-Disease 0 0.007101056165993214
infection I-Disease 0 0.0009814902441576123
. O 0 3.533843937475467e-07
. O 0 1.6768183286330895e-06

Susceptibility O 1 0.7270452380180359
to O 0 0.004802823532372713
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 0.01751297153532505
twins O 0 0.00021982338512316346
: O 0 3.275953375236895e-08
the O 0 2.7542903513477768e-09
role O 0 1.9931684747120926e-08
of O 0 3.6593525987171915e-09
genes O 0 2.1278003714542137e-07
, O 0 5.976605876867325e-08
HLA O 0 1.4283078598964494e-05
, O 0 4.249445595405632e-08
and O 0 2.179955060910288e-08
the O 0 5.479506981487248e-08
environment O 0 1.9246679130446864e-06
. O 0 6.753078309884586e-07

OBJECTIVE O 0 4.546510899672285e-05
To O 0 6.053588208487781e-07
determine O 0 1.3191771586207324e-07
the O 0 1.0838550501546251e-08
relative O 0 1.075941966632854e-07
effects O 0 3.291741279554117e-07
of O 0 7.907240195947907e-09
genetic O 0 2.6634845653461525e-06
and O 0 2.509106309389608e-07
environmental O 0 2.6208459757981473e-07
factors O 0 2.3556012251901848e-08
in O 0 1.3465971449022618e-07
susceptibility O 0 0.0014365522656589746
to O 0 0.13324062526226044
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.00017059619131032377
AS B-Disease 1 0.9980818033218384
) O 0 9.408545338374097e-07
. O 0 1.244919644705078e-06

METHODS O 0 3.695282430271618e-05
Twins O 0 6.230688450159505e-05
with O 0 4.988796149518748e-07
AS B-Disease 1 0.9957016110420227
were O 0 3.435774544868764e-07
identified O 0 3.747302059764479e-07
from O 0 8.093874015457914e-09
the O 0 2.127296738763107e-08
Royal O 0 2.507850695110392e-06
National O 0 2.447724227749859e-07
Hospital O 0 8.8510805653641e-06
for O 0 7.864269377932942e-07
Rheumatic B-Disease 1 0.9729369878768921
Diseases I-Disease 0 0.004392580129206181
database O 0 1.8445300156599842e-05
. O 0 4.656340024666861e-06

Clinical O 0 0.001660425215959549
and O 0 1.808715524020954e-06
radiographic O 0 6.854407547507435e-05
examinations O 0 4.517994057096075e-06
were O 0 4.866710128226259e-07
performed O 0 4.2519428689047345e-07
to O 0 5.4836686302905946e-08
establish O 0 1.4507837704513804e-06
diagnoses O 0 0.03518223389983177
, O 0 1.0924318303295877e-06
and O 0 1.221812181029236e-05
disease O 0 0.02327183447778225
severity O 0 0.0002253649872727692
was O 0 4.838461791223381e-06
assessed O 0 5.310621986609476e-07
using O 0 6.841125355094846e-08
a O 0 8.149303454274559e-08
combination O 0 2.405509746949974e-07
of O 0 1.4099996725747133e-08
validated O 0 4.375273761070275e-07
scoring O 0 1.1711015446280726e-07
systems O 0 5.6239136938529555e-06
. O 0 7.565721489299904e-07

HLA O 0 0.004111397545784712
typing O 0 6.809454498579726e-05
for O 0 3.0429259822994936e-07
HLA O 0 8.44382302602753e-05
- O 0 1.3669513464265037e-05
B27 O 0 2.2209392227523495e-06
, O 0 7.122238798729086e-08
HLA O 0 2.6726572741608834e-06
- O 0 1.0135894399354584e-06
B60 O 0 3.363371661180281e-07
, O 0 1.9908698689619087e-08
and O 0 4.928662633574277e-08
HLA O 0 6.768415187252685e-05
- O 0 6.236901390366256e-05
DR1 O 0 0.14894874393939972
was O 0 2.7218925424676854e-06
performed O 0 3.959770467076851e-08
by O 0 4.658562424708634e-09
polymerase O 0 2.660179347913072e-07
chain O 0 1.4357658528751926e-06
reaction O 0 1.3952322852617272e-08
with O 0 1.5821267629334557e-09
sequence O 0 2.7944446756578145e-08
- O 0 5.354091285880713e-07
specific O 0 1.0066516509255052e-08
primers O 0 9.25575648125232e-07
, O 0 2.0820287716105668e-08
and O 0 3.3798272625062964e-08
zygosity O 0 1.042803251039004e-05
was O 0 5.95730455188459e-07
assessed O 0 2.725940078107669e-07
using O 0 2.5073913434425776e-07
microsatellite O 0 3.358750473125838e-05
markers O 0 4.62655043520499e-05
. O 0 2.49020285991719e-06

Genetic O 0 0.0013776158448308706
and O 0 1.9395081380935153e-06
environmental O 0 4.925599341731868e-07
variance O 0 2.2558397461125423e-07
components O 0 1.6248499150606222e-06
were O 0 1.9735922762720293e-07
assessed O 0 1.8848282934413874e-07
with O 0 6.282366626919611e-09
the O 0 1.3920505637088354e-08
program O 0 9.037866988137466e-08
Mx O 0 6.318414307315834e-07
, O 0 5.317384754732757e-09
using O 0 1.0016719897976145e-08
data O 0 1.5173489487096958e-07
from O 0 2.966442425034188e-09
this O 0 4.1014236451530905e-09
and O 0 5.952795234520636e-08
previous O 0 2.9758379582744965e-07
studies O 0 8.419139163606815e-09
of O 0 2.633903317672548e-09
twins O 0 5.735550416829938e-07
with O 0 9.97639659772176e-08
AS B-Disease 1 0.9980558156967163
. O 0 4.073538093507523e-06

RESULTS O 0 0.0004587692383211106
Six O 0 5.528269184651435e-07
of O 0 5.472530162364819e-08
8 O 0 1.8785631255013868e-06
monozygotic O 0 1.9719831470865756e-05
( O 0 1.6277673466902343e-06
MZ O 0 0.1216953694820404
) O 0 3.970707496137038e-07
twin O 0 1.373631675960496e-05
pairs O 0 2.4928856419137446e-06
were O 0 1.9903532120224554e-06
disease O 0 2.0987517928006127e-05
concordant O 0 2.486156972736353e-06
, O 0 1.0271293149344274e-07
compared O 0 7.487484054991e-08
with O 0 3.9481697911014635e-09
4 O 0 1.4877183218686696e-07
of O 0 6.207765856913738e-09
15 O 0 1.8355035535932984e-07
B27 O 0 1.4418719729292206e-06
- O 0 1.8272516172146425e-05
positive O 0 7.985515821928857e-07
dizygotic O 0 2.1048094822617713e-06
( O 0 7.729465778538724e-08
DZ O 0 0.0021971308160573244
) O 0 1.3129368880981929e-07
twin O 0 2.000467702600872e-06
pairs O 0 2.2644400132776354e-07
( O 0 3.9993082623368537e-08
27 O 0 2.0140770118359796e-07
% O 0 9.86375781053539e-09
) O 0 2.656460607042277e-09
and O 0 8.932978801112768e-09
4 O 0 3.9877839697055606e-08
of O 0 3.4172731311343796e-09
32 O 0 5.739391326642362e-07
DZ O 0 0.0008275711443275213
twin O 0 1.2668556337303016e-05
pairs O 0 2.861917209884268e-07
overall O 0 2.6381339921499602e-06
( O 0 1.826234985458086e-08
12 O 0 3.597979159053466e-08
. O 0 7.502606536036183e-09
5 O 0 4.429145050721672e-08
% O 0 2.6714257472804093e-08
) O 0 2.805692211893529e-08
. O 0 3.261521044350957e-07

Nonsignificant O 0 0.0006523497286252677
increases O 0 8.966531822807156e-06
in O 0 8.691964126228413e-08
similarity O 0 2.2968073665197153e-07
with O 0 2.1633368874063308e-08
regard O 0 5.720762885630393e-08
to O 0 1.2603196353211388e-07
age O 0 3.4585860930747003e-07
at O 0 7.004653070907807e-06
disease O 0 0.0001312699168920517
onset O 0 4.232800165482331e-06
and O 0 2.6254783236367985e-08
all O 0 1.7703134513880059e-09
of O 0 6.646686756539566e-09
the O 0 6.426140544135706e-07
disease O 0 0.00021817257220391184
severity O 0 1.5794004866620526e-05
scores O 0 9.454886367166182e-07
assessed O 0 2.7861851776833646e-06
were O 0 1.550110084735934e-07
noted O 0 1.7705397681311297e-07
in O 0 3.610901160300273e-07
disease O 0 0.0003838031261693686
- O 0 0.00028715698863379657
concordant O 0 0.006011181510984898
MZ O 1 0.8173921704292297
twins O 0 5.542662620428018e-05
compared O 0 1.346645035482652e-06
with O 0 3.3062985949072754e-07
concordant O 0 0.0010782008757814765
DZ O 1 0.9754093289375305
twins O 0 0.0003366276796441525
. O 0 4.387568424135679e-06

HLA O 0 0.25651103258132935
- O 0 0.00028517571627162397
B27 O 0 1.0098660823132377e-05
and O 0 1.9215194413391146e-07
B60 O 0 3.828601506938867e-07
were O 0 3.547687654759102e-08
associated O 0 1.7418280151559884e-08
with O 0 6.892267201408231e-09
the O 0 3.960522860779747e-07
disease O 0 2.607691931189038e-05
in O 0 6.478975222989902e-08
probands O 0 2.7551450330065563e-05
, O 0 6.410507324972059e-08
and O 0 7.83434028761576e-09
the O 0 7.288548431461095e-09
rate O 0 3.2787482950880076e-07
of O 0 2.734051918196201e-08
disease O 0 1.1961868949583732e-05
concordance O 0 5.036581569584087e-07
was O 0 4.6505749651259976e-07
significantly O 0 2.8983794209125335e-07
increased O 0 5.722967699739456e-08
among O 0 3.5071320070301226e-08
DZ O 0 0.0005566061590798199
twin O 0 9.828894690144807e-06
pairs O 0 2.181681679758185e-07
in O 0 3.364846890008266e-08
which O 0 2.4368837614474614e-08
the O 0 3.723452124404503e-08
co O 0 4.554943006951362e-05
- O 0 2.5000252207973972e-05
twin O 0 2.8595772164408118e-05
was O 0 9.561886145093013e-07
positive O 0 9.859751237684122e-09
for O 0 2.0360877428515778e-09
both O 0 1.1016374479311253e-08
B27 O 0 1.631810050639615e-06
and O 0 6.61528474665829e-07
DR1 O 0 0.005163976922631264
. O 0 9.90332637229585e-07

Additive O 0 8.25895622256212e-05
genetic O 0 0.0002542116562835872
effects O 0 2.1744586774730124e-05
were O 0 2.5045997631423234e-07
estimated O 0 1.7971782995118701e-07
to O 0 3.7459333412925844e-08
contribute O 0 3.064247877659909e-08
97 O 0 5.285787452180557e-08
% O 0 1.1002073918575661e-08
of O 0 2.1564068308776996e-09
the O 0 1.772750657380584e-08
population O 0 8.356923331120925e-08
variance O 0 3.5821278743242146e-07
. O 0 6.236987815100292e-07

CONCLUSION O 0 2.7653373763314448e-05
Susceptibility O 0 0.00022187306603882462
to O 0 2.2758893010177417e-06
AS B-Disease 1 0.7838751077651978
is O 0 1.4293526362507691e-07
largely O 0 7.454752193325476e-08
genetically O 0 1.344616180176672e-06
determined O 0 5.006650667382928e-07
, O 0 2.4932647946229736e-08
and O 0 2.3211343957996178e-08
the O 0 2.6160158483889973e-08
environmental O 0 2.1009780937220057e-07
trigger O 0 1.7001717651510262e-06
for O 0 6.06894090537935e-08
the O 0 7.812242870386399e-07
disease O 0 5.5030413932399824e-05
is O 0 5.968882277329612e-08
probably O 0 4.0450780147693877e-07
ubiquitous O 0 5.290213266562205e-06
. O 0 1.144755970017286e-06

HLA O 0 0.07551680505275726
- O 0 0.00027680580387823284
B27 O 0 1.1583721970964689e-05
accounts O 0 5.47199249467667e-07
for O 0 6.606670321929187e-09
a O 0 1.1255442800006676e-08
minority O 0 5.126327806692643e-08
of O 0 2.435869506101085e-09
the O 0 1.7788066131174674e-08
overall O 0 8.488585081067868e-06
genetic O 0 4.315633123042062e-05
susceptibility O 0 3.7587524275295436e-05
to O 0 1.5273446933861123e-06
AS B-Disease 1 0.9848734140396118
. O 0 2.483455546098412e-06

Cell O 0 0.0007462543435394764
cycle O 0 0.00012100808089599013
- O 0 4.131974856136367e-05
dependent O 0 3.5686157389136497e-06
colocalization O 0 4.631013780453941e-06
of O 0 2.806752164019599e-08
BARD1 O 0 1.3951750588603318e-05
and O 0 1.2756794376400649e-07
BRCA1 O 0 2.3525715278083226e-06
proteins O 0 2.931632181457644e-08
in O 0 7.412849889476547e-09
discrete O 0 6.691234375466593e-07
nuclear O 0 1.886571953946259e-05
domains O 0 5.892320132261375e-06
. O 0 1.6308842987200478e-06

Germ O 0 0.004912377335131168
- O 0 0.00032983903656713665
line O 0 2.698185562621802e-05
mutations O 0 3.892042514053173e-06
of O 0 9.531731848255731e-09
the O 0 3.0012511587074187e-08
BRCA1 O 0 1.839309697970748e-05
gene O 0 2.1664438918378437e-06
predispose O 0 2.951167061837623e-06
women O 0 8.038875165539139e-08
to O 0 1.702783691825971e-08
early O 0 1.0045113185697119e-06
- O 0 0.4187765419483185
onset O 0 0.48712044954299927
breast B-Disease 1 0.9997276663780212
and I-Disease 1 0.9943674206733704
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999990463256836
by O 0 4.4702307633315286e-08
compromising O 0 1.5411202411996783e-06
the O 0 2.8443363220276296e-08
genes O 0 4.729129727820691e-07
presumptive O 0 5.5773762142052874e-05
function O 0 1.065172980929674e-07
as O 0 3.722230701441731e-08
a O 0 1.2082064131391235e-06
tumor B-Disease 0 0.00019871912081725895
suppressor O 0 0.0002702541241887957
. O 0 4.6246186684584245e-06

Although O 0 1.7775927290131222e-06
the O 0 5.7271936526603895e-08
biochemical O 0 8.323928568643169e-07
properties O 0 1.917991085065296e-06
of O 0 4.1061067435066434e-08
BRCA1 O 0 0.00011376297334209085
polypeptides O 0 2.8389165436237818e-06
are O 0 3.578753648980637e-08
not O 0 1.7809929531154012e-08
understood O 0 2.3135230620141556e-08
, O 0 2.351586703142061e-09
their O 0 5.857541118814424e-09
expression O 0 3.68323220811817e-08
pattern O 0 5.872175279364455e-07
and O 0 4.467520042794604e-08
subcellular O 0 1.628312247703434e-06
localization O 0 1.10176563339337e-06
suggest O 0 7.452107553262977e-08
a O 0 1.7801099261305353e-08
role O 0 3.858080788177176e-08
in O 0 3.546375282326153e-08
cell O 0 4.005077789770439e-05
- O 0 6.442734593292698e-05
cycle O 0 6.128536188043654e-05
regulation O 0 2.453988827255671e-06
. O 0 7.064535338940914e-07

When O 0 6.350816420308547e-06
resting O 0 1.1480542525532655e-05
cells O 0 1.8344271666137502e-06
are O 0 3.829860872883728e-08
induced O 0 1.3834383025823627e-06
to O 0 1.0784814463704606e-07
proliferate O 0 2.7787764338427223e-06
, O 0 1.2770299484543557e-08
the O 0 3.3045373104556575e-09
steady O 0 3.356360593897989e-07
- O 0 3.196626323642704e-07
state O 0 1.0939321448688588e-08
levels O 0 7.2000085893364485e-09
of O 0 2.2034849500585096e-09
BRCA1 O 0 2.553541207817034e-06
increase O 0 5.860393770262817e-08
in O 0 9.385011878748628e-09
late O 0 3.081244699387753e-07
G1 O 0 8.824565156828612e-06
and O 0 1.7123198858826072e-08
reach O 0 2.5779106849199707e-08
a O 0 4.481431403746683e-08
maximum O 0 8.773948678708621e-08
during O 0 1.3093506368022645e-07
S O 0 0.0001866408420028165
phase O 0 3.94703829442733e-06
. O 0 1.0610258414089913e-06

Moreover O 0 4.089430512976833e-05
, O 0 6.534929752888274e-07
in O 0 1.840766117311432e-07
S O 0 0.00017156255489680916
phase O 0 1.02469266494154e-06
cells O 0 1.1626890454863315e-06
, O 0 3.644142410053064e-08
BRCA1 O 0 4.574682407110231e-06
polypeptides O 0 4.983014605386415e-07
are O 0 2.123591436031802e-08
hyperphosphorylated O 0 2.388029088251642e-06
and O 0 5.8535125191383486e-08
accumulate O 0 3.698019099829253e-07
into O 0 5.528744040361744e-08
discrete O 0 1.7423534472982283e-06
subnuclear O 0 7.616992661496624e-05
foci O 0 7.210098556242883e-05
termed O 0 2.432801920804195e-05
" O 0 3.1241388569469564e-06
BRCA1 O 0 7.68347381381318e-05
nuclear O 0 2.3326314476435073e-05
dots O 0 0.00012888699711766094
. O 0 4.466337941266829e-06

" O 0 0.00015298437210731208
BRCA1 O 0 0.005103293340653181
associates O 0 0.03242594003677368
in O 0 5.998539336360409e-07
vivo O 0 8.161545702023432e-05
with O 0 3.069817111622797e-08
a O 0 6.162896966088738e-07
structurally O 0 0.00012275240442249924
related O 0 1.1130732673336752e-06
protein O 0 5.621817308565369e-06
termed O 0 3.1213399779517204e-05
BARD1 O 0 0.0008231479441747069
. O 0 1.991201997952885e-06

Here O 0 3.554465592969791e-06
we O 0 2.062268151803437e-07
show O 0 9.154943825251394e-08
that O 0 4.859259217226963e-09
the O 0 3.989074848220753e-09
steady O 0 6.553727871505544e-07
- O 0 1.0493347417650511e-06
state O 0 2.1837836428062474e-08
levels O 0 9.929711275447062e-09
of O 0 1.8607124729896896e-09
BARD1 O 0 5.879168838873738e-06
, O 0 1.7253418249651986e-08
unlike O 0 5.604933850378302e-09
those O 0 1.4978046580793603e-09
of O 0 4.369658412883837e-09
BRCA1 O 0 6.196061440277845e-05
, O 0 1.8056617534512043e-07
remain O 0 7.633006759988348e-08
relatively O 0 9.158922509300282e-09
constant O 0 2.551626820945785e-08
during O 0 5.370818811911704e-08
cell O 0 5.3713065426563844e-05
cycle O 0 9.949225932359695e-05
progression O 0 0.00011811815784312785
. O 0 2.864163889171323e-06

However O 0 7.488207302230876e-06
, O 0 4.52033305009536e-07
immunostaining O 0 1.5319385056500323e-05
revealed O 0 6.742042842233786e-06
that O 0 3.204408827173211e-08
BARD1 O 0 1.1631587767624296e-05
resides O 0 3.076027610404708e-07
within O 0 2.1466780353307513e-08
BRCA1 O 0 2.2826319764135405e-05
nuclear O 0 6.597300398425432e-06
dots O 0 2.2218873709789477e-05
during O 0 6.77967022966186e-07
S O 0 3.253975592087954e-05
phase O 0 8.102172444068856e-08
of O 0 3.963607220214271e-09
the O 0 2.3939108473314263e-08
cell O 0 1.3669486179423984e-05
cycle O 0 5.085986686026445e-06
, O 0 6.863474766305444e-08
but O 0 1.5932593910861215e-08
not O 0 4.992020130600849e-09
during O 0 5.7525348928777476e-09
the O 0 1.2626193424125631e-08
G1 O 0 2.2798129066359252e-05
phase O 0 9.282859423365153e-07
. O 0 4.864900233769731e-07

Nevertheless O 0 9.879522258415818e-05
, O 0 1.0173440614380524e-06
BARD1 O 0 5.4424188419943675e-05
polypeptides O 0 5.958956990070874e-06
are O 0 3.7339848546480425e-08
found O 0 2.2278575428913427e-08
exclusively O 0 1.2683735839402743e-08
in O 0 6.154407206082624e-09
the O 0 7.845914140602872e-09
nuclear O 0 2.673452570434165e-07
fractions O 0 1.8188654138384663e-08
of O 0 1.609624655785069e-09
both O 0 6.0552487468612526e-09
G1 O 0 9.687001693237107e-06
- O 0 3.5226598811277654e-06
and O 0 2.6604229219628905e-07
S O 0 8.089107723208144e-05
- O 0 4.508533493208233e-06
phase O 0 1.614891971257748e-06
cells O 0 4.989794433640782e-06
. O 0 4.2880628825514577e-07

Therefore O 0 4.0127060856320895e-06
, O 0 2.982955038532964e-07
progression O 0 3.2406719583377708e-06
to O 0 2.457571497416211e-07
S O 0 0.0003093890263698995
phase O 0 9.991208571591415e-07
is O 0 2.4724847946799855e-08
accompanied O 0 2.6666098662531112e-08
by O 0 2.0285830792943216e-09
the O 0 3.541304138821033e-09
aggregation O 0 7.564567994222671e-08
of O 0 7.422697123615762e-09
nuclear O 0 3.06474157696357e-06
BARD1 O 0 1.4929836652299855e-05
polypeptides O 0 5.440998620542814e-07
into O 0 2.0610609396953805e-07
BRCA1 O 0 5.837765638716519e-05
nuclear O 0 8.906813491194043e-06
dots O 0 8.154902025125921e-05
. O 0 3.834711151284864e-06

This O 0 2.314389803359518e-06
cell O 0 2.5997414923040196e-05
cycle O 0 2.629555092426017e-05
- O 0 4.1977262299042195e-05
dependent O 0 1.543085090816021e-06
colocalization O 0 3.009970669154427e-06
of O 0 2.0258077881862846e-08
BARD1 O 0 6.65955594740808e-05
and O 0 6.788326913920173e-07
BRCA1 O 0 2.668226807145402e-05
indicates O 0 6.893111503813998e-08
a O 0 1.35410189727736e-08
role O 0 2.1288878215841578e-08
for O 0 1.3456260994360036e-08
BARD1 O 0 3.7107143725734204e-05
in O 0 2.3587445241446403e-07
BRCA1 O 0 0.0005378592759370804
- O 0 0.000888106063939631
mediated O 0 0.029834013432264328
tumor B-Disease 0 0.0039008527528494596
suppression O 0 7.6084133979748e-06
. O 0 7.952805276545405e-07

Ethnic O 0 1.3889501133235171e-05
differences O 0 6.012427093082806e-06
in O 0 1.433710536957733e-07
the O 0 2.1561697849392658e-07
HFE O 0 0.00013998457870911807
codon O 0 1.8122524124919437e-05
282 O 0 1.0477734576852527e-05
( O 0 1.2848111055063782e-06
Cys O 0 0.014437501318752766
/ O 0 0.0005219433805905282
Tyr O 0 0.0001063723539118655
) O 0 7.628057119291043e-07
polymorphism O 0 1.404251997882966e-05
. O 0 2.0298864455980947e-06

Recent O 0 1.1864718544529751e-05
studies O 0 1.3569688235293142e-06
have O 0 1.5198152425455191e-07
shown O 0 1.8736805031949189e-06
that O 0 0.00010732663940871134
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.43534573912620544
HH B-Disease 1 0.9968384504318237
) O 0 7.443327945111378e-07
is O 0 5.3445869951929126e-08
likely O 0 1.7052774126113945e-07
to O 0 1.2360783330223057e-07
be O 0 1.8639391896613233e-07
caused O 0 3.08345533994725e-07
by O 0 7.129221657464768e-09
homozygosity O 0 2.2005874598107766e-06
for O 0 4.673870623861376e-09
a O 0 5.473219033547139e-08
Cys282Tyr O 0 5.617497663479298e-06
mutation O 0 3.9277722407859983e-07
in O 0 7.400813739621981e-09
the O 0 3.4059329578894904e-08
HFE O 0 2.4998749722726643e-05
gene O 0 2.3894369860499864e-06
located O 0 4.144259833083197e-07
4 O 0 1.4607589946535882e-06
. O 0 9.428611633666151e-07

5 O 0 2.3490370949730277e-05
Mb O 0 0.000140918287797831
telomeric O 0 0.0001063193121808581
to O 0 1.6701058029866545e-06
HLA O 0 0.0003336688387207687
- O 0 3.142282002954744e-05
A O 0 7.77808509155875e-06
. O 0 1.4023365793036646e-06

Population O 0 6.0201437008799985e-06
studies O 0 2.166744366149942e-07
of O 0 1.064810906115099e-08
this O 0 1.125718185335245e-08
polymorphism O 0 6.595768695660809e-07
are O 0 8.411307206301899e-09
facilitated O 0 1.6917583423037286e-07
by O 0 8.7320728425766e-09
the O 0 1.1894899287767657e-08
fact O 0 1.0346004941652609e-08
that O 0 2.6089537197293566e-09
the O 0 5.369894306994638e-09
Cys282Tyr O 0 4.378222456580261e-06
mutation O 0 6.844975359854288e-07
creates O 0 5.1341462636855795e-08
a O 0 5.917859269288783e-08
Rsal O 0 3.93145910493331e-06
restriction O 0 3.3416435485378315e-07
site O 0 1.7139101373686572e-06
. O 0 8.630244110463536e-07

We O 0 2.911521278292639e-06
have O 0 1.3330911485809338e-07
studied O 0 7.330237394853611e-08
the O 0 5.277909309597817e-08
codon O 0 4.2298142943764105e-06
282 O 0 5.132382284500636e-06
( O 0 9.521693868919101e-07
Cys O 0 0.0036438361275941133
/ O 0 0.00029104662826284766
Tyr O 0 2.3481301468564197e-05
) O 0 4.001818965093662e-08
polymorphism O 0 1.067098693852131e-07
in O 0 8.967633746692627e-09
different O 0 9.16808051698581e-09
ethnic O 0 3.0089609026617836e-07
groups O 0 1.6139267700054916e-07
. O 0 8.867056635608606e-07

In O 0 2.28999306273181e-06
agreement O 0 4.955943495588144e-07
with O 0 4.4917431551994014e-08
previous O 0 7.211610295598803e-07
observations O 0 7.067499723234505e-07
the O 0 6.618427761395651e-08
Tyr O 0 4.425355200510239e-06
allele O 0 1.292764409299707e-06
appeared O 0 6.369057246047305e-07
to O 0 1.4394395009276195e-08
be O 0 1.0551208795561706e-08
rare O 0 3.413392590800868e-08
or O 0 3.2000059491110733e-07
absent O 0 7.826083106010628e-07
in O 0 6.740872748878246e-08
Asiatic O 0 2.527045353417634e-06
( O 0 1.2782484404283423e-08
Indian O 0 3.815407989549158e-09
, O 0 3.880558541169421e-09
Chinese O 0 6.646902139806343e-09
) O 0 3.561328654200224e-08
populations O 0 3.994003350271669e-07
. O 0 6.301438588707242e-07

The O 0 1.3877394167138846e-06
highest O 0 1.5711054857092677e-06
allele O 0 3.9736501094012056e-06
frequency O 0 3.779160351768951e-06
( O 0 5.114452150678517e-08
7 O 0 1.7445286459860654e-07
. O 0 1.0612445144886351e-08
5 O 0 6.92426169734972e-08
% O 0 3.6376423651063305e-08
) O 0 1.1572818259253381e-08
was O 0 5.344923579286842e-07
found O 0 1.5126258290365513e-07
in O 0 1.2373108404517552e-07
Swedes O 0 5.532122668228112e-05
. O 0 1.0772638461276074e-06

Saamis O 0 0.001627320540137589
( O 0 1.936019089043839e-06
2 O 0 4.374965101305861e-07
% O 0 8.816356711349727e-08
) O 0 1.3530899067859536e-08
and O 0 6.372410865651545e-08
Mordvinians O 0 4.8798297029861715e-06
( O 0 1.497374135794871e-08
1 O 0 2.9408562696175977e-08
. O 0 1.4394668568229463e-08
8 O 0 1.5999842162273126e-07
% O 0 2.5104531786723783e-08
) O 0 7.4388832871363775e-09
had O 0 2.8560143050526676e-07
significantly O 0 4.525202541572071e-07
lower O 0 2.4810736931613064e-07
frequencies O 0 1.5205864656309132e-07
of O 0 7.591391515404666e-09
the O 0 2.3566444440348278e-07
Tyr O 0 3.969116369262338e-05
allele O 0 1.81350224011112e-05
. O 0 8.823470238894515e-07

Comparisons O 0 7.100811671989504e-06
with O 0 2.2577724223538098e-07
allele O 0 1.4146729654385126e-06
frequencies O 0 6.230923759176221e-07
based O 0 5.124544486534433e-07
on O 0 1.9128287931380328e-06
prevalence O 0 3.1052393751451746e-05
estimates O 0 5.022124696552055e-06
of O 0 9.898438690925104e-08
HH B-Disease 0 0.47070369124412537
showed O 0 1.5048609384393785e-05
some O 0 5.959506221842048e-09
disagreements O 0 1.358238534976408e-07
with O 0 1.0603319111623932e-08
the O 0 2.7672985680737838e-08
RFLP O 0 1.67266080097761e-05
data O 0 1.8574070281829336e-06
, O 0 1.014868278303993e-08
particularly O 0 1.2734252763380027e-08
in O 0 4.5762828193574023e-08
Finns O 0 1.96675810002489e-05
. O 0 1.0670553365343949e-06

The O 0 2.5804299639275996e-06
newly O 0 4.016484581370605e-06
described O 0 3.9697333704680204e-06
HFE O 0 3.112173726549372e-05
marker O 0 1.6311161061821622e-06
provides O 0 2.5695358729649342e-08
a O 0 1.6290776727601042e-08
new O 0 3.5170931056427435e-08
approach O 0 7.219813369374606e-08
to O 0 1.963356766054858e-08
the O 0 6.5994911757627506e-09
screening O 0 7.37571852482688e-08
of O 0 1.1737207650241999e-08
HH B-Disease 0 0.0004468054976314306
as O 0 1.9054462541134853e-07
well O 0 1.752806078059166e-08
as O 0 1.2617622502375525e-08
studies O 0 3.0384699201135845e-09
of O 0 6.52282561297568e-10
the O 0 1.2411393690570094e-08
relationship O 0 1.0841159792107646e-07
between O 0 5.952954040822078e-08
the O 0 2.1425061902391462e-07
HFE O 0 9.169917029794306e-05
Tyr O 0 6.624648904107744e-06
allele O 0 1.061807211044652e-06
and O 0 3.9590304368175566e-08
different O 0 1.2391294035296596e-07
disorders O 0 0.004505744203925133
including O 0 5.6898093134805094e-06
cancer B-Disease 0 0.0023399374913424253

Autosomal B-Disease 1 0.9999017715454102
dominant I-Disease 1 0.9872937202453613
neurohypophyseal I-Disease 1 0.9999711513519287
diabetes I-Disease 1 0.9999994039535522
insipidus I-Disease 1 0.9940880537033081
associated O 0 1.1425666343711782e-05
with O 0 4.610442161379069e-08
a O 0 2.9151786407055624e-07
missense O 0 2.6355379304732196e-05
mutation O 0 1.6641168940623174e-06
encoding O 0 1.1020420060958713e-06
Gly23 O 0 5.864073318662122e-05
- O 0 0.00013742120063398033
- O 0 0.0004626438894774765
> O 0 9.980048162105959e-06
Val O 0 0.0002605759655125439
in O 0 6.702155133098131e-07
neurophysin O 0 0.0002548105549067259
II O 0 0.00012502966274041682
. O 0 1.5839503930692445e-06

Autosomal B-Disease 1 0.9999327659606934
dominant I-Disease 1 0.9941587448120117
neurohypophyseal I-Disease 1 0.9999805688858032
diabetes I-Disease 1 0.9999995231628418
insipidus I-Disease 1 0.9999039173126221
( O 0 7.326916238525882e-05
ADNDI B-Disease 0 0.020574558526277542
) O 0 1.3366600342124002e-06
is O 0 4.246237210736581e-07
an O 0 6.309518357738853e-05
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 0.00019824808987323195
by O 0 3.145452751596167e-07
progressive O 0 0.0003221464576199651
degeneration O 0 0.011297274380922318
of O 0 2.0694033153745295e-08
the O 0 4.913447781973446e-08
magnocellular O 0 6.449165994126815e-06
neurons O 0 2.5396204819116974e-06
of O 0 7.221614861663284e-09
the O 0 4.975473189006152e-08
hypothalamus O 0 1.7787118622436537e-06
leading O 0 4.2358831819910847e-07
to O 0 9.722698735004087e-08
decreased O 0 7.34803506929893e-07
ability O 0 1.4284828431243568e-08
to O 0 2.3114941072321926e-08
produce O 0 2.895981197070796e-07
the O 0 1.5900012328984303e-07
hormone O 0 2.1431530967674917e-06
arginine O 0 2.602613903945894e-06
vasopressin O 0 1.919681835715892e-06
( O 0 9.657143351660125e-08
AVP O 0 1.3738884263148066e-05
) O 0 1.4672201587018208e-07
. O 0 3.209021031125303e-07

Affected O 0 0.00010250041668768972
individuals O 0 7.823441023901978e-07
are O 0 7.491698283956794e-08
not O 0 1.160097866659271e-07
symptomatic O 0 7.933829692774452e-06
at O 0 7.979548172443174e-06
birth O 0 1.1429960977693554e-05
, O 0 1.3038530255471414e-07
but O 0 3.6751483634134274e-08
usually O 0 2.4670302423146495e-07
develop O 0 1.0110841685673222e-05
diabetes B-Disease 0 0.04062376171350479
insipidus I-Disease 0 0.00021791561448480934
at O 0 2.3454322217730805e-06
1 O 0 2.0887564460281283e-06
- O 0 7.636089867446572e-05
6 O 0 9.938647963281255e-06
yr O 0 8.784603414824232e-05
of O 0 5.308318051788774e-08
age O 0 5.167051995158545e-07
. O 0 4.797376504939166e-07

The O 0 1.2390376014081994e-06
genetic O 0 5.520910690393066e-06
locus O 0 2.8794570425816346e-06
of O 0 4.4844242097497045e-08
the O 0 9.934060472005513e-07
disease O 0 0.00020886397396679968
is O 0 6.171406852217842e-08
the O 0 8.320295563635227e-08
AVP O 0 0.00023845801479183137
- O 0 0.0002876233484130353
neurophysin O 0 0.00036478752736002207
II O 0 6.372106145136058e-05
( O 0 4.45092638301503e-08
NPII O 0 4.43500493929605e-06
) O 0 1.170394270388897e-08
gene O 0 1.0193557642423912e-07
, O 0 1.598144372394472e-08
and O 0 7.33260065999275e-08
mutations O 0 3.566740815585945e-06
that O 0 1.6407470582180395e-07
cause O 0 9.970298151529278e-07
ADNDI B-Disease 0 0.000840212102048099
have O 0 4.3280630279696197e-07
been O 0 1.4016343641287676e-07
found O 0 4.192142455394787e-08
in O 0 2.935989673602535e-09
both O 0 1.9609680546039954e-09
the O 0 3.4548850447180257e-09
signal O 0 1.495913153348738e-07
peptide O 0 1.2912973801348926e-08
of O 0 1.1137916144932092e-09
the O 0 9.066144279756827e-09
prepro O 0 1.1416386769269593e-05
- O 0 1.1196943887625821e-05
AVP O 0 3.9915114030009136e-05
- O 0 2.6105537926923716e-06
NPII O 0 9.079712981474586e-06
precursor O 0 6.138945991551736e-07
and O 0 2.1557086782308943e-08
within O 0 4.755469262818224e-08
NPII O 0 2.6193038138444535e-05
itself O 0 4.450906999409199e-06
. O 0 7.399842161248671e-07

An O 0 7.940468094602693e-06
affected O 0 6.65791958454065e-06
girl O 0 5.982319999020547e-05
who O 0 2.770166702248389e-06
presented O 0 5.47963736607926e-07
at O 0 6.760095061508764e-07
9 O 0 8.78142941473925e-07
months O 0 1.0330963107207936e-07
of O 0 3.043144625181071e-09
age O 0 1.9130565576119807e-08
and O 0 6.742350677768627e-08
her O 0 1.8048541505777393e-06
similarly O 0 5.993981631036149e-07
affected O 0 9.657861710365978e-08
younger O 0 2.5798541969379585e-07
brother O 0 1.1185139783265186e-06
and O 0 2.1859615628727624e-07
father O 0 8.902609920369287e-07
were O 0 3.6345976894835985e-08
all O 0 1.6635982591495235e-09
found O 0 3.113340341087678e-08
to O 0 1.3851457758562447e-08
have O 0 3.845295637461277e-09
a O 0 4.128795083602199e-08
novel O 0 6.974922825975227e-07
missense O 0 2.1395066141849384e-05
mutation O 0 2.470397475917707e-06
( O 0 2.216219385786644e-08
G1758 O 0 1.2559800097733387e-06
- O 0 2.8463218768592924e-05
- O 0 0.0002865913847927004
> O 0 1.9334247554070316e-06
T O 0 1.5859994164202362e-05
) O 0 2.0746346862665632e-09
encoding O 0 4.3074801503451e-09
the O 0 1.1145758760378044e-09
amino O 0 2.1734283706109636e-08
acid O 0 5.8001223379733347e-08
substitution O 0 3.764203881928552e-08
Gly23 O 0 1.4935396848159144e-06
- O 0 5.346786110749235e-06
- O 0 2.876655889849644e-05
> O 0 1.8623397863848368e-06
Val O 0 4.027069007861428e-05
within O 0 2.779375734007772e-07
NPII O 0 0.00014171021757647395
. O 0 1.1582875458771014e-06

The O 0 2.3346890429820633e-06
mutation O 0 2.223803494416643e-05
was O 0 1.982603180294973e-06
confirmed O 0 8.173663559318811e-07
by O 0 2.404124010979558e-08
restriction O 0 3.729910247329826e-07
endonuclease O 0 2.4847326130839065e-05
analysis O 0 3.315371031931136e-06
. O 0 1.57292265612341e-06

A O 0 1.6162837709998712e-05
T1 O 0 0.0011135897366330028
- O 0 1.7189851860166527e-05
weighted O 0 1.2037072565362905e-06
magnetic O 0 1.2551107602121192e-06
resonance O 0 9.970287919713883e-07
imaging O 0 2.7891312129213475e-05
of O 0 1.8783213207029803e-08
the O 0 1.793952293382972e-07
fathers O 0 6.428398137359181e-06
pituitary O 0 2.5481756892986596e-05
gland O 0 2.3471495296689682e-05
demonstrates O 0 2.0091390240395413e-07
an O 0 2.8163508858369823e-08
attenuated O 0 3.0035478630452417e-05
posterior O 0 0.00017921395192388445
pituitary O 0 0.00031719804974272847
bright O 0 7.048733095871285e-06
spot O 0 2.8864658816019073e-05
. O 0 2.2236476979742292e-06

This O 0 2.4425878564215964e-06
mutation O 0 3.490881499601528e-05
may O 0 3.26648773807392e-06
be O 0 1.1193314719548653e-08
valuable O 0 1.4580970209010502e-08
for O 0 4.942187548095944e-09
developing O 0 2.7960123105685852e-08
models O 0 3.675899051813758e-07
of O 0 3.2934394766925834e-08
dominantly B-Disease 0 0.00017376801406498998
inherited I-Disease 1 0.5907205939292908
neurodegeneration I-Disease 1 1.0
, O 0 7.267769888130715e-07
as O 0 1.2779851843447432e-08
the O 0 2.915665486824537e-09
early O 0 9.138823031662469e-08
age O 0 1.2675900329384149e-08
of O 0 4.061596836635317e-09
onset O 0 2.539082743169274e-06
of O 0 1.6093405008632544e-07
symptoms O 0 2.23313327296637e-05
suggests O 0 8.960096664623052e-08
that O 0 8.33938962330194e-09
this O 0 9.687930457857874e-09
mutation O 0 1.928732217493234e-06
may O 0 7.230706842165091e-07
be O 0 1.3308728341598908e-08
particularly O 0 1.4731391217992496e-08
deleterious O 0 1.4955893448131974e-06
to O 0 2.9334053408547334e-08
the O 0 8.267632267688896e-08
magnocellular O 0 1.9084240193478763e-05
neuron O 0 4.881377753918059e-05
. O 0 1.6249229872755677e-07
. O 0 5.953805271019519e-07

Frequent O 0 0.0003769212926272303
inactivation O 0 0.001153895165771246
of O 0 8.933269555200241e-07
PTEN O 0 0.00355453509837389
/ O 0 0.0011245517525821924
MMAC1 O 0 0.0009382536518387496
in O 0 2.0457311620702967e-05
primary O 1 0.5305364727973938
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 1.0156553798879031e-05

Sporadic B-Disease 1 0.9568371176719666
prostate I-Disease 1 0.999998927116394
carcinoma I-Disease 1 1.0
is O 0 3.6874471334158443e-06
the O 0 1.9155359964884155e-08
most O 0 1.635004487354763e-08
common O 0 2.464194608364778e-07
male B-Disease 0 3.6857666145806434e-06
cancer I-Disease 0 4.867949428444263e-06
in O 0 5.518521639658047e-09
the O 0 8.556648722901627e-09
Western O 0 2.4169059997802833e-07
world O 0 3.5678937138072797e-07
, O 0 1.2375511282414209e-08
yet O 0 2.931859865995534e-09
many O 0 1.8666905521325106e-10
of O 0 2.7520732914787516e-10
the O 0 4.173774659221863e-09
major O 0 3.822672312026043e-08
genetic O 0 4.722459721051564e-07
events O 0 1.2757738865332158e-08
involved O 0 2.2204421412652664e-08
in O 0 7.191005124695948e-09
the O 0 2.5387281610278478e-08
progression O 0 1.7237996416952228e-06
of O 0 4.826864241636031e-09
this O 0 7.97444528188862e-08
often O 0 6.989032044657506e-06
fatal O 1 0.9143161177635193
cancer B-Disease 0 0.0007508486742153764
remain O 0 3.3254900699830614e-07
to O 0 6.058068890979484e-08
be O 0 3.6428852467906836e-07
elucidated O 0 4.7958594223018736e-05
. O 0 1.5251105196512071e-06

Numerous O 0 1.7054648196790367e-05
cytogenetic O 0 0.0015651226276531816
and O 0 8.017015716177411e-06
allelotype O 0 0.0005273764254525304
studies O 0 1.7806247569751577e-06
have O 0 3.181174008659582e-07
reported O 0 9.82980418484658e-06
frequent O 0 2.064945874735713e-06
loss O 0 4.47397678726702e-06
of O 0 2.8253685613321977e-08
heterozygosity O 0 4.3171523429919034e-05
on O 0 1.718709791020956e-05
chromosomal O 0 0.18344253301620483
arm O 0 0.0002487019810359925
10q O 0 1.4026004464540165e-05
in O 0 1.7895981727633625e-06
sporadic B-Disease 0 0.14964978396892548
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
. O 0 3.4159729693783447e-06

Deletion O 0 0.0007183459820225835
mapping O 0 0.00016102491645142436
studies O 0 2.8099125302105676e-06
have O 0 2.511845309527416e-07
unambiguously O 0 1.399923894496169e-05
identified O 0 1.526388018646685e-06
a O 0 1.1747179229359972e-07
region O 0 1.2162607845311868e-06
of O 0 4.2504510133767326e-08
chromosome O 0 4.502810043049976e-05
10q23 O 0 1.001853547677456e-06
to O 0 7.801999402090587e-08
be O 0 8.431674025644043e-09
the O 0 4.532369590748431e-09
minimal O 0 7.593827433538536e-08
area O 0 2.806897327900515e-07
of O 0 8.995937861300263e-08
loss O 0 1.6849096937221475e-05
. O 0 1.572334554111876e-06

A O 0 6.076926638343139e-06
new O 0 2.4376986402785406e-06
tumor B-Disease 0 6.547281373059377e-05
suppressor O 0 3.6379980883793905e-05
gene O 0 1.3284809028846212e-05
, O 0 3.9821219388613827e-07
PTEN O 0 0.000701167737133801
/ O 0 0.0006196473259478807
MMAC1 O 0 0.0005838872166350484
, O 0 4.6131341946420434e-07
was O 0 6.197150810294261e-07
isolated O 0 7.116534561646404e-07
recently O 0 1.1249239832977764e-06
at O 0 6.850905975852584e-08
this O 0 4.4603405413568e-09
region O 0 2.4292876332765445e-07
of O 0 1.4022409011715808e-08
chromosome O 0 5.335911919246428e-05
10q23 O 0 6.761048894077248e-07
and O 0 4.6083499682936235e-08
found O 0 2.51600411615982e-08
to O 0 1.3327169590127141e-08
be O 0 7.421479875091563e-09
inactivated O 0 2.7228216126218285e-08
by O 0 1.878657229781311e-09
mutation O 0 1.4419762806028302e-07
in O 0 4.815023046944589e-08
three O 0 6.86267449054867e-05
prostate B-Disease 1 1.0
cancer I-Disease 1 0.9999957084655762
cell O 0 0.00022743814042769372
lines O 0 0.00016281820717267692
. O 0 2.7050100470660254e-06

We O 0 1.2814880392397754e-05
screened O 0 4.3951571569778025e-05
80 O 0 3.419940549065359e-05
prostate B-Disease 1 0.9512779712677002
tumors I-Disease 1 0.999998927116394
by O 0 2.5525886826471833e-07
microsatellite O 0 1.9600061932578683e-05
analysis O 0 8.154976853802509e-07
and O 0 3.0354016189448885e-07
found O 0 6.941888841538457e-07
chromosome O 0 2.3027714632917196e-05
10q23 O 0 1.0326506298952154e-06
to O 0 6.778532934959003e-08
be O 0 1.6766788846211966e-08
deleted O 0 8.979358767646772e-07
in O 0 7.466648099807571e-08
23 O 0 6.523030720018141e-07
cases O 0 1.2220283451824798e-07
. O 0 4.542922624750645e-07

We O 0 2.9749203349638265e-06
then O 0 8.253358174670211e-08
proceeded O 0 6.186492385040765e-08
with O 0 3.248592728155586e-09
sequence O 0 2.031863921558852e-08
analysis O 0 1.9408901152928593e-08
of O 0 1.4364053280147004e-09
the O 0 1.800423454767497e-08
entire O 0 6.355630262078193e-07
PTEN O 0 0.0004654840740840882
/ O 0 3.701510649989359e-05
MMAC1 O 0 2.6833433366846293e-05
coding O 0 3.071080209338106e-05
region O 0 3.015984475496225e-06
and O 0 1.3598274506421149e-07
tested O 0 1.5320654256356647e-07
for O 0 6.754293568889125e-09
homozygous O 0 1.9293823072530358e-07
deletion O 0 2.1215170420418872e-07
with O 0 4.7743524689281e-09
new O 0 1.2151785711012053e-07
intragenic O 0 7.757076673442498e-06
markers O 0 1.5509708646277431e-06
in O 0 2.2502140595292985e-08
these O 0 6.199175395238399e-09
23 O 0 9.266251765893685e-08
cases O 0 6.285794551530444e-09
with O 0 6.772250316089412e-09
10q23 O 0 6.65791958454065e-06
loss O 0 4.029129740956705e-06
of O 0 7.386897493688593e-08
heterozygosity O 0 0.00012299235095269978
. O 0 3.1914098599372664e-06

The O 0 6.27883537163143e-07
identification O 0 3.557011893917661e-07
of O 0 1.0544066952888898e-08
the O 0 1.8325716055755947e-08
second O 0 5.945515795247047e-07
mutational O 0 1.4226797020455706e-06
event O 0 2.746476468473702e-07
in O 0 5.1663178624039574e-08
10 O 0 5.241923162202511e-08
( O 0 1.0226290036996488e-08
43 O 0 9.236589448846644e-08
% O 0 7.246578093145217e-08
) O 0 9.282363748752687e-07
tumors B-Disease 1 0.9999991655349731
establishes O 0 2.7536636480363086e-05
PTEN O 0 0.0007678839028812945
/ O 0 4.914661985822022e-05
MMAC1 O 0 1.803167469915934e-05
as O 0 2.148115640920878e-08
a O 0 1.9916218008120268e-08
main O 0 4.2826604840229265e-07
inactivation O 0 5.147165666130604e-06
target O 0 2.6005449171861983e-07
of O 0 1.1788991116645775e-08
10q O 0 1.5341577181970933e-06
loss O 0 4.304852154746186e-06
in O 0 1.0750450201157946e-06
sporadic B-Disease 1 0.7987825274467468
prostate I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 3.5550007737583655e-07
. O 0 7.801953074704215e-07

Risk O 0 0.0010303888702765107
reversals O 0 8.017954678507522e-05
in O 0 3.805192250183609e-07
predictive O 0 1.4090599506744184e-05
testing O 0 8.801419426163193e-06
for O 0 4.127702413825318e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 0.9999992847442627
. O 0 6.795984518248588e-06

The O 0 4.90697630084469e-07
first O 0 2.1352038004351925e-07
predictive O 0 2.9389100291155046e-06
testing O 0 2.2642032035946613e-06
for O 0 2.7971220333711244e-05
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
( O 0 2.1134001144673675e-06
HD B-Disease 0 0.021275991573929787
) O 0 1.7983219890993496e-07
was O 0 8.060037544055376e-07
based O 0 1.3572234536241012e-07
on O 0 1.9473131374070363e-07
analysis O 0 4.629988481497094e-08
of O 0 3.551626326370183e-09
linked O 0 5.096105269331019e-06
polymorphic O 0 2.517572511351318e-06
DNA O 0 5.4540719247597735e-06
markers O 0 1.739011736390239e-06
to O 0 1.4897997857588052e-07
estimate O 0 3.1388469778903527e-06
the O 0 1.4523098279539681e-08
likelihood O 0 6.226718340940351e-08
of O 0 5.009131331945582e-09
inheriting O 0 7.272956281667575e-07
the O 0 8.537661244645278e-08
mutation O 0 7.322906867557322e-07
for O 0 6.065469193572426e-08
HD B-Disease 0 0.0002348546258872375
. O 0 1.810137518987176e-06

Limits O 0 5.396600499807391e-06
to O 0 2.374145111616599e-07
accuracy O 0 7.778973554195545e-07
included O 0 2.07276080743668e-08
recombination O 0 5.955770987497999e-08
between O 0 9.714352877665533e-09
the O 0 1.1850853631756308e-08
DNA O 0 8.490872573929664e-07
markers O 0 1.0676316151148058e-06
and O 0 7.833566684212201e-08
the O 0 1.3281822752730932e-08
mutation O 0 5.967698371023289e-07
, O 0 2.609388083385511e-08
pedigree O 0 4.690340915658453e-07
structure O 0 5.956372319815273e-07
, O 0 5.3880668815509125e-08
and O 0 2.9438981030693867e-08
whether O 0 9.35882482622219e-09
DNA O 0 3.037805527128512e-07
samples O 0 6.144181696754458e-08
were O 0 5.347429166135953e-09
available O 0 5.4745110666942765e-09
from O 0 4.793825336690816e-09
family O 0 9.827311231447311e-08
members O 0 1.56416106733559e-07
. O 0 3.9658104356021795e-07

With O 0 4.340326995588839e-07
direct O 0 8.133710593938304e-07
tests O 0 2.1509983127998566e-07
for O 0 8.63732374511983e-09
the O 0 2.596811832233925e-08
HD B-Disease 0 8.562325820093974e-05
mutation O 0 7.45240527066926e-07
, O 0 2.131935339377833e-08
we O 0 9.351045271444036e-09
have O 0 4.651158125312804e-09
assessed O 0 7.76848523287299e-08
the O 0 1.515296155218948e-08
accuracy O 0 2.8016979740641546e-06
of O 0 2.833506762556226e-08
results O 0 1.04132766409748e-06
obtained O 0 8.50233234928055e-08
by O 0 4.6227328631687215e-09
linkage O 0 5.547418595597264e-07
approaches O 0 3.1869524264038773e-07
when O 0 6.941584729247552e-08
requested O 0 3.369926915297583e-08
to O 0 3.5495965278187214e-08
do O 0 1.927417514480112e-08
so O 0 3.2858893384002386e-09
by O 0 2.1127668503595487e-09
the O 0 7.86096876481679e-09
test O 0 6.238975203132213e-08
individuals O 0 2.348651939598767e-08
. O 0 2.6373942318969057e-07

For O 0 1.5194906382021145e-06
six O 0 2.1420362372737145e-07
such O 0 1.1893197537915512e-08
individuals O 0 8.608706636437091e-09
, O 0 3.283228267036975e-08
there O 0 8.452187394425437e-09
was O 0 6.160481689221342e-07
significant O 0 2.1041456577108875e-08
disparity O 0 8.320533595451707e-08
between O 0 1.5178475365473787e-08
the O 0 1.2113002867408795e-07
tests O 0 3.88578996535216e-07
. O 0 5.159016609468381e-07

Three O 0 2.649222096806625e-06
went O 0 1.4887929182805237e-06
from O 0 3.7587728485277694e-08
a O 0 1.767083261938751e-07
decreased O 0 2.0825724277528934e-05
risk O 0 4.5815144744665304e-07
to O 0 2.26412417703159e-08
an O 0 5.7629929273161906e-08
increased O 0 1.6311161061821622e-06
risk O 0 1.454857169846946e-06
, O 0 1.7975926525082286e-08
while O 0 2.4183718139170196e-08
in O 0 3.5802061315592937e-09
another O 0 1.8662332124108616e-08
three O 0 1.3984720936832673e-08
the O 0 1.448399018499913e-07
risk O 0 2.1551102236117003e-06
was O 0 3.1475460673391353e-06
decreased O 0 6.425064384529833e-06
. O 0 6.613783511966176e-07

Knowledge O 0 4.670634552894626e-06
of O 0 1.644309151060952e-07
the O 0 7.341010643813206e-08
potential O 0 9.835261494117731e-08
reasons O 0 2.457810133194016e-08
for O 0 4.227712402382622e-09
these O 0 2.3161887963141226e-09
changes O 0 2.208530958114352e-08
in O 0 8.89997266995124e-08
results O 0 2.520707766962005e-06
and O 0 1.3863171943739871e-07
impact O 0 4.969990996528395e-08
of O 0 3.210574028855717e-09
these O 0 2.377701768807583e-08
risk O 0 3.698558828091336e-07
reversals O 0 6.520406827803527e-07
on O 0 1.5389099417006946e-06
both O 0 4.4067897420063673e-07
patients O 0 5.42577993201121e-07
and O 0 1.3579557034404388e-08
the O 0 1.9592118150058013e-08
counseling O 0 2.7178456818433006e-08
team O 0 4.4392414189076135e-09
can O 0 2.6002102693212237e-09
assist O 0 2.904946505566386e-09
in O 0 1.7680897856919842e-09
the O 0 2.546155952742879e-09
development O 0 4.82008388758004e-09
of O 0 1.8329761042323867e-09
strategies O 0 4.217325155764229e-08
for O 0 9.558932312359048e-09
the O 0 2.2339593286346826e-08
prevention O 0 4.0859472960619314e-07
and O 0 1.0270137096313192e-07
, O 0 2.3279088878780385e-08
where O 0 1.1497572671714806e-08
necessary O 0 1.5506183004276863e-08
, O 0 1.825601181337788e-08
management O 0 3.605095599823471e-08
of O 0 1.0107163994632629e-09
a O 0 7.558307970612077e-07
risk O 0 1.9569058622437296e-06
reversal O 0 9.201560260407859e-07
in O 0 1.3226256534437653e-08
any O 0 1.968092178117331e-08
predictive O 0 1.854866695794044e-06
testing O 0 2.2007102984389348e-07
program O 0 9.542777235083122e-08
. O 0 5.62840902773587e-08
. O 0 5.222776735536172e-07

A O 0 1.7463295080233365e-05
novel O 0 4.29610781793599e-06
common O 0 8.916834417505015e-07
missense O 0 5.346175021259114e-05
mutation O 0 5.638118182105245e-06
G301C O 0 9.583990276951226e-07
in O 0 4.670860676014854e-08
the O 0 1.8772038146153136e-08
N O 0 4.67283753096126e-05
- O 0 1.3775120351056103e-05
acetylgalactosamine O 0 5.3674924856750295e-05
- O 0 1.5268527931766585e-05
6 O 0 1.8738860489975195e-06
- O 0 2.4453576770611107e-05
sulfate O 0 3.5788025343208574e-06
sulfatase O 0 5.934247838013107e-06
gene O 0 7.067189926601714e-07
in O 0 8.229778813984012e-08
mucopolysaccharidosis B-Disease 0 0.00010209908214164898
IVA I-Disease 0 0.007201222702860832
. O 0 3.6198659927322296e-06

Mucopolysaccharidosis B-Disease 1 0.7851964235305786
IVA I-Disease 1 0.9999240636825562
( O 0 0.006903455127030611
MPS B-Disease 1 0.9999903440475464
IVA I-Disease 1 0.9999998807907104
) O 0 3.7513500501518138e-06
is O 0 5.668313463047525e-08
an O 0 1.980017003688772e-07
autosomal B-Disease 1 0.9368417263031006
recessive I-Disease 1 0.9951751232147217
lysosomal I-Disease 1 0.9999305009841919
storage I-Disease 1 0.999956488609314
disorder I-Disease 1 0.9997982382774353
caused O 0 7.034140253381338e-06
by O 0 4.190959401739747e-08
a O 0 7.703158189542592e-06
genetic B-Disease 1 0.9999986886978149
defect I-Disease 1 0.9999698400497437
in O 0 3.056082675811922e-07
N O 0 0.00019755329412873834
- O 0 7.200534309959039e-05
acetylgalactosamine O 0 0.00028364206082187593
- O 0 4.493060623644851e-05
6 O 0 1.0015764928539284e-05
- O 0 0.00036367811844684184
sulfate O 0 6.846934411441907e-05
sulfatase O 0 7.150351302698255e-05
( O 0 2.0152604918166617e-07
GALNS O 0 2.221533577539958e-05
) O 0 2.111161165885278e-07
. O 0 7.844276979085407e-07

In O 0 3.419542053961777e-06
previous O 0 1.9413807876844658e-06
studies O 0 3.6722829577229277e-07
, O 0 8.729429623599572e-08
we O 0 2.4421369815286198e-08
have O 0 2.896045403488756e-09
found O 0 1.1436136482245729e-08
two O 0 6.384440975892858e-09
common O 0 1.6160092286554573e-07
mutations O 0 1.8003346440309542e-06
in O 0 1.929072723783065e-08
Caucasians O 0 2.5558556444593705e-06
and O 0 5.851123319189355e-08
Japanese O 0 3.084364266214834e-07
, O 0 5.5076622373917417e-08
respectively O 0 8.778934557085449e-07
. O 0 4.6735877390347014e-07

To O 0 4.3571994865487795e-06
characterize O 0 8.58157090988243e-06
the O 0 2.2429836121773405e-07
mutational O 0 5.936449724686099e-06
spectrum O 0 6.143233122202219e-07
in O 0 1.1597412807873297e-08
various O 0 1.936924620693503e-09
ethnic O 0 3.100344869721994e-08
groups O 0 1.0751701751132714e-08
, O 0 1.273347649544121e-08
mutations O 0 7.892220565963726e-08
in O 0 2.5332318465132175e-09
the O 0 8.205996770982438e-09
GALNS O 0 2.0991261408198625e-05
gene O 0 1.1698740536303376e-06
in O 0 6.301498700622687e-08
Colombian O 0 2.1656383978552185e-05
MPS B-Disease 1 0.999974250793457
IVA I-Disease 1 1.0
patients O 0 0.0001420976041117683
were O 0 5.123307289522927e-08
investigated O 0 2.6858495516535186e-07
, O 0 2.4404652521070602e-08
and O 0 3.963238981441464e-08
genetic O 0 4.2867995375672763e-07
backgrounds O 0 1.5791405871823372e-07
were O 0 7.127321310917978e-08
extensively O 0 1.3790436526051053e-07
analyzed O 0 7.531125447712839e-07
to O 0 3.412376869960099e-08
identify O 0 2.143505355434172e-07
racial O 0 7.701769533241531e-08
origin O 0 5.32070494330128e-08
, O 0 1.9250000704573722e-08
based O 0 3.6345770837442615e-08
on O 0 3.182791488143266e-07
mitochondrial O 0 7.877129064581823e-06
DNA O 0 6.123757339082658e-05
( O 0 1.672511160677459e-07
mtDNA O 0 1.128928374782845e-06
) O 0 1.4060792352665885e-07
lineages O 0 2.5835129235929344e-06
. O 0 5.609770710179873e-07

Three O 0 4.192513642919948e-06
novel O 0 5.413424787548138e-06
missense O 0 0.00029409167473204434
mutations O 0 0.0003022250602953136
never O 0 1.0410474715172313e-05
identified O 0 2.056828861896065e-06
previously O 0 3.080851058712142e-07
in O 0 1.632804114137798e-08
other O 0 2.1335504030162156e-08
populations O 0 6.477454661535376e-08
and O 0 6.665529639349188e-08
found O 0 1.2726196985113347e-07
in O 0 1.871098298522611e-08
16 O 0 5.0399833639858116e-08
out O 0 1.368608959495532e-08
of O 0 7.603041751735873e-09
19 O 0 1.426276980964758e-06
Colombian O 0 1.571938264532946e-05
MPS B-Disease 1 0.9939823746681213
IVA I-Disease 1 0.9999926090240479
unrelated O 0 7.84454732638551e-06
alleles O 0 1.3456308352033375e-06
account O 0 5.143540988683526e-07
for O 0 1.2369073942863906e-07
84 O 0 1.6579626844759332e-06
. O 0 1.1171345022376045e-06

2 O 0 9.962607691704761e-06
% O 0 4.075432116223965e-07
of O 0 8.077050139831954e-09
the O 0 1.0736108002618039e-08
alleles O 0 1.1547609801709768e-07
in O 0 2.601719906181188e-08
this O 0 2.7298206362047495e-08
study O 0 2.847257292160066e-07
. O 0 8.163451070686278e-07

The O 0 1.386493295285618e-06
G301C O 0 9.537820915284101e-06
and O 0 3.5492723782226676e-07
S162F O 0 4.440384600457037e-06
mutations O 0 9.64061837294139e-06
account O 0 6.257434961298713e-07
for O 0 1.4157996020003338e-07
68 O 0 1.91703634300211e-06
. O 0 1.1902932328666793e-06

4 O 0 1.462682121200487e-05
% O 0 1.122553499044443e-06
and O 0 2.61112120369944e-07
10 O 0 5.211338134358812e-07
. O 0 6.563741408172064e-07

5 O 0 5.707091531803599e-06
% O 0 3.0011486273906485e-07
of O 0 2.631243489759072e-08
mutations O 0 4.416130650497507e-06
, O 0 8.486583880085163e-08
respectively O 0 6.865247996756807e-07
, O 0 1.930714432774039e-08
whereas O 0 2.8016868824920493e-08
the O 0 9.670650058524188e-09
remaining O 0 1.3236635254543216e-07
F69V O 0 4.540548616205342e-05
is O 0 3.3676332833465494e-08
limited O 0 6.684280240421003e-09
to O 0 9.708389647755666e-09
a O 0 5.821712534270773e-08
single O 0 1.3614330782729667e-06
allele O 0 1.2957975741301198e-05
. O 0 1.493867330282228e-06

The O 0 4.0173044908442535e-06
skewed O 0 2.5326926333946176e-05
prevalence O 0 2.303214932908304e-05
of O 0 4.3682192085725546e-08
G301C O 0 9.080786185222678e-07
in O 0 4.210597737142052e-08
only O 0 2.0135155764933188e-08
Colombian O 0 2.336049874429591e-06
patients O 0 7.59126294269663e-07
and O 0 7.178058325507664e-08
haplotype O 0 1.7101556295529008e-05
analysis O 0 1.6621534371097368e-07
by O 0 7.313210481640908e-09
restriction O 0 3.0529360373066083e-08
fragment O 0 8.511871669725224e-07
length O 0 5.903665396544966e-07
polymorphisms O 0 8.606084520579316e-06
in O 0 4.1324192068259435e-08
the O 0 2.557254141777321e-08
GALNS O 0 2.237016633444e-05
gene O 0 5.054124585512909e-07
suggest O 0 4.539163356298559e-08
that O 0 3.5444125412453786e-09
G301C O 0 6.297569399293934e-08
originated O 0 2.4184041436114967e-08
from O 0 2.6484621162836675e-09
a O 0 2.367664286850868e-08
common O 0 1.9114450822144136e-07
ancestor O 0 3.263044163759332e-06
. O 0 1.3693056644115131e-06

Investigation O 0 1.7264223060919903e-05
of O 0 6.759966453273591e-08
the O 0 2.7455797635411727e-08
genetic O 0 8.130825790431118e-07
background O 0 1.9828402741950413e-07
by O 0 1.3365073492366264e-08
means O 0 1.381720782234197e-08
of O 0 2.4294941614044774e-09
mtDNA O 0 2.5523235080981976e-07
lineages O 0 2.61716934346623e-07
indicate O 0 1.6471750541313668e-07
that O 0 3.887826505177827e-09
all O 0 3.4830911488370475e-09
our O 0 2.254514868127444e-07
patients O 0 2.3590189357491909e-07
are O 0 2.2189845516606965e-09
probably O 0 2.1749835710238585e-08
of O 0 4.780511986268721e-09
native O 0 8.193369467335287e-07
American O 0 3.242826551286271e-06
descent O 0 0.00011232392716920003

Low O 0 1.8905684555647895e-05
frequency O 0 9.649309504311532e-06
of O 0 3.225903526526963e-07
BRCA1 O 0 0.0001197013771161437
germline O 0 0.00013020353799220175
mutations O 0 1.8336002540308982e-05
in O 0 7.818027825123863e-08
45 O 0 1.0855596883629914e-06
German O 1 0.9980251789093018
breast B-Disease 1 0.9999990463256836
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
families O 0 4.600288775691297e-06
. O 0 2.370349420743878e-06

In O 0 1.296014715990168e-06
this O 0 3.2124987114912074e-08
study O 0 2.6107121797736e-08
we O 0 1.8740593077382073e-08
investigated O 0 2.9525023137466633e-07
45 O 0 4.21203566247641e-07
German O 1 0.941775381565094
breast B-Disease 1 0.9999856948852539
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 1.3131923992659722e-07
for O 0 5.817716797196226e-08
germline O 0 5.523709478438832e-05
mutations O 0 7.835537871869747e-06
in O 0 2.094915352301996e-08
the O 0 1.3193331938055053e-07
BRCA1 O 0 0.00045048128231428564
gene O 0 1.4208168067852966e-05
. O 0 1.643559585318144e-06

We O 0 4.861862180405296e-06
identified O 0 1.1457356094979332e-06
four O 0 1.302739320863111e-07
germline O 0 2.4799674065434374e-05
mutations O 0 2.9154723961255513e-05
in O 0 4.62125427702631e-07
three O 0 6.328518793452531e-06
breast B-Disease 1 0.9537622332572937
cancer I-Disease 0 0.0020768505055457354
families O 0 4.5853873587020644e-08
and O 0 8.120908745468114e-08
in O 0 2.5704042627694434e-07
one O 0 0.0004183553683105856
breast B-Disease 1 0.9999951124191284
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.3913796692577307e-06
. O 0 2.3343739385950357e-08
among O 0 2.3653969893899784e-09
these O 0 1.0801356475909074e-09
were O 0 1.3654044117572539e-08
one O 0 4.5946933369123144e-08
frameshift O 0 3.5912944440497085e-05
mutation O 0 1.0909919865298434e-06
, O 0 1.01490691406525e-08
one O 0 1.0116078641431159e-08
nonsense O 0 9.905688784783706e-07
mutation O 0 2.4711226842555334e-07
, O 0 8.423990394135217e-09
one O 0 6.157999887790311e-09
novel O 0 7.247518141184628e-08
splice O 0 9.914138354361057e-05
site O 0 1.3039842997386586e-05
mutation O 0 3.0730152502655983e-06
, O 0 1.7869680846160918e-08
and O 0 1.9915686877425287e-08
one O 0 1.2681540795256296e-07
missense O 0 6.379531259881333e-05
mutation O 0 2.7071806471212767e-05
. O 0 1.3733440482610604e-06

The O 0 5.995552783133462e-06
missense O 0 0.00046042000758461654
mutation O 0 0.00018320474191568792
was O 0 8.102331776171923e-06
also O 0 1.9304572163036937e-07
found O 0 1.2576157359944773e-07
in O 0 4.3843879637961436e-08
2 O 0 2.162484861401026e-06
. O 0 1.0468878599567688e-06

8 O 0 1.1278434612904675e-05
% O 0 1.9808216222827468e-07
of O 0 4.443069911985731e-09
the O 0 1.3999238213102672e-08
general O 0 3.2218014922591465e-08
population O 0 2.7186128903622375e-08
, O 0 1.1799744292773084e-08
suggesting O 0 1.0818190787631465e-07
that O 0 2.0865011052251248e-08
it O 0 9.22817235959883e-08
is O 0 2.191123087413871e-07
not O 0 1.3609397910840926e-06
disease O 0 3.790486152865924e-05
associated O 0 7.0011805064496e-07
. O 0 8.892554888006998e-07

The O 0 1.3217667174103553e-06
average O 0 4.370646365714492e-06
age O 0 3.647404298590118e-07
of O 0 9.812626444727357e-08
disease O 0 0.0010167098371312022
onset O 0 2.3147311367210932e-05
in O 0 1.058307859125307e-07
those O 0 2.4443972179710727e-08
families O 0 5.853244289255599e-08
harbouring O 0 2.9353386707953177e-05
causative O 0 3.545075378497131e-05
mutations O 0 7.31912296032533e-05
was O 0 3.323483497297275e-07
between O 0 5.299122562973935e-08
32 O 0 1.799021788428945e-06
. O 0 1.3501762623491231e-06

3 O 0 3.105988071183674e-05
and O 0 3.071274932153756e-06
37 O 0 5.30178886037902e-06
. O 0 1.8171301690017572e-06

4 O 0 3.0626339139416814e-05
years O 0 9.31841839246772e-07
, O 0 4.4888398775810856e-08
whereas O 0 4.053248403579346e-08
the O 0 1.4592655084300077e-08
family O 0 4.665429571559798e-07
harbouring O 0 1.245199473487446e-05
the O 0 7.25728455108765e-08
missense O 0 2.2814263502368703e-05
mutation O 0 4.431758043210721e-06
had O 0 2.728993990785966e-07
an O 0 1.2149811823292112e-08
average O 0 2.4775317797320895e-07
age O 0 3.7900313998306956e-08
of O 0 1.2057308040880343e-08
onset O 0 1.5210941910481779e-06
of O 0 4.019918975473047e-08
51 O 0 4.350204108050093e-06
. O 0 6.101294616200903e-07

2 O 0 6.785470759496093e-05
years O 0 1.0382644177298062e-05
. O 0 2.966675765492255e-06

These O 0 2.4929379378590966e-06
findings O 0 2.6904638161795447e-06
show O 0 9.59437784331385e-07
that O 0 6.910224215062044e-08
BRCA1 O 0 4.149788583163172e-05
is O 0 1.2372552760098188e-07
implicated O 0 7.612497370246274e-07
in O 0 5.1401793932370765e-09
a O 0 1.4617196342214811e-08
small O 0 1.2253023484731784e-08
fraction O 0 2.675758707937348e-07
of O 0 3.1054132705321535e-06
breast B-Disease 1 0.9999979734420776
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 1.960565612080245e-07
suggesting O 0 2.460235464241123e-07
the O 0 1.0888383528140366e-08
involvement O 0 1.2467189947074075e-07
of O 0 6.196527735369273e-09
another O 0 8.233591870521195e-07
susceptibility O 0 9.164234506897628e-05
gene O 0 1.816779149521608e-05
( O 0 1.3193423455959419e-06
s O 0 0.000839283165987581
) O 0 3.486254854578874e-06

Paternal O 0 0.30805885791778564
transmission O 1 0.8699625730514526
of O 0 0.0021269400604069233
congenital B-Disease 1 0.9999998807907104
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 0.0025205151177942753

We O 0 1.9969178538303822e-05
report O 0 9.382972621096997e-07
a O 0 5.543579817413047e-08
rare O 0 9.840159265195325e-08
case O 0 1.974631516077352e-07
of O 0 2.7756939857681573e-07
paternally O 1 0.9223365187644958
transmitted O 1 0.9999980926513672
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.789172351360321
DM B-Disease 1 1.0
) O 0 1.8143326087738387e-05
. O 0 2.6132838684134185e-06

The O 0 2.075999191220035e-06
proband O 0 3.2852993172127753e-05
is O 0 1.0256923133056262e-07
a O 0 9.291471769756754e-08
23 O 0 3.609437726481701e-07
year O 0 1.2208774080590956e-07
old O 0 1.8180946426582523e-05
, O 0 6.436814874177799e-05
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 0.9999994039535522
male O 0 0.00023566932941321284
who O 0 0.00026250522932969034
suffers O 1 0.9970412850379944
severe O 0 0.026330256834626198
muscular B-Disease 0 0.21527759730815887
weakness I-Disease 0 0.018485628068447113
. O 0 5.876595878362423e-06

He O 0 1.873026485554874e-05
presented O 0 1.5107358422028483e-06
with O 0 9.378605909660109e-07
respiratory O 0 0.37829986214637756
and O 0 2.610628371257917e-06
feeding O 0 2.443455559841823e-05
difficulties O 0 4.0882223402149975e-06
at O 0 2.1833084247191437e-06
birth O 0 9.154991857940331e-06
. O 0 1.4158039221001673e-06

His O 0 1.6188339941436425e-05
two O 0 7.869793080317322e-06
sibs O 1 0.588895320892334
suffer O 0 0.01648988574743271
from O 0 2.2681301743432414e-06
childhood O 0 0.0005370168364606798
onset O 0 0.44542261958122253
DM B-Disease 1 0.9999998807907104
. O 0 6.795825174776837e-05

Their O 0 2.751084593910491e-06
late O 0 4.451505446922965e-06
father O 0 7.755735964565247e-07
had O 0 9.192177685690694e-08
the O 0 6.66417987460477e-09
adult O 0 2.8896462112015797e-08
type O 0 1.647775320634537e-07
of O 0 1.8024202574906667e-07
DM B-Disease 1 1.0
, O 0 5.449146556202322e-07
with O 0 4.903224848362697e-08
onset O 0 1.91417916539649e-06
around O 0 9.002545908742832e-08
30 O 0 1.9107343973701063e-07
years O 0 1.323033700373344e-07
. O 0 3.191779569533537e-07

Only O 0 4.3453715647956415e-07
six O 0 8.260996509079632e-08
other O 0 1.1407205846580837e-08
cases O 0 1.0728103738699701e-08
of O 0 6.599617297098348e-09
paternal O 0 4.23448218498379e-05
transmission O 0 0.12635013461112976
of O 0 0.00016930789570324123
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0001930623548105359
been O 0 3.3646913379925536e-06
reported O 0 4.0607737901154906e-05
recently O 0 3.8197499634406995e-06
. O 0 6.978123678891279e-07

We O 0 5.909776518819854e-06
review O 0 3.57417036411789e-07
the O 0 2.1361278967901853e-08
sex O 0 1.6312858974742994e-07
related O 0 1.4298136363777303e-07
effects O 0 1.2823481938539771e-06
on O 0 7.160539098549634e-06
transmission O 0 0.04391327500343323
of O 0 7.235383236547932e-05
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 0.00012979867460671812

Decreased O 0 0.001851448556408286
fertility O 0 0.00014603236922994256
of O 0 1.1635815155841556e-07
males O 0 9.943133250089886e-08
with O 0 6.475762859281531e-08
adult O 0 8.614722901256755e-06
onset O 0 0.0012600829359143972
DM B-Disease 1 1.0
and O 0 1.0287189070368186e-05
contraction O 0 5.363138825487113e-06
of O 0 2.204212146139639e-09
the O 0 2.1273576678026984e-08
repeat O 0 1.556454662932083e-06
upon O 0 2.7056392681856778e-08
male O 0 1.3415366595381784e-07
transmission O 0 1.9656108634080738e-06
contribute O 0 2.1394468419089208e-08
to O 0 6.923467132935457e-09
the O 0 6.1065832390738706e-09
almost O 0 3.8629995202654754e-08
absent O 0 1.746566198335131e-07
occurrence O 0 1.0502321856620256e-07
of O 0 1.6723541662599928e-08
paternal O 0 2.85647274722578e-05
transmission O 0 0.014932151883840561
of O 0 5.061680349172093e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 9.888201748253778e-05

Also O 0 9.883844541036524e-06
the O 0 2.373656116105849e-07
fathers O 0 4.338369592460367e-07
of O 0 2.5316925444940352e-08
the O 0 2.6927176577373757e-07
reported O 0 0.00039593243855051696
congenitally O 0 0.002251331927254796
affected O 0 3.2405978345195763e-06
children O 0 6.229159339454782e-07
showed O 0 1.0154528808925534e-06
, O 0 1.0261576477432754e-08
on O 0 2.01623308271337e-07
average O 0 6.152637297418551e-07
, O 0 1.4655211089120712e-07
shorter O 0 3.1074189337232383e-06
CTG O 0 2.193450927734375e-05
repeat O 0 3.5826751627610065e-06
lengths O 0 3.6422252378542908e-06
and O 0 8.41175946675321e-08
hence O 0 1.7187767298310064e-07
less O 0 5.930854172220279e-07
severe O 0 5.4239582823356614e-05
clinical O 0 1.7278058294323273e-05
symptoms O 0 8.002433787623886e-06
than O 0 6.6224159489536305e-09
the O 0 4.074385984154105e-08
mothers O 0 2.748829501797445e-07
of O 0 1.6653768142305125e-08
children O 0 2.866666818590602e-06
with O 0 9.252624295186251e-05
congenital B-Disease 1 0.9999998807907104
DM I-Disease 1 1.0
. O 0 9.435367974219844e-05

We O 0 8.997910299513023e-06
conclude O 0 1.2108595001336653e-05
that O 0 2.500308937669615e-07
paternal O 0 1.0663662578735966e-05
transmission O 0 0.0018779258243739605
of O 0 8.367410191567615e-05
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 1.407821400789544e-05
rare O 0 4.307018173221877e-07
and O 0 1.1201221639112191e-07
preferentially O 0 7.056077606648614e-07
occurs O 0 4.040589729470412e-08
with O 0 1.8339143537104974e-08
onset O 0 7.726503099547699e-06
of O 0 4.6303503609124164e-07
DM B-Disease 1 1.0
past O 0 6.508653314085677e-06
30 O 0 2.535404632908467e-07
years O 0 1.492256274104875e-08
in O 0 7.625799547383849e-09
the O 0 3.020224426109053e-08
father O 0 1.3181651183913345e-06
. O 0 9.239356302259694e-08
. O 0 3.9500253024016274e-07

The O 0 4.5994815991434734e-06
RB1 O 0 0.00047095571062527597
gene O 0 1.407544914400205e-05
mutation O 0 5.987039457977517e-06
in O 0 6.919456296827775e-08
a O 0 7.885553259256994e-07
child O 0 3.894373367074877e-05
with O 0 9.800459338293876e-06
ectopic B-Disease 1 0.9999985694885254
intracranial I-Disease 1 0.9999176263809204
retinoblastoma I-Disease 1 0.7553737163543701
. O 0 1.859959593275562e-05

The O 0 6.234327429410769e-06
RB1 O 0 0.0006220571231096983
gene O 0 4.1372903069714084e-05
mutation O 0 3.185038440278731e-05
was O 0 3.5637929158838233e-06
investigated O 0 2.2578078642254695e-06
in O 0 3.518844593486392e-08
a O 0 7.711345233474276e-07
child O 0 1.060276736097876e-05
with O 0 1.8332850686419988e-06
ectopic B-Disease 1 0.9999915361404419
intracranial I-Disease 1 0.8306977152824402
retinoblastoma I-Disease 0 0.0001184365464723669
using O 0 6.488249937319779e-07
DNA O 0 5.937310561421327e-06
obtained O 0 1.5722102375548275e-07
from O 0 8.268164819469348e-09
both O 0 5.991681373274105e-09
the O 0 7.646791289062094e-08
pineal B-Disease 0 0.00011807840928668156
and I-Disease 0 9.217217666446231e-06
retinal I-Disease 1 0.6835638880729675
tumours I-Disease 1 1.0
of O 0 1.2331182119851292e-07
the O 0 4.805243634109502e-07
patient O 0 6.576795840373961e-06
. O 0 5.364476010072394e-07

A O 0 1.5994142813724466e-05
nonsense O 0 3.8526839489350095e-05
mutation O 0 6.576940450031543e-06
in O 0 2.9154509206819057e-07
exon O 0 1.652530590945389e-05
17 O 0 2.3479947230953258e-06
( O 0 3.668284875857353e-08
codon O 0 4.036415361952095e-07
556 O 0 1.5560763699795643e-07
) O 0 9.858792004990846e-09
of O 0 2.498547813090113e-09
the O 0 4.0386090915944806e-08
RB1 O 0 1.835461807786487e-05
gene O 0 5.164647518540733e-07
was O 0 3.7056270230095834e-07
found O 0 3.99164186148937e-08
to O 0 1.7101363880556164e-08
be O 0 9.755537710987028e-09
present O 0 7.129751899981329e-09
homozygously O 0 1.4927964002708904e-06
in O 0 5.368399502714283e-09
both O 0 4.980056367287489e-09
the O 0 3.241970958356433e-08
retinal B-Disease 0 6.817758549004793e-05
and I-Disease 0 6.846972837593057e-07
the I-Disease 0 1.6134341649376438e-06
pineal I-Disease 0 0.46485358476638794
tumours I-Disease 1 0.9999996423721313
. O 0 3.848273536277702e-06

The O 0 8.116802518998156e-07
same O 0 2.5798888714234636e-07
mutation O 0 1.1659190022328403e-06
was O 0 5.268415179671138e-07
present O 0 3.148261029650712e-08
heterozygously O 0 2.573548954387661e-06
in O 0 1.919361380942064e-08
the O 0 7.674256785605849e-09
DNA O 0 7.62688614486251e-07
from O 0 8.736971146561245e-09
the O 0 7.261656609358624e-09
constitutional O 0 1.3500994100468233e-08
cells O 0 3.833514838902374e-08
of O 0 1.1292013990527039e-09
the O 0 9.57400700940525e-08
patient O 0 2.824794592015678e-06
, O 0 3.862933084519682e-08
proving O 0 1.241400440221696e-07
it O 0 2.4314703139793892e-08
to O 0 1.3152045674758028e-08
be O 0 2.2373535912834086e-08
of O 0 1.8275523316901854e-08
germline O 0 3.0032040740479715e-05
origin O 0 2.1392056623881217e-06
. O 0 1.0746207408374175e-06

The O 0 9.83837367130036e-07
initial O 0 1.9782817162194988e-06
mutation O 0 3.873110927088419e-06
was O 0 1.0352301842431189e-06
shown O 0 8.525131534042885e-08
to O 0 2.28196022078464e-08
have O 0 1.0579401354959828e-08
occurred O 0 6.04041616725226e-08
in O 0 1.2555900319455304e-08
the O 0 3.300545259321552e-08
paternally O 0 5.8149594224232715e-06
derived O 0 2.010249772865791e-06
RB1 O 0 0.00016372925892937928
allele O 0 4.3524090870050713e-05
. O 0 1.9738210994546534e-06

The O 0 1.4643939039160614e-06
mutation O 0 7.99824465502752e-06
is O 0 8.036867171767881e-08
in O 0 1.515420500197706e-08
an O 0 1.8293167869387617e-08
area O 0 9.685292923222732e-08
of O 0 2.9432227766079677e-09
the O 0 9.618444707371054e-09
gene O 0 6.987187362028635e-08
that O 0 1.6563920235412866e-09
encodes O 0 2.160813217244595e-08
the O 0 2.444396018930206e-09
protein O 0 1.8909877042005974e-07
- O 0 6.210278797880164e-07
binding O 0 2.7471259045341867e-07
region O 0 4.1578465470593073e-07
known O 0 7.074797281347855e-08
as O 0 1.8112627842015172e-08
the O 0 3.073267507147648e-08
pocket O 0 0.00021325628040358424
region O 0 5.156466158950934e-06
and O 0 4.192214930753835e-07
has O 0 2.650743624599272e-07
been O 0 7.325233752908389e-08
detected O 0 3.309203577828157e-07
in O 0 2.4094477524272406e-09
other O 0 5.061936203532014e-09
cases O 0 1.4870114029008619e-08
of O 0 1.372213365158359e-08
retinoblastoma B-Disease 0 3.558810203685425e-05
. O 0 5.959753366369114e-07
. O 0 1.3032505421506357e-06

Low O 0 1.989128941204399e-05
levels O 0 6.541376933455467e-07
of O 0 1.4771372569555297e-08
beta O 0 9.413161450311236e-08
hexosaminidase O 0 6.505772489617812e-07
A O 0 2.2815648037521896e-07
in O 0 3.7329808577624135e-08
healthy O 0 1.0566458996663641e-07
individuals O 0 3.281705573954241e-09
with O 0 6.759915294196617e-08
apparent O 0 0.00036278768675401807
deficiency O 0 0.00016558755305595696
of O 0 5.257119628510054e-09
this O 0 5.033460226400166e-08
enzyme O 0 5.818709723826032e-06
. O 0 9.746889872985776e-07

Appreciable O 0 0.00034817514824680984
beta O 0 2.006883551075589e-05
hexosaminidase O 0 5.891589535167441e-05
A O 0 5.7438769545115065e-06
( O 0 2.555674996074231e-07
hex O 0 3.797893668888719e-06
A O 0 1.4344369674290647e-06
) O 0 2.9026606895854457e-08
activity O 0 3.7250998730087304e-08
has O 0 2.3446013130978827e-08
been O 0 3.381400404123269e-08
detected O 0 2.873998141694756e-07
in O 0 1.763358703499307e-08
cultured O 0 2.994767237396445e-05
skin O 0 0.09450782835483551
fibroblasts O 0 3.1924158975016326e-05
and O 0 7.720175744907465e-06
melanoma B-Disease 1 0.9787291288375854
tissue O 0 4.6798784751445055e-05
from O 0 1.2468797194742365e-07
healthy O 0 4.995242193217564e-07
individuals O 0 1.010873074136498e-08
previously O 0 1.0482405059519806e-06
reported O 0 1.2908664757560473e-05
as O 0 1.6846968264871975e-07
having O 0 4.756975613418035e-06
deficiency B-Disease 0 1.8815408111549914e-05
of I-Disease 0 4.401553788113688e-09
hex I-Disease 0 4.736459686682792e-06
A I-Disease 0 3.6564313177223084e-07
activity O 0 6.323990930923173e-08
indistinguishable O 0 1.4419858018754894e-07
from O 0 2.268203402877589e-09
that O 0 3.507264256796816e-09
of O 0 1.010001948742456e-08
patients O 0 1.086404836314614e-06
with O 0 6.161067176435608e-06
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9976067543029785
( O 0 5.964330398455786e-07
TSD B-Disease 0 0.00013543489330913872
) O 0 2.815777122577856e-07
. O 0 9.40341465138772e-07

Identification O 0 1.0812092114065308e-05
and O 0 5.02816362768499e-07
quantitation O 0 1.4069663848204073e-05
of O 0 5.0742638535439255e-08
hex O 0 2.3427908672601916e-05
A O 0 3.5628959267341997e-06
, O 0 1.0672472683381784e-07
amounting O 0 1.3866635129033966e-07
to O 0 6.278644093526964e-08
3 O 0 6.618187171625323e-07
. O 0 9.020022844197229e-07

5 O 0 1.3841290638083592e-05
% O 0 1.365555135635077e-06
- O 0 2.5900064429151826e-05
6 O 0 6.143001883174293e-06
. O 0 1.131116050601122e-06

9 O 0 1.0408548405393958e-05
% O 0 1.3922023356371938e-07
of O 0 7.104408172864396e-09
total O 0 4.312044765697465e-08
beta O 0 1.3108800089867145e-07
hexosaminidase O 0 1.1380559499230003e-06
activity O 0 8.938624063148382e-08
, O 0 1.5729474611703154e-08
has O 0 3.928430913902048e-08
been O 0 1.6230730537358795e-08
obtained O 0 2.5084524679641618e-08
by O 0 8.272124318864371e-09
cellulose O 0 3.408548582228832e-05
acetate O 0 1.0682399988581892e-05
gel O 0 1.0395066965429578e-05
electrophoresis O 0 5.462122203425679e-07
, O 0 1.0317470433562903e-08
DEAE O 0 1.16104797598382e-06
- O 0 1.1667700619000243e-06
cellulose O 0 1.039326252794126e-05
ion O 0 7.925186196189316e-07
- O 0 5.845283794769784e-07
exchange O 0 1.9856787503158557e-07
chromatography O 0 3.553726344307506e-07
, O 0 2.856078928914485e-08
radial O 0 4.267133590474259e-06
immunodiffusion O 0 9.341319127997849e-06
, O 0 5.67031364084869e-08
and O 0 7.152351599870599e-08
radioimmunoassay O 0 2.199523260060232e-05
. O 0 6.437396109504334e-07

Previous O 0 2.9098146114847623e-05
family O 0 4.4725047700922005e-06
studies O 0 3.289406436124409e-07
suggested O 0 4.2749559270305326e-07
that O 0 2.3131702775458507e-08
these O 0 9.554338653572358e-09
individuals O 0 8.426850328646651e-09
may O 0 2.8559981046782923e-07
be O 0 9.407593815069504e-09
compound O 0 1.3283296596000582e-07
heterozygotes O 0 2.9593499561997305e-07
for O 0 3.5591607439044992e-09
the O 0 6.05040018086811e-09
common O 0 1.475209217005613e-07
mutant O 0 1.0842312576642144e-06
TSD B-Disease 0 1.0645666407071985e-05
gene O 0 1.3379417396208737e-06
and O 0 5.148365289642243e-08
a O 0 2.6624636006999935e-07
rare O 0 1.6598532965872437e-06
( O 0 9.764737285422598e-08
allelic O 0 1.6082282172646956e-06
) O 0 6.624426873713674e-08
mutant O 0 1.5787293250468792e-06
gene O 0 5.43204214409343e-06
. O 0 9.919623380483245e-07

Thus O 0 8.37919105833862e-06
, O 0 1.6893592658107082e-07
the O 0 2.608362947853493e-08
postulated O 0 3.4427935702296963e-07
rate O 0 1.9113467430997844e-07
mutant O 0 1.8240650945244852e-07
gene O 0 2.8445134603316546e-07
appears O 0 1.9880586421550106e-07
to O 0 8.047923216736308e-09
code O 0 6.951558884082942e-09
for O 0 5.9622236037171206e-09
the O 0 6.75756606227651e-09
expression O 0 2.544725141717663e-08
of O 0 2.3246331526394215e-09
low O 0 1.2291440043554758e-07
amounts O 0 3.3925832809700296e-08
of O 0 1.0685626605777543e-08
hex O 0 2.340591345273424e-05
A O 0 6.018881322233938e-06
. O 0 1.4635799061579746e-06

Heterozygotes O 0 0.00021938512509223074
for O 0 3.9248101302291616e-07
the O 0 3.89294108060767e-08
rare O 0 1.4066131370782387e-07
mutant O 0 2.7172654881724156e-06
may O 0 1.736080434966425e-06
be O 0 1.0658879112668274e-08
indistinguishable O 0 1.5504870987115282e-07
from O 0 1.1351469986209395e-08
heterozygotes O 0 3.781641169098293e-07
for O 0 9.161961855852496e-09
the O 0 2.460253512026611e-08
common O 0 1.5685335483794915e-06
TSD B-Disease 0 0.00010092646698467433
mutant O 0 2.1914771423325874e-05
. O 0 1.8466773781256052e-06

However O 0 3.924427801393904e-06
, O 0 4.988177693121543e-08
direct O 0 7.810024982290997e-08
visualization O 0 2.8409992864908418e-06
and O 0 2.324892278693369e-07
quantitation O 0 8.283365787065122e-06
of O 0 1.4492521849263085e-08
hex O 0 3.129387096123537e-06
A O 0 2.5189820007653907e-07
by O 0 4.2256163013121295e-09
the O 0 5.743041153749573e-09
methods O 0 3.4693357520154677e-07
described O 0 6.218680482561467e-06
may O 0 7.311908802876133e-07
prevent O 0 5.435289551769529e-08
false O 0 2.2040499914055545e-07
- O 0 6.714196388202254e-06
positive O 0 5.188299496694526e-07
prenatal O 0 4.833660932490602e-05
diagnosis O 0 2.8696686058538035e-05
of O 0 1.575226171723898e-08
TSD B-Disease 0 4.219253969495185e-05
in O 0 4.1784525706134445e-07
fetuses O 0 4.01309625885915e-06
having O 0 4.544109799553553e-08
the O 0 1.750587586002439e-08
incomplete O 0 6.749839940312086e-07
hex B-Disease 0 0.0002102913276758045
A I-Disease 0 0.0005034756031818688
deficiency I-Disease 0 0.00018809919129125774
of O 0 3.006107807124181e-09
the O 0 4.306865974967877e-08
type O 0 1.4833848354101065e-06
described O 0 3.7140334825380705e-06
in O 0 1.4274669446479038e-08
the O 0 1.4799686809396917e-08
four O 0 2.94804010536609e-07
healthy O 0 2.489293365215417e-06
individuals O 0 7.943216928651964e-07

The O 0 8.784614692558534e-06
tumor B-Disease 0 0.00015273469034582376
suppressor O 0 5.1372990128584206e-05
gene O 0 2.1490930521395057e-05
Smad4 O 0 0.00016607202996965498
/ O 0 0.0002988888300023973
Dpc4 O 0 2.5249197278753854e-05
is O 0 4.678403797697683e-08
required O 0 1.0602268396553427e-08
for O 0 7.423235359738101e-09
gastrulation O 0 6.245725785447576e-07
and O 0 1.8899474696354446e-07
later O 0 3.724649104697164e-07
for O 0 2.509275454087856e-08
anterior O 0 3.4181530281784944e-06
development O 0 3.045352769959209e-08
of O 0 6.833089649660451e-09
the O 0 7.071842134109829e-08
mouse O 0 1.9122424419037998e-05
embryo O 0 3.323478813399561e-05
. O 0 2.0755758214363595e-06

Mutations O 0 0.0006721718236804008
in O 0 8.853713779899408e-07
the O 0 3.866840643240721e-07
SMAD4 O 0 0.007694769650697708
/ O 0 0.004794213455170393
DPC4 O 0 0.0008472545305266976
tumor B-Disease 0 7.988419383764267e-05
suppressor O 0 5.119213255966315e-06
gene O 0 1.3737579820372048e-06
, O 0 1.3030743595265903e-08
a O 0 1.430860585571736e-08
key O 0 4.4644539798355254e-07
signal O 0 2.259571829199558e-06
transducer O 0 7.564588599962008e-07
in O 0 1.8367357412785168e-08
most O 0 1.2314901987053872e-08
TGFbeta O 0 8.217767572205048e-06
- O 0 6.471308097388828e-06
related O 0 4.251922689491039e-07
pathways O 0 2.8352374670248537e-07
, O 0 3.308878149255179e-08
are O 0 1.933447846269587e-09
involved O 0 4.217660443117666e-09
in O 0 7.760958098401716e-09
50 O 0 2.2245284725386227e-08
% O 0 5.553432558258464e-08
of O 0 2.604828637231549e-07
pancreatic B-Disease 1 0.961740255355835
cancers I-Disease 1 0.5062001943588257
. O 0 2.51737333201163e-06

Homozygous O 0 0.0021483551245182753
Smad4 O 0 0.0017172455554828048
mutant O 0 0.0007342893513850868
mice O 0 0.04984158277511597
die O 0 0.04682077467441559
before O 0 6.316582812360139e-07
day O 0 2.9802538392686984e-07
7 O 0 1.2854925444116816e-06
. O 0 7.048236057016766e-07

5 O 0 9.428932571609039e-06
of O 0 9.90924036159413e-07
embryogenesis O 0 8.486847946187481e-05
. O 0 5.291913112159818e-06

Mutant O 0 7.517082121921703e-05
embryos O 0 7.343291508732364e-05
have O 0 5.409793857324985e-07
reduced O 0 3.083743536080874e-07
size O 0 3.269749129231059e-07
, O 0 3.035830218323099e-07
fail O 0 1.0554629170655971e-06
to O 0 5.0234184811870364e-08
gastrulate O 0 1.1242074833717197e-05
or O 0 1.1389600729216909e-07
express O 0 2.4562501721447916e-07
a O 0 5.254134904930652e-08
mesodermal O 0 2.22863445742405e-06
marker O 0 7.696270586166065e-06
, O 0 1.51087846234077e-07
and O 0 5.5442352930867855e-08
show O 0 3.4070910714945057e-06
abnormal O 0 6.055457561160438e-06
visceral O 0 4.265021743776742e-06
endoderm O 0 3.196869874955155e-05
development O 0 1.7135571397375315e-06
. O 0 2.0771635718119796e-06

Growth B-Disease 1 0.9999972581863403
retardation I-Disease 1 0.9999995231628418
of O 0 1.8151023084556073e-07
the O 0 2.551232967107353e-07
Smad4 O 0 0.0003139931068290025
- O 0 0.0034061262849718332
deficient O 0 0.00037371832877397537
embryos O 0 4.635706318367738e-06
results O 0 7.210729791040649e-07
from O 0 1.1996289295268525e-08
reduced O 0 2.8041736754857993e-07
cell O 0 8.532646461389959e-06
proliferation O 0 2.851730300790223e-07
rather O 0 1.5603820457954498e-08
than O 0 2.8100890503424125e-08
increased O 0 2.4625265382383077e-07
apoptosis O 0 3.977350388595369e-06
. O 0 6.377420618264296e-07

Aggregation O 0 5.817120836582035e-05
of O 0 5.569884820033622e-07
mutant O 0 7.144591563701397e-06
Smad4 O 0 5.7528573961462826e-05
ES O 0 5.785244866274297e-05
cells O 0 7.586428409922519e-07
with O 0 1.2826983031288819e-08
wild O 0 3.682600606680353e-07
- O 0 2.433806730550714e-05
type O 0 3.1626116197003284e-06
tetraploid O 0 3.065237615373917e-05
morulae O 0 0.00010360465967096388
rescues O 0 2.7610341930994764e-05
the O 0 6.158613814477576e-07
gastrulation B-Disease 0 8.451063331449404e-05
defect I-Disease 0 0.00019768878701142967
. O 0 2.280808530485956e-06

These O 0 2.030031737376703e-06
results O 0 8.367389455088414e-06
indicate O 0 6.931634857210156e-07
that O 0 3.876758114529366e-08
Smad4 O 0 8.155612704285886e-06
is O 0 4.841314904524552e-08
initially O 0 4.6310834278529e-08
required O 0 1.820988804190904e-09
for O 0 1.1361839247214789e-09
the O 0 2.272997567942525e-09
differentiation O 0 1.6722010443004365e-08
of O 0 3.3423424028455884e-09
the O 0 2.7980288308526724e-08
visceral O 0 1.5151292700466001e-06
endoderm O 0 5.129827968630707e-06
and O 0 3.350322330675226e-08
that O 0 5.273649961168303e-09
the O 0 1.3016087763162432e-08
gastrulation B-Disease 0 2.398061724306899e-06
defect I-Disease 0 3.7554016216745367e-06
in O 0 1.0835015551435845e-08
the O 0 1.6857599760555786e-08
epiblast O 0 7.176180588430725e-06
is O 0 3.4452597219569725e-08
secondary O 0 4.196206759843335e-08
and O 0 2.32666597099751e-08
non O 0 3.5112557839056535e-07
- O 0 1.7295946236117743e-05
cell O 0 0.00017157659749500453
autonomous O 0 7.657279638806358e-06
. O 0 1.4915696056050365e-06

Rescued O 0 0.003693661652505398
embryos O 0 0.0007033937145024538
show O 0 0.00024218225735239685
severe O 0 0.0003849898639600724
anterior O 0 0.000525388983078301
truncations O 0 0.00011516848462633789
, O 0 1.2723930922220461e-06
indicating O 0 3.778760913064616e-07
a O 0 3.887998900609091e-08
second O 0 2.945319863556506e-07
important O 0 1.1119264620162994e-08
role O 0 4.327650060531596e-08
for O 0 3.0622089752796455e-08
Smad4 O 0 1.3295935787027702e-05
in O 0 3.9031385767884785e-07
anterior O 0 9.586901433067396e-05
patterning O 0 0.00039096095133572817
during O 0 4.0085365071718115e-06
embryogenesis O 0 5.084156146040186e-05
. O 0 2.0627178400900448e-06

Prevalence O 0 0.001481270301155746
of O 0 4.924659720018099e-07
p16 O 0 1.214669373439392e-05
and O 0 4.6387657448576647e-07
CDK4 O 0 0.00020468287402763963
germline O 0 0.00011031098256353289
mutations O 0 2.314978337381035e-05
in O 0 1.2983313979475497e-07
48 O 0 7.176577582868049e-06
melanoma B-Disease 1 0.9773658514022827
- O 0 0.009286991320550442
prone O 0 0.0008013200713321567
families O 0 1.9439212906036119e-07
in O 0 1.5935883368456416e-07
France O 0 0.00015080907905939966
. O 0 2.800351694531855e-06

The O 0 4.5821620915376116e-06
French O 0 0.00014520272088702768
Familial B-Disease 0 0.3749532401561737
Melanoma I-Disease 1 0.9999845027923584
Study O 0 1.2371647244435735e-05
Group O 0 2.3197473637992516e-05
. O 0 3.2115699468704406e-06

Germline O 0 0.006616927683353424
mutations O 0 0.00046486000064760447
in O 0 2.321311995956421e-07
the O 0 2.607010074484606e-08
p16 O 0 4.963312676409259e-07
and O 0 6.850278566616907e-08
CDK4 O 0 2.1579280655714683e-05
genes O 0 8.50766696203209e-07
have O 0 6.164536614505778e-08
been O 0 1.3914232965817064e-07
reported O 0 7.030312190181576e-07
in O 0 2.8387741046742576e-09
a O 0 1.3776996432568467e-08
subset O 0 1.5451450963155366e-07
of O 0 1.8713629401645449e-07
melanoma B-Disease 1 0.7346152067184448
pedigrees O 0 5.753487585025141e-06
, O 0 1.8784794519888237e-07
but O 0 3.008771187751336e-08
their O 0 1.3049651670371532e-07
prevalence O 0 1.3358035175770056e-05
is O 0 3.180296559435192e-08
not O 0 2.2522494091958833e-08
well O 0 3.555118865961049e-08
known O 0 6.203690645634197e-07
. O 0 1.4564925550075714e-06

We O 0 1.8148614344681846e-06
searched O 0 1.6501039681315888e-06
for O 0 3.184314678605915e-08
such O 0 6.520814110899664e-09
germline O 0 6.226769073691685e-06
mutations O 0 2.081310185531038e-06
in O 0 4.000391840008888e-08
48 O 0 1.3489998309523799e-06
French O 0 9.15723794605583e-05
melanoma B-Disease 1 0.9941661357879639
- O 0 0.004707834217697382
prone O 0 9.493627294432372e-05
families O 0 6.473848657151393e-08
selected O 0 2.143956834288474e-08
according O 0 7.168218463249332e-09
to O 0 3.901428069497115e-09
two O 0 8.354800407062157e-09
major O 0 3.32946576975246e-08
criteria O 0 5.8973743222168196e-08
families O 0 3.4844735985473108e-09
with O 0 6.797848506323589e-09
at O 0 1.5585416690555576e-07
least O 0 1.7428515519668508e-08
three O 0 3.07621164097327e-08
affected O 0 5.5951637989437586e-08
members O 0 1.4835947581559594e-08
( O 0 7.735539320208318e-09
n O 0 1.624223955332127e-06
= O 0 1.853354888226022e-06
20 O 0 1.9102351700439613e-07
) O 0 5.566622274244537e-09
or O 0 1.2326322185174377e-08
families O 0 2.1082742218681005e-09
with O 0 3.8209648778320116e-09
two O 0 1.4066586118133273e-07
affected O 0 1.1615060202530003e-07
members O 0 8.994081035496038e-09
, O 0 2.647341013073401e-09
one O 0 1.5869471292617732e-09
of O 0 8.320875100054081e-10
them O 0 1.1181024106576842e-08
affected O 0 1.927858761519019e-08
before O 0 1.5810597275844884e-08
the O 0 5.149619841660069e-09
age O 0 4.4898649242952615e-09
of O 0 1.0252962923118503e-09
50 O 0 4.197959668772455e-08
( O 0 1.2781265823491594e-08
n O 0 2.674271399882855e-06
= O 0 3.5769189707934856e-06
28 O 0 1.5982425338734174e-06
) O 0 9.72236069429755e-09
, O 0 9.046107862786812e-09
and O 0 1.750247058396326e-08
one O 0 2.8968200282974976e-08
additional O 0 5.186083029684596e-08
minor O 0 1.296777156767348e-07
criterion O 0 5.0702183216344565e-06
. O 0 9.02217436760111e-07

Sixteen O 0 7.403114068438299e-06
different O 0 4.61029316056738e-07
p16 O 0 1.0313729944755323e-05
germline O 0 8.432299364358187e-05
mutations O 0 7.908877887530252e-05
were O 0 3.3457698123129376e-07
found O 0 1.5570203970582952e-07
in O 0 6.828258847235702e-08
21 O 0 2.1378892256507243e-07
families O 0 1.4411865478791697e-08
, O 0 1.221296219711121e-08
while O 0 1.7334924606871027e-08
one O 0 2.9012104718617593e-08
germline O 0 4.658201305574039e-06
mutation O 0 7.25904897080909e-07
, O 0 2.931984433018897e-08
Arg24His O 0 5.360643172025448e-06
, O 0 6.276428621276864e-08
was O 0 2.8994909939683566e-07
detected O 0 4.1646006820883485e-07
in O 0 1.000304994391854e-08
the O 0 4.050775359587533e-08
CDK4 O 0 0.00016595140914432704
gene O 0 7.356214155151974e-06
. O 0 8.583777457715769e-07

The O 0 4.847958621212456e-07
frequency O 0 8.6056212467156e-07
of O 0 1.753321043906908e-08
p16 O 0 4.348488857885968e-07
gene O 0 4.286574721845682e-07
mutation O 0 4.35531632092534e-07
in O 0 1.3862293535282788e-08
our O 0 2.8808356589138384e-08
sample O 0 9.107953502507371e-08
( O 0 1.0281559603697588e-08
44 O 0 3.1128116972922726e-08
% O 0 1.144626260440873e-08
) O 0 2.2745283434488783e-09
is O 0 2.687533307010881e-09
among O 0 7.927258849349528e-10
the O 0 2.901474616123778e-09
highest O 0 3.217064659111202e-07
rates O 0 2.214422920587822e-06
yet O 0 1.874585251471217e-07
reported O 0 1.4931737268852885e-06
and O 0 7.0495920212465535e-09
the O 0 1.0762207125480927e-08
CDK4 O 0 2.382576531090308e-05
mutation O 0 3.4790835456988134e-07
is O 0 2.5174045070741613e-09
the O 0 1.7565067178537674e-09
second O 0 1.9009014806670166e-07
mutation O 0 6.528071594402718e-07
detected O 0 2.1553927354034386e-07
in O 0 2.4469335446752893e-09
this O 0 7.066540241851271e-09
gene O 0 1.0395257277195924e-06
worldwide O 0 9.720072284835624e-07
. O 0 6.084472374823235e-07

In O 0 3.322008342365734e-05
summary O 0 4.763238030136563e-05
, O 0 2.8336481250335055e-07
our O 0 8.121109829062334e-08
results O 0 4.4043446223440696e-07
show O 0 1.4123151004241663e-07
frequent O 0 8.025394038213562e-08
involvement O 0 6.520455997360841e-08
of O 0 2.5350299637239004e-09
the O 0 8.986227761909049e-09
p16 O 0 1.0208870548922278e-07
gene O 0 4.524529515492759e-07
in O 0 4.437998768480611e-08
familial B-Disease 0 0.0005474915378727019
melanoma I-Disease 1 0.9994818568229675
and O 0 1.8960072338813916e-06
confirm O 0 2.8211227345309453e-06
the O 0 1.0666119543145669e-08
role O 0 2.631323781088213e-08
of O 0 1.7379312433618566e-09
the O 0 1.2805227100898264e-08
CDK4 O 0 1.2848580809077248e-05
gene O 0 2.696876038044138e-07
as O 0 1.9114555271926292e-08
a O 0 4.6847350176904e-07
melanoma B-Disease 0 0.43607744574546814
- O 0 4.8259873437928036e-05
predisposing O 0 1.344864722341299e-05
gene O 0 3.7754107324872166e-06
. O 0 1.7880989844343276e-07
. O 0 6.149892328721762e-07

Progression O 0 0.0005437505315057933
of O 0 2.2807389541412704e-06
somatic O 0 8.205685298889875e-05
CTG O 0 0.0005684003699570894
repeat O 0 5.0460035708965734e-05
length O 0 1.4488191482087132e-06
heterogeneity O 0 4.892154265689896e-06
in O 0 8.023434361348336e-08
the O 0 2.99668094783101e-08
blood O 0 6.067238700779853e-06
cells O 0 2.9319811801542528e-05
of O 0 6.625110472668894e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.006500824820250273
. O 0 2.3689640329394024e-06

The O 0 2.067704826913541e-06
genetic O 0 1.3740916074311826e-05
basis O 0 1.9042270196223399e-06
of O 0 4.2640876927180216e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.6712483167648315
DM B-Disease 1 1.0
) O 0 1.53105622757721e-06
is O 0 1.2010414884855436e-08
the O 0 1.5856612689546523e-09
expansion O 0 2.958262435015513e-08
of O 0 8.240581550467141e-09
an O 0 2.222069639401525e-07
unstable O 0 0.0001466665999032557
CTG O 0 3.581208875402808e-05
repeat O 0 3.081928298342973e-06
in O 0 8.632251358164922e-09
the O 0 7.856217898449813e-09
34 O 0 4.119128149682183e-08
UTR O 0 1.1669035302475095e-06
of O 0 1.171730001914284e-08
the O 0 2.4034002876760496e-07
DM B-Disease 1 0.999997615814209
protein O 0 1.9103713384538423e-06
kinase O 0 4.121236997889355e-06
gene O 0 6.51686889341363e-07
on O 0 1.0417935527584632e-06
chromosome O 0 0.00012758643424604088
19 O 0 1.881991806840233e-06
. O 0 4.7075849352040677e-07

One O 0 9.463077503824024e-07
of O 0 2.417855426983806e-08
the O 0 1.3417101207835458e-08
principal O 0 1.02781328337187e-07
features O 0 4.634680195181318e-08
of O 0 9.04697028403234e-09
the O 0 2.562841245890013e-06
DM B-Disease 1 1.0
mutation O 0 2.632463292684406e-05
is O 0 1.6992862228448757e-08
an O 0 9.94153648292695e-09
extraordinarily O 0 3.4531615256128134e-07
high O 0 6.66283455075245e-08
level O 0 1.966812490650227e-08
of O 0 4.434806744058051e-09
somatic O 0 8.665708151056606e-07
mosaicism O 0 1.8086249838233925e-05
, O 0 6.830264709378753e-08
due O 0 5.025785654311221e-08
to O 0 2.6119124640899827e-08
an O 0 5.296343985605745e-08
extremely O 0 1.5159733379732643e-07
high O 0 1.0808207662194036e-07
degree O 0 7.190033812776164e-08
of O 0 1.4854182772694458e-08
somatic O 0 2.3068991140462458e-05
instability O 0 2.2014880869392073e-06
both O 0 1.8296518078386725e-08
within O 0 9.549236956729601e-09
and O 0 3.3097176554974794e-08
between O 0 5.4478274336133836e-08
different O 0 2.4002116560950526e-07
tissues O 0 3.197491605533287e-05
. O 0 1.167462414741749e-06

This O 0 3.529253717715619e-06
instability O 0 1.066048935172148e-05
appears O 0 1.40775523504999e-06
to O 0 1.0473137024291646e-07
be O 0 2.5922490820562416e-08
biased O 0 2.3111377345230721e-07
towards O 0 1.205746880117431e-08
further O 0 1.8077942698369043e-08
expansion O 0 3.9289478337423134e-08
and O 0 1.890065703946675e-08
continuous O 0 9.076235585325776e-08
throughout O 0 2.0965982727716437e-08
the O 0 1.3862876180326111e-08
life O 0 3.517327940016912e-08
of O 0 1.45553979979951e-09
an O 0 1.8592730910427235e-08
individual O 0 7.358362363873994e-09
, O 0 1.8541662427651318e-08
features O 0 1.5205634440462745e-07
that O 0 2.637580394093675e-07
could O 0 2.287477798290638e-07
be O 0 1.3892043959629063e-08
associated O 0 7.250086753174401e-09
with O 0 4.947884324479901e-09
the O 0 6.958394038747429e-08
progressive O 0 5.664741820510244e-06
nature O 0 1.6063015095824085e-07
of O 0 1.683096506610582e-08
the O 0 1.2689829418377485e-06
disease O 0 0.000218125554965809
. O 0 7.854000614315737e-07

Although O 0 2.3657062229176518e-06
increasing O 0 5.173018280402175e-07
measured O 0 1.575485271132493e-06
allele O 0 1.2383311513985973e-06
size O 0 2.3083710232185695e-07
between O 0 2.483654100160493e-07
patients O 0 2.804940777423326e-06
clearly O 0 7.462006834657586e-08
correlates O 0 6.550047260134306e-08
with O 0 7.446975480718265e-09
an O 0 6.66233859192289e-08
increased O 0 5.001982685826079e-07
severity O 0 7.275978532561567e-06
of O 0 1.2883174349553883e-07
symptoms O 0 6.016090264893137e-05
and O 0 3.1766656860554576e-08
an O 0 3.440032969592721e-08
earlier O 0 8.410104896938719e-07
age O 0 2.1793230331468294e-08
of O 0 6.335397095824646e-09
onset O 0 2.054198148471187e-06
, O 0 1.852059661189287e-08
this O 0 3.575238105568701e-09
correlation O 0 9.858287342012773e-08
is O 0 8.256947836571271e-08
not O 0 1.4578355411742905e-08
precise O 0 4.984378279004886e-07
and O 0 2.595421051410085e-07
measured O 0 7.43776467970747e-07
allele O 0 4.1685069618324633e-07
length O 0 6.769217293367547e-07
cannot O 0 1.6797491753095528e-07
be O 0 2.5904780542873596e-09
used O 0 1.1582866221715449e-08
as O 0 7.541025581758731e-09
an O 0 2.191502979087545e-08
accurate O 0 4.6036025196372066e-06
predictor O 0 4.9335998483002186e-05
of O 0 4.210115989167207e-08
age O 0 1.8236946175420599e-07
of O 0 7.347509978217204e-08
onset O 0 3.286214268882759e-05
. O 0 1.893105491035385e-06

In O 0 2.409431999694789e-06
order O 0 1.7655504791491694e-07
to O 0 4.841314904524552e-08
further O 0 6.751256620418644e-08
characterize O 0 1.5897752518867492e-06
the O 0 7.99320645228363e-08
dynamics O 0 1.5916722986730747e-05
of O 0 5.178294486540835e-07
DM B-Disease 1 0.9999998807907104
CTG O 0 0.001016145688481629
repeat O 0 2.8434189516701736e-05
somatic O 0 8.5505198512692e-06
instability O 0 1.6509274018972064e-06
, O 0 2.8633660775767567e-08
we O 0 1.584997022519019e-08
have O 0 8.719889699193573e-09
studied O 0 3.916624891076026e-08
repeat O 0 5.530536668629793e-07
length O 0 2.1466250643698004e-07
changes O 0 2.794700471042688e-08
over O 0 1.7912745065018498e-08
time O 0 6.761385407116904e-08
in O 0 1.4633242528816481e-07
111 O 0 0.00013336377742234617
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 5.9404399507911876e-05
with O 0 1.3112895658196067e-08
varying O 0 1.37643974085222e-06
clinical O 0 2.6095302018802613e-05
severity O 0 5.1893541240133345e-05
and O 0 1.1245978157603531e-06
CTG O 0 0.00016495624731760472
repeat O 0 8.600472028774675e-06
size O 0 1.0018862894867198e-07
over O 0 2.631805706698742e-08
time O 0 3.628370492947397e-08
intervals O 0 1.0692031793269052e-07
of O 0 4.062294056694782e-09
1 O 0 3.60869080395787e-07
- O 0 9.73225360212382e-06
7 O 0 3.6414890018932056e-06
years O 0 2.274467334473229e-07
. O 0 3.323185637782444e-07

We O 0 1.127980158344144e-05
have O 0 1.0922437354565773e-07
found O 0 3.584574059800616e-08
a O 0 1.6556347404161897e-08
direct O 0 1.227756882826725e-07
progression O 0 2.0120585304539418e-06
of O 0 3.730530551138145e-09
the O 0 2.8607241020495167e-08
size O 0 1.744971314110444e-07
heterogeneity O 0 9.173504622594919e-07
over O 0 4.5483933064360826e-08
time O 0 6.009366870785016e-08
related O 0 4.08038971499991e-08
to O 0 3.138524462542591e-08
initial O 0 2.73220223334647e-07
CTG O 0 5.997720563755138e-06
repeat O 0 1.5780912008267478e-06
size O 0 4.5973145290645334e-08
and O 0 1.930927773230451e-08
the O 0 5.241290068624949e-09
time O 0 3.7754858794869506e-08
interval O 0 7.101823484845227e-08
and O 0 4.2890853535482165e-08
always O 0 3.528414893594345e-08
biased O 0 2.477668772371544e-07
towards O 0 4.3805762572901585e-08
further O 0 7.00893068028563e-08
expansion O 0 6.399744734153501e-07
. O 0 1.1903044878636138e-06

Attempts O 0 2.2982516384217888e-05
to O 0 1.104557782127813e-06
mathematically O 0 3.7275917748047505e-06
model O 0 8.179987958101265e-07
the O 0 9.859152783064928e-08
dynamics O 0 2.1165236830711365e-05
have O 0 2.3229353018905385e-07
proved O 0 4.990042725694366e-07
only O 0 1.0032398023440692e-08
partially O 0 1.1747464441214106e-06
successful O 0 1.0004751516135002e-07
suggesting O 0 4.650707907671858e-08
that O 0 2.58715981971136e-09
individual O 0 1.0049054921523748e-09
specific O 0 5.972683236876719e-09
genetic O 0 2.234915427834494e-06
and O 0 1.5290892179109505e-06
/ O 0 0.0006768592866137624
or O 0 1.7341195643894025e-06
environmental O 0 3.2591080412203155e-07
factors O 0 2.121130293630813e-08
also O 0 2.2024060797321e-08
play O 0 1.3603536963557872e-08
a O 0 3.499474132695468e-08
role O 0 1.0298442987277667e-07
in O 0 6.02371130753454e-08
somatic O 0 5.664525815518573e-06
mosaicism O 0 8.434116170974448e-05
. O 0 3.331731193156884e-07
. O 0 7.029937023617094e-07

Aspartylglucosaminuria B-Disease 1 0.9999243021011353
among O 0 5.3929989007883705e-06
Palestinian O 0 2.7571848477236927e-05
Arabs O 0 3.0286519177025184e-05
. O 0 3.6623189316742355e-06

Aspartylglucosaminuria B-Disease 1 0.9999995231628418
( O 0 0.2658766806125641
AGU B-Disease 1 0.9999994039535522
) O 0 2.688573658815585e-06
is O 0 2.8308219768291565e-08
a O 0 1.4070383258513175e-07
rare O 0 3.1859331102168653e-06
disorder B-Disease 0 0.0005136298132129014
of I-Disease 0 2.3272429316989474e-08
glycoprotein I-Disease 0 3.2899049983825535e-05
metabolism I-Disease 0 0.001981621840968728
caused O 0 8.294423423649278e-06
by O 0 5.80982124631646e-08
the O 0 1.418699071109586e-06
deficiency B-Disease 0 4.45711484644562e-05
of I-Disease 0 4.033111622447905e-09
the I-Disease 0 4.886876325826961e-08
lysosomal I-Disease 0 0.0004119458608329296
enzyme I-Disease 0 3.314913556096144e-05
aspartylglucosaminidase I-Disease 0 0.00014339749759528786
( O 0 1.4694060723741131e-07
AGA O 0 1.4097829989623278e-05
) O 0 2.464572901317297e-07
. O 0 4.903739068140567e-07

AGU B-Disease 1 0.9999972581863403
is O 0 4.2193743865936995e-05
inherited O 0 0.00012872571824118495
as O 0 1.8557236103333707e-07
an O 0 1.7944211094800266e-07
autosomal O 0 0.36289218068122864
recessive O 0 0.3444667458534241
trait O 0 0.00020246949861757457
and O 0 9.198910220220569e-07
occurs O 0 3.715782881386076e-08
with O 0 3.4456650865877236e-09
a O 0 6.872566160609495e-08
high O 0 2.0171140135971655e-07
frequency O 0 8.920312666305108e-07
in O 0 4.7463892371979455e-08
Finland O 0 2.2383013856597245e-05
because O 0 2.6855465407038537e-08
of O 0 1.7365594517926297e-09
a O 0 1.980001940182774e-07
founder O 0 1.567650724609848e-05
effect O 0 1.6233011592703406e-06
. O 0 6.217354098225769e-07

While O 0 4.304355115891667e-06
very O 0 1.556999649210411e-07
few O 0 1.0733429434139907e-07
patients O 0 6.423481409001397e-07
with O 0 3.715694560924021e-07
AGU B-Disease 1 1.0
have O 0 1.296170353271009e-06
been O 0 2.9667191370208457e-07
reported O 0 1.5194644902294385e-06
from O 0 9.650676702221972e-09
non O 0 9.236060805051238e-08
- O 0 3.832605216302909e-06
Finnish O 0 8.647250979265664e-06
origin O 0 1.5085777249623789e-07
, O 0 8.338438561850126e-08
we O 0 2.6876892889049486e-07
diagnosed O 0 4.110140071134083e-05
the O 0 8.57982698221349e-08
disorder O 0 3.406075484235771e-05
in O 0 3.955015159817776e-08
8 O 0 7.570383786514867e-07
patients O 0 3.827458172622755e-08
originating O 0 8.594793321492489e-09
from O 0 1.5076853543405377e-08
3 O 0 2.4475329496453924e-07
unrelated O 0 4.380609652798739e-07
families O 0 3.165246553749057e-08
, O 0 9.441730952630678e-09
all O 0 1.1857449466745607e-09
Palestinian O 0 8.835705216370116e-07
Arabs O 0 3.015501874870097e-07
from O 0 1.2286045070197815e-08
the O 0 1.4078929133631846e-08
region O 0 5.238794642536959e-07
of O 0 2.23020002465546e-08
Jerusalem O 0 0.00025300943525508046
. O 0 5.534015599550912e-06

The O 0 5.267679171083728e-06
clinical O 0 0.00020263425540179014
diagnosis O 0 0.10448657721281052
of O 0 3.4986217087862315e-06
AGU B-Disease 1 0.9999998807907104
is O 0 4.186767910141498e-06
often O 0 1.830483284948059e-07
difficult O 0 5.737776973546715e-07
, O 0 4.459993974137433e-08
in O 0 8.095711656608273e-09
particular O 0 7.069425489447667e-09
early O 0 1.1649382969380895e-07
in O 0 4.912676931922988e-09
the O 0 6.130203011878166e-09
course O 0 1.468875012733406e-07
of O 0 8.155161879130901e-09
the O 0 5.470145083563693e-07
disease O 0 3.761308835237287e-05
, O 0 9.855952498583065e-09
and O 0 6.150487674716487e-09
most O 0 2.108728747174382e-09
of O 0 2.313883751270396e-09
the O 0 1.9478108015391626e-07
patients O 0 1.6440126273664646e-06
are O 0 5.760729138160059e-08
diagnosed O 0 7.004027429502457e-05
after O 0 1.0013341977810342e-07
the O 0 1.4381934754226222e-08
age O 0 1.9649977645030958e-08
of O 0 2.767212459175994e-09
5 O 0 3.500262835132162e-07
years O 0 2.2989529213646165e-07
. O 0 3.123982139641157e-07

However O 0 7.980400368978735e-06
, O 0 1.863455594275365e-07
since O 0 4.397930553068363e-08
these O 0 1.1707225411328182e-08
patients O 0 8.384608918277081e-08
excrete O 0 8.668537532230403e-08
early O 0 1.4024414518587491e-08
large O 0 4.332131986473087e-09
amounts O 0 7.238880606053044e-09
of O 0 3.713478191613717e-09
aspartylglucosamine O 0 6.341339030768722e-06
in O 0 1.0157981478187139e-07
urine O 0 8.901328101273975e-07
, O 0 8.920106431276054e-09
biochemical O 0 9.008626733475467e-08
screening O 0 7.305824567538366e-08
is O 0 1.69289382512261e-08
easy O 0 1.9368320636203862e-07
by O 0 5.4917070002602486e-08
urine O 0 6.156667495815782e-06
chromatography O 0 2.8850367925770115e-06
. O 0 9.70122897570036e-08
. O 0 3.825094267995155e-07

Detection O 0 2.6666344638215378e-05
of O 0 2.933817313532927e-07
heterozygous O 0 3.933615516871214e-06
carriers O 0 8.122300414470374e-07
of O 0 8.194567158170685e-08
the O 0 4.933101445203647e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999996423721313
telangiectasia I-Disease 1 1.0
( O 0 4.630978764907923e-06
ATM O 0 8.673437696415931e-05
) O 0 5.580891837553281e-08
gene O 0 1.6958678372702707e-07
by O 0 2.7173896910426265e-08
G2 O 0 4.177328082732856e-05
phase O 0 3.189127937730518e-06
chromosomal O 0 0.0006176470196805894
radiosensitivity O 0 5.591685476247221e-05
of O 0 1.546188741485821e-07
peripheral O 0 0.0005755004822276533
blood O 0 0.00029433067538775504
lymphocytes O 0 7.222251588245854e-05
. O 0 2.6198388241027715e-06

In O 0 0.0037532909773290157
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999995231628418
telangiectasia I-Disease 1 1.0
( O 0 0.0060350121930241585
A B-Disease 1 0.9999986886978149
- I-Disease 1 0.9999980926513672
T I-Disease 1 1.0
) O 0 4.7029548113641795e-06
patients O 0 8.133741289384488e-07
, O 0 1.0954500417881263e-08
mutations O 0 1.383770609209023e-07
in O 0 3.0771609704771663e-09
a O 0 2.7530944635145715e-08
single O 0 4.771414410242869e-07
gene O 0 3.9773738080839394e-07
, O 0 1.3401858289796564e-08
ATM O 0 1.7519507309771143e-05
, O 0 2.558029699173403e-08
result O 0 2.069718973984891e-08
in O 0 6.517733197597408e-08
an O 0 0.00018421263666823506
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 5.371443307922164e-07
embraces O 0 3.036073508155823e-07
a O 0 3.315789953717285e-08
variety O 0 1.8820724534407418e-08
of O 0 8.64081695084451e-09
clinical O 0 4.4638753138315224e-07
features O 0 8.679280654178001e-07
and O 0 6.710827733513725e-07
manifests O 0 4.440380052983528e-06
extreme O 0 1.392655349263805e-06
radiosensitivity O 0 9.622173820389435e-06
and O 0 1.7192677503885534e-08
a O 0 2.2160547175076317e-08
strong O 0 1.0571820752147687e-07
pre O 0 7.208576789707877e-06
- O 0 4.493236338021234e-05
disposition O 0 2.22560265683569e-05
to O 0 1.2844950560975121e-06
malignancy B-Disease 0 0.0002683960774447769
. O 0 1.4202613556335564e-06

Heterozygotes O 0 0.0002929999609477818
for O 0 6.221969215403078e-07
the O 0 3.4881324495472654e-08
ATM O 0 1.7858876162790693e-05
gene O 0 1.324906520494551e-06
have O 0 2.643537833080245e-08
no O 0 1.6149702020129553e-08
clinical O 0 5.5732225945348546e-08
expression O 0 2.90157569082794e-08
of O 0 2.446804359124144e-08
A B-Disease 1 0.9999948740005493
- I-Disease 1 0.9999847412109375
T I-Disease 1 1.0
but O 0 1.4237929462979082e-05
may O 0 6.435906470869668e-06
be O 0 8.012566468096338e-07
cancer B-Disease 0 1.356714801659109e-05
prone O 0 5.130651743456838e-07
with O 0 5.357413623841012e-09
a O 0 5.034074774812325e-07
moderate O 0 2.3764084744470892e-06
increase O 0 2.6921424023385043e-07
in O 0 4.134579256742654e-08
in O 0 1.9891054137133324e-07
vitro O 0 4.0468414226779714e-05
radiosensitivity O 0 6.588078394997865e-05
. O 0 1.1694882005031104e-06

We O 0 4.9688715080264956e-06
performed O 0 2.283516096213134e-06
a O 0 2.577164082140371e-07
blind O 0 6.5110994000860956e-06
chromosomal O 0 0.00043251889292150736
analysis O 0 6.932937708370446e-07
on O 0 1.6554567991988733e-06
G2 O 0 0.00033942825393751264
- O 0 2.2422733309213072e-05
phase O 0 9.528124564894824e-07
lymphocytes O 0 7.218993687274633e-07
from O 0 1.5451121271325974e-08
7 O 0 1.847787416409119e-07
unrelated O 0 8.978553864835703e-07
A B-Disease 1 0.9999171495437622
- I-Disease 1 0.9999977350234985
T I-Disease 1 1.0
patients O 0 4.588324372889474e-05
, O 0 1.0027347840946277e-08
13 O 0 2.3803155002610765e-08
obligate O 0 2.2902894158960407e-07
A B-Disease 1 0.9998552799224854
- I-Disease 1 0.9999904632568359
T I-Disease 1 1.0
heterozygotes O 0 7.184711284935474e-05
( O 0 5.2707161302123495e-08
parents O 0 9.655574118028198e-09
of O 0 1.9408448181934546e-09
the O 0 3.7013606402069854e-07
patients O 0 2.190969553339528e-06
) O 0 8.846639865112138e-09
, O 0 1.5149899112998355e-08
and O 0 2.1232228419876265e-08
14 O 0 6.031448407384232e-08
normal O 0 7.613624575242284e-08
controls O 0 7.738323120065616e-07
following O 0 8.737325174479338e-08
X O 0 2.304028021171689e-05
- O 0 2.4183018467738293e-06
irradiation O 0 1.7119647566232743e-07
with O 0 1.076228883789554e-08
1 O 0 1.6044550932292623e-07
Gy O 0 3.9471510717703495e-06
in O 0 1.0618013135399451e-08
order O 0 3.656756897285618e-09
to O 0 8.350323987826869e-09
evaluate O 0 3.5703472178738593e-08
this O 0 4.189359081863131e-09
cytogenetic O 0 6.090091915211815e-07
method O 0 6.46799875880788e-08
as O 0 6.395775908885071e-09
a O 0 1.1894377927035293e-08
tool O 0 1.371079889622706e-07
for O 0 7.944398028314481e-09
detection O 0 1.9404482998197636e-07
of O 0 2.6690932131145928e-08
ATM O 0 0.00032213536906056106
carriers O 0 2.21398590838362e-06
. O 0 8.470216812384024e-07

Both O 0 2.0032446627737954e-05
A B-Disease 1 0.9978373646736145
- I-Disease 1 0.9995785355567932
T I-Disease 1 0.9999997615814209
homozygotes O 0 0.00029332531266845763
and O 0 2.2137358257623418e-07
heterozygotes O 0 1.9453805180091877e-06
showed O 0 4.0997448991220153e-07
significantly O 0 1.0684775020308734e-07
increased O 0 2.2015074208070473e-08
levels O 0 1.924361292537924e-08
of O 0 1.166899199489535e-08
radiation O 0 0.00017597430269233882
- O 0 0.0019066445529460907
induced O 0 0.0037561061326414347
chromatid O 0 0.03013843297958374
damage O 0 0.00015568248636554927
relative O 0 2.2897388873843738e-07
to O 0 5.559505211749638e-08
that O 0 1.270107041762003e-08
of O 0 8.033415710428926e-09
normal O 0 1.0987781706717215e-06
controls O 0 4.423881910042837e-05
. O 0 3.2322643619409064e-06

These O 0 2.084840161842294e-06
results O 0 1.7983835505219758e-06
show O 0 1.1082173756449265e-07
that O 0 6.522082873772206e-09
the O 0 7.80999087623968e-09
G2 O 0 1.4509647371596657e-05
- O 0 6.858403139631264e-06
phase O 0 9.380807455272588e-07
chromosomal O 0 6.0991918871877715e-05
radiosensitivity O 0 6.252613275137264e-06
assay O 0 2.4904995825636433e-06
can O 0 2.0522811894352344e-08
be O 0 2.4142043919539447e-09
used O 0 3.878893650721693e-09
for O 0 8.863912936973861e-10
the O 0 4.828825339586729e-09
detection O 0 3.8919537814763316e-07
of O 0 4.487324645197077e-08
A B-Disease 1 0.9999092817306519
- I-Disease 1 0.9999096393585205
T I-Disease 1 0.9999998807907104
heterozygotes O 0 0.00017791282152757049
. O 0 1.671995960350614e-06

In O 0 2.061127133856644e-06
combination O 0 6.349862360366387e-07
with O 0 4.1055113086940764e-08
molecular O 0 2.8341742108750623e-06
genetic O 0 1.639305082790088e-05
analyses O 0 4.558012733468786e-06
, O 0 1.275801082556427e-07
this O 0 1.4041919627061361e-08
test O 0 9.969415515342916e-08
may O 0 3.9466135604016017e-07
be O 0 2.1318204979081656e-09
of O 0 5.86554305126441e-10
value O 0 4.47966215233464e-08
in O 0 2.8446294209061307e-08
studies O 0 1.8225499331947503e-08
of O 0 4.812844345281064e-09
familial B-Disease 0 1.1630500921455678e-05
and I-Disease 0 1.0144907491849153e-06
sporadic I-Disease 0 3.0640683689853176e-05
cancers I-Disease 0 0.0023882086388766766
aimed O 0 4.5063313791615656e-07
at O 0 9.599054919817718e-07
determination O 0 1.378991072442659e-07
of O 0 1.7996982792922722e-09
the O 0 1.2386302650213565e-08
potential O 0 2.314573599448977e-08
involvement O 0 3.018001493160227e-08
of O 0 5.11602982200543e-09
ATM O 0 0.00017153915541712195
mutations O 0 1.799439633032307e-05
in O 0 1.9450821753252967e-07
tumor B-Disease 0 0.00013274971570353955
risk O 0 7.617915116497898e-07
or O 0 4.449534429795676e-08
development O 0 5.596358931825307e-08
. O 0 1.4035713036264497e-07
. O 0 7.440446552209323e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999953508377075
telangiectasia I-Disease 1 0.9999997615814209
: O 0 6.293820661085192e-06
identification O 0 4.778340780831059e-07
and O 0 3.501557443996717e-08
detection O 0 1.715048369987926e-07
of O 0 1.1250699927245478e-08
founder O 0 5.202904048928758e-06
- O 0 2.44719376496505e-05
effect O 0 1.2071134278812679e-06
mutations O 0 3.3715321023919387e-07
in O 0 2.9629647624318523e-09
the O 0 5.725890872554373e-09
ATM O 0 1.877382783277426e-05
gene O 0 4.026265685297403e-07
in O 0 2.7092333709788363e-08
ethnic O 0 1.1823736940641538e-06
populations O 0 2.3598724965268048e-06
. O 0 9.602205182090984e-07

To O 0 1.2711911949736532e-06
facilitate O 0 4.7292019189626444e-07
the O 0 7.34713196948178e-08
evaluation O 0 9.403309775279922e-08
of O 0 1.45002365670166e-08
ATM O 0 2.068660978693515e-05
heterozygotes O 0 1.0012261100200703e-06
for O 0 2.067911708536485e-08
susceptibility O 0 1.306490958086215e-06
to O 0 1.1141156619487447e-07
other O 0 2.277829764807393e-07
diseases O 0 3.217974881408736e-05
, O 0 1.2201460286576093e-08
such O 0 4.493549088380178e-09
as O 0 7.583046226500301e-06
breast B-Disease 1 0.8378970623016357
cancer I-Disease 0 0.0005965391756035388
, O 0 8.930904016324348e-08
we O 0 3.2263951510458355e-08
have O 0 1.056576959257427e-08
attempted O 0 3.385583227100142e-07
to O 0 1.9968862119412734e-08
define O 0 3.5908012563368175e-08
the O 0 4.053153812577648e-09
most O 0 4.489976390686934e-09
common O 0 5.8508000222445844e-08
mutations O 0 5.186261091694178e-07
and O 0 6.2872937967028975e-09
their O 0 6.887654446785518e-09
frequencies O 0 1.7672396097623277e-06
in O 0 2.1633037249557674e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999992847442627
telangiectasia I-Disease 1 1.0
( O 0 0.00010993000614689663
A B-Disease 1 0.9999991655349731
- I-Disease 1 0.9999862909317017
T I-Disease 1 1.0
) O 0 5.116428383189486e-07
homozygotes O 0 1.7274479660045472e-06
from O 0 1.4917183932539047e-08
10 O 0 2.9089346043065234e-08
ethnic O 0 3.5077547977380164e-07
populations O 0 1.3551892834584578e-06
. O 0 7.809799171809573e-07

Both O 0 5.176534614292905e-06
genomic O 0 2.8779015337931924e-05
mutations O 0 0.00010746303451014683
and O 0 3.715492482569971e-07
their O 0 2.546942425851739e-07
effects O 0 2.1528812794713303e-06
on O 0 8.20840909909748e-07
cDNA O 0 2.8108290734962793e-06
were O 0 5.005748562325607e-07
characterized O 0 4.109714154765243e-06
. O 0 1.5801392692083027e-06

Protein O 0 5.5722510296618566e-05
- O 0 3.2226616895059124e-05
truncation O 0 1.7654809198575094e-05
testing O 0 3.2884244660635886e-07
of O 0 6.2317768723119116e-09
the O 0 1.0854853016439847e-08
entire O 0 1.0025592445117582e-07
ATM O 0 4.434404218045529e-06
cDNA O 0 4.4241173213777074e-07
detected O 0 6.412690254364861e-07
92 O 0 4.5866816122952514e-08
( O 0 7.681550506788426e-09
66 O 0 1.0412407647208965e-07
% O 0 2.3451827146914184e-08
) O 0 8.666895645603745e-09
truncating O 0 1.736229478410678e-06
mutations O 0 2.918716290878365e-06
in O 0 1.509132552257597e-08
140 O 0 6.225234017165349e-08
mutant O 0 1.1852705483761383e-06
alleles O 0 2.9040008939773543e-06
screened O 0 2.2057916794437915e-05
. O 0 1.9683002392412163e-06

The O 0 1.3281235169415595e-06
haplotyping O 0 2.6905232516583055e-05
of O 0 1.1733183669093705e-07
patients O 0 7.706970563958748e-07
with O 0 1.3723913561136669e-08
identical O 0 8.983727639133576e-06
mutations O 0 4.506986078922637e-05
indicates O 0 6.77434513818298e-07
that O 0 1.0636255431961672e-08
almost O 0 9.382148391523515e-09
all O 0 1.3101538742787966e-09
of O 0 1.005496019779173e-09
these O 0 1.4850435325897138e-09
represent O 0 1.1011122680315566e-08
common O 0 1.5138813580506394e-07
ancestry O 0 1.8620484070197563e-06
and O 0 1.2132008464504906e-07
that O 0 1.0548774298513308e-08
very O 0 1.0212489520711188e-08
few O 0 2.247001695820927e-08
spontaneously O 0 4.037789835820149e-07
recurring O 0 1.155504946837027e-06
ATM O 0 0.0002631055540405214
mutations O 0 4.139022348681465e-05
exist O 0 9.843225825534319e-07
. O 0 4.941511519973574e-07

Assays O 0 6.989376561250538e-05
requiring O 0 2.753089802354225e-06
minimal O 0 9.937120921676978e-07
amounts O 0 1.8685238956095418e-07
of O 0 3.1358197816189204e-08
genomic O 0 8.49015975745715e-07
DNA O 0 6.369546554196859e-06
were O 0 9.419304092261882e-08
designed O 0 5.329836483269901e-08
to O 0 2.2836060153963444e-08
allow O 0 1.21165566469017e-08
rapid O 0 1.2029195772811363e-07
screening O 0 3.317624575061018e-08
for O 0 3.251605429355209e-09
common O 0 6.110989403396161e-08
ethnic O 0 1.029215468406619e-06
mutations O 0 2.067164496111218e-05
. O 0 8.944760452322953e-07

These O 0 9.383222732139984e-07
rapid O 0 2.4049002149695298e-06
assays O 0 4.017116680188337e-06
detected O 0 3.850791927106911e-06
mutations O 0 1.612755795576959e-06
in O 0 3.0902903347396204e-08
76 O 0 1.593460723370299e-07
% O 0 9.837941128409966e-09
of O 0 3.642750545651552e-09
Costa O 0 3.3305318538623396e-06
Rican O 0 1.590610850144003e-06
patients O 0 5.113930114930554e-07
( O 0 5.050960982799779e-09
3 O 0 8.772710202720191e-08
) O 0 1.5308556200466228e-08
, O 0 1.3163966805507243e-08
50 O 0 1.0877195144587404e-08
% O 0 8.386860095299653e-09
of O 0 5.139179304336494e-09
Norwegian O 0 0.012561766430735588
patients O 0 5.937083642493235e-06
( O 0 8.966298814527818e-09
1 O 0 8.951641206067507e-08
) O 0 9.985511972843142e-09
, O 0 1.0374776593380375e-08
25 O 0 8.643916693529263e-09
% O 0 4.4333265947216205e-09
of O 0 6.044240219438279e-09
Polish O 0 0.001166291767731309
patients O 0 3.6234789604350226e-06
( O 0 1.0475510237029084e-08
4 O 0 2.33532091442612e-07
) O 0 1.6874874830818953e-08
, O 0 2.0510132259232705e-08
and O 0 4.038270517980891e-08
14 O 0 5.768711730524956e-08
% O 0 6.687289388906947e-09
of O 0 1.7516421646490699e-09
Italian O 0 4.078420897712931e-05
patients O 0 3.29308636537462e-06
( O 0 1.4483098276230066e-08
1 O 0 5.154997779754922e-07
) O 0 3.4184875374876356e-08
, O 0 2.104342300413009e-08
as O 0 1.4089082789325857e-08
well O 0 7.425954073880803e-09
as O 0 1.841808483504792e-08
in O 0 4.4157246748000034e-08
patients O 0 4.0495468311974037e-08
of O 0 3.0595042055381327e-09
Amish O 0 3.996470695710741e-05
/ O 0 0.00028662089607678354
Mennonite O 0 1.6811443856568076e-05
and O 0 6.758367590009584e-07
Irish O 0 4.834527658204024e-07
English O 0 1.942116369946234e-07
backgrounds O 0 8.274997753687785e-07
. O 0 6.425981382562895e-07

Additional O 0 4.274362709111301e-06
mutations O 0 4.278833876014687e-05
were O 0 2.001758474534654e-07
observed O 0 1.9724330968529102e-07
in O 0 1.380364178515947e-08
Japanese O 0 9.649612309203803e-08
, O 0 1.7465254131820984e-08
Utah O 0 7.091806253356481e-08
Mormon O 0 9.170759796006678e-08
, O 0 1.833088880687228e-08
and O 0 1.3524423359001503e-08
African O 0 4.208229142932396e-08
American O 0 4.919261868963076e-07
patients O 0 5.478519256030268e-07
. O 0 3.637892689312139e-07

These O 0 6.060624286874372e-07
assays O 0 1.6450006796731031e-06
should O 0 2.6851777690239942e-08
facilitate O 0 2.867475856760393e-08
screening O 0 1.0991549004302215e-07
for O 0 9.427841973774775e-08
A B-Disease 1 0.9997358918190002
- I-Disease 1 0.9998762607574463
T I-Disease 1 0.9999998807907104
heterozygotes O 0 8.1789094110718e-06
in O 0 1.5027989519467155e-08
the O 0 1.4550908922217332e-08
populations O 0 1.2954274097864982e-07
studied O 0 1.1907161479030037e-07
. O 0 4.577016099460707e-08
. O 0 4.943415774505411e-07

The O 0 1.310689276579069e-05
von B-Disease 1 0.925375759601593
Hippel I-Disease 1 0.9842504262924194
- I-Disease 1 0.9712753295898438
Lindau I-Disease 1 0.9964871406555176
tumor I-Disease 0 0.002703020116314292
suppressor O 0 3.901164745911956e-05
gene O 0 4.115624051337363e-06
is O 0 3.709954299324636e-08
required O 0 1.4679417681406903e-08
for O 0 2.253388053929939e-08
cell O 0 9.477108505961951e-06
cycle O 0 1.936488479259424e-05
exit O 0 1.4407173694053199e-05
upon O 0 3.581352530090953e-07
serum O 0 5.9532426348596346e-06
withdrawal O 0 8.517949027009308e-06
. O 0 1.0372530141466996e-06

The O 0 3.3680560136417625e-06
inactivation O 0 7.207597082015127e-05
of O 0 1.0731852739809256e-07
the O 0 6.427121093111055e-07
von B-Disease 1 0.9915390610694885
Hippel I-Disease 1 0.998890221118927
- I-Disease 1 0.9951819777488708
Lindau I-Disease 1 0.9995598196983337
( I-Disease 0 4.161700417171232e-06
VHL I-Disease 0 0.00017115929222200066
) I-Disease 0 3.3117009934358066e-07
tumor I-Disease 0 1.6535332179046236e-05
suppressor O 0 1.5758183508296497e-05
gene O 0 8.329341653734446e-06
predisposes O 0 1.6636196960462257e-05
affected O 0 5.304750629875343e-07
individuals O 0 1.1707515845671423e-08
to O 0 3.926805192122629e-08
the O 0 4.054532780628506e-07
human O 0 0.00012028939090669155
VHL B-Disease 1 0.9999879598617554
cancer I-Disease 1 0.9999991655349731
syndrome I-Disease 1 0.99998939037323
and O 0 7.640492185601033e-07
is O 0 1.3962751665985706e-07
associated O 0 1.2522563963557332e-07
with O 0 2.2491290962989297e-07
sporadic B-Disease 0 0.07491091638803482
renal I-Disease 1 0.9999990463256836
cell I-Disease 1 0.9999967813491821
carcinomas I-Disease 1 1.0
( O 0 0.00027520040748640895
RCC B-Disease 1 0.8515848517417908
) O 0 1.6994570160022704e-06
and O 0 5.15415058544022e-06
brain B-Disease 0 0.0050521232187747955
hemangioblastomas I-Disease 0 0.0006046059424988925
. O 0 2.8752422167599434e-06

VHL O 0 0.02407870814204216
- O 0 0.0011596677359193563
negative O 0 2.9598471883218735e-05
786 O 0 3.021607335540466e-05
- O 0 0.00011325975356157869
0 O 0 3.837019448837964e-06
RCC B-Disease 0 0.0001198663012473844
cells O 0 1.4298996120487573e-06
are O 0 1.5236894412851143e-08
tumorigenic O 0 3.009720785485115e-06
in O 0 3.623074178449315e-07
nude O 0 0.00014017718785908073
mice O 0 6.425603351090103e-05
which O 0 2.786706545521156e-07
is O 0 2.711539082156378e-08
suppressed O 0 3.3804333554599e-08
by O 0 2.0797614741496773e-09
the O 0 1.0306573372531602e-08
reintroduction O 0 2.7286969270789996e-06
of O 0 1.0578234821423393e-07
VHL B-Disease 0 9.180766937788576e-05
. O 0 2.649979933266877e-06

Remarkably O 0 0.00018122220353689045
, O 0 3.166810813581833e-07
this O 0 1.7095526771981895e-08
occurs O 0 2.1397653426902252e-08
without O 0 9.193541927743354e-09
affecting O 0 2.7985198158830826e-08
the O 0 8.638147974693311e-09
growth O 0 1.6010541230571107e-06
rate O 0 5.62402476589341e-07
and O 0 4.538375719675969e-08
cell O 0 5.7368315538042225e-06
cycle O 0 3.6317196645541117e-06
profile O 0 2.2772908891965926e-07
of O 0 2.1544579453802726e-09
these O 0 3.9612193525329076e-09
cells O 0 2.2879446248680324e-07
in O 0 3.779059554176456e-08
culture O 0 6.748842338311078e-07
. O 0 8.117824563669274e-07

The O 0 2.491934765203041e-06
786 O 0 1.6534260794287547e-05
- O 0 3.7252935726428404e-05
0 O 0 2.0057209439983126e-06
cell O 0 1.7587321053724736e-05
line O 0 3.3604233067308087e-06
, O 0 2.9572806425903764e-08
like O 0 8.030290210570001e-09
many O 0 1.7316386546895046e-08
cancer B-Disease 0 4.569759767036885e-06
cells O 0 3.5630074535220047e-07
, O 0 4.7045329409911574e-08
fails O 0 6.955023081900435e-07
to O 0 1.5606262948608673e-08
exit O 0 6.516937105516263e-07
the O 0 2.2234679875055008e-08
cell O 0 5.255305040918756e-06
cycle O 0 1.8063039988192031e-06
upon O 0 1.486932603711466e-07
serum O 0 1.6928167951846262e-06
withdrawal O 0 4.762403932545567e-06
. O 0 8.311989745379833e-07

Here O 0 1.0674650184228085e-05
, O 0 2.7249157596997975e-07
it O 0 2.2938472454825387e-08
is O 0 5.629511967697454e-09
shown O 0 1.211750433327552e-08
that O 0 3.6798459834841424e-09
reintroduction O 0 1.1066184413266456e-07
of O 0 3.3121159148663537e-09
the O 0 5.3027395807703215e-09
wild O 0 2.0212695517329848e-07
- O 0 7.79126366978744e-06
type O 0 1.7707656070342637e-06
VHL B-Disease 0 9.173782927973662e-06
gene O 0 6.969350465624302e-07
restores O 0 1.0633617648636573e-06
the O 0 1.2448996500324938e-08
ability O 0 3.347678045884095e-08
of O 0 1.601116039751105e-08
VHL O 0 0.0001098455541068688
- O 0 0.0008094180375337601
negative O 0 3.6261833884054795e-05
RCC B-Disease 0 0.0902278795838356
cancer I-Disease 0 7.81112612457946e-05
cells O 0 2.5375186396559e-07
to O 0 2.3956465255992043e-08
exit O 0 1.7109410919147194e-06
the O 0 2.622825512332838e-08
cell O 0 8.772441105975304e-06
cycle O 0 2.9342279503907776e-06
and O 0 7.244284461194184e-08
enter O 0 2.701988535136479e-07
G0 O 0 3.9622340409550816e-05
/ O 0 1.8251303117722273e-05
quiescence O 0 6.054106506780954e-06
in O 0 1.1283218981361642e-07
low O 0 2.347622967135976e-06
serum O 0 8.598569365858566e-06
. O 0 9.90298758551944e-07

Both O 0 1.8937209461000748e-05
VHL O 0 0.001332596642896533
- O 0 8.860547677613795e-05
positive O 0 1.7375596144120209e-06
and O 0 3.476290828530182e-07
VHL O 0 0.0001532160531496629
- O 0 0.00011343106598360464
negative O 0 8.515625268046279e-06
RCC B-Disease 0 0.00016233856149483472
cells O 0 1.98931161321525e-06
exit O 0 1.1780750810430618e-06
the O 0 2.157954881454316e-08
cell O 0 1.1447829820099287e-05
cycle O 0 2.0293116449465742e-06
by O 0 3.827618755281037e-08
contact O 0 1.4010425957167172e-06
inhibition O 0 2.765921863101539e-06
. O 0 7.2254471206179e-07

The O 0 3.28756664202956e-06
cyclin O 0 7.381702016573399e-05
- O 0 1.787390465324279e-05
dependent O 0 4.255214662407525e-06
kinase O 0 1.8108945369021967e-05
inhibitor O 0 2.6803916171047604e-06
, O 0 5.4029371199249e-08
p27 O 0 9.151702897725045e-07
, O 0 2.9022455549920778e-08
accumulates O 0 1.3682179655916116e-07
upon O 0 2.50736178486477e-08
serum O 0 3.677448887628998e-07
withdrawal O 0 6.516570465464611e-07
, O 0 6.764271809345246e-09
only O 0 1.1543228595201072e-09
in O 0 2.0067818518043623e-09
the O 0 2.4554893673922606e-09
presence O 0 8.87719941999876e-09
of O 0 4.899361361054844e-09
VHL B-Disease 0 4.076989625900751e-06
, O 0 4.26292139366069e-08
as O 0 6.796655238616722e-09
a O 0 2.538094001636182e-08
result O 0 2.1124495930280318e-08
of O 0 1.0197943600687154e-09
the O 0 1.091955859067184e-08
stabilization O 0 8.395570461061652e-08
of O 0 3.1202227468440924e-09
the O 0 1.9040472309939105e-08
protein O 0 1.5401373048007372e-06
. O 0 6.030408030710532e-07

We O 0 3.7530139707087073e-06
propose O 0 1.6182714261958608e-06
that O 0 2.8072873803353104e-08
the O 0 2.2382927511443995e-08
loss O 0 4.857603244090569e-07
of O 0 4.373227113774192e-09
wild O 0 6.662293685621989e-07
- O 0 2.5376799385412596e-05
type O 0 3.515347543725511e-06
VHL B-Disease 0 1.1305809493933339e-05
gene O 0 1.385493987982045e-06
results O 0 2.0066879358182632e-07
in O 0 1.2777993108059604e-09
a O 0 1.4542362869462977e-08
specific O 0 1.874048471961487e-08
cellular O 0 2.509407750039827e-05
defect O 0 1.4170509530231357e-05
in O 0 7.510612221039992e-08
serum O 0 1.120818296840298e-06
- O 0 7.574502888019197e-06
dependent O 0 4.575263119477313e-06
growth O 0 2.4802270672807936e-06
control O 0 7.22327058610972e-07
, O 0 5.907089928314235e-08
which O 0 3.742762828551349e-07
may O 0 2.34687081501761e-06
initiate O 0 3.328283582959557e-06
tumor B-Disease 0 6.57967830193229e-05
formation O 0 2.4030066470004385e-06
. O 0 1.6139219951583073e-06

This O 0 1.9541027995728655e-06
is O 0 2.061430564026523e-07
corrected O 0 6.4780879256431945e-06
by O 0 9.686600854763583e-09
the O 0 6.84037937404014e-09
reintroduction O 0 2.428717778002465e-07
of O 0 6.875093383484909e-09
wild O 0 3.585853391996352e-07
- O 0 4.0401704609394073e-05
type O 0 4.320962943893392e-06
VHL B-Disease 0 5.157655323273502e-05
, O 0 1.809861487345188e-07
implicating O 0 5.909731498832116e-06
VHL B-Disease 0 7.669791557418648e-06
as O 0 3.0132561334994534e-08
the O 0 6.619902404025879e-09
first O 0 2.924049340435886e-07
tumor B-Disease 0 3.5056220895057777e-06
suppressor O 0 2.5136739623121684e-06
involved O 0 4.41580070287273e-08
in O 0 5.080798448631185e-09
the O 0 3.740106002680932e-09
regulation O 0 2.98009421584311e-08
of O 0 5.324001683959523e-09
cell O 0 1.1117292160633951e-05
cycle O 0 1.1574998097785283e-05
exit O 0 2.6326793886255473e-05
, O 0 9.107727549917399e-08
which O 0 3.1557760848954786e-08
is O 0 1.258695103700802e-08
consistent O 0 3.489849120796862e-08
with O 0 4.67305971696419e-09
its O 0 4.481281905555079e-07
gatekeeper O 0 4.9027521527023055e-06
function O 0 6.83134615542258e-08
in O 0 2.0636800712736658e-08
the O 0 1.8427859060921037e-07
kidney O 0 0.00010086085239890963
. O 0 1.6562638904815685e-07
. O 0 6.366397542478808e-07

Piebaldism B-Disease 1 0.999996542930603
with O 0 0.033352967351675034
deafness B-Disease 1 1.0
: O 0 6.4725486481620464e-06
molecular O 0 7.791642019583378e-06
evidence O 0 1.7576947186626057e-07
for O 0 2.5571956996373046e-08
an O 0 6.080226739868522e-07
expanded O 0 0.00025656793150119483
syndrome O 1 0.9992615580558777
. O 0 2.502179086150136e-06

In O 0 1.114083261199994e-06
a O 0 3.278226188285771e-07
South O 0 1.9628855341125018e-07
African O 0 8.857279709673094e-08
girl O 0 7.342578101088293e-07
of O 0 1.1520688403265922e-08
Xhosa O 0 7.361878670053557e-05
stock O 0 1.6867939848452806e-05
with O 0 1.1084478046541335e-07
severe O 0 4.353106487542391e-05
piebaldism B-Disease 0 0.0003239950747229159
and O 0 2.9961212931084447e-05
profound O 0 0.0012799660908058286
congenital O 1 1.0
sensorineural B-Disease 1 0.9999998807907104
deafness I-Disease 1 1.0
we O 0 3.772808486246504e-05
identified O 0 1.1478025498945499e-06
a O 0 3.5249978935780746e-08
novel O 0 1.3504502760497417e-07
missense O 0 1.3051235328020994e-06
substitution O 0 3.3066697824324365e-08
at O 0 4.510596340878692e-08
a O 0 1.2966258289281996e-08
highly O 0 2.0189840910234125e-08
conserved O 0 6.476454927906161e-08
residue O 0 3.414057232475898e-07
in O 0 4.1254946125945935e-09
the O 0 2.7223006071608324e-09
intracellular O 0 6.834083166040728e-08
kinase O 0 6.877234000057797e-07
domain O 0 4.236771644627879e-08
of O 0 3.2366931357330486e-09
the O 0 2.986245206670901e-08
KIT O 0 8.643219189252704e-06
proto O 0 4.55256704299245e-05
- O 0 1.45366011565784e-05
oncogene O 0 2.0674660845543258e-05
, O 0 8.795831263341825e-08
R796G O 0 2.2919550701772096e-06
. O 0 5.695850973097549e-07

Though O 0 2.9038876164122485e-05
auditory B-Disease 0 0.0013267238391563296
anomalies I-Disease 1 0.6297926902770996
have O 0 5.821329409627651e-07
been O 0 1.2102690050141973e-07
observed O 0 2.3873954546616005e-07
in O 0 3.950996685375685e-08
mice O 0 2.0266097635612823e-06
with O 0 3.037938256511552e-08
dominant O 0 8.256896762759425e-06
white O 0 1.1359188647475094e-05
spotting O 0 0.0001796166761778295
( O 0 1.5846333099034382e-06
W O 0 0.007326193153858185
) O 0 5.7927476149188806e-08
due O 0 8.265866568990532e-08
to O 0 6.950646991299436e-08
KIT O 0 0.0007203545537777245
mutations O 0 0.0016755834221839905
, O 0 8.106969289656263e-06
deafness B-Disease 1 1.0
is O 0 9.055551117853611e-07
not O 0 4.011746312926334e-08
typical O 0 1.828236122491944e-07
in O 0 1.7799139584440127e-07
human O 0 6.417027407223941e-07
piebaldism B-Disease 0 0.00010267338075209409
. O 0 1.7764251651897212e-06

Thus O 0 6.5102426560770255e-06
, O 0 1.7477091773798747e-07
the O 0 3.473261500630542e-08
occurrence O 0 2.7187222713109804e-06
of O 0 1.8865200672735227e-06
sensorineural B-Disease 1 0.9999972581863403
deafness I-Disease 1 1.0
in O 0 9.431576472707093e-06
this O 0 2.0034677561397984e-07
patient O 0 8.828066029309412e-07
extends O 0 4.9711569971577774e-08
considerably O 0 1.6815636172395898e-07
the O 0 5.958085580459738e-09
phenotypic O 0 1.0776631143016857e-07
range O 0 3.7824193555024976e-08
of O 0 5.23924148509991e-09
piebaldism B-Disease 0 7.914236448414158e-06
due O 0 1.3940463361450384e-07
to O 0 1.2534866478119966e-08
KIT O 0 1.5533851183135994e-06
gene O 0 4.017126116195868e-07
mutation O 0 1.9877059287409793e-07
in O 0 5.5165010337532294e-09
humans O 0 3.0875387579953895e-08
and O 0 3.480954546830617e-08
tightens O 0 2.742049764492549e-05
the O 0 6.369567984165769e-08
clinical O 0 1.5012008702797175e-07
similarity O 0 6.431437071796609e-08
between O 0 2.917563968196646e-08
piebaldism B-Disease 0 2.3573873477289453e-05
and O 0 6.185088352594903e-08
the O 0 2.816908262204265e-09
various O 0 1.5671878239587045e-09
forms O 0 1.920621599538208e-07
of O 0 1.15628870389628e-06
Waardenburg B-Disease 1 0.9999837875366211
syndrome I-Disease 1 0.9999423027038574
. O 0 3.033624977888394e-07
. O 0 8.734506877772219e-07

Cycloheximide O 0 0.00026601357967592776
facilitates O 0 6.341544121823972e-06
the O 0 1.2148703376624326e-07
identification O 0 1.1643651731674254e-07
of O 0 1.155656192963761e-08
aberrant O 0 3.268382215537713e-06
transcripts O 0 2.5663530323072337e-06
resulting O 0 2.7205641117689083e-07
from O 0 9.249614407735862e-09
a O 0 3.4728969922070974e-08
novel O 0 2.515357095944637e-07
splice O 0 0.00019142784003634006
- O 0 4.162538971286267e-05
site O 0 5.22506115885335e-06
mutation O 0 1.0943932693407987e-06
in O 0 1.6375885536490387e-08
COL17A1 O 0 1.8699282009038143e-05
in O 0 3.868750653168718e-08
a O 0 2.3863393039391667e-07
patient O 0 2.3746461010887288e-06
with O 0 3.836017299363448e-07
generalized O 0 0.0009312473121099174
atrophic B-Disease 1 0.9971592426300049
benign I-Disease 1 0.9105628728866577
epidermolysis I-Disease 1 0.9941102862358093
bullosa I-Disease 1 0.9340677857398987
. O 0 5.4585791076533496e-05

Patients O 0 0.00134788837749511
with O 0 3.2876012028282275e-06
generalized O 0 0.002070736140012741
atrophic B-Disease 1 0.9998375177383423
benign I-Disease 1 0.9969999194145203
epidermolysis I-Disease 1 0.9986600875854492
bullosa I-Disease 1 0.9479588270187378
often O 0 1.0923674381047022e-05
show O 0 3.1033321192808216e-06
decreased O 0 1.816546273403219e-06
expression O 0 1.241556617515016e-07
of O 0 2.7639856625683024e-08
type O 0 4.991859896108508e-06
XVII O 0 0.00010031316196545959
collagen O 0 2.2913211068953387e-05
, O 0 4.148711596485555e-08
a O 0 5.364542943198103e-08
transmembrane O 0 1.3047825859757722e-06
hemidesmosomal O 0 1.944013547472423e-06
protein O 0 1.8791138245433103e-07
encoded O 0 1.3273242416289577e-07
by O 0 5.9131433971515435e-08
COL17A1 O 0 8.230544335674495e-05
. O 0 1.066196887222759e-06

This O 0 5.242655788606498e-06
report O 0 2.5490837742836447e-06
documents O 0 1.466386549964227e-07
a O 0 4.5732640785445255e-08
novel O 0 1.5636510397598613e-07
splice O 0 0.00020389261771924794
- O 0 4.7849818656686693e-05
site O 0 4.8890296966419555e-06
mutation O 0 1.6293374756060075e-06
in O 0 2.1741540123798586e-08
COL17A1 O 0 1.2674430763581768e-05
in O 0 3.015792060523381e-08
a O 0 3.517516518058983e-07
patient O 0 2.475248265909613e-06
with O 0 2.19223935005175e-07
generalized O 0 0.0006530763348564506
atrophic B-Disease 1 0.9993879795074463
benign I-Disease 1 0.9165111780166626
epidermolysis I-Disease 1 0.9350938200950623
bullosa I-Disease 0 0.4004024267196655
, O 0 5.316907390806591e-06
and O 0 9.167559511524814e-08
applies O 0 3.045271412815964e-08
a O 0 2.319709224707367e-08
new O 0 5.1527763389458414e-08
methodology O 0 1.7122162887517334e-07
to O 0 3.8406579250249706e-08
define O 0 2.517320183414995e-07
and O 0 7.363012599626018e-08
characterize O 0 7.232065399875864e-07
the O 0 2.0211878393183724e-08
resulting O 0 1.6833092786328052e-07
mRNA O 0 8.922303891267802e-07
splice O 0 0.00010099069186253473
variants O 0 9.832288924371824e-06
. O 0 1.4461837736234884e-06

Mutational O 0 0.0007584011182188988
analysis O 0 8.31192301120609e-06
of O 0 2.0962627900189545e-07
COL17A1 O 0 9.87046369118616e-05
identified O 0 3.38842050950916e-06
a O 0 2.9113834898453206e-07
maternally O 0 2.4396835215156898e-05
inherited O 0 0.00012131227413192391
G O 0 0.0018971204990521073
- O 0 1.4883776202623267e-05
to O 0 1.5124714991543442e-06
- O 0 4.232576611684635e-05
T O 0 0.00010785931226564571
transversion O 0 1.1229645906496444e-06
at O 0 5.791863699755595e-08
the O 0 4.440104728331562e-09
- O 0 7.327245157284779e-07
1 O 0 9.290709357401283e-08
position O 0 9.749550855531197e-08
of O 0 1.1486591233733634e-08
exon O 0 3.1038352972245775e-06
32 O 0 6.92570779392554e-07
. O 0 4.2949633893840655e-07

This O 0 5.58593910682248e-07
acceptor O 0 1.9156802864017664e-06
splice O 0 8.472130866721272e-05
- O 0 3.387314427527599e-05
site O 0 2.816625283230678e-06
mutation O 0 1.2012279739792575e-06
led O 0 2.3416159677935866e-08
to O 0 7.969150672693104e-09
the O 0 5.319291673799853e-09
formation O 0 2.203347371221298e-08
of O 0 5.687446513746863e-09
aberrant O 0 5.030868805988575e-07
transcripts O 0 3.1983702797333535e-07
present O 0 3.2493378654407934e-08
at O 0 6.187660517298355e-08
extremely O 0 2.2823309109298862e-07
low O 0 1.0599860615911894e-06
levels O 0 6.968560342102137e-07
. O 0 7.135386113077402e-07

Based O 0 9.22605613595806e-06
on O 0 5.974828809485189e-07
our O 0 1.2346880851055175e-07
recent O 0 1.5122998320293846e-07
finding O 0 8.728280675995848e-08
that O 0 4.238945905399305e-08
cycloheximide O 0 1.460725070501212e-05
stabilized O 0 2.2622825781581923e-05
mutant O 0 9.70564997260226e-07
COL17A1 O 0 1.139078722189879e-05
transcripts O 0 8.613224053988233e-07
in O 0 4.557259458692897e-08
keratinocytes O 0 5.272192083793925e-06
homozygous O 0 8.424939892393013e-07
for O 0 1.4262067971060333e-08
a O 0 1.4551304161614098e-07
frameshift O 0 0.00026367188547737896
mutation O 0 7.456907951564062e-06
, O 0 1.7170195931726084e-08
the O 0 8.52394066441775e-09
effects O 0 1.3933977527358365e-07
of O 0 2.0512860299248814e-09
the O 0 1.8009970403909392e-08
splice O 0 0.0005090865888632834
- O 0 1.8409768017590977e-05
site O 0 2.0849854536209023e-06
mutation O 0 1.2544964533844905e-07
on O 0 1.0454233034806748e-08
splicing O 0 2.472787059559778e-07
of O 0 9.430140224253591e-09
COL17A1 O 0 1.0659737199603114e-05
transcripts O 0 4.6864329306117725e-07
were O 0 9.508199561025776e-09
determined O 0 8.80359873889347e-09
using O 0 1.6731455332319456e-08
reverse O 0 7.603624112562102e-07
transcriptase O 0 3.1857173325988697e-06
polymerase O 0 8.019485449040076e-07
chain O 0 1.952763568624505e-06
reaction O 0 2.0032913994327828e-08
of O 0 1.42154576998621e-09
total O 0 1.1453644255254858e-08
RNA O 0 3.744090975033032e-07
from O 0 1.8366586473916868e-08
keratinocytes O 0 1.0097584208779153e-06
incubated O 0 2.886077652419772e-07
for O 0 1.8732551509970108e-08
2 O 0 3.9934093365445733e-07
. O 0 6.314420488706673e-07

5 O 0 1.3537551240005996e-05
h O 0 5.302630961523391e-05
in O 0 8.207440771457186e-08
the O 0 2.1574198427742886e-08
presence O 0 3.146658400510205e-08
or O 0 3.4831593609396805e-08
absence O 0 1.3067754878193227e-08
of O 0 2.511917562841859e-09
10 O 0 4.7710052797356184e-08
microg O 0 5.7752786233322695e-06
cycloheximide O 0 1.0669084076653235e-05
per O 0 1.0727959534051479e-06
ml O 0 5.334299567039125e-05
. O 0 1.3638253903991426e-06

Using O 0 1.7827419469540473e-06
this O 0 6.017039311245753e-08
approach O 0 3.3820046496657596e-07
, O 0 8.30764079751134e-08
an O 0 9.721437521648113e-08
abnormally O 0 8.245635399362072e-06
spliced O 0 0.0004714846145361662
transcript O 0 0.0005015444476157427
was O 0 4.051304131280631e-06
identified O 0 3.269296939834021e-07
that O 0 2.8764142179227292e-09
contains O 0 1.4499011991020438e-09
an O 0 2.9511262322756693e-09
extra O 0 6.2083107543742244e-09
264 O 0 1.1531064991743278e-08
bases O 0 5.0938591122928756e-09
upstream O 0 5.211159148643674e-08
from O 0 9.430229930273981e-09
exon O 0 3.192933206719317e-07
32 O 0 4.996366698151178e-08
, O 0 7.789640044109092e-09
resulting O 0 2.14673523402098e-08
in O 0 1.4018637806145762e-08
a O 0 1.60708134444576e-06
premature O 0 1.4988911061664112e-05
termination O 0 1.776199837877357e-06
codon O 0 3.1617641980119515e-06
27 O 0 2.5118001758528408e-06
bp O 0 1.88196081580827e-05
downstream O 0 9.357450494462682e-07
from O 0 4.3338946653648236e-08
the O 0 3.608748855299382e-08
cryptic O 0 5.386804787121946e-06
splice O 0 0.00032891464070416987
site O 0 2.0103161659790203e-05
. O 0 1.144449242929113e-06

Three O 0 1.4182512586558005e-06
other O 0 5.2216265089555236e-08
splice O 0 3.347685924381949e-05
variants O 0 2.6113057174370624e-06
, O 0 3.8787920431104794e-08
including O 0 2.125235321059904e-09
one O 0 5.588985274584957e-09
derived O 0 1.6256322510344035e-08
from O 0 2.2115986819670752e-09
the O 0 2.8925728479123336e-09
skipping O 0 9.772208642289115e-08
of O 0 3.5974558887374997e-09
exon O 0 1.8534396986069623e-06
32 O 0 2.6131340291613014e-07
, O 0 1.1809876632185023e-08
were O 0 1.479742817167562e-08
also O 0 2.0174411474727094e-07
identified O 0 1.8309823417439475e-06
. O 0 6.35776359558804e-07

These O 0 2.3970098936842987e-06
results O 0 4.788723799720174e-06
indicate O 0 2.79211178622063e-07
the O 0 1.5174828504882498e-08
usefulness O 0 9.336986295238603e-08
of O 0 7.985294203649573e-09
cycloheximide O 0 1.7271617252845317e-05
treatment O 0 8.250948440036154e-07
in O 0 1.0258523808204245e-08
evaluating O 0 5.3502475338973454e-08
the O 0 1.9197861078623646e-08
abnormal O 0 3.451818031408038e-07
processing O 0 3.746790611103279e-08
of O 0 1.5653744966925842e-09
mRNA O 0 4.999970215635585e-08
due O 0 3.90370011871255e-08
to O 0 1.53869486041458e-08
splice O 0 6.21033032075502e-05
- O 0 2.9576265660580248e-05
site O 0 1.6193511328310706e-05
mutations O 0 7.85017527960008e-06
, O 0 3.010476135045792e-08
because O 0 2.293549883347623e-08
( O 0 4.056156299725444e-08
i O 0 2.4945927634689724e-07
) O 0 2.2711958536092425e-08
aberrant O 0 2.2299795432445535e-07
splicing O 0 1.2897904753117473e-06
often O 0 5.1349100971265216e-08
generates O 0 1.0247752157965806e-07
a O 0 2.281421132011019e-07
premature O 0 5.578918717219494e-06
termination O 0 5.635632760458975e-07
codon O 0 1.3366013718041359e-06
, O 0 2.2565110668892885e-07
( O 0 5.975557115789343e-08
ii O 0 3.503315838315757e-06
) O 0 5.615745024556418e-08
transcripts O 0 2.854962986020837e-07
with O 0 4.374489037672902e-08
premature O 0 3.5822206427837955e-06
termination O 0 2.870037576485629e-07
codons O 0 4.0727042005528347e-07
can O 0 4.988291735230632e-08
occur O 0 3.074809740155615e-08
at O 0 4.079105764276392e-08
low O 0 4.3494966917023703e-07
or O 0 4.18298952808982e-07
undetectable O 0 2.7982798656012164e-06
levels O 0 3.879183907429251e-08
due O 0 2.4437632362150907e-08
to O 0 1.3105845297900487e-08
nonsense O 0 2.2690963419336185e-07
- O 0 5.828522944284487e-07
mediated O 0 1.1637339412118308e-06
mRNA O 0 1.3282904376410443e-07
decay O 0 4.3986187847622205e-07
, O 0 3.2411922035180396e-08
and O 0 1.2974228980056068e-07
( O 0 4.842395284754275e-08
iii O 0 3.416321533222799e-06
) O 0 2.3680390981439814e-08
the O 0 8.511105598074664e-09
levels O 0 1.3044246571780604e-08
of O 0 9.99087923503339e-10
these O 0 2.3834672013833824e-09
transcripts O 0 1.3574862123277853e-07
can O 0 1.9052640354288997e-08
be O 0 8.433732823220907e-09
increased O 0 1.5994707780464523e-08
by O 0 4.840816458795416e-08
cycloheximide O 0 5.2610768761951476e-05
. O 0 9.63772777140548e-07

A O 0 1.7888809452415444e-05
deletion O 0 0.00013311019574757665
mutation O 0 1.4510186701954808e-05
in O 0 3.710029545800353e-07
COL17A1 O 0 9.538698213873431e-05
in O 0 1.122425459243459e-07
five O 0 6.836938126753012e-08
Austrian O 0 4.46676931460388e-05
families O 0 1.4179197194152948e-07
with O 0 2.805585950227396e-07
generalized O 0 0.000378163909772411
atrophic B-Disease 1 0.9991322159767151
benign I-Disease 1 0.9638335704803467
epidermolysis I-Disease 1 0.9289983510971069
bullosa I-Disease 0 0.11726144701242447
represents O 0 4.201947376714088e-06
propagation O 0 1.45608146340237e-06
of O 0 3.548351301674302e-08
an O 0 1.0551212881182437e-07
ancestral O 0 2.0107878299313597e-05
allele O 0 0.0001655067317187786
. O 0 2.460278210492106e-06

Patients O 0 0.003077553119510412
with O 0 3.737608722076402e-06
generalized O 0 0.0028729308396577835
atrophic B-Disease 1 0.9999270439147949
benign I-Disease 1 0.99950110912323
epidermolysis I-Disease 1 0.9993975162506104
bullosa I-Disease 1 0.9843140840530396
, O 0 2.413995161987259e-06
a O 0 1.1882092820769685e-07
usually O 0 6.926877915702789e-08
nonlethal O 0 1.2939991620442015e-06
form O 0 1.4804801651280286e-07
of O 0 2.51475768209275e-07
junctional B-Disease 0 0.19155417382717133
epidermolysis I-Disease 1 0.9227568507194519
bullosa I-Disease 0 0.14234735071659088
, O 0 6.105805709921697e-07
have O 0 6.07253056728041e-08
generalized O 0 1.6955198134382954e-06
blistering B-Disease 0 0.0002473608765285462
, O 0 1.278488889511209e-05
nail B-Disease 1 0.9999984502792358
dystrophy I-Disease 1 0.9999860525131226
, O 0 1.2879596397397108e-05
patchy B-Disease 1 0.5683603882789612
alopecia I-Disease 1 0.9999957084655762
, O 0 2.2652550342172617e-06
and O 0 3.849976565106772e-06
dental B-Disease 0 0.0391266867518425
abnormalities I-Disease 1 0.7063770294189453
. O 0 3.6081821690459037e-06

Skin B-Disease 1 0.9999462366104126
fragility I-Disease 0 0.28616219758987427
in O 0 9.645827958593145e-07
most O 0 6.062034429987762e-08
cases O 0 2.9941784163156626e-08
is O 0 1.7514157235609673e-08
due O 0 9.410486256911099e-08
to O 0 1.0777986858556687e-07
mutations O 0 3.82825106726159e-07
in O 0 3.2486733303471738e-09
the O 0 3.0135824946597722e-09
gene O 0 1.237386300090293e-07
encoding O 0 4.858715101363487e-07
type O 0 8.729812179808505e-06
XVII O 0 0.0002941247948911041
collagen O 0 0.00022939623158890754
( O 0 4.290435526854708e-07
COL17A1 O 0 0.000136027651024051
) O 0 2.8258489237487083e-07
. O 0 5.746253464167239e-07

Recently O 0 0.00015134048589970917
, O 0 1.0407856052552233e-06
we O 0 8.510477300660568e-08
reported O 0 3.6707842809846625e-07
five O 0 1.5264586039620553e-08
Austrian O 0 7.2897578320407774e-06
families O 0 5.741039643680779e-08
with O 0 2.508400314127357e-07
generalized O 0 0.00022907186939846724
atrophic B-Disease 1 0.9975636005401611
benign I-Disease 1 0.9078255891799927
epidermolysis I-Disease 1 0.9793164134025574
bullosa I-Disease 1 0.6038544774055481
who O 0 1.2086710739822593e-05
share O 0 1.1806833981609088e-06
the O 0 2.0140916490163363e-08
same O 0 1.83969191880351e-07
COL17A1 O 0 0.0003429563366807997
mutation O 0 2.820377267198637e-05
. O 0 7.081155217747437e-07

Affected O 0 0.00012035891268169507
individuals O 0 2.592121006728121e-07
in O 0 3.9553697206429206e-08
three O 0 4.350965099320092e-08
families O 0 4.574755863018254e-08
are O 0 1.049210762715802e-08
homozygous O 0 1.7037039867773274e-07
for O 0 1.931712390046414e-08
4003delTC O 0 2.2897615963302087e-06
, O 0 8.05671263037766e-08
whereas O 0 2.5883064580511927e-08
those O 0 2.2369386343257247e-09
in O 0 3.801120307400652e-09
two O 0 2.2224504903078923e-08
others O 0 3.2808691230457043e-07
are O 0 1.594341547672684e-08
compound O 0 2.58382351603359e-06
heterozygotes O 0 1.555880044179503e-05
. O 0 6.046370799595024e-07

To O 0 3.6545316106639802e-06
determine O 0 4.6387393126678944e-07
if O 0 2.2871279981018233e-08
the O 0 6.233976446168299e-09
occurrence O 0 1.8752540142941143e-07
of O 0 6.649121253587964e-09
4003delTC O 0 1.7750178358255653e-06
in O 0 3.3804397503445216e-08
these O 0 2.5705688688759665e-09
unrelated O 0 4.28229256499435e-08
families O 0 9.299428782583163e-09
signifies O 0 8.523635131041374e-08
propagation O 0 5.905073408030148e-08
of O 0 2.6429314292641948e-09
an O 0 9.755407148759332e-09
ancestral O 0 8.281582495328621e-07
allele O 0 6.557093456649454e-06
or O 0 8.415097596525811e-08
a O 0 7.885795838546983e-08
mutational O 0 4.98484314448433e-06
hot O 0 4.163010544289136e-06
spot O 0 8.654939847474452e-06
, O 0 5.3168196956221436e-08
haplotypes O 0 1.2780482165908325e-06
were O 0 6.06153705007273e-08
determined O 0 5.776639255827831e-08
for O 0 1.636414559413879e-08
polymorphisms O 0 6.429532277252292e-06
both O 0 4.6522426799811e-08
within O 0 2.6475847292317667e-08
and O 0 2.989841618727951e-07
flanking O 0 7.46061559766531e-05
COL17A1 O 0 0.0031911982223391533
. O 0 2.6936036192637403e-06

Five O 0 1.1862773135362659e-05
intragenic O 0 0.00036575630656443536
polymorphisms O 0 0.0004369043745100498
were O 0 1.3532766161006293e-06
chosen O 0 2.4503307827217213e-07
based O 0 1.4131610726053623e-07
on O 0 2.4849950364114193e-07
their O 0 5.741636073253176e-07
informativeness O 0 0.0002442849799990654
. O 0 1.5203181646938901e-06

One O 0 1.129632778429368e-06
of O 0 3.300822015717131e-08
these O 0 9.748357676642172e-09
, O 0 6.181290501672265e-08
not O 0 5.916877299227963e-08
previously O 0 1.270758389182447e-06
reported O 0 1.3540778127207886e-05
, O 0 2.2704725211042387e-08
was O 0 1.9202646228677622e-07
2988 O 0 1.8847636340524332e-07
A O 0 5.216867862145591e-07
or O 0 3.1406239031639416e-07
C O 0 2.3653678908885922e-06
that O 0 5.170701644630071e-09
introduces O 0 2.5758463806369036e-08
a O 0 1.3044544999729624e-08
new O 0 1.2853506703436324e-08
restriction O 0 1.1267407451498457e-08
site O 0 1.6430175264758873e-07
for O 0 2.213287686458898e-08
Eco0109 O 0 1.4576514786313055e-06
I O 0 2.3962168143043527e-06
. O 0 4.3022481577281724e-07

All O 0 8.457139983875095e-07
the O 0 1.0559305962942744e-07
4003delTC O 0 1.6168029333130107e-06
alleles O 0 7.833370432308584e-07
showed O 0 3.857658157357946e-07
the O 0 6.025110188545568e-09
same O 0 2.0444046455736498e-08
haplotype O 0 4.697074018622516e-06
for O 0 1.3425549560963645e-08
these O 0 3.2040161634938613e-09
five O 0 4.138350817584069e-08
polymorphic O 0 1.0701253813749645e-05
markers O 0 1.4209184882929549e-05
. O 0 1.598834046490083e-06

Fourteen O 0 4.9674155889078975e-05
microsatellite O 0 0.00016639586829114705
polymorphisms O 0 0.0003737329097930342
were O 0 2.6528678063186817e-06
selected O 0 8.22910379838504e-08
based O 0 5.198372932113671e-08
on O 0 2.2415187572732975e-07
their O 0 9.220272545462649e-08
high O 0 3.760186473300564e-07
heterozygosity O 0 9.8666089343169e-07
and O 0 3.516824875759994e-08
their O 0 1.7346799552342418e-08
location O 0 3.630074161264929e-07
within O 0 3.249349944667301e-08
10q23 O 0 9.289590252592461e-07
- O 0 2.2524548057845095e-06
q25 O 0 2.4283247057610424e-06
near O 0 2.8425631626305403e-06
COL17A1 O 0 0.0001618624955881387
. O 0 1.457942062188522e-06

Three O 0 3.6677715797850396e-06
families O 0 8.400277806686063e-07
shared O 0 1.5001605788711458e-06
microsatellite O 0 8.026990690268576e-05
polymorphisms O 0 0.0001544148981338367
covering O 0 1.0111959454661701e-05
at O 0 3.508592044454417e-06
most O 0 7.251860267842858e-08
19 O 0 5.407973162618873e-07
cM O 0 7.39463587251521e-07
, O 0 2.3652720670952476e-08
whereas O 0 2.524946118853677e-08
the O 0 6.989143486180183e-09
others O 0 4.8865782531493096e-08
shared O 0 1.1142788025608752e-08
smaller O 0 5.292859839300945e-08
regions O 0 1.0037952336006128e-07
consistent O 0 9.544907442204931e-08
with O 0 1.1428658019951854e-08
cross O 0 1.898714231174381e-06
- O 0 1.5628294931957498e-05
over O 0 3.564666144484363e-07
events O 0 2.8397719731287907e-08
during O 0 1.421812267921041e-08
passage O 0 1.6901902100130428e-08
of O 0 1.879693067863286e-09
this O 0 4.966416167206944e-09
mutation O 0 9.966791481019754e-08
through O 0 8.242609261799316e-09
several O 0 2.827082568046535e-08
generations O 0 3.943611375234468e-07
. O 0 5.279530910229369e-07

These O 0 2.5388624180777697e-06
results O 0 5.61128126719268e-06
indicate O 0 6.064336162125983e-07
that O 0 2.0527039623630117e-08
4003delTC O 0 1.4876872000968433e-06
occurs O 0 1.7791798256894253e-08
on O 0 1.514464109675373e-08
a O 0 1.5933597552475476e-08
single O 0 1.7291459641910478e-07
ancestral O 0 1.21351024517935e-06
allele O 0 4.623851509677479e-06
. O 0 1.2849110930801544e-07
. O 0 4.6281164145511866e-07

The O 0 4.890577656624373e-06
haptoglobin O 0 0.00013514449528884143
- O 0 7.428775279549882e-05
gene O 0 1.537058960821014e-05
deletion O 0 3.090417885687202e-05
responsible O 0 3.735125346793211e-06
for O 0 1.9299712050724338e-07
anhaptoglobinemia B-Disease 0 0.0001788900699466467
. O 0 2.995303702846286e-06

We O 0 1.452933793189004e-05
have O 0 2.0159640712336113e-07
found O 0 5.702134941998338e-08
an O 0 1.706301588910719e-08
allelic O 0 8.492006600135937e-07
deletion O 0 4.840566816710634e-06
of O 0 2.44406166416411e-08
the O 0 1.706126653289175e-07
haptoglobin O 0 4.2049177864100784e-05
( O 0 1.923048245089376e-07
Hp O 0 4.494135282584466e-06
) O 0 1.4279924798188404e-08
gene O 0 7.697202875078801e-08
from O 0 4.6469903480783614e-09
an O 0 8.466789935823726e-09
individual O 0 1.2163167362189142e-08
with O 0 1.5985322932010604e-07
anhaptoglobinemia B-Disease 0 0.00047606826410628855
. O 0 3.106429176114034e-06

The O 0 2.1195908175286604e-06
Hp O 0 2.8502770874183625e-05
gene O 0 2.3969230369402794e-06
cluster O 0 3.2062769150797976e-07
consists O 0 1.2979075592056688e-08
of O 0 4.50515136307672e-09
coding O 0 4.694718427344924e-06
regions O 0 2.2612719874359755e-07
of O 0 4.669896469522428e-09
the O 0 1.722822773331245e-08
alpha O 0 1.0042855080882873e-07
chain O 0 7.959937988744059e-07
and O 0 1.3512690522077264e-08
beta O 0 1.2494145273933555e-08
chain O 0 5.768876576439652e-08
of O 0 1.2220785494676534e-09
the O 0 1.3735383497248677e-08
haptoglobin O 0 1.8282864857610548e-06
gene O 0 9.608149866835447e-07
( O 0 1.836959917511649e-08
Hp O 0 1.276983311981894e-06
) O 0 6.17375883749105e-09
and O 0 2.6473863101728057e-09
of O 0 5.631742849843135e-10
the O 0 8.699356790486945e-09
alpha O 0 1.0458125387913242e-07
chain O 0 3.2118072113007656e-07
and O 0 1.0322746213375922e-08
beta O 0 8.977182552882823e-09
chain O 0 5.604306352324784e-08
of O 0 1.0248134563184408e-09
the O 0 1.8822088776460077e-08
haptoglobin O 0 3.857606316159945e-06
- O 0 7.206583632068941e-06
related O 0 1.0277744877384976e-06
gene O 0 2.0293502984713996e-06
( O 0 6.115910622384035e-08
Hpr O 0 1.279492789763026e-05
) O 0 5.1409077883590726e-08
, O 0 2.1058038868204676e-08
in O 0 7.514807442987603e-09
tandem O 0 7.496092848668923e-07
from O 0 2.0039296444451793e-08
the O 0 1.8086634412384228e-08
5 O 0 3.7330383406697365e-07
side O 0 1.7425677469873335e-06
. O 0 2.197842150053475e-06

Southern O 0 7.76127417339012e-05
blot O 0 0.0033074927050620317
and O 0 1.4285420775195234e-06
PCR O 0 1.5127040569495875e-05
analyses O 0 6.898371225361188e-07
have O 0 4.5690615735338724e-08
indicated O 0 2.6700206490204437e-07
that O 0 2.6785982321086976e-09
the O 0 2.2326802628924725e-09
individual O 0 2.498938389550176e-09
with O 0 1.4268271897321938e-08
anhaptoglobinemia B-Disease 0 1.0585501513560303e-05
was O 0 9.460045475861989e-07
homozygous O 0 6.076736269733374e-08
for O 0 1.9551120722383075e-09
the O 0 8.050748512289374e-09
gene O 0 2.0162063663065055e-07
deletion O 0 8.195792133847135e-07
and O 0 1.4822737703923394e-08
that O 0 5.1814526003113315e-09
the O 0 6.331000612647131e-09
gene O 0 4.6080734250608657e-07
deletion O 0 2.4954592845460866e-06
was O 0 4.144536660533049e-07
included O 0 7.346722341594614e-09
at O 0 7.578750427228442e-08
least O 0 9.201769124445036e-09
from O 0 5.284776616321096e-09
the O 0 8.339850587901765e-09
promoter O 0 6.78024707667646e-06
region O 0 6.439250341827574e-07
of O 0 1.0211301137985629e-08
Hp O 0 1.124191499002336e-06
to O 0 3.77131144091436e-08
Hpr O 0 9.374913361170911e-07
alpha O 0 9.183135318835411e-08
but O 0 1.1505316699356172e-08
not O 0 9.346017293410114e-09
to O 0 1.9991345467929023e-08
Hpr O 0 8.356081707461271e-06
beta O 0 3.7304900502022065e-07
( O 0 4.907285244826198e-08
Hpdel O 0 5.6169083109125495e-06
) O 0 1.0594549593179181e-07
. O 0 3.208751877536997e-07

In O 0 2.8630822725972394e-06
addition O 0 1.5649251849936263e-07
, O 0 7.217060016273535e-08
we O 0 2.4343426829886994e-08
found O 0 1.8542051449799146e-08
seven O 0 9.263491307365257e-09
individuals O 0 9.760426911142872e-10
with O 0 6.308796152154628e-09
hypohaptoglobinemia B-Disease 0 8.6252621258609e-06
in O 0 7.98953294633975e-08
three O 0 5.7552924204173905e-08
families O 0 3.715910068535777e-08
, O 0 2.0082763896311917e-08
and O 0 1.2668577298313721e-08
the O 0 1.7200811441853148e-08
genotypes O 0 2.4873827442206675e-07
of O 0 9.543915657772573e-10
six O 0 1.1547571787673405e-08
of O 0 2.70585442940785e-09
the O 0 2.7369580379854597e-08
seven O 0 1.0952937401498275e-07
individuals O 0 2.823664635442924e-09
were O 0 9.098782172145548e-09
found O 0 3.697719108686215e-08
to O 0 1.9684488705706826e-08
be O 0 4.945047038518169e-08
Hp2 O 0 1.9195616914657876e-05
/ O 0 3.009534702869132e-05
Hpdel O 0 3.678778011817485e-05
. O 0 7.20641253337817e-07

The O 0 3.413742206248571e-06
phenotypes O 0 3.131862104055472e-05
and O 0 1.5749609474369208e-06
genotypes O 0 8.304008588311262e-06
in O 0 1.2348564837338927e-07
one O 0 1.871605270764576e-08
of O 0 2.1347501544255465e-09
these O 0 3.88775989179635e-09
three O 0 3.411049576129699e-08
families O 0 4.301488942815013e-08
showed O 0 4.3198693333579286e-07
the O 0 1.81965997825273e-08
father O 0 2.2454899806234607e-07
to O 0 6.389559814579115e-08
be O 0 1.06918896847219e-07
hypohaptoglobinemic B-Disease 0 7.958647984196432e-06
( O 0 2.2329965432277277e-08
Hp2 O 0 1.4159578540784423e-06
) O 0 8.202710510829547e-09
and O 0 2.7130496960126038e-08
Hp2 O 0 1.4330683370644692e-05
/ O 0 1.14333188321325e-05
Hpdel O 0 2.6314853585063247e-06
, O 0 1.7213414693628692e-08
the O 0 4.242672879684051e-09
mother O 0 1.6790349377515668e-07
to O 0 8.65559623974832e-09
be O 0 9.151117197347958e-09
Hp2 O 0 7.3006833645195e-07
- O 0 1.5285658037100802e-06
1 O 0 2.092128710273755e-07
and O 0 1.2211103239678778e-07
Hp1 O 0 1.4064070455788169e-05
/ O 0 5.604456873697927e-06
Hp2 O 0 1.738623836899933e-06
, O 0 1.4557572036721922e-08
one O 0 2.2384878395342866e-09
of O 0 8.358048142476093e-10
the O 0 7.960946568630334e-09
two O 0 5.1341462636855795e-08
children O 0 9.855598648300656e-08
to O 0 3.015199467881757e-08
be O 0 1.6542149694487307e-07
hypohaptoglobinemic B-Disease 0 1.4166968867357355e-05
( O 0 3.0174202692023755e-08
Hp2 O 0 1.4513733503918047e-06
) O 0 7.843356186754136e-09
and O 0 3.994772512783129e-08
Hp2 O 0 1.2419714039424434e-05
/ O 0 1.1414242180762812e-05
Hpdel O 0 3.1457516342925373e-06
, O 0 3.824553829190336e-08
and O 0 6.2735416861414706e-09
the O 0 3.9398946327651174e-09
other O 0 9.220374685980914e-09
child O 0 9.415656876399225e-08
to O 0 1.995435638946219e-08
be O 0 3.1321736315703674e-08
Hp1 O 0 3.004361133207567e-06
and O 0 1.614541247363377e-07
Hp1 O 0 1.844962935138028e-05
/ O 0 2.0466404748731293e-05
Hpdel O 0 7.682031537115108e-06
, O 0 4.656690677506958e-08
showing O 0 1.5973435552041337e-07
an O 0 1.309470132326851e-08
anomalous O 0 3.2193279366765637e-06
inheritance O 0 3.4067077194777085e-06
of O 0 8.927599992603064e-08
Hp O 0 5.528572728508152e-05
phenotypes O 0 2.6130344394914573e-06
in O 0 2.990314484918599e-08
the O 0 5.155892779384885e-08
child O 0 9.282204587179876e-07
with O 0 9.513772170066659e-08
Hp1 O 0 0.0002700089244171977
. O 0 3.4431557196512586e-06

The O 0 6.325007689156337e-06
Hp2 O 0 0.0007844476494938135
/ O 0 0.0012549279490485787
Hpdel O 0 0.00014114798977971077
individuals O 0 1.5027966071556875e-07
had O 0 3.0310567922242626e-07
an O 0 1.800073157198767e-08
extremely O 0 1.0261208416295631e-07
low O 0 1.5525068874922e-07
level O 0 5.1293010727704313e-08
of O 0 1.2871686827509166e-08
Hp O 0 1.2659197636821773e-05
( O 0 3.044481289293799e-08
mean O 0 4.466080483211954e-08
+ O 0 1.1735605767171364e-06
/ O 0 6.470789685408818e-06
- O 0 3.894526344083715e-06
SD O 0 4.137357245781459e-05
= O 0 4.776859441335546e-07
0 O 0 3.333354570145275e-08
. O 0 1.5403040620753927e-08
049 O 0 7.493569569305691e-07
+ O 0 4.1087002955464413e-07
/ O 0 1.5283544598787557e-06
- O 0 6.238117862267245e-07
0 O 0 6.744370040223657e-08
. O 0 2.0729981287104238e-08
043 O 0 1.048576450557448e-06
mg O 0 1.0238076356472448e-05
/ O 0 3.377783059477224e-06
ml O 0 2.8269641916267574e-06
; O 0 1.5760917904117377e-08
n O 0 7.30942701920867e-07
= O 0 1.1166966942255385e-06
6 O 0 4.511904307946679e-07
) O 0 1.7019784692706708e-08
, O 0 9.178088511418991e-09
compared O 0 3.5836510647868636e-08
with O 0 1.880170019674665e-09
the O 0 1.8842095883542243e-08
level O 0 7.57412550456138e-08
( O 0 4.4529873122201025e-09
1 O 0 1.7746586422617838e-08
. O 0 4.185413793322823e-09
64 O 0 1.2886327560579502e-08
+ O 0 1.5871363245878456e-07
/ O 0 9.973426813303377e-07
- O 0 6.830433676441316e-07
1 O 0 2.60792575090818e-07
. O 0 2.100196283549849e-08
07 O 0 1.9716847532436077e-07
mg O 0 1.1605670806602575e-05
/ O 0 3.771070623770356e-06
ml O 0 1.4831471162324306e-06
) O 0 2.2212289785272787e-09
obtained O 0 1.393976756247639e-08
from O 0 5.940802960680003e-09
52 O 0 2.2111616715392302e-07
healthy O 0 4.561903210742457e-08
volunteers O 0 1.7689171016854743e-08
having O 0 4.4971180557240586e-08
phenotype O 0 1.371346797895967e-06
Hp2 O 0 4.847080163017381e-06
, O 0 4.384797591683309e-08
whereas O 0 3.298135098361854e-08
the O 0 1.1842131719674853e-08
serum O 0 2.758256698598416e-07
Hp O 0 6.334668682939082e-07
level O 0 7.002059820848672e-09
of O 0 9.39082700490701e-10
an O 0 1.0065402733516748e-08
individual O 0 5.126471691596635e-09
with O 0 3.4970121021160594e-08
Hp1 O 0 0.0002641101600602269
/ O 0 6.814702646806836e-05
Hpdel O 0 1.810564754123334e-05
was O 0 8.769395094532229e-07
0 O 0 4.638155530756194e-07
. O 0 6.682267894575489e-07

50 O 0 3.8780559407314286e-05
mg O 0 0.0008345707319676876
/ O 0 0.00028576000477187335
ml O 0 0.00012908082862850279
, O 0 2.1371960201577167e-07
which O 0 1.8881921803881596e-08
was O 0 9.884892904210574e-08
approximately O 0 4.7896024923943514e-09
half O 0 9.071887241418608e-09
the O 0 1.9429708952856117e-09
level O 0 6.092831128512444e-09
of O 0 2.2355268747276114e-09
Hp O 0 1.8017843785855803e-06
in O 0 2.9355545549947237e-08
control O 0 3.442501395056752e-07
sera O 0 7.525943601649487e-06
from O 0 5.620692355989831e-09
the O 0 1.461284782067196e-08
Hp1 O 0 1.631481973163318e-05
phenotype O 0 6.261557246034499e-06
( O 0 7.217690445315839e-09
1 O 0 2.043289804021242e-08
. O 0 9.511174070553352e-09
26 O 0 3.3030769230890655e-08
+ O 0 6.15227406797203e-07
/ O 0 1.6486537788296118e-06
- O 0 7.667119348298002e-07
0 O 0 1.0235484637632908e-07
. O 0 2.2569667024185947e-08
33 O 0 1.1934446320083225e-07
mg O 0 7.0571204560110345e-06
/ O 0 2.7177372885489604e-06
ml O 0 2.3868408334237756e-06
; O 0 3.0652358873339836e-08
n O 0 1.7410014834240428e-06
= O 0 1.6242410083577852e-06
9 O 0 8.692277333466336e-07
) O 0 8.149859453965291e-09
, O 0 3.9588323730299635e-09
showing O 0 3.7488707249622166e-08
a O 0 2.3831773887650343e-08
gene O 0 1.0126611869054614e-06
- O 0 1.628994505153969e-05
dosage O 0 5.1683939091162756e-05
effect O 0 2.56317321145616e-06
. O 0 5.226598887020373e-07

The O 0 1.2381198075672728e-06
other O 0 2.18977788790653e-07
allele O 0 5.519557817024179e-06
( O 0 1.7154754061721178e-07
Hp2 O 0 8.431134119746275e-06
) O 0 2.582073932444473e-08
of O 0 1.4553871441336241e-09
individuals O 0 1.641584312928046e-09
with O 0 2.1452903453678118e-08
Hp2 O 0 0.0001728676725178957
/ O 0 6.825427408330142e-05
Hpdel O 0 1.265067567146616e-05
was O 0 2.6797831651492743e-06
found O 0 1.0656139437514867e-07
to O 0 2.9329576989312045e-08
have O 0 2.424297207426207e-08
, O 0 1.0459339172541604e-08
in O 0 3.5447031976332255e-09
all O 0 1.0983345344328654e-09
exons O 0 1.2114543324059923e-06
, O 0 2.126242115707555e-08
no O 0 1.6932425239701843e-08
mutation O 0 6.4998801008187e-08
, O 0 6.058991974811079e-09
by O 0 9.264091715976974e-09
DNA O 0 2.1435291728266748e-06
sequencing O 0 4.926566361973528e-06
. O 0 1.387934048580064e-06

On O 0 4.30888121627504e-06
the O 0 3.9653333061551166e-08
basis O 0 2.7624890819311076e-08
of O 0 2.8726638845455454e-09
the O 0 2.1247542392188734e-08
present O 0 3.04436547082787e-08
study O 0 1.2907236168757663e-08
, O 0 3.3850258152057222e-09
the O 0 1.6026674432012555e-09
mechanism O 0 6.3650711368268276e-09
of O 0 5.765782518096785e-09
anhaptoglobinemia B-Disease 0 5.682153641828336e-06
and O 0 2.8604839386048297e-08
the O 0 4.719260537910941e-09
mechanism O 0 3.458091057950696e-08
of O 0 1.170693586516336e-08
anomalous O 0 8.219053597713355e-06
inheritance O 0 4.6356535676750354e-06
of O 0 9.059787231535665e-08
Hp O 0 6.785542063880712e-05
phenotypes O 0 3.4058273286063923e-06
were O 0 1.6065956742750132e-07
well O 0 9.890946017776514e-08
explained O 0 2.263747546749073e-06
. O 0 5.930129418629804e-07

However O 0 1.0454088624101132e-05
, O 0 1.0805713657191518e-07
the O 0 1.1678165101614013e-08
mechanism O 0 7.412245395244099e-08
of O 0 6.94241961696207e-08
hypohaptoglobinemia B-Disease 0 0.00021073190146125853
remains O 0 1.9496745153446682e-05
unknown O 0 2.049351496680174e-05

ATM O 0 0.004027440678328276
mutations O 0 0.0007941811927594244
and O 0 2.730873347900342e-06
phenotypes O 0 0.00020496075740084052
in O 0 0.00018793175695464015
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999991655349731
telangiectasia I-Disease 1 1.0
families O 0 3.2396674214396626e-05
in O 0 2.6139716169382154e-07
the O 0 1.6333844143900933e-07
British O 0 8.920397704059724e-06
Isles O 0 5.4593228924204595e-06
: O 0 1.0719820586757578e-08
expression O 0 7.588438322159163e-09
of O 0 9.093277797411758e-10
mutant O 0 5.33571551386558e-08
ATM O 0 5.69943313166732e-06
and O 0 3.2581876752146854e-08
the O 0 1.989951137204571e-08
risk O 0 6.774674261578184e-07
of O 0 1.481918303625207e-07
leukemia B-Disease 1 0.9470170736312866
, O 0 0.0003461090673226863
lymphoma B-Disease 1 1.0
, O 0 1.4729327631357592e-05
and O 0 6.549286626977846e-05
breast B-Disease 1 0.8974592089653015
cancer I-Disease 0 0.0010074503952637315
. O 0 2.2746871763956733e-06

We O 0 1.0562339411990251e-05
report O 0 5.130343652126612e-07
the O 0 7.3005419487515155e-09
spectrum O 0 6.918361350471969e-08
of O 0 8.861923639358338e-09
59 O 0 5.77921753119881e-07
ATM O 0 0.00011001158418366686
mutations O 0 4.307632116251625e-05
observed O 0 3.4800730190909235e-06
in O 0 3.450848089414649e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.0003791276831179857
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999996423721313
T I-Disease 1 1.0
) O 0 2.8914080303366063e-06
patients O 0 5.3521159770753e-07
in O 0 5.9399982710317545e-09
the O 0 7.97779193817405e-08
British O 0 5.08328093928867e-06
Isles O 0 4.6595549065386876e-05
. O 0 1.2407771237121779e-06

Of O 0 1.1835355735456687e-06
51 O 0 4.53263737654197e-06
ATM O 0 7.418680615955964e-05
mutations O 0 1.105687624658458e-05
identified O 0 1.1133715815958567e-06
in O 0 2.0004316425570323e-08
families O 0 1.1092108564980663e-08
native O 0 3.469169840286668e-08
to O 0 5.5122441722232907e-08
the O 0 3.298399064988189e-08
British O 0 3.287413164798636e-06
Isles O 0 7.83077939559007e-06
, O 0 1.6297433091949642e-07
11 O 0 7.278327274207186e-08
were O 0 2.7181981110402376e-08
founder O 0 1.116508201448596e-06
mutations O 0 1.324307845607109e-06
, O 0 1.0857710286416022e-08
and O 0 1.454641296305681e-08
2 O 0 1.4399562076050643e-07
of O 0 1.4424645922161972e-09
these O 0 4.429201894140533e-09
11 O 0 9.986544569073885e-08
conferred O 0 4.210477300148341e-08
a O 0 1.0412030349016277e-07
milder O 0 6.070539166103117e-05
clinical O 0 2.3118129774957197e-06
phenotype O 0 2.2928754788154038e-06
with O 0 1.090590462382579e-08
respect O 0 2.5901236710978992e-08
to O 0 1.401471223516637e-07
both O 0 1.0011706308432622e-06
cerebellar B-Disease 0 0.1757804900407791
degeneration I-Disease 1 0.9254637360572815
and O 0 1.2801742741430644e-06
cellular O 0 1.0171025678573642e-05
features O 0 6.301531811914174e-06
. O 0 2.7915525606658775e-06

We O 0 5.302448698785156e-05
report O 0 5.079597940493841e-06
, O 0 1.9492595981773775e-08
in O 0 1.1189749571371976e-08
two O 0 7.080642916434954e-08
A B-Disease 1 0.9999557733535767
- I-Disease 1 0.9999169111251831
T I-Disease 1 1.0
families O 0 3.171786033817625e-07
, O 0 1.2582246355918869e-08
an O 0 1.2933432103068299e-08
ATM O 0 6.76855124766007e-05
mutation O 0 2.457506525388453e-06
( O 0 1.5406243392135366e-08
7271T O 0 2.3520057368386915e-07
- O 0 5.94637140238774e-06
- O 0 6.089533053454943e-05
> O 0 1.3774009630651562e-06
G O 0 0.00019577790226321667
) O 0 6.631746174434738e-08
that O 0 5.344668707607525e-08
may O 0 4.4297496515355306e-07
be O 0 1.0927308835562144e-08
associated O 0 6.913438266309413e-09
with O 0 3.807963278035231e-09
an O 0 6.97938205007631e-08
increased O 0 7.986391779013502e-07
risk O 0 8.701749152351113e-07
of O 0 1.5917413520583068e-07
breast B-Disease 1 0.6913531422615051
cancer I-Disease 0 0.00011869116133311763
in O 0 3.086861966039578e-08
both O 0 9.586816673845533e-08
homozygotes O 0 2.139720891136676e-05
and O 0 2.6808902475750074e-07
heterozygotes O 0 1.5192775890682242e-06
( O 0 1.7606701874228747e-08
relative O 0 9.775787646049139e-08
risk O 0 5.044369117968017e-07
12 O 0 6.870835989047919e-08
. O 0 2.2873200222761625e-08
7 O 0 2.94154688162962e-07
; O 0 1.107820111201363e-07
P O 0 0.0011592138325795531
= O 0 4.3579807424976025e-06
. O 0 1.1500538477093869e-07
0025 O 0 7.779248107908643e-07
) O 0 1.3711564328389159e-08
, O 0 7.161522042054003e-09
although O 0 3.5772298456748786e-09
there O 0 1.3536880505427007e-09
is O 0 3.891907240927139e-09
a O 0 1.0579122999843094e-07
less O 0 2.4314390429935884e-06
severe O 0 0.0001289073989028111
A B-Disease 1 0.9999961853027344
- I-Disease 1 0.9999983310699463
T I-Disease 1 1.0
phenotype O 0 0.0010978569043800235
in O 0 3.680985116716329e-08
terms O 0 2.903557572153659e-08
of O 0 3.5490803629301126e-09
the O 0 4.252153473771614e-08
degree O 0 8.449489428130619e-07
of O 0 6.93918821070838e-07
cerebellar B-Disease 1 0.9191266894340515
degeneration I-Disease 1 0.9985523819923401
. O 0 1.060097747540567e-05

This O 0 2.1650248527294025e-06
mutation O 0 9.787439012143295e-06
( O 0 2.069396174420035e-07
7271T O 0 3.0460896596196108e-06
- O 0 3.0312554372358136e-05
- O 0 9.49608875089325e-05
> O 0 1.9790459191426635e-06
G O 0 5.1869497838197276e-05
) O 0 1.8674686685926645e-08
also O 0 5.34708233246306e-09
allows O 0 1.2168822616231978e-09
expression O 0 2.850667701892462e-09
of O 0 6.33381069814476e-10
full O 0 6.9993091322828604e-09
- O 0 1.5735751901502226e-07
length O 0 6.449913314554578e-08
ATM O 0 1.5010091374279e-06
protein O 0 5.81344608008294e-08
at O 0 1.9215518065607284e-08
a O 0 6.316020151331259e-09
level O 0 1.4182099050685792e-08
comparable O 0 4.8847514477756704e-08
with O 0 3.729847541933395e-09
that O 0 2.9013930813448496e-08
in O 0 9.412605095349136e-08
unaffected O 0 1.3399910130829085e-05
individuals O 0 7.645420652124812e-08
. O 0 4.970441978002782e-07

In O 0 2.063414513031603e-06
addition O 0 1.8164598714065505e-07
, O 0 4.224949279318935e-08
we O 0 1.5769124672715407e-08
have O 0 1.0503940828243685e-08
studied O 0 1.4580392360130645e-07
18 O 0 6.270427661547728e-07
A B-Disease 1 0.999950647354126
- I-Disease 1 0.9999986886978149
T I-Disease 1 1.0
patients O 0 5.5356158554786816e-05
, O 0 8.207154955641727e-09
in O 0 7.99193689005051e-09
15 O 0 5.103771627545939e-08
families O 0 1.173456620762181e-08
, O 0 3.7085040816009496e-08
who O 0 5.727733878302388e-07
developed O 0 2.5230974642909132e-05
leukemia B-Disease 1 0.9567571878433228
, O 0 8.886609430192038e-05
lymphoma B-Disease 1 1.0
, O 0 1.7862033701021574e-06
preleukemic O 0 0.00014468582230620086
T O 0 0.001966705545783043
- O 0 3.8901085645193234e-05
cell O 0 0.00024015533563215286
proliferation O 0 5.31783553014975e-06
, O 0 3.938743873277417e-07
or O 0 0.0009122898336499929
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 2.148004568880424e-06
mostly O 0 3.948126447994582e-08
in O 0 1.244090697127831e-07
childhood O 0 6.401797236321727e-06
. O 0 2.2351989628077717e-06

A O 0 5.248788966127904e-06
wide O 0 2.7107228106615366e-07
variety O 0 7.015471226168302e-08
of O 0 9.614995910567359e-09
ATM O 0 7.126104173948988e-05
mutation O 0 3.5784373721980955e-06
types O 0 1.0401787875480295e-07
, O 0 1.3457596814703265e-08
including O 0 1.2665459792060574e-08
missense O 0 7.824971362424549e-06
mutations O 0 1.4370835742738564e-05
and O 0 1.8622512243382516e-07
in O 0 7.709089544505332e-08
- O 0 9.616788702260237e-06
frame O 0 0.00012426599278114736
deletions O 0 2.464738645358011e-05
, O 0 1.4047067509181943e-07
were O 0 2.4160113909488246e-08
seen O 0 7.488340969530327e-08
in O 0 1.3440152990540355e-08
these O 0 3.647174295906552e-08
patients O 0 4.7409429271283443e-07
. O 0 2.503577718471206e-07

We O 0 5.548695753532229e-06
also O 0 2.288979175091299e-07
show O 0 1.539086014190616e-07
that O 0 4.369008710369826e-09
25 O 0 7.89117837740605e-09
% O 0 4.3650270065143104e-09
of O 0 1.4660997971205347e-09
all O 0 3.131647829945905e-08
A B-Disease 1 0.9999927282333374
- I-Disease 1 0.999998927116394
T I-Disease 1 1.0
patients O 0 9.416315151611343e-06
carried O 0 1.167878309615844e-07
in O 0 2.0429235192409578e-08
- O 0 1.978655291168252e-06
frame O 0 2.130029497493524e-05
deletions O 0 7.786977221257985e-06
or O 0 4.7382715706589806e-07
missense O 0 1.0017274689744227e-05
mutations O 0 5.015734586777398e-06
, O 0 6.1434994869102866e-09
many O 0 5.17707432479142e-10
of O 0 3.938076531539991e-09
which O 0 5.681344532604271e-07
were O 0 1.1513422037978671e-07
also O 0 7.795752310357784e-08
associated O 0 1.0739711342466762e-08
with O 0 2.7863107376902008e-09
expression O 0 3.8445204353365625e-08
of O 0 5.9937730334524986e-09
mutant O 0 6.151041702651128e-07
ATM O 0 2.9846629331586882e-05
protein O 0 3.6910639664711198e-06
. O 0 8.367847499357595e-07

The O 0 1.8345181160839275e-06
DMPK O 0 0.00012719746155198663
gene O 0 1.3501811736205127e-05
of O 0 9.343931424155016e-07
severely O 1 0.9519490003585815
affected O 0 0.20194034278392792
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.8218339085578918
is O 0 4.729625970867346e-07
hypermethylated O 0 4.7381767217302695e-05
proximal O 0 0.00013328090426512063
to O 0 3.9372531546177925e-07
the O 0 4.784811125091437e-08
largely O 0 2.8242001803846506e-07
expanded O 0 1.2130011555200326e-06
CTG O 0 0.00022029044339433312
repeat O 0 3.331475454615429e-05
. O 0 8.874323498275771e-07

Using O 0 2.9437658213282702e-06
methylation O 0 1.2305541531532072e-05
- O 0 2.4556917196605355e-05
sensitive O 0 2.8650542844843585e-06
restriction O 0 6.931185936309703e-08
enzymes O 0 1.4241170731565944e-07
, O 0 1.1244929432052686e-08
we O 0 4.254958607674553e-09
characterized O 0 2.2373962238475542e-08
the O 0 4.194780078847771e-09
methylation O 0 5.692071454177494e-07
pattern O 0 2.790817688946845e-06
on O 0 1.6487543916809955e-06
the O 0 9.256183375327964e-08
5 O 0 1.8550831271113566e-07
side O 0 1.569743446339089e-08
of O 0 2.642649210571335e-09
the O 0 6.396010121534346e-08
CTG O 0 1.641838207433466e-05
repeat O 0 1.1053523394366493e-06
in O 0 5.038202299800787e-09
the O 0 4.23636548063655e-09
DMPK O 0 1.8759386648525833e-06
gene O 0 7.250809375136669e-08
of O 0 1.938639693221944e-09
normal O 0 6.138360220120376e-08
individuals O 0 3.064743347991339e-09
and O 0 1.6121356694043243e-08
of O 0 4.413081100551608e-08
patients O 0 2.4231035240518395e-06
affected O 0 6.580733611372125e-07
with O 0 9.034985851030797e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.372762653772952e-06
showing O 0 2.9228897346911253e-07
expansions O 0 1.724937703784235e-07
of O 0 1.016615769344753e-08
the O 0 1.1229244734067834e-07
repetitive O 0 2.597709135443438e-05
sequence O 0 4.083149178768508e-06
. O 0 1.7441008139940095e-06

The O 0 1.1443531775512383e-06
gene O 0 2.0684385617641965e-06
segment O 0 1.4142061672828277e-06
analyzed O 0 5.920557555327832e-07
corresponds O 0 1.3417695754469605e-07
to O 0 1.431136276153211e-08
the O 0 1.1755176387850952e-08
genomic O 0 6.550022817464196e-07
SacI O 0 1.379257628286723e-05
- O 0 4.06614435632946e-06
HindIII O 0 3.942302100767847e-06
fragment O 0 5.608668516288162e-07
carrying O 0 1.6475961217565782e-07
exons O 0 1.3027832892476e-06
11 O 0 8.151246788656863e-08
- O 0 1.5034432863103575e-06
15 O 0 5.346483931134571e-07
. O 0 5.866343144589337e-07

There O 0 1.8641806036612252e-06
is O 0 1.4199508768797386e-07
constitutive O 0 1.1714505490090232e-06
methylation O 0 2.2494859877042472e-06
in O 0 2.539344166052615e-07
intron O 0 5.7683599152369425e-05
12 O 0 3.7292664956112276e-07
at O 0 2.227190343262464e-08
restriction O 0 5.7673443798478274e-09
sites O 0 5.752019305305112e-09
of O 0 2.681869837317663e-09
SacII O 0 2.156576101697283e-06
and O 0 6.739766433838668e-08
HhaI O 0 2.072474444503314e-06
, O 0 1.1517919951131717e-08
localized O 0 1.214455664921843e-07
1 O 0 1.3885163241411647e-07
, O 0 1.3746208615827982e-08
159 O 0 4.926839380914316e-08
- O 0 1.0382228765593027e-06
1 O 0 3.167487534483371e-07
, O 0 1.9382154547997743e-08
232 O 0 3.506135470843219e-08
bp O 0 2.946700988104567e-06
upstream O 0 6.230733617940132e-08
of O 0 2.345038385698217e-09
the O 0 3.510545454332714e-08
CTG O 0 7.750118129479233e-06
repeat O 0 2.7669982500810875e-06
, O 0 7.107390231908539e-09
whereas O 0 6.8472187919610406e-09
most O 0 3.2496523250102882e-09
, O 0 1.0159372898499441e-08
if O 0 6.56599352666376e-09
not O 0 3.848260377026236e-09
all O 0 1.3163558021389576e-09
, O 0 2.1705026664875504e-09
of O 0 3.1091593188925515e-10
the O 0 1.1573496605521427e-09
other O 0 1.1202109240215918e-09
sites O 0 7.829082271371135e-09
of O 0 2.4016020283568196e-09
SacII O 0 2.057397750832024e-06
, O 0 2.6341057335343976e-08
HhaI O 0 2.7904613375540066e-07
, O 0 1.2813436534031553e-08
and O 0 1.0104392877963164e-08
HpaII O 0 6.211973300196405e-07
in O 0 1.2541036653601623e-08
this O 0 7.872837493039242e-09
region O 0 6.289268981163332e-07
are O 0 1.4557349103938577e-08
unmethylated O 0 4.819001446776383e-07
, O 0 1.862893661552789e-08
in O 0 4.919672225156546e-09
normal O 0 1.6772136746112665e-07
individuals O 0 2.209309402090298e-09
and O 0 8.756055436265342e-09
most O 0 7.914542798914681e-09
of O 0 6.95366786374052e-09
the O 0 4.059442346715514e-07
patients O 0 2.89169724965177e-06
. O 0 5.711331709790102e-07

In O 0 1.123585889217793e-06
a O 0 1.1220702589298526e-07
number O 0 1.813482164436664e-08
of O 0 9.108713783234634e-09
young O 0 1.6188766949198907e-07
and O 0 2.190046188843553e-06
severely O 0 0.047528449445962906
affected O 0 5.586936822510324e-06
patients O 0 9.464241657042294e-07
, O 0 1.90299402902383e-08
however O 0 2.6238762274033434e-08
, O 0 7.353115005770405e-09
complete O 0 1.827405782250935e-08
methylation O 0 1.8101100351941568e-07
of O 0 2.9569691140096666e-09
these O 0 2.1841031205838135e-09
restriction O 0 5.230235355924151e-09
sites O 0 9.666357669857462e-08
was O 0 1.21739230962703e-06
found O 0 3.367491885342133e-08
in O 0 1.9445760557346148e-09
the O 0 7.694234582800163e-09
mutated O 0 3.7285803955455776e-06
allele O 0 8.028652700886596e-06
. O 0 7.31548709609342e-07

In O 0 1.6096273611765355e-06
most O 0 3.7098551786129974e-08
of O 0 9.98080906811083e-09
these O 0 1.873373101091147e-08
patients O 0 3.029010997579462e-07
, O 0 7.968162130111978e-09
the O 0 2.1609945832778976e-08
onset O 0 2.2139627162687248e-06
of O 0 3.9455517963915554e-08
the O 0 9.748872798809316e-06
disease O 0 0.3647708594799042
was O 0 0.0006944331689737737
congenital O 1 0.9999730587005615
. O 0 5.216074441705132e-06

Preliminary O 0 7.391225517494604e-05
in O 0 2.9134434953448363e-06
vivo O 0 0.0003168151597492397
footprinting O 0 0.00023451696324627846
data O 0 2.4395592390646925e-06
gave O 0 8.466713552479632e-08
evidence O 0 3.821301675088762e-08
for O 0 6.8267973496460854e-09
protein O 0 1.1672714350652313e-07
- O 0 2.097455535476911e-06
DNA O 0 2.625664592414978e-06
contact O 0 1.1492688400949191e-07
in O 0 1.1090839358018911e-08
normal O 0 1.1053464277210878e-07
genes O 0 9.585445326365516e-08
at O 0 1.2285042316761974e-07
an O 0 1.301804974929155e-08
Sp1 O 0 1.5829657513677375e-06
consensus O 0 3.224752376240758e-08
binding O 0 4.8913058492416894e-08
site O 0 1.867536951749571e-07
upstream O 0 1.0002614914128571e-07
of O 0 3.0009290608035144e-09
the O 0 3.727189223923233e-08
CTG O 0 1.7173824744531885e-05
repeat O 0 3.5367943382880185e-06
and O 0 1.073678390639543e-08
for O 0 1.8169331594819482e-09
a O 0 1.1260683052682907e-08
significant O 0 1.410521477396287e-08
reduction O 0 7.57284013275239e-08
of O 0 1.2528335036066096e-09
this O 0 1.6977530492567894e-09
interaction O 0 5.617477150110517e-09
in O 0 7.931135748151519e-09
cells O 0 5.923777024463561e-08
with O 0 6.270001406960546e-09
a O 0 6.115898827374622e-07
hypermethylated O 0 4.4678643462248147e-05
DMPK O 0 3.478654980426654e-05
gene O 0 1.3297660643729614e-06
. O 0 9.10003521426006e-08
. O 0 3.9234481619132566e-07

The O 0 3.42085404554382e-05
hemochromatosis B-Disease 1 0.99998939037323
gene O 0 4.293683377909474e-05
product O 0 1.119115722758579e-06
complexes O 0 1.6358535503968596e-07
with O 0 1.0167921615789055e-08
the O 0 3.6437114658838254e-08
transferrin O 0 8.696389386386727e-07
receptor O 0 1.4300809425549232e-07
and O 0 4.3883865430416336e-08
lowers O 0 1.313336611019622e-06
its O 0 1.9236567894154177e-08
affinity O 0 2.83092447261879e-08
for O 0 9.347692397909668e-09
ligand O 0 6.820201292612182e-07
binding O 0 2.239002924397937e-06
. O 0 6.870009769954777e-07

We O 0 2.7552450774237514e-05
recently O 0 1.859592339314986e-05
reported O 0 2.8010674668621505e-06
the O 0 1.2673361915460646e-08
positional O 0 7.663479664188344e-07
cloning O 0 2.906467670982238e-07
of O 0 5.06366459873675e-09
a O 0 8.763612413531519e-08
candidate O 0 1.1767500609494164e-06
gene O 0 1.5288693248294294e-05
for O 0 5.1091039495076984e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.14718246459960938
HFE O 0 0.08378911763429642
. O 0 1.139665528171463e-05

The O 0 7.622392104167375e-07
gene O 0 1.6046540167735657e-06
product O 0 8.971731517704029e-07
, O 0 1.919471159794739e-08
a O 0 2.0896795405178636e-08
member O 0 1.8161822268325523e-08
of O 0 1.392881143758018e-09
the O 0 8.405757867535613e-09
major O 0 3.556617400590767e-08
histocompatibility O 0 3.269954902407335e-07
complex O 0 8.615872104655864e-08
class O 0 7.613043351284432e-08
I O 0 3.443201649133698e-06
- O 0 3.4246331779286265e-06
like O 0 1.443229535880164e-07
family O 0 7.112708431122883e-07
, O 0 1.0038910147613933e-07
was O 0 2.6354356919000566e-07
found O 0 1.5732144476032772e-08
to O 0 5.066842945211647e-09
have O 0 2.2337707239472593e-09
a O 0 1.72040284240893e-08
mutation O 0 3.6515527312985796e-07
, O 0 2.1830423690971656e-08
Cys O 0 1.0353928701078985e-05
- O 0 1.6895476164791035e-06
282 O 0 1.1455521189418505e-06
- O 0 1.0262641808367334e-05
- O 0 4.46420963271521e-05
> O 0 9.241758220923657e-07
Tyr O 0 5.296573363011703e-06
( O 0 2.2985860326230068e-08
C282Y O 0 9.087459318379842e-08
) O 0 5.224323196273417e-09
, O 0 2.7704658567273555e-09
in O 0 4.284373744667391e-09
85 O 0 5.045879447607149e-08
% O 0 1.0958742358013751e-08
of O 0 6.968844168397936e-09
patient O 0 2.2748238279746147e-06
chromosomes O 0 6.805933480791282e-06
. O 0 1.4528648080158746e-06

This O 0 1.707465912659245e-06
mutation O 0 7.234967142721871e-06
eliminates O 0 2.6699647150962846e-06
the O 0 8.398934880915476e-08
ability O 0 1.3550378241689032e-07
of O 0 1.4995405805962037e-08
HFE O 0 2.6194960810244083e-05
to O 0 3.2602335409137595e-07
associate O 0 3.3248275599362387e-07
with O 0 2.0055814786701376e-08
beta2 O 0 9.186669194605201e-05
- O 0 0.00043072988046333194
microglobulin O 0 0.00037234934279695153
( O 0 6.221387849336679e-08
beta2m O 0 4.796654138772283e-06
) O 0 1.5625383653627978e-08
and O 0 2.2816120548441177e-08
prevents O 0 1.5746050507914333e-07
cell O 0 2.0510409740381874e-05
- O 0 3.9065551391104236e-05
surface O 0 4.872052522841841e-05
expression O 0 5.0112639655708335e-06
. O 0 6.003151611366775e-07

A O 0 9.150654477707576e-06
second O 0 9.903299542202149e-06
mutation O 0 4.409115717862733e-06
that O 0 4.6888111171483615e-08
has O 0 6.075264735727615e-08
no O 0 2.7687978132462376e-08
effect O 0 8.707213794423296e-08
on O 0 1.210068830914679e-06
beta2m O 0 6.654306343989447e-05
association O 0 6.510849459573365e-08
, O 0 9.338639195277665e-09
H63D O 0 5.595597031060606e-06
, O 0 8.030814768744676e-08
was O 0 1.70163858115302e-07
found O 0 2.5993786678668584e-08
in O 0 2.4932256259546648e-09
eight O 0 5.581804796150891e-09
out O 0 1.1271857225381154e-08
of O 0 4.17452294954046e-09
nine O 0 4.4317650349512405e-07
patients O 0 1.241511711214116e-07
heterozygous O 0 4.301571010500993e-08
for O 0 6.301508204131778e-09
the O 0 2.8764706172523802e-08
C282Y O 0 2.956104708573548e-06
mutant O 0 6.09017797614797e-06
. O 0 1.1033197324650246e-06

In O 0 7.354881290666526e-06
this O 0 1.403839036129284e-07
report O 0 5.906019282519992e-07
, O 0 1.8598830919813736e-08
we O 0 8.336590084923046e-09
demonstrate O 0 2.486146577496129e-08
in O 0 1.501188862107483e-08
cultured O 0 2.576923407104914e-06
293 O 0 6.22763252522418e-07
cells O 0 1.4540833035425749e-06
overexpressing O 0 1.1283168532827403e-05
wild O 0 4.325785027958773e-07
- O 0 4.459834144654451e-06
type O 0 3.3616464634178556e-07
or O 0 1.2534776772099576e-07
mutant O 0 5.768226856162073e-07
HFE O 0 3.936944267479703e-06
proteins O 0 3.928565917021842e-08
that O 0 3.4587686048581645e-09
both O 0 1.7563056564640078e-09
the O 0 6.966704102495669e-09
wild O 0 2.3493291223530832e-07
- O 0 1.3240665794000961e-05
type O 0 7.580881629110081e-07
and O 0 1.7655942485816922e-07
H63D O 0 1.9143515601172112e-05
HFE O 0 5.891078217246104e-06
proteins O 0 5.235558120375572e-08
form O 0 2.9033692783286824e-08
stable O 0 7.562749146927672e-07
complexes O 0 4.133081077384304e-08
with O 0 7.808770519091013e-09
the O 0 5.486053922254541e-08
transferrin O 0 5.037080427428009e-06
receptor O 0 9.733402066558483e-07
( O 0 1.332936108155991e-07
TfR O 0 7.464948339475086e-06
) O 0 1.4052830010768957e-07
. O 0 7.689189942539087e-07

The O 0 1.0772073437692598e-06
C282Y O 0 1.42586632136954e-05
mutation O 0 1.821150362957269e-05
nearly O 0 1.0047259593193303e-06
completely O 0 9.844230817179778e-07
prevents O 0 7.822026049097985e-08
the O 0 1.6779711842218603e-08
association O 0 8.062243317397133e-09
of O 0 1.9869199618938183e-09
the O 0 9.148341639786395e-09
mutant O 0 4.852686288359109e-07
HFE O 0 5.195516223466257e-06
protein O 0 3.6341822351459996e-07
with O 0 1.4088922029031892e-08
the O 0 1.6326461604876386e-07
TfR O 0 4.7680281568318605e-05
. O 0 1.7347002767564845e-06

Studies O 0 1.7548354662721977e-05
on O 0 1.4454723213930265e-06
cell O 0 2.5239301976398565e-05
- O 0 3.7919828173471615e-05
associated O 0 1.3416483852779493e-06
transferrin O 0 1.0349310741730733e-06
at O 0 2.5252813884435454e-07
37 O 0 1.3445441027215566e-07
degrees O 0 4.166046494447073e-07
C O 0 4.104332219867501e-06
suggest O 0 1.2210753652652784e-07
that O 0 9.182850924105423e-09
the O 0 2.176531488373712e-08
overexpressed O 0 4.603220531862462e-06
wild O 0 2.3846058638810064e-07
- O 0 1.8483174244465772e-06
type O 0 7.855574040149804e-07
HFE O 0 9.007077096612193e-06
protein O 0 5.090083732284256e-07
decreases O 0 1.1422570622698913e-07
the O 0 2.6577124945248443e-09
affinity O 0 2.6321570700815755e-08
of O 0 3.350997923590171e-09
the O 0 4.0898722630799966e-08
TfR O 0 4.914079909212887e-06
for O 0 9.948311685548106e-08
transferrin O 0 7.533153620897792e-06
. O 0 1.1868936553582898e-06

The O 0 5.516463716048747e-06
overexpressed O 0 7.31266409275122e-05
H63D O 0 5.405137926572934e-05
protein O 0 4.995031758880941e-06
does O 0 1.7321183065632795e-07
not O 0 1.8249814104365214e-08
have O 0 5.417898130133381e-09
this O 0 4.784671769897386e-09
effect O 0 6.463546498025607e-08
, O 0 1.344081912435513e-08
providing O 0 3.728680919579119e-09
the O 0 4.8509063432788935e-09
first O 0 4.195918634763984e-08
direct O 0 4.006783527188418e-08
evidence O 0 4.5817500904377084e-08
for O 0 6.908824623508281e-09
a O 0 8.891064595673015e-08
functional O 0 3.513158333134925e-07
consequence O 0 1.2980318331301532e-07
of O 0 5.692992299799471e-09
the O 0 1.408599814567424e-07
H63D O 0 0.0010364328045397997
mutation O 0 1.8602790078148246e-05
. O 0 5.825033326800622e-07

Addition O 0 1.123982428907766e-06
of O 0 1.205416140237503e-07
soluble O 0 1.660926841395849e-06
wild O 0 2.2655899556411896e-06
- O 0 0.00011041716788895428
type O 0 1.734867510094773e-05
HFE O 0 0.0005495483637787402
/ O 0 6.560413021361455e-05
beta2m O 0 6.813752861489775e-06
heterodimers O 0 1.3936929690316902e-06
to O 0 9.9324992675065e-08
cultured O 0 2.565506292739883e-06
cells O 0 1.4863145452181925e-06
also O 0 1.0779529446836023e-07
decreased O 0 3.437213251800131e-07
the O 0 4.565983591220402e-09
apparent O 0 7.549606806378506e-08
affinity O 0 2.6414813447672714e-08
of O 0 2.4664450481992617e-09
the O 0 1.6854931672583007e-08
TfR O 0 6.225364472811634e-07
for O 0 5.1813637824693615e-09
its O 0 1.9670300943630536e-08
ligand O 0 1.1290064350077955e-07
under O 0 1.8536429280402444e-08
steady O 0 1.0250972763969912e-06
- O 0 3.393526640138589e-06
state O 0 1.0105534897775215e-07
conditions O 0 9.921345736074727e-07
, O 0 1.0116002258087065e-08
both O 0 5.748235665237189e-09
in O 0 1.857302223129409e-08
293 O 0 1.1037158742510655e-07
cells O 0 3.295104988865205e-07
and O 0 2.2064595484039273e-08
in O 0 7.390787004624144e-08
HeLa O 0 0.00010264146112604067
cells O 0 1.0789297448354773e-05
. O 0 5.579315711656818e-07

Furthermore O 0 1.8010157873504795e-05
, O 0 4.875276431448583e-07
at O 0 1.1085154483225779e-07
4 O 0 1.571995795757175e-07
degrees O 0 1.5709451872680802e-06
C O 0 1.0204008503933437e-05
, O 0 2.860014802763544e-08
the O 0 1.0448252041328487e-08
added O 0 3.611069701037195e-07
soluble O 0 1.5680204512591445e-07
complex O 0 3.0400364892102516e-08
of O 0 2.014314581799681e-08
HFE O 0 0.00019246022566221654
/ O 0 3.931993342121132e-05
beta2m O 0 9.00123814062681e-06
inhibited O 0 2.523923683384055e-07
binding O 0 5.7438985123781094e-08
of O 0 7.3550783241671525e-09
transferrin O 0 8.518626941622642e-07
to O 0 8.642486193366494e-08
HeLa O 0 1.0638085768732708e-05
cell O 0 1.9868199160555378e-05
TfR O 0 2.711485194595298e-06
in O 0 1.521673809179447e-08
a O 0 6.391351092815967e-08
concentration O 0 4.444281785254134e-06
- O 0 1.6379735825466923e-05
dependent O 0 6.725571438437328e-06
manner O 0 3.967390966863604e-06
. O 0 1.9274600617791293e-06

Scatchard O 0 0.0006494830013252795
plots O 0 2.4547551220166497e-05
of O 0 2.7563950766307244e-07
these O 0 4.313237411679438e-08
data O 0 8.157310276146745e-07
indicate O 0 1.4825769767412567e-07
that O 0 6.57413901095083e-09
the O 0 1.638425928263132e-08
added O 0 2.1909956160470756e-07
heterodimer O 0 2.864415478143201e-07
substantially O 0 6.529392067022854e-07
reduced O 0 8.74667946959562e-08
the O 0 9.66235358390577e-09
affinity O 0 2.904588036756195e-08
of O 0 1.0362791513784941e-08
TfR O 0 4.315189471526537e-06
for O 0 1.5552602405932703e-07
transferrin O 0 6.3659031184215564e-06
. O 0 8.432134563918225e-07

These O 0 2.3654176857235143e-06
results O 0 2.0667625904025044e-06
establish O 0 1.697006837275694e-07
a O 0 2.454433172260906e-07
molecular O 0 3.4929607863887213e-06
link O 0 1.4799264135945123e-05
between O 0 4.2395529931127385e-07
HFE O 0 0.00010977665078826249
and O 0 2.018996241304194e-07
a O 0 6.608815539266288e-08
key O 0 3.002511164140742e-07
protein O 0 2.186391157010803e-07
involved O 0 2.506310003980161e-08
in O 0 1.4646807322549193e-08
iron O 0 1.3422341908153612e-05
transport O 0 2.079809746646788e-06
, O 0 5.013358617134145e-08
the O 0 1.2191968323804758e-08
TfR O 0 1.004793034553586e-06
, O 0 3.799730308173821e-08
and O 0 2.1071135947181574e-08
raise O 0 2.6814621634230207e-08
the O 0 5.533446145733478e-09
possibility O 0 1.48803565025446e-08
that O 0 1.1642980801696012e-08
alterations O 0 1.8496244535981532e-07
in O 0 1.2689616468719578e-08
this O 0 8.62014193359073e-09
regulatory O 0 6.900530991060805e-08
mechanism O 0 1.1530431009987296e-07
may O 0 6.648932640018757e-07
play O 0 1.0075948964072268e-08
a O 0 1.7989165712606336e-08
role O 0 2.9370665899364212e-08
in O 0 7.287297876246157e-09
the O 0 1.0106748504767893e-07
pathogenesis O 0 0.00029517654911614954
of O 0 1.925043216033373e-05
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 2.3430879082297906e-05
. O 0 2.219205043729744e-06

Genomic O 0 0.00028312302310951054
organization O 0 3.499158992781304e-06
of O 0 1.7491132098257367e-07
the O 0 3.1900663088890724e-07
UBE3A O 0 0.0004925122484564781
/ O 0 0.00018711731536313891
E6 O 0 0.0002785106189548969
- O 0 0.00022567977430298924
AP O 0 0.00010122912499355152
gene O 0 9.666676987762912e-07
and O 0 1.1758095297409454e-07
related O 0 1.3513729300029809e-06
pseudogenes O 0 3.560371624189429e-05
. O 0 1.6470208947794163e-06

The O 0 6.530900918733096e-06
UBE3A O 0 0.00013111640873830765
gene O 0 5.589639386016643e-06
encodes O 0 2.3390994101646356e-06
the O 0 8.793784900262835e-08
E6 O 0 4.064706445205957e-05
- O 0 5.128977500135079e-05
AP O 0 2.389088513155002e-05
ubiquitin O 0 6.297545951383654e-07
- O 0 1.1625792240010924e-06
protein O 0 1.45528858297439e-07
ligase O 0 5.990872153915916e-08
and O 0 4.030744804595088e-08
has O 0 3.5963875433253634e-08
recently O 0 2.3597030462951807e-07
been O 0 1.5481209203471735e-08
shown O 0 5.280393899909086e-09
to O 0 4.3271772831587896e-09
be O 0 3.2069031874470966e-08
mutated O 0 2.636940735101234e-05
in O 0 0.0022820658050477505
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.007751479744911194
who O 0 2.2379902020475129e-07
lack O 0 5.325039964532152e-08
15q11 O 0 7.138231694625574e-07
- O 0 5.105337550048716e-06
q13 O 0 3.386989192222245e-06
deletions O 0 8.631523996882606e-06
or O 0 7.32853095541941e-07
chromosome O 0 0.00021764650591649115
15 O 0 3.2797252060845494e-06
paternal O 0 4.4149477616883814e-05
uniparental B-Disease 0 0.002384697552770376
disomy I-Disease 0 0.002339109545573592
. O 0 6.9769980655109975e-06

Previous O 0 4.070808790856972e-05
UBE3A O 0 0.00018981566245201975
cDNA O 0 2.349846181459725e-05
analysis O 0 2.8598074095498305e-06
has O 0 1.3402680565377523e-07
shown O 0 2.2263028753854996e-08
a O 0 4.8272440267282946e-08
coding O 0 1.2399546903907321e-05
region O 0 1.180198182737513e-06
of O 0 2.405096211077762e-08
approximately O 0 1.8836477977401955e-07
2 O 0 1.0839976312126964e-06
. O 0 9.785597967493231e-07

6 O 0 2.9628941774717532e-05
kb O 0 0.00026836126926355064
and O 0 3.734590734438825e-07
a O 0 1.6749470432841917e-07
3 O 0 1.8182447547587799e-06
- O 0 0.0005814595497213304
untranslated O 0 0.00747698824852705
region O 0 4.12881636293605e-05
( O 0 1.1399837518411005e-07
UTR O 0 4.899493887933204e-06
) O 0 1.8243097699155442e-08
of O 0 3.9768135451367925e-09
< O 0 1.680043908436346e-07
50 O 0 1.212784326298788e-07
bp O 0 2.5759485652088188e-05
, O 0 2.713623992178782e-08
whereas O 0 2.6702133837375186e-08
Northern O 0 6.229593196849237e-08
analysis O 0 9.314857862818826e-08
has O 0 4.6103103557015856e-08
indicated O 0 3.289697403374703e-08
mRNA O 0 1.5979248146891223e-08
sizes O 0 4.400238040602744e-08
of O 0 2.9968623138643125e-09
5 O 0 1.738924169103484e-07
- O 0 7.270657988556195e-06
8 O 0 1.257678377442062e-06
kb O 0 5.6088010751409456e-05
. O 0 1.047235286932846e-06

We O 0 8.3256245488883e-06
have O 0 2.13452381103707e-07
analyzed O 0 4.997033897780057e-07
additional O 0 7.271541591080677e-08
cDNA O 0 5.819025545861223e-07
clones O 0 6.268040124268737e-06
and O 0 7.330866225174759e-08
provide O 0 2.7547018888185448e-08
evidence O 0 3.125453673646916e-08
for O 0 5.441759487467834e-09
an O 0 2.0499649977523404e-08
additional O 0 1.7471792546075449e-07
0 O 0 1.3931349940321525e-06
. O 0 1.3586094382844749e-06

5 O 0 1.9293565856060013e-05
kb O 0 0.00010964253306156024
of O 0 1.8587097372346761e-07
5 O 0 5.876298700968619e-07
- O 0 1.1349713531672023e-05
UTR O 0 3.3525739127071574e-05
and O 0 1.7248785866286198e-07
> O 0 8.278646390635913e-08
2 O 0 5.484651666165519e-08
kb O 0 3.7630522911058506e-06
of O 0 1.3792193165329536e-08
3 O 0 1.1169789786436013e-06
- O 0 6.222305091796443e-05
UTR O 0 0.0005666720098815858
. O 0 2.759008793873363e-06

We O 0 4.067207100888481e-06
have O 0 7.094187992606749e-08
established O 0 1.9447773169645188e-08
the O 0 9.312278947959385e-09
genomic O 0 2.3273678095847572e-07
organization O 0 1.9354631675128076e-08
of O 0 5.1867128370020055e-09
UBE3A O 0 4.641404302674346e-06
and O 0 1.2284427697295541e-08
the O 0 3.8880267894114695e-09
sequence O 0 3.279004090472881e-08
of O 0 9.637120435002089e-09
intron O 0 5.929833059781231e-05
- O 0 1.5090789020177908e-05
exon O 0 3.715338607435115e-05
borders O 0 7.3793166848190594e-06
. O 0 8.945238505475572e-07

We O 0 1.220081867359113e-05
have O 0 1.6842453476328956e-07
also O 0 7.650555744476151e-08
mapped O 0 9.690481874713441e-07
two O 0 2.3250159131293913e-08
highly O 0 3.4868818943323276e-08
homologous O 0 2.1913571401910303e-07
processed O 0 2.108047738147434e-06
pseudogenes O 0 6.867572892588214e-07
, O 0 3.395574310616212e-08
UBE3AP1 O 0 3.7039383187220665e-06
and O 0 9.056072514113112e-08
UBE3AP2 O 0 1.447484737582272e-05
, O 0 4.024399302693382e-08
to O 0 1.2471716104300867e-08
chromosomes O 0 1.2075274469225405e-07
2 O 0 2.4316378244293446e-07
and O 0 1.918919139143327e-07
21 O 0 2.8067475454918167e-07
, O 0 1.869107890684063e-08
respectively O 0 1.6315908624164877e-07
, O 0 1.573970820345494e-08
and O 0 2.2821605938361245e-08
determined O 0 1.064973886855114e-07
their O 0 4.155252852910962e-08
genomic O 0 1.3079956033834605e-06
organization O 0 4.021990491764882e-07
. O 0 4.037562462144706e-07

These O 0 1.6467179193568882e-06
results O 0 3.869374722853536e-06
will O 0 4.493542604677714e-08
form O 0 8.085064173712908e-09
the O 0 4.480284143681956e-09
basis O 0 3.485326161012381e-08
for O 0 1.319045761505322e-08
studies O 0 7.601998142092725e-09
of O 0 3.139313253797127e-09
mutation O 0 9.704353942652233e-07
and O 0 6.365705473854177e-08
imprinting O 0 1.1641906894510612e-05
of O 0 2.496048807643092e-07
UBE3A O 0 0.0004985572886653244
. O 0 2.488187419658061e-06

Mutation O 0 0.00035412676515989006
spectrum O 0 2.3345142835751176e-05
and O 0 2.7654471068672137e-06
genotype O 0 0.0005346394027583301
- O 0 0.00046576105523854494
phenotype O 0 0.0006453231908380985
analyses O 0 6.02116551817744e-06
in O 0 9.007284234030521e-07
Cowden B-Disease 1 0.9774633646011353
disease I-Disease 0 0.18643824756145477
and O 0 1.6966359908110462e-06
Bannayan B-Disease 0 0.1551227867603302
- I-Disease 1 0.9997652173042297
Zonana I-Disease 1 0.9999884366989136
syndrome I-Disease 1 0.9999980926513672
, O 0 3.8726238926756196e-07
two O 0 7.755633077977109e-07
hamartoma B-Disease 1 0.7817105054855347
syndromes I-Disease 0 0.1341746598482132
with O 0 2.6449758934177225e-06
germline O 0 0.017352329567074776
PTEN O 0 0.17359700798988342
mutation O 0 0.0005948531324975193
. O 0 2.9447626275214134e-06

The O 0 5.5928852816578e-05
tumour B-Disease 1 0.999990701675415
suppressor O 0 0.0014158787671476603
gene O 0 9.897645941236988e-05
PTEN O 0 0.0008963592117652297
, O 0 3.413552462916414e-07
which O 0 3.838548678913867e-08
maps O 0 1.031876877277682e-06
to O 0 2.4467908588121645e-07
10q23 O 0 1.4204916624294128e-05
. O 0 9.388817261424265e-07

3 O 0 4.494949735089904e-06
and O 0 8.167494058852753e-08
encodes O 0 2.517435291338188e-07
a O 0 2.674183718909262e-08
403 O 0 3.836397155509985e-08
amino O 0 1.2760249035181914e-07
acid O 0 4.553844803467655e-07
dual O 0 8.298707143694628e-07
specificity O 0 9.267698146686598e-07
phosphatase O 0 0.00025866160285659134
( O 0 6.99773607948373e-08
protein O 0 2.3862529019424983e-07
tyrosine O 0 3.517547156661749e-06
phosphatase O 0 0.00028328585904091597
; O 0 3.1637077313462214e-07
PTPase O 0 4.824777533940505e-06
) O 0 3.1014980805821324e-08
, O 0 1.2850688513310615e-08
was O 0 2.1380625980782497e-07
shown O 0 5.603248354191237e-08
recently O 0 1.907133366785274e-07
to O 0 1.1957933310213775e-08
play O 0 1.2784776792784669e-08
a O 0 2.4814326593514124e-08
broad O 0 1.9151420360685734e-07
role O 0 1.2703304719252628e-07
in O 0 1.4955394078697282e-07
human O 0 1.3415818784778821e-06
malignancy B-Disease 0 0.00029570554033853114
. O 0 2.0781146758963587e-06

Somatic O 0 0.0011867325520142913
PTEN O 0 0.005622736178338528
deletions O 0 0.0005686563672497869
and O 0 9.29843372432515e-06
mutations O 0 3.73186485376209e-05
were O 0 1.1590848458808978e-07
observed O 0 2.688119877802819e-07
in O 0 1.124961030996019e-07
sporadic B-Disease 0 0.00010868507524719462
breast I-Disease 1 0.7396974563598633
, I-Disease 0 8.129468369588722e-06
brain I-Disease 0 0.03188483789563179
, I-Disease 0 3.284912281742436e-06
prostate I-Disease 0 0.20732083916664124
and I-Disease 0 1.302834425587207e-05
kidney I-Disease 1 0.6419101357460022
cancer I-Disease 0 0.0005416800850071013
cell O 0 1.3639629287354182e-05
lines O 0 1.0972203199344222e-05
and O 0 2.1278309247918514e-07
in O 0 2.9155778236145125e-08
several O 0 6.136803420986325e-08
primary O 0 2.2906067897565663e-05
tumours B-Disease 1 0.9999983310699463
such O 0 5.811926939713885e-08
as O 0 1.3647605555888731e-05
endometrial B-Disease 1 0.9938878417015076
carcinomas I-Disease 1 1.0
, O 1 0.8020040392875671
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 0 0.41568976640701294
thyroid B-Disease 1 0.9999973773956299
tumours I-Disease 1 0.9999997615814209
. O 0 2.0967852833564393e-05

In O 0 2.6173390779149486e-06
addition O 0 2.4195443870667077e-07
, O 0 1.4834539285857318e-07
PTEN O 0 6.7109263909515e-05
was O 0 2.146806309610838e-06
identified O 0 1.540965826052343e-07
as O 0 6.550370024172025e-09
the O 0 9.757193275561349e-09
susceptibility O 0 8.419823416261352e-07
gene O 0 4.4941086230210203e-07
for O 0 4.936914166364659e-08
two O 0 7.726060175627936e-06
hamartoma B-Disease 1 0.9997124075889587
syndromes I-Disease 1 0.9998518228530884
Cowden B-Disease 1 0.9996180534362793
disease I-Disease 1 0.9963322281837463
( O 0 7.245631081786996e-07
CD B-Disease 0 0.00012454632087610662
; O 0 1.1093504781456431e-06
MIM O 0 0.00025154868490062654
158350 O 0 2.8252497941139154e-06
) O 0 2.1209601186455984e-08
and O 0 3.814500360022066e-08
Bannayan B-Disease 0 6.016021143295802e-05
- I-Disease 0 0.005509357433766127
Zonana I-Disease 0 0.0034852386452257633
( I-Disease 0 1.3356363126604265e-07
BZS I-Disease 0 3.4686979688558495e-06
) I-Disease 0 2.43946480793511e-08
or I-Disease 0 6.372751215621975e-08
Ruvalcaba I-Disease 0 3.348707832628861e-05
- I-Disease 0 7.71883424022235e-05
Riley I-Disease 0 0.00017904282140079886
- I-Disease 1 0.9393280148506165
Smith I-Disease 1 0.9328699111938477
syndrome I-Disease 1 0.9998776912689209
( O 0 8.915728244573984e-07
MIM O 0 0.0008325937669724226
153480 O 0 2.3386814063997008e-05
) O 0 2.9092240083627985e-07
. O 0 6.704366910526005e-07

Constitutive O 0 0.0001368881348753348
DNA O 0 5.9599817177513614e-05
from O 0 4.5565900563815376e-07
37 O 0 4.850132313549693e-07
CD B-Disease 0 3.6235965126252268e-06
families O 0 8.289027420005368e-08
and O 0 5.798086633035382e-08
seven O 0 7.521980904812153e-08
BZS B-Disease 0 5.619635430775816e-06
families O 0 4.366802741628817e-08
was O 0 3.5862501590600004e-07
screened O 0 9.78994762590446e-07
for O 0 2.179606326535577e-07
germline O 0 0.0002133024245267734
PTEN O 0 0.0013131365412846208
mutations O 0 0.00011146585893584415
. O 0 1.3890768286728417e-06

PTEN O 0 0.018189746886491776
mutations O 0 0.0008193189278244972
were O 0 1.6606370536464965e-06
identified O 0 4.38248576983824e-07
in O 0 3.766610134903203e-08
30 O 0 6.055712731267704e-08
of O 0 7.51760342865282e-09
37 O 0 7.056461299725925e-07
( O 0 4.565420042013102e-08
81 O 0 1.0359733693121598e-07
% O 0 1.4520246338634024e-08
) O 0 4.827720445632622e-09
CD B-Disease 0 1.5910644606265123e-06
families O 0 1.4199367903700022e-08
, O 0 7.378094135646052e-09
including O 0 6.305355793045919e-09
missense O 0 2.4977614430099493e-06
and O 0 2.074604878998798e-07
nonsense O 0 2.097571496051387e-06
point O 0 3.1066899737197673e-06
mutations O 0 3.5438947634247597e-06
, O 0 1.785380376873036e-08
deletions O 0 4.820637968805386e-07
, O 0 2.4130086373475024e-08
insertions O 0 1.134715944317577e-06
, O 0 3.8879619523868314e-08
a O 0 1.3512978114249563e-07
deletion O 0 2.5973426090786234e-05
/ O 0 1.753142714733258e-05
insertion O 0 1.085298890757258e-06
and O 0 1.6395254931467207e-07
splice O 0 0.001107306801714003
site O 0 9.974028216674924e-05
mutations O 0 0.00010194908099947497
. O 0 7.255443392750749e-07

These O 0 1.8152163647755515e-06
mutations O 0 2.6524869099375792e-05
were O 0 1.8862920114770532e-07
scattered O 0 1.193817951161691e-07
over O 0 8.011613772396231e-08
the O 0 1.2548023065050984e-08
entire O 0 5.299193261976143e-08
length O 0 3.2308264508174034e-07
of O 0 2.0072423723149768e-08
PTEN O 0 2.2336274923873134e-05
, O 0 2.7003494551536278e-08
with O 0 1.857141995742495e-09
the O 0 4.846033352379209e-09
exception O 0 5.512272860386247e-09
of O 0 8.065714762750531e-10
the O 0 8.408290952388597e-09
first O 0 3.7036872413409583e-07
, O 0 8.134411189075763e-08
fourth O 0 2.403884536761325e-06
and O 0 1.9882634205714567e-07
last O 0 1.4141603514872259e-06
exons O 0 3.777999882004224e-05
. O 0 8.37631091599178e-07

A O 0 7.377564543276094e-06
hot O 0 1.148822957475204e-05
spot O 0 5.167069957678905e-06
for O 0 9.6857910136805e-08
PTEN O 0 2.4984377887449227e-05
mutation O 0 1.4990879435572424e-06
in O 0 3.4138349036538784e-08
CD B-Disease 0 1.4560729141521733e-05
was O 0 2.7443450107966783e-06
identified O 0 1.1981566672147892e-07
in O 0 6.009455599809144e-09
exon O 0 3.945138473682164e-07
5 O 0 5.7178397128154757e-08
that O 0 1.3317660307876622e-09
contains O 0 1.7635900517731784e-09
the O 0 6.277623754158412e-09
PTPase O 0 1.1073949508499936e-06
core O 0 6.14495604622789e-07
motif O 0 1.5669382946725818e-07
, O 0 4.8978008315714305e-09
with O 0 9.346582396929648e-10
13 O 0 1.660846926654358e-08
of O 0 1.4219742050514128e-09
30 O 0 4.6601734027262864e-08
( O 0 6.3503984293333815e-09
43 O 0 7.34678167191305e-08
% O 0 1.145082606512915e-08
) O 0 2.74278888490187e-09
CD B-Disease 0 5.335808964446187e-06
mutations O 0 3.391799054952571e-06
identified O 0 2.4815469146233227e-07
in O 0 7.657793510418287e-09
this O 0 3.242737989239686e-08
exon O 0 4.516976696322672e-05
. O 0 1.4666762808701606e-06

Seven O 0 5.4778370213171e-06
of O 0 1.285924895455537e-07
30 O 0 4.3781119529739954e-07
( O 0 4.7920906354192994e-08
23 O 0 1.9619834290551807e-07
% O 0 3.123981784369789e-08
) O 0 6.940364283281042e-09
were O 0 2.9509572563313213e-09
within O 0 4.691195210071442e-10
the O 0 2.2413459976888817e-09
core O 0 5.119439947520732e-07
motif O 0 5.426846314549039e-07
, O 0 1.8379413546654177e-08
the O 0 5.65404656427404e-09
majority O 0 3.9271498053494724e-08
( O 0 5.490363719218294e-09
five O 0 8.888584979160896e-09
of O 0 3.0372355741548063e-09
seven O 0 9.074936713204806e-08
) O 0 6.50113030076227e-09
of O 0 9.560677804998363e-10
which O 0 1.5035105604965793e-07
were O 0 4.4513257080325275e-08
missense O 0 4.068921953148674e-06
mutations O 0 2.819793962771655e-06
, O 0 1.8351109076775174e-08
possibly O 0 7.928778700261319e-08
pointing O 0 3.969060458075546e-07
to O 0 2.239052854235979e-08
the O 0 7.965214265936993e-09
functional O 0 9.38632211955337e-08
significance O 0 4.681769283365611e-08
of O 0 9.698413627745595e-09
this O 0 3.8961424309036374e-08
region O 0 7.88544821261894e-06
. O 0 1.4972019926062785e-06

Germline O 0 0.03810549154877663
PTEN O 0 0.14520171284675598
mutations O 0 0.015197424218058586
were O 0 4.467121925699757e-06
identified O 0 9.214485885422619e-07
in O 0 2.177553071192051e-08
four O 0 2.524931552727594e-08
of O 0 6.3719221010671845e-09
seven O 0 1.271479419528987e-07
( O 0 4.2215582141125196e-08
57 O 0 1.5292073385353433e-07
% O 0 2.05044603518445e-08
) O 0 1.794434290047775e-08
BZS B-Disease 0 3.1587806006427854e-06
families O 0 7.814226421487547e-08
studied O 0 3.7943135566820274e-07
. O 0 5.998441565679968e-07

Interestingly O 0 0.0001644203148316592
, O 0 1.3007620509597473e-06
none O 0 1.8697109283039026e-07
of O 0 7.582621641688547e-09
these O 0 8.46772696405651e-09
mutations O 0 2.7409969334257767e-06
was O 0 1.0914425274677342e-06
observed O 0 1.3389420416842768e-07
in O 0 5.712288420056666e-09
the O 0 1.4635553213793173e-08
PTPase O 0 7.862305210437626e-06
core O 0 3.0683734166814247e-06
motif O 0 9.958275768440217e-06
. O 0 7.080277555360226e-07

It O 0 6.895681508467533e-06
is O 0 8.755108638069942e-08
also O 0 2.4147121635564872e-08
worthy O 0 1.2961856477033962e-08
of O 0 3.920898272724571e-09
note O 0 2.1137640260349144e-07
that O 0 4.779582063463295e-09
a O 0 1.5681216325447167e-08
single O 0 3.661693881440442e-07
nonsense O 0 7.64603953484766e-07
point O 0 4.737408119126485e-07
mutation O 0 4.0242233012577344e-07
, O 0 9.081703389313134e-09
R233X O 0 1.494738057772338e-07
, O 0 3.810152193750582e-08
was O 0 2.9792937539241393e-07
observed O 0 4.422198074394146e-08
in O 0 2.602998927514477e-09
the O 0 8.879468715861094e-09
germline O 0 1.2952411907463102e-06
DNA O 0 7.705060056650836e-07
from O 0 6.126438911735477e-09
two O 0 7.64813012921195e-09
unrelated O 0 2.260474190052264e-07
CD B-Disease 0 1.2437099940143526e-05
families O 0 4.378921758529941e-08
and O 0 3.834392359181038e-08
one O 0 1.8667748236111947e-07
BZS B-Disease 0 3.804065636359155e-05
family O 0 2.310094032509369e-06
. O 0 1.0052090146928094e-06

Genotype O 0 0.09936501830816269
- O 0 0.020946688950061798
phenotype O 0 0.0012402292340993881
studies O 0 1.4665308754047146e-06
were O 0 2.321582144304557e-07
not O 0 3.106329060642565e-08
performed O 0 1.0519964632749179e-07
on O 0 4.71865995166354e-08
this O 0 3.361740441576444e-09
small O 0 1.1741708938473039e-08
group O 0 7.610856869177951e-07
of O 0 3.1581368631350415e-08
BZS B-Disease 0 2.03644267458003e-05
families O 0 4.1045805687645043e-07
. O 0 6.317974339253851e-07

However O 0 5.318231160345022e-06
, O 0 3.501438072817109e-07
genotype O 0 3.806112727033906e-05
- O 0 6.740623211953789e-05
phenotype O 0 6.574709550477564e-05
analysis O 0 5.5834681234046e-07
inthe O 0 7.724778697593138e-06
group O 0 1.7545456785228453e-06
of O 0 9.791945032588956e-09
CD B-Disease 0 1.1819985957117751e-05
families O 0 1.3019469236041914e-07
revealed O 0 2.3805027922207955e-06
two O 0 2.9227047448898702e-08
possible O 0 6.136171037951499e-08
associations O 0 3.2970957075662e-09
worthy O 0 8.190047751099883e-09
of O 0 2.3547106486887515e-09
follow O 0 7.78177309257444e-08
- O 0 2.3782472453603987e-06
up O 0 9.813784345169552e-07
in O 0 1.0045939546898808e-07
independent O 0 6.463447448368242e-07
analyses O 0 1.1308270586596336e-06
. O 0 7.151696195251134e-07

The O 0 2.2939952941669617e-06
first O 0 2.5423439637961565e-06
was O 0 2.397906200712896e-06
an O 0 7.550845282366936e-08
association O 0 8.94401210871365e-08
noted O 0 5.283156667701405e-08
in O 0 5.897607735505517e-09
the O 0 1.1223009188654487e-08
group O 0 4.6478658077830914e-07
of O 0 2.714476865506299e-09
CD B-Disease 0 1.2030694961140398e-05
families O 0 1.0210389689291333e-07
with O 0 2.5275728603446623e-06
breast B-Disease 1 0.7994076609611511
disease I-Disease 0 0.00038058884092606604
. O 0 6.617486860704958e-07

A O 0 1.663126386119984e-05
correlation O 0 2.496399247320369e-05
was O 0 5.800132839794969e-06
observed O 0 2.96483278816595e-07
between O 0 2.380787655908989e-08
the O 0 2.9483034680310993e-08
presence O 0 1.4898637346050236e-07
/ O 0 2.8648453735513613e-05
absence O 0 4.066800585178498e-08
of O 0 3.1359379537576615e-09
a O 0 1.272017868814146e-07
PTEN O 0 0.0001359292509732768
mutation O 0 2.497706873327843e-06
and O 0 1.17433662794042e-08
the O 0 1.1941545530191888e-08
type O 0 1.0952118145723944e-06
of O 0 4.217466198497277e-07
breast O 0 0.07791918516159058
involvement O 0 1.8359520254307427e-05
( O 0 7.431688686665439e-07
unaffected O 0 2.1209083570283838e-05
versus O 0 4.914071541861631e-05
benign O 0 0.00216675060801208
versus O 0 0.0003061516908928752
malignant O 0 0.13114295899868011
) O 0 6.205247018442606e-07
. O 0 1.4066548601476825e-06

Specifically O 0 3.665142230602214e-06
and O 0 3.1432458058588963e-07
more O 0 1.6565095961595944e-08
directly O 0 6.435756461087294e-08
, O 0 1.392247526155188e-07
an O 0 1.8864072615087935e-07
association O 0 7.177250438417104e-08
was O 0 8.431595688307425e-07
also O 0 1.3906949902775523e-07
observed O 0 4.217357130187338e-08
between O 0 4.017770560693634e-09
the O 0 4.6226884542477364e-09
presence O 0 3.169751794374065e-09
of O 0 1.2963136120092145e-09
a O 0 3.0773978210163477e-07
PTEN O 0 0.000845650618430227
mutation O 0 4.419075048645027e-05
and O 0 1.888905171654187e-05
malignant B-Disease 1 0.9999436140060425
breast I-Disease 1 0.9989401698112488
disease I-Disease 0 0.19376949965953827
. O 0 2.907123871409567e-06

Secondly O 0 0.002411474008113146
, O 0 1.7866394728116575e-06
there O 0 2.1105647007857442e-08
appeared O 0 2.873548510251567e-07
to O 0 3.1548612611231874e-08
be O 0 1.909466007532501e-08
an O 0 2.5557131522191412e-08
interdependent O 0 7.135720079531893e-05
association O 0 6.123602247498638e-08
between O 0 2.1899611013509457e-08
mutations O 0 9.570088650434627e-07
upstream O 0 2.1025093133175687e-07
and O 0 1.7848254429964072e-08
within O 0 2.8161615261979023e-09
the O 0 7.295502868487347e-09
PTPase O 0 2.93108973892231e-06
core O 0 7.294266879398492e-07
motif O 0 3.2018067486205837e-07
, O 0 5.459016350073398e-09
the O 0 1.4838231754410458e-09
core O 0 8.080412072786203e-08
motif O 0 6.022378329362255e-08
containing O 0 1.3927224706833385e-08
the O 0 2.8342079794185793e-09
majority O 0 5.467498898070744e-09
of O 0 3.035411477725347e-09
missense O 0 5.387241799326148e-06
mutations O 0 4.600411557476036e-06
, O 0 2.539803212187053e-08
and O 0 1.9920015859042906e-08
the O 0 1.7448671840725183e-08
involvement O 0 2.0829868674354657e-07
of O 0 4.27661728252815e-09
all O 0 9.832763048223114e-09
major O 0 1.7638708982303797e-07
organ O 0 8.263777999673039e-05
systems O 0 3.782997009693645e-05
( O 0 8.094294656757484e-08
central O 0 4.1498560676700436e-07
nervous O 0 2.7751218567573233e-06
system O 0 3.883382078129216e-07
, O 0 1.5053153674671194e-06
thyroid O 0 0.138456329703331
, O 0 2.497392415534705e-06
breast O 0 0.04350288584828377
, O 0 8.700888429302722e-06
skin O 1 0.9986107349395752
and O 0 0.029832523316144943
gastrointestinal O 1 0.9199649095535278
tract O 0 0.019100571051239967
) O 0 1.6216918083955534e-06
. O 0 2.046564304691856e-06

However O 0 8.895184691937175e-06
, O 0 1.2298335150262574e-07
these O 0 1.5240702921914817e-08
observations O 0 1.693018845116967e-07
would O 0 1.0159396168774038e-07
need O 0 1.1679813560760977e-08
to O 0 6.875148983453983e-08
be O 0 7.699625115265007e-08
confirmed O 0 3.077996382216952e-07
by O 0 1.6932998336827154e-09
studying O 0 2.482974714723696e-09
a O 0 1.0655058169106724e-08
larger O 0 1.5859887625424562e-08
number O 0 1.6241477496237167e-08
of O 0 6.204214919591777e-09
CD B-Disease 0 2.7053018129663542e-05
families O 0 3.8965370663390786e-07
. O 0 3.573372850951273e-07

Molecular O 0 0.08407854288816452
defects O 1 0.998976469039917
leading O 0 5.432228590507293e-06
to O 0 2.8832934617639694e-07
human O 0 1.5973039069194783e-07
complement B-Disease 0 3.581052396839368e-06
component I-Disease 0 0.0024357279762625694
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.850753291904766e-08
an O 0 2.0197697736534792e-08
African O 0 5.3309239689269816e-08
- O 0 2.7777591640187893e-06
American O 0 1.421770889464824e-06
family O 0 1.3325043255463243e-06
. O 0 1.069372046913486e-06

Complement B-Disease 0 0.0006183093064464629
component I-Disease 0 0.324660062789917
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.5308754882426e-05
C6D B-Disease 0 0.0006382330320775509
) O 0 7.946013056425727e-07
was O 0 8.544429874746129e-06
diagnosed O 0 8.655847341287881e-05
in O 0 8.598892264899405e-09
a O 0 7.759318521038949e-08
16 O 0 2.922953967754438e-07
- O 0 3.1602507988282014e-06
year O 0 7.491939868486952e-07
- O 0 9.818371609071619e-07
old O 0 5.432899570223526e-07
African O 0 1.8271130386438017e-08
- O 0 5.910098934691632e-07
American O 0 2.034610275813975e-07
male O 0 3.7263367858031415e-07
with O 0 1.0889773420785787e-06
meningococcal B-Disease 1 0.9999932050704956
meningitis I-Disease 1 0.9999771118164062
. O 0 6.5431263465143275e-06

The O 0 1.9690363842528313e-05
patients O 0 8.91630188561976e-05
father O 0 4.094519681530073e-06
and O 0 3.665949748210551e-07
two O 0 3.351265718265495e-07
brothers O 0 7.610799366375431e-05
also O 0 1.0190132115894812e-06
had O 0 1.91822141459852e-06
C6D B-Disease 0 5.4264059144770727e-05
, O 0 1.3354070915738703e-07
but O 0 1.1666789312414494e-08
gave O 0 3.500161938063684e-08
no O 0 1.166120444651142e-08
history O 0 9.192541838842772e-09
of O 0 1.2367185320272256e-07
meningitis B-Disease 1 0.9997871518135071
or O 0 3.041226079858461e-07
other O 0 1.1682759293307754e-07
neisserial B-Disease 0 0.008310613222420216
infection I-Disease 0 0.0001711795193841681
. O 0 1.147676698565192e-06

By O 0 5.462700300995493e-07
using O 0 4.0112306010087195e-07
exon O 0 1.2005536518699955e-05
- O 0 4.205860932415817e-06
specific O 0 1.3023965550473804e-07
polymerase O 0 3.0033240818738705e-06
chain O 0 2.4644119548611343e-05
reaction O 0 4.594789970724378e-07
( O 0 2.190078163266662e-08
PCR O 0 1.0396119023425854e-06
) O 0 1.2495861234640415e-08
/ O 0 3.281181761849439e-07
single O 0 1.1685155243412737e-07
- O 0 1.367564777865482e-06
strand O 0 5.2472372772172093e-05
conformation O 0 7.623220881214365e-07
polymorphism O 0 9.486881680231818e-08
as O 0 2.0885904117307064e-09
a O 0 4.734668657135899e-09
screening O 0 2.0762033869914376e-08
step O 0 2.0767101815977185e-08
and O 0 1.972988439291612e-09
nucleotide O 0 2.545341537540935e-08
sequencing O 0 2.5848184037613464e-08
of O 0 1.8184274086507912e-09
target O 0 2.3734432375022152e-07
exons O 0 1.8536466086516157e-06
, O 0 5.4874245591918225e-08
we O 0 7.2605215173382476e-09
determined O 0 1.552538719806762e-08
that O 0 3.532493630942213e-09
the O 0 1.1710173275503166e-08
proband O 0 9.539495295030065e-06
was O 0 1.1861090598586088e-07
a O 0 7.059373974271921e-09
compound O 0 1.1928644028103008e-07
heterozygote O 0 2.2255730414144637e-07
for O 0 8.78553318983677e-09
two O 0 3.318371000204934e-08
C6 O 0 0.00045204965863376856
gene O 0 1.4010603081260342e-05
mutations O 0 2.2583726604352705e-05
. O 0 6.9050719275765e-07

The O 0 9.189703860101872e-07
first O 0 4.148182313201687e-07
, O 0 3.1204979933363575e-08
1195delC O 0 3.06551697804025e-07
located O 0 4.6230081096609865e-08
in O 0 1.0851747944684575e-08
exon O 0 1.7568044086146983e-06
7 O 0 1.2502891877375077e-06
, O 0 9.084129004577335e-09
is O 0 2.7346398479011214e-09
a O 0 2.123988274149724e-08
novel O 0 2.5534748715472233e-07
mutation O 0 4.875573722529225e-07
, O 0 1.2688405881533527e-08
while O 0 1.073432631670812e-08
the O 0 4.301601741474315e-09
second O 0 1.9250043692409236e-07
, O 0 1.311519692848151e-08
1936delG O 0 8.915296945133377e-08
in O 0 7.084894892983584e-09
exon O 0 7.455077479789907e-07
12 O 0 2.860239192159497e-07
, O 0 3.8681530867279434e-08
has O 0 6.244391670406912e-08
been O 0 9.04443737681504e-08
described O 0 4.002999105523486e-07
before O 0 6.756679482577965e-08
to O 0 9.489469476875456e-08
cause O 0 3.379666964065109e-07
C6D B-Disease 0 1.7598764316062443e-05
in O 0 1.3424038769471736e-08
an O 0 9.796391253757974e-09
unrelated O 0 1.1547135869705016e-07
African O 0 1.659612003379607e-08
- O 0 1.3671996157427202e-06
American O 0 6.478258001152426e-07
individual O 0 1.139756591328478e-07
. O 0 6.151065008452861e-07

Both O 0 9.284602128900588e-06
mutations O 0 0.00016063124348875135
result O 0 2.446198550387635e-06
in O 0 1.1479656905066804e-06
premature O 0 9.079337905859575e-05
termination O 0 5.891275122849038e-06
codons O 0 9.776273145689629e-06
and O 0 9.234377102984581e-07
C6 O 0 0.00405937060713768
null O 0 0.0004282937734387815
alleles O 0 1.2321795111347456e-05
. O 0 1.733488034005859e-06

Allele O 0 0.00031857306021265686
- O 0 6.62340535200201e-05
specific O 0 3.368205625520204e-07
PCR O 0 8.379814971704036e-06
indicated O 0 7.446515724041092e-07
that O 0 4.2643746311910036e-09
the O 0 6.8048793266939356e-09
probands O 0 2.2130191155156353e-06
two O 0 2.2423868983878492e-07
brothers O 0 1.1872868526552338e-05
also O 0 5.874718453924288e-07
inherited O 0 1.7768689986041863e-06
the O 0 2.482843619588948e-08
1195delC O 0 2.0936483906552894e-06
mutation O 0 3.9150197039816703e-07
from O 0 1.2393037707170151e-08
their O 0 5.756203691476003e-08
heterozygous O 0 9.982790061258129e-07
mother O 0 1.4884649317536969e-06
and O 0 1.7581232469865427e-08
the O 0 2.8180274114220083e-08
1936delG O 0 3.830120476777665e-06
mutation O 0 7.895530984569632e-07
from O 0 1.5627946936547232e-08
their O 0 5.716269413369446e-08
homozygous O 0 1.371578377984406e-06
father O 0 4.7540322611894226e-07
. O 0 5.915591216876237e-08
. O 0 2.925617081928067e-07

PAX6 O 0 0.09098782390356064
mutations O 0 0.03995855525135994
reviewed O 0 0.0002510383492335677
. O 0 1.2161227459728252e-05

Mutations O 0 0.0015424356097355485
in O 0 1.2473236665755394e-06
PAX6 O 0 0.00012311074533499777
are O 0 2.136825258958197e-07
responsible O 0 1.1114217386420933e-06
for O 0 1.6310043804423913e-07
human O 0 2.4076564386632526e-06
aniridia B-Disease 1 0.9999997615814209
and O 0 5.28823056811234e-06
have O 0 1.1783263431652813e-07
also O 0 1.4401182113488176e-07
been O 0 8.272616724980253e-08
found O 0 9.884816876137847e-08
in O 0 5.498174004969769e-08
patients O 0 2.409601336239575e-07
with O 0 4.0459809724779916e-07
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999995231628418
, O 0 1.4379322692548158e-06
with O 0 1.4628258213633671e-05
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999821186065674
, O 0 5.566836875914305e-07
with O 0 2.591787335859408e-07
autosomal B-Disease 1 0.9338797926902771
dominant I-Disease 0 0.008983628824353218
keratitis I-Disease 1 0.9268406629562378
, O 0 1.1572049629648973e-07
and O 0 4.865902525352794e-08
with O 0 5.382237304729642e-07
isolated B-Disease 0 0.07450281828641891
foveal I-Disease 1 0.9999997615814209
hypoplasia I-Disease 1 0.9999997615814209
. O 0 1.715896178211551e-05

No O 0 6.640266292379238e-06
locus O 0 1.2239695934113115e-05
other O 0 7.047081140854061e-08
than O 0 1.1695891544150072e-07
chromosome O 0 0.00012822233838960528
11p13 O 0 4.984401130059268e-06
has O 0 6.295269940892467e-07
been O 0 1.7248112271772698e-07
implicated O 0 1.8484937527318834e-06
in O 0 6.429720542655559e-07
aniridia B-Disease 1 0.9999991655349731
, O 0 4.0297842929248873e-07
and O 0 7.704326776547532e-08
PAX6 O 0 9.404568118043244e-06
is O 0 7.692960934946314e-08
clearly O 0 2.8497014525896702e-08
the O 0 3.2321525456069367e-09
major O 0 3.513291702006427e-08
, O 0 5.433019723000143e-08
if O 0 1.4901258893473823e-08
not O 0 6.570879396150531e-09
only O 0 3.4810323512601826e-09
, O 0 1.786600023478968e-08
gene O 0 6.724724244122626e-07
responsible O 0 2.161113570764428e-06
. O 0 8.071183401625603e-07

Twenty O 0 9.724858500703704e-06
- O 0 7.42146403354127e-06
eight O 0 5.104005253997457e-07
percent O 0 2.4282667254738044e-06
of O 0 1.2209980582156277e-08
identified O 0 1.1616937172220787e-06
PAX6 O 0 2.5471794288023375e-05
mutations O 0 8.450371751678176e-06
are O 0 2.58010448561663e-08
C O 0 6.951541308808373e-06
- O 0 4.2873783968389034e-05
T O 0 0.0005327961989678442
changes O 0 8.497582371091994e-08
at O 0 9.826654689959469e-08
CpG O 0 1.1179849934705999e-06
dinucleotides O 0 3.227225079172058e-06
, O 0 1.1886440276498433e-08
20 O 0 5.2849480347560984e-09
% O 0 3.6701868211252986e-09
are O 0 9.131114198090984e-10
splicing O 0 1.1457640312073636e-06
errors O 0 3.121512236248236e-06
, O 0 1.5898747207643282e-08
and O 0 6.9582579698135305e-09
more O 0 3.223016742381901e-09
than O 0 1.0933459471118567e-08
30 O 0 3.4402034998493036e-08
% O 0 8.567297093975412e-09
are O 0 3.2401645810864466e-09
deletion O 0 7.151736554078525e-07
or O 0 8.016765207230492e-08
insertion O 0 1.4009476672072196e-06
events O 0 4.1480637946733623e-07
. O 0 1.1809829629783053e-06

There O 0 2.1920563995081466e-06
is O 0 4.728480007543112e-08
a O 0 6.172665933945609e-08
noticeably O 0 5.099848749523517e-06
elevated O 0 1.925158130688942e-06
level O 0 3.119676605933819e-08
of O 0 2.8058566581279365e-09
mutation O 0 1.2576278152209852e-07
in O 0 6.394348606164613e-09
the O 0 4.467279435260707e-09
paired O 0 1.348774389953178e-07
domain O 0 7.353229847240073e-08
compared O 0 8.360000691709502e-08
with O 0 2.051888658982648e-09
the O 0 9.690480418100833e-09
rest O 0 2.1178152564971242e-08
of O 0 2.1174506592558373e-09
the O 0 4.89388156665882e-08
gene O 0 2.5269030174968066e-06
. O 0 4.633508581264323e-07

Increased O 0 5.9845965552085545e-06
mutation O 0 1.0256888344883919e-05
in O 0 9.326520711283592e-08
the O 0 2.6620059045967537e-08
homeodomain O 0 3.565278348105494e-06
is O 0 1.2976789776075748e-07
accounted O 0 2.585721574632771e-07
for O 0 6.563163790218596e-09
by O 0 1.0417428697451214e-08
the O 0 6.474194691463708e-08
hypermutable O 0 4.629834074876271e-05
CpG O 0 1.8807550077326596e-05
dinucleotide O 0 3.9361448216368444e-06
in O 0 5.678301207012737e-08
codon O 0 2.200033577537397e-06
240 O 0 7.736840075267537e-07
. O 0 5.699426992578083e-07

Very O 0 5.865241291758139e-06
nearly O 0 7.276730116245744e-07
all O 0 3.2043477204979354e-08
mutations O 0 2.414660457361606e-06
appear O 0 6.300297172856517e-07
to O 0 3.5244337937001546e-07
cause O 0 2.662219685589662e-06
loss O 0 1.2669926263697562e-06
of O 0 3.3841800473055628e-09
function O 0 3.194815434426346e-08
of O 0 3.845295637461277e-09
the O 0 1.0906507696972767e-08
mutant O 0 2.989342817727447e-07
allele O 0 5.685588462256419e-07
, O 0 2.281803546111405e-08
and O 0 4.9278989777690185e-09
more O 0 2.0421899726841275e-09
than O 0 4.782801266145498e-09
80 O 0 7.890124997800285e-09
% O 0 4.368250205999402e-09
of O 0 1.6918341172456053e-09
exonic O 0 1.90778973774286e-06
substitutions O 0 2.548363795540354e-07
result O 0 8.876746449004713e-08
in O 0 4.5126444803145205e-08
nonsense O 0 7.052982709865319e-06
codons O 0 1.814978168113157e-05
. O 0 1.086949964701489e-06

In O 0 9.238983125214872e-07
a O 0 1.720951559036621e-07
gene O 0 4.0150538893612975e-07
with O 0 3.086909217131506e-08
such O 0 1.1209723815852612e-08
extraordinarily O 0 7.595593274345447e-07
high O 0 1.7228367710231396e-07
sequence O 0 8.745611523863772e-08
conservation O 0 1.9500481229783873e-08
throughout O 0 1.2780047242699766e-08
evolution O 0 4.2833544711129434e-08
, O 0 8.939660567364172e-09
there O 0 2.05129002672777e-09
are O 0 4.80722972540093e-09
presumed O 0 4.877461833530106e-06
undiscovered O 0 1.036625872075092e-05
missense O 0 9.609436347091105e-06
mutations O 0 4.279698259779252e-06
, O 0 1.3117098518478087e-08
these O 0 1.5871802760969445e-09
are O 0 3.73350594884414e-09
hypothesized O 0 1.75142332636824e-07
to O 0 4.080031601461087e-08
exist O 0 2.9585898175810144e-08
in O 0 1.1888979578600356e-08
as O 0 7.397120072027974e-08
- O 0 1.205672015203163e-05
yet O 0 1.185997575703368e-06
unidentified O 0 1.15942439151695e-05
phenotypes O 0 2.7951994070463115e-06
. O 0 9.879464357709367e-08
. O 0 4.302137313061394e-07

Genetic O 0 0.0033775849733501673
heterogeneity O 0 0.0003317014779895544
and O 0 2.355692231503781e-06
penetrance O 0 3.514433410600759e-05
analysis O 0 5.719671207771171e-07
of O 0 9.66362545540278e-09
the O 0 5.113350098895353e-08
BRCA1 O 0 7.588847074657679e-05
and O 0 1.0423370895296102e-06
BRCA2 O 0 0.00038375338772311807
genes O 0 6.962721272429917e-06
in O 0 7.636036571057048e-06
breast B-Disease 1 0.941280722618103
cancer I-Disease 0 0.0036055485252290964
families O 0 9.224791028827894e-07
. O 0 1.591260229361069e-06

The O 0 0.004310842137783766
Breast B-Disease 1 0.9999998807907104
Cancer I-Disease 1 0.9999971389770508
Linkage O 0 0.006085430737584829
Consortium O 0 0.00021011453645769507
. O 0 1.305742534896126e-05

The O 0 1.1785347169279703e-06
contribution O 0 8.379203109143418e-07
of O 0 5.8977569494800264e-08
BRCA1 O 0 0.000196596491150558
and O 0 7.60977764002746e-06
BRCA2 O 0 0.168081134557724
to O 0 0.0034916370641440153
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 4.9295784265268594e-05
assessed O 0 2.6371430976723786e-06
by O 0 2.515346864129242e-08
linkage O 0 5.608295850834111e-06
and O 0 4.08089618986196e-07
mutation O 0 7.670271884308022e-07
analysis O 0 5.341060926866703e-08
in O 0 1.1225128382363891e-08
237 O 0 4.701608702362137e-08
families O 0 1.2723764264421789e-08
, O 0 5.0652393390748784e-09
each O 0 2.6323263568883704e-09
with O 0 1.4807874926248132e-08
at O 0 5.981071353744483e-07
least O 0 2.3365476664594098e-08
four O 0 2.2339593286346826e-08
cases O 0 2.4614363880459678e-08
of O 0 1.6587867435191583e-07
breast B-Disease 1 0.6725332140922546
cancer I-Disease 0 0.00028267072048038244
, O 0 9.954856494687192e-09
collected O 0 1.6778049172216924e-08
by O 0 3.739394571766752e-08
the O 0 2.7086938644060865e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 0.9999942779541016
Linkage O 0 0.00014179563731886446
Consortium O 0 1.798957418941427e-05
. O 0 2.460067207721295e-06

Families O 0 2.0614061213564128e-05
were O 0 5.767973902948142e-07
included O 0 2.2680660904939032e-08
without O 0 9.705723336139727e-09
regard O 0 7.1530990020107765e-09
to O 0 1.0066210087700256e-08
the O 0 1.519049419584917e-08
occurrence O 0 2.1393302631622646e-06
of O 0 6.329625534817751e-07
ovarian B-Disease 0 0.08604424446821213
or I-Disease 0 1.30012222143705e-06
other I-Disease 0 9.707093795441324e-07
cancers I-Disease 0 0.005566236563026905
. O 0 1.7356913986077416e-06

Overall O 0 0.0013699809787794948
, O 0 2.5280376576120034e-05
disease O 0 0.0002684644132386893
was O 0 1.5832828239581431e-06
linked O 0 5.18030765306321e-06
to O 0 4.7657209734097705e-07
BRCA1 O 0 3.834141170955263e-05
in O 0 5.366272404216943e-08
an O 0 2.601858639650345e-08
estimated O 0 2.9711023330492026e-07
52 O 0 1.2556837702959456e-07
% O 0 5.147390513826622e-09
of O 0 6.666413532308013e-10
families O 0 8.266604289985935e-09
, O 0 1.757432599447384e-08
to O 0 6.795556117822343e-08
BRCA2 O 0 2.0463399778236635e-05
in O 0 3.7270332597927336e-08
32 O 0 6.010535713585341e-08
% O 0 4.667109365641409e-09
of O 0 1.650352965398838e-09
families O 0 1.6873071828626962e-08
, O 0 1.915875635916109e-08
and O 0 1.9522101268876213e-08
to O 0 1.6229863675221168e-08
neither O 0 2.407225707656835e-08
gene O 0 7.233211363200098e-08
in O 0 6.197497182114375e-09
16 O 0 4.867155567467307e-08
% O 0 1.59959601120363e-08
( O 0 3.2187656984206114e-09
95 O 0 2.1077406486824657e-08
% O 0 1.7234999205584245e-08
confidence O 0 5.9400129259756795e-08
interval O 0 2.88478986476548e-07
[ O 0 3.2021975471252517e-07
CI O 0 5.3150644816923887e-05
] O 0 1.0480450640670824e-07
6 O 0 3.276234750160256e-08
% O 0 7.344368668782408e-09
- O 0 9.662649063102435e-07
28 O 0 9.060042884811992e-07
% O 0 1.8424621828216914e-08
) O 0 4.478438508925819e-09
, O 0 7.745682317761293e-09
suggesting O 0 7.916629130022557e-08
other O 0 3.469255815957695e-08
predisposition O 0 9.39939491217956e-06
genes O 0 2.9939385512989247e-06
. O 0 1.3675673926627496e-06

The O 0 3.070264483540086e-06
majority O 0 1.559311726850865e-06
( O 0 1.385703853884479e-07
81 O 0 1.547469281604208e-07
% O 0 2.6988152157514378e-08
) O 0 4.04343269977403e-09
of O 0 5.235385458490782e-09
the O 0 8.526692909072153e-06
breast B-Disease 1 0.9999971389770508
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.912066817856612e-08
were O 0 2.0232167941003354e-08
due O 0 4.2862801308274356e-08
to O 0 8.77076971050883e-08
BRCA1 O 0 2.2347525373334065e-05
, O 0 4.281148946461144e-08
with O 0 6.158540344358698e-09
most O 0 3.993149633174653e-08
others O 0 4.1167174913425697e-07
( O 0 1.209321442985356e-08
14 O 0 9.216825702651477e-08
% O 0 2.204860827248467e-08
) O 0 8.282007080140374e-09
due O 0 1.1314014614072221e-07
to O 0 1.5840470268813078e-06
BRCA2 O 0 0.0016425669891759753
. O 0 2.253679667774122e-06

Conversely O 0 0.0001313219836447388
, O 0 7.063740099511051e-07
the O 0 2.6248974549503146e-08
majority O 0 2.8791491857305118e-08
of O 0 4.590302804530211e-09
families O 0 1.0174188602718459e-08
with O 0 1.8179497018877555e-08
male B-Disease 0 1.1120897625005455e-06
and I-Disease 0 1.1040880281143473e-06
female I-Disease 0 3.3370528399245813e-05
breast I-Disease 0 0.15222515165805817
cancer I-Disease 0 9.762775880517438e-05
were O 0 4.29057465112237e-08
due O 0 1.3375968421769358e-07
to O 0 6.323725187939999e-07
BRCA2 O 0 0.0007137889042496681
( O 0 1.1609256489464315e-07
76 O 0 2.9510610488614475e-07
% O 0 7.632162635218265e-08
) O 0 1.1650472231394815e-07
. O 0 6.919152042428323e-07

The O 0 1.876418195934093e-06
largest O 0 1.7901103319672984e-06
proportion O 0 5.810159109387314e-07
( O 0 7.075242081100441e-08
67 O 0 3.0737726319784997e-07
% O 0 2.4883714644374777e-08
) O 0 4.022693733674032e-09
of O 0 8.42382552601606e-10
families O 0 1.716066932999638e-08
due O 0 6.53259277783036e-08
to O 0 2.2986911929478993e-08
other O 0 4.665952069160539e-09
genes O 0 1.4811185167218355e-07
was O 0 2.1587798073596787e-06
found O 0 1.4909170431565144e-07
in O 0 8.198581369356361e-09
families O 0 3.201218401471806e-09
with O 0 5.729845486968088e-09
four O 0 4.145452692227991e-08
or O 0 8.700539666506302e-08
five O 0 1.937221227876762e-08
cases O 0 7.510881694372529e-09
of O 0 9.675188650248856e-09
female O 0 5.184338442631997e-05
breast B-Disease 0 0.11756458878517151
cancer I-Disease 0 2.4791421310510486e-05
only O 0 7.887525299565823e-08
. O 0 7.01910437328479e-07

These O 0 2.412968569842633e-06
estimates O 0 1.5501693269470707e-05
were O 0 1.696003693041348e-07
not O 0 3.132364767566287e-08
substantially O 0 4.0528667000216956e-07
affected O 0 2.8323126954887812e-08
either O 0 7.870705864831962e-09
by O 0 3.964968353642462e-09
changing O 0 1.1912715791595474e-07
the O 0 3.163043515996833e-08
assumed O 0 1.2029693152726395e-06
penetrance O 0 1.028262772706512e-06
model O 0 3.0030781772438786e-07
for O 0 3.025667183464975e-08
BRCA1 O 0 1.3645457329403143e-05
or O 0 7.355698983246839e-08
by O 0 3.8956948777979505e-09
including O 0 1.0854397380910541e-08
or O 0 2.6663104790713987e-07
excluding O 0 1.5710931620560586e-05
BRCA1 O 0 0.0002688101667445153
mutation O 0 1.5232936675602105e-05
data O 0 3.4962502013513586e-06
. O 0 1.064380398929643e-06

Among O 0 1.8605733203003183e-06
those O 0 1.2347975086868246e-07
families O 0 4.918586071767095e-08
with O 0 3.109557269453944e-07
disease O 0 0.0001690343051450327
due O 0 4.815854595108249e-07
to O 0 8.925954375627043e-07
BRCA1 O 0 0.00012098419392714277
that O 0 1.413446852893685e-07
were O 0 7.756803199754359e-08
tested O 0 3.2553177931049504e-08
by O 0 1.0264507022128555e-09
one O 0 2.1983257436630765e-09
of O 0 4.1115569282546005e-10
the O 0 3.560355565923601e-09
standard O 0 7.723718198349161e-08
screening O 0 2.959458811346849e-08
methods O 0 5.6492741151714654e-08
, O 0 1.8250791100626884e-08
mutations O 0 4.332209186941327e-07
were O 0 2.3469189258662482e-08
detected O 0 1.6330463381564186e-07
in O 0 2.738585802575244e-09
the O 0 4.470407599654891e-09
coding O 0 1.7020292943925597e-06
sequence O 0 8.933016459877763e-08
or O 0 2.3075076072132106e-08
splice O 0 3.8558778214792255e-06
sites O 0 1.1594298143791093e-07
in O 0 6.076537051313835e-09
an O 0 7.880139207827597e-09
estimated O 0 1.6645202549625537e-07
63 O 0 1.280541539472324e-07
% O 0 1.2385806158476953e-08
( O 0 2.0854060700514765e-09
95 O 0 3.935615566774686e-08
% O 0 4.6716003510027804e-08
CI O 0 2.7271849830867723e-05
51 O 0 5.071487407803943e-07
% O 0 1.9588979327522793e-08
- O 0 8.796055226412136e-07
77 O 0 3.0400775585803785e-07
% O 0 6.660242490852397e-08
) O 0 4.4239609309215666e-08
. O 0 3.9276673646782e-07

The O 0 2.8915210350533016e-06
estimated O 0 4.2304354792577215e-06
sensitivity O 0 4.0630521880302695e-07
was O 0 8.262034612016578e-07
identical O 0 2.3156120221301535e-07
for O 0 8.56451887187859e-09
direct O 0 4.819295185143346e-08
sequencing O 0 5.643398708343739e-07
and O 0 4.8238199212846666e-08
other O 0 2.210263083668451e-08
techniques O 0 1.6112122693812125e-06
. O 0 1.0664297178664128e-06

The O 0 1.4901933127475786e-06
penetrance O 0 4.957879718858749e-05
of O 0 4.851219159718312e-07
BRCA2 O 0 0.0005918905953876674
was O 0 2.48667856794782e-06
estimated O 0 8.096240122767995e-08
by O 0 6.029582610977968e-09
maximizing O 0 2.6363079541624757e-07
the O 0 7.60345102435167e-08
LOD O 0 0.0002781056973617524
score O 0 2.7337242158864683e-07
in O 0 8.591010924874354e-08
BRCA2 O 0 0.00023441415396519005
- O 0 0.00013687455793842673
mutation O 0 9.374606634082738e-06
families O 0 3.020673489118053e-08
, O 0 9.355754393425286e-09
over O 0 1.8316070438118004e-08
all O 0 1.0058148980363057e-08
possible O 0 1.6206547570618568e-07
penetrance O 0 1.1462797374406364e-05
functions O 0 4.0106183973875886e-07
. O 0 5.363295372262655e-07

The O 0 1.5927329286569147e-06
estimated O 0 1.3749586287303828e-06
cumulative O 0 1.7466657027398469e-06
risk O 0 1.5806065221113386e-06
of O 0 1.987755240406841e-07
breast B-Disease 0 0.2818630337715149
cancer I-Disease 0 0.0010801561875268817
reached O 0 1.0439337074785726e-06
28 O 0 5.09727783537528e-07
% O 0 1.6527414103961746e-08
( O 0 2.67494781880373e-09
95 O 0 3.107123092149777e-08
% O 0 2.6717826173694448e-08
CI O 0 1.5963756595738232e-05
9 O 0 2.4318882196894265e-07
% O 0 5.804214442406419e-09
- O 0 2.842214144038735e-07
44 O 0 6.732674506793046e-08
% O 0 6.3946661299496554e-09
) O 0 1.5949126463965513e-09
by O 0 2.9848428173551156e-09
age O 0 1.0631022284712799e-08
50 O 0 5.532950542175286e-09
years O 0 1.3356128647501464e-08
and O 0 1.907158342362436e-08
84 O 0 2.739036375487558e-08
% O 0 8.05567879069713e-09
( O 0 1.4233634271221263e-09
95 O 0 9.361895259019093e-09
% O 0 1.6453217455136837e-08
CI O 0 8.128429726639297e-06
43 O 0 1.0370665393111267e-07
% O 0 8.994270217499434e-09
- O 0 2.3604749799233105e-07
95 O 0 2.2527397902649682e-07
% O 0 3.941820736486079e-08
) O 0 4.7065498165466124e-09
by O 0 7.833114601396574e-09
age O 0 3.555607008820516e-08
70 O 0 5.836755789800918e-08
years O 0 1.8577244986772712e-07
. O 0 5.023227345191117e-07

The O 0 3.308193481643684e-05
corresponding O 0 0.33268803358078003
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0005915104411542416
were O 0 1.2202459629406803e-06
0 O 0 1.981669129236252e-06
. O 0 1.4958960719013703e-06

4 O 0 1.3697544090973679e-05
% O 0 1.0095359357364941e-06
( O 0 8.683447560997593e-08
95 O 0 1.1656027965045723e-07
% O 0 7.251459521739889e-08
CI O 0 2.4616099835839123e-05
0 O 0 1.3882038274459774e-07
% O 0 2.2696411861033994e-08
- O 0 3.357506841439317e-07
1 O 0 3.044754635084246e-07
% O 0 1.75272916180802e-08
) O 0 2.5435398232076523e-09
by O 0 1.3545791155422648e-09
age O 0 4.647398021973004e-09
50 O 0 6.152775622325635e-09
years O 0 6.3057163934843175e-09
and O 0 1.0122120031041959e-08
27 O 0 1.1103691832659024e-07
% O 0 5.2558362106935874e-09
( O 0 2.1908415082094734e-09
95 O 0 1.061019805348451e-08
% O 0 1.2981700159286902e-08
CI O 0 5.313085694069741e-06
0 O 0 6.860163637156802e-08
% O 0 1.2451132569424317e-08
- O 0 4.863100571128598e-07
47 O 0 6.158461474115029e-07
% O 0 2.531272613737201e-08
) O 0 2.9067810380922765e-09
by O 0 2.6187252366582925e-09
age O 0 1.9877395729395175e-08
70 O 0 6.266607499583188e-08
years O 0 8.971810672164793e-08
. O 0 2.9014660185566754e-07

The O 0 2.883023626054637e-06
lifetime O 0 8.276630069303792e-06
risk O 0 7.666179044463206e-06
of O 0 6.568387789229746e-07
breast B-Disease 1 0.951834499835968
cancer I-Disease 0 0.002463932614773512
appears O 0 4.820748245037976e-07
similar O 0 1.9219037028506136e-08
to O 0 5.6188198982454196e-08
the O 0 4.116261109743391e-08
risk O 0 3.88578996535216e-07
in O 0 3.784930768802042e-08
BRCA1 O 0 1.8493810785003006e-05
carriers O 0 1.5727906088613963e-07
, O 0 2.0080157980828517e-08
but O 0 1.1324999604767072e-08
there O 0 3.903228851243057e-09
was O 0 1.4842294149275403e-07
some O 0 6.652390860395485e-10
suggestion O 0 6.795177753815551e-09
of O 0 9.363962938380155e-10
a O 0 1.4996756192431349e-07
lower O 0 1.1618262760748621e-05
risk O 0 6.03457863235235e-07
in O 0 2.9403063095401194e-08
BRCA2 O 0 2.2093239749665372e-05
carriers O 0 1.6014085701954173e-07
< O 0 1.2514506408933812e-07
50 O 0 3.4688124372905804e-08
years O 0 1.3621270333885604e-08
of O 0 1.2312553643312185e-08
age O 0 4.1652202753539314e-07
. O 0 7.815581284376094e-07

Eye B-Disease 1 0.9850217700004578
movement I-Disease 0 0.0009341193945147097
abnormalities I-Disease 1 0.9050240516662598
correlate O 0 2.2135332983452827e-05
with O 0 4.654275471693836e-07
genotype O 0 0.0013484334340319037
in O 0 7.957616617204621e-06
autosomal O 1 0.9992536902427673
dominant O 1 0.7818475961685181
cerebellar B-Disease 1 0.9997554421424866
ataxia I-Disease 1 0.9999927282333374
type I-Disease 0 0.0009706328855827451
I I-Disease 0 0.00022916296438779682
. O 0 4.5487417992262635e-06

We O 0 1.0932146324194036e-05
compared O 0 8.583543603890575e-06
horizontal O 0 7.199635001597926e-05
eye O 0 0.2294291853904724
movements O 0 3.218819256289862e-05
( O 0 4.332799790063291e-07
visually O 0 1.5429599216076895e-06
guided O 0 2.3934578621265246e-06
saccades O 0 4.161351898801513e-05
, O 0 2.1022809448822954e-07
antisaccades O 0 5.023997346143005e-06
, O 0 4.4964401979541435e-08
and O 0 2.836015511320511e-08
smooth O 0 9.592612286724034e-07
pursuit O 0 1.854721745075949e-06
) O 0 4.8375394356980905e-08
in O 0 2.103098495354061e-08
control O 0 1.0274383157593547e-06
subjects O 0 4.319152537846094e-07
( O 0 5.14551850017142e-08
n O 0 8.469775821140502e-06
= O 0 8.605436050856952e-06
14 O 0 1.0509792218726943e-06
) O 0 3.958464134257156e-08
and O 0 1.775319589114588e-07
patients O 0 5.702276340002754e-08
with O 0 1.0453469201365806e-09
three O 0 1.2947772631832777e-08
forms O 0 1.1382564224504677e-07
of O 0 1.2663919335409446e-07
autosomal O 0 0.14786647260189056
dominant O 0 0.00021062603627797216
cerebellar B-Disease 0 0.004305921029299498
ataxias I-Disease 0 0.0005560711724683642
type I-Disease 0 1.2156879165559076e-05
I I-Disease 0 2.6644585886970162e-05
spinocerebellar B-Disease 0 0.018462177366018295
ataxias I-Disease 0 0.00013726585893891752
1 I-Disease 0 1.3704081993637374e-06
and I-Disease 0 9.139660051005194e-08
2 I-Disease 0 6.326571906356548e-07
( O 0 2.4762602635064468e-08
SCA1 B-Disease 0 8.282662747660652e-06
, O 0 5.5636743212517104e-08
n O 0 1.7103734535339754e-06
= O 0 1.1387302265575272e-06
11 O 0 2.117880484320267e-07
; O 0 1.8417102509715733e-08
SCA2 B-Disease 0 6.5135468503285665e-06
, O 0 3.5813346954682856e-08
n O 0 9.920114507622202e-07
= O 0 5.486576242219598e-07
10 O 0 5.1975799664205624e-08
) O 0 1.5456928181833973e-08
and O 0 1.887983813730898e-07
SCA3 B-Disease 1 0.9999994039535522
/ O 0 0.0008960501290857792
Machado B-Disease 0 1.4179268873704132e-05
- I-Disease 0 0.0010539049981161952
Joseph I-Disease 0 0.01675642840564251
disease I-Disease 1 0.572380781173706
( O 0 7.911661441539763e-07
MJD B-Disease 1 0.9999996423721313
) O 0 6.662592682005197e-07
( O 0 3.622029964844842e-08
n O 0 1.039127164403908e-05
= O 0 5.522538231161889e-06
16 O 0 5.769442736891506e-07
) O 0 1.1723631132554146e-07
. O 0 6.056325219105929e-07

In O 0 3.451170414336957e-06
SCA1 B-Disease 0 0.00013563080574385822
, O 0 1.3484142868946947e-07
saccade O 0 6.2178983171179425e-06
amplitude O 0 6.286264806476538e-07
was O 0 1.0570132644716068e-06
significantly O 0 4.297757811855263e-07
increased O 0 1.0916189552290234e-07
, O 0 3.842042772816967e-08
resulting O 0 1.332809063114837e-07
in O 0 1.6739858210712555e-07
hypermetria B-Disease 0 0.0002679172030184418
. O 0 2.6972768409905257e-06

The O 0 2.758548589554266e-06
smooth O 0 1.4864270269754343e-05
pursuit O 0 8.471827641187701e-06
gain O 0 3.461691812844947e-05
was O 0 6.999684956099372e-06
decreased O 0 1.4200988516677171e-05
. O 0 1.2415866876835935e-06

In O 0 9.816089004743844e-06
SCA2 B-Disease 0 0.0002897509257309139
, O 0 6.935297847121547e-07
saccade O 0 1.7582293367013335e-05
velocity O 0 7.516812729591038e-06
was O 0 3.6313836062618066e-06
markedly O 0 1.919301757880021e-05
decreased O 0 2.5634577468736097e-05
. O 0 1.7737114603733062e-06

The O 0 2.132178906322224e-06
percentage O 0 4.674462161347037e-06
of O 0 4.075645065881872e-08
errors O 0 3.060815743083367e-06
in O 0 1.1834729463089388e-07
antisaccades O 0 4.075014658155851e-05
was O 0 2.2291787900030613e-06
greatly O 0 6.030435883985774e-08
increased O 0 9.162210545810012e-08
and O 0 5.812093206714053e-08
was O 0 4.780432618645136e-07
significantly O 0 1.2794612302968744e-07
correlated O 0 9.731455463679595e-08
with O 0 2.2023389334435706e-08
age O 0 3.36455229899002e-07
at O 0 8.680118298798334e-06
disease O 0 0.0006774150533601642
onset O 0 3.834514427580871e-05
. O 0 1.7828608633863041e-06

In O 0 3.6237518088455545e-06
addition O 0 2.0260114297343534e-07
, O 0 1.913257463570517e-08
a O 0 1.1535419730535068e-08
correlation O 0 1.1567018276537055e-07
between O 0 4.690672028573317e-08
smooth O 0 5.267061169433873e-06
pursuit O 0 1.1741566595446784e-05
gain O 0 2.0866240447503515e-05
and O 0 3.430087147648919e-08
the O 0 6.3555725127173446e-09
number O 0 1.39620128791762e-08
of O 0 2.710949509321381e-08
trinucleotide O 0 4.706634354079142e-05
repeats O 0 2.5344244932057336e-05
was O 0 9.675595720182173e-07
found O 0 4.1330821431984077e-07
. O 0 3.269512092174409e-07

In O 0 4.385874854051508e-05
SCA3 B-Disease 1 0.9999892711639404
, O 0 7.772449862386566e-06
gaze B-Disease 0 0.00011911350156879053
- I-Disease 0 0.000194982421817258
evoked I-Disease 0 3.0029377739992924e-05
nystagmus I-Disease 0 0.00024102083989419043
was O 0 1.2946014749104506e-06
often O 0 1.550112393999825e-08
present O 0 1.0755906387771574e-08
as O 0 1.773061697463163e-08
was O 0 2.2805248534041311e-07
saccade O 0 3.2244993235508446e-06
hypometria O 0 1.3021003724134061e-05
and O 0 4.885338711346776e-08
smooth O 0 1.3143616115485202e-06
pursuit O 0 3.64900142812985e-06
gain O 0 1.383146081934683e-05
was O 0 3.533173867253936e-06
markedly O 0 2.6703959520091303e-05
decreased O 0 2.5097357138292864e-05
. O 0 1.2426255580066936e-06

Three O 0 1.6016634845072986e-06
major O 0 4.836492166759854e-07
criteria O 0 3.1951694268173014e-07
, O 0 5.091025556680506e-08
saccade O 0 2.8132401439506793e-06
amplitude O 0 1.8140050883630465e-07
, O 0 2.8011363895075192e-08
saccade O 0 1.2719150390694267e-06
velocity O 0 6.108251682235277e-07
, O 0 1.6490101728550144e-08
and O 0 6.131184893121144e-09
presence O 0 1.5810295295182186e-08
of O 0 2.1562472696246004e-08
gaze B-Disease 0 5.442782276077196e-05
- I-Disease 0 8.753746806178242e-05
evoked I-Disease 0 7.277435543073807e-06
nystagmus I-Disease 0 1.7248275980819017e-05
, O 0 1.015102490953268e-08
permitted O 0 4.35830527223402e-09
the O 0 4.338714720830694e-09
correct O 0 8.250868859249749e-07
assignment O 0 3.100480938655892e-08
of O 0 6.981945022133118e-10
90 O 0 4.7667456648525786e-09
% O 0 1.9298296294323336e-09
of O 0 5.613126075054709e-10
the O 0 1.1177058389932881e-08
SCA1 B-Disease 0 2.0398907508933917e-05
, O 0 2.0041207804410988e-08
90 O 0 5.153205862029608e-09
% O 0 2.531826304164042e-09
of O 0 8.196888723333018e-10
the O 0 1.3707954771291497e-08
SCA2 B-Disease 0 2.545105598983355e-05
, O 0 5.247865075830305e-08
and O 0 1.2221677891943727e-08
93 O 0 1.5282736853805545e-08
% O 0 2.1545978334813753e-09
of O 0 8.158254072299087e-10
the O 0 6.123847384742476e-08
patients O 0 1.9731783140741754e-07
with O 0 2.1634360081179693e-08
SCA3 B-Disease 1 0.9999990463256836
to O 0 5.26219878338452e-07
their O 0 1.525401529534065e-07
genetically O 0 1.90361406566808e-05
confirmed O 0 1.5821064152987674e-05
patient O 0 4.982966856914572e-07
group O 0 7.589163715238101e-07
and O 0 1.4714520091274608e-07
, O 0 3.460169040181427e-08
therefore O 0 4.786080154417505e-08
, O 0 3.7416416631685934e-08
may O 0 1.3634037543397426e-07
help O 0 2.0107830067672694e-08
orient O 0 0.0006659345235675573
diagnoses O 0 0.0001408802781952545
of O 0 2.1417333684325968e-08
SCA1 B-Disease 0 7.731527148280293e-05
, O 0 2.6081198711835896e-07
SCA2 B-Disease 0 1.8406484741717577e-05
, O 0 7.135386681511591e-08
and O 0 1.659752086879962e-07
SCA3 B-Disease 1 0.9999929666519165
at O 0 9.862591241471819e-07
early O 0 2.3070110444223246e-07
clinical O 0 1.1840057823064853e-07
stages O 0 9.563713376792293e-08
of O 0 1.6922738765856593e-08
the O 0 9.83846803137567e-07
diseases O 0 0.00023311808763537556
. O 0 1.01875130553708e-07
. O 0 5.335623995961214e-07

Genetic O 0 0.00020695121202152222
basis O 0 1.608476736691955e-06
and O 0 4.5973146711730806e-07
molecular O 0 1.4290885701484513e-05
mechanism O 0 1.8110604287358e-05
for O 0 0.00028281359118409455
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999983310699463
fibrillation I-Disease 1 1.0
. O 0 0.00021003722213208675

Ventricular B-Disease 1 0.9997861981391907
fibrillation I-Disease 1 0.9999614953994751
causes O 0 0.0004235953383613378
more O 0 2.666371585746674e-07
than O 0 2.9419052083312636e-08
300 O 0 1.8535120105411806e-08
, O 0 1.6197949648244503e-08
000 O 0 1.5104578210412e-07
sudden O 0 7.499045864278742e-07
deaths O 0 7.562367159152927e-07
each O 0 7.531768986268617e-09
year O 0 5.6066262743570405e-08
in O 0 2.1990398835214364e-08
the O 0 1.640534321722953e-07
USA O 0 4.364288179203868e-05
alone O 0 1.4953012623664108e-06
. O 0 3.5138620546604216e-07

In O 0 3.8206353565328754e-06
approximately O 0 8.213005457946565e-07
5 O 0 5.821290187668637e-07
- O 0 5.574653187068179e-06
12 O 0 1.96917227412996e-07
% O 0 5.901703570287964e-09
of O 0 7.228846410356482e-10
these O 0 3.0967677311366515e-09
cases O 0 1.6899193155950343e-08
, O 0 1.2839810104026128e-08
there O 0 2.460787573710377e-09
are O 0 3.978118279235332e-09
no O 0 1.1152913970136069e-07
demonstrable O 0 0.0001991350727621466
cardiac O 0 0.002603455213829875
or O 0 1.066957679540792e-06
non O 0 1.447021077183308e-05
- O 1 0.5876321196556091
cardiac O 1 0.9108362793922424
causes O 0 2.0530503661575494e-06
to O 0 1.4000686121562467e-07
account O 0 3.288869834250363e-07
for O 0 4.0971880110873826e-08
the O 0 5.025603400099499e-08
episode O 0 6.191785359987989e-06
, O 0 1.4555189409293234e-07
which O 0 3.721286390145906e-08
is O 0 2.2275941091720597e-08
therefore O 0 1.2302628249472036e-07
classified O 0 2.4698892957530916e-05
as O 0 0.0002431697939755395
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999988079071045
fibrillation I-Disease 1 1.0
( O 0 0.017227139323949814
IVF B-Disease 1 0.9999998807907104
) O 0 3.104456709479564e-06
. O 0 1.7237584870599676e-06

A O 0 3.3735045690264087e-06
distinct O 0 1.1315843266856973e-06
group O 0 1.5089321095729247e-05
of O 0 1.593659817444859e-06
IVF B-Disease 1 1.0
patients O 0 0.007714999374002218
has O 0 3.9859290268395853e-07
been O 0 2.502188465314248e-07
found O 0 1.1025775137341043e-07
to O 0 1.3273768750821091e-08
present O 0 8.836049225635634e-09
with O 0 3.882972166024956e-09
a O 0 1.782914011982939e-07
characteristic O 0 1.8976075807586312e-05
electrocardiographic O 0 0.0003149104886688292
pattern O 0 3.1336487154476345e-05
. O 0 1.4067957181396196e-06

Because O 0 1.3210936913310434e-06
of O 0 2.5906921052865073e-08
the O 0 7.719709316234002e-09
small O 0 4.8259529705774185e-09
size O 0 2.6054541635289752e-08
of O 0 4.6689345722938924e-09
most O 0 1.2409666183543777e-08
pedigrees O 0 3.941618444969208e-07
and O 0 3.5032673650903234e-08
the O 0 2.4507649243332708e-08
high O 0 9.55895075094304e-07
incidence O 0 1.332067131443182e-05
of O 0 6.014159481537718e-08
sudden B-Disease 0 1.5583971617161296e-05
death I-Disease 0 6.023014975653496e-06
, O 0 1.7396233786826087e-08
however O 0 1.1085171891522805e-08
, O 0 4.8426604948303975e-09
molecular O 0 2.4657458652654896e-07
genetic O 0 2.547341182435048e-06
studies O 0 1.0116739446175416e-07
of O 0 1.660671955505677e-07
IVF B-Disease 1 1.0
have O 0 1.1550256431291928e-06
not O 0 8.906035020572745e-08
yet O 0 5.8101097266671786e-08
been O 0 1.0206787237621029e-07
done O 0 2.0967266323168587e-07
. O 0 2.9254943001433276e-07

Because O 0 0.0016799570294097066
IVF B-Disease 1 0.9999997615814209
causes O 0 0.027437957003712654
cardiac O 1 0.982854962348938
rhythm O 0 0.1809491068124771
disturbance O 0 0.0024626601953059435
, O 0 6.741656761732884e-07
we O 0 1.0171902431466151e-07
investigated O 0 8.171473382390104e-07
whether O 0 7.585692429756818e-08
malfunction O 0 2.2328884369926527e-05
of O 0 6.743094971284336e-09
ion O 0 9.330947818853019e-07
channels O 0 1.0402080761195975e-06
could O 0 6.25539428256161e-07
cause O 0 2.0943265610640083e-07
the O 0 4.601200842557773e-08
disorder O 0 1.7731141269905493e-05
by O 0 2.9771838327974365e-09
studying O 0 1.1323854742784079e-08
mutations O 0 5.42314182894188e-07
in O 0 9.245293419724021e-09
the O 0 1.2224292333939957e-07
cardiac O 0 0.0001248217886313796
sodium O 0 4.777671165356878e-06
channel O 0 1.3772754755336791e-05
gene O 0 3.5747161746257916e-06
SCN5A O 0 0.0001023501026793383
. O 0 9.154225040219899e-07

We O 0 1.2533222616184503e-05
have O 0 1.3023866074490797e-07
now O 0 3.511831181413072e-08
identified O 0 9.861390992682573e-08
a O 0 4.6675655340777666e-08
missense O 0 1.6230585970333777e-05
mutation O 0 2.114870085279108e-06
, O 0 1.3595469638971736e-08
a O 0 2.5529168112825573e-08
splice O 0 0.00048720926861278713
- O 0 0.00037441079621203244
donor O 0 4.7033672672114335e-06
mutation O 0 3.0048654480197e-06
, O 0 1.6405149239062666e-08
and O 0 1.040775643446068e-08
a O 0 1.533448283908001e-07
frameshift O 0 9.139066241914406e-05
mutation O 0 1.1474086250018445e-06
in O 0 1.1843216185525307e-08
the O 0 2.5763229771769147e-08
coding O 0 2.0863655663561076e-05
region O 0 2.173672555727535e-06
of O 0 2.5033047634792638e-08
SCN5A O 0 0.00010816202848218381
in O 0 2.577321538410615e-07
three O 0 2.3378772766591283e-06
IVF B-Disease 1 0.9999969005584717
families O 0 1.4748914054507622e-06
. O 0 7.534464998570911e-07

We O 0 5.37470532435691e-06
show O 0 5.70292797874572e-07
that O 0 2.0007215439932224e-08
sodium O 0 4.8460726986832015e-08
channels O 0 3.437081375068374e-08
with O 0 3.5189231528676146e-09
the O 0 2.091689310645961e-08
missense O 0 7.422462658723816e-06
mutation O 0 3.8035555007809307e-06
recover O 0 4.102445927856024e-06
from O 0 2.917113128830806e-08
inactivation O 0 2.095578111038776e-06
more O 0 5.50109735542037e-09
rapidly O 0 3.970918882600927e-08
than O 0 5.838222350007527e-09
normal O 0 5.4381722236485075e-08
and O 0 9.395776601195394e-09
that O 0 4.3193106868955056e-09
the O 0 1.185869979991594e-08
frameshift O 0 0.00011478814121801406
mutation O 0 4.047859420097666e-06
causes O 0 1.0721274890101995e-07
the O 0 5.827186733142753e-09
sodium O 0 3.317428820537316e-07
channel O 0 7.730888000878622e-07
to O 0 1.544893990512719e-08
be O 0 9.712982418363936e-09
non O 0 9.47304883425204e-08
- O 0 2.3562517981190467e-06
functional O 0 1.9728254301298875e-06
. O 0 1.0469198059581686e-06

Our O 0 1.4353716323967092e-05
results O 0 1.0249330443912186e-05
indicate O 0 4.306077698856825e-07
that O 0 2.4397532882858286e-08
mutations O 0 7.533351435995428e-07
in O 0 8.64261764377261e-08
cardiac O 0 5.418173168436624e-05
ion O 0 3.937601377401734e-06
- O 0 1.126599727285793e-05
channel O 0 7.30828833184205e-06
genes O 0 1.197074084302585e-07
contribute O 0 2.593450787458096e-08
to O 0 1.3240820884163895e-08
the O 0 1.8698996129273837e-08
risk O 0 2.465797876993747e-07
of O 0 8.209237734035923e-09
developing O 0 7.2740845098451246e-06
IVF B-Disease 1 0.9999988079071045
. O 0 5.404534135777794e-07
. O 0 6.090591568863601e-07

Molecular O 0 0.00010851814295165241
heterogeneity O 0 7.991117308847606e-05
in O 0 1.1558697678992758e-06
mucopolysaccharidosis B-Disease 0 0.00019590786541812122
IVA I-Disease 0 0.03332644701004028
in O 0 6.319896783679724e-07
Australia O 0 1.9759727365453728e-07
and O 0 6.235524807607362e-08
Northern O 0 8.718403705643141e-07
Ireland O 0 3.2538146115257405e-06
: O 0 1.4785127788741192e-08
nine O 0 2.4877451210159052e-08
novel O 0 2.0320737803558586e-07
mutations O 0 7.839558406885772e-07
including O 0 7.525436274136155e-09
T312S O 0 3.632280254350917e-07
, O 0 1.3423679945390177e-08
a O 0 1.4343390475346496e-08
common O 0 5.5864408210482e-08
allele O 0 6.042790801075171e-07
that O 0 1.3105594831586131e-08
confers O 0 3.7221141724330664e-07
a O 0 1.215720430991496e-06
mild O 0 6.614215817535296e-05
phenotype O 0 0.00018971360987052321
. O 0 3.017650215042522e-06

Mucopolysaccharidosis B-Disease 1 0.8380152583122253
IVA I-Disease 1 0.9999017715454102
( O 0 0.021224407479166985
MPS B-Disease 1 0.9999946355819702
IVA I-Disease 1 0.9999998807907104
) O 0 1.214328676724108e-06
is O 0 4.8291042276105145e-08
an O 0 2.903193205838761e-07
autosomal B-Disease 1 0.9895931482315063
recessive I-Disease 1 0.9992901086807251
lysosomal I-Disease 1 0.9999842643737793
storage I-Disease 1 0.9999831914901733
disorder I-Disease 1 0.9998905658721924
caused O 0 1.1764665941882413e-05
by O 0 2.8347825420382833e-08
a O 0 9.814171789912507e-06
genetic B-Disease 1 0.9999991655349731
defect I-Disease 1 0.9999901056289673
in O 0 4.138035762935033e-07
N O 0 0.0007544861873611808
- O 0 0.00010745167674031109
acetylgalactosamine O 0 0.0002879421808756888
- O 0 8.738842734601349e-05
6 O 0 1.5614827134413645e-05
- O 0 0.0010115148033946753
sulfate O 0 8.97833815542981e-05
sulfatase O 0 5.5307773436652496e-05
( O 0 1.0185841858856293e-07
GALNS O 0 2.3642702217330225e-05
) O 0 2.5422806970709644e-07
. O 0 6.23412176992133e-07

Previous O 0 3.377089524292387e-05
studies O 0 6.846476594546402e-07
of O 0 4.917441742691153e-08
patients O 0 1.58339923927997e-06
from O 0 2.2952040268364726e-08
a O 0 3.7570177369161684e-07
British O 0 2.515750384191051e-05
- O 0 0.0011992062209174037
Irish O 0 1.1881680620717816e-05
population O 0 6.335955760050638e-08
showed O 0 1.0673490180579392e-07
that O 0 1.7583838829438037e-09
the O 0 3.6986480544953793e-09
I113F O 0 3.1250695542439644e-07
mutation O 0 2.2718701586654788e-07
is O 0 1.6957820703211723e-09
the O 0 6.728727575122662e-10
most O 0 1.4223431321624957e-09
common O 0 1.6020294424379244e-08
single O 0 6.255322659853846e-07
mutation O 0 3.5949310586147476e-06
among O 0 3.8634311749774497e-07
MPS B-Disease 1 0.9998893737792969
IVA I-Disease 1 1.0
patients O 0 5.256422809907235e-05
and O 0 3.168611328874249e-08
produces O 0 1.3827458360538003e-06
a O 0 4.131196419621119e-06
severe O 0 0.0002932497882284224
clinical O 0 2.1428673790069297e-05
phenotype O 0 0.0002497444220352918
. O 0 4.39580207967083e-06

We O 0 6.322245553747052e-06
studied O 0 1.1584434105316177e-06
mutations O 0 2.6504146717343247e-06
in O 0 2.9186159267169387e-08
the O 0 1.2899212364914092e-08
GALNS O 0 1.1552931027836166e-05
gene O 0 7.67430321957363e-07
from O 0 3.418409377786702e-08
23 O 0 9.452905658235977e-08
additional O 0 2.7094458232568286e-07
MPS B-Disease 1 0.9999071359634399
IVA I-Disease 1 1.0
patients O 0 0.00011898352386197075
( O 0 7.319852723952636e-09
15 O 0 1.037271868398193e-08
from O 0 5.684995585397701e-09
Australia O 0 8.352414226919791e-08
, O 0 1.5322138224860282e-08
8 O 0 4.245556795012817e-08
from O 0 6.073779257320666e-09
Northern O 0 3.05689610513582e-07
Ireland O 0 3.7896918456681306e-06
) O 0 1.412233618935943e-08
, O 0 1.6129622082416972e-09
with O 0 6.307036004571387e-10
various O 0 1.1638495500676527e-08
clinical O 0 2.031365966104204e-06
phenotypes O 0 8.259842616098467e-06
( O 0 1.1156312211824115e-06
severe O 0 3.730363096110523e-05
, O 0 1.8531062551119248e-07
16 O 0 2.4270320864161476e-07
cases O 0 1.5031686118049947e-08
; O 0 9.89530146711104e-09
intermediate O 0 1.476461903848758e-07
, O 0 4.513884022117054e-08
4 O 0 6.33782235581748e-07
cases O 0 1.3480541838362115e-07
; O 0 1.787708612255301e-07
mild O 0 3.6658411772805266e-06
, O 0 1.0140598050156768e-07
3 O 0 9.819832484936342e-07
cases O 0 1.7507620952983416e-07
) O 0 1.285216342239437e-07
. O 0 6.881346621412376e-07

We O 0 3.191561972926138e-06
found O 0 1.3797330211673398e-07
two O 0 1.0942200034946836e-08
common O 0 1.3782678820462024e-07
mutations O 0 1.467561901336012e-06
that O 0 9.866202965724824e-09
together O 0 2.7403636693179578e-08
accounted O 0 4.908553705718077e-07
for O 0 1.4581637231003697e-08
32 O 0 4.2478571771198403e-08
% O 0 6.597502988370252e-09
of O 0 1.22529475454769e-09
the O 0 1.959615403279713e-08
44 O 0 5.814532855197285e-08
unrelated O 0 5.345208720086703e-08
alleles O 0 1.0363369540300482e-07
in O 0 3.391716418832402e-08
these O 0 8.826485498047987e-08
patients O 0 2.3421353034791537e-06
. O 0 8.259758033091202e-07

One O 0 9.748655429575592e-07
is O 0 5.87905724103166e-08
the O 0 1.05849320419793e-08
T312S O 0 4.5675366777686577e-07
mutation O 0 5.858001941305702e-07
, O 0 8.675828055970669e-09
a O 0 1.8198162976545973e-08
novel O 0 1.5219561078083643e-07
mutation O 0 6.633263751609775e-07
found O 0 3.9174317123524816e-08
exclusively O 0 3.378634971795691e-08
in O 0 1.5791555085797881e-07
milder O 0 0.0002049386821454391
patients O 0 1.8970393284689635e-05
. O 0 1.0618821306707105e-06

The O 0 4.855899078393122e-07
other O 0 3.229639844448684e-08
is O 0 2.108343721829442e-08
the O 0 2.0111972531822175e-08
previously O 0 5.799723226118658e-07
described O 0 4.494438314850413e-07
I113F O 0 3.226127773814369e-07
that O 0 3.088404909590281e-08
produces O 0 1.086085831047967e-06
a O 0 4.322327185946051e-06
severe O 0 0.0001287779159611091
phenotype O 0 0.00019807463104370981
. O 0 1.927039193105884e-06

The O 0 1.959161636477802e-06
I113F O 0 7.763137546135113e-06
and O 0 1.5236305728194566e-07
T312S O 0 1.469703420298174e-06
mutations O 0 4.750709649670171e-06
accounted O 0 8.663873813929968e-07
for O 0 3.0536586592688764e-08
8 O 0 3.8313262962219596e-07
( O 0 2.6393308871774934e-08
18 O 0 7.0288514564254e-08
% O 0 1.9784685889590037e-08
) O 0 1.2677399574556603e-08
and O 0 1.064721999455287e-07
6 O 0 1.2317907476244727e-06
( O 0 2.4802684350788695e-08
14 O 0 9.223263219837463e-08
% O 0 1.1203353800226523e-08
) O 0 2.492360096084667e-09
of O 0 2.053153203007696e-09
44 O 0 4.393579544625936e-08
unrelated O 0 1.2390253800731443e-07
alleles O 0 3.092814893079776e-07
, O 0 1.0763360336341066e-07
respectively O 0 2.4383541585848434e-06
. O 0 1.1638816204140312e-06

The O 0 1.4223621747078141e-06
relatively O 0 4.835030154026754e-07
high O 0 4.990799880033592e-07
residual O 0 2.5641659249231452e-06
GALNS O 0 2.8865511922049336e-05
activity O 0 2.1273946515520947e-07
seen O 0 6.832466681316873e-08
when O 0 5.790391721660626e-09
the O 0 3.0511648763109633e-09
T312S O 0 1.0757285906493053e-07
mutant O 0 6.938766006214792e-08
cDNA O 0 2.1424099827527243e-07
is O 0 1.2476046862275325e-08
overexpressed O 0 4.798204713551968e-07
in O 0 1.6185349949182637e-08
mutant O 0 3.9759893866175844e-07
cells O 0 3.434906545862759e-07
provides O 0 2.136759569282276e-08
an O 0 1.1041048963988942e-08
explanation O 0 3.071386700526091e-08
for O 0 9.349440333039638e-09
the O 0 8.251894456634545e-08
mild O 0 1.855243681347929e-05
phenotype O 0 3.640965587692335e-05
in O 0 2.796231513002567e-07
patients O 0 3.2785732173579163e-07
with O 0 4.879710857608188e-09
this O 0 1.2120918313485163e-07
mutation O 0 1.0918945008597802e-05
. O 0 9.273232421946886e-07

The O 0 8.547026482119691e-07
distribution O 0 5.61714728064544e-07
and O 0 3.4443004892636964e-08
relative O 0 2.9844343885088165e-08
frequencies O 0 3.611523879953893e-08
of O 0 1.865420928837125e-09
the O 0 9.501835762648625e-09
I113F O 0 2.4917062546592206e-07
and O 0 2.4851699365058266e-08
T312S O 0 2.4411596655227186e-07
mutations O 0 5.148650643604924e-07
in O 0 8.944844864799961e-09
Australia O 0 5.12905664606933e-08
corresponded O 0 8.653603345010197e-08
to O 0 1.6854640350061345e-08
those O 0 3.3254088371847956e-09
observed O 0 8.991872135766243e-08
in O 0 1.7760063641958368e-08
Northern O 0 3.3416688438592246e-07
Ireland O 0 3.0583269108319655e-06
and O 0 5.858739626773968e-08
are O 0 1.3287010380835795e-09
unique O 0 3.120609326501267e-09
to O 0 1.3122027908707423e-08
these O 0 1.1549196043958432e-09
two O 0 1.057758591826996e-08
populations O 0 4.695272792787364e-08
, O 0 9.92565940549639e-09
suggesting O 0 3.7931265239876666e-08
that O 0 6.211176906134597e-09
both O 0 9.314375049029877e-09
mutations O 0 5.002775083084998e-07
were O 0 1.631285151404427e-08
probably O 0 2.2967892476799534e-08
introduced O 0 1.5866183034063397e-08
to O 0 1.6788293422109746e-08
Australia O 0 1.519458159293663e-08
by O 0 3.142536009193009e-09
Irish O 0 7.065977314368865e-08
migrants O 0 5.8287788817779074e-08
during O 0 8.849323052118052e-09
the O 0 7.815982527858978e-09
19th O 0 4.818854790755722e-07
century O 0 8.682193879394617e-07
. O 0 1.6084612752820249e-06

Haplotype O 0 0.002554180333390832
analysis O 0 4.328362138039665e-06
using O 0 5.169925429981959e-07
6 O 0 5.877222974959295e-07
RFLPs O 0 2.392296210018685e-06
provides O 0 2.739705351473276e-08
additional O 0 1.3678703503217093e-08
data O 0 1.0219547164069809e-07
that O 0 2.0246442300475564e-09
the O 0 9.365574094033491e-09
I113F O 0 6.625866717513418e-07
mutation O 0 3.467615954377834e-07
originated O 0 2.3548015093410868e-08
from O 0 3.7739429359362475e-09
a O 0 3.4130017922962e-08
common O 0 3.8445281802523823e-07
ancestor O 0 7.994111001607962e-06
. O 0 2.563138878031168e-06

The O 0 7.358729590123403e-07
other O 0 5.1294772873689e-08
9 O 0 3.397411489913793e-07
novel O 0 1.960251552191039e-07
mutations O 0 2.3024399524729233e-06
identified O 0 9.810892152017914e-07
in O 0 5.3744365402508265e-08
these O 0 1.9193393541172554e-08
23 O 0 2.5818972062552348e-06
patients O 0 2.283441205008785e-07
were O 0 5.177501094522086e-09
each O 0 5.628094879028822e-09
limited O 0 2.5958213356602755e-08
to O 0 3.0595465716487524e-08
a O 0 9.041642812235295e-08
single O 0 1.6336022099494585e-06
family O 0 3.6983437894377857e-06
. O 0 1.2896281305074808e-06

These O 0 1.1212448498554295e-06
data O 0 1.247511704605131e-06
provide O 0 4.6496701600062806e-08
further O 0 2.9810664159413136e-08
evidence O 0 3.9497308534919284e-08
for O 0 1.672966831733902e-08
extensive O 0 2.3276298577457055e-07
allelic O 0 3.752598786377348e-06
heterogeneity O 0 2.4576902433182113e-05
in O 0 7.543339961557649e-06
MPS B-Disease 1 0.9996933937072754
IVA I-Disease 1 0.9999996423721313
in O 0 1.6359907704099896e-06
British O 0 7.075726898619905e-06
- O 0 0.001265884842723608
Irish O 0 0.00019355042604729533
patients O 0 6.8891213231836446e-06
and O 0 2.0333526862259532e-08
provide O 0 1.410429995019058e-08
evidence O 0 2.0966140823475143e-08
for O 0 3.37624994628527e-09
their O 0 3.163200545941436e-08
transmission O 0 4.181380973022897e-06
to O 0 5.462310426196382e-08
Australia O 0 2.493341000331384e-08
by O 0 4.156408106581466e-09
British O 0 4.0034456105786376e-07
- O 0 1.0362620741943829e-05
Irish O 0 1.7160331253762706e-06
migrants O 0 3.709219242864492e-07
. O 0 3.0923779092972836e-08
. O 0 2.3817942462756037e-07

Identification O 0 3.4596258046803996e-05
of O 0 1.0670573828974739e-06
constitutional O 0 1.8081051393892267e-06
WT1 O 0 0.000515693158376962
mutations O 0 0.00027183667407371104
, O 0 1.7634503990393569e-07
in O 0 5.6598327802248605e-08
patients O 0 5.867081540600338e-07
with O 0 6.853363032632842e-08
isolated O 0 0.004383135586977005
diffuse B-Disease 1 0.9988254904747009
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.2052851111075142e-06
and O 0 9.598984718195425e-08
analysis O 0 1.3934217690803052e-07
of O 0 4.548055088093861e-08
genotype O 0 0.0044652679935097694
/ O 0 0.021918851882219315
phenotype O 0 7.883833313826472e-05
correlations O 0 2.7708749712473946e-06
by O 0 6.753726466968146e-09
use O 0 2.4843403778618267e-08
of O 0 6.500919802476801e-09
a O 0 3.444557137299853e-07
computerized O 0 9.20113452593796e-05
mutation O 0 2.163452336390037e-05
database O 0 3.8772564039391e-06
. O 0 9.615088174541597e-07

Constitutional O 0 1.2099683772248682e-05
mutations O 0 1.6970299839158542e-05
of O 0 4.323467095446176e-08
the O 0 5.109966849659031e-08
WT1 O 0 1.22189121611882e-05
gene O 0 7.292375130418804e-07
, O 0 1.5326669711157592e-08
encoding O 0 6.720230061318944e-08
a O 0 1.6553512693917583e-07
zinc O 0 0.00010166986612603068
- O 0 1.758879625413101e-05
finger O 0 1.8475599063094705e-05
transcription O 0 9.276116657019884e-07
factor O 0 9.119164445792194e-08
involved O 0 4.3127684534738364e-08
in O 0 3.125358887245966e-07
renal O 0 0.19133330881595612
and O 0 1.1220439546377747e-06
gonadal O 0 5.759554551332258e-05
development O 0 2.4500130280102894e-07
, O 0 2.5793271518637084e-08
are O 0 1.5226397920287127e-09
found O 0 2.2665005872113397e-08
in O 0 7.341315555464689e-09
most O 0 5.784224654803438e-08
patients O 0 1.9582411425744795e-07
with O 0 3.0467762712760305e-07
Denys B-Disease 1 0.9999903440475464
- I-Disease 1 0.9999992847442627
Drash I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 6.4165101321123075e-06
DDS B-Disease 1 1.0
) O 0 7.634563417013851e-07
, O 0 1.3807623133743618e-07
or O 0 1.7305812434642576e-05
diffuse B-Disease 1 0.998773992061615
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 3.124717477476224e-05
DMS B-Disease 0 0.20325462520122528
) O 0 2.5273848791584896e-07
associated O 0 1.3324429914973734e-07
with O 0 1.438941694686946e-07
pseudohermaphroditism B-Disease 1 0.9999997615814209
and O 0 2.5022198315127753e-05
/ O 0 0.014905481599271297
or O 0 1.6734997188905254e-05
Wilms B-Disease 1 0.8505551815032959
tumor I-Disease 0 0.2199813425540924
( O 0 5.010460881749168e-06
WT B-Disease 1 0.9999737739562988
) O 0 6.169653943288722e-07
. O 0 7.17921466275584e-07

Most O 0 5.069483904662775e-06
mutations O 0 0.000330535345710814
in O 0 1.1712076229741797e-05
DDS B-Disease 1 1.0
patients O 0 0.11121443659067154
lie O 0 1.4331803868117277e-05
in O 0 1.6977709549337305e-07
exon O 0 8.360992069356143e-06
8 O 0 5.169235350876988e-07
or O 0 3.046148222551892e-08
exon O 0 1.0185827932218672e-06
9 O 0 2.4202043391596817e-07
, O 0 7.439195481850902e-09
encoding O 0 1.7722088330174302e-07
zinc O 0 3.757677040994167e-05
finger O 0 5.672672705259174e-05
2 O 0 2.950260750367306e-06
or O 0 1.3175795174902305e-06
zinc O 0 8.505205914843827e-05
finger O 0 3.0398445233004168e-05
3 O 0 6.492409170277824e-07
, O 0 4.8493273396843506e-08
respectively O 0 1.11920599010773e-07
, O 0 1.5212783255336149e-09
with O 0 1.178844577509608e-09
a O 0 9.022452474027887e-08
hot O 0 7.1297936301562e-06
spot O 0 7.116360211512074e-05
( O 0 1.0299896757715032e-07
R394W O 0 1.720259064086349e-07
) O 0 5.559990245984636e-09
in O 0 1.0791250559805121e-08
exon O 0 5.210371909925016e-06
9 O 0 1.952377942870953e-06
. O 0 8.609151223026856e-07

We O 0 3.0907233394827927e-06
analyzed O 0 1.1095452236986603e-06
a O 0 5.89253943417134e-08
series O 0 8.355473823939974e-08
of O 0 1.5176565781871432e-08
24 O 0 3.307810175101622e-06
patients O 0 2.4058448389041587e-07
, O 0 7.81962050666607e-09
10 O 0 1.029553242659631e-08
with O 0 7.529028778208158e-08
isolated B-Disease 0 0.004834821447730064
DMS I-Disease 1 0.9468152523040771
( O 0 1.1188446933374507e-06
IDMS B-Disease 0 0.00011169024219270796
) O 0 6.655924522647183e-08
, O 0 2.2850002778795897e-08
10 O 0 5.394092639221526e-08
with O 0 5.397770905801735e-07
DDS B-Disease 1 1.0
, O 0 1.0513360848563025e-06
and O 0 5.5457160641481096e-08
4 O 0 2.8353511538625753e-07
with O 0 3.5097460227007105e-07
urogenital B-Disease 0 0.05312123894691467
abnormalities I-Disease 1 0.9784544706344604
and O 0 7.256250228238059e-06
/ O 0 0.03143930435180664
or O 0 9.115358261624351e-05
WT B-Disease 1 0.9999946355819702
. O 0 3.722806468431372e-06

We O 0 1.2339879503997508e-05
report O 0 4.2502097130636685e-06
WT1 O 0 5.885642167413607e-05
heterozygous O 0 7.238465968839591e-06
mutations O 0 1.197282563225599e-05
in O 0 2.1205319455930294e-07
16 O 0 3.578464884412824e-06
patients O 0 2.3512034204031806e-06
, O 0 3.86148215625326e-08
4 O 0 1.635763169360871e-07
of O 0 2.3583886843425717e-08
whom O 0 2.2585315946344053e-06
presented O 0 7.085708375598188e-07
with O 0 5.231225941315643e-07
IDMS B-Disease 0 0.0072722588665783405
. O 0 4.219162292429246e-06

One O 0 4.630395324056735e-06
male O 0 1.6894057353056269e-06
and O 0 1.0053357613060143e-07
two O 0 1.0416141549285385e-07
female O 0 6.5986596382572316e-06
IDMS B-Disease 0 0.012597516179084778
patients O 0 7.1978192863753065e-06
with O 0 9.65469411084996e-08
WT1 O 0 0.006709930952638388
mutations O 0 0.001624082331545651
underwent O 0 0.00019253090431448072
normal O 0 2.5939512852346525e-05
puberty O 0 4.521222217590548e-05
. O 0 3.0268447517300956e-06

Two O 0 3.182194859618903e-06
mutations O 0 8.198645082302392e-05
associated O 0 7.734146834081912e-07
with O 0 7.075431796010889e-08
IDMS B-Disease 0 0.0013325999025255442
are O 0 3.9852366739978606e-08
different O 0 8.204963819480326e-09
from O 0 2.4557623490295555e-08
those O 0 3.136848647500301e-08
described O 0 7.653373359062243e-06
in O 0 6.497719368780963e-06
DDS B-Disease 1 1.0
patients O 0 0.0002491943014319986
. O 0 8.127848332151189e-07

No O 0 1.9156628695782274e-05
WT1 O 0 0.0005538059631362557
mutations O 0 0.0002578504791017622
were O 0 7.8909619105616e-07
detected O 0 1.4236038623494096e-06
in O 0 1.4165661532672402e-08
the O 0 1.4942443726795318e-08
six O 0 1.0464810173971273e-07
other O 0 1.6456237972306553e-07
IDMS B-Disease 0 0.015341480262577534
patients O 0 4.263810296833981e-06
, O 0 2.6233257344188132e-08
suggesting O 0 4.87790373426833e-07
genetic O 0 2.231269490948762e-06
heterogeneity O 0 2.8342824407445733e-06
of O 0 5.8079596243487686e-08
this O 0 1.359554403279617e-06
disease O 0 0.00025664822896942496
. O 0 1.3525578879125533e-06

We O 0 2.989704989886377e-05
analyzed O 0 3.8506012060679495e-05
genotype O 0 0.0013867114903405309
/ O 0 0.008526728488504887
phenotype O 0 0.00023721875913906842
correlations O 0 6.009862772771157e-05
, O 0 2.114901178629225e-07
on O 0 3.147463303321274e-07
the O 0 1.1085467654936565e-08
basis O 0 4.0397495126853755e-08
of O 0 3.006727089527317e-09
the O 0 4.7434571825988314e-08
constitution O 0 2.0707298986621936e-08
of O 0 1.4703930295567602e-09
a O 0 1.237948197285732e-07
WT1 O 0 1.4726898371009156e-05
mutation O 0 2.6407190034660744e-07
database O 0 4.0262115419409383e-08
of O 0 4.24531165776898e-09
84 O 0 2.1037850217453524e-07
germ O 0 2.317058897460811e-05
- O 0 2.672441587492358e-05
line O 0 8.150540816131979e-05
mutations O 0 2.29090619541239e-06
, O 0 8.872037327023463e-09
to O 0 5.178083739565409e-09
compare O 0 4.0918152421909326e-08
the O 0 2.8665776419245503e-09
distribution O 0 1.4325118513625057e-07
and O 0 4.0428947301052176e-08
type O 0 6.280200892661014e-08
of O 0 7.76668951374404e-09
mutations O 0 2.0458460312511306e-06
, O 0 2.1585517373523544e-08
according O 0 6.406800867608808e-09
to O 0 6.392080642569908e-09
the O 0 1.4339369691640513e-08
different O 0 3.1224391250361805e-07
symptoms O 0 3.511780232656747e-05
. O 0 5.844520387654484e-07

This O 0 2.584498588475981e-06
demonstrated O 0 2.3790591967554064e-06
( O 0 7.919528854927194e-08
1 O 0 2.081666252706782e-07
) O 0 1.5301900191388995e-08
the O 0 9.911433451748053e-09
association O 0 9.373420262193122e-09
between O 0 5.161645777462809e-09
mutations O 0 7.801461947565258e-07
in O 0 2.8921162353867658e-08
exons O 0 4.517261459113797e-06
8 O 0 4.679479559399624e-07
and O 0 7.926631440113852e-08
9 O 0 1.1921130180780892e-06
and O 0 9.155168640972988e-07
DMS B-Disease 0 0.004720412194728851
; O 0 2.084477301877996e-07
( O 0 2.4038854462560266e-08
2 O 0 3.1610539963367046e-07
) O 0 4.7579280959553216e-08
among O 0 1.4208605847443323e-08
patients O 0 7.384559097545207e-08
with O 0 2.46311770979446e-08
DMS B-Disease 0 0.0037883014883846045
, O 0 1.445255115584132e-08
a O 0 1.452564735160422e-08
higher O 0 3.014492122588308e-08
frequency O 0 9.847124715633981e-08
of O 0 6.118731299409319e-09
exon O 0 1.4029250223757117e-06
8 O 0 2.31888250823431e-07
mutations O 0 4.2799655375347356e-07
among O 0 1.085934631106511e-08
46 O 0 1.5041099743484665e-07
, O 0 1.744235760270385e-07
XY O 0 5.738989420933649e-05
patients O 0 4.232919081914588e-07
with O 0 5.169360051127114e-09
female O 0 7.199612355179852e-07
phenotype O 0 6.113582458056044e-06
than O 0 6.522819262499979e-08
among O 0 3.296311490430526e-08
46 O 0 6.419120950340584e-07
, O 0 3.082914474816789e-07
XY O 0 0.0001413159043295309
patients O 0 4.963616220265976e-07
with O 0 7.821082448344896e-09
sexual O 0 8.039918242275235e-08
ambiguity O 0 1.9897011327429937e-07
or O 0 7.401641823889804e-07
male O 0 1.3649223546963185e-06
phenotype O 0 1.804435123631265e-05
; O 0 2.218943819798369e-07
and O 0 3.7313509437808534e-07
( O 0 4.739912284890124e-08
3 O 0 6.323664365481818e-07
) O 0 4.896915939411883e-08
statistically O 0 6.531197982440062e-07
significant O 0 6.0591882622418325e-09
evidence O 0 2.2903412499886144e-08
that O 0 2.6432553923427804e-08
mutations O 0 5.382621566241141e-07
in O 0 1.7182317790798152e-08
exons O 0 2.752706677711103e-06
8 O 0 2.729050834204827e-07
and O 0 3.090567446406567e-08
9 O 0 1.1753969886285631e-07
preferentially O 0 1.1248538100971928e-07
affect O 0 2.810046417778267e-08
amino O 0 2.3933859338853836e-08
acids O 0 2.2317021119988567e-08
with O 0 6.617816294962608e-10
different O 0 2.70800226687129e-09
functions O 0 1.8169167503856443e-08
. O 0 3.391412306541497e-08
. O 0 3.213645527466724e-07

The O 0 6.674436008324847e-06
185delAG O 0 7.593234477099031e-05
BRCA1 O 0 0.0003196759498678148
mutation O 0 3.979376742790919e-06
originated O 0 2.6824963583749195e-07
before O 0 8.272427720612541e-08
the O 0 6.4350178519134715e-09
dispersion O 0 4.043643571094435e-07
of O 0 4.461174096803688e-09
Jews O 0 3.0443047194239625e-07
in O 0 4.3705444596753296e-08
the O 0 2.0018818602807187e-08
diaspora O 0 3.204296206149593e-07
and O 0 1.0252444582192766e-07
is O 0 3.165131801097232e-08
not O 0 1.5816628007314648e-08
limited O 0 2.5205286746654565e-08
to O 0 1.7599221280306665e-07
Ashkenazim O 0 3.204017775715329e-05
. O 0 8.482228395223501e-07

The O 0 2.11428118745971e-06
185delAG O 0 1.84578475455055e-05
mutation O 0 9.703052455733996e-06
in O 0 1.8837322102172038e-07
BRCA1 O 0 7.876814197516069e-05
is O 0 2.0519216548109398e-07
detected O 0 1.4762663340661675e-06
in O 0 1.7900724458286277e-08
Ashkenazi O 0 4.989489752915688e-06
Jews O 0 1.319194637972032e-07
both O 0 1.4199042830398412e-08
in O 0 3.448182326337701e-07
familial B-Disease 1 0.5047435164451599
breast I-Disease 1 0.9999982118606567
and I-Disease 1 0.9999425411224365
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 2.3243957514296198e-07
in O 0 1.8046213412503675e-08
the O 0 2.123105424800542e-08
general O 0 9.053361083033451e-08
population O 0 1.422097568593017e-07
. O 0 4.9214861519431e-07

All O 0 1.8728426312009105e-06
tested O 0 8.853166036715265e-06
Ashkenazi O 0 0.00015718906070105731
mutation O 0 3.2423195079900324e-06
carriers O 0 1.426400473292233e-07
share O 0 1.6005093073090393e-07
the O 0 9.510991993977314e-09
same O 0 2.5128629843607087e-08
allelic O 0 3.61796736569886e-07
pattern O 0 2.235256488347659e-06
at O 0 3.132323342924792e-07
the O 0 1.298908500757534e-07
BRCA1 O 0 0.00021085630578454584
locus O 0 3.416166146053001e-05
. O 0 2.367810111536528e-06

Our O 0 8.265144970209803e-06
previous O 0 1.8111269355358672e-06
study O 0 1.9391517014355486e-07
showed O 0 5.445286319627485e-07
that O 0 7.934555235067364e-09
this O 0 1.257241066809911e-08
Ashkenazi O 0 6.570123514393345e-05
mutation O 0 1.5745074506412493e-06
also O 0 1.723334577263813e-07
occurs O 0 1.36863231858797e-08
in O 0 5.732666341629056e-09
Iraqi O 0 3.488797872819305e-08
Jews O 0 5.426091576055114e-08
with O 0 3.766931211401925e-09
a O 0 5.831425653468614e-08
similar O 0 1.4981402784997044e-07
allelic O 0 7.1296167334367055e-06
pattern O 0 3.027990533155389e-05
. O 0 1.412862047800445e-06

We O 0 2.0565757949952967e-06
extended O 0 2.5007904014273663e-07
our O 0 6.283100617565651e-08
analysis O 0 4.283746690703083e-08
to O 0 5.299038985384641e-09
other O 0 5.237902556132212e-09
non O 0 8.942596707584016e-08
- O 0 2.3354441509582102e-06
Ashkenazi O 0 1.0355844096920919e-05
subsets O 0 1.5296186006708012e-07
354 O 0 4.754517135552305e-08
of O 0 2.7627826693077395e-09
Moroccan O 0 9.965981462300988e-07
origin O 0 1.0235152814175308e-07
, O 0 1.446090536205702e-08
200 O 0 1.2089547141158619e-08
Yemenites O 0 6.432474037865177e-07
and O 0 2.8141711183593543e-08
150 O 0 4.025888955538903e-08
Iranian O 0 3.3097339269261283e-07
Jews O 0 1.5632142549293349e-06
. O 0 7.050703629829513e-07

Heteroduplex O 0 0.00100036954972893
analysis O 0 7.6645346780424e-06
complemented O 0 2.0323213902884163e-06
by O 0 2.4462908143618733e-08
direct O 0 9.812158907607227e-08
DNA O 0 7.106307293724967e-07
sequencing O 0 4.5846789475945116e-07
of O 0 2.443241164939991e-08
abnormally O 0 1.7078176597351558e-06
migrating O 0 9.802768374811421e-08
bands O 0 1.4029423311967548e-07
were O 0 7.777529020813745e-08
employed O 0 4.6630898964394873e-07
. O 0 6.511544938803127e-07

Four O 0 2.1708801796194166e-06
of O 0 9.835392944523846e-08
Moroccan O 0 6.363499323924771e-06
origin O 0 5.207577373766981e-07
( O 0 2.3675559290836645e-08
1 O 0 4.559676369808585e-08
. O 0 1.2726531828377574e-08
1 O 0 9.617841811859762e-08
% O 0 3.383058810868533e-08
) O 0 4.288837729404804e-09
and O 0 1.62743774012597e-08
none O 0 6.788312134631269e-09
of O 0 1.0461128630012695e-09
the O 0 1.4125973279988102e-08
Yemenites O 0 2.0888899143756134e-06
or O 0 6.625387527492421e-08
Iranians O 0 7.758874431829099e-08
was O 0 7.177852978657029e-08
a O 0 1.6645891776079225e-08
carrier O 0 1.367602209256802e-07
of O 0 4.267507236477286e-09
the O 0 3.7371982841705176e-08
185delAG O 0 1.713721030682791e-05
mutation O 0 9.420231435797177e-06
. O 0 6.528445055664633e-07

BRCA1 O 0 0.006447834428399801
allelic O 0 0.00016443768981844187
patterns O 0 0.00013413923443295062
were O 0 1.3744643183599692e-06
determined O 0 1.932940421056628e-07
for O 0 2.445628410896461e-08
four O 0 1.9008538743037207e-08
of O 0 3.957043137603478e-09
these O 0 5.486720855429894e-09
individuals O 0 1.6634840172002896e-09
and O 0 1.3733471249111062e-08
for O 0 7.769667575985295e-09
12 O 0 1.154263884473039e-08
additional O 0 1.69768590296826e-08
non O 0 1.918735961226048e-07
- O 0 4.08764890380553e-06
Ashkenazi O 0 3.600742275011726e-05
185delAG O 0 1.9437818536971463e-06
mutation O 0 6.498783591268875e-07
carriers O 0 2.437925843423727e-07
who O 0 1.1310631862215814e-06
had O 0 0.0006812165956944227
breast B-Disease 1 0.9999598264694214
/ I-Disease 1 0.9999998807907104
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
. O 0 4.675478976423619e-06

Six O 0 5.899742063775193e-06
non O 0 1.0803424629557412e-05
- O 0 0.00019514183804858476
Ashkenazi O 0 0.0005030304891988635
individuals O 0 2.701714585384707e-08
shared O 0 4.2077797246520277e-08
the O 0 2.9699993575604822e-08
common O 0 1.2511312661445118e-06
Ashkenazi O 0 0.0023465522099286318
haplotype O 0 0.00016253991634584963
, O 0 9.730732131174591e-08
four O 0 2.0776610654138494e-08
had O 0 1.221306007437306e-07
a O 0 3.0064764899861984e-08
closely O 0 3.1554878887618543e-07
related O 0 5.860616738573299e-07
pattern O 0 8.229830200434662e-06
, O 0 2.8260967610549415e-07
and O 0 5.2400938699292965e-08
the O 0 1.9923399818821963e-08
rest O 0 1.94821211607632e-07
( O 0 2.4592214487029196e-08
n O 0 3.3695273486955557e-06
= O 0 1.446801775273343e-06
6 O 0 4.1967990682678646e-07
) O 0 6.470895375088048e-09
displayed O 0 2.3473353039094036e-08
a O 0 8.458739131356197e-08
distinct O 0 1.0106793979502982e-06
BRCA1 O 0 0.0002260648470837623
allelic O 0 2.358381425437983e-05
pattern O 0 3.698547152453102e-05
. O 0 1.3894133417124976e-06

We O 0 5.660600436385721e-06
conclude O 0 3.104048346358468e-06
that O 0 1.911761771111742e-08
the O 0 9.317929539065517e-09
185delAG O 0 2.164201305276947e-06
BRCA1 O 0 3.193408701918088e-05
mutation O 0 1.3990184015710838e-06
occurs O 0 2.4874982074152285e-08
in O 0 2.0887298557425993e-09
some O 0 2.321628889134786e-09
non O 0 2.734720396802004e-07
- O 0 1.1517937309690751e-05
Ashkenazi O 0 0.0001777563156792894
populations O 0 1.1265756683087602e-07
at O 0 5.604370301171002e-08
rates O 0 8.595617373430287e-08
comparable O 0 2.7897154808442792e-08
with O 0 2.9301494564037966e-09
that O 0 2.1027535268558495e-08
of O 0 3.794414382696232e-08
Ashkenazim O 0 6.021595254424028e-05
. O 0 1.6582108628426795e-06

The O 0 6.803388714615721e-07
majority O 0 2.048097655915626e-07
of O 0 1.376386382645478e-08
Jewish O 0 5.665027060786088e-07
185delAG O 0 4.941016413795296e-06
mutation O 0 2.965742169180885e-06
carriers O 0 6.820462061796206e-08
have O 0 4.469529635287017e-09
a O 0 1.4515456392416581e-08
common O 0 6.736951974062322e-08
allelic O 0 1.4115180420049e-06
pattern O 0 6.684016625513323e-06
, O 0 4.471868209066088e-08
supporting O 0 1.3617061256354646e-08
the O 0 1.6166898930691787e-08
founder O 0 1.700501002233068e-06
effect O 0 9.282402402277512e-08
notion O 0 1.9803790607397787e-08
, O 0 1.024382001446611e-08
but O 0 7.96670374114683e-09
dating O 0 1.7202944846417267e-08
the O 0 1.0378695236568092e-08
mutations O 0 2.85549674572394e-07
origin O 0 2.168848389771938e-08
to O 0 1.754177425539183e-08
an O 0 1.3583441926812156e-08
earlier O 0 4.2694395574471855e-07
date O 0 6.071210805203009e-07
than O 0 2.7116113798797414e-08
currently O 0 1.6734685459596221e-07
estimated O 0 8.782358804637624e-07
. O 0 9.466020287618448e-07

However O 0 2.5477640974713722e-06
, O 0 3.823795324819912e-08
the O 0 4.507214157456474e-09
different O 0 3.3918374775510074e-09
allelic O 0 3.222865530005947e-07
pattern O 0 2.5749802716745762e-06
at O 0 2.623071395646548e-07
the O 0 2.974007173861537e-08
BRCA1 O 0 1.4036910215509124e-05
locus O 0 6.858318215563486e-07
even O 0 3.179520646767742e-08
in O 0 3.3643123842352907e-09
some O 0 1.5922438922899573e-09
Jewish O 0 1.0233532066195039e-07
mutation O 0 5.780672722721647e-07
carriers O 0 4.646513929174034e-08
, O 0 1.5316032886403264e-08
might O 0 3.25778977128266e-08
suggest O 0 1.675623728658593e-08
that O 0 4.701211420155005e-09
the O 0 1.1833235724623137e-08
mutation O 0 7.145137601582974e-07
arose O 0 1.0361155489135854e-07
independently O 0 2.397262903741648e-07
. O 0 4.414360788018712e-08
. O 0 2.9628938591486076e-07

Crystal O 0 0.0016900041373446584
structure O 0 1.1516542144818231e-05
of O 0 2.630907829370699e-07
the O 0 1.4186205135047203e-06
hemochromatosis B-Disease 1 0.9999995231628418
protein O 0 3.774233118747361e-05
HFE O 0 0.00015374259965028614
and O 0 3.6726297025779786e-07
characterization O 0 1.1076622286054771e-06
of O 0 5.98559335429627e-09
its O 0 1.326957175251664e-07
interaction O 0 3.219368949203272e-08
with O 0 3.8646280842158376e-08
transferrin O 0 3.518630592225236e-06
receptor O 0 1.9191106730431784e-06
. O 0 6.248549766496581e-07

HFE O 0 0.006067776586860418
is O 0 4.9193458835361525e-06
an O 0 2.8328861390036764e-07
MHC O 0 8.428512956015766e-06
- O 0 2.5894334612530656e-05
related O 0 6.311939841907588e-07
protein O 0 2.7080741915597173e-07
that O 0 4.964446187472049e-09
is O 0 2.7828905846405405e-09
mutated O 0 5.3769483088217385e-08
in O 0 5.356432630776453e-09
the O 0 5.707466854687482e-08
iron B-Disease 0 0.36553698778152466
- I-Disease 1 0.999901533126831
overload I-Disease 1 0.9996602535247803
disease I-Disease 1 0.9999716281890869
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 0.00021429642220027745

HFE O 0 0.0018598117167130113
binds O 0 3.0006791348569095e-05
to O 0 2.507319777578232e-06
transferrin O 0 8.708193490747362e-06
receptor O 0 2.9412765343295177e-06
( O 0 2.0231634323408798e-07
TfR O 0 2.6557004275673535e-06
) O 0 2.167012347342734e-08
and O 0 1.3808198140452532e-08
reduces O 0 6.362149207461698e-08
its O 0 1.4460437292029837e-08
affinity O 0 1.640327162988342e-08
for O 0 1.0123780036508379e-08
iron O 0 5.050567779107951e-06
- O 0 2.4021862827794394e-06
loaded O 0 6.891710881973268e-07
transferrin O 0 7.407665520986484e-07
, O 0 3.301458306737004e-08
implicating O 0 2.9748521228611935e-06
HFE O 0 1.4830247891950421e-05
in O 0 1.299000160770447e-07
iron O 0 0.00017694612324703485
metabolism O 0 0.00015329729649238288
. O 0 2.301241465829662e-06

The O 0 7.486664799216669e-06
2 O 0 7.634957910340745e-06
. O 0 5.334130037226714e-06

6 O 0 3.4042473998852074e-05
A O 0 1.928728579514427e-06
crystal O 0 7.061684300424531e-05
structure O 0 2.1057392132206587e-06
of O 0 8.901499626290388e-08
HFE O 0 7.223732973216102e-05
reveals O 0 2.541854428272927e-06
the O 0 1.0858787646839119e-08
locations O 0 3.794328051753837e-07
of O 0 2.4205181148317934e-07
hemochromatosis B-Disease 1 1.0
mutations O 0 0.0009777424857020378
and O 0 2.443889854930603e-07
a O 0 3.5801775766231003e-07
patch O 0 0.007288056891411543
of O 0 1.4227541100808594e-07
histidines O 0 5.000685996492393e-05
that O 0 1.7906704385950434e-07
could O 0 1.1703032498644461e-07
be O 0 1.2008972483101843e-08
involved O 0 9.943945222801176e-09
in O 0 5.1022531977196195e-08
pH O 0 2.8759151973645203e-05
- O 0 3.721845496329479e-05
dependent O 0 5.023528046876891e-06
interactions O 0 5.420990873972187e-07
. O 0 5.122457764628052e-07

We O 0 5.4676338550052606e-06
also O 0 1.6456802143238747e-07
demonstrate O 0 7.990294648152485e-08
that O 0 1.8647707378249834e-08
soluble O 0 1.0049903949038708e-06
TfR O 0 9.759886779647786e-06
and O 0 1.1773647656809771e-07
HFE O 0 9.454378414375242e-06
bind O 0 6.56738563975523e-07
tightly O 0 7.954535590215528e-07
at O 0 2.3172687235728517e-07
the O 0 3.509793566891517e-09
basic O 0 5.371997247038962e-08
pH O 0 2.7956261305916996e-07
of O 0 1.9736585699092757e-09
the O 0 4.448125778822032e-08
cell O 0 2.871568540285807e-05
surface O 0 8.715372132428456e-06
, O 0 8.535446482937914e-08
but O 0 1.064526689020795e-08
not O 0 4.0648986399105524e-09
at O 0 1.4402522729994871e-08
the O 0 3.0083004531888946e-08
acidic O 0 1.4918663509888574e-05
pH O 0 3.060760263906559e-06
of O 0 3.5907806505974804e-08
intracellular O 0 5.347887508833082e-06
vesicles O 0 3.153208672301844e-05
. O 0 1.4317568002297776e-06

TfR O 0 0.3088682293891907
HFE O 0 0.019960995763540268
stoichiometry O 0 0.0002571709337644279
( O 0 3.516812512316392e-06
2 O 0 5.994735943204432e-07
1 O 0 2.0764814223639405e-07
) O 0 2.958866218705225e-08
differs O 0 1.5642179107544507e-07
from O 0 4.647524676215653e-08
TfR O 0 8.539086593373213e-06
transferrin O 0 2.5065212412300752e-06
stoichiometry O 0 6.437985575757921e-07
( O 0 2.9794177791586662e-08
2 O 0 1.5279930209999293e-07
2 O 0 4.716959267625498e-07
) O 0 2.414316035981301e-08
, O 0 8.822677699527048e-09
implying O 0 1.719002185041063e-08
a O 0 3.895048727997619e-09
different O 0 1.1017609047314636e-09
mode O 0 2.847691149554521e-08
of O 0 3.7315976975094145e-09
binding O 0 1.58924180482245e-07
for O 0 5.5184614211611915e-08
HFE O 0 1.957081440195907e-05
and O 0 2.4285276367663755e-07
transferrin O 0 8.831434570311103e-07
to O 0 1.7534824792164727e-07
TfR O 0 2.5697720502648735e-06
, O 0 2.2565492585613356e-08
consistent O 0 3.818052363158131e-08
with O 0 4.1807859396669755e-09
our O 0 3.858102815001985e-08
demonstration O 0 2.605414977097098e-07
that O 0 1.871794452767972e-08
HFE O 0 3.9606052268936764e-06
, O 0 3.884625954242438e-08
transferrin O 0 3.3139883726107655e-07
, O 0 3.730389863676464e-08
and O 0 2.603695570257969e-08
TfR O 0 8.886095201887656e-07
form O 0 1.945819860793563e-08
a O 0 1.1171436398171863e-07
ternary O 0 1.508432319496933e-06
complex O 0 2.400340463282191e-06
. O 0 1.833493229241867e-06

Identification O 0 3.998853571829386e-06
of O 0 1.4727042696449644e-07
three O 0 1.5073324277636857e-07
novel O 0 7.334376164180867e-07
mutations O 0 7.598284355481155e-06
and O 0 5.0022592290588364e-08
a O 0 5.6818002747149876e-08
high O 0 9.351511209843011e-08
frequency O 0 2.291691885147884e-07
of O 0 2.1202959388233467e-09
the O 0 2.4137312593097704e-08
Arg778Leu O 0 5.1389256441325415e-06
mutation O 0 4.2350106355115713e-07
in O 0 9.871474304645744e-09
Korean O 0 2.9867067041777773e-07
patients O 0 2.1766358315744583e-07
with O 0 5.154909388238593e-08
Wilson B-Disease 0 0.0001617381494725123
disease I-Disease 0 0.0002104236773448065
. O 0 1.133648424911371e-06

Four O 0 7.049256964819506e-06
mutations O 0 8.694738789927214e-05
- O 0 1.4838410606898833e-05
- O 0 1.7287964510614984e-05
R778L O 0 3.1304916774388403e-06
, O 0 2.4125945685682382e-08
A874V O 0 1.613308313608286e-07
, O 0 6.875198188538434e-09
L1083F O 0 5.395316904355241e-08
, O 0 4.808715647897088e-09
and O 0 7.162177517727741e-09
2304delC O 0 4.2275331679775263e-07
- O 0 7.222030262710177e-07
- O 0 1.5183027244347613e-06
in O 0 4.717966817224806e-08
the O 0 2.7744915698235673e-08
copper O 0 3.320402129247668e-06
- O 0 2.5451041096857807e-07
transporting O 0 1.0804249939155852e-07
enzyme O 0 6.48873239583736e-08
, O 0 9.582041826661225e-09
P O 0 1.0078678315039724e-05
- O 0 1.0530509371164953e-06
type O 0 4.942576765643025e-07
ATPase O 0 2.2087573597673327e-05
( O 0 1.1000106070468973e-07
ATP7B O 0 1.5232341866067145e-05
) O 0 1.740300525909788e-08
, O 0 5.470357056225339e-09
were O 0 1.1379434283753653e-08
identified O 0 1.5518821783189196e-07
in O 0 1.2584046693575601e-08
Korean O 0 3.639121075593721e-07
Patients O 0 2.1884082457290788e-07
with O 0 8.556278174864929e-08
Wilson B-Disease 0 0.0002476830268278718
disease I-Disease 0 0.0002150151995010674
. O 0 1.4175914202496642e-06

Arg778Leu O 0 0.0012295867782086134
, O 0 8.051026156863372e-07
the O 0 1.909338465111432e-08
most O 0 1.7242101080228167e-08
frequently O 0 2.2570104363239807e-07
reported O 0 2.3310649339691736e-06
mutation O 0 1.0716613729755409e-07
of O 0 1.9044528176692666e-09
this O 0 3.6811940162806422e-09
enzyme O 0 3.990668346887105e-07
, O 0 9.964321634470252e-08
was O 0 1.0183563290411257e-06
found O 0 3.93648633689736e-08
in O 0 3.4640106338912346e-09
six O 0 3.5939651255034732e-09
of O 0 1.8296997250644154e-09
eight O 0 9.402342016073817e-08
unrelated O 0 1.0757937616290292e-06
patients O 0 3.466802525053936e-07
studied O 0 3.8855304751450603e-08
, O 0 5.046512097095501e-09
an O 0 5.4537605542748224e-09
allele O 0 2.856095875358733e-07
frequency O 0 3.36446248638822e-07
of O 0 2.9478142593575285e-08
37 O 0 1.1329080962241278e-06
. O 0 5.533543117053341e-07

5 O 0 2.0766823581652716e-05
% O 0 6.041039455340069e-07
, O 0 3.553538974188086e-08
which O 0 1.5364308936227644e-08
is O 0 1.0536910011182954e-08
considerably O 0 1.660660728930452e-07
higher O 0 3.733942222083897e-08
than O 0 9.071350781653109e-09
those O 0 1.5051963009327096e-09
in O 0 1.810125827006459e-09
other O 0 6.192357293599571e-09
Asian O 0 9.35918507138922e-08
populations O 0 3.0503582593155443e-07
. O 0 2.8550829256346333e-07

The O 0 1.2063217127433745e-06
novel O 0 6.521861450892175e-07
single O 0 4.749423396788188e-07
nucleotide O 0 3.1270392355509102e-06
deletion O 0 8.210827218135819e-06
, O 0 7.200024754183687e-08
2304delC O 0 2.00986460185959e-06
, O 0 9.820097091051139e-08
was O 0 4.3422065232334717e-07
found O 0 5.6937665249279235e-08
in O 0 1.1124801524431405e-08
one O 0 2.9078870511511923e-07
patient O 0 2.293201305292314e-06
. O 0 5.586349516306655e-07

Since O 0 5.378453806770267e-06
a O 0 6.841398771939566e-07
mutation O 0 3.1578890684613725e-06
at O 0 1.6495802412919147e-07
cDNA O 0 2.1541977730521467e-06
nucleotide O 0 1.085137773770839e-05
2302 O 0 0.00011648023064481094
( O 0 2.023140268647694e-07
2302insC O 0 2.662108045115019e-06
) O 0 5.5661050879507457e-08
had O 0 3.2958814699668437e-07
been O 0 1.0668279770698064e-07
previously O 0 1.0110150014952524e-06
described O 0 1.4690167517983355e-06
, O 0 2.115271868774471e-08
this O 0 2.8703526222528808e-09
region O 0 6.885174741455558e-08
of O 0 1.935668958452652e-09
the O 0 2.0893685004352847e-08
ATP7B O 0 7.668168836971745e-05
gene O 0 5.751139724452514e-06
may O 0 1.0529174687690102e-06
be O 0 2.8410291008640343e-08
susceptible O 0 9.53092353483953e-07
to O 0 5.8956651116659486e-08
gene O 0 8.562637049180921e-06
rearrangements O 0 0.0004041173087898642
causing O 0 0.0008097420795820653
Wilson B-Disease 0 0.00040369064663536847
disease I-Disease 0 0.0012802239507436752
. O 0 3.778083055294701e-06

Disruption O 0 6.845752795925364e-05
of O 0 7.248637956536186e-08
splicing O 0 2.121544639521744e-06
regulated O 0 4.1756641167012276e-07
by O 0 1.7630528148515623e-08
a O 0 7.399264490004498e-08
CUG O 0 3.277660653111525e-05
- O 0 6.611383469135035e-06
binding O 0 1.9125643575534923e-06
protein O 0 7.724963325017598e-06
in O 0 7.235636076075025e-06
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 0.9999998807907104
. O 0 2.054225842584856e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9997151494026184
DM B-Disease 1 1.0
) O 0 8.187362982425839e-05
is O 0 4.6625740424133255e-07
caused O 0 4.687568093686423e-07
by O 0 1.3462526204932601e-08
a O 0 1.825817577127964e-07
CTG O 0 1.636562228668481e-05
expansion O 0 1.2168602836482023e-07
in O 0 1.717802611267416e-08
the O 0 1.6459745566521633e-08
3 O 0 4.0903213971432706e-07
untranslated O 0 2.0665673218900338e-05
region O 0 1.1174478231623652e-06
of O 0 4.0568835402154946e-08
the O 0 3.8078310353739653e-06
DM B-Disease 1 0.9999996423721313
gene O 0 4.904455636278726e-05
. O 0 1.308188984694425e-06

One O 0 1.7403889387423988e-06
model O 0 3.5006844427698525e-06
of O 0 1.3235564892966067e-06
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 0.007224927190691233
suggests O 0 1.1995176691925735e-06
that O 0 2.7075389041897324e-08
RNAs O 0 3.242664377012261e-07
from O 0 7.553060399345668e-09
the O 0 2.7327315965663956e-09
expanded O 0 1.972191832066983e-08
allele O 0 1.0380521331398995e-07
create O 0 6.9150472015167e-09
a O 0 2.220683548159741e-08
gain O 0 9.171527040052752e-07
- O 0 7.45544753044669e-07
of O 0 3.080662480670071e-08
- O 0 3.2756090604380006e-06
function O 0 1.2394555426453735e-07
mutation O 0 1.5782282503096212e-07
by O 0 1.5790215801558816e-09
the O 0 5.074880515820723e-09
inappropriate O 0 4.8181007628045336e-08
binding O 0 2.391491982223215e-08
of O 0 1.3835581569310307e-09
proteins O 0 8.930252981542708e-09
to O 0 1.064869881162167e-08
the O 0 3.3738821514361916e-08
CUG O 0 0.0002651453542057425
repeats O 0 3.999803084298037e-05
. O 0 5.913109362154501e-07

Data O 0 3.9961621951078996e-05
presented O 0 1.9231049463996897e-06
here O 0 1.196898296029758e-07
indicate O 0 9.732902839232338e-08
that O 0 3.8960217274564e-09
the O 0 6.760569881691936e-09
conserved O 0 2.36886634752409e-07
heterogeneous O 0 2.9487080155377043e-06
nuclear O 0 3.544060518834158e-06
ribonucleoprotein O 0 8.52781226967636e-07
, O 0 2.992574010818316e-08
CUG O 0 1.7993013443629025e-06
- O 0 7.326287914111163e-07
binding O 0 2.20289408048302e-07
protein O 0 3.7313864709176414e-07
( O 0 1.4262448999602384e-08
CUG O 0 1.240986239281483e-05
- O 0 5.551787398871966e-05
BP O 0 0.023811418563127518
) O 0 5.540810121829054e-08
, O 0 2.3705561957854115e-08
may O 0 1.9246371607550827e-07
mediate O 0 2.5652373096818337e-06
the O 0 1.0642285985795752e-07
trans O 0 1.326781784882769e-05
- O 0 9.547795343678445e-06
dominant O 0 2.0943814433849184e-06
effect O 0 1.1628559803966709e-07
of O 0 4.3891628109804515e-09
the O 0 2.713484370531205e-08
RNA O 0 4.837539563595783e-06
. O 0 1.139683035944472e-06

CUG O 0 0.05211999639868736
- O 0 0.1799442023038864
BP O 0 0.26131218671798706
was O 0 3.4078805128956446e-06
found O 0 4.9011301683776765e-08
to O 0 7.472600316305034e-09
bind O 0 4.0602746054219097e-08
to O 0 2.1429020335972382e-08
the O 0 6.57839365203472e-08
human O 0 3.005822691193316e-06
cardiac O 0 0.0017424669349566102
troponin O 0 5.961880015092902e-05
T O 0 0.0005532648647204041
( O 0 7.308988614340706e-08
cTNT O 0 7.200216600722342e-07
) O 0 1.7173503508161048e-08
pre O 0 4.1663207639430766e-07
- O 0 1.5047886563479551e-06
messenger O 0 9.278168704440759e-07
RNA O 0 2.427073582111916e-07
and O 0 7.95835042310955e-09
regulate O 0 2.5753454480081928e-08
its O 0 4.0135372358918175e-08
alternative O 0 3.2214796874541207e-07
splicing O 0 1.2268232239875942e-05
. O 0 9.162347964775108e-07

Splicing O 0 7.906569953775033e-05
of O 0 9.423056326340884e-07
cTNT O 0 3.2080261007649824e-05
was O 0 6.837733963038772e-06
disrupted O 0 0.00012395686644595116
in O 0 1.7595255485503003e-05
DM B-Disease 1 1.0
striated O 0 0.007493684533983469
muscle O 0 0.00011127649486297742
and O 0 2.2792724507780804e-07
in O 0 3.41575017159812e-08
normal O 0 4.6928599317652697e-07
cells O 0 1.1004058251273818e-06
expressing O 0 1.227974735229509e-07
transcripts O 0 5.082065968053939e-07
that O 0 3.9761030024010324e-08
contain O 0 3.232142375964031e-07
CUG O 0 0.0002557731932029128
repeats O 0 5.333974331733771e-05
. O 0 8.153234603014425e-07

Altered O 0 7.357485446846113e-05
expression O 0 2.6254540443915175e-06
of O 0 5.832026417351699e-08
genes O 0 6.533745704473404e-07
regulated O 0 7.012988589849556e-07
posttranscriptionally O 0 1.1239910236326978e-05
by O 0 1.1782498887669135e-07
CUG O 0 0.0002816527849063277
- O 0 0.0004048821283504367
BP O 0 0.016553720459342003
therefore O 0 8.308241490340151e-07
may O 0 4.207338406558847e-07
contribute O 0 8.810002327663824e-08
to O 0 2.729331754380837e-06
DM B-Disease 1 1.0
pathogenesis O 0 0.0013769363285973668
. O 0 2.6784570650306705e-07
. O 0 5.751604703618796e-07

Identification O 0 1.1723194802470971e-05
of O 0 1.6930559354477737e-07
a O 0 4.0596438566353754e-07
novel O 0 1.8262772982780007e-06
nonsense O 0 8.47139108373085e-06
mutation O 0 2.7992571176582715e-06
and O 0 2.9060398532010367e-08
a O 0 4.117415741689001e-08
missense O 0 8.490079039802367e-07
substitution O 0 4.664770969498022e-08
in O 0 1.925033110694585e-08
the O 0 2.0808972323038688e-08
vasopressin O 0 2.1647688299708534e-06
- O 0 1.0518362614675425e-05
neurophysin O 0 1.815568612073548e-05
II O 0 2.660526888575987e-06
gene O 0 1.1659919607609481e-07
in O 0 2.929031683862604e-09
two O 0 1.3112045671448413e-08
Spanish O 0 2.91126127649477e-07
kindreds O 0 8.630157026345842e-06
with O 0 2.8774866223102435e-07
familial B-Disease 0 0.0865154042840004
neurohypophyseal I-Disease 1 0.9996322393417358
diabetes I-Disease 1 0.9999140501022339
insipidus I-Disease 0 0.44958609342575073
. O 0 7.857215678086504e-06

Familial B-Disease 1 0.9999005794525146
neurohypophyseal I-Disease 1 0.9999856948852539
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999935626983643
( O 0 0.03541380912065506
FNDI B-Disease 1 0.9999998807907104
) O 0 3.6453004668146605e-06
is O 0 3.533014591994288e-08
an O 0 1.4535963543949038e-07
autosomal B-Disease 1 0.994776725769043
dominant I-Disease 1 0.9648473858833313
disease I-Disease 1 0.9972963929176331
caused O 0 3.2130319596035406e-05
by O 0 9.113641681324225e-07
deficiency O 0 0.0003908754442818463
in O 0 4.6397303776757326e-08
the O 0 3.16638534059166e-07
antidiuretic O 0 0.0002851645404007286
hormone O 0 7.923146768007427e-06
arginine O 0 4.129199624003377e-06
vasopressin O 0 2.7447035790828522e-06
( O 0 3.001462900442675e-08
AVP O 0 1.5171131053648423e-06
) O 0 3.1172600056805777e-09
encoded O 0 9.031849934615366e-09
by O 0 1.7584275147086714e-09
the O 0 2.1932173410732503e-08
AVP O 0 0.0001070357538992539
- O 0 9.73082278505899e-05
neurophysin O 0 9.399141708854586e-05
II O 0 2.2100868591223843e-05
( O 0 8.467456069638502e-08
AVP O 0 1.314222754444927e-05
- O 0 8.758615877013654e-06
NPII O 0 2.4753197067184374e-05
) O 0 1.553089745698344e-08
gene O 0 8.58627728916872e-08
on O 0 3.1120225685299374e-07
chromosome O 0 0.00011636588169494644
20p13 O 0 1.722237175272312e-05
. O 0 1.113433086175064e-06

In O 0 2.1004123027523747e-06
this O 0 7.560154813290865e-08
study O 0 8.679820240331537e-08
, O 0 6.296476584566335e-08
we O 0 3.332045395154637e-08
analyzed O 0 6.2448563653561e-08
two O 0 4.943714770888619e-09
families O 0 8.759130309954344e-09
with O 0 1.623661205485405e-08
FNDI B-Disease 1 0.9997830986976624
using O 0 7.041276717245637e-08
direct O 0 3.7739667391178955e-08
automated O 0 1.8110577002516948e-06
fluorescent O 0 2.273211663350594e-07
, O 0 1.465407262202234e-08
solid O 0 7.689219927442537e-08
phase O 0 6.604089719530748e-08
, O 0 7.198031060084986e-09
single O 0 2.7605823404996954e-08
- O 0 9.407971788277791e-07
stranded O 0 1.9346204283010593e-07
DNA O 0 1.1649427733573248e-07
sequencing O 0 3.4952584826442035e-08
of O 0 1.5212319182111855e-09
PCR O 0 1.247333216269908e-06
- O 0 3.072077333854395e-06
amplified O 0 9.764281458046753e-06
AVP O 0 2.8227586881257594e-05
- O 0 7.590664608869702e-06
NPII O 0 3.1039871828397736e-05
DNA O 0 1.4374947568285279e-05
. O 0 7.115183962014271e-07

In O 0 2.1247719814709853e-06
one O 0 1.119547690109357e-07
of O 0 4.100790373939844e-09
the O 0 1.2142305827467226e-08
families O 0 4.3372271107955385e-08
, O 0 6.042674982609242e-08
affected O 0 4.778982898301365e-08
individuals O 0 3.195697262370345e-09
presented O 0 4.9799833590213893e-08
a O 0 4.566003397599161e-08
novel O 0 3.429214530115132e-07
nonsense O 0 1.8666124788069283e-06
mutation O 0 2.3481283051296487e-07
in O 0 1.0463968358465081e-08
exon O 0 4.4180504232826934e-07
3 O 0 8.216117919346289e-08
of O 0 2.894532169506192e-09
the O 0 1.5358509131147002e-08
gene O 0 3.290033703251538e-07
, O 0 6.242400374389945e-09
consisting O 0 1.5890159188458597e-09
in O 0 5.028794269890113e-09
a O 0 1.1730072912996548e-07
G O 0 5.302423596731387e-05
to O 0 2.5208635179296834e-07
T O 0 3.964985080529004e-05
transition O 0 8.026327691368351e-08
at O 0 6.581004186045902e-08
nucleotide O 0 3.6787150747841224e-07
2101 O 0 1.2970805300938082e-06
, O 0 1.934902194022925e-08
which O 0 1.057726173314677e-08
produces O 0 3.7680759845670764e-08
a O 0 1.4761177169475559e-08
stop O 0 1.8184324801495677e-07
signal O 0 4.786855924976408e-07
in O 0 2.890368300256796e-08
codon O 0 1.9604381122917403e-06
82 O 0 6.184982339618728e-07
( O 0 5.553527770985056e-08
Glu O 0 2.5369032300659455e-05
) O 0 3.276634785720489e-08
of O 0 3.4466395959498186e-08
NPII O 0 0.0003074849955737591
. O 0 2.980958015541546e-06

The O 0 1.4464678315562196e-05
premature O 0 0.00013017003948334605
termination O 0 6.298407697613584e-06
eliminates O 0 6.440496918003191e-07
part O 0 3.050538310844786e-08
of O 0 4.309304468819164e-09
the O 0 2.5940938286339588e-08
C O 0 9.219274943461642e-06
- O 0 5.085700649942737e-06
terminal O 0 5.256307758827461e-06
domain O 0 4.149035959244429e-08
of O 0 3.490293387642396e-09
NPII O 0 8.681808139954228e-06
, O 0 6.011312780884737e-09
including O 0 6.455519452330805e-10
a O 0 2.690456746279324e-09
cysteine O 0 1.0307832809530737e-08
residue O 0 2.590919905287592e-07
in O 0 9.596710093262573e-09
position O 0 1.9000206918917684e-07
85 O 0 4.636130057633636e-08
, O 0 1.8919772415415537e-08
which O 0 2.7892047782529517e-08
could O 0 7.816358049694827e-08
be O 0 1.890945711124914e-08
involved O 0 1.1572796054792889e-08
in O 0 2.294009071590608e-08
the O 0 8.566516385144496e-08
correct O 0 1.544828228361439e-05
folding O 0 1.964398279596935e-06
of O 0 1.276392058713327e-08
the O 0 1.2355727108115389e-07
prohormone O 0 0.0002682195627130568
. O 0 1.4159146530801081e-06

In O 0 2.4201174255722435e-06
the O 0 6.217248227358141e-08
second O 0 1.0459217492098105e-06
family O 0 2.7264599111731513e-07
, O 0 1.4740695775117274e-08
a O 0 6.030479671181865e-09
G279A O 0 4.018799870664225e-08
substitution O 0 8.495535830377321e-09
at O 0 6.119737605558839e-08
position O 0 7.198761409199506e-08
- O 0 5.761942816207011e-07
1 O 0 3.6542555648111374e-08
of O 0 9.463902994610862e-10
the O 0 6.028467058882825e-09
signal O 0 5.971758127998328e-07
peptide O 0 7.104153354475784e-08
was O 0 1.5390259022751707e-07
observed O 0 2.555050393482361e-08
in O 0 3.04012748308935e-09
all O 0 9.029248460024064e-09
affected O 0 1.4872360054596356e-07
individuals O 0 6.190693824237314e-08
. O 0 4.186665307770454e-07

This O 0 3.582787712730351e-06
missense O 0 0.0002554889942985028
mutation O 0 0.00010147218563361093
, O 0 4.4527692466544977e-07
which O 0 2.0585778770509933e-07
replaces O 0 1.3537898666982073e-05
Ala O 0 1.0070762073155493e-05
with O 0 8.463871381536592e-08
Thr O 0 0.0020019307266920805
, O 0 8.684556718208114e-08
is O 0 8.947302454487271e-09
frequent O 0 2.1570089359101985e-07
among O 0 5.794676098958007e-07
FNDI B-Disease 1 1.0
patients O 0 7.370814273599535e-05
and O 0 6.0749286490136e-08
is O 0 1.7455862533211075e-08
thought O 0 1.3273693255655417e-08
to O 0 5.0981747712341985e-09
reduce O 0 6.319420720046764e-08
the O 0 2.669682475087143e-09
efficiency O 0 5.062373631403716e-08
of O 0 4.59572513378248e-09
cleavage O 0 3.8138059608172625e-06
by O 0 7.788885625359399e-08
signal O 0 4.5934934860270005e-06
peptidases O 0 9.968186532205436e-06
. O 0 8.350645686050484e-08
. O 0 2.879188230053842e-07

Genetic O 0 0.00043069824459962547
heterogeneity O 0 5.86684764130041e-05
of O 0 4.871845931120333e-07
Saethre B-Disease 0 0.05275699496269226
- I-Disease 1 0.9985365867614746
Chotzen I-Disease 1 0.9998632669448853
syndrome I-Disease 1 0.9999970197677612
, O 0 1.118200998462271e-07
due O 0 1.1537096611391462e-07
to O 0 6.245129924309367e-08
TWIST O 0 2.4912194930948317e-05
and O 0 1.3748667697655037e-06
FGFR O 0 0.0006855357205495238
mutations O 0 9.003562445286661e-05
. O 0 9.270907526115479e-07

Thirty O 0 3.428568015806377e-05
- O 0 4.328996510594152e-05
two O 0 1.6377829581415426e-07
unrelated O 0 1.2310579222685192e-06
patients O 0 3.3465548199274053e-07
with O 0 2.2018380452237807e-09
features O 0 1.2255213732714765e-07
of O 0 5.292364946285488e-08
Saethre B-Disease 0 0.06608445197343826
- I-Disease 1 0.9917418956756592
Chotzen I-Disease 1 0.9994320273399353
syndrome I-Disease 1 0.9998786449432373
, O 0 9.320346272545521e-09
a O 0 4.29384918732012e-08
common O 0 3.2720186027290765e-06
autosomal B-Disease 0 0.05601869523525238
dominant I-Disease 0 0.00019190646708011627
condition I-Disease 0 0.0004062329535372555
of O 0 4.923467145090399e-07
craniosynostosis B-Disease 1 0.7330378293991089
and O 0 0.0003151041455566883
limb B-Disease 1 0.9554562568664551
anomalies I-Disease 0 0.4484064280986786
, O 0 3.1798666100257833e-07
were O 0 6.219691073283684e-08
screened O 0 2.8206954993947875e-07
for O 0 2.017267419773816e-08
mutations O 0 8.587511501900735e-07
in O 0 3.53021896160044e-08
TWIST O 0 3.0198931199265644e-05
, O 0 4.62790467281593e-07
FGFR2 O 0 4.4843753130408004e-05
, O 0 7.424965531299677e-08
and O 0 2.14402888332188e-07
FGFR3 O 0 0.00018321994866710156
. O 0 1.2272751064301701e-06

Nine O 0 1.3698562725039665e-05
novel O 0 2.2962606180954026e-06
and O 0 1.8286476688444964e-07
three O 0 1.2318899678120943e-07
recurrent O 0 2.557943844294641e-05
TWIST O 0 0.00013046676758676767
mutations O 0 0.0001605269790161401
were O 0 3.0412491014431e-07
found O 0 1.0754597923323672e-07
in O 0 3.7241903783069574e-08
12 O 0 2.2539087751738407e-07
families O 0 1.7355876025249017e-07
. O 0 6.410005539692065e-07

Seven O 0 7.805541827110574e-06
families O 0 1.7218345647052047e-06
were O 0 3.254430964716448e-07
found O 0 7.4698675689433e-08
to O 0 1.601296339970304e-08
have O 0 7.2420429653163865e-09
the O 0 1.1423797019460835e-08
FGFR3 O 0 1.2907594282296486e-05
P250R O 0 7.464233249265817e-07
mutation O 0 6.06214427989471e-07
, O 0 1.769190305367374e-08
and O 0 1.581288877616771e-08
one O 0 1.9940392448347666e-08
individual O 0 1.2057238762963607e-08
was O 0 1.8392515812593047e-06
found O 0 8.679671736899763e-08
to O 0 1.6799246438381488e-08
have O 0 1.127417892377025e-08
an O 0 1.552367123736076e-08
FGFR2 O 0 1.4887536963215098e-05
VV269 O 0 1.0585031304799486e-06
- O 0 4.425869974511443e-06
270 O 0 2.3897196115285624e-06
deletion O 0 2.9116019504726864e-05
. O 0 8.487974128001952e-07

To O 0 3.4251950182806468e-06
date O 0 1.1476560075607267e-06
, O 0 2.9911248589087336e-08
our O 0 2.1115230453006006e-08
detection O 0 9.816876200829938e-08
rate O 0 1.79489347829076e-07
for O 0 6.9155481341454106e-09
TWIST O 0 2.5499248295091093e-06
or O 0 5.743755195908307e-07
FGFR O 0 4.108478970010765e-05
mutations O 0 2.3406548734783428e-06
is O 0 8.673412210669085e-09
68 O 0 5.19233829265886e-08
% O 0 7.867643425640836e-09
in O 0 5.187415386131988e-09
our O 0 2.494412001396995e-07
Saethre B-Disease 0 0.0033257941249758005
- I-Disease 1 0.9918516278266907
Chotzen I-Disease 1 0.9998076558113098
syndrome I-Disease 1 0.9999974966049194
patients O 0 4.4387920752342325e-06
, O 0 2.94776203446645e-09
including O 0 1.6272632130664988e-09
our O 0 3.4771321821835954e-08
five O 0 2.5264884584430547e-07
patients O 0 2.521673820865544e-07
elsewhere O 0 1.4528174574479635e-07
reported O 0 1.4540582924382761e-06
with O 0 3.495565081834684e-08
TWIST O 0 0.00031639524968340993
mutations O 0 0.00020538725948426872
. O 0 1.2282738452995545e-06

More O 0 4.989438480151875e-07
than O 0 1.2469557475469628e-07
35 O 0 6.383980633017927e-08
different O 0 4.992953606119954e-09
TWIST O 0 2.11811584449606e-06
mutations O 0 9.867777407635003e-06
are O 0 1.3797929909742379e-08
now O 0 2.1430574648206857e-08
known O 0 2.2494887730317714e-08
in O 0 1.0629785940352576e-08
the O 0 2.0975621239927023e-08
literature O 0 1.3661083642091398e-07
. O 0 3.706312838858139e-07

The O 0 6.422874889722152e-07
most O 0 6.67673916154854e-08
common O 0 4.995842317612187e-08
phenotypic O 0 1.9150506602727546e-07
features O 0 2.7278022685095493e-07
, O 0 5.500386990320294e-08
present O 0 5.070942776796983e-09
in O 0 3.8312690797681626e-09
more O 0 2.780025543103193e-09
than O 0 2.0368917663660113e-09
a O 0 1.5722184443234255e-08
third O 0 5.365714059735183e-07
of O 0 8.314088972838363e-09
our O 0 6.679566695311223e-07
patients O 0 9.040953585781608e-08
with O 0 2.690980105413132e-09
TWIST O 0 2.2470447220257483e-05
mutations O 0 1.1129704034829047e-05
, O 0 1.5224635774302442e-08
are O 0 6.386633000232678e-09
coronal B-Disease 0 1.9879682440659963e-05
synostosis I-Disease 0 3.7947436794638634e-05
, O 0 9.785656374106111e-08
brachycephaly B-Disease 0 9.291023161495104e-06
, O 0 1.2328349896506552e-07
low B-Disease 0 9.246543413610198e-06
frontal I-Disease 0 0.18967577815055847
hairline I-Disease 1 0.9999574422836304
, O 0 3.088231824222021e-05
facial B-Disease 1 0.8191229701042175
asymmetry I-Disease 0 0.0003670920559670776
, O 0 5.311297627486056e-06
ptosis B-Disease 0 0.02616771124303341
, O 0 1.371828261653718e-06
hypertelorism B-Disease 0 9.967354708351195e-05
, O 0 1.0116604443055621e-07
broad B-Disease 0 2.6363733240941656e-07
great I-Disease 0 5.256641202322498e-07
toes I-Disease 0 0.0017161488067358732
, O 0 2.109146635120851e-07
and O 0 2.77097001344373e-07
clinodactyly B-Disease 0 8.207140490412712e-05
. O 0 1.302755890719709e-06

Significant O 0 5.088252692075912e-06
intra O 0 1.7004189430736005e-05
- O 0 9.268006397178397e-05
and O 0 8.015348953449575e-07
interfamilial O 0 4.466219979804009e-05
phenotypic O 0 9.87156181508908e-06
variability O 0 1.830587825679686e-05
is O 0 5.986577633620982e-08
present O 0 1.613033795422325e-08
for O 0 1.290413464971607e-08
either O 0 6.257423024180753e-08
TWIST O 0 7.589180313516408e-05
mutations O 0 8.375320612685755e-05
or O 0 9.706677701615263e-07
FGFR O 0 0.0006296193460002542
mutations O 0 9.733280603541061e-05
. O 0 1.3200522062106756e-06

The O 0 1.133100340666715e-06
overlap O 0 2.4321532237081556e-06
in O 0 2.2902237617472565e-07
clinical O 0 4.91323248752451e-07
features O 0 2.0233950692727376e-07
and O 0 1.3384722308273922e-07
the O 0 1.8684485070252776e-08
presence O 0 3.1849708648223896e-08
, O 0 1.2095659585042995e-08
in O 0 1.2343962518812646e-09
the O 0 1.1063199245597843e-09
same O 0 1.0391452143210245e-08
genes O 0 3.308916163291542e-08
, O 0 4.765163819087093e-09
of O 0 1.8472113838541304e-09
mutations O 0 1.9253127447882434e-07
for O 0 5.2438404729571175e-09
more O 0 5.5582618507799e-09
than O 0 1.0453914178754076e-08
one O 0 1.9348769342286687e-07
craniosynostotic B-Disease 0 7.35973080736585e-05
condition I-Disease 0 6.470610514952568e-06
- O 0 5.142550776326971e-07
such O 0 1.0504602521166362e-08
as O 0 7.95383243712422e-08
Saethre B-Disease 0 1.5581043044221587e-05
- I-Disease 0 1.218693250848446e-05
Chotzen I-Disease 0 1.2842039723182097e-05
, I-Disease 0 5.018438642423462e-08
Crouzon I-Disease 0 1.761968974278716e-06
, I-Disease 0 4.846322099183453e-08
and I-Disease 0 4.267192537099618e-07
Pfeiffer I-Disease 0 0.41741153597831726
syndromes I-Disease 0 0.0019225870491936803
- O 0 5.583411166298902e-06
support O 0 4.963918698308589e-08
the O 0 2.877513338717108e-08
hypothesis O 0 3.438603641825466e-07
that O 0 1.1567721003302722e-08
TWIST O 0 1.2979702432858176e-06
and O 0 8.493077530147275e-08
FGFRs O 0 8.563279152440373e-07
are O 0 1.7282457687173292e-09
components O 0 1.3125607267738815e-08
of O 0 7.997026374439997e-10
the O 0 4.270471531953035e-09
same O 0 1.7869474788767548e-08
molecular O 0 1.818366399675142e-07
pathway O 0 7.100305765561643e-08
involved O 0 2.2576641001137432e-08
in O 0 4.2263095245687055e-09
the O 0 8.475806723140522e-09
modulation O 0 9.026614407048328e-07
of O 0 1.5389922225494956e-07
craniofacial O 0 0.14131690561771393
and O 0 1.0573536201263778e-05
limb O 0 0.0001317819842370227
development O 0 1.4235710921184364e-07
in O 0 9.667721911910121e-08
humans O 0 3.6167358530292404e-07
. O 0 1.0096518110458419e-07
. O 0 4.1385092686141434e-07

Mutation O 0 0.0004371214599814266
analysis O 0 9.083401891984977e-06
of O 0 9.528660598334682e-07
UBE3A O 1 0.6891217231750488
in O 0 0.4884403347969055
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.19391924142837524
. O 0 6.940479124750709e-06

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.06396719813346863
AS B-Disease 1 0.9999384880065918
) O 0 1.3846605497747078e-06
is O 0 1.1861486370889907e-07
caused O 0 6.92274284119776e-07
by O 0 6.21262472577655e-08
chromosome O 0 0.00011893860209966078
15q11 O 0 4.846728188567795e-06
- O 0 4.978814104106277e-06
q13 O 0 8.820559287414653e-07
deletions O 0 1.6691791415723856e-06
of O 0 1.4926349933830352e-08
maternal O 0 2.251076239190297e-06
origin O 0 2.432338419566804e-07
, O 0 3.916624891076026e-08
by O 0 3.9964948683746115e-08
paternal O 0 2.3599113774253055e-05
uniparental B-Disease 0 0.028776511549949646
disomy I-Disease 0 0.4525538980960846
( O 0 8.739575605432037e-06
UPD B-Disease 1 0.9999974966049194
) O 0 4.5609161247739394e-07
15 O 0 4.801504971396753e-08
, O 0 1.0034618469489942e-08
by O 0 2.7418485260000125e-08
imprinting O 0 0.013373739086091518
defects O 1 0.9961655139923096
, O 0 1.0603687883303792e-07
and O 0 5.3025502211312414e-08
by O 0 1.583697439855314e-08
mutations O 0 8.401487434639421e-07
in O 0 1.0963593588542153e-08
the O 0 1.0343799061729442e-07
UBE3A O 0 0.00018563770572654903
gene O 0 1.2005021744698752e-05
. O 0 7.973652600412606e-07

UBE3A O 0 0.0016301778377965093
encodes O 0 4.0414073737338185e-05
a O 0 2.482259787939256e-06
ubiquitin O 0 7.217470283649163e-06
- O 0 7.617874416609993e-06
protein O 0 1.5727935078757582e-06
ligase O 0 6.181898584145529e-07
and O 0 2.0669108380388934e-07
shows O 0 7.464169584636693e-07
brain O 0 3.7378875276772305e-05
- O 0 7.227243258967064e-06
specific O 0 6.614855578845891e-07
imprinting O 0 0.00012640813656616956
. O 0 2.0008567389595555e-06

Here O 0 4.8761689868115354e-06
we O 0 4.2051203763548983e-07
describe O 0 1.6241682487816433e-06
UBE3A O 0 8.770791464485228e-05
coding O 0 0.00016637523367535323
- O 0 0.00010957846825476736
region O 0 2.6670488296076655e-05
mutations O 0 2.6008894565165974e-05
detected O 0 1.9175338366039796e-06
by O 0 9.242842935464068e-09
SSCP O 0 1.0571820894256234e-05
analysis O 0 2.969915442463389e-07
in O 0 7.600826279485773e-08
13 O 0 7.089844871188689e-07
AS B-Disease 1 0.9854720234870911
individuals O 0 3.345444099522865e-08
or O 0 2.2792987408593035e-07
families O 0 4.392989012558246e-07
. O 0 1.2057937510689953e-06

Two O 0 2.7786570626631146e-06
identical O 0 7.160204404499382e-06
de O 0 9.960973329725675e-06
novo O 0 2.6071449610753916e-05
5 O 0 1.059610099218844e-06
- O 0 1.5123247976589482e-05
bp O 0 7.337753777392209e-05
duplications O 0 1.8990981516253669e-06
in O 0 2.99145561655223e-08
exon O 0 2.163850467695738e-06
16 O 0 1.457041207686416e-07
were O 0 8.325787348439917e-08
found O 0 2.69834742994135e-07
. O 0 4.349766413724865e-07

Among O 0 5.412864538811846e-07
the O 0 2.7446949601994675e-08
other O 0 7.336430130067129e-09
11 O 0 1.9647915294740415e-08
unique O 0 1.5208238224317938e-08
mutations O 0 1.5797655805727118e-06
, O 0 1.3990324454482561e-08
8 O 0 2.910721796922644e-08
were O 0 5.553620230358547e-09
small O 0 5.30043386959278e-09
deletions O 0 6.455192647081276e-07
or O 0 1.38618233336274e-07
insertions O 0 5.914563189435285e-06
predicted O 0 5.107141623739153e-05
to O 0 3.8357609355443856e-07
cause O 0 1.0804864132296643e-06
frameshifts O 0 2.1088817447889596e-05
, O 0 1.4517870283725642e-07
1 O 0 1.7219660719547392e-07
was O 0 1.7604929780645762e-07
a O 0 3.061835229800636e-08
mutation O 0 7.937812540603773e-08
to O 0 7.722522177289193e-09
a O 0 2.919929897871043e-08
stop O 0 3.50036970075962e-07
codon O 0 3.217006110389775e-07
, O 0 1.7376668992596933e-08
1 O 0 2.7340153252453092e-08
was O 0 6.228749072079154e-08
a O 0 3.285069993808065e-08
missense O 0 4.677142442233162e-06
mutation O 0 1.5949095768519328e-06
, O 0 1.4868667186362927e-08
and O 0 2.7715771011571633e-08
1 O 0 5.834384637637413e-07
was O 0 6.946047506062314e-06
predicted O 0 8.362905646208674e-06
to O 0 5.996188434664873e-08
cause O 0 7.378716304629052e-08
insertion O 0 1.4249199864480033e-07
of O 0 6.149783793318875e-09
an O 0 1.5669560582409758e-07
isoleucine O 0 0.0013356271665543318
in O 0 5.829902249843144e-08
the O 0 1.4291068772820381e-08
hect O 0 1.3151189932614216e-06
domain O 0 2.4369393614165347e-08
of O 0 1.0445975195949586e-09
the O 0 1.1068354233145783e-08
UBE3A O 0 2.199939217462088e-06
protein O 0 2.398962237748492e-07
, O 0 3.2055440524203505e-09
which O 0 1.5418200050021369e-09
functions O 0 1.3961473088741627e-09
in O 0 4.473102777069471e-09
E2 O 0 1.1413710581109626e-06
binding O 0 1.565614837772955e-07
and O 0 3.1192719518458034e-08
ubiquitin O 0 2.390477789049328e-07
transfer O 0 6.602194275728834e-07
. O 0 7.362379506048455e-07

Eight O 0 3.621150653998484e-06
of O 0 4.3922721459921377e-08
the O 0 2.919373010001891e-08
cases O 0 6.116890460816649e-08
were O 0 1.1944477762426686e-07
familial O 0 8.32160822028527e-06
, O 0 4.8481160774827e-07
and O 0 1.3099163709284767e-07
five O 0 8.923004202188167e-08
were O 0 1.7981726330162928e-07
sporadic O 0 3.7874478948651813e-06
. O 0 1.4128742122920812e-06

In O 0 1.8248930473419023e-06
two O 0 3.333590541387821e-07
familial O 0 0.00035758610465563834
cases O 0 1.0446834494359791e-05
and O 0 7.524520242441213e-07
one O 0 2.412912465388217e-07
sporadic O 0 4.302344223106047e-06
case O 0 9.54409415498958e-07
, O 0 1.1134549993130349e-07
mosaicism O 0 1.0235626177745871e-05
for O 0 8.920110161625416e-08
UBE3A O 0 7.897949399193749e-05
mutations O 0 2.4866192688932642e-05
was O 0 1.5817373650861555e-06
detected O 0 1.021309230964107e-06
in O 0 1.4092845113111707e-08
the O 0 1.9675779228123247e-08
mother O 0 1.238495428879105e-06
of O 0 4.380139362325508e-09
three O 0 4.09602478157467e-07
AS B-Disease 1 0.999987006187439
sons O 0 1.6898015019251034e-05
, O 0 2.1727529997406236e-08
in O 0 6.768349880559299e-09
the O 0 1.926531822959987e-08
maternal O 0 8.761102776588814e-07
grandfather O 0 4.345234856373281e-07
of O 0 6.575693767274515e-09
two O 0 2.7198584007237514e-07
AS B-Disease 1 0.9997723698616028
first O 0 2.920684664786677e-06
cousins O 0 5.259196314000292e-06
, O 0 5.238205247337646e-08
and O 0 1.7075127090038222e-08
in O 0 1.452947184787945e-08
the O 0 2.1074752609706593e-08
mother O 0 8.183600357369869e-07
of O 0 4.496480965343608e-09
an O 0 4.7138246372924186e-07
AS B-Disease 1 0.9999449253082275
daughter O 0 0.0006358283571898937
. O 0 1.1569583193704602e-06

The O 0 4.2034079683617165e-07
frequencies O 0 2.811183605899714e-07
with O 0 1.8708627536057065e-08
which O 0 2.3710354568606817e-08
we O 0 2.9842805560065244e-08
detected O 0 4.603948582371231e-07
mutations O 0 4.062126492954121e-07
were O 0 3.232678125186794e-08
5 O 0 6.094089144426107e-08
( O 0 1.2020911377419452e-08
14 O 0 8.127199180307798e-08
% O 0 9.413391843793306e-09
) O 0 1.587519338208665e-09
of O 0 1.0021110607993933e-09
35 O 0 6.85740388917111e-08
in O 0 1.5130376951333346e-08
sporadic O 0 1.5953233969412395e-06
cases O 0 8.23791381776573e-08
and O 0 1.0010172246666116e-07
8 O 0 3.403654034173087e-07
( O 0 1.3826486622292578e-08
80 O 0 1.8915010002729105e-08
% O 0 9.235899156578853e-09
) O 0 2.2889337092379947e-09
of O 0 1.4316761109967047e-09
10 O 0 7.161224147012035e-08
in O 0 6.980607025752761e-08
familial O 0 4.43811368313618e-05
cases O 0 5.242008001005161e-07
. O 0 8.349451263711671e-08
. O 0 7.760737616990809e-07

The O 0 3.599591946112923e-05
hemochromatosis B-Disease 1 0.9999954700469971
845 O 0 0.00022809221991337836
G O 0 0.0010221973061561584
- O 0 3.1082166970008984e-05
- O 0 1.7627991837798618e-05
> O 0 2.0919091525684053e-07
A O 0 9.965708613890456e-08
and O 0 2.670508791879911e-08
187 O 0 4.8905594240977734e-08
C O 0 9.46228283282835e-07
- O 0 2.8594938612513943e-06
- O 0 2.5574412575224414e-05
> O 0 1.4154420568956994e-06
G O 0 5.981355570838787e-05
mutations O 0 5.218000296736136e-06
: O 0 1.6241443745457218e-08
prevalence O 0 5.131591365170607e-07
in O 0 9.923236454767448e-09
non O 0 5.458643954625586e-07
- O 0 2.9746746804448776e-05
Caucasian O 0 0.0001224166771862656
populations O 0 3.704845994434436e-06
. O 0 1.0600841733321431e-06

Hemochromatosis B-Disease 1 0.9960089921951294
, O 0 6.442402809625491e-05
the O 0 3.773448406718671e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 4.999016596229922e-07
iron I-Disease 0 0.10494217276573181
metabolism I-Disease 0 0.006098266690969467
, O 0 2.447108045089408e-07
leads O 0 7.338672389778367e-07
, O 0 1.4929315739209414e-07
if O 0 1.7695488452318386e-07
untreated O 0 1.0783764992083889e-05
, O 0 2.0416146995216877e-08
to O 0 4.671885633911188e-08
progressive O 0 1.1360651114955544e-05
iron B-Disease 0 0.09345342963933945
overload I-Disease 0 0.0051426962018013
and O 0 8.605624316260219e-06
premature B-Disease 0 4.3798438127851114e-05
death I-Disease 0 4.6150180423865095e-06
. O 0 4.496500594086683e-07

The O 0 4.960509613738395e-05
hemochromatosis B-Disease 1 0.9999978542327881
gene O 0 0.00021855815430171788
, O 0 9.238331699634728e-07
HFE O 0 0.00015357906522694975
, O 0 8.87058320131473e-07
recently O 0 1.6479699525007163e-06
has O 0 2.488557129254332e-07
been O 0 1.2432153084773745e-07
identified O 0 6.092555508985242e-07
, O 0 1.9679308849163135e-08
and O 0 8.649458038689772e-09
characterization O 0 2.7573204874897783e-07
of O 0 5.26157339919564e-09
this O 0 1.734276544596014e-08
gene O 0 2.604123210403486e-07
has O 0 2.0828439062370308e-07
shown O 0 4.6532900199736105e-08
that O 0 3.547009574944582e-09
it O 0 1.0945750084090378e-08
contains O 0 1.572145746919773e-09
two O 0 1.2754526323988102e-08
mutations O 0 3.7592397461594373e-07
that O 0 2.7137727620640817e-09
result O 0 6.3763234692260085e-09
in O 0 1.7369635729735933e-09
amino O 0 2.8382773464841193e-08
acid O 0 6.972409494210297e-08
substitutions O 0 3.3720230163680753e-08
- O 0 5.513327394623957e-08
cDNA O 0 1.6904230903946882e-07
nucleotides O 0 8.842813770115754e-08
845 O 0 2.5947130666281737e-07
G O 0 3.1665256301494082e-06
- O 0 2.9407044621621026e-06
- O 0 3.602989863793482e-06
> O 0 9.099531439460407e-08
A O 0 3.38192080562294e-07
( O 0 1.6893295651243534e-08
C282Y O 0 7.098113030679087e-08
) O 0 2.5306434725536064e-09
and O 0 5.2229180980134515e-09
187 O 0 3.2140800243496415e-08
C O 0 1.2501055834945873e-06
- O 0 1.3515673344954848e-05
- O 0 0.00022810156224295497
> O 0 3.5396085422689794e-06
G O 0 0.00015087149222381413
( O 0 1.8203824936335877e-07
H63D O 0 4.5361601223703474e-05
) O 0 1.591704972270236e-07
. O 0 3.324726094433572e-07

Although O 0 0.0002830857993103564
hemochromatosis B-Disease 1 0.9999988079071045
is O 0 2.1407834083220223e-06
common O 0 5.787418899672048e-07
in O 0 1.664802766754292e-07
Caucasians O 0 3.8631915231235325e-05
, O 0 2.1583875309261202e-07
affecting O 0 2.636629687913228e-07
> O 0 2.3391613979129033e-07
= O 0 3.896290763805155e-06
1 O 0 2.7732594389817677e-06
/ O 0 7.162622296164045e-06
300 O 0 1.3184270564181588e-08
individuals O 0 6.461186030648491e-10
of O 0 9.220370578155723e-10
northern O 0 4.1903760461536876e-07
European O 0 6.562314638358657e-07
origin O 0 1.2978560448573262e-07
, O 0 5.401752645184388e-08
it O 0 6.504406968588228e-08
has O 0 1.3186614467031177e-07
not O 0 1.1411623646040425e-08
been O 0 2.1209441314340438e-08
recognized O 0 6.306823063795264e-09
in O 0 5.339866770981416e-09
other O 0 2.2696411861033994e-08
populations O 0 7.000566029091715e-07
. O 0 4.101372041986906e-07

The O 0 8.404139748563466e-07
present O 0 1.992215032942113e-07
study O 0 3.20014557075865e-08
used O 0 4.5634958922846636e-08
PCR O 0 1.018601210489578e-06
and O 0 1.2267241444874344e-08
restriction O 0 9.321982297194609e-09
- O 0 1.3981978952415375e-07
enzyme O 0 1.5301789346722217e-07
digestion O 0 1.124214605852103e-07
to O 0 1.817450545615884e-08
analyze O 0 5.308895012490211e-08
the O 0 1.5753695015163771e-09
frequency O 0 2.4521490615825314e-08
of O 0 7.734030638140155e-10
the O 0 9.55951495740237e-09
845 O 0 1.453576885523944e-07
G O 0 1.121629884437425e-05
- O 0 2.1929827198619023e-06
- O 0 1.8208459096058505e-06
> O 0 3.539388160334056e-08
A O 0 8.622941294333941e-08
and O 0 1.8063637696741353e-08
187 O 0 1.3845594004635586e-08
C O 0 3.970639284034405e-07
- O 0 1.3001531442569103e-06
- O 0 6.122714239609195e-06
> O 0 4.6394339392463735e-07
G O 0 1.3254741134005599e-05
mutations O 0 6.742196205777873e-07
in O 0 1.6172450045814912e-08
HLA O 0 8.234446795540862e-06
- O 0 8.806337632449868e-07
typed O 0 5.057307248534926e-07
samples O 0 3.3590115577908364e-08
from O 0 5.239081612984364e-09
non O 0 1.0713998221945076e-07
- O 0 5.818232239107601e-06
Caucasian O 0 7.239087608468253e-06
populations O 0 1.450654849577404e-07
, O 0 3.805037618320739e-09
comprising O 0 8.886987257206158e-10
Australian O 0 6.259820217735523e-09
Aboriginal O 0 5.530111923945924e-09
, O 0 1.941044658337887e-09
Chinese O 0 8.756502745121963e-10
, O 0 6.409367703241742e-09
and O 0 4.489892901915482e-08
Pacific O 0 6.374247050189297e-07
Islanders O 0 2.0570405467879027e-06
. O 0 6.803278438383131e-07

Results O 0 0.00033344500116072595
showed O 0 4.557556167128496e-06
that O 0 1.7722639356065883e-08
the O 0 1.4200721487611645e-08
845 O 0 6.137851187304477e-07
G O 0 7.74899817770347e-05
- O 0 2.551173747633584e-05
- O 0 2.1426405510283075e-05
> O 0 9.256218191922017e-08
A O 0 2.3697091933172487e-07
mutation O 0 4.5465978359970904e-07
was O 0 2.0651731347243185e-07
present O 0 6.4636793695171946e-09
in O 0 6.065513424857727e-09
these O 0 5.295765159729626e-09
populations O 0 2.9971612747203835e-08
( O 0 7.515553512860151e-09
allele O 0 8.00898618535939e-08
frequency O 0 2.2810861821653816e-07
0 O 0 4.332184033728481e-08
. O 0 9.181240656630507e-09
32 O 0 4.0489755548378525e-08
% O 0 1.6201903818569008e-08
) O 0 5.5735278614577055e-09
, O 0 1.851416975284792e-08
and O 0 8.183930333416356e-08
, O 0 9.502002029648793e-08
furthermore O 0 6.763693960465389e-08
, O 0 2.3749731070665803e-08
it O 0 6.115711670418023e-08
was O 0 5.480437152982631e-07
always O 0 1.669278937299623e-08
seen O 0 4.832660849274362e-08
in O 0 3.5560052680239096e-09
conjunction O 0 2.3279888239358115e-08
with O 0 1.80211383593587e-08
HLA O 0 3.762531923712231e-05
haplotypes O 0 2.8172698876005597e-06
common O 0 1.5424156174503878e-07
in O 0 4.168732203879699e-08
Caucasians O 0 2.9668228762602666e-06
, O 0 2.800864074004039e-08
suggesting O 0 9.242880594229064e-08
that O 0 1.1473081151791575e-08
845 O 0 3.5399392572799115e-07
G O 0 6.66112537146546e-05
- O 0 2.3107786546461284e-05
- O 0 7.11977481842041e-05
> O 0 7.249875011439144e-07
A O 0 4.335219728091033e-06
may O 0 2.238627303086105e-06
have O 0 7.458062611931382e-09
been O 0 7.367996435192481e-09
introduced O 0 4.096920580565211e-09
into O 0 3.005867110772442e-09
these O 0 2.0699983949157286e-09
populations O 0 1.9930885386543196e-08
by O 0 1.8886964880948653e-08
Caucasian O 0 1.0634495083650108e-05
admixture O 0 3.526260843500495e-05
. O 0 3.0916696687199874e-06

187 O 0 4.7038520278874785e-05
C O 0 7.720895519014448e-05
- O 0 2.9806267775711603e-05
- O 0 4.626073859981261e-05
> O 0 1.2764135135512333e-06
G O 0 2.3889720978331752e-05
was O 0 2.9616083452310704e-07
present O 0 6.522133055852919e-09
at O 0 1.1330357985173123e-08
an O 0 4.3411811923022015e-09
allele O 0 2.1875236200230574e-07
frequency O 0 1.610863904488724e-07
of O 0 9.155010083361503e-09
2 O 0 8.89386114977242e-07
. O 0 7.802905201970134e-07

68 O 0 5.2050152589799836e-05
% O 0 5.100122848489264e-07
in O 0 4.528327934849585e-08
the O 0 1.1910904262890654e-08
two O 0 8.338215451431097e-08
populations O 0 2.854729075352225e-07
analyzed O 0 2.901736479543615e-06
( O 0 2.1517035264650985e-08
Australian O 0 3.268756998409117e-08
Aboriginal O 0 4.3789384562842315e-08
and O 0 2.2386386078210307e-08
Chinese O 0 1.4239561529905131e-08
) O 0 8.149319086214746e-08
. O 0 4.1121580807157443e-07

In O 0 7.506608881158172e-07
the O 0 7.779175348332501e-08
Australian O 0 1.0352010093583885e-07
Aboriginal O 0 6.00888512281017e-08
samples O 0 6.417064213337653e-08
, O 0 7.565459370084682e-09
187 O 0 2.9516851185462656e-08
C O 0 6.69156634103274e-07
- O 0 3.934741016564658e-06
- O 0 3.58341567334719e-05
> O 0 9.98652240014053e-07
G O 0 0.00013240371481515467
was O 0 7.933980441521271e-07
found O 0 4.0589270611235406e-08
to O 0 1.0992049048752506e-08
be O 0 1.1265881560973412e-08
associated O 0 2.1469768185511384e-08
with O 0 1.7686707209918495e-08
HLA O 0 5.002589023206383e-05
haplotypes O 0 3.276690222264733e-06
common O 0 4.088886100817035e-07
in O 0 7.576842619982926e-08
Caucasians O 0 6.405816293408861e-06
, O 0 7.128517154342262e-08
suggesting O 0 1.5417920451454847e-07
that O 0 1.179128439332544e-08
it O 0 4.178173185209744e-08
was O 0 1.4534356296280748e-07
introduced O 0 2.1065350352955647e-08
by O 0 6.576345690234575e-09
recent O 0 1.404937250981675e-07
admixture O 0 7.912251021480188e-06
. O 0 1.7473004163548467e-06

In O 0 5.623831498269283e-07
the O 0 2.87757924155585e-08
Chinese O 0 1.666234616948259e-08
samples O 0 7.121776945950842e-08
analyzed O 0 9.906824516292545e-08
, O 0 6.839100841204981e-09
187 O 0 2.0930860600287815e-08
C O 0 7.185427080003137e-07
- O 0 4.298899057175731e-06
- O 0 2.641204082465265e-05
> O 0 7.380939450740698e-07
G O 0 2.7646412490867078e-05
was O 0 1.472658027523721e-06
present O 0 2.32627552776421e-08
in O 0 2.6815849096806232e-08
association O 0 1.140076832939485e-08
with O 0 1.7645792604881194e-09
a O 0 5.605268071917635e-08
wide O 0 5.684239212655484e-08
variety O 0 5.765829413917345e-08
of O 0 2.9654144029223062e-08
HLA O 0 6.657340418314561e-05
haplotypes O 0 8.333902769663837e-06
, O 0 6.609168679005961e-08
showing O 0 1.305186572153616e-07
this O 0 3.5211655813327525e-09
mutation O 0 6.364260229929641e-08
to O 0 8.784527771865669e-09
be O 0 1.0409900497165836e-08
widespread O 0 1.846796671145512e-08
and O 0 8.032928633383563e-08
likely O 0 7.514753264104002e-08
to O 0 1.3884362104477077e-08
predate O 0 3.8044012740101607e-07
the O 0 6.981682343365492e-09
more O 0 6.078809011711428e-09
genetically O 0 1.7281222142173647e-07
restricted O 0 1.8644293220404506e-08
845 O 0 2.4506582008143596e-07
G O 0 3.312553235446103e-05
- O 0 5.532168415811611e-06
- O 0 1.194855121866567e-05
> O 0 2.341312921316785e-07
A O 0 5.773796942776244e-07
mutation O 0 5.573292582994327e-06
. O 0 3.8237084254433285e-07

Genotype O 0 0.31590718030929565
- O 0 0.02366831712424755
phenotype O 0 0.006582764443010092
correlations O 0 0.0006494004046544433
in O 0 5.473304190672934e-05
attenuated B-Disease 1 0.9963992834091187
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999958276748657
coli I-Disease 1 0.999996542930603
. O 0 7.026318780845031e-05

Germ O 0 0.004575732164084911
- O 0 0.00027792761102318764
line O 0 3.009999454661738e-05
mutations O 0 7.84222902439069e-06
of O 0 1.6529462243397575e-08
the O 0 9.860939087502629e-08
tumor B-Disease 0 3.898806608049199e-05
suppressor O 0 3.333417043904774e-05
APC O 0 1.4812989320489578e-05
are O 0 5.4863676268723793e-08
implicated O 0 2.4118040528264828e-05
in O 0 5.326926384441322e-06
attenuated B-Disease 1 0.9961114525794983
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 1.0
( O 0 0.0018258430063724518
AAPC B-Disease 1 0.9999996423721313
) O 0 2.7755559131037444e-06
, O 0 3.28052429665604e-08
a O 0 2.0621108376417396e-07
variant O 0 0.0014034410705789924
of O 0 8.233691187342629e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
( O 0 0.00019422518380451947
FAP B-Disease 0 0.0004151166358496994
) O 0 2.3922507352835964e-06
. O 0 2.409542275927379e-06

AAPC B-Disease 1 0.9999879598617554
is O 0 2.0285537175368518e-05
recognized O 0 2.8749821012752363e-07
by O 0 2.2502611329855426e-08
the O 0 1.8965479853250145e-08
occurrence O 0 5.330792305358045e-07
of O 0 2.148693312165051e-08
< O 0 6.969643209231435e-07
100 O 0 9.79394698674696e-08
colonic B-Disease 0 7.246091172419256e-06
adenomas I-Disease 0 7.948435086291283e-05
and O 0 4.2949057643681954e-08
a O 0 9.511812493201433e-08
later O 0 3.595112957555102e-06
onset O 0 0.00013242808927316219
of O 0 0.0299328975379467
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 9.384144732393906e-07
age O 0 1.0303158148872171e-07
> O 0 1.6658127321989014e-07
40 O 0 1.3572673651651712e-07
years O 0 1.0892728852240907e-07
) O 0 6.531023188927065e-08
. O 0 2.8647463068409706e-07

The O 0 5.596635901383706e-07
aim O 0 5.802788223263633e-07
of O 0 9.336930339998162e-09
this O 0 7.942943192063012e-09
study O 0 2.1486114221147545e-08
was O 0 3.9297353282563563e-07
to O 0 1.2906133406431763e-07
assess O 0 2.792878376567387e-06
genotype O 0 0.00011938663374166936
- O 0 0.00021526258205994964
phenotype O 0 0.00045441073598340154
correlations O 0 2.840557135641575e-05
in O 0 5.486521331476979e-06
AAPC B-Disease 1 0.9999940395355225
families O 0 2.2154574253363535e-05
. O 0 1.985132712434279e-06

By O 0 9.468006396673445e-07
protein O 0 2.5481188004050637e-06
- O 0 9.520853382127825e-06
truncation O 0 3.5550321626942605e-05
test O 0 1.6600764638496912e-06
( O 0 4.3773184188466985e-08
PTT O 0 5.3916769502393436e-06
) O 0 7.93649235220073e-09
assay O 0 1.1783734521486622e-07
, O 0 2.4615949278938842e-09
the O 0 1.7133089391663248e-09
entire O 0 4.476049397794668e-08
coding O 0 3.740750344150001e-06
region O 0 3.1552141877000395e-07
of O 0 4.0871563911082376e-09
the O 0 2.2714601755069452e-08
APC B-Disease 0 5.508964022737928e-07
gene O 0 2.2076977757023997e-07
was O 0 1.1365165875076855e-07
screened O 0 1.4453866015173844e-07
in O 0 2.0153713364834402e-08
affected O 0 9.44598568253241e-08
individuals O 0 6.413158004647812e-09
from O 0 4.259735320033542e-08
11 O 0 5.119647539686412e-06
AAPC B-Disease 1 0.999992847442627
kindreds O 0 5.434473496279679e-05
, O 0 8.139594598333133e-08
and O 0 1.1203952432481401e-08
their O 0 2.6649880524587388e-08
phenotypic O 0 2.6536417863098904e-06
differences O 0 1.8004892581302556e-06
were O 0 8.255725560957217e-07
examined O 0 7.080006525939098e-06
. O 0 8.252033580902207e-07

Five O 0 5.354553195502376e-06
novel O 0 3.3963012811000226e-06
germ O 0 0.00014515234215650707
- O 0 0.00011136854300275445
line O 0 6.712789763696492e-05
APC B-Disease 0 2.5069348339457065e-05
mutations O 0 1.0548377758823335e-05
were O 0 7.750162467345945e-08
identified O 0 2.1079301859572297e-07
in O 0 3.11001677744116e-08
seven O 0 3.4420548900016e-07
kindreds O 0 8.459182572551072e-05
. O 0 1.6625639318590402e-06

Mutations O 0 0.002330210991203785
were O 0 2.4570094865339343e-06
located O 0 1.9558967778721126e-07
in O 0 1.4154534433430399e-08
three O 0 3.467222953190685e-09
different O 0 1.7243769745434179e-09
regions O 0 1.862716025868849e-08
of O 0 2.9011979485460415e-09
the O 0 5.6690051764007876e-08
APC B-Disease 0 1.5661584029658115e-06
gene O 0 3.843838953798695e-07
( O 0 9.744565154790052e-09
1 O 0 5.92552851230721e-08
) O 0 9.356861063736233e-09
at O 0 5.0478625723826553e-08
the O 0 1.0004137074304253e-08
5 O 0 1.2522015424565325e-07
end O 0 7.465850870858048e-08
spanning O 0 1.0792943072601702e-07
exons O 0 1.1453466868260875e-06
4 O 0 1.1759665596855484e-07
and O 0 4.263197794784901e-08
5 O 0 1.7340919100661267e-07
, O 0 2.3440154706122485e-08
( O 0 5.2916862003371534e-09
2 O 0 8.116030869587121e-08
) O 0 5.460849550331659e-09
within O 0 2.364080042838168e-09
exon O 0 2.836416683749121e-07
9 O 0 5.280950290398323e-07
, O 0 4.3584154951759047e-08
and O 0 8.391617001279883e-08
( O 0 1.1109725583935415e-08
3 O 0 2.2324137205487204e-07
) O 0 1.7225074699922516e-08
at O 0 7.406775637264218e-08
the O 0 2.4186947555904226e-08
3 O 0 5.043324904363544e-07
distal O 0 8.828335921862163e-06
end O 0 5.526977133740729e-07
of O 0 7.160401604977551e-09
the O 0 8.380163762922166e-08
gene O 0 3.86812007491244e-06
. O 0 9.949770856110263e-07

Variability O 0 0.0008472249610349536
in O 0 3.951532505652722e-07
the O 0 2.7669502244975774e-08
number O 0 4.5775360035804624e-07
of O 0 3.1356787076219916e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0001820681063691154
most O 0 3.2106918013141694e-08
apparent O 0 4.816869818569103e-07
in O 0 1.723782538931573e-08
individuals O 0 6.651857953343665e-10
with O 0 7.416796066195275e-09
mutations O 0 2.240981075374293e-06
in O 0 4.6180637980342e-08
region O 0 1.5021878425613977e-06
1 O 0 1.4797648191233748e-06
, O 0 6.78066669479449e-08
and O 0 1.7670632246336027e-07
upper O 0 2.6967345547745936e-05
- O 1 0.9934025406837463
gastrointestinal O 0 0.39952191710472107
manifestations O 0 1.3897146345698275e-05
were O 0 1.917503027470957e-07
more O 0 1.132381513002656e-07
severe O 0 5.954299012955744e-06
in O 0 7.45807966495704e-08
them O 0 2.089305439767486e-07
. O 0 1.4917575299477903e-06

In O 0 2.101706741086673e-06
individuals O 0 3.651852154007429e-08
with O 0 1.1143892919562859e-08
mutations O 0 2.2401050046028104e-06
in O 0 5.5527124231957714e-08
either O 0 1.1951848932767462e-07
region O 0 1.1906689678653493e-06
2 O 0 1.2837015219702153e-06
or O 0 2.5224218802577525e-07
region O 0 6.19631805420795e-07
3 O 0 3.6169220152260095e-07
, O 0 1.3699068546202398e-08
the O 0 1.2229924850615248e-09
average O 0 2.992163317117047e-08
number O 0 7.828036885371148e-09
of O 0 5.904090549790908e-09
adenomas B-Disease 0 1.8920347429229878e-05
tended O 0 4.1204683043361e-07
to O 0 8.071815926768977e-08
be O 0 2.79796470437077e-08
lower O 0 1.5027191579974897e-07
than O 0 2.134743226633873e-08
those O 0 3.0000075756930755e-09
in O 0 5.220587517840158e-09
individuals O 0 7.670916679636264e-10
with O 0 5.785567580574025e-09
mutations O 0 1.9312649328639964e-06
in O 0 4.7665299263144334e-08
region O 0 1.457429107176722e-06
1 O 0 2.41190787164669e-06
, O 0 1.4273312842760788e-07
although O 0 5.610766251606947e-08
age O 0 4.303138112504712e-08
at O 0 4.411053282638022e-07
diagnosis O 0 4.822495247935876e-05
was O 0 7.36011941171455e-07
similar O 0 1.546800945106952e-07
. O 0 6.874269615764206e-07

In O 0 1.9480874470900744e-05
all O 0 2.122127398251905e-06
AAPC B-Disease 1 0.9999743700027466
kindreds O 0 0.00047819266910664737
, O 0 1.1676767286417089e-07
a O 0 4.6207514259322124e-08
predominance O 0 1.6477608824061463e-06
of O 0 1.3394912912190193e-07
right O 0 0.0001204120708280243
- O 1 0.999929666519165
sided O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.0015111746033653617
rectal B-Disease 1 0.9997642636299133
polyp I-Disease 0 0.15070068836212158
sparing O 0 4.10999491577968e-05
was O 0 9.257996680389624e-06
observed O 0 1.7558429590280866e-06
. O 0 6.622203159167839e-07

No O 0 0.00019943741790484637
desmoid B-Disease 1 0.8527066111564636
tumors I-Disease 1 1.0
were O 0 5.131795205670642e-06
found O 0 2.409265675851202e-07
in O 0 2.4656984010107408e-08
these O 0 5.026974392308148e-08
kindreds O 0 6.15084936725907e-05
. O 0 1.6025832110244664e-06

Our O 0 8.605247785453685e-06
data O 0 3.962531991419382e-06
suggest O 0 2.945980099866574e-07
that O 0 2.2632173468650763e-08
, O 0 6.047609701909096e-08
in O 0 3.7352745607677207e-07
AAPC B-Disease 1 0.9999969005584717
families O 0 2.873419759907847e-07
, O 0 8.570958165421416e-09
the O 0 2.443431013077202e-09
location O 0 1.3761665229594655e-07
of O 0 7.0473467062015516e-09
the O 0 1.1363149354792768e-07
APC B-Disease 0 2.4628963728901e-05
mutation O 0 6.516230769193498e-06
may O 0 1.0802236829476897e-06
partially O 0 3.7763934415124822e-06
predict O 0 5.695829372598382e-07
specific O 0 4.3009887207290376e-08
phenotypic O 0 3.522166252878378e-06
expression O 0 1.6083401987998514e-06
. O 0 1.0371412599852192e-06

This O 0 1.7320205643045483e-06
should O 0 1.6721571682865033e-07
help O 0 2.74937939082065e-08
in O 0 7.637662946535784e-09
the O 0 4.714717061204965e-09
design O 0 1.8756438180389523e-07
of O 0 2.5039875950483292e-08
tailored O 0 7.967973942868412e-06
clinical O 0 7.470966920664068e-06
- O 0 2.9154529329389334e-05
management O 0 2.032995780609781e-06
protocols O 0 2.446874702854984e-07
in O 0 9.301770020897493e-09
this O 0 5.087353649457782e-09
subset O 0 4.4019756728630455e-08
of O 0 2.4673873610936425e-08
FAP B-Disease 0 1.398644053551834e-05
patients O 0 9.264746267945156e-07
. O 0 4.168732203879699e-08
. O 0 3.6847859519184567e-07

Wilms B-Disease 0 0.44069433212280273
' I-Disease 0 0.0007015567389316857
tumor I-Disease 0 0.00025338842533528805
1 O 0 1.0602509519230807e-06
and O 0 2.426726553039771e-07
Dax O 0 0.2187463492155075
- O 0 8.40318352857139e-06
1 O 0 4.163036066984205e-07
modulate O 0 4.2805532984857564e-07
the O 0 1.705419627739957e-08
orphan O 0 2.3298707674257457e-07
nuclear O 0 1.5145022871365654e-06
receptor O 0 1.661861830370981e-07
SF O 0 7.586228457512334e-05
- O 0 1.3533940546039958e-06
1 O 0 9.879068585405548e-08
in O 0 6.969760768527067e-09
sex O 0 2.4524297259631567e-08
- O 0 2.2461111370830622e-07
specific O 0 3.583883767532825e-08
gene O 0 5.284658755044802e-07
expression O 0 4.942878035762988e-07
. O 0 6.242534027478541e-07

Products O 0 1.6449474060209468e-05
of O 0 3.2132044225363643e-07
steroidogenic O 0 2.109770866809413e-05
factor O 0 8.002272124940646e-07
1 O 0 1.772864152371767e-06
( O 0 1.7230799187473167e-07
SF O 0 0.0023631330113857985
- O 0 1.3288128684507683e-05
1 O 0 8.475064987578662e-07
) O 0 2.6400357455713674e-08
and O 0 1.2090612244719523e-07
Wilms B-Disease 0 0.0004016979073639959
tumor I-Disease 0 6.824223964940757e-05
1 O 0 8.153405701705196e-07
( O 0 5.62864528319551e-08
WT1 O 0 4.3349223233235534e-06
) O 0 1.4406396964261603e-08
genes O 0 2.3318728281651602e-08
are O 0 1.6039425343450375e-09
essential O 0 6.713040345829313e-09
for O 0 1.77320718108831e-08
mammalian O 0 1.4091455113884876e-06
gonadogenesis O 0 5.903546480112709e-06
prior O 0 5.976549033448464e-08
to O 0 3.504944956489453e-08
sexual O 0 7.883630104288386e-08
differentiation O 0 6.885311449877918e-07
. O 0 1.0994585863954853e-06

In O 0 7.231180461531039e-06
males O 0 2.7679591312335106e-06
, O 0 4.0827998759596085e-07
SF O 0 0.01860331930220127
- O 0 2.5042345441761427e-05
1 O 0 6.085459176574659e-07
participates O 0 1.4743990561782994e-07
in O 0 2.3812690486124666e-08
sexual O 0 1.2959359807496185e-08
development O 0 4.140172205069348e-09
by O 0 3.1897477992259837e-09
regulating O 0 1.2901554669042525e-07
expression O 0 8.328408540592136e-08
of O 0 3.865680664461024e-09
the O 0 3.751739541257848e-08
polypeptide O 0 8.464922757411841e-06
hormone O 0 1.2170544323453214e-06
Mullerian O 0 5.889797193958657e-06
inhibiting O 0 3.869134616252268e-06
substance O 0 3.1615891202818602e-06
( O 0 4.365404038253473e-07
MIS O 0 0.0033929760102182627
) O 0 6.328810968625476e-07
. O 0 1.0201488294114824e-06

Here O 0 6.5274134612991475e-06
, O 0 2.9560780490101024e-07
we O 0 3.7586151080404306e-08
show O 0 2.3038934671149036e-07
that O 0 5.587047979815907e-08
WT1 O 0 2.824422699632123e-05
- O 0 3.336377994855866e-05
KTS O 0 4.15508657169994e-05
isoforms O 0 4.895571237284457e-07
associate O 0 4.4844969693258463e-07
and O 0 2.7875667996113407e-08
synergize O 0 6.0688762459903955e-06
with O 0 6.921277417859528e-07
SF O 1 0.5601221919059753
- O 0 3.0068093110457994e-05
1 O 0 4.5404880211208365e-07
to O 0 6.707437449904319e-08
promote O 0 3.0075148060859647e-07
MIS O 0 0.0009391095954924822
expression O 0 2.9386969799816143e-06
. O 0 5.907607487642963e-07

In O 0 6.691720955132041e-06
contrast O 0 7.976764209161047e-06
, O 0 7.945225206640316e-07
WT1 O 0 0.000175683933775872
missense O 0 0.0004003694048151374
mutations O 0 0.00021870678756386042
, O 0 1.5279842102700059e-07
associated O 0 1.478719440228815e-07
with O 0 1.0424628982264039e-07
male B-Disease 0 1.6236670489888638e-05
pseudohermaphroditism I-Disease 1 0.9999971389770508
in O 0 2.159752148145344e-05
Denys B-Disease 1 0.9996799230575562
- I-Disease 1 0.9990953207015991
Drash I-Disease 1 0.999932050704956
syndrome I-Disease 1 0.9999961853027344
, O 0 1.9792467753632081e-07
fail O 0 6.915774406479613e-07
to O 0 2.474843796562709e-08
synergize O 0 1.4687851034977939e-05
with O 0 7.748462280687818e-07
SF O 1 0.8603902459144592
- O 0 0.00019619760860223323
1 O 0 4.189447736280272e-06
. O 0 1.2634174026970868e-06

Additionally O 0 1.614158281881828e-05
, O 0 2.6051665713566763e-07
the O 0 4.136590803227591e-08
X O 0 0.00020566080638673156
- O 0 8.396752673434094e-05
linked O 0 7.346604252234101e-05
, O 0 4.901167827142672e-08
candidate O 0 1.026085669764143e-07
dosage O 0 5.309918265083979e-07
- O 0 1.4000728469909518e-06
sensitive O 0 1.6701839058441692e-06
sex O 0 1.350172027514418e-07
- O 0 1.039434437188902e-06
reversal O 0 2.091582928187563e-06
gene O 0 3.4097232060048555e-07
, O 0 1.4471141618344063e-08
Dax O 0 0.016079531982541084
- O 0 5.773571501777042e-06
1 O 0 3.100155936408555e-07
, O 0 3.365077816397388e-08
antagonizes O 0 5.888359737582505e-07
synergy O 0 2.103957541521595e-07
between O 0 1.1649160569504602e-07
SF O 0 0.018878133967518806
- O 0 1.1149771125928964e-05
1 O 0 7.825724992471805e-07
and O 0 7.108301502967151e-08
WT1 O 0 4.399673343868926e-06
, O 0 1.653356207498291e-08
most O 0 3.129998038531312e-09
likely O 0 1.4555350702494252e-08
through O 0 1.8261993028900747e-09
a O 0 9.398716471764601e-09
direct O 0 4.061420710854691e-08
interaction O 0 3.800520786967354e-08
with O 0 4.964306867805135e-07
SF O 1 0.9706830382347107
- O 0 0.00014128198381513357
1 O 0 2.7465598577691708e-06
. O 0 9.708852530820877e-07

We O 0 3.820179699687287e-06
propose O 0 3.152695398966898e-06
that O 0 1.3422072697721887e-07
WT1 O 0 2.7200421754969284e-05
and O 0 1.7005869494823855e-06
Dax O 1 0.8858413100242615
- O 0 5.461207911139354e-05
1 O 0 8.519195944245439e-07
functionally O 0 7.753029649393284e-07
oppose O 0 1.8270608137527233e-08
each O 0 3.7880059089445695e-09
other O 0 4.989507029762308e-09
in O 0 2.223760731112634e-08
testis O 0 7.306085990421707e-06
development O 0 2.8386240913391703e-08
by O 0 4.344132165101655e-08
modulating O 0 2.6851379516301677e-05
SF O 0 0.1571407914161682
- O 0 5.139043423696421e-05
1 O 0 4.523379175225273e-06
- O 0 2.566814328019973e-05
mediated O 0 6.034258331055753e-05
transactivation O 0 6.0230420785956085e-05
. O 0 1.7260040863220638e-07
. O 0 7.23663276858133e-07

A O 0 8.924175745050889e-06
mouse O 0 2.2895670554134995e-05
model O 0 6.682945695501985e-06
for O 0 5.6369026424363256e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
imprinting O 0 0.007649300619959831
- O 0 0.0005072967032901943
centre O 0 0.00014100069529376924
mutations O 0 0.00017263871268369257
. O 0 2.177093620048254e-06

Imprinting O 0 0.0004957754863426089
in O 0 1.8282952396475594e-06
the O 0 2.0491330587901757e-07
15q11 O 0 6.7444352680468e-06
- O 0 2.4231374482042156e-05
q13 O 0 3.930165803467389e-06
region O 0 3.6617427667806624e-07
involves O 0 4.6481183346713806e-08
an O 0 3.5326571889982006e-08
imprinting O 0 1.2267367310414556e-05
centre O 0 2.5610972443246283e-05
( O 0 2.0927153343563987e-07
IC O 0 1.510364563728217e-05
) O 0 3.7546026732115934e-08
, O 0 7.628258025249579e-09
mapping O 0 1.3829578904278605e-07
in O 0 2.3874358490161285e-08
part O 0 4.005110199045703e-08
to O 0 3.932531811301487e-08
the O 0 1.4124222680322873e-08
promoter O 0 2.807997134368634e-06
and O 0 3.11347072567969e-08
first O 0 6.933407092901689e-08
exon O 0 2.819328756231698e-06
of O 0 7.353693121103788e-08
SNRPN O 0 0.00017330337141174823
. O 0 1.354470896330895e-06

Deletion O 0 0.0005647495854645967
of O 0 9.982009032682981e-07
this O 0 1.9715605503733968e-07
IC O 0 3.2806659874040633e-05
abolishes O 0 1.0859814210562035e-05
local O 0 1.757563978799226e-07
paternally O 0 1.5539081914539565e-06
derived O 0 1.493569641297654e-07
gene O 0 4.09850969163017e-07
expression O 0 1.2015782147045684e-07
and O 0 9.460337935252028e-08
results O 0 3.7698698633903405e-06
in O 0 2.6494359190110117e-05
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 9.525682253297418e-05
PWS B-Disease 1 0.9999988079071045
) O 0 2.623186446726322e-06
. O 0 1.2703706033789786e-06

We O 0 4.202677246212261e-06
have O 0 6.920433293089445e-08
created O 0 5.268706360084252e-08
two O 0 3.3410564981295465e-08
deletion O 0 5.193703145778272e-06
mutations O 0 7.68528479966335e-06
in O 0 7.945128999153894e-08
mice O 0 2.7438860342954285e-05
to O 0 1.1756183084798977e-06
understand O 0 5.537589458981529e-06
PWS B-Disease 1 0.9999990463256836
and O 0 3.046305607767863e-07
the O 0 7.7367783291038e-09
mechanism O 0 2.4511855656328407e-08
of O 0 8.482905933249185e-09
this O 0 7.378927335821572e-08
IC O 0 0.0001958576322067529
. O 0 7.875992764638795e-07

Mice O 0 0.010622686706483364
harbouring O 0 0.0010667151072993875
an O 0 1.4600514077756088e-06
intragenic O 0 9.075461275642738e-05
deletion O 0 3.1983152439352125e-05
in O 0 1.5885748894106655e-07
Snrpn O 0 3.197589467163198e-05
are O 0 4.945962217561828e-08
phenotypically O 0 1.979530907192384e-06
normal O 0 3.9039574062371685e-07
, O 0 2.6396380192750257e-08
suggesting O 0 9.553831858966078e-08
that O 0 1.058594101266408e-08
mutations O 0 3.761391269563319e-07
of O 0 6.942786789920774e-09
SNRPN O 0 0.00010286956239724532
are O 0 2.228138029636284e-08
not O 0 1.1169215774486929e-08
sufficient O 0 2.965708389979227e-08
to O 0 2.912094316798175e-07
induce O 0 1.651875390962232e-05
PWS B-Disease 1 0.9999606609344482
. O 0 6.105623015173478e-06

Mice O 0 0.0019711684435606003
with O 0 2.5893095312312653e-07
a O 0 1.4905700140843692e-07
larger O 0 1.568729572909433e-07
deletion O 0 1.7043586240106379e-06
involving O 0 3.8922056688761586e-08
both O 0 3.940979098615571e-08
Snrpn O 0 1.236761272593867e-05
and O 0 1.0392923144308952e-07
the O 0 1.3154271982784849e-07
putative O 0 0.00019460594921838492
PWS O 1 0.9999992847442627
- O 0 0.001285984879359603
IC O 0 7.178540545282885e-05
lack O 0 5.9588387557596434e-08
expression O 0 2.6852802648136276e-08
of O 0 2.4640141038645424e-09
the O 0 3.262827164007831e-08
imprinted O 0 2.6702862669480965e-05
genes O 0 1.856335643424245e-06
Zfp127 O 0 1.7171581930597313e-05
( O 0 5.825667059866646e-08
mouse O 0 1.7625874306759215e-06
homologue O 0 6.8779550019826274e-06
of O 0 6.546213171532145e-08
ZNF127 O 0 0.0001560043601784855
) O 0 2.2302283753106167e-07
, O 0 1.2930181014780828e-07
Ndn O 0 3.9105958421714604e-05
and O 0 1.4420560034977825e-07
Ipw O 0 7.720705980318598e-06
, O 0 7.009919755773808e-08
and O 0 6.212044212361434e-08
manifest O 0 1.7457963394917897e-06
several O 0 2.9363944165083922e-08
phenotypes O 0 2.7205717287870357e-06
common O 0 2.3456200324289966e-06
to O 0 2.1535388441407122e-05
PWS B-Disease 1 0.9999997615814209
infants O 0 0.12256912887096405
. O 0 3.20582921631285e-06

These O 0 1.167043819805258e-06
data O 0 8.779235258771223e-07
demonstrate O 0 1.2097670776256564e-07
that O 0 4.9621555753276425e-09
both O 0 3.522354630192126e-09
the O 0 7.195670281845423e-09
position O 0 2.5071520326491736e-07
of O 0 3.125225855882263e-09
the O 0 2.6239263206662145e-08
IC O 0 2.3330787371378392e-05
and O 0 5.119995805102917e-08
its O 0 6.819043818495629e-08
role O 0 1.627431700512716e-08
in O 0 2.166879120579779e-09
the O 0 1.674146932195697e-09
coordinate O 0 1.2330372101132525e-07
expression O 0 2.038882840338374e-08
of O 0 1.9798647166169303e-09
genes O 0 3.333475362410354e-08
is O 0 5.338135267152211e-09
conserved O 0 3.207692600426526e-08
between O 0 4.672625308899114e-08
mouse O 0 9.596312338544521e-06
and O 0 9.351883818453643e-07
human O 0 1.3423428413261718e-07
, O 0 8.855016631059698e-08
and O 0 8.442169985301007e-08
indicate O 0 8.342733792687795e-08
that O 0 6.636349692001886e-09
the O 0 4.4366763596315195e-09
mouse O 0 6.230151257113903e-07
is O 0 1.011968819852882e-08
a O 0 1.2540917637693383e-08
suitable O 0 1.0154107599191775e-07
model O 0 2.0100627295960294e-07
system O 0 3.531228998099323e-08
in O 0 1.2785556613437166e-08
which O 0 6.226528626029904e-08
to O 0 3.1160492852677635e-08
investigate O 0 2.0393729371903646e-08
the O 0 1.2736530718981953e-09
molecular O 0 3.786079361134398e-08
mechanisms O 0 1.0093471836114531e-08
of O 0 2.367373852507626e-09
imprinting O 0 2.859774895114242e-06
in O 0 4.893676219808185e-08
this O 0 7.149184355625948e-09
region O 0 2.5304620976385195e-07
of O 0 4.164550038154857e-09
the O 0 2.730242520954107e-08
genome O 0 9.129491331805184e-07
. O 0 8.992129352236589e-08
. O 0 3.0748222457077645e-07

Mutations O 0 0.0006938730948604643
of O 0 1.4555106986335886e-07
the O 0 6.517048944942871e-08
ATM O 0 2.9348881071200594e-05
gene O 0 2.883848537749145e-06
detected O 0 3.130712684651371e-06
in O 0 9.086090813070768e-08
Japanese O 0 6.814046355430037e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.6881259083747864
: O 0 5.1682395252328206e-08
possible O 0 8.894778602552833e-08
preponderance O 0 2.326511321371072e-07
of O 0 4.09413924984392e-09
the O 0 1.4260217895412097e-08
two O 0 1.1275753308837011e-07
founder O 0 1.6350737496395595e-05
mutations O 0 2.315118308615638e-06
4612del165 O 0 3.8316625250445213e-07
and O 0 7.370445587184804e-08
7883del5 O 0 3.4527736261225073e-06
. O 0 9.216964826919138e-07

The O 0 2.2996575808065245e-06
ATM O 0 0.0005077655077911913
( O 0 1.453451091038005e-06
A O 1 0.9945842623710632
- O 1 0.9981412887573242
T O 1 0.9999998807907104
, O 0 5.0722030664474e-07
mutated O 0 8.160547508850868e-07
) O 0 1.4695385353036272e-08
gene O 0 1.0142125717038653e-07
on O 0 4.118001299957541e-07
human O 0 4.083847500169213e-07
chromosome O 0 0.00011770844139391556
11q22 O 0 1.5616911696270108e-05
. O 0 1.483544679103943e-06

3 O 0 5.884396159672178e-05
has O 0 1.4244839121602126e-06
recently O 0 8.228669798882038e-07
been O 0 4.887528604058389e-08
identified O 0 5.066140573717348e-08
as O 0 3.1091371699432102e-09
the O 0 5.733442609567874e-09
gene O 0 9.133455591836537e-08
responsible O 0 9.24018479508959e-08
for O 0 7.769964227577475e-09
the O 0 1.2493458712015126e-07
human O 0 4.535710468189791e-05
recessive B-Disease 1 0.9999973773956299
disease I-Disease 1 0.9999996423721313
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.00019992786110378802
A B-Disease 1 0.9999974966049194
- I-Disease 1 0.9999945163726807
T I-Disease 1 1.0
) O 0 2.5300112156401156e-06
. O 0 1.5749728845548816e-06

In O 0 1.8928781173599418e-06
order O 0 1.0305418385314624e-07
to O 0 1.6705241634440426e-08
define O 0 7.732400320037414e-08
the O 0 1.2332955101612697e-08
types O 0 1.060607459635321e-07
of O 0 1.1493050067201693e-07
disease O 0 0.00037876461283303797
- O 0 1.763530781317968e-05
causing O 0 1.2746831089316402e-05
ATM O 0 6.451033550547436e-05
mutations O 0 3.7994770991645055e-06
in O 0 1.033243712811327e-08
Japanese O 0 8.355240765922645e-07
A B-Disease 1 0.9999897480010986
- I-Disease 1 0.999997615814209
T I-Disease 1 1.0
patients O 0 1.4399700376088731e-05
as O 0 8.020830222221775e-09
well O 0 5.795154134347058e-09
as O 0 1.0328299104855887e-08
to O 0 1.8238887733446063e-08
look O 0 6.174656164148473e-08
for O 0 9.348084972771176e-09
possible O 0 3.3483932071476374e-08
mutational O 0 1.2740955526169273e-06
hotspots O 0 1.9446292753855232e-06
, O 0 3.4410891913694286e-08
reverse O 0 3.254509920225246e-06
- O 0 3.423555654080701e-06
transcribed O 0 2.4294249669765122e-06
RNA O 0 1.0350035495321208e-07
derived O 0 1.8465291518054983e-08
from O 0 5.4444693198263394e-09
ten O 0 2.7601505081520372e-08
patients O 0 3.4412995120192136e-08
belonging O 0 1.780514047311499e-08
to O 0 6.906874183698619e-09
eight O 0 1.559489604119335e-08
unrelated O 0 7.50072004507274e-08
Japanese O 0 2.3514763825005502e-07
A B-Disease 1 0.9949997663497925
- I-Disease 1 0.999262273311615
T I-Disease 1 1.0
families O 0 8.450593895759084e-07
was O 0 4.937262474413728e-07
analyzed O 0 1.6787610945812048e-07
for O 0 9.714427484652788e-09
mutations O 0 2.7524549750523875e-07
by O 0 3.1263942545933787e-09
the O 0 9.162731906542376e-09
restriction O 0 8.449064381466087e-08
endonuclease O 0 4.760633146361215e-06
fingerprinting O 0 4.4754447117156815e-06
method O 0 1.824181367737765e-06
. O 0 1.1697045465552947e-06

As O 0 5.671390681527555e-06
has O 0 4.045780315209413e-07
been O 0 1.7135688779035263e-07
reported O 0 1.729757400426024e-06
by O 0 1.094455992500798e-08
others O 0 2.8462176260291017e-07
, O 0 3.0216650515058063e-08
mutations O 0 2.2164863366924692e-07
that O 0 3.0289801777882985e-09
lead O 0 9.495553143779034e-08
to O 0 4.443478829330161e-08
exon O 0 1.9878057173627894e-06
skipping O 0 1.8117038962373044e-06
or O 0 8.117081051750574e-07
premature O 0 1.7340039448754396e-06
protein O 0 3.149715155359445e-07
truncation O 0 4.65889434053679e-06
were O 0 5.521893697846281e-08
also O 0 1.9524856398334123e-08
predominant O 0 2.0390041299833683e-07
in O 0 3.046729446509744e-08
our O 0 2.296351908626093e-07
mutants O 0 5.389533725974616e-06
. O 0 5.293677531881258e-07

Six O 0 1.7366467091051163e-06
different O 0 1.113151313347771e-07
mutations O 0 3.4088654956576647e-06
were O 0 1.167373895327728e-07
identified O 0 3.5936312769990764e-07
on O 0 3.6472721376412665e-07
12 O 0 5.779306277986507e-08
of O 0 4.4587329384171426e-09
the O 0 4.784948259839439e-08
16 O 0 2.932376901298994e-07
alleles O 0 5.51693460693059e-07
examined O 0 3.3951130262721563e-06
. O 0 9.076742912839109e-07

Four O 0 6.321232376649277e-06
were O 0 2.670341530119913e-07
deletions O 0 7.990902304300107e-07
involving O 0 4.909766104788105e-08
a O 0 3.846035667720571e-07
loss O 0 4.261541562300408e-06
of O 0 3.49807116606371e-09
a O 0 7.873352103615616e-08
single O 0 4.410716769598366e-07
exon O 0 2.0080099147889996e-06
exon O 0 1.4419682656807709e-06
7 O 0 1.96093211002335e-07
, O 0 1.2749710620596488e-08
exon O 0 5.634127546727541e-07
16 O 0 6.634125071514063e-08
, O 0 2.6055536395119816e-08
exon O 0 1.946386191775673e-06
33 O 0 2.749259522261127e-07
or O 0 2.6565490429675265e-07
exon O 0 1.208837147714803e-05
35 O 0 1.6196408978430554e-06
. O 0 1.156699113380455e-06

The O 0 2.325454033780261e-06
others O 0 7.865004363338812e-07
were O 0 5.231425248553023e-08
minute O 0 1.5369386119346018e-07
deletions O 0 9.500667488282488e-07
, O 0 3.664264269787054e-08
4649delA O 0 3.990112702467741e-07
in O 0 2.7162288418480784e-08
exon O 0 1.1229013807678712e-06
33 O 0 1.736816130915031e-07
and O 0 2.2981959446610745e-08
7883del5 O 0 2.5671803882687527e-07
in O 0 3.0042695442489276e-08
exon O 0 7.4101772042922676e-06
55 O 0 1.4615936834161403e-06
. O 0 7.531434107477253e-07

The O 0 1.0404620525150676e-06
mutations O 0 9.159856745100114e-06
4612del165 O 0 1.9569374671846163e-06
and O 0 1.1127968235769004e-07
7883del5 O 0 6.905150939928717e-07
were O 0 1.0122491289621394e-07
found O 0 2.4731214409712265e-08
in O 0 4.127383324004086e-09
more O 0 1.2105946245455357e-09
than O 0 2.3437460860975534e-09
two O 0 7.132676671517402e-09
unrelated O 0 5.106128142529087e-08
families O 0 9.918316834500729e-09
; O 0 1.2890702727474945e-08
44 O 0 2.8300283005933125e-08
% O 0 1.3367316142876007e-08
( O 0 3.137002657638277e-09
7 O 0 8.639766235774005e-08
of O 0 5.1673891832138e-09
16 O 0 1.6077422060334357e-07
) O 0 2.670120347048055e-09
of O 0 3.605628573488673e-10
the O 0 7.86428255850069e-09
mutant O 0 1.7980492827973649e-07
alleles O 0 6.651038830796097e-08
had O 0 1.1071124816908195e-07
one O 0 2.5501802891625402e-09
of O 0 6.047511935669547e-10
the O 0 9.885567031631126e-09
two O 0 3.232567848954204e-07
mutations O 0 2.4999560992000625e-05
. O 0 6.139988499853644e-07

The O 0 1.7753327483660541e-06
4612del165 O 0 7.113961601135088e-06
mutations O 0 1.0878379725909326e-05
in O 0 4.735140990419495e-08
three O 0 1.1763429341726805e-08
different O 0 4.682937149169675e-09
families O 0 1.1300099522770779e-08
were O 0 1.1451460224520815e-08
all O 0 1.8020338554691762e-09
ascribed O 0 9.902668551831084e-08
to O 0 1.1655201248572666e-08
the O 0 9.489466101797461e-09
same O 0 9.789857102759925e-08
T O 0 7.234761869767681e-05
- O 0 5.980704827379668e-06
- O 0 3.481888825263013e-06
> O 0 2.6341659520312533e-08
A O 0 2.1115150516948233e-08
substitution O 0 1.1798912069593825e-08
at O 0 1.464568999409721e-08
the O 0 4.972653400159288e-09
splice O 0 1.449457249691477e-05
donor O 0 3.0317448818095727e-07
site O 0 6.982883178352495e-07
in O 0 1.559796629635457e-07
intron O 0 0.00012423614680301398
33 O 0 2.0421812223503366e-06
. O 0 6.618951147174812e-07

Microsatellite O 0 0.0007996647618710995
genotyping O 0 0.0002471802872605622
around O 0 2.113968776029651e-06
the O 0 1.7471792546075449e-07
ATM O 0 3.503942207316868e-05
locus O 0 8.858174624037929e-06
also O 0 5.941202516623889e-07
indicated O 0 3.0359663583112706e-07
that O 0 5.882396791889732e-09
a O 0 3.2549827722050395e-08
common O 0 3.504304117996071e-07
haplotype O 0 5.931258056079969e-05
was O 0 1.7378347365593072e-06
shared O 0 1.793267578875657e-08
by O 0 2.3098096768592313e-09
the O 0 4.831533839677604e-09
mutant O 0 1.9090478531325061e-07
alleles O 0 1.1318675774418807e-07
in O 0 1.2445506847313936e-08
both O 0 1.1529024135370491e-07
mutations O 0 2.162190321541857e-05
. O 0 1.1528401273608324e-06

This O 0 7.479789019271266e-07
suggests O 0 5.244383487479354e-07
that O 0 1.097518431691924e-08
these O 0 2.2661101883869605e-09
two O 0 1.831320695089289e-08
founder O 0 1.82331568794325e-05
mutations O 0 1.4674466001451947e-05
may O 0 3.537789439178596e-07
be O 0 3.922192348682074e-09
predominant O 0 7.376788602186934e-08
among O 0 4.370783734941597e-09
Japanese O 0 5.9390387718849524e-08
ATM O 0 9.701590897748247e-06
mutant O 0 2.4854221010173205e-06
alleles O 0 3.966562417190289e-06
. O 0 8.968146971710667e-07

W474C O 0 3.2398838811786845e-05
amino O 0 2.5401652692380594e-06
acid O 0 8.719368338461209e-07
substitution O 0 8.19420762354639e-08
affects O 0 5.5859082692677475e-08
early O 0 1.0252440674207719e-08
processing O 0 1.3879014382212063e-08
of O 0 6.889963599654436e-10
the O 0 4.379128615283889e-09
alpha O 0 1.5719455959128936e-08
- O 0 1.2057101095308553e-08
subunit O 0 5.064949348820846e-09
of O 0 1.3322284386774186e-09
beta O 0 1.623853407295428e-08
- O 0 2.924356294897734e-07
hexosaminidase O 0 8.606893402429705e-07
A O 0 2.642263154939428e-07
and O 0 4.7820559956335273e-08
is O 0 1.563796558912145e-08
associated O 0 3.8454594175618695e-08
with O 0 1.9580356536152976e-07
subacute O 0 0.0014299469767138362
G B-Disease 0 0.02331787534058094
( I-Disease 0 2.9737046247646504e-07
M2 I-Disease 0 0.00022267925669439137
) I-Disease 0 3.139039677080291e-07
gangliosidosis I-Disease 0 3.7550224078586325e-05
. O 0 2.1510854821826797e-06

Mutations O 0 0.0010993242030963302
in O 0 1.064516368387558e-06
the O 0 1.4498361622372613e-07
HEXA O 0 0.00015917941345833242
gene O 0 2.0383286027936265e-06
, O 0 1.5782935847141744e-08
encoding O 0 4.526238228663715e-08
the O 0 7.500917220681913e-09
alpha O 0 2.9956808589304273e-08
- O 0 2.2200694616003602e-08
subunit O 0 1.7435432653201133e-08
of O 0 2.191689940644892e-09
beta O 0 3.718249885764635e-08
- O 0 5.161516014595691e-07
hexosaminidase O 0 1.914717813633615e-06
A O 0 5.340480697668681e-07
( O 0 1.494181667283101e-08
Hex O 0 6.92971809712617e-07
A O 0 9.026743441609142e-07
) O 0 1.713430819449968e-08
, O 0 6.855321199594755e-09
that O 0 5.1686011026674805e-09
abolish O 0 9.941332024254734e-08
Hex O 0 4.733822436264745e-07
A O 0 5.640929501282699e-08
enzyme O 0 7.160759309954301e-07
activity O 0 1.5636614989489317e-06
cause O 0 0.0010267366888001561
Tay B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9924945831298828
( O 0 4.942628493154189e-07
TSD B-Disease 0 4.560545494314283e-05
) O 0 4.322279778534721e-08
, O 0 2.0262367783629998e-08
the O 0 1.278582999475475e-07
fatal O 0 0.043761953711509705
infantile B-Disease 0 0.00018787640146911144
form I-Disease 0 4.365208496892592e-07
of I-Disease 0 1.0519924842355977e-07
G I-Disease 0 0.02476656064391136
( I-Disease 0 1.4845323903500685e-07
M2 I-Disease 0 0.00013420599862001836
) I-Disease 0 1.0590690635581268e-07
gangliosidosis I-Disease 0 3.494890052024857e-06
, I-Disease 0 2.3954500605327667e-08
Type I-Disease 0 1.3441683677228866e-07
1 I-Disease 0 8.50709909627767e-07
. O 0 1.2211446573928697e-06

Less O 0 0.00022418495791498572
severe O 0 0.019416388124227524
, O 0 5.911044809181476e-06
subacute O 0 0.012081559747457504
( O 0 1.5384346625069156e-05
juvenile O 0 0.01193125732243061
- O 1 0.8453684449195862
onset O 0 0.43184414505958557
) O 0 3.487851245154161e-06
and O 0 1.8520266166888177e-05
chronic O 0 0.1902667135000229
( O 0 1.6956154524905287e-07
adult O 0 2.9821437692589825e-06
- O 0 0.02933933027088642
onset O 0 0.0001888772239908576
) O 0 4.435045397599424e-08
variants O 0 2.3308597008053766e-07
are O 0 5.022620541694778e-09
characterized O 0 4.607699821690403e-08
by O 0 5.430468075218187e-09
a O 0 1.2115751246710715e-07
broad O 0 2.1131290850462392e-07
spectrum O 0 3.805526205269416e-07
of O 0 2.364441975544196e-08
clinical O 0 1.837871536736202e-06
manifestations O 0 1.309682033934223e-06
and O 0 1.4905032230672077e-07
are O 0 8.106836979493437e-09
associated O 0 3.1748179196711135e-08
with O 0 1.2964897599943015e-08
residual O 0 3.5161792766302824e-06
levels O 0 4.475340986687115e-08
of O 0 2.0419641533209187e-09
Hex O 0 9.95121354208095e-07
A O 0 2.507458134459739e-07
enzyme O 0 1.2478709550123313e-06
activity O 0 3.6445808859753015e-07
. O 0 3.7654254469998705e-07

We O 0 6.903366738697514e-06
identified O 0 1.151598439719237e-06
a O 0 3.7695610899390886e-07
1422 O 0 2.816114829329308e-05
G O 0 0.0007065162644721568
- O 0 4.722730227513239e-05
- O 0 5.6488126574549824e-05
> O 0 9.540208338876255e-07
C O 0 1.9048263766308082e-06
( O 0 7.86072895664347e-09
amino O 0 3.206450926995785e-08
acid O 0 4.8700897536946286e-08
W474C O 0 2.3048814412618412e-08
) O 0 4.672602860189556e-10
substitution O 0 8.526114814166874e-10
in O 0 1.6208447917165358e-09
the O 0 2.3196460308128053e-09
first O 0 4.909503914518609e-08
position O 0 8.32159727792714e-08
of O 0 2.480257776937833e-09
exon O 0 6.081490937503986e-07
13 O 0 1.8478397478816078e-08
of O 0 1.207935307334651e-09
HEXA O 0 5.88637203691178e-06
of O 0 4.799313835235353e-09
a O 0 1.35166388304242e-07
non O 0 9.340947144664824e-07
- O 0 5.801775841973722e-06
Jewish O 0 5.468738891067915e-06
proband O 0 7.45844590710476e-05
who O 0 8.378436291422986e-07
manifested O 0 3.6602276054509275e-07
a O 0 1.9647883675588673e-07
subacute O 0 4.0697839722270146e-05
variant O 0 1.6437397789559327e-05
of O 0 1.1016967249588561e-07
G B-Disease 0 0.014180394820868969
( I-Disease 0 4.1759108171390835e-07
M2 I-Disease 0 0.00028752515208907425
) I-Disease 0 3.5548481491787243e-07
gangliosidosis I-Disease 0 2.512007995392196e-05
. O 0 1.1851450381072937e-06

On O 0 3.761132802537759e-06
the O 0 3.022587691248191e-07
second O 0 1.7123940097008017e-06
maternally O 0 2.9952358090667985e-05
inherited O 0 6.28782290732488e-05
allele O 0 7.579163593618432e-06
, O 0 8.536358109267894e-08
we O 0 1.9254114747013773e-08
identified O 0 1.1463177429504867e-07
the O 0 1.4543251047882677e-08
common O 0 1.5739275113446638e-05
infantile O 1 0.9464119076728821
disease O 0 0.3161045014858246
- O 0 0.00010464361548656598
causing O 0 0.0001520476653240621
4 O 0 3.864123300445499e-06
- O 0 6.820704584242776e-05
bp O 0 0.00028655011556111276
insertion O 0 9.901986004479113e-07
, O 0 5.690205640007662e-08
+ O 0 1.239324888047122e-06
TATC O 0 2.6341960619902238e-05
1278 O 0 3.2001021281757858e-06
, O 0 2.9195845741014637e-08
in O 0 4.3371112923296096e-08
exon O 0 1.0268947335134726e-05
11 O 0 1.3983021744934376e-06
. O 0 8.117661423057143e-07

Pulse O 0 0.0022967674303799868
- O 0 0.0001290578074986115
chase O 0 1.9074104784522206e-05
analysis O 0 1.3004007826111774e-07
using O 0 8.469007184430666e-08
proband O 0 5.565564606513362e-06
fibroblasts O 0 1.1860076938319253e-06
revealed O 0 1.6863843939063372e-06
that O 0 2.5307833606547092e-09
the O 0 2.7221969123303325e-09
W474C O 0 1.0401728189890491e-07
- O 0 8.032070297758764e-08
containing O 0 1.531346249805665e-08
alpha O 0 1.56026302988721e-08
- O 0 1.0241437031766054e-08
subunit O 0 1.4180017160470015e-08
precursor O 0 8.243147675557339e-08
was O 0 3.061309783447541e-08
normally O 0 4.2568575331358716e-09
synthesized O 0 2.85787713494301e-08
, O 0 1.4468733988692861e-09
but O 0 1.5773419237419262e-09
not O 0 1.3782692764863214e-09
phosphorylated O 0 1.5344394199701128e-08
or O 0 1.5169213440913154e-08
secreted O 0 2.575984048291957e-08
, O 0 3.5229659189894846e-09
and O 0 3.2047005049662403e-09
the O 0 1.3883355798327557e-08
mature O 0 1.8697966197578353e-07
lysosomal O 0 1.2506541224865941e-06
alpha O 0 1.6594971441463713e-07
- O 0 2.0132550559992524e-07
subunit O 0 1.3020984113154555e-07
was O 0 4.3025559648413036e-07
not O 0 3.4316443020543375e-08
detected O 0 1.4129470855550608e-06
. O 0 3.539422550602467e-07

When O 0 2.0720001430163393e-06
the O 0 5.99330647332863e-08
W474C O 0 1.012638904285268e-06
- O 0 2.9443958737829234e-07
containing O 0 2.6909765082905324e-08
alpha O 0 4.293275779332362e-08
- O 0 6.265341312428063e-08
subunit O 0 5.1019128477491904e-08
was O 0 1.2677017480200448e-07
transiently O 0 3.0496079261865816e-07
co O 0 1.1601404139582883e-06
- O 0 4.5898062239757564e-07
expressed O 0 4.698880839981712e-09
with O 0 4.4125209042178426e-10
the O 0 1.9004904316943794e-09
beta O 0 5.425136340164727e-09
- O 0 9.634786302115117e-09
subunit O 0 4.622538796184017e-09
to O 0 5.89866511191417e-09
produce O 0 2.5408596115994442e-08
Hex O 0 4.6772888140367286e-07
A O 0 5.814987389385351e-07
( O 0 2.5330981756610527e-08
alphabeta O 0 7.696335160289891e-07
) O 0 8.634392756334819e-09
in O 0 3.800245096385879e-08
COS O 0 0.0015418871771544218
- O 0 5.642350515699945e-06
7 O 0 3.359008928782714e-07
cells O 0 7.170600468953126e-08
, O 0 3.4696971962233647e-09
the O 0 4.202339809467048e-09
mature O 0 1.247319136865599e-08
alpha O 0 1.3275541554946813e-08
- O 0 1.770422564106866e-08
subunit O 0 1.2066763588336471e-08
was O 0 1.359003078960086e-07
present O 0 4.715949408762299e-09
, O 0 2.201884230501605e-09
but O 0 2.019737932457133e-09
its O 0 1.3159899836523437e-08
level O 0 2.0554775659320512e-08
was O 0 1.3173692536838644e-07
much O 0 4.7620929422009795e-09
lower O 0 1.0738650502162272e-07
than O 0 9.017579571946044e-09
that O 0 2.391062015050238e-09
from O 0 1.504249169670402e-09
normal O 0 1.1497529150972241e-08
alpha O 0 1.48478367378857e-08
- O 0 1.8813834046227385e-08
subunit O 0 1.591874365658441e-08
transfections O 0 3.744383718640165e-07
, O 0 4.040541679017906e-09
although O 0 2.927713405043164e-09
higher O 0 5.536592073696056e-09
than O 0 3.3192304460527566e-09
in O 0 5.526210600237391e-09
those O 0 5.01343278003219e-09
cells O 0 6.760534176919464e-08
transfected O 0 2.487124106664851e-07
with O 0 5.067172015316146e-09
an O 0 1.0436222552812069e-08
alpha O 0 6.102742844404929e-08
- O 0 1.199325083689473e-07
subunit O 0 7.505872190449736e-08
associated O 0 1.8028845261142123e-07
with O 0 1.761346197781677e-07
infantile O 0 0.0009173108846880496
TSD B-Disease 0 0.0006712710601277649
. O 0 1.6374299320887076e-06

Furthermore O 0 2.159583345928695e-05
, O 0 1.848183757147126e-07
the O 0 2.2671404309448917e-08
precursor O 0 2.879589260373905e-07
level O 0 1.566719376455694e-08
of O 0 1.020518225480771e-09
the O 0 5.885168352648407e-09
W474C O 0 8.45954630790402e-08
alpha O 0 2.681242072810619e-08
- O 0 2.7155346415952408e-08
subunit O 0 1.5041466738807685e-08
was O 0 7.654013955971095e-08
found O 0 1.304947261360212e-08
to O 0 8.038656851283577e-09
accumulate O 0 1.1114497766584464e-07
in O 0 2.78015299670642e-09
comparison O 0 1.9533537454208272e-08
to O 0 1.2620029465892912e-08
the O 0 3.6361906818882517e-09
normal O 0 4.161748989872649e-08
alpha O 0 2.8877506608182557e-08
- O 0 7.224910802960949e-08
subunit O 0 8.81916477624145e-08
precursor O 0 4.6584673896177264e-07
levels O 0 3.203535641205235e-07
. O 0 1.8993105754816497e-07

We O 0 4.838171207666164e-06
conclude O 0 1.8574016849015607e-06
that O 0 2.222484418723525e-08
the O 0 2.4610796955926162e-08
1422 O 0 3.355072522026603e-06
G O 0 9.452245285501704e-05
- O 0 1.2972714102943428e-05
- O 0 2.3675052943872288e-05
> O 0 5.098050905871787e-07
C O 0 2.741059688560199e-06
mutation O 0 1.887958660518052e-07
is O 0 4.407190612454315e-09
the O 0 7.686005609741642e-09
cause O 0 1.8304098148291814e-07
of O 0 6.430502352827716e-09
Hex B-Disease 0 0.00010361937893321738
A I-Disease 0 0.0034392166417092085
enzyme I-Disease 1 0.9999998807907104
deficiency I-Disease 1 0.999998927116394
in O 0 3.919636526461545e-08
the O 0 1.2072776200966473e-07
proband O 0 0.00014848295541014522
. O 0 1.2225136742927134e-06

The O 0 8.511871669725224e-07
resulting O 0 5.587697273767844e-07
W474C O 0 4.4880567884320044e-07
substitution O 0 1.2826035344915e-07
clearly O 0 8.844973109489729e-08
interferes O 0 1.1779926012422948e-07
with O 0 3.6725749108512673e-09
alpha O 0 4.30630748837757e-08
- O 0 2.2417021128262604e-08
subunit O 0 1.4865916497797116e-08
processing O 0 8.960746100683536e-08
, O 0 8.08191913392875e-09
but O 0 3.5028517864077457e-09
because O 0 1.195676446741345e-09
the O 0 9.205574635906544e-10
base O 0 8.865219669473845e-09
substitution O 0 1.1034416935729041e-08
falls O 0 1.827508867791039e-06
at O 0 2.741953331053537e-08
the O 0 2.711775692887386e-09
first O 0 2.5637396205979712e-08
position O 0 4.412483178839466e-08
of O 0 1.7964402188042072e-09
exon O 0 7.03213572705863e-07
13 O 0 5.6777487600356835e-08
, O 0 5.741616959653584e-09
aberrant O 0 1.3564185508130322e-07
splicing O 0 4.867536063102307e-06
may O 0 3.210939212294761e-06
also O 0 2.840097046430401e-08
contribute O 0 1.272648386674291e-08
to O 0 3.5604863057869807e-08
Hex B-Disease 0 4.1205832530977204e-05
A I-Disease 0 0.00022374892432708293
deficiency I-Disease 0 6.651229341514409e-05
in O 0 7.973818050288628e-09
this O 0 3.0099648995474126e-08
proband O 0 2.7048115953220986e-05
. O 0 1.4816694715591439e-07
. O 0 4.122760230984568e-07

Two O 0 5.29867020304664e-06
frequent O 0 5.835177216795273e-05
missense O 0 0.004846830386668444
mutations O 0 0.06291469931602478
in O 0 0.000623938103672117
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 5.016883369535208e-05

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 0.00024619270698167384
an O 0 0.0011552072828635573
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.2661987841129303
by O 0 3.4177458019257756e-06
early O 0 0.0001373591076117009
childhood O 1 0.9014652371406555
deafness B-Disease 1 1.0
and O 1 0.5302385091781616
goiter B-Disease 1 1.0
. O 0 5.910372419748455e-05

A O 0 9.645206773711834e-06
century O 0 5.388004069573071e-07
after O 0 2.376986003582715e-07
its O 0 2.6945922826371316e-08
recognition O 0 1.6310517381157297e-08
as O 0 6.649580086559581e-08
a O 0 9.06559216673486e-06
syndrome O 1 0.7958734631538391
by O 0 3.820376548446802e-08
Vaughan O 0 2.9396080662991153e-06
Pendred O 0 5.843294275109656e-06
, O 0 6.644711447734153e-08
the O 0 1.6441461525573686e-07
disease O 0 4.720716970041394e-05
gene O 0 3.7888135011598933e-06
( O 0 2.110412395950334e-07
PDS O 0 0.00040173716843128204
) O 0 7.169793292405302e-08
was O 0 6.970454364818579e-07
mapped O 0 3.3706746762618423e-06
to O 0 3.2948724992820644e-07
chromosome O 0 8.877766958903521e-05
7q22 O 0 8.821611118037254e-06
- O 0 3.030316293006763e-05
q31 O 0 1.7826665498432703e-05
. O 0 1.1401776873753988e-06

1 O 0 3.7249530578264967e-05
and O 0 1.8380084156888188e-06
, O 0 2.069857885089732e-07
recently O 0 8.739064583096479e-07
, O 0 1.5999651381548574e-08
found O 0 9.956566238145115e-09
to O 0 5.4368007873506485e-09
encode O 0 1.5454280344329163e-07
a O 0 4.814600629288179e-07
putative O 0 6.596377352252603e-05
sulfate O 0 9.209087147610262e-05
transporter O 0 0.0012233031447976828
. O 0 3.2388738873123657e-06

We O 0 6.7848077378585e-06
performed O 0 1.3440161410471774e-06
mutation O 0 4.7362701138808916e-07
analysis O 0 3.929180181216907e-08
of O 0 2.7772273369919276e-09
the O 0 2.7869926810808465e-08
PDS B-Disease 0 0.00013984220277052373
gene O 0 2.7828605198010337e-06
in O 0 5.946859715777464e-08
patients O 0 1.489509884322615e-07
from O 0 8.359008596414697e-09
14 O 0 6.218564152504769e-08
Pendred B-Disease 0 8.729651881367317e-07
families O 0 8.239529059039796e-09
originating O 0 1.8182271688260698e-08
from O 0 7.988949946025059e-09
seven O 0 1.728563248093451e-08
countries O 0 5.489484422582791e-09
and O 0 2.9456053596277343e-08
identified O 0 3.5172348589185276e-07
all O 0 3.353666144789713e-08
mutations O 0 4.578794232656946e-06
. O 0 3.660440484054561e-07

The O 0 2.6683558189688483e-06
mutations O 0 1.123560195992468e-05
include O 0 3.023273364988199e-08
three O 0 1.4566626127532345e-08
single O 0 1.5407543685341807e-07
base O 0 2.454592049616622e-07
deletions O 0 6.373693395289592e-07
, O 0 1.4029284400862707e-08
one O 0 1.3153827360667947e-08
splice O 0 6.141483754618093e-05
site O 0 5.3889375521976035e-06
mutation O 0 2.7846922421304043e-06
and O 0 7.149392189376158e-08
10 O 0 1.9865159117671283e-07
missense O 0 6.731448956998065e-05
mutations O 0 4.314739999244921e-05
. O 0 1.957934500751435e-06

One O 0 9.68047243077308e-06
missense O 0 0.0005733345751650631
mutation O 0 0.00015095512208063155
( O 0 9.823775144468527e-07
L236P O 0 3.7446482110681245e-06
) O 0 2.3226363055073307e-07
was O 0 5.567611651713378e-07
found O 0 4.3408107330833445e-08
in O 0 7.96504728839409e-09
a O 0 1.2301853757890058e-07
homozygous O 0 4.853690143136191e-07
state O 0 7.22962223420609e-09
in O 0 9.288013025354758e-09
two O 0 2.6681465925548764e-08
consanguineous O 0 2.4613530058559263e-06
families O 0 5.1277460499932204e-08
and O 0 1.938622062880313e-08
in O 0 9.579374626866866e-09
a O 0 7.468186424830492e-08
heterozygous O 0 9.846148429915047e-08
state O 0 3.957586702796334e-09
in O 0 4.9188653150622486e-09
five O 0 3.894558009420734e-09
additional O 0 1.35568347658932e-08
non O 0 3.2373617386838305e-07
- O 0 6.975427822908387e-06
consanguineous O 0 2.4731441953917965e-05
families O 0 4.816042746824678e-07
. O 0 5.391005970523111e-07

Another O 0 1.8538234144216403e-05
missense O 0 0.001319372677244246
mutation O 0 0.00040901772445067763
( O 0 2.0704869712062646e-06
T416P O 0 6.230701728782151e-06
) O 0 2.0687330959390238e-07
was O 0 4.5821175831406435e-07
found O 0 3.838541573486509e-08
in O 0 4.037452150384979e-09
a O 0 3.476833754234576e-08
homozygous O 0 2.560847178756376e-07
state O 0 1.0799590555166105e-08
in O 0 2.462526005331256e-08
one O 0 1.2214503897212126e-07
family O 0 3.3714513847371563e-07
and O 0 6.995294654643658e-08
in O 0 4.99891861238666e-09
a O 0 6.381582551284737e-08
heterozygous O 0 8.37388540730899e-08
state O 0 5.99077853991048e-09
in O 0 7.121420786404542e-09
four O 0 4.661071528744287e-08
families O 0 1.268221723194074e-07
. O 0 3.8225454090934363e-07

Pendred B-Disease 0 0.011879113502800465
patients O 0 0.00019564763351809233
in O 0 8.02017581236214e-08
three O 0 5.167440875197826e-08
non O 0 8.602978596172761e-07
- O 0 3.1779294658917934e-05
consanguineous O 0 2.2822119717602618e-05
families O 0 2.6428628530084097e-07
were O 0 6.258628815203338e-08
shown O 0 2.0213112961187107e-08
to O 0 8.892755865019808e-09
be O 0 1.0543503847770808e-08
compound O 0 4.6526687924597354e-07
heterozygotes O 0 1.1859240203193622e-06
for O 0 2.130065723804364e-08
L236P O 0 8.318437494381214e-07
and O 0 1.0020315954761827e-07
T416P O 0 7.4628915172070265e-06
. O 0 8.596729230703204e-07

In O 0 4.169848580204416e-06
total O 0 7.020336170171504e-07
, O 0 5.3175398306848365e-08
one O 0 1.404132987659068e-08
or O 0 1.1844593750254262e-08
both O 0 2.6962925225859635e-09
of O 0 1.4300987061233172e-09
these O 0 8.801180229056627e-09
mutations O 0 1.343171788903419e-06
were O 0 6.201295121854855e-08
found O 0 3.8116205303140305e-08
in O 0 6.649653716550574e-09
nine O 0 1.2820183137307595e-08
of O 0 1.911892200112675e-09
the O 0 3.7152865672851476e-08
14 O 0 2.158404157626137e-07
families O 0 6.528569684860486e-08
analyzed O 0 2.299868128829985e-06
. O 0 1.5434883380294195e-06

The O 0 4.0626335362503596e-07
identification O 0 4.2329514826633385e-07
of O 0 1.094491430819744e-08
two O 0 3.693559946782443e-08
frequent O 0 2.2616479782300303e-06
PDS B-Disease 0 0.004127755295485258
mutations O 0 2.250175384688191e-05
will O 0 1.2749248767818244e-08
facilitate O 0 1.813126004890364e-08
the O 0 2.645338348372661e-08
molecular O 0 2.706276973185595e-05
diagnosis O 0 0.03165001422166824
of O 0 2.679645513126161e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.175094166683266e-05

Insertional O 0 0.00145269266795367
mutation O 0 4.739351061289199e-05
by O 0 3.069249601139745e-07
transposable O 0 2.1776335415779613e-05
element O 0 1.4918656461304636e-06
, O 0 2.7957781867371523e-07
L1 O 0 3.437136183492839e-05
, O 0 6.001554453405333e-08
in O 0 1.3869541071187541e-08
the O 0 2.3233495483054867e-07
DMD B-Disease 1 0.9999991655349731
gene O 0 1.7708058294374496e-05
results O 0 1.5766742080813856e-06
in O 0 1.1896163698565942e-07
X B-Disease 1 0.8982712030410767
- I-Disease 1 0.9857258796691895
linked I-Disease 1 0.9995546936988831
dilated I-Disease 1 0.9992339611053467
cardiomyopathy I-Disease 1 0.9999997615814209
. O 0 1.3730802493228111e-05

X B-Disease 1 0.9993403553962708
- I-Disease 1 0.9991284012794495
linked I-Disease 1 0.9966092109680176
dilated I-Disease 1 0.9999721050262451
cardiomyopathy I-Disease 1 1.0
( O 0 2.8682321499218233e-05
XLDCM B-Disease 0 0.0053464630618691444
) O 0 1.8614629482271994e-07
is O 0 1.96814848862914e-08
a O 0 1.7457469425607997e-07
clinical O 0 2.602683252916904e-06
phenotype O 0 1.0423527783132158e-05
of O 0 5.379872192179391e-08
dystrophinopathy B-Disease 0 0.00011941703269258142
which O 0 1.0386773965365137e-06
is O 0 1.240808558122808e-07
characterized O 0 4.309602843477478e-07
by O 0 3.3634478313615546e-08
preferential O 0 2.4473663870594464e-05
myocardial B-Disease 0 0.3650170564651489
involvement I-Disease 0 1.9703491034306353e-06
without O 0 2.698856249594428e-08
any O 0 1.1920677778221034e-08
overt O 0 6.18395631590829e-07
clinical O 0 1.4420301113204914e-06
signs O 0 2.413675019852235e-06
of O 0 5.981064532534219e-06
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 0.00010502008080948144

To O 0 3.791531753449817e-06
date O 0 1.2359774927972467e-06
, O 0 2.2025488988219877e-08
several O 0 1.1047347037163036e-08
mutations O 0 5.445270971904392e-07
in O 0 3.3045136405007725e-08
the O 0 1.3517881143343402e-06
Duchenne B-Disease 1 0.9999817609786987
muscular I-Disease 1 0.9887145161628723
dystrophy I-Disease 1 0.9930016398429871
gene O 0 0.00019010258256457746
, O 0 4.899928626400651e-06
DMD O 1 1.0
, O 0 1.7035786186170299e-06
have O 0 7.336671359325919e-08
been O 0 1.332265071596339e-07
identified O 0 8.277958158942056e-07
in O 0 9.01675747400077e-08
patients O 0 1.7949756170310138e-07
with O 0 9.947719981084902e-09
XLDCM B-Disease 0 0.00029488347354345024
, O 0 9.259697719699034e-08
but O 0 4.670983155818931e-09
a O 0 5.317384754732757e-09
pathogenic O 0 2.7941782221319045e-08
correlation O 0 3.965658379456727e-08
of O 0 4.298419398196529e-09
these O 0 1.640671243308134e-08
cardiospecific O 0 8.12434300314635e-05
mutations O 0 3.4803808375727385e-05
in O 0 6.932401674930588e-07
DMD O 1 0.9999996423721313
with O 0 2.3527975656634226e-07
the O 0 2.8992226930313336e-07
XLDCM B-Disease 0 0.022098196670413017
phenotype O 0 0.00017668768123257905
has O 0 5.077817490928282e-07
remained O 0 5.385446115724335e-07
to O 0 4.222291138944456e-08
be O 0 1.2342418642674602e-07
elucidated O 0 1.4392272532859351e-05
. O 0 8.480359952045546e-07

We O 0 4.6466284402413294e-05
report O 0 2.212099161624792e-06
here O 0 9.81855752257843e-09
the O 0 1.852807796076661e-09
identification O 0 1.5540440045924697e-08
of O 0 2.042057634099592e-09
a O 0 3.455130581642152e-08
unique O 0 1.1479762207500244e-07
de O 0 9.676241461420432e-07
novo O 0 2.148209205188323e-06
L1 O 0 2.9195095976319863e-06
insertion O 0 2.1031472385857342e-07
in O 0 1.3714545943344092e-08
the O 0 1.2190829679070703e-08
muscle O 0 2.956283537969284e-07
exon O 0 1.3380476957536303e-06
1 O 0 6.350546186695283e-07
in O 0 5.852970730302332e-07
DMD O 1 0.9999997615814209
in O 0 4.92740355184651e-07
three O 0 2.569629771187465e-07
XLDCM B-Disease 0 0.005860296543687582
patients O 0 1.407992954227666e-06
from O 0 4.16323953089659e-09
two O 0 9.745866336174913e-09
unrelated O 0 3.642304875484115e-07
Japanese O 0 4.2694600210779754e-07
families O 0 1.738566055564661e-07
. O 0 6.298747052824183e-07

The O 0 6.061306407900702e-07
insertion O 0 1.4103326293479768e-06
was O 0 3.8826195236651984e-07
a O 0 2.928619835529389e-08
5 O 0 1.1031076496692549e-07
- O 0 8.318143613905704e-07
truncated O 0 7.752246347081382e-07
form O 0 2.6343668579897894e-08
of O 0 3.4811784566102233e-09
human O 0 2.5372951739655036e-08
L1 O 0 1.8852035736927064e-06
inversely O 0 1.6360097276901797e-07
integrated O 0 3.029958577371872e-07
in O 0 2.1142191997114423e-08
the O 0 1.6570185223940825e-08
5 O 0 5.875833721802337e-07
- O 0 9.36456308409106e-06
untranslated O 0 8.785482350504026e-05
region O 0 1.7321989389529335e-06
in O 0 1.749666367345526e-08
the O 0 1.1778921837901635e-08
muscle O 0 3.3199543736373016e-07
exon O 0 1.0839211199709098e-06
1 O 0 1.872426906857072e-07
, O 0 1.4563791950195082e-08
which O 0 1.847300445945166e-08
affected O 0 6.991997203442679e-09
the O 0 3.246362956232929e-09
transcription O 0 1.5287291432741767e-07
or O 0 8.868487810786974e-08
the O 0 1.7493091419851226e-08
stability O 0 3.3641609320511634e-07
of O 0 5.337992714515849e-09
the O 0 3.12572794314292e-08
muscle O 0 2.880517513403902e-07
form O 0 1.878701105795244e-08
of O 0 8.685712593603512e-09
dystrophin O 0 1.7342435967293568e-06
transcripts O 0 8.059353717726481e-07
but O 0 1.6923644707844687e-08
not O 0 2.9692557301785882e-09
that O 0 2.0326886840393854e-09
of O 0 2.1063490951434005e-09
the O 0 8.540071405604976e-08
brain O 0 2.6078261726070195e-05
or O 0 3.978637153068121e-07
Purkinje O 0 8.304302900796756e-05
cell O 0 4.514014290180057e-05
form O 0 4.2732889937724394e-07
, O 0 2.670820435923815e-07
probably O 0 2.5320119334537594e-07
due O 0 3.231266632042207e-08
to O 0 1.2037982166646088e-08
its O 0 7.137033719573083e-08
unique O 0 1.4578022344835517e-08
site O 0 4.715646184649813e-07
of O 0 1.6501553901093757e-08
integration O 0 1.1923631291210768e-06
. O 0 8.9654707835507e-07

We O 0 1.0671982636267785e-05
speculate O 0 1.8430441741656978e-06
that O 0 1.9776688731099057e-08
this O 0 2.2841974978149437e-09
insertion O 0 5.5509968177602786e-08
of O 0 5.232530408960656e-09
an O 0 2.8164370391436933e-08
L1 O 0 1.9572791643440723e-05
sequence O 0 6.44059525711782e-07
in O 0 1.9619326394604286e-06
DMD O 1 1.0
is O 0 2.2313504359772196e-06
responsible O 0 4.365549841622851e-07
for O 0 5.352980725348289e-09
some O 0 9.011419943583121e-10
of O 0 1.2442532559830966e-09
the O 0 1.1993796178444427e-08
population O 0 1.4649377710895806e-08
of O 0 2.715419222809601e-09
Japanese O 0 3.8146174574649194e-07
patients O 0 6.895767512560269e-08
with O 0 7.743702568063782e-09
XLDCM B-Disease 0 6.557322922162712e-05
. O 0 2.1477103473444004e-07
. O 0 5.520419108506758e-07

Severe O 0 0.19362594187259674
early O 0 7.361063762800768e-05
- O 1 0.9863457083702087
onset O 1 0.9997115731239319
obesity B-Disease 1 1.0
, O 0 0.008300048299133778
adrenal B-Disease 1 0.9999998807907104
insufficiency I-Disease 1 0.9999998807907104
and O 0 1.022362630465068e-05
red O 0 4.4522170355776325e-05
hair O 1 0.9896088242530823
pigmentation O 0 0.3708573281764984
caused O 0 1.7906542780110613e-05
by O 0 7.159243864407472e-08
POMC O 0 0.00034942280035465956
mutations O 0 2.3942771804286167e-05
in O 0 8.209428870031843e-08
humans O 0 1.192877221001254e-06
. O 0 1.5518675127168535e-06

Sequential O 0 0.00016334551037289202
cleavage O 0 5.632224565488286e-05
of O 0 1.3636534390570887e-07
the O 0 3.948367321982005e-08
precursor O 0 5.943707037658896e-07
protein O 0 4.09357227226792e-07
pre O 0 1.8303345541426097e-06
- O 0 6.309933269221801e-06
pro O 0 3.3098551739385584e-06
- O 0 5.29081116837915e-05
opiomelanocortin O 0 7.589947199448943e-05
( O 0 8.390320260787121e-08
POMC O 0 4.696303221862763e-06
) O 0 1.203871669019918e-08
generates O 0 6.303771016291648e-08
the O 0 2.216566130641695e-08
melanocortin O 0 5.700476776837604e-06
peptides O 0 6.196571575856069e-07
adrenocorticotrophin O 0 2.0698569642263465e-05
( O 0 1.8643871158019465e-07
ACTH O 0 6.952211151656229e-06
) O 0 2.2312935499257947e-08
, O 0 1.7974279842292162e-08
melanocyte O 0 5.9249455262033734e-06
- O 0 3.490132439765148e-05
stimulating O 0 1.746014822856523e-05
hormones O 0 1.8937790855488856e-06
( O 0 3.05720746496263e-08
MSH O 0 3.2346415537176654e-06
) O 0 3.3721117009832824e-09
alpha O 0 1.3902170081792065e-08
, O 0 2.1777677439160925e-09
beta O 0 3.1445868131640964e-09
and O 0 8.535877560333915e-10
gamma O 0 9.581712312467516e-09
as O 0 1.5438210709817213e-09
well O 0 9.634119058077317e-10
as O 0 1.494269263879744e-09
the O 0 3.3095457485643465e-09
opioid O 0 5.775207156943907e-08
- O 0 1.613625215668435e-07
receptor O 0 6.717448997051179e-08
ligand O 0 2.5976248707593186e-07
beta O 0 3.8346456676663365e-07
- O 0 3.995354290964315e-06
endorphin O 0 7.461391214746982e-05
. O 0 6.035396040715568e-07

While O 0 2.144631253031548e-06
a O 0 1.4419542537780217e-07
few O 0 2.8682856978434756e-08
cases O 0 2.4071797000146944e-08
of O 0 3.536985815344451e-08
isolated O 0 0.01096600852906704
ACTH B-Disease 1 0.9995844960212708
deficiency I-Disease 0 0.15047629177570343
have O 0 1.3779130370039638e-07
been O 0 1.2139339560235385e-06
reported O 0 3.355321678100154e-05
( O 0 1.393676853922443e-07
OMIM O 0 0.00011186260235263035
201400 O 0 4.047087259095861e-06
) O 0 4.620637028551755e-08
, O 0 2.5091321020909163e-08
an O 0 2.5397847025487863e-07
inherited O 0 0.015386277809739113
POMC O 1 0.9041160345077515
defect O 0 0.028208566829562187
has O 0 7.387192795249575e-07
not O 0 6.184392020713858e-08
been O 0 8.27891497579003e-08
described O 0 7.876998893152631e-07
so O 0 8.273658380630877e-08
far O 0 4.243731268616102e-07
. O 0 6.507764283014694e-07

Recent O 0 1.2306093594816048e-05
studies O 0 4.4236745111447817e-07
in O 0 6.886462244892755e-08
animal O 0 3.7001709074502287e-07
models O 0 8.966770224105858e-07
elucidated O 0 8.742873660594341e-07
a O 0 3.2937030880475504e-08
central O 0 3.003192361461515e-08
role O 0 1.7964341125775718e-08
of O 0 5.0142836549582626e-09
alpha O 0 2.0737780914714676e-07
- O 0 3.0316489301185356e-06
MSH O 0 1.5201938367681578e-05
in O 0 1.0572219544258132e-08
the O 0 2.3082415978592508e-09
regulation O 0 1.0501958414010915e-08
of O 0 1.9137527118573416e-09
food O 0 4.3798742410672276e-08
intake O 0 3.280468163779915e-08
by O 0 1.7414685249406148e-09
activation O 0 1.3145224464494731e-08
of O 0 1.6601875429955726e-09
the O 0 1.1159680468608713e-07
brain O 0 2.776689871097915e-05
melanocortin O 0 6.332968496280955e-06
- O 0 2.8015697353112046e-06
4 O 0 8.0807490121515e-07
- O 0 2.6031477773358347e-06
receptor O 0 2.322357062212177e-07
( O 0 3.176489826728357e-08
MC4 O 0 7.5232314884488005e-06
- O 0 4.471336069400422e-06
R O 0 1.3579626283899415e-05
; O 0 5.288731941277547e-08
refs O 0 4.3100754965053056e-07
3 O 0 1.434156331470149e-07
- O 0 1.2976199741387973e-06
5 O 0 1.799232904886594e-07
) O 0 4.740904113731403e-09
and O 0 2.6653474982651915e-09
the O 0 6.177869771306632e-09
linkage O 0 2.297368837389513e-06
of O 0 8.99357033290471e-08
human O 0 1.3678067261935212e-05
obesity B-Disease 1 0.9999740123748779
to O 0 9.973663281925838e-07
chromosome O 0 5.510766277438961e-05
2 O 0 8.243059141932463e-07
in O 0 3.618377419911667e-08
close O 0 2.6026287969216355e-07
proximity O 0 1.4168126938329806e-07
to O 0 1.608107140782522e-07
the O 0 8.118662719880376e-08
POMC O 0 1.7141019270638935e-05
locus O 0 1.1749862096621655e-06
, O 0 2.4232708284444016e-08
led O 0 4.938663256126574e-09
to O 0 7.804228374652666e-09
the O 0 5.539983138902471e-09
proposal O 0 4.5874518406208153e-08
of O 0 2.719192426781092e-09
an O 0 8.11578289017234e-08
association O 0 3.9084010694523386e-08
of O 0 1.0498372837730585e-08
POMC O 0 7.504418317694217e-05
with O 0 7.280895033545676e-07
human O 0 4.2036066588480026e-05
obesity B-Disease 1 0.9999289512634277
. O 0 2.7971061626885785e-06

The O 0 8.128639024107542e-07
dual O 0 2.5303199890913675e-06
role O 0 4.5249953473103233e-07
of O 0 4.692103772185874e-08
alpha O 0 1.110375137614028e-06
- O 0 1.3725552889809478e-05
MSH O 0 4.541900125332177e-05
in O 0 2.734599569009788e-08
regulating O 0 7.633399690121223e-08
food O 0 6.583590561604069e-08
intake O 0 2.543017956213589e-07
and O 0 7.81585143272423e-08
influencing O 0 4.9505856623e-06
hair O 0 0.10498553514480591
pigmentation O 0 0.0018680841894820333
predicts O 0 0.00010373207624070346
that O 0 1.9642556026155944e-08
the O 0 1.650139580533505e-08
phenotype O 0 6.135707735666074e-06
associated O 0 6.946697084231346e-08
with O 0 8.904671666698505e-09
a O 0 1.4367287803906947e-06
defect O 0 2.0727784431073815e-05
in O 0 4.662298280777577e-08
POMC O 0 1.74152464751387e-05
function O 0 1.83566115197209e-07
would O 0 2.919145742907858e-07
include O 0 4.5184881969362323e-07
obesity B-Disease 1 0.99997878074646
, O 0 3.1009247436486476e-07
alteration O 0 6.428668257285608e-06
in O 0 9.452398330722644e-07
pigmentation O 0 0.4551771879196167
and O 0 0.001338303554803133
ACTH B-Disease 1 0.9786489605903625
deficiency I-Disease 0 0.00511924410238862
. O 0 1.1491409850350465e-06

The O 0 1.4277208038038225e-06
observation O 0 2.1206988094490953e-06
of O 0 4.62905234144273e-08
these O 0 7.473187935147507e-08
symptoms O 0 5.928913196839858e-06
in O 0 6.6409335808259584e-09
two O 0 3.850134433491803e-08
probands O 0 1.4067235497350339e-05
prompted O 0 1.068387760483347e-07
us O 0 3.333647313752408e-08
to O 0 7.845047278465245e-09
search O 0 2.463846193734298e-08
for O 0 1.7371897698126304e-08
mutations O 0 4.109648727990134e-07
within O 0 1.8526037592891953e-08
their O 0 3.828952230833238e-07
POMC O 0 0.00034274012432433665
genes O 0 6.692595434287796e-06
. O 0 1.726491177578282e-06

Patient O 0 0.009429384022951126
1 O 0 2.048331589321606e-05
was O 0 4.376423021312803e-06
found O 0 1.5540622655407788e-07
to O 0 1.9178024501798063e-08
be O 0 4.0859484684574454e-09
a O 0 1.308501307306642e-08
compound O 0 2.089355035650442e-07
heterozygote O 0 4.823028803002671e-07
for O 0 7.990443862126995e-09
two O 0 1.4154319494252832e-08
mutations O 0 7.206591590147582e-07
in O 0 2.068732385396288e-08
exon O 0 4.067148893227568e-06
3 O 0 1.9045083945457009e-06
( O 0 3.564332118344282e-08
G7013T O 0 2.657638447089994e-07
, O 0 5.685735970928363e-08
C7133delta O 0 5.2795285228057764e-06
) O 0 1.9230954606541673e-08
which O 0 1.280405470538426e-08
interfere O 0 3.0892294944351306e-08
with O 0 2.8967079845898525e-09
appropriate O 0 9.00245655799381e-09
synthesis O 0 3.8204424868126807e-07
of O 0 6.485329606675805e-08
ACTH O 0 2.2799737052991986e-05
and O 0 6.713951705705767e-08
alpha O 0 6.20553123553691e-07
- O 0 1.1699974493240006e-05
MSH O 0 0.00028305096202529967
. O 0 7.300474749172281e-07

Patient O 0 0.006084006279706955
2 O 0 1.2455938303901348e-05
was O 0 2.29434317589039e-06
homozygous O 0 4.7269293190765893e-07
for O 0 7.516213429425989e-09
a O 0 4.997624714064841e-08
mutation O 0 6.10994106864382e-07
in O 0 4.679804987972602e-08
exon O 0 5.223307198320981e-06
2 O 0 3.363732275829534e-06
( O 0 4.688498123073259e-08
C3804A O 0 5.884014626644785e-07
) O 0 4.2802266619901275e-08
which O 0 2.0375500753289089e-07
abolishes O 0 0.00010161046520806849
POMC O 0 0.00045473012141883373
translation O 0 7.906216524133924e-06
. O 0 1.3079595646559028e-06

These O 0 1.4074814771447564e-06
findings O 0 1.3343991440706304e-06
represent O 0 3.100835854752404e-08
the O 0 5.448219209114313e-09
first O 0 3.240722534769702e-08
examples O 0 7.557685144377047e-09
of O 0 7.429382442580845e-09
a O 0 1.2322829206823371e-05
genetic B-Disease 1 0.9999988079071045
defect I-Disease 1 0.9997254014015198
within O 0 2.6953067333579384e-08
the O 0 2.8698504905833033e-08
POMC O 0 1.2958247680217028e-05
gene O 0 3.604367293519317e-07
and O 0 9.870042561033188e-09
define O 0 8.947868934683356e-08
a O 0 2.46787749347277e-07
new O 0 9.611763744032942e-06
monogenic B-Disease 1 0.9023115038871765
endocrine I-Disease 1 0.9965567588806152
disorder I-Disease 0 0.030900444835424423
resulting O 0 4.29281755032207e-07
in O 0 6.368632199382773e-08
early O 0 6.3566149037797e-06
- O 1 0.9969403743743896
onset O 1 0.9990009665489197
obesity B-Disease 1 1.0
, O 0 0.0008541489951312542
adrenal B-Disease 1 0.9999997615814209
insufficiency I-Disease 1 0.9999997615814209
and O 0 2.8909942102472996e-06
red O 0 2.1266461772029288e-05
hair O 1 0.7643610239028931
pigmentation O 0 0.0024523595348000526
. O 0 4.6517106966348365e-07
. O 0 7.456677622030838e-07

A O 0 3.776537414523773e-05
European O 0 1.412401888956083e-05
multicenter O 0 0.00021562330948654562
study O 0 2.2006483959557954e-06
of O 0 3.0940352644392988e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 4.4523150677378e-07
classification O 0 4.491803053952026e-07
of O 0 5.669608338365606e-09
105 O 0 1.07283327110963e-07
mutations O 0 1.5150512808759231e-06
and O 0 2.0970821523746963e-08
a O 0 3.586919916642728e-08
general O 0 1.3046336455602159e-08
system O 0 2.4731448888815066e-08
for O 0 2.1371549863147266e-08
genotype O 0 8.436505595454946e-06
- O 0 1.962611531780567e-05
based O 0 5.022924142394913e-06
prediction O 0 1.061943476088345e-05
of O 0 1.4494352740257455e-07
metabolic O 0 0.0016371001256629825
phenotype O 0 0.0004655344528146088
. O 0 2.642716935952194e-06

Phenylketonuria B-Disease 1 0.9994783997535706
( O 0 0.000584818422794342
PKU B-Disease 0 0.028210891410708427
) O 0 4.323064786149189e-06
and O 0 5.416461590357358e-06
mild B-Disease 0 0.18329982459545135
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.005802202504128218
MHP B-Disease 1 1.0
) O 0 4.099995294382097e-07
are O 0 3.3639096841397986e-08
allelic B-Disease 0 8.190939843188971e-05
disorders I-Disease 1 0.8432416319847107
caused O 0 2.4853036393324146e-06
by O 0 2.7375010702712643e-08
mutations O 0 1.5323649904530612e-06
in O 0 1.1807713917733054e-08
the O 0 2.7125944157546655e-08
gene O 0 1.6904598396649817e-06
encoding O 0 4.667664597945986e-06
phenylalanine O 0 0.0006163841462694108
hydroxylase O 0 0.0702819973230362
( O 0 3.91577668779064e-06
PAH O 0 0.000752990716136992
) O 0 9.538388212604332e-07
. O 0 1.372973429170088e-06

Previous O 0 5.456928920466453e-05
studies O 0 2.2204733340913663e-06
have O 0 1.3161537992800731e-07
suggested O 0 1.2251931025275553e-07
that O 0 6.292452336964516e-09
the O 0 8.531650053100748e-09
highly O 0 1.1318546455640899e-07
variable O 0 7.069414095894899e-06
metabolic O 0 0.0006474988185800612
phenotypes O 0 5.337545371730812e-05
of O 0 4.0087888919515535e-06
PAH B-Disease 1 0.9999866485595703
deficiency I-Disease 1 0.8972267508506775
correlate O 0 1.8014983652392402e-05
with O 0 1.719857095849875e-06
PAH O 1 0.8443254232406616
genotypes O 0 0.0005724201910197735
. O 0 2.2208587324712425e-06

We O 0 3.388197683307226e-06
identified O 0 4.170017575688689e-07
both O 0 1.707193497679782e-08
causative O 0 2.2868939595355187e-06
mutations O 0 1.9364257241250016e-05
in O 0 3.351952955199522e-07
686 O 0 3.809467671089806e-05
patients O 0 8.584614988649264e-06
from O 0 2.5471724285353048e-08
seven O 0 6.015042686158267e-08
European O 0 8.711048735676741e-07
centers O 0 3.7844984035473317e-07
. O 0 6.442468816203473e-07

On O 0 1.672889084147755e-06
the O 0 2.0027565383884394e-08
basis O 0 2.0239927067677854e-08
of O 0 2.6194397761969412e-09
the O 0 9.805775746940526e-09
phenotypic O 0 3.9471331092499895e-07
characteristics O 0 1.34996085421335e-07
of O 0 1.330344989725063e-08
297 O 0 7.890276947364327e-07
functionally O 0 1.1494553291413467e-05
hemizygous O 0 7.491448923246935e-05
patients O 0 1.9576264094212092e-06
, O 0 5.811669367972172e-09
105 O 0 9.395454192429042e-09
of O 0 3.0400755246517974e-09
the O 0 4.20859045391353e-08
mutations O 0 2.770296077869716e-06
were O 0 5.206628728160467e-08
assigned O 0 1.6418638892901072e-08
to O 0 6.275863384530567e-09
one O 0 4.882718229737293e-09
of O 0 2.1687811546655666e-09
four O 0 4.1321587929132875e-08
arbitrary O 0 2.7402129489928484e-06
phenotype O 0 2.9337881642277353e-05
categories O 0 1.8439600353303831e-06
. O 0 9.940418976839283e-07

We O 0 4.245291620463831e-06
proposed O 0 7.837958833079028e-07
and O 0 1.7084484227325447e-07
tested O 0 1.5187706026154046e-07
a O 0 2.5273648063262044e-08
simple O 0 2.5101945411165616e-08
model O 0 1.7665912821485108e-07
for O 0 1.8041774296762014e-08
correlation O 0 4.289449577754567e-07
between O 0 2.933546170424961e-07
genotype O 0 7.1376322011929e-05
and O 0 1.0858756240850198e-06
phenotypic O 0 1.2459157005650923e-05
outcome O 0 6.88997579345596e-06
. O 0 1.7458197589803603e-06

The O 0 2.3039117422740674e-06
observed O 0 2.9987563721078914e-06
phenotype O 0 1.3146826859156135e-05
matched O 0 1.367614231639891e-06
the O 0 9.187129279553119e-08
predicted O 0 8.727697604626883e-06
phenotype O 0 4.869486474490259e-06
in O 0 9.696456970686995e-08
79 O 0 2.815132802425069e-07
% O 0 8.532821560436332e-09
of O 0 2.126411269287587e-09
the O 0 4.25903685652429e-08
cases O 0 7.798711010309489e-08
, O 0 4.006217935170753e-08
and O 0 4.3797740545414854e-08
in O 0 1.3045839075687127e-08
only O 0 6.762594928488852e-09
5 O 0 3.5686994692696317e-08
of O 0 2.6754884974167226e-09
184 O 0 1.7778916117094923e-07
patients O 0 3.8178893646545475e-07
was O 0 9.893870611676903e-08
the O 0 1.1733358284971018e-08
observed O 0 4.055012254866597e-07
phenotype O 0 6.835725230303069e-07
more O 0 4.374661966011217e-09
than O 0 3.256844127719205e-09
one O 0 1.0760810909005158e-08
category O 0 7.186208961229568e-08
away O 0 8.420700936540015e-08
from O 0 1.5129337782582297e-08
that O 0 5.0051319533395144e-08
expected O 0 1.2207906365802046e-06
. O 0 5.38399831384595e-07

Among O 0 1.0394066976004979e-06
the O 0 4.90706035805033e-08
seven O 0 5.6458915764778794e-08
contributing O 0 9.399293787737406e-08
centers O 0 2.2470187488465854e-08
, O 0 6.574866429076565e-09
the O 0 2.7587490070146714e-09
proportion O 0 4.504320472165091e-08
of O 0 1.600404786472609e-08
patients O 0 2.896053103995655e-07
for O 0 1.84957471560665e-08
whom O 0 1.946648353623459e-07
the O 0 4.6989999447077935e-08
observed O 0 1.4792201454838505e-06
phenotype O 0 5.152106496097986e-06
did O 0 1.7658098272477218e-07
not O 0 5.144867643025464e-09
match O 0 3.256826985875705e-08
the O 0 2.7228006516111236e-08
predicted O 0 5.708805929316441e-06
phenotype O 0 1.2822160897485446e-06
was O 0 1.42092630994739e-07
4 O 0 7.809622104559821e-08
% O 0 1.7597972856719934e-08
- O 0 1.0812120763148414e-06
23 O 0 6.345176757349691e-07
% O 0 4.399868558380149e-08
( O 0 3.15036956521908e-08
P O 0 7.19811869203113e-05
< O 0 3.498253988709621e-07
. O 0 5.130827673838212e-08
0001 O 0 2.617918426039978e-06
) O 0 1.4586588825693525e-08
, O 0 6.124218909775436e-09
suggesting O 0 3.45863178097261e-08
that O 0 3.905239687185258e-09
differences O 0 3.019924577074562e-08
in O 0 7.384091116335867e-09
methods O 0 2.738837956428597e-08
used O 0 5.412343995203628e-08
for O 0 1.968358631643241e-08
mutation O 0 3.648872279882198e-07
detection O 0 6.283303832788079e-07
or O 0 6.309923605840595e-07
phenotype O 0 5.273021088214591e-05
classification O 0 3.141134584438987e-05
may O 0 6.094785476307152e-06
account O 0 5.504322331262301e-08
for O 0 4.8169219724059076e-09
a O 0 2.2424718082447725e-08
considerable O 0 2.1596884280938866e-08
proportion O 0 1.6893109489046765e-07
of O 0 4.132631659103936e-08
genotype O 0 0.0003125878283753991
- O 0 0.009127766825258732
phenotype O 0 0.0030740746296942234
inconsistencies O 0 0.0001926385157275945
. O 0 1.7896528561323066e-06

Our O 0 7.656964953639545e-06
data O 0 3.988517619291088e-06
indicate O 0 5.587835971709865e-07
that O 0 2.5637591605232046e-08
the O 0 3.463246045498636e-08
PAH O 0 0.0003466552298050374
- O 0 0.00019896675075870007
mutation O 0 6.260231657506665e-06
genotype O 0 4.21924642068916e-06
is O 0 8.552341057566082e-09
the O 0 1.9216022106860464e-09
main O 0 7.568002757807335e-08
determinant O 0 9.780260370462202e-07
of O 0 2.514363650618634e-08
metabolic O 0 8.110278577078134e-05
phenotype O 0 2.094243245664984e-05
in O 0 1.1774029218258875e-07
most O 0 3.584858063732099e-07
patients O 0 4.1840976336970925e-06
with O 0 2.549499413362355e-06
PAH B-Disease 1 0.9999692440032959
deficiency I-Disease 1 0.7589075565338135
. O 0 1.6318848565788358e-06

In O 0 2.44092757384351e-06
the O 0 8.425874398199085e-08
present O 0 6.845315425607623e-08
study O 0 3.897770284311264e-08
, O 0 1.1014231304784516e-08
the O 0 5.756991328098593e-09
classification O 0 3.169376157075021e-07
of O 0 9.485484397941946e-09
105 O 0 5.9020669596066e-07
PAH O 0 0.0011193840764462948
mutations O 0 4.272249134373851e-05
may O 0 3.0874926437718386e-07
allow O 0 3.7051226531303882e-09
the O 0 6.387474105196134e-09
prediction O 0 8.079269377958553e-07
of O 0 1.8569754622888013e-09
the O 0 1.2867611864919581e-08
biochemical O 0 1.5348103943324531e-06
phenotype O 0 4.119024652027292e-06
in O 0 2.6964379173932684e-08
> O 0 1.6593121188179794e-07
10 O 0 8.040209564796896e-08
, O 0 8.377075921828236e-09
000 O 0 3.311687990503742e-08
genotypes O 0 3.6467849895416293e-07
, O 0 5.2054968335824015e-08
which O 0 2.7809161906588997e-07
may O 0 6.303061468315718e-07
be O 0 3.589156305494612e-09
useful O 0 6.8007270925818375e-09
for O 0 6.9498491406250196e-09
the O 0 2.1737021071999152e-08
management O 0 1.919617716339417e-06
of O 0 8.096456127759666e-08
hyperphenylalaninemia B-Disease 1 0.9999924898147583
in O 0 2.859109599739895e-06
newborns O 0 3.345078221173026e-05
. O 0 6.808367061239551e-07

Somatic O 0 0.0015063235769048333
instability O 0 0.0001380899193463847
of O 0 3.896165594596823e-07
the O 0 3.714380056862865e-07
CTG O 0 0.0002549065393395722
repeat O 0 2.6108347810804844e-05
in O 0 9.263424516348095e-08
mice O 0 2.289416443090886e-06
transgenic O 0 1.8799933059199248e-06
for O 0 2.072512614859079e-07
the O 0 8.195290320145432e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 0.0003065673226956278
is O 0 1.0025570418292773e-06
age O 0 4.796013186592063e-08
dependent O 0 1.0189903321133897e-07
but O 0 3.42253230201095e-08
not O 0 7.583518701892444e-09
correlated O 0 8.362983550114222e-08
to O 0 5.351857179647368e-09
the O 0 3.3950091626877565e-09
relative O 0 5.072076803003256e-08
intertissue O 0 1.2155210242781322e-06
transcription O 0 5.717402586924436e-07
levels O 0 1.8881117114233348e-07
and O 0 1.3015696254115028e-07
proliferative O 0 0.0001827821251936257
capacities O 0 4.1957614484999795e-06
. O 0 9.274532999370422e-07

A O 0 6.330219184746966e-05
( O 0 1.757090785758919e-06
CTG O 0 5.5601700296392664e-05
) O 0 1.741785666808937e-07
nexpansion O 0 1.9042960275328369e-06
in O 0 2.0431961900158058e-08
the O 0 2.109759833501812e-08
3 O 0 1.4193553852237528e-06
- O 0 0.00030653460999019444
untranslated O 0 0.005145319737493992
region O 0 2.500387745385524e-05
( O 0 5.987764950532437e-08
UTR O 0 3.953864961658837e-06
) O 0 7.679147984163137e-09
of O 0 3.029280826183367e-09
the O 0 3.1092872632143553e-07
DM O 1 0.9999995231628418
protein O 0 4.612774318957236e-06
kinase O 0 1.1965759767917916e-05
gene O 0 2.4020719138206914e-06
( O 0 3.4615027288964484e-08
DMPK O 0 2.2103526134742424e-05
) O 0 4.211826620803549e-08
is O 0 3.138093518373353e-08
responsible O 0 2.2986532712820917e-06
for O 0 8.363902452401817e-06
causing O 1 0.9931198358535767
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.012529034167528152
DM B-Disease 1 1.0
) O 0 4.910135430691298e-06
. O 0 1.5431674000865314e-06

Major O 0 1.8785161955747753e-05
instability O 0 1.740422158036381e-05
, O 0 1.7063381108073372e-07
with O 0 1.1901684970894166e-08
very O 0 1.0632158264911595e-08
large O 0 6.965534815606134e-09
expansions O 0 1.47494191082842e-07
between O 0 1.3268731891002972e-08
generations O 0 5.802789004860642e-08
and O 0 3.7769549265931346e-08
high O 0 5.3080142947692366e-08
levels O 0 6.933206009307469e-09
of O 0 2.3806683291383024e-09
somatic O 0 9.762713943928247e-07
mosaicism O 0 1.5047547094582114e-05
, O 0 4.5850548247017286e-08
is O 0 1.2996440368340245e-08
observed O 0 1.4664284719856369e-07
in O 0 1.571652603615803e-07
patients O 0 1.1431184248067439e-06
. O 0 4.747471393784508e-07

There O 0 2.370204811086296e-06
is O 0 5.564194438534287e-08
a O 0 9.265015421533462e-08
good O 0 1.8185676253779093e-07
correlation O 0 4.536540814115142e-07
between O 0 1.357663563794631e-07
repeat O 0 2.4283466700580902e-05
size O 0 1.0676926649466623e-06
( O 0 6.620233250487217e-08
at O 0 2.104575571593159e-07
least O 0 3.4069010723669635e-08
in O 0 4.133569930786507e-08
leucocytes O 0 2.425204002065584e-05
) O 0 6.294015264529662e-08
, O 0 7.071006535852575e-08
clinical O 0 5.838815582137613e-07
severity O 0 6.122813374531688e-06
and O 0 2.9199921414146957e-07
age O 0 5.9569522647962e-08
of O 0 4.277337239955159e-08
onset O 0 2.6772240744321607e-05
. O 0 1.5409997331516934e-06

The O 0 6.447615760407643e-06
trinucleotide O 0 0.0007924968376755714
repeat O 0 0.000125860286061652
instability O 0 5.623887318506604e-06
mechanisms O 0 7.039865863589512e-07
involved O 0 4.547677860955446e-07
in O 0 3.2014449971029535e-06
DM B-Disease 1 1.0
and O 0 5.4752204050600994e-06
other O 0 2.6968501742885564e-07
human O 0 1.2027481716359034e-05
genetic B-Disease 1 0.9999997615814209
diseases I-Disease 1 0.9999998807907104
are O 0 3.6852989637736755e-07
unknown O 0 3.8628154470643494e-06
. O 0 1.2678290204348741e-06

We O 0 3.4145170957344817e-06
studied O 0 1.6194325098695117e-06
somatic O 0 1.0939446838165168e-05
instability O 0 4.573169007926481e-06
by O 0 6.271749697361884e-08
measuring O 0 9.437082553631626e-06
the O 0 3.621505584305851e-07
CTG O 0 6.699314690195024e-05
repeat O 0 2.7124187909066677e-06
length O 0 2.2942505495393561e-07
at O 0 7.46314583466301e-08
several O 0 6.934197660513064e-09
ages O 0 6.556297194038052e-08
in O 0 2.926295428196113e-09
various O 0 1.961244944226337e-09
tissues O 0 1.233895829955145e-07
of O 0 4.915638562863478e-09
transgenic O 0 1.1788566553150304e-05
mice O 0 8.587678166804835e-06
carrying O 0 1.8041400551283004e-07
a O 0 3.49517932818344e-07
( O 0 2.1225027069249336e-07
CTG O 0 2.403345388302114e-05
) O 0 2.903530038622648e-08
55expansion O 0 4.921016625303309e-07
surrounded O 0 4.13315213165788e-08
by O 0 4.1659800054105744e-09
45 O 0 6.588775747218278e-09
kb O 0 5.39957795808732e-07
of O 0 3.026520145610334e-09
the O 0 2.1896525481679419e-07
human O 0 2.0802737708436325e-05
DM B-Disease 1 1.0
region O 0 1.0752792150015011e-05
, O 0 2.6062940250426436e-08
using O 0 1.9802582684746994e-08
small O 0 2.8590983802700976e-08
- O 0 7.529885806434322e-06
pool O 0 1.9256226551078726e-06
PCR O 0 1.2675070138357114e-05
. O 0 5.55300289306615e-07

These O 0 3.433239953665179e-06
mice O 0 6.596603634534404e-05
have O 0 3.041788545488089e-07
been O 0 7.54100071276298e-08
shown O 0 4.181465840247256e-08
to O 0 2.2622893780521736e-08
reproduce O 0 1.5165763898039586e-06
the O 0 1.9035168108416656e-08
intergenerational O 0 1.6173148651432712e-06
and O 0 1.4728419728271547e-07
somatic O 0 1.6831114635351696e-06
instability O 0 3.174906169078895e-07
of O 0 4.0640690812665525e-09
the O 0 2.6191161239808025e-08
55 O 0 6.717038445458456e-07
CTG O 0 2.581907574494835e-05
repeat O 0 4.850631285080453e-06
suggesting O 0 2.236048857184869e-07
that O 0 4.1266439154696855e-09
surrounding O 0 4.620264171251165e-09
sequences O 0 1.7829847820394207e-08
and O 0 9.456869953794467e-09
the O 0 5.345613729446086e-09
chromatin O 0 1.8775088506117754e-07
environment O 0 2.683831894501054e-07
are O 0 4.576062639927159e-09
involved O 0 1.8169098225939706e-08
in O 0 6.244284378453813e-08
instability O 0 1.990693135667243e-06
mechanisms O 0 1.9047899968427373e-06
. O 0 2.021421323661343e-06

As O 0 4.581524535751669e-06
observed O 0 1.6942623233262566e-06
in O 0 3.0081974244922094e-08
some O 0 3.3370428642598426e-09
of O 0 2.869789073045581e-09
the O 0 6.192252754999572e-08
tissues O 0 6.018398835294647e-06
of O 0 1.8490455886421842e-06
DM B-Disease 1 1.0
patients O 0 0.0022545629180967808
, O 0 1.9688807029183408e-08
there O 0 3.748647614543188e-09
is O 0 6.3507865633027905e-09
a O 0 4.664184061198284e-08
tendency O 0 5.755325105383235e-07
for O 0 5.0497689585427e-08
repeat O 0 3.2969294352369616e-06
length O 0 5.56372697246843e-07
and O 0 8.41737701762213e-08
somatic O 0 4.3159448637197784e-07
mosaicism O 0 2.3861441604822176e-06
to O 0 2.7321803486302088e-08
increase O 0 4.967470346173286e-08
with O 0 8.21022361208179e-09
the O 0 4.488634530730451e-08
age O 0 2.4147121635564872e-08
of O 0 4.391131014358507e-09
the O 0 6.627067961062494e-08
mouse O 0 2.0491424947977066e-05
. O 0 1.049956381393713e-06

Furthermore O 0 7.435521547449753e-05
, O 0 1.2734881238429807e-06
we O 0 7.810546520659045e-08
observed O 0 6.977624877890776e-08
no O 0 7.735066809289037e-09
correlation O 0 5.1566793501933716e-08
between O 0 1.0396268734780278e-08
the O 0 1.3655006902979494e-08
somatic O 0 1.5140849427552894e-06
mutation O 0 5.886445251235273e-06
rate O 0 1.7725836869431078e-06
and O 0 1.6315534878685867e-07
tissue O 0 1.3409344319370575e-05
proliferation O 0 3.978891072620172e-06
capacity O 0 8.023279178814846e-07
. O 0 1.1431991424615262e-06

The O 0 7.922942018012691e-07
somatic O 0 7.406871191051323e-06
mutation O 0 8.770818567427341e-06
rates O 0 8.460673939225671e-07
in O 0 1.2640699154076174e-08
different O 0 9.949883583715291e-09
tissues O 0 1.061141119862441e-06
were O 0 1.3687426303476968e-07
also O 0 1.3480028826506896e-07
not O 0 1.902268387254935e-08
correlated O 0 5.876388797787513e-08
to O 0 6.908640326486193e-09
the O 0 6.559759402335885e-09
relative O 0 3.707888751591781e-08
inter O 0 1.58102409386629e-06
- O 0 3.1876701541477814e-05
tissue O 0 6.117175416875398e-06
difference O 0 3.449843077873993e-08
in O 0 4.803948350229348e-09
transcriptional O 0 3.382916702321381e-08
levels O 0 1.6569110528052988e-08
of O 0 6.310068023651638e-10
the O 0 4.1642325143698145e-09
three O 0 3.282308114194166e-08
genes O 0 3.572714888377959e-07
( O 0 2.7570514760100195e-08
DMAHP O 0 1.3962106095277704e-05
, O 0 8.091732439652333e-08
DMPK O 0 1.0721142643888015e-05
and O 0 2.70556768100505e-07
59 O 0 3.0596990541198466e-07
) O 0 5.196724384148865e-09
surrounding O 0 1.4961178962380473e-08
the O 0 6.53553371421367e-08
repeat O 0 1.0797738468681928e-05
. O 0 8.052088418253334e-08
. O 0 2.705706947381259e-07

A O 0 1.4203277714841533e-05
novel O 0 5.329884061211487e-06
missense O 0 0.00021580654720310122
mutation O 0 7.750565418973565e-05
in O 0 5.678029992850497e-07
patients O 0 3.5367133932595607e-06
from O 0 3.8389369905189596e-08
a O 0 8.297804470203118e-07
retinoblastoma B-Disease 0 0.0006338417297229171
pedigree O 0 8.352486474905163e-05
showing O 0 1.057314239005791e-05
only O 0 1.182067563831879e-07
mild O 0 4.6443875589829986e-07
expression O 0 3.263013681475968e-08
of O 0 5.027528171552831e-09
the O 0 3.943212902868254e-07
tumor B-Disease 0 0.0003021371958311647
phenotype O 0 7.2486225690227e-05
. O 0 8.64140361045429e-07

We O 0 6.8952736000937875e-06
have O 0 4.796928365635722e-08
used O 0 4.143152310120968e-08
single O 0 1.2661142534398095e-07
strand O 0 2.3448987121810205e-05
conformation O 0 1.105527303479903e-06
polymorphism O 0 8.17417060261505e-07
analysis O 0 8.173540777534072e-08
to O 0 3.383406976809056e-08
study O 0 1.218517908796457e-08
the O 0 1.1828000801017424e-08
27 O 0 1.3935797937847383e-07
exons O 0 2.6717376044871344e-07
of O 0 3.978786633496156e-09
the O 0 1.9312667021154084e-08
RB1 O 0 6.765784291928867e-06
gene O 0 2.3812741289930273e-07
in O 0 1.2349572919845286e-08
individuals O 0 2.609361837713209e-09
from O 0 7.048704286916063e-09
a O 0 3.7635513194800296e-07
family O 0 1.01907544376445e-05
showing O 0 3.236869815737009e-05
mild O 0 2.4734811177040683e-06
expression O 0 6.327163504238342e-08
of O 0 1.1093971075126774e-08
the O 0 3.025754153895832e-07
retinoblastoma B-Disease 0 0.0005435629864223301
phenotype O 0 0.00046548008685931563
. O 0 2.1808173187309876e-06

In O 0 1.4399660130948178e-06
this O 0 4.139763731814128e-08
family O 0 2.5551631210873893e-07
affected O 0 1.7662510742866289e-07
individuals O 0 9.746981888270057e-09
developed O 0 9.833777312451275e-07
unilateral B-Disease 0 0.03506571799516678
tumors I-Disease 1 1.0
and O 0 4.775201887241565e-06
, O 0 9.263955291771708e-08
as O 0 2.2366368312987106e-08
a O 0 3.707379647721609e-08
result O 0 4.514383533660293e-08
of O 0 3.841557294492759e-09
linkage O 0 5.495381628861651e-06
analysis O 0 3.4110468050130294e-07
, O 0 5.701656036194436e-08
unaffected O 0 1.2284425565667334e-06
mutation O 0 3.2366520485993533e-07
carriers O 0 3.8818932068807044e-08
were O 0 2.8338202895383802e-08
also O 0 8.458304279201911e-08
identified O 0 1.8086777231474116e-07
within O 0 8.516042093731357e-09
the O 0 5.781665635140598e-08
pedigree O 0 2.185514495067764e-05
. O 0 1.760947611728625e-06

A O 0 4.041668034915347e-06
single O 0 1.0784088999571395e-06
band O 0 4.929184456159419e-07
shift O 0 2.836486885371414e-07
using O 0 6.337030811209843e-08
SSCP O 0 1.4492055925074965e-05
was O 0 1.4760776139155496e-06
identified O 0 1.6531473079339776e-07
in O 0 2.0772491282627925e-08
exon O 0 3.435205144342035e-06
21 O 0 6.131433565315092e-07
which O 0 3.129450476535567e-08
resulted O 0 2.041832658505882e-08
in O 0 3.611150267701646e-09
a O 0 6.388073359175905e-08
missense O 0 5.661836894432781e-06
mutation O 0 3.567805322290951e-07
converting O 0 1.5258727614764211e-07
a O 0 2.580252953521267e-07
cys O 0 0.00041125802090391517
- O 0 3.9094586099963635e-05
- O 0 2.8668842787737958e-05
> O 0 4.4252567477087723e-07
arg O 0 5.327305530045123e-07
at O 0 1.96674498909033e-08
nucleotide O 0 1.5685694165767927e-07
position O 0 2.843187303369632e-07
28 O 0 6.164489008142482e-08
in O 0 7.368952559261288e-09
the O 0 4.82587232397691e-08
exon O 0 2.205995588155929e-05
. O 0 9.225494750353391e-07

The O 0 2.1609323539450997e-06
mutation O 0 8.408762369072065e-06
destroyed O 0 4.946877197653521e-06
an O 0 1.0928104643426195e-07
NdeI O 0 1.0311252481187694e-05
restriction O 0 5.810906600345334e-07
enzyme O 0 2.3219040485855658e-06
site O 0 4.1045282159757335e-06
. O 0 9.206282243212627e-07

Analysis O 0 5.583693109656451e-06
of O 0 7.560731773992302e-08
all O 0 1.901056911890464e-08
family O 0 1.975629828621095e-07
members O 0 1.624200329786163e-08
demonstrated O 0 3.207600940413613e-08
that O 0 2.2436772439959896e-09
the O 0 7.24757054371139e-09
missense O 0 6.019684860802954e-06
mutation O 0 1.8722425920714159e-06
co O 0 1.1457321306806989e-05
- O 0 2.9264729164424352e-06
segregated O 0 2.4461749603688077e-07
with O 0 9.169972514655456e-08
patients O 0 1.305047703681339e-06
with O 0 9.508907510280551e-07
tumors B-Disease 1 1.0
or O 0 1.2805229744117241e-05
who O 0 2.10193093153066e-06
, O 0 2.0773045505961818e-08
as O 0 8.544987828429385e-09
a O 0 4.5430002870716635e-08
result O 0 3.2724251752824784e-08
of O 0 7.265147594637256e-09
linkage O 0 1.0676523743313737e-05
analysis O 0 1.499100790169905e-06
had O 0 2.945829919553944e-06
been O 0 4.2831175051105674e-07
predicted O 0 1.209941842716944e-06
to O 0 1.0161000929542752e-08
carry O 0 8.129788398036908e-08
the O 0 3.874178133855821e-08
predisposing O 0 6.585457413166296e-06
mutation O 0 6.950507668079808e-06
. O 0 6.561626264556253e-07

These O 0 1.4587250234399107e-06
observations O 0 1.9955077732447535e-06
point O 0 6.016408633513493e-07
to O 0 2.8374007143838753e-08
another O 0 3.005840198966325e-08
region O 0 2.0589352800470806e-07
of O 0 6.533313001710894e-09
the O 0 2.40126887263159e-08
RB1 O 0 9.090663297683932e-06
gene O 0 2.2774648300583067e-07
where O 0 1.7897651360954114e-08
mutations O 0 1.2184047193386505e-07
only O 0 3.1031295311123586e-09
modify O 0 7.350018904617173e-08
the O 0 6.489943249476937e-09
function O 0 7.085300346432177e-09
of O 0 7.956009184795221e-10
the O 0 9.121126964828363e-09
gene O 0 2.550126225742133e-07
and O 0 3.8665746160404524e-08
raise O 0 5.313261297601457e-08
important O 0 5.9044737987790086e-09
questions O 0 7.14461778628106e-09
for O 0 9.389255595237955e-09
genetic O 0 1.0510112815609318e-06
counseling O 0 4.11206322326052e-08
in O 0 1.2688478712163942e-08
families O 0 7.807429369677266e-09
with O 0 7.759300757470555e-09
these O 0 1.339449795523251e-08
distinctive O 0 6.849678356957156e-06
phenotypes O 0 8.289655852422584e-06
. O 0 1.0587661591898723e-07
. O 0 3.640023464868136e-07

Maternal B-Disease 0 0.019672689959406853
disomy I-Disease 0 0.15010325610637665
and O 0 0.023885808885097504
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 8.167934538505506e-06
with O 0 5.4464560861333666e-08
gamete O 0 5.224856977292802e-06
complementation O 0 6.697922071907669e-05
in O 0 1.0092070823475296e-07
a O 0 1.295288996061572e-07
case O 0 1.3003661081256723e-07
of O 0 2.1633617564020824e-08
familial O 0 4.2503004806349054e-05
translocation O 0 0.00023692917602602392
( O 0 5.394292088567454e-07
3 O 0 7.90843273534847e-07
; O 0 2.6207808900835516e-07
15 O 0 1.4472583131919237e-07
) O 0 2.2329709636892403e-08
( O 0 8.53223625085775e-09
p25 O 0 1.2670393800817692e-07
; O 0 1.483065759089186e-08
q11 O 0 1.7170138733035856e-07
. O 0 1.4563543260237566e-08
2 O 0 2.8518064709714963e-07
) O 0 1.649400900305409e-07
. O 0 6.038959554643952e-07

Maternal B-Disease 0 0.32147741317749023
uniparental I-Disease 1 0.926598072052002
disomy I-Disease 1 0.9754230380058289
( I-Disease 0 0.0005885215359739959
UPD I-Disease 1 0.9999970197677612
) I-Disease 0 3.167745944665512e-06
for I-Disease 0 1.5986266532763693e-07
chromosome I-Disease 0 0.0001839323522290215
15 I-Disease 0 9.237556355401466e-07
is O 0 3.5620892901988555e-08
responsible O 0 2.481797878317593e-07
for O 0 2.790205222424902e-08
an O 0 4.72367567283527e-08
estimated O 0 3.400176353807183e-07
30 O 0 7.171585281184889e-08
% O 0 5.612657894005224e-09
of O 0 1.3152013922379524e-09
cases O 0 8.706266640956528e-08
of O 0 3.842032128886785e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00013740309805143625
PWS B-Disease 1 0.999997615814209
) O 0 5.9146759667783044e-06
. O 0 2.5381943942193175e-06

We O 0 2.6554382202448323e-05
report O 0 2.6707284632720985e-06
on O 0 1.0978998687960484e-07
an O 0 7.592969808456473e-09
unusual O 0 2.1518511417184527e-08
case O 0 1.0703111996690495e-07
of O 0 8.656108718696487e-09
maternal B-Disease 0 1.5825672790015233e-06
disomy I-Disease 0 3.9241418562596664e-05
15 I-Disease 0 7.806046369296382e-07
in O 0 8.581256452089292e-07
PWS B-Disease 1 0.9999988079071045
that O 0 3.8732258644813555e-07
is O 0 1.0550424534017111e-08
most O 0 3.4416587357810613e-09
consistent O 0 2.914655183872128e-08
with O 0 2.425271539152618e-09
adjacent O 0 2.953522084681026e-07
- O 0 7.2502248258388136e-06
1 O 0 4.34414914707304e-07
segregation O 0 2.409541011161309e-08
of O 0 6.320475809395987e-10
a O 0 6.5230302936925e-08
paternal O 0 3.053791715501575e-06
t O 0 0.0001802868500817567
( O 0 2.7378979083891863e-08
3 O 0 1.1110428488336765e-07
; O 0 6.033967991925238e-08
15 O 0 6.62232935155771e-08
) O 0 1.1020072854250884e-08
( O 0 6.108318739705965e-09
p25 O 0 5.670421998615893e-08
; O 0 1.0924308568860397e-08
q11 O 0 5.6073965026826045e-08
. O 0 8.594662759264793e-09
2 O 0 4.099478445596105e-08
) O 0 3.3359863760296093e-09
with O 0 4.001603493009043e-09
simultaneous O 0 2.7223441065871157e-06
maternal O 0 8.013407750695478e-06
meiotic O 0 2.4878054318833165e-05
nondisjunction O 0 5.1815208280459046e-05
for O 0 4.1916470649994153e-07
chromosome O 0 0.00011206288763787597
15 O 0 1.881241587398108e-06
. O 0 9.586979103914928e-07

The O 0 1.161846194008831e-05
patient O 0 0.0002325229434063658
( O 0 1.0673393262550235e-06
J O 0 0.0007104621035978198
. O 0 1.5972095468441694e-07
B O 0 6.762944622096256e-07
. O 0 7.740143637136043e-09
) O 0 4.751876669928379e-09
, O 0 3.5408851406515396e-09
a O 0 2.9026606895854457e-08
17 O 0 1.8500637111174e-07
- O 0 3.491405323075014e-06
year O 0 9.775133094080957e-07
- O 0 2.370439688093029e-06
old O 0 2.982846353916102e-06
white O 0 9.638517894927645e-07
male O 0 1.6100344168989977e-07
with O 0 7.271084712101583e-08
PWS B-Disease 1 0.9999947547912598
, O 0 7.726767421445402e-07
was O 0 7.044002927614201e-07
found O 0 3.4388058622880635e-08
to O 0 9.63092805505994e-09
have O 0 9.135822764960722e-09
47 O 0 2.93384161409449e-08
chromosomes O 0 2.302166279832818e-08
with O 0 3.2353966172848914e-09
a O 0 3.7181263223828864e-07
supernumerary O 0 3.494455086183734e-05
, O 0 6.556897460541222e-07
paternal O 0 1.837626587075647e-05
der O 1 0.9973279237747192
( O 0 1.5323196578265197e-07
15 O 0 3.344703713992203e-08
) O 0 1.8970571780130285e-09
consisting O 0 9.265713196704439e-10
of O 0 1.6523497015086264e-09
the O 0 6.756937409591046e-08
short O 0 3.962528353440575e-06
arm O 0 2.7689737180480734e-05
and O 0 1.8145379954148666e-07
the O 0 4.265052311325235e-08
proximal O 0 2.7089368813904002e-05
long O 0 3.0676217193104094e-06
arm O 0 8.688052730576601e-06
of O 0 2.9368875331670097e-08
chromosome O 0 2.909969953179825e-05
15 O 0 2.6843642331186857e-07
, O 0 2.858116943116329e-08
and O 0 2.0682597323684604e-07
distal O 0 0.0009530875249765813
chromosome O 0 0.2258443832397461
arm O 0 0.0010430982802063227
3p O 0 0.0016966501716524363
. O 0 6.405712611012859e-06

The O 0 1.9305105524836108e-05
t O 0 0.0002473510103300214
( O 0 1.5712089407315943e-07
3 O 0 2.2947362765535217e-07
; O 0 8.816877539175039e-08
15 O 0 8.263959472287752e-08
) O 0 7.093359233323326e-09
was O 0 1.3467513326759217e-07
present O 0 5.710207862108518e-09
in O 0 8.74614158874465e-09
the O 0 6.950670705663242e-09
balanced O 0 2.1285433149387245e-07
state O 0 1.912958147443078e-08
in O 0 2.9873842066763245e-08
the O 0 2.0158718427865097e-07
patients O 0 8.846919854477164e-07
father O 0 1.5034387956802675e-07
and O 0 5.0833598663757584e-08
a O 0 5.319030833561555e-07
sister O 0 0.0001004050427582115
. O 0 9.317023454968876e-07

Fluorescent O 0 8.338248881045729e-05
in O 0 1.0179467153648147e-06
situ O 0 2.698619937291369e-06
hybridization O 0 5.231520390225342e-07
analysis O 0 2.0694908187124383e-07
demonstrated O 0 2.1121095983289706e-07
that O 0 1.5513636597574987e-08
the O 0 1.341598050430548e-07
PWS B-Disease 1 0.9999982118606567
critical O 0 3.351960685904487e-06
region O 0 1.5220475688693114e-06
resided O 0 5.202668376114161e-07
on O 0 2.522905617752258e-07
the O 0 2.1897061941444917e-08
derivative O 0 5.252261416899273e-07
chromosome O 0 2.3793361833668314e-05
3 O 0 7.526701892857091e-07
and O 0 1.0979082532003304e-07
that O 0 1.0263142335986686e-08
there O 0 4.430249500586569e-09
was O 0 3.7082605786054046e-07
no O 0 1.6916542833200765e-08
deletion O 0 2.773539904410427e-07
of O 0 1.4280087334839209e-08
the O 0 1.0307684306098963e-06
PWS B-Disease 1 0.9999996423721313
region O 0 1.4761220882064663e-05
on O 0 2.1853561520401854e-06
the O 0 2.24634177925509e-08
normal O 0 6.86267611627045e-08
pair O 0 6.906903848857837e-08
of O 0 9.137147038984494e-09
15s O 0 1.91788160464057e-07
present O 0 6.590123291516647e-08
in O 0 1.0225299007515787e-07
J O 0 0.0009388474863953888
. O 0 4.059770617459435e-06

B O 0 0.001501757651567459
. O 0 5.259100362309255e-05

Methylation O 0 6.176670285640284e-05
analysis O 0 2.032408474406111e-06
at O 0 3.1521733490080805e-07
exon O 0 1.1907440011782455e-06
alpha O 0 1.3307285939845315e-07
of O 0 4.069879100399021e-09
the O 0 5.871187980233117e-09
small O 0 3.733970643793327e-08
nuclear O 0 2.240478806925239e-06
ribonucleoprotein O 0 1.818326381908264e-06
- O 0 3.6515637020784197e-06
associated O 0 4.417999548422813e-07
polypeptide O 0 1.3144181139068678e-06
N O 0 2.5066048692679033e-05
( O 0 3.714903940021941e-08
SNRPN O 0 5.011135272070533e-06
) O 0 1.9118493455039243e-08
gene O 0 8.182743727047637e-08
showed O 0 5.396304914029315e-08
a O 0 1.7805479757271314e-08
pattern O 0 1.302517375734169e-06
characteristic O 0 5.973819838800409e-07
of O 0 7.060895867994077e-09
only O 0 6.624348181105688e-09
the O 0 3.382677959962166e-08
maternal O 0 1.5486665461139637e-06
chromosome O 0 2.3364076696452685e-05
15 O 0 3.168164255384909e-07
in O 0 1.2464420251490083e-07
J O 0 0.003451197175309062
. O 0 4.2274755287508015e-06

B O 0 0.0009720923844724894
. O 0 3.8050598959671333e-05

Maternal B-Disease 0 0.08396147191524506
disomy I-Disease 0 0.0051919096149504185
was O 0 4.850977347814478e-05
confirmed O 0 1.2505872746260138e-06
by O 0 1.519188508325442e-08
polymerase O 0 1.008599610941019e-06
chain O 0 6.250019850995159e-06
reaction O 0 1.126184727695545e-07
analysis O 0 2.442607538455377e-08
of O 0 4.685465349041351e-09
microsatellite O 0 2.265257307954016e-06
repeats O 0 5.694945230061421e-06
at O 0 3.656375469063278e-08
the O 0 8.327658562734541e-09
gamma O 0 4.430657725151832e-07
- O 0 4.053928478242597e-06
aminobutyric O 0 9.080449672183022e-06
acid O 0 7.230603387142764e-07
receptor O 0 1.570384995375207e-07
beta3 O 0 1.5224220533127664e-06
subunit O 0 4.138016151955526e-07
( O 0 1.742084663192145e-07
GABRB3 O 0 2.5596127670723945e-05
) O 0 2.0759586050189682e-07
locus O 0 9.1255815277691e-06
. O 0 1.4640406789112603e-06

A O 0 0.00010817428847076371
niece O 0 0.00059960299404338
( O 0 9.520049957245647e-07
B O 0 1.832995053518971e-06
. O 0 2.0646012899305788e-08
B O 0 2.78260074537684e-07
. O 0 5.215392562263332e-09
) O 0 1.6510393052726613e-09
with O 0 1.7698678078659213e-09
45 O 0 1.3094451745132574e-08
chromosomes O 0 4.9362455456503085e-08
and O 0 1.6419734905070982e-08
the O 0 4.212290516392159e-09
derivative O 0 9.347160556671952e-08
3 O 0 1.0532333050150555e-07
but O 0 1.547577710425685e-08
without O 0 7.424368231312428e-09
the O 0 1.1028593149831067e-07
der O 1 0.6169300079345703
( O 0 5.747273945644338e-08
15 O 0 3.4329474374317215e-08
) O 0 5.5495754658352325e-09
demonstrated O 0 2.2067371929779256e-08
a O 0 8.825492159303394e-08
phenotype O 0 1.2501885976234917e-05
consistent O 0 2.526102775846084e-07
with O 0 4.142875908996757e-08
that O 0 4.2644543896130926e-07
reported O 0 8.135238203976769e-06
for O 0 1.458402909548795e-08
haploinsufficiency O 0 5.834451712871669e-06
of O 0 4.1063259459406254e-08
distal O 0 0.00017677951836958528
3 O 0 1.94786462088814e-05
p O 0 0.00036930167698301375
. O 0 1.2548402992251795e-06

Uniparental B-Disease 1 0.9999783039093018
disomy I-Disease 1 0.9999833106994629
associated O 0 0.00010158070654142648
with O 0 3.0185202604116057e-07
unbalanced O 0 9.701294038677588e-05
segregation O 0 2.117398707923712e-06
of O 0 3.388515423807803e-08
non O 0 8.058754019657499e-07
- O 0 2.7638187020784244e-05
Robertsonian O 0 5.504111686605029e-05
translocations O 0 9.586736268829554e-05
has O 0 1.9818223790935008e-06
been O 0 4.158401338827389e-07
reported O 0 6.001828296575695e-06
previously O 0 7.510948307754006e-07
but O 0 3.27048432779975e-08
has O 0 8.85547208895332e-08
not O 0 2.6394719299105418e-08
, O 0 6.991503820330536e-09
to O 0 5.703197913931035e-09
our O 0 1.0315148735173807e-08
knowledge O 0 1.1147677447809201e-08
, O 0 1.400602389622918e-08
been O 0 2.9643173249382926e-08
observed O 0 3.021797212454658e-08
in O 0 4.037560064062973e-09
a O 0 1.2174673713616357e-07
case O 0 1.3418070921034086e-06
of O 0 6.367411629071285e-07
PWS B-Disease 1 0.9999970197677612
. O 0 8.353189514309634e-06

Furthermore O 0 5.5716292990837246e-05
, O 0 4.927520649289363e-07
our O 0 1.1323339776936336e-07
findings O 0 1.5395205821278068e-07
are O 0 2.4075734739170684e-09
best O 0 2.525822750953921e-08
interpreted O 0 5.696786331554904e-08
as O 0 1.6005756720005593e-08
true O 0 8.034583487415148e-08
gamete O 0 1.7769538089851267e-06
complementation O 0 3.2356045267079026e-05
resulting O 0 1.2966080475962372e-06
in O 0 4.0032242054621747e-07
maternal B-Disease 0 0.0002645908098202199
UPD I-Disease 1 0.9999978542327881
15 I-Disease 0 8.994439849629998e-05
and O 0 3.921380630345084e-05
PWS B-Disease 1 0.999971866607666

Schwartz B-Disease 1 0.9876922965049744
- I-Disease 1 0.997708797454834
Jampel I-Disease 1 0.9990094900131226
syndrome I-Disease 1 0.9999922513961792
type I-Disease 0 2.720506699915859e-06
2 I-Disease 0 8.463901508548588e-07
and O 0 6.175145585984865e-07
Stuve B-Disease 0 0.2777257263660431
- I-Disease 1 0.9999558925628662
Wiedemann I-Disease 1 0.9999985694885254
syndrome I-Disease 1 0.9999910593032837
: O 0 2.509974272868476e-08
a O 0 1.133092411009784e-07
case O 0 3.287772472049255e-07
for O 0 5.155470006457108e-08
" O 0 1.1924108775929199e-06
lumping O 0 2.573862957433448e-06
" O 0 1.8756971940092626e-06
. O 0 6.505449618998682e-07

Recent O 0 2.561263318057172e-05
studies O 0 2.2763083507015835e-06
demonstrated O 0 2.3178742480922665e-07
the O 0 1.6420550252860266e-08
existence O 0 7.009866465068626e-08
of O 0 2.5222877120256726e-09
a O 0 7.700168680457864e-08
genetically O 0 2.1829482648172416e-06
distinct O 0 1.1464948812545117e-07
, O 0 1.2847698016571485e-08
usually O 0 4.24329593684547e-09
lethal O 0 2.3962954287526372e-08
form O 0 4.574614020924628e-09
of O 0 1.9879091706087593e-09
the O 0 2.466103410370124e-07
Schwartz B-Disease 1 0.7286204695701599
- I-Disease 1 0.9988775849342346
Jampel I-Disease 1 0.9999704360961914
syndrome I-Disease 1 0.9999990463256836
( O 0 2.730258756855619e-06
SJS B-Disease 1 0.5682106018066406
) O 0 1.4541718940108694e-07
of O 0 7.512546318366731e-08
myotonia B-Disease 1 0.7477653622627258
and O 0 1.573417102918029e-05
skeletal B-Disease 0 0.4678349792957306
dysplasia I-Disease 1 0.9994674324989319
, O 0 1.7182258034154074e-06
which O 0 1.7336157043246203e-07
we O 0 4.0824446045917284e-08
called O 0 9.915480632116669e-07
SJS B-Disease 0 0.02068258635699749
type I-Disease 0 6.935126179996587e-07
2 I-Disease 0 7.875887604313903e-07
. O 0 9.044779858413676e-07

This O 0 2.2878382878843695e-05
disorder O 0 0.018061809241771698
is O 0 8.589208988496466e-08
reminiscent O 0 3.881249597270653e-07
of O 0 1.758726853040571e-08
another O 0 5.168052439330495e-07
rare O 0 1.609427840776334e-06
condition O 0 1.3168297300580889e-05
, O 0 6.018301945687199e-08
the O 0 2.266652359139698e-07
Stuve B-Disease 0 0.46784332394599915
- I-Disease 1 0.9999970197677612
Wiedemann I-Disease 1 0.9999997615814209
syndrome I-Disease 1 0.9999998807907104
( O 0 7.018708402029006e-06
SWS B-Disease 1 0.6624472737312317
) O 0 1.3939479970304092e-07
, O 0 8.47572501072591e-09
which O 0 7.2717472043848375e-09
comprises O 0 8.897829140153135e-09
campomelia B-Disease 0 2.337970954613411e-06
at O 0 4.198452359105431e-07
birth O 0 1.0599042070680298e-06
with O 0 2.1116605353199702e-07
skeletal B-Disease 1 0.5534473657608032
dysplasia I-Disease 1 0.9995248317718506
, O 0 2.5018500764417695e-06
contractures B-Disease 0 0.00038509853766299784
, O 0 1.3132073206634232e-07
and O 0 7.75341604253299e-08
early B-Disease 0 6.066892979106342e-07
death I-Disease 0 5.984938979963772e-06
. O 0 5.478524371937965e-07

To O 0 3.3839735351648415e-06
test O 0 4.5328431497182464e-07
for O 0 1.3062471104774431e-08
possible O 0 6.620611969765378e-08
nosologic O 0 5.219881586526753e-06
identity O 0 1.6870245644895476e-06
between O 0 1.2186301034944336e-07
these O 0 2.8205610647091817e-07
disorders O 0 0.005597956944257021
, O 0 1.1649427733573248e-07
we O 0 5.86023745086095e-08
reviewed O 0 5.229540178675052e-08
the O 0 3.769871081971132e-09
literature O 0 8.58489723754019e-09
and O 0 2.2361547280524974e-08
obtained O 0 3.496992206919458e-08
a O 0 2.5045704177273365e-08
follow O 0 5.530262470188063e-08
- O 0 9.11691074634291e-07
up O 0 2.469322737397306e-07
of O 0 1.6953616288617468e-09
the O 0 5.154110471750073e-09
only O 0 4.620652305220574e-09
two O 0 2.3899508150293514e-08
surviving O 0 3.4356048672634643e-06
patients O 0 1.2049726194618415e-07
, O 0 2.1962889285020992e-09
one O 0 6.721111667218338e-09
with O 0 5.040646300358276e-08
SJS B-Disease 0 0.025363298133015633
type I-Disease 0 3.593562780679349e-07
2 I-Disease 0 3.530091703396465e-07
at O 0 6.98056567216554e-07
age O 0 2.708354962521753e-08
10 O 0 1.387694936738626e-08
years O 0 1.3230723183710325e-08
and O 0 1.143142647208606e-08
another O 0 2.1529801941255755e-08
with O 0 8.895796810293177e-08
SWS B-Disease 0 0.02014946937561035
at O 0 2.0005172700621188e-06
age O 0 7.036322102749182e-08
7 O 0 1.5815639642369206e-07
years O 0 1.3073568538857216e-07
. O 0 3.4759659683913924e-07

Patients O 0 0.3780010938644409
reported O 0 0.00010141269012819976
as O 0 1.0238120751182578e-07
having O 0 3.398211845251353e-07
either O 0 9.336848961538635e-06
neonatal O 1 0.9999620914459229
SJS B-Disease 1 0.999975323677063
or O 0 4.751954838866368e-05
SWS B-Disease 0 0.028446495532989502
presented O 0 1.9166584763752326e-07
a O 0 1.794061255111501e-08
combination O 0 1.1966928070705762e-07
of O 0 7.64801288966055e-09
a O 0 3.1975273486750666e-06
severe O 0 0.0001698255946394056
, O 0 5.790643058389833e-07
prenatal O 0 0.013809015043079853
- O 1 0.9703384637832642
onset O 1 0.9359667897224426
neuromuscular B-Disease 1 0.9999619722366333
disorder I-Disease 1 0.997712254524231
( O 0 7.498309173570306e-07
with O 0 5.941473773418693e-06
congenital B-Disease 1 0.9999997615814209
joint I-Disease 0 0.06645424664020538
contractures I-Disease 1 0.9999618530273438
, O 0 0.00012581481132656336
respiratory O 1 0.6347517967224121
and O 0 8.825523991617956e-07
feeding O 0 7.1371950980392285e-06
difficulties O 0 2.077646968245972e-06
, O 0 7.882758268351608e-08
tendency O 0 7.138204409784521e-07
to O 0 5.215758847043617e-07
hyperthermia B-Disease 0 0.004431294277310371
, O 0 1.7825841780449991e-07
and O 0 7.542539748328636e-08
frequent O 0 2.4069561277428875e-06
death O 0 8.570374120608903e-06
in O 0 2.939757735020976e-07
infancy O 0 5.932035492151044e-06
) O 0 5.025859728391424e-09
with O 0 2.1667798666413773e-09
a O 0 1.1889493833905362e-07
distinct O 0 2.1428770651255036e-06
campomelic B-Disease 0 0.0005619989242404699
- I-Disease 0 0.009284526109695435
metaphyseal I-Disease 0 0.0949392095208168
skeletal I-Disease 0 0.4380761682987213
dysplasia I-Disease 1 0.9961227774620056
. O 0 6.467322236858308e-06

The O 0 7.765416967231431e-07
similarity O 0 8.820189236757869e-07
of O 0 2.2770993979293053e-08
the O 0 9.884458762599024e-08
clinical O 0 1.5248282352331444e-06
and O 0 3.352234330122883e-07
radiographic O 0 6.825160380685702e-05
findings O 0 4.858121883444255e-06
is O 0 3.431003037235314e-08
so O 0 2.1190071919363618e-08
extensive O 0 6.344456693341272e-08
that O 0 1.4338746723296936e-07
these O 0 1.5564532418466115e-07
disorders O 0 0.0002446439175400883
appear O 0 3.9163452925095044e-07
to O 0 3.2477764477789606e-08
be O 0 1.8326204553886782e-08
a O 0 5.72255309805314e-08
single O 0 1.391240289194684e-06
entity O 0 1.065091691998532e-05
. O 0 1.5195180367300054e-06

The O 0 1.3329110970516922e-06
follow O 0 7.343663810388534e-07
- O 0 7.724653187324293e-06
up O 0 6.946736448298907e-07
observation O 0 2.8569132837219513e-07
of O 0 2.011027344650529e-09
an O 0 8.344145818739435e-09
identical O 0 1.8613350505347626e-07
and O 0 1.5379789886083017e-08
unique O 0 5.362824140320299e-08
pattern O 0 8.700548278284259e-06
of O 0 3.2815825079524075e-07
progressive O 0 0.0015295095508918166
bone B-Disease 1 0.9278122782707214
dysplasia I-Disease 1 0.9843944907188416
in O 0 2.593367298686644e-07
the O 0 9.47052001265547e-08
two O 0 1.5547886960121104e-06
patients O 0 1.8363771232543513e-06
( O 0 7.880410102245605e-09
one O 0 2.6144046927356612e-08
with O 0 2.5256667868234217e-07
SJS B-Disease 0 0.17555925250053406
type I-Disease 0 1.2455834621505346e-06
2 I-Disease 0 4.3977129848826735e-07
, O 0 2.431776380262818e-08
one O 0 3.00326696844877e-08
with O 0 2.483540413322771e-07
SWS B-Disease 0 0.12488944828510284
) O 0 5.565521021821951e-08
surviving O 0 2.2115159481472801e-07
beyond O 0 1.847052715220343e-07
infancy O 0 2.5378142254339764e-06
adds O 0 2.829276297688921e-07
to O 0 1.531281945688079e-08
the O 0 6.158411114398632e-09
evidence O 0 3.24702078557948e-08
in O 0 7.3518529042360115e-09
favor O 0 1.413942474215446e-08
of O 0 1.0946855866222904e-08
identity O 0 3.8109553770482307e-06
. O 0 9.951517085937667e-07

The O 0 4.5579781726701185e-06
hypothesis O 0 1.8735945559456013e-05
that O 0 9.366700055579713e-07
SWS B-Disease 0 0.022083520889282227
and O 0 2.5916119739122223e-06
SJS B-Disease 0 0.09505848586559296
type I-Disease 0 5.083103360448149e-07
2 I-Disease 0 1.3580493885001488e-07
are O 0 3.0139732931644403e-09
the O 0 6.723201995129102e-09
same O 0 7.137850275285018e-07
disorder O 0 6.086525900173001e-05
should O 0 1.7905845695054268e-08
be O 0 7.79882736168247e-09
testable O 0 1.0866001787235291e-07
by O 0 6.010441477855011e-09
molecular O 0 3.3565208923391765e-07
methods O 0 9.577237278790562e-07
. O 0 1.5231496774958941e-07
. O 0 6.418080147341243e-07

A O 0 1.7919835954671726e-05
mouse O 0 3.930778257199563e-05
model O 0 9.407860488863662e-06
of O 0 2.124038701367681e-06
severe O 1 0.982471764087677
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.003021242329850793
defects O 1 0.998771607875824
in O 0 7.604880465805763e-06
hemostasis O 0 0.25199034810066223
and O 0 0.00015129073290154338
thrombosis B-Disease 1 0.7285564541816711
. O 0 4.3732648009608965e-06

von B-Disease 1 0.9985241293907166
Willebrand I-Disease 1 0.9948911666870117
factor I-Disease 0 0.00037803594022989273
( I-Disease 0 1.3957634109829087e-05
vWf I-Disease 0 0.001606371020898223
) I-Disease 0 0.00044737805728800595
deficiency I-Disease 1 0.9847608208656311
causes O 0 0.009232677519321442
severe O 1 0.9997084736824036
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 1.3141939234628808e-05
humans O 0 1.487374356656801e-05
. O 0 3.7818031159986276e-06

We O 0 1.691283841864788e-06
generated O 0 1.6914340505991277e-07
a O 0 4.368193984305435e-08
mouse O 0 6.421030889214308e-07
model O 0 3.8210910702218825e-07
for O 0 2.4996692715717472e-08
this O 0 7.165063209413347e-08
disease O 0 2.8435608783183852e-06
by O 0 2.9969651205163927e-09
using O 0 1.6240616673712793e-07
gene O 0 1.6879756685739267e-06
targeting O 0 4.609590178006329e-06
. O 0 9.73058149611461e-07

vWf B-Disease 0 0.01211389061063528
- I-Disease 1 0.9039455056190491
deficient I-Disease 1 0.5916402339935303
mice O 0 0.000770058308262378
appeared O 0 4.10935354011599e-06
normal O 0 6.324412993308215e-07
at O 0 1.7074611378120608e-06
birth O 0 3.1166728149401024e-06
; O 0 4.678064868812726e-08
they O 0 2.707146506963909e-08
were O 0 4.512300222359045e-08
viable O 0 5.777079081781267e-07
and O 0 1.5097666050678527e-07
fertile O 0 6.54797031529597e-06
. O 0 1.8872470946007525e-06

Neither O 0 0.00036446776357479393
vWf O 0 0.0014844550751149654
nor O 0 0.00016146201232913882
vWf O 0 0.00043117356835864484
propolypeptide O 0 0.0021709527354687452
( O 0 1.0555329936323687e-05
von B-Disease 1 0.7044676542282104
Willebrand I-Disease 1 0.7967352271080017
antigen O 0 0.0004963712417520583
II O 0 0.00029762971098534763
) O 0 2.631781228501495e-07
were O 0 4.647559848081073e-08
detectable O 0 2.227913284968963e-07
in O 0 1.3267921872284205e-08
plasma O 0 2.3913792119856225e-06
, O 0 1.7081909220451053e-07
platelets O 0 3.228090008633444e-06
, O 0 6.174573741191125e-08
or O 0 4.8334168667452104e-08
endothelial O 0 1.0492747151147341e-06
cells O 0 4.3343374045434757e-07
of O 0 5.321808327352073e-09
the O 0 9.303370518409793e-08
homozygous O 0 1.0501182259758934e-05
mutant O 0 1.914702261274215e-05
mice O 0 0.00011309690307825804
. O 0 1.49518155012629e-06

The O 0 1.4844474662822904e-06
mutant O 0 3.668411955004558e-05
mice O 0 0.000876157428137958
exhibited O 0 0.00023951505136210471
defects O 1 0.8383805751800537
in O 0 2.8748917202392477e-07
hemostasis O 0 4.341328894952312e-05
with O 0 5.8591311358213716e-08
a O 0 9.896189112623688e-07
highly O 0 9.436975233256817e-06
prolonged O 0 0.0005713777500204742
bleeding O 0 0.2287105768918991
time O 0 6.122131708252709e-07
and O 0 3.640488728251512e-07
spontaneous O 0 2.596153763079201e-06
bleeding O 0 0.0018547129584476352
events O 0 5.713315331945523e-08
in O 0 1.3146277844100496e-08
approximately O 0 2.846550728463626e-08
10 O 0 3.1160968916310594e-08
% O 0 1.8031968807008525e-08
of O 0 2.6362116045675066e-08
neonates O 0 2.685330036911182e-05
. O 0 1.2143381127316388e-06

As O 0 1.2263648159205331e-06
in O 0 9.116590860003271e-08
the O 0 7.968561277493791e-08
human O 0 6.039633717591641e-07
disease O 0 2.4429942641290836e-05
, O 0 1.7525586315514374e-08
the O 0 1.6038454120348433e-08
factor O 0 8.439835852414035e-08
VIII O 0 1.624192009330727e-05
level O 0 2.2892476181368693e-07
in O 0 6.653792183897167e-08
these O 0 1.7997678014580742e-08
mice O 0 6.550581019837409e-06
was O 0 1.0700167649702053e-06
reduced O 0 2.223023329861462e-07
strongly O 0 2.981731839213353e-08
as O 0 5.500614630449263e-09
a O 0 2.1374239267402118e-08
result O 0 2.397525378228238e-08
of O 0 2.99781710566549e-09
the O 0 3.192421260678202e-08
lack O 0 3.370537626778969e-08
of O 0 7.805181390097005e-09
protection O 0 6.30417957836471e-08
provided O 0 4.9630475729145473e-08
by O 0 8.042571408850563e-08
vWf O 0 9.395057531946804e-06
. O 0 1.1009715308318846e-06

Defective O 1 0.9730724096298218
thrombosis B-Disease 1 0.982930064201355
in O 0 4.484279543248704e-06
mutant O 0 5.4904397984500974e-05
mice O 0 0.0013166040880605578
was O 0 5.276689080346841e-06
also O 0 1.0877094780425978e-07
evident O 0 5.161215810289832e-08
in O 0 6.947383557331932e-09
an O 0 1.3347037253197414e-08
in O 0 8.687008090646486e-08
vivo O 0 7.319870201172307e-05
model O 0 1.1359697964508086e-06
of O 0 4.673026410273451e-07
vascular B-Disease 1 0.8506079316139221
injury I-Disease 0 0.0003267483552917838
. O 0 2.020677356995293e-06

In O 0 1.012127199828683e-06
this O 0 3.244055690743153e-08
model O 0 1.5922347529340186e-07
, O 0 3.153357397422951e-08
the O 0 1.7134896168613523e-08
exteriorized O 0 1.510756464995211e-05
mesentery O 0 2.356830009375699e-05
was O 0 1.5691709904785967e-06
superfused O 0 1.1744607490982162e-06
with O 0 1.528165682884719e-08
ferric O 0 2.4131802547344705e-06
chloride O 0 6.904735982971033e-07
and O 0 1.3166076229254031e-08
the O 0 8.482161639733476e-09
accumulation O 0 2.069735529630634e-07
of O 0 8.784896365909844e-09
fluorescently O 0 2.987256993947085e-05
labeled O 0 1.599974166310858e-05
platelets O 0 1.9327286281622946e-05
was O 0 8.149510790644854e-07
observed O 0 1.4909552703556983e-07
by O 0 4.886755178290514e-08
intravital O 0 3.2922493119258434e-05
microscopy O 0 1.3887871318729594e-05
. O 0 1.72107934304222e-06

We O 0 2.6345302103436552e-05
conclude O 0 3.0075891572778346e-06
that O 0 2.7979753625118065e-08
these O 0 7.466260498745214e-09
mice O 0 1.1884806099260459e-06
very O 0 6.435830357531813e-08
closely O 0 2.2968565644987393e-06
mimic O 0 0.0011873884359374642
severe O 0 0.0034998494666069746
human O 0 0.0007258114055730402
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 1.4057018233870622e-05
will O 0 1.5413304481626255e-06
be O 0 5.5171668122966366e-08
very O 0 1.0034082897902863e-08
useful O 0 1.636477087174626e-08
for O 0 2.4197607473297467e-08
investigating O 0 1.4444427165472007e-07
the O 0 8.649193361520702e-09
role O 0 2.6337540148801963e-08
of O 0 9.075313833761811e-09
vWf O 0 9.481216807216697e-07
in O 0 7.786018585420607e-08
normal O 0 8.98977759788977e-07
physiology O 0 3.9657074921706226e-06
and O 0 2.620830912292149e-07
in O 0 4.903247941001609e-07
disease O 0 1.876130045275204e-05
models O 0 1.2340035482338862e-06
. O 0 1.3936303844275244e-07
. O 0 4.823442623091978e-07

Oral O 0 0.001455805730074644
contraceptives O 0 0.0034838018473237753
and O 0 8.940785960476205e-07
the O 0 3.6730989450006746e-07
risk O 0 8.393363714276347e-06
of O 0 6.760521955584409e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
. O 0 8.930765034165233e-06

Hereditary B-Disease 1 0.999998927116394
Ovarian I-Disease 1 0.9999996423721313
Cancer I-Disease 1 0.9997863173484802
Clinical O 0 0.0003019430732820183
Study O 0 3.3711282867443515e-06
Group O 0 3.155326339765452e-05
. O 0 5.746353508584434e-06

BACKGROUND O 0 5.5114236602094024e-05
Women O 0 9.984408961827285e-07
with O 0 3.143508919833948e-08
mutations O 0 1.2780883480445482e-06
in O 0 1.319649722830718e-08
either O 0 4.18640553334626e-08
the O 0 3.594919562033283e-08
BRCA1 O 0 2.8173451937618665e-05
or O 0 1.7522820883186796e-07
the O 0 2.3467309873126396e-08
BRCA2 O 0 2.2989772332948633e-05
gene O 0 2.530891833885107e-07
have O 0 3.6730931629591623e-09
a O 0 1.6476111142083028e-08
high O 0 4.2541330458334414e-07
lifetime O 0 1.9270041775598656e-06
risk O 0 1.2213973604957573e-05
of O 0 4.886141687165946e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999984502792358
. O 0 4.4023718146490864e-06

Oral O 0 0.0034864312037825584
contraceptives O 0 0.16243183612823486
protect O 0 0.0007069137063808739
against O 0 0.19446209073066711
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
in O 0 6.56111296848394e-07
general O 0 8.203934953598946e-08
, O 0 3.761656230949484e-08
but O 0 1.4646975188270517e-08
it O 0 3.63773970946113e-08
is O 0 1.4599447872853943e-08
not O 0 9.18043419062542e-09
known O 0 3.2710833153259955e-08
whether O 0 1.6101289190828538e-08
they O 0 1.5116013329929956e-08
also O 0 1.172045642761077e-07
protect O 0 8.775840143471214e-08
against O 0 6.228666649121806e-08
hereditary B-Disease 0 0.00014709404786117375
forms I-Disease 0 1.7107247913372703e-05
of I-Disease 0 0.004286640323698521
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999988079071045
. O 0 4.4032326513843145e-06

METHODS O 0 1.5282061212928966e-05
We O 0 3.338372209782392e-07
enrolled O 0 2.648883423717052e-07
207 O 0 1.0299027053406462e-06
women O 0 4.3543690253500245e-07
with O 0 7.120755981304683e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 3.3561207146703964e-07
161 O 0 7.225296627666467e-08
of O 0 4.730245972695002e-09
their O 0 1.7637194105191156e-07
sisters O 0 2.6306245217710966e-06
as O 0 2.6688690368814605e-08
controls O 0 4.019137804789352e-07
in O 0 3.181977348276632e-08
a O 0 2.3481105415612546e-07
case O 0 5.317549494066043e-07
- O 0 2.413575566606596e-05
control O 0 8.791696018306538e-06
study O 0 6.932203291398764e-07
. O 0 6.617152052967867e-07

All O 0 4.6917145368752244e-07
the O 0 1.8455050110333104e-07
patients O 0 4.794326287083095e-07
carried O 0 3.391367187077776e-08
a O 0 5.134518588079118e-08
pathogenic O 0 6.681407853648125e-07
mutation O 0 1.7624092834012117e-06
in O 0 5.0386955052772464e-08
either O 0 2.7652311018755427e-07
BRCA1 O 0 0.00022878832533024251
( O 0 1.5603886538428924e-07
179 O 0 2.5183621232827136e-07
women O 0 4.30569173204276e-07
) O 0 5.518903734014202e-08
or O 0 2.0103516362723894e-06
BRCA2 O 0 0.00623234873637557
( O 0 6.099985512264539e-07
28 O 0 1.4156580618873704e-06
women O 0 1.941805152227971e-07
) O 0 9.412820389798071e-08
. O 0 5.031334353589045e-07

The O 0 2.4739481432334287e-06
control O 0 6.6891561800730415e-06
women O 0 7.210317676253908e-07
were O 0 8.872836332329825e-08
enrolled O 0 5.112306666887889e-08
regardless O 0 3.623515709705316e-08
of O 0 9.217737684252825e-09
whether O 0 1.0729130650588559e-07
or O 0 1.8926095890492434e-07
not O 0 6.635225702211756e-08
they O 0 1.9935828987627247e-08
had O 0 1.8168515225625015e-07
either O 0 1.5770545758186927e-07
mutation O 0 4.255177827872103e-06
. O 0 4.3819969164360373e-07

Lifetime O 0 8.234350389102474e-05
histories O 0 1.047591558744898e-05
of O 0 1.8786155919769953e-07
oral O 0 4.874467322224518e-06
- O 0 3.357760579092428e-05
contraceptive O 0 3.2605075830360875e-05
use O 0 1.067186161662903e-07
were O 0 2.5271189585396314e-08
obtained O 0 2.1912313741268008e-08
by O 0 7.728121254046982e-09
interview O 0 3.737765609912458e-06
or O 0 1.8101646404034e-08
by O 0 4.32954649909334e-09
written O 0 3.764247225035433e-08
questionnaire O 0 7.180030081599398e-08
and O 0 2.498749118728938e-08
were O 0 2.719914782289834e-08
compared O 0 1.0276917095097815e-07
between O 0 4.069267944828425e-08
patients O 0 2.8920069894411427e-07
and O 0 4.0893961994470374e-08
control O 0 1.0070626785818604e-06
women O 0 2.3585781150359253e-07
, O 0 1.952631123458559e-08
after O 0 6.201626234769719e-08
adjustment O 0 5.329531305164892e-08
for O 0 7.695422965525722e-09
year O 0 6.029803500950948e-08
of O 0 7.1424515191154114e-09
birth O 0 2.095200443363865e-06
and O 0 1.3483551697390794e-07
parity O 0 2.8255249162612017e-06
. O 0 1.5345514157161233e-06

RESULTS O 0 9.446406329516321e-05
The O 0 3.0370031822712917e-07
adjusted O 0 9.939166193362325e-05
odds O 0 1.9086022803094238e-05
ratio O 0 1.7913342162501067e-05
for O 0 0.06945771723985672
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 8.074801485236094e-07
with O 0 1.54036570165772e-08
any O 0 2.023463707701012e-08
past O 0 7.407214042132182e-08
use O 0 1.7406364349881187e-07
of O 0 5.6322104313721866e-08
oral O 0 6.818361725891009e-06
contraceptives O 0 0.0001611199986655265
was O 0 1.6696440070518292e-06
0 O 0 7.009638807176088e-07
. O 0 9.022191420626768e-07

5 O 0 1.5520243323408067e-05
( O 0 1.8172742954902787e-07
95 O 0 3.0143777962621243e-07
percent O 0 1.2172274182375986e-05
confidence O 0 3.020357439709187e-07
interval O 0 1.0753510792937959e-07
, O 0 1.9308137311213613e-08
0 O 0 2.61055799199994e-08
. O 0 2.9023823344687116e-09
3 O 0 2.5611591070173745e-08
to O 0 3.505988388496917e-08
0 O 0 5.2714000275955186e-08
. O 0 1.2412388450400158e-08
8 O 0 9.212872242869707e-08
) O 0 3.817491744939616e-08
. O 0 2.724723628944048e-07

The O 0 4.995484232495073e-06
risk O 0 1.5365534636657685e-05
decreased O 0 1.0891934607570875e-06
with O 0 9.042001813952538e-09
increasing O 0 4.799911579311811e-08
duration O 0 1.2273238780835527e-07
of O 0 5.841631178782336e-09
use O 0 2.58125226082484e-07
( O 0 6.783628947459874e-08
P O 0 2.73200585070299e-05
for O 0 4.441978873614971e-08
trend O 0 6.35393291759101e-07
, O 0 1.6574293937310358e-08
< O 0 2.6821268761523243e-08
0 O 0 3.346324461972472e-08
. O 0 6.09355188530003e-09
001 O 0 3.467740583573686e-08
) O 0 3.3883007510837615e-09
; O 0 1.6151510129347457e-09
use O 0 5.291302063170633e-09
for O 0 2.7713815242691453e-08
six O 0 4.9620727082810845e-08
or O 0 7.490912423691043e-08
more O 0 1.8977058147129355e-08
years O 0 4.064582626028823e-08
was O 0 2.533470819798822e-07
associated O 0 6.161219090472514e-09
with O 0 8.607421442263785e-10
a O 0 4.031144484883953e-08
60 O 0 8.409465834802177e-08
percent O 0 2.841722789526102e-06
reduction O 0 3.400889738713886e-07
in O 0 1.913143137244333e-07
risk O 0 3.0860021524858894e-06
. O 0 5.082768552711059e-07

Oral O 0 0.00016229382890742272
- O 0 0.00014441428356803954
contraceptive O 0 0.00014163875312078744
use O 0 7.827322292541794e-07
protected O 0 1.228001929121092e-05
against O 0 0.0009817254031077027
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999799728393555
both O 0 3.6862193297793056e-08
for O 0 1.3804931420224875e-08
carriers O 0 3.1199146377502984e-08
of O 0 4.790114083164099e-09
the O 0 1.1286103074326093e-07
BRCA1 O 0 0.0002689319371711463
mutation O 0 8.078814062173478e-06
( O 0 4.98406897975201e-08
odds O 0 5.726701601815876e-07
ratio O 0 7.868833051816182e-08
, O 0 2.4117202457318854e-08
0 O 0 1.8557512859729286e-08
. O 0 8.137557294674025e-09
5 O 0 1.638825963823365e-08
; O 0 5.162394511870616e-09
95 O 0 3.875087273286226e-08
percent O 0 5.503594820766011e-06
confidence O 0 5.1477467621907635e-08
interval O 0 2.022518508226767e-08
, O 0 4.5875103715786736e-09
0 O 0 1.081399858549048e-08
. O 0 2.741606719425249e-09
3 O 0 1.4312701246410597e-08
to O 0 9.124990540954059e-09
0 O 0 2.5114683666060955e-08
. O 0 1.0331136834906829e-08
9 O 0 1.7378731342887477e-07
) O 0 3.7281262521560166e-09
and O 0 3.101236156766163e-09
for O 0 2.9623601349726414e-09
carriers O 0 5.846412687304792e-09
of O 0 1.7626349269050934e-09
the O 0 1.4357956956700946e-07
BRCA2 O 0 0.0008456522482447326
mutation O 0 6.8033314164495096e-06
( O 0 3.1390033683464935e-08
odds O 0 5.742900839322829e-07
ratio O 0 7.378279320846559e-08
, O 0 8.295445219630437e-09
0 O 0 1.7599280255353733e-08
. O 0 4.394213881653286e-09
4 O 0 2.6539652253632084e-08
; O 0 8.541532814376751e-09
95 O 0 1.0682207118861697e-07
percent O 0 5.633452929032501e-06
confidence O 0 9.210008045101858e-08
interval O 0 5.0748059976513105e-08
, O 0 8.166197495995675e-09
0 O 0 7.197536788794423e-09
. O 0 3.0546762896932478e-09
2 O 0 1.7829439258321145e-08
to O 0 2.2065393068260164e-08
1 O 0 8.279609886585604e-08
. O 0 1.2167018503816962e-08
1 O 0 1.362579666874808e-07
) O 0 5.408505288073684e-08
. O 0 1.5461947100448015e-07

CONCLUSIONS O 0 0.0003914764092769474
Oral O 0 2.0487927031354047e-05
- O 0 4.939442078466527e-05
contraceptive O 0 5.518949546967633e-05
use O 0 2.280875293081408e-07
may O 0 2.580174225386145e-07
reduce O 0 1.2359957679564104e-07
the O 0 9.437430747993858e-08
risk O 0 1.0682309039111715e-05
of O 0 4.042906948598102e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 0.9999996423721313
in O 0 1.2403305049701885e-07
women O 0 2.0498868380514068e-08
with O 0 6.797770346622656e-09
pathogenic O 0 5.3000474053988e-07
mutations O 0 1.797994286789617e-06
in O 0 1.0995969468297062e-08
the O 0 1.299433876056355e-07
BRCA1 O 0 0.0005813498282805085
or O 0 2.0520699763437733e-05
BRCA2 O 0 0.00927214790135622
gene O 0 0.0002543496375437826

A O 0 8.99241967999842e-06
Japanese O 0 2.893926648539491e-06
family O 0 1.8846392322302563e-06
with O 0 8.674521723150974e-07
adrenoleukodystrophy B-Disease 1 0.9999992847442627
with O 0 1.4122664993010403e-07
a O 0 2.995938359617867e-07
codon O 0 2.3975380827323534e-06
291 O 0 1.174459612229839e-06
deletion O 0 5.1182660172344185e-06
: O 0 2.1501035618598507e-08
a O 0 8.761673342405629e-08
clinical O 0 7.318480470530631e-07
, O 0 4.9384961897658286e-08
biochemical O 0 1.2176326436019735e-06
, O 0 1.4817062776728562e-07
pathological O 0 9.798590326681733e-06
, O 0 1.6130098856592667e-07
and O 0 7.086485425134015e-07
genetic O 0 5.4130865464685485e-05
report O 0 1.4205011211743113e-05
. O 0 1.9342694486113032e-06

We O 0 7.565068244730355e-06
report O 0 4.838166773879493e-07
a O 0 4.642235396090655e-08
Japanese O 0 3.499735612422228e-07
family O 0 3.2515565635549137e-06
with O 0 4.894045923720114e-05
adrenoleukodystrophy B-Disease 1 1.0
( O 0 0.022058160975575447
ALD B-Disease 1 1.0
) O 0 3.20532024034037e-07
with O 0 7.176015781595879e-09
a O 0 7.546511682221535e-08
three O 0 1.24090675512889e-07
base O 0 1.9159384123668133e-07
pair O 0 1.3676065009349259e-06
deletion O 0 1.076917124009924e-05
( O 0 4.6579515355915646e-08
delGAG O 0 1.1380819842088385e-06
291 O 0 3.3519719977448403e-07
) O 0 2.0187146176908755e-08
in O 0 3.0496536851387646e-08
the O 0 1.515529561402218e-06
ALD B-Disease 1 0.9999998807907104
gene O 0 0.00010504994133953005
. O 0 1.6178069017769303e-06

A O 0 3.367217914274079e-06
variety O 0 2.462700479100022e-07
of O 0 3.905405421278374e-08
phenotypes O 0 5.218497790338006e-06
were O 0 2.563217265105777e-07
observed O 0 2.143701607337789e-07
within O 0 1.3521249897507914e-08
this O 0 1.666883164830324e-08
family O 0 1.4109272115092608e-06
. O 0 1.2699393892035005e-06

While O 0 3.4422296266711783e-06
the O 0 2.088775374886609e-07
proband O 0 0.00011335818999214098
( O 0 9.307681239079102e-07
patient O 0 2.3831241833249805e-06
1 O 0 5.614694487121596e-07
) O 0 6.986174128087441e-08
was O 0 8.68083702698641e-07
classified O 0 4.754199949275062e-07
as O 0 3.444530349838715e-08
having O 0 1.8881417318539206e-08
a O 0 1.9228753700417656e-08
rare O 0 3.5915682872200705e-08
intermediate O 0 1.355084293663822e-07
type O 0 8.423255337675073e-08
of O 0 1.4696394323721051e-08
adult O 0 1.247623572453449e-06
cerebral O 0 2.3624692403245717e-05
and O 0 4.6761380190218915e-07
cerebello O 0 0.006437721662223339
- O 0 0.14613953232765198
brain O 0 0.024867581203579903
stem O 0 2.551471879996825e-06
forms O 0 2.900314939324744e-07
, O 0 1.8794077050188207e-07
his O 0 1.7543130752528668e-06
younger O 0 2.4287485302920686e-06
brother O 0 7.587704203615431e-06
( O 0 3.7105496630829293e-07
patient O 0 8.305009373543726e-07
2 O 0 9.07164576346986e-07
) O 0 8.261216777327718e-08
and O 0 7.555669867542747e-07
nephew O 0 0.00039779458893463016
( O 0 1.1364595593477134e-06
patient O 0 4.227301815262763e-06
3 O 0 4.05021239657799e-07
) O 0 7.258156387024428e-08
had O 0 1.1341014669596916e-06
a O 0 7.82372535468312e-06
childhood O 0 0.001540780533105135
ALD B-Disease 1 0.9999998807907104
type O 0 0.00010956414917018265
. O 0 1.7255002831007005e-06

Another O 0 4.84168813272845e-05
nephew O 0 0.0012517274590209126
( O 0 8.643935871077701e-06
patient O 0 1.1725285730790347e-05
4 O 0 9.39937990551698e-07
) O 0 3.8204344576797666e-08
of O 0 1.810268379642821e-08
patient O 0 4.56783845947939e-06
1 O 0 1.5989696748874849e-06
was O 0 4.890899617748801e-06
classified O 0 1.2509929092630045e-06
as O 0 8.017010344474329e-08
having O 0 5.0167539455969745e-08
an O 0 4.0167691395254224e-08
adolescent O 0 7.847337428756873e-07
form O 0 3.1192010396807746e-07
. O 0 1.122977437262307e-06

The O 0 1.5169032394624082e-06
tau O 0 2.112336460413644e-06
level O 0 2.6485602688808285e-07
in O 0 7.202290674968026e-08
the O 0 2.4022224920372537e-07
cerebrospinal O 0 0.0003224687825422734
fluid O 0 0.000143321231007576
( O 0 9.644581041357014e-06
CSF O 1 0.8791278600692749
) O 0 2.0004856082778133e-07
in O 0 1.2010259808903356e-07
patient O 0 1.0288935072821914e-06
1 O 0 3.286913283773174e-07
was O 0 1.702055328678398e-06
as O 0 2.55837626639277e-08
high O 0 4.131339537138956e-08
as O 0 1.3253252717504438e-08
that O 0 5.146290948943033e-09
of O 0 1.3684235966593405e-08
patients O 0 9.475991760155011e-07
with O 0 1.6871871366674895e-06
Alzheimers B-Disease 1 0.9999954700469971
disease I-Disease 1 0.8987210988998413
( O 0 3.564917676612822e-07
AD B-Disease 0 2.878565646824427e-05
) O 0 6.802363827773661e-07
. O 0 1.152646746049868e-06

His O 0 4.604323476087302e-05
brain O 0 0.0004515858308877796
magnetic O 0 2.5463972633588128e-05
resonance O 0 5.442823749035597e-05
image O 0 0.00027744469116441905
( O 0 3.763974746107124e-06
MRI O 0 0.0023056427016854286
) O 0 1.1947648772547836e-06
showed O 0 1.564535341458395e-05
abnormalities B-Disease 0 0.0002448511659167707
in I-Disease 0 2.6288306642641146e-08
the I-Disease 0 4.707854373009468e-08
bilateral I-Disease 0 2.2400281523005106e-06
cerebellar I-Disease 0 0.04383845254778862
hemispheres I-Disease 0 0.0072967279702425
and O 0 1.902523399621714e-05
brain O 0 0.0016782904276624322
stem O 0 1.1302488928777166e-05
, O 0 1.2606056998265558e-07
but O 0 3.193426323377935e-08
not O 0 1.0470835754006202e-08
in O 0 1.926579606958967e-08
the O 0 2.3635271872990415e-07
cerebral O 0 4.137649011681788e-05
white O 0 7.851567147554306e-07
matter O 0 5.911136113923021e-08
, O 0 7.66980878807999e-09
where O 0 6.235439276025545e-09
marked O 0 9.779200382808995e-08
reductions O 0 8.974786283033609e-07
of O 0 6.822293396879786e-09
the O 0 1.868249341896444e-07
cerebral O 0 4.743411409435794e-05
blood O 0 2.3726652216282673e-06
flow O 0 8.820314860713552e-07
and O 0 3.0545677986992814e-07
oxygen O 0 6.04476781518315e-07
metabolism O 0 1.4210930885383277e-06
were O 0 1.4119913238630488e-08
clearly O 0 2.061158532740137e-08
demonstrated O 0 1.799815763092738e-08
by O 0 4.982821710797225e-09
positron O 0 1.2874364074377809e-05
emission O 0 2.7340336600900628e-05
tomography O 0 0.0008913798374123871
( O 0 2.675276391528314e-07
PET O 0 4.950561924488284e-05
) O 0 3.355829676365829e-07
. O 0 4.590721118802321e-07

In O 0 3.3412179618608207e-05
patients O 0 4.4194246584083885e-05
2 O 0 9.8009331850335e-07
and O 0 1.3218658523328486e-07
3 O 0 3.3003757948790735e-07
, O 0 4.4054111469904456e-08
the O 0 1.1032106783659401e-07
autopsy O 0 0.0022841610480099916
findings O 0 2.9413411084533436e-06
showed O 0 2.3187531041912735e-06
massive O 0 2.4137189029715955e-06
demyelination B-Disease 1 0.9999960660934448
of I-Disease 0 2.221450898787225e-07
the I-Disease 0 2.5320314307464287e-06
cerebral I-Disease 0 0.0002860383247025311
white I-Disease 0 2.61272043644567e-06
matter I-Disease 0 3.586406904787509e-08
with O 0 3.815066040857573e-09
sparing O 0 5.9195642165832396e-08
of O 0 3.987081775846946e-09
the O 0 5.920828627381525e-08
U O 0 0.00019038119353353977
- O 0 0.00012984573550056666
fibers O 0 0.0002295018930453807
, O 0 1.8084875819113222e-08
compatible O 0 3.601920539608727e-08
with O 0 3.523799474436373e-09
the O 0 2.8591420786483468e-08
findings O 0 3.5332374181962223e-07
of O 0 1.325247467320878e-07
childhood O 0 0.000168197468155995
ALD B-Disease 1 0.9999995231628418
. O 0 9.659400348027702e-06

Oleic O 0 0.007712958846241236
and O 0 2.0891229723929428e-05
erucic O 0 0.0028395631816238165
acids O 0 5.652994514093734e-05
( O 0 5.760948056376947e-07
Lorenzos O 0 8.474800779367797e-06
Oil O 0 6.549275440193014e-06
) O 0 1.9366597214798276e-08
were O 0 8.008234075873588e-09
administered O 0 4.85296114405287e-09
to O 0 4.0219283903297764e-08
patients O 0 8.759351288745165e-08
1 O 0 6.647259453984589e-08
and O 0 9.881914309062267e-08
4 O 0 4.6762764327468176e-07
, O 0 2.8363940529629872e-08
but O 0 1.1339870376048111e-08
sufficient O 0 1.8133231804995376e-08
effectiveness O 0 8.785369232100493e-08
was O 0 7.322648230001505e-07
not O 0 2.487337091849895e-08
obtained O 0 2.946443657947384e-07
. O 0 4.83988344512909e-07

The O 0 3.6525109408103162e-06
findings O 0 2.8684332846751204e-06
in O 0 7.550038816361848e-08
this O 0 2.59288199799812e-08
family O 0 4.043951946641755e-07
suggest O 0 2.0245261111995205e-07
that O 0 1.9563179520787344e-08
delGAG291 O 0 9.299243401983404e-07
is O 0 1.3080073024696048e-08
part O 0 8.018917974084161e-09
of O 0 2.0008998902198982e-09
the O 0 3.6822207505338156e-08
cause O 0 6.011877644596098e-07
of O 0 1.6207621911235037e-08
Japanese O 0 2.0256384232197888e-05
ALD B-Disease 1 0.9999992847442627
with O 0 2.788990229873889e-07
phenotypic O 0 7.625797024957137e-06
variations O 0 7.63886964705307e-06
. O 0 1.173252826447424e-06

Moreover O 0 9.948937986337114e-06
, O 0 9.464741168585533e-08
although O 0 1.064372323611451e-08
the O 0 3.693741090771141e-09
scale O 0 1.4876927423301822e-07
of O 0 7.560482906399102e-09
the O 0 4.4611169869313017e-08
study O 0 6.258127172031891e-08
is O 0 2.4653552088693687e-08
limited O 0 2.5559083738357913e-08
, O 0 2.749609961938404e-08
there O 0 2.9112532384800716e-09
is O 0 3.8681142733310026e-09
a O 0 2.0023707136829216e-08
possibility O 0 4.2311189218935397e-08
that O 0 1.5626158145209956e-08
PET O 0 6.1657810874748975e-06
can O 0 1.3192979508858116e-07
detect O 0 2.7878277251147665e-06
an O 0 1.8779779509259242e-07
insidious B-Disease 0 5.432701436802745e-05
lesion I-Disease 0 0.013873319141566753
which O 0 3.1884241025181836e-07
is O 0 3.058368136521494e-08
undetectable O 0 3.297953128367226e-07
by O 0 1.475385769111881e-08
computed O 0 2.9917293886683183e-06
tomogram O 0 0.0001603414275450632
( O 0 8.289143806905486e-07
CT O 1 0.8283289074897766
) O 0 1.2229330081936496e-07
or O 0 2.081616656823826e-07
MRI O 0 8.597260602982715e-05
analysis O 0 1.7438134136682493e-07
, O 0 3.7445975209493554e-08
and O 0 3.413086346881755e-08
that O 0 5.907425215667672e-09
the O 0 8.025803133193676e-09
higher O 0 4.831665378901562e-08
level O 0 5.0550474917088195e-09
of O 0 8.24653678677123e-10
tau O 0 4.671261777389191e-08
reflects O 0 1.530309567954191e-08
the O 0 3.2441964670226753e-09
process O 0 2.0873052619663213e-08
of O 0 2.2486650763653415e-08
neuronal B-Disease 0 0.00041705643525347114
degeneration I-Disease 1 0.9774785041809082
in O 0 2.4046934413490817e-05
ALD B-Disease 1 0.9999998807907104
. O 0 1.6492875147378072e-05

Lorenzos O 0 0.00138579320628196
Oil O 0 0.00011429031292209402
should O 0 2.707601822748984e-07
be O 0 1.2425629414281048e-08
given O 0 4.074492299110943e-09
in O 0 4.397441966119686e-09
the O 0 9.087386843020795e-09
early O 0 3.745687422451738e-07
stage O 0 1.4412410109798657e-06
. O 0 9.15043969484941e-08
. O 0 2.9702553661081765e-07

Nonsense O 0 0.0003616275789681822
mutation O 0 4.909195195068605e-05
in O 0 3.144960771805927e-07
exon O 0 5.82309485253063e-06
4 O 0 3.464544988673879e-07
of O 0 8.642630611177538e-09
human O 0 4.079237925225243e-08
complement O 0 1.9363611158951244e-07
C9 O 0 6.483563993242569e-06
gene O 0 1.5220228988255258e-06
is O 0 2.1198076183281955e-08
the O 0 7.782110955645294e-09
major O 0 7.29717655190143e-08
cause O 0 1.868634313950679e-07
of O 0 1.5268138753299354e-08
Japanese O 0 6.953723072911089e-07
complement B-Disease 0 5.135560058988631e-06
C9 I-Disease 0 0.05228903517127037
deficiency I-Disease 0 0.012415234930813313
. O 0 2.284561560372822e-06

Deficiency B-Disease 1 0.9974786639213562
of I-Disease 0 1.7083343095691816e-07
the I-Disease 0 5.741226161148916e-08
ninth I-Disease 0 1.2933033985973452e-06
component I-Disease 0 1.9599787037805072e-07
of I-Disease 0 7.79130449046761e-09
human I-Disease 0 5.009477632711423e-08
complement I-Disease 0 1.503810267422523e-07
( O 0 6.265317153975047e-08
C9 O 0 3.8158250390551984e-06
) O 0 2.5226785993481826e-08
is O 0 1.4324108565944016e-09
the O 0 1.1585710169015329e-09
most O 0 6.896291093738682e-09
common O 0 1.3888436569686746e-06
complement B-Disease 1 0.9999724626541138
deficiency I-Disease 1 0.999998927116394
in O 0 1.0769192471116185e-07
Japan O 0 7.263529369083699e-07
but O 0 3.171235007926043e-08
is O 0 1.3010453159267854e-08
rare O 0 1.2504825619430449e-08
in O 0 4.804406650293913e-09
other O 0 4.726169677837788e-09
countries O 0 2.0830775326885487e-08
. O 0 2.2793724951952754e-07

We O 0 3.7354743653850164e-06
studied O 0 5.21677861797798e-07
the O 0 2.309493396523976e-08
molecular O 0 2.2231633067804069e-07
basis O 0 1.423125866040209e-07
of O 0 1.519896386525943e-07
C9 B-Disease 0 0.1558428406715393
deficiency I-Disease 0 0.016451232135295868
in O 0 1.6281207493307193e-08
four O 0 4.106091111566457e-08
Japanese O 0 8.661543802190863e-07
C9 B-Disease 0 0.00039827535510994494
- I-Disease 0 0.21872475743293762
deficient I-Disease 0 0.28734833002090454
patients O 0 3.728215233422816e-05
who O 0 2.656275228218874e-06
had O 0 4.400794205139391e-05
suffered O 0 0.14183948934078217
from O 0 1.564410194987431e-05
meningococcal B-Disease 1 0.9999991655349731
meningitis I-Disease 1 0.9999932050704956
. O 0 1.1132888175779954e-05

Direct O 0 8.557257388019934e-06
sequencing O 0 5.783049346064217e-06
of O 0 1.5566254774057597e-07
amplified O 0 5.00656324220472e-06
C9 O 0 1.2368249372229911e-05
cDNA O 0 1.5026433857201482e-06
and O 0 2.0234992348378e-07
DNA O 0 1.5975614360286272e-06
revealed O 0 8.294671829389699e-07
a O 0 4.148592935848683e-08
nonsense O 0 3.6273402770348184e-07
substitution O 0 4.9876451413410905e-08
( O 0 2.0373086329072976e-08
CGA O 0 2.1554678824031726e-06
- O 0 1.5364155842689797e-05
- O 0 2.2072306819609366e-05
> O 0 4.365033703379595e-07
TGA O 0 3.234672703911201e-06
) O 0 8.433764797644017e-09
at O 0 1.3909861706906668e-08
codon O 0 7.111012934046812e-08
95 O 0 1.6943086933451923e-08
in O 0 2.716330937957423e-09
exon O 0 1.8278315394582023e-07
4 O 0 6.058970569711164e-08
in O 0 3.892790534365531e-09
the O 0 1.2063403609374745e-08
four O 0 1.7477859159953368e-07
C9 B-Disease 0 0.00021346926223486662
- I-Disease 0 0.013078839518129826
deficient I-Disease 0 0.0010817188303917646
individuals O 0 2.1850507891940651e-07
. O 0 8.09813798241521e-07

An O 0 1.5903195844657603e-06
allele O 0 1.0646377631928772e-05
- O 0 5.406877789937425e-06
specific O 0 1.1280270229008238e-07
polymerase O 0 2.421604222035967e-06
chain O 0 3.6556889426719863e-06
reaction O 0 9.13258517698523e-08
system O 0 2.9597185147167693e-08
designed O 0 9.304559256406719e-08
to O 0 8.959754893567151e-08
detect O 0 7.744723689029342e-07
exclusively O 0 2.0866087524495924e-08
only O 0 2.7647752975923368e-09
one O 0 4.163342559593275e-09
of O 0 8.840461140913192e-10
the O 0 1.0493428348468115e-08
normal O 0 9.837869896500706e-08
and O 0 3.594391628780613e-08
mutant O 0 1.9021346986392018e-07
alleles O 0 1.2182327679965965e-07
indicated O 0 2.0601177652679326e-07
that O 0 2.4478017390805462e-09
all O 0 1.0376750569918158e-09
the O 0 5.093130361899512e-09
four O 0 1.2786024683464348e-07
patients O 0 9.500806896767244e-08
were O 0 7.456042006026564e-09
homozygous O 0 4.650024720831425e-08
for O 0 2.4086757033359163e-09
the O 0 4.683329724031182e-09
mutation O 0 8.483153379756914e-08
in O 0 6.673388508460221e-09
exon O 0 5.11444227413449e-07
4 O 0 4.77319872516091e-07
and O 0 3.2549142048310387e-08
that O 0 9.453695604122458e-09
the O 0 6.46067199738809e-09
parents O 0 1.7930487317130428e-08
of O 0 5.713236106430486e-09
patient O 0 4.837050369133067e-07
2 O 0 4.1055278643398196e-07
were O 0 2.7458216322884255e-07
heterozygous O 0 1.1542284710230888e-06
. O 0 3.1691857316218375e-07

The O 0 9.495549306848261e-07
common O 0 7.006136684140074e-07
mutation O 0 2.0116019641136518e-06
at O 0 2.0356971219825937e-07
codon O 0 6.353690196192474e-07
95 O 0 9.049096405533419e-08
in O 0 2.3392143333467175e-08
exon O 0 1.3288419040691224e-06
4 O 0 9.056881253854954e-07
might O 0 1.3284437727634213e-07
be O 0 1.756815848352744e-08
responsible O 0 6.167135069290453e-08
for O 0 8.280743202249141e-09
most O 0 4.732811120788938e-08
Japanese O 0 4.1327057260787115e-06
C9 B-Disease 0 0.020298071205615997
deficiency I-Disease 0 0.0008609681972302496
. O 0 8.213658020395087e-08
. O 0 5.594906724581961e-07

BRCA1 O 0 0.004258313681930304
required O 0 2.7628163934423355e-06
for O 0 1.174627115574367e-07
transcription O 0 2.3439674805558752e-06
- O 0 5.6868961110012606e-05
coupled O 0 2.2491176423500292e-05
repair O 0 0.00019970817083958536
of O 0 5.9601003243869854e-08
oxidative O 0 8.362171683984343e-06
DNA O 0 0.0002136160765076056
damage O 0 0.0003486404602881521
. O 0 3.1850277082412504e-06

The O 0 9.956971916835755e-05
breast B-Disease 1 0.999830961227417
and I-Disease 1 0.9691683053970337
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
susceptibility O 0 0.0006456910632550716
gene O 0 2.724301884882152e-05
BRCA1 O 0 0.00011618536518653855
encodes O 0 2.191149178543128e-06
a O 0 1.2960740605194587e-06
zinc O 0 0.00016644332208670676
finger O 0 3.4990767744602636e-05
protein O 0 9.702558827484609e-07
of O 0 1.654946402140922e-08
unknown O 0 3.945108630887262e-07
function O 0 7.210571766336216e-07
. O 0 5.981584081382607e-07

Association O 0 8.426833119301591e-06
of O 0 4.365620398516512e-08
the O 0 2.7413570080625504e-08
BRCA1 O 0 7.05948286849889e-06
protein O 0 1.5125307584185066e-07
with O 0 5.5938906839969604e-09
the O 0 1.4791164737459894e-08
DNA O 0 2.8454651328502223e-06
repair O 0 9.978801244869828e-06
protein O 0 8.49812295200536e-07
Rad51 O 0 6.075964392948663e-06
and O 0 3.3814266942044924e-08
changes O 0 3.868977582754951e-09
in O 0 1.5904166872360292e-09
the O 0 1.1580959524692958e-09
phosphorylation O 0 1.790270331980537e-08
and O 0 5.372735145670049e-08
cellular O 0 9.7939823717752e-07
localization O 0 1.485430232150975e-07
of O 0 1.3420063948998973e-09
the O 0 7.337619845060317e-09
protein O 0 1.9907146509012819e-07
after O 0 1.7008694896958332e-07
exposure O 0 2.0263573219381215e-07
to O 0 1.2116071701484543e-08
DNA O 0 3.865472535835579e-06
- O 0 2.8794001991627738e-05
damaging O 0 3.0179842724464834e-05
agents O 0 1.1432171476144504e-07
are O 0 2.2758390727517508e-09
consistent O 0 1.3067131376942598e-08
with O 0 3.4403719872955207e-09
a O 0 6.887880488193332e-08
role O 0 7.857419603851667e-08
for O 0 8.216462532573132e-08
BRCA1 O 0 3.252014721510932e-05
in O 0 1.3930311126841843e-07
DNA O 0 3.574057700461708e-05
repair O 0 0.0004732417582999915
. O 0 2.846235929609975e-06

Here O 0 1.2149914255132899e-05
, O 0 4.824059374186618e-07
it O 0 3.573399354195317e-08
is O 0 9.263385614133313e-09
shown O 0 1.498585611159342e-08
that O 0 5.164117578004834e-09
mouse O 0 1.2712262105196714e-06
embryonic O 0 3.321086296637077e-06
stem O 0 5.3269673117029015e-06
cells O 0 1.9689370674313977e-05
deficient B-Disease 0 3.9573395042680204e-05
in I-Disease 0 7.808117885588217e-08
BRCA1 I-Disease 0 4.7008121327962726e-05
are O 0 3.396876024908124e-08
defective O 0 3.833475147985155e-06
in O 0 2.465439763454924e-08
the O 0 1.5696954847044253e-08
ability O 0 5.8540816638696924e-08
to O 0 1.4026742434225525e-08
carry O 0 1.818546202514426e-08
out O 0 9.69774749393082e-09
transcription O 0 2.43727953375128e-07
- O 0 5.158906333235791e-06
coupled O 0 1.9636715933302185e-06
repair O 0 2.1363706764532253e-05
of O 0 1.5847792411705086e-08
oxidative O 0 2.050931016128743e-06
DNA O 0 0.00027499767020344734
damage O 0 0.0013599731028079987
, O 0 2.0973385517208953e-07
and O 0 5.867137886639284e-08
are O 0 2.1515845105568587e-08
hypersensitive O 0 9.192988727591e-06
to O 0 4.137933160563989e-07
ionizing O 0 9.020960533234756e-06
radiation O 0 1.7336338714812882e-05
and O 0 1.2402904303598916e-07
hydrogen O 0 1.676946340012364e-06
peroxide O 0 8.88345020939596e-05
. O 0 1.8721713104241644e-06

These O 0 2.036758587564691e-06
results O 0 4.062156222062185e-06
suggest O 0 2.4947593146862346e-07
that O 0 6.914047645523169e-08
BRCA1 O 0 1.4821297554590274e-05
participates O 0 4.161063600349735e-07
, O 0 2.8025580078860912e-08
directly O 0 2.842546642511934e-08
or O 0 1.1848892000898559e-07
indirectly O 0 5.747853606408171e-07
, O 0 1.0060528410349434e-08
in O 0 6.021950937906695e-09
transcription O 0 4.7062920316420787e-07
- O 0 2.0612253138097003e-05
coupled O 0 1.632599378353916e-05
repair O 0 9.480020526098087e-05
of O 0 6.141767983081081e-08
oxidative O 0 7.786026799294632e-06
DNA O 0 0.000166333673405461
damage O 0 0.0001509873545728624
. O 0 3.387266076515516e-07
. O 0 1.0267800689689466e-06

Truncation O 0 0.0014899343950673938
mutations O 0 0.0008207872742787004
in O 0 5.389144916989608e-07
the O 0 1.2691123174590757e-07
transactivation O 0 2.730909181991592e-05
region O 0 3.868430212605745e-06
of O 0 3.5761402727985114e-08
PAX6 O 0 2.8484671929618344e-05
result O 0 2.3340717802966537e-07
in O 0 2.996035064484204e-08
dominant O 0 4.721806817542529e-06
- O 0 5.6006829254329205e-05
negative O 0 5.416704425442731e-06
mutants O 0 2.0425653929123655e-05
. O 0 8.042017043408123e-07

PAX6 O 0 0.0026294596027582884
is O 0 9.868349479802419e-07
a O 0 4.773298556415284e-08
transcription O 0 1.4366202094606706e-07
factor O 0 2.0528526434304695e-08
with O 0 2.621993955287394e-09
two O 0 1.4908993151152572e-08
DNA O 0 2.9479319891834166e-06
- O 0 3.972100785176735e-06
binding O 0 1.4549127627105918e-06
domains O 0 2.92172188665063e-07
( O 0 1.2879397992549002e-08
paired O 0 1.6845072536852967e-07
box O 0 6.76379670494498e-07
and O 0 2.077309204651101e-07
homeobox O 0 1.4396172218766878e-06
) O 0 1.055676523975535e-08
and O 0 3.275758331255929e-09
a O 0 1.7930931406340278e-08
proline O 0 6.766656042600516e-06
- O 0 2.915939603553852e-06
serine O 0 5.347102614905452e-06
- O 0 2.948738620034419e-05
threonine O 0 0.0002272495476063341
( O 0 1.2556742490232864e-07
PST O 0 3.7480713217519224e-05
) O 0 2.674015320280887e-08
- O 0 1.0685494089557324e-06
rich O 0 6.485187782345747e-07
transactivation O 0 3.1470957765122876e-05
domain O 0 3.6847018236585427e-06
. O 0 2.9147106488380814e-06

PAX6 O 0 0.02971309795975685
regulates O 0 0.0009189352858811617
eye O 0 0.006361433304846287
development O 0 3.945706907870772e-07
in O 0 8.058863443238806e-08
animals O 0 9.785245680404842e-08
ranging O 0 1.350250613540993e-07
from O 0 2.389531417179569e-08
jellyfish O 0 1.306352288565904e-07
to O 0 2.4745604676468247e-08
Drosophila O 0 9.454438298917012e-08
to O 0 6.391521623072549e-08
humans O 0 5.037667278884328e-07
. O 0 4.562538720165321e-07

Heterozygous O 0 0.00027938722632825375
mutations O 0 0.00020056958601344377
in O 0 3.3219305350939976e-07
the O 0 6.342786917912235e-08
human O 0 1.7991746403822617e-07
PAX6 O 0 2.152575871150475e-05
gene O 0 3.925475994037697e-06
result O 0 8.332825274237621e-08
in O 0 3.3726199610839558e-09
various O 0 4.459532298994873e-09
phenotypes O 0 1.8344621821597684e-06
, O 0 9.446525695011587e-08
including O 0 1.5046251178318926e-07
aniridia B-Disease 1 1.0
, O 0 8.88906724867411e-05
Peters B-Disease 1 0.9999998807907104
anomaly I-Disease 1 0.9999951124191284
, O 0 1.731317070152727e-06
autosomal B-Disease 0 0.05758385732769966
dominant I-Disease 0 0.00035838744952343404
keratitis I-Disease 1 0.9796878695487976
, O 0 2.452486796755693e-06
and O 0 2.760451252470375e-06
familial B-Disease 0 0.0977846160531044
foveal I-Disease 1 0.9915311336517334
dysplasia I-Disease 1 0.9999711513519287
. O 0 2.1153495254111476e-05

It O 0 3.126466708636144e-06
is O 0 1.2636509438834764e-07
believed O 0 1.0984821585680038e-07
that O 0 4.0170351489621225e-09
the O 0 3.984953256264134e-09
mutated O 0 2.422254681277991e-07
allele O 0 3.1296298175220727e-07
of O 0 1.5966545419132672e-08
PAX6 O 0 6.25344227955793e-06
produces O 0 3.782946862429526e-07
an O 0 2.5933074354611563e-08
inactive O 0 1.1890004714132374e-07
protein O 0 3.6177016227156855e-07
and O 0 6.706208637297095e-07
aniridia B-Disease 1 0.9999990463256836
is O 0 1.6646566791678197e-06
caused O 0 5.758607812822447e-07
due O 0 1.7404373409135587e-07
to O 0 3.0269202966337616e-07
genetic O 0 1.618782880541403e-05
haploinsufficiency O 0 0.0002520485140848905
. O 0 2.606163207019563e-06

However O 0 4.556539352051914e-06
, O 0 4.52494361979916e-08
several O 0 1.4282430349510378e-08
truncation O 0 6.0288994063739665e-06
mutations O 0 4.392287155496888e-05
have O 0 1.6960586890490958e-07
been O 0 1.1615835404654717e-07
found O 0 9.40270012961264e-08
to O 0 2.619191263875109e-08
occur O 0 1.2934665782893262e-08
in O 0 3.5943077403288726e-09
the O 0 2.0980023052175056e-08
C O 0 9.562903869664297e-06
- O 0 7.415294930979144e-06
terminal O 0 7.899313459347468e-06
half O 0 6.98584088354437e-08
of O 0 4.42192549243714e-09
PAX6 O 0 3.7657232496712822e-06
in O 0 1.198457368900563e-07
patients O 0 1.2032282370455505e-07
with O 0 1.2659421955163452e-08
Aniridia B-Disease 1 0.9999157190322876
resulting O 0 3.4580685337459727e-07
in O 0 5.300676786390568e-09
mutant O 0 3.9315040112342103e-08
proteins O 0 8.299766207642278e-09
that O 0 3.876194032415015e-09
retain O 0 5.747613585072031e-08
the O 0 3.1910196707229943e-09
DNA O 0 4.6258486463557347e-07
- O 0 6.056845336388506e-07
binding O 0 1.7197571366978082e-07
domains O 0 8.067768675346088e-08
but O 0 4.834744515846978e-08
have O 0 2.38135982044696e-08
lost O 0 4.1796161553975253e-07
most O 0 1.621286993547244e-09
of O 0 1.303349539405474e-09
the O 0 6.043551081802434e-08
transactivation O 0 1.2271486411918886e-05
domain O 0 1.7478488416600158e-06
. O 0 6.029263204254676e-07

It O 0 2.6641780550562544e-06
is O 0 1.0228146152257978e-07
not O 0 1.2257535431103861e-08
clear O 0 3.306733020735919e-08
whether O 0 7.655544642659606e-09
such O 0 2.725147663085181e-09
mutants O 0 7.393408623102005e-07
really O 0 3.056633488540683e-07
behave O 0 1.48192114579615e-07
as O 0 2.217356787070912e-08
loss O 0 2.9946042445772036e-07
- O 0 7.880064458731795e-07
of O 0 1.6187634344078106e-08
- O 0 4.838683707930613e-06
function O 0 1.9921353100471606e-07
mutants O 0 7.827255217307538e-07
as O 0 3.831146599964086e-08
predicted O 0 1.3319072422746103e-06
by O 0 2.7501659616291363e-08
haploinsufficiency O 0 1.6749159840401262e-05
. O 0 8.581517931816052e-07

Contrary O 0 1.348851674265461e-05
to O 0 1.7473826119385194e-07
this O 0 2.0208911877261926e-08
theory O 0 5.022259230713644e-08
, O 0 2.1870183886107952e-08
our O 0 2.2876516680980785e-08
data O 0 1.1811271178885363e-06
showed O 0 2.5212412424480135e-07
that O 0 2.407568810980365e-09
these O 0 5.950144266186896e-10
mutants O 0 9.095211339626985e-08
are O 0 1.3445633495479115e-09
dominant O 0 1.5156669519456045e-07
- O 0 1.979368789761793e-06
negative O 0 2.5463668862357736e-07
in O 0 1.3846016777563364e-08
transient O 0 2.595707826458238e-07
transfection O 0 9.65186882240232e-06
assays O 0 5.884873530703771e-07
when O 0 1.6479914322076183e-08
they O 0 4.7032027161719725e-09
are O 0 1.475365385417149e-09
coexpressed O 0 3.274748507919867e-07
with O 0 7.829649817381323e-09
wild O 0 8.027060403037467e-07
- O 0 7.230251503642648e-05
type O 0 2.0437581042642705e-05
PAX6 O 0 0.00046256498899310827
. O 0 3.559207698344835e-06

We O 0 3.3779053865146125e-06
found O 0 1.4342001009026717e-07
that O 0 3.3494007567469453e-09
the O 0 5.145761150515682e-09
dominant O 0 1.0340835387978586e-06
- O 0 1.7929100067703985e-05
negative O 0 1.5361912346634199e-06
effects O 0 7.622923021699535e-07
result O 0 3.4179397090383645e-08
from O 0 3.263597392333395e-09
the O 0 3.779763613209752e-09
enhanced O 0 8.421135078151565e-08
DNA O 0 7.703604865128e-07
binding O 0 1.340315378683954e-07
ability O 0 3.12036689820161e-08
of O 0 4.877087178556394e-09
these O 0 3.116619851084579e-08
mutants O 0 6.0877214309584815e-06
. O 0 6.413026767404517e-07

Kinetic O 0 4.64083204860799e-05
studies O 0 1.3366943676373921e-06
of O 0 1.538712623982974e-08
binding O 0 5.145067234479939e-07
and O 0 5.714235271625512e-07
dissociation O 0 4.445867034519324e-06
revealed O 0 1.6525150385859888e-06
that O 0 3.869206288698024e-09
various O 0 1.4440668660853362e-09
truncation O 0 9.020470770337852e-07
mutants O 0 1.1279081491011311e-06
have O 0 2.1327243970858945e-08
3 O 0 7.326728734824428e-08
- O 0 9.98760810944077e-07
5 O 0 1.9193802813788352e-07
- O 0 7.82279926170304e-07
fold O 0 5.692033937521046e-07
higher O 0 1.838049890068305e-08
affinity O 0 4.5305545981477735e-09
to O 0 1.2111027736239066e-09
various O 0 6.218878745301026e-10
DNA O 0 1.493806109920115e-07
- O 0 3.235275585211639e-07
binding O 0 5.537545888500972e-08
sites O 0 3.0567061770625514e-08
when O 0 1.1444320158204846e-08
compared O 0 2.0602506367595197e-08
with O 0 1.0671811212503712e-09
the O 0 1.1842537617212656e-08
wild O 0 6.685327775812766e-07
- O 0 5.15239080414176e-05
type O 0 7.580797046102816e-06
PAX6 O 0 0.0001938089553732425
. O 0 2.7492014851304702e-06

These O 0 2.5041319986485178e-06
results O 0 1.7893473795993486e-06
provide O 0 2.9008452528955786e-08
a O 0 3.314904617468528e-08
new O 0 9.454655014451419e-08
insight O 0 2.1262690097501036e-07
into O 0 8.44989855863787e-09
the O 0 4.6836872158451115e-09
role O 0 1.9655223226777707e-08
of O 0 7.374098220935821e-09
mutant O 0 1.116632802222739e-06
PAX6 O 0 2.660162681422662e-05
in O 0 5.238694598119764e-07
causing O 0 3.6139485018793494e-05
aniridia B-Disease 1 0.999987006187439
. O 0 1.3022342955082422e-06
. O 0 1.183997369480494e-06

Reversal O 0 0.0032082649413496256
of O 0 2.846376082743518e-05
severe O 1 0.9103041291236877
hypertrophic B-Disease 1 0.9999737739562988
cardiomyopathy I-Disease 1 1.0
and O 0 5.518944453797303e-05
excellent O 0 5.087364570499631e-06
neuropsychologic O 0 0.00010057234612759203
outcome O 0 1.7263182598981075e-06
in O 0 3.486735522528761e-08
very B-Disease 0 3.622859168217474e-08
- I-Disease 0 8.365490430151112e-06
long I-Disease 0 1.858420432654384e-06
- I-Disease 0 9.657447662902996e-06
chain I-Disease 0 2.5658595404820517e-05
acyl I-Disease 0 7.889991024967458e-07
- I-Disease 0 2.847601535904687e-06
coenzyme I-Disease 0 6.812666697442182e-07
A I-Disease 0 4.940696271660272e-06
dehydrogenase I-Disease 0 0.00432974798604846
deficiency I-Disease 0 0.002264956710860133
. O 0 1.135233333116048e-06

Very B-Disease 0 8.424422958341893e-06
- I-Disease 0 2.427339495625347e-05
long I-Disease 0 1.7002610093186377e-06
- I-Disease 0 1.1391655789338984e-05
chain I-Disease 0 7.856152478780132e-06
acyl I-Disease 0 3.7942015751468716e-07
- I-Disease 0 9.298169629801123e-07
coenzyme I-Disease 0 2.472141034104425e-07
A I-Disease 0 2.1585482556929492e-07
dehydrogenase I-Disease 0 9.473133104620501e-06
( I-Disease 0 3.531310710513935e-07
VLCAD I-Disease 0 0.001060463604517281
) I-Disease 0 8.867488759278785e-06
deficiency I-Disease 0 6.536913133459166e-05
is O 0 2.0943717871091394e-08
a O 0 4.927990744363342e-07
disorder O 0 7.902108336566016e-05
of O 0 9.900209541058302e-09
fatty O 0 1.2964708275831072e-06
acid O 0 1.2611121746886056e-06
beta O 0 5.025220062293556e-08
oxidation O 0 9.394740629886655e-08
that O 0 2.280689770373101e-08
reportedly O 0 4.134446385251067e-07
has O 0 3.850626129064949e-08
high O 0 4.2153146750933956e-08
rates O 0 1.5754640969589673e-07
of O 0 2.07713810596033e-08
morbidity O 0 0.04116607457399368
and O 0 3.6116728097113082e-06
mortality O 0 7.617922528879717e-05
. O 0 8.860099569574231e-07

We O 0 2.944139168903348e-06
describe O 0 4.12011104344856e-07
the O 0 2.4250324415220348e-08
outcome O 0 4.459279523416626e-08
of O 0 1.9601229528376507e-09
a O 0 5.25514742832911e-08
5 O 0 3.931174603621912e-07
- O 0 4.33307877756306e-06
year O 0 5.899692041566595e-07
- O 0 3.849903350783279e-06
old O 0 6.023014975653496e-06
girl O 0 1.8156810256186873e-05
with O 0 5.447912371892016e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 2.440638809275697e-06
was O 0 5.028130090067862e-07
first O 0 1.139540231065439e-07
seen O 0 3.504692074329796e-07
at O 0 1.3450775782075652e-07
5 O 0 9.470266348898804e-08
months O 0 5.273572156738737e-08
of O 0 2.6883228976259943e-09
age O 0 7.497587262150773e-08
with O 0 9.147487958216516e-07
severe O 0 0.2445911318063736
hypertrophic B-Disease 1 0.9998517036437988
cardiomyopathy I-Disease 1 1.0
, O 0 0.012161608785390854
hepatomegaly B-Disease 1 1.0
, O 0 0.0015402312856167555
encephalopathy B-Disease 1 0.9989927411079407
, O 0 6.396278422471369e-07
and O 0 1.5267810340446886e-06
hypotonia B-Disease 0 0.001962930429726839
. O 0 5.453468929772498e-06

Biochemical O 0 0.0033206644002348185
studies O 0 9.06995774130337e-05
indicated O 0 0.09853123128414154
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 4.353376425569877e-05
by O 0 3.0181283250385604e-08
a O 0 3.0811861506663263e-07
stable O 0 1.6777888959040865e-05
yet O 0 6.896647732901329e-07
inactive O 0 1.371365215163678e-06
enzyme O 0 2.8932477107446175e-06
. O 0 6.424975822483248e-07

Molecular O 0 0.00039132972597144544
genetic O 0 0.00017445364210288972
analysis O 0 1.5108726074686274e-06
of O 0 1.0016340468155249e-07
her O 0 1.1675129826471675e-05
VLCAD O 0 0.002876762067899108
gene O 0 1.7414797184756026e-05
revealed O 0 4.005292794317938e-06
a O 0 1.4257287261898455e-07
T1372C O 0 5.161736226000357e-06
( O 0 9.057851002580719e-08
F458L O 0 9.617601790523622e-07
) O 0 8.463500478228525e-08
missense O 0 1.574702218931634e-05
mutation O 0 8.875872481439728e-06
and O 0 2.3404822968586814e-07
a O 0 2.505613110770355e-06
1668 O 0 0.002558603882789612
ACAG O 0 0.003943430259823799
1669 O 0 0.00010845099313883111
splice O 0 0.0011530854972079396
site O 0 4.552549944492057e-05
mutation O 0 4.061245999764651e-05
. O 0 2.07215430236829e-06

After O 0 1.632580824662e-05
initial O 0 2.277465455335914e-06
treatment O 0 1.1451828640929307e-06
with O 0 4.283714005737238e-08
intravenous O 0 2.830347057170002e-06
glucose O 0 8.79429280757904e-05
and O 0 5.060404077994463e-07
carnitine O 0 1.8197106328443624e-06
, O 0 3.705569895373628e-08
the O 0 2.3076792032838966e-08
patient O 0 3.1901271313472535e-07
has O 0 4.3234010149717506e-08
thrived O 0 5.673440384157402e-08
on O 0 4.761922411944397e-08
a O 0 1.0132072247870383e-07
low O 0 1.2955537158632069e-06
- O 0 9.095017048821319e-06
fat O 0 1.3055419913143851e-05
diet O 0 5.3745697670137815e-08
supplemented O 0 1.6330098162598006e-08
with O 0 2.691303402357903e-09
medium O 0 1.6351329179542518e-07
- O 0 3.4719314498943277e-06
chain O 0 1.0544595170358662e-05
triglyceride O 0 3.461368578427937e-06
oil O 0 2.9192117381171556e-06
and O 0 9.9072408943357e-08
carnitine O 0 9.67642563409754e-07
and O 0 3.755469535349221e-08
avoidance O 0 1.3428798411041498e-06
of O 0 5.8448435424907075e-08
fasting O 0 7.300298420886975e-06
. O 0 1.384574716212228e-06

Her O 0 0.0009526644716970623
ventricular O 0 0.14026732742786407
hypertrophy O 0 0.009653872810304165
resolved O 0 4.402150079840794e-05
significantly O 0 4.916048965242226e-06
over O 0 1.5144401288580411e-07
1 O 0 7.859515562813613e-07
year O 0 4.7285973892030597e-07
, O 0 4.713038137538206e-08
and O 0 2.1294651730840997e-07
cognitively O 0 6.185304755490506e-06
, O 0 6.609445790672908e-08
she O 0 1.6357724064164358e-07
is O 0 4.200584768909721e-09
in O 0 4.280583887350531e-09
the O 0 1.7530000562260284e-08
superior O 0 3.912481645329535e-07
range O 0 1.3501127682502556e-07
for O 0 7.026692827594161e-08
age O 0 1.8917434374543518e-07
. O 0 3.161904089665768e-07

Clinical O 0 0.00012025130854453892
recognition O 0 3.498171508908854e-06
of O 0 6.856186701043043e-06
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 8.292235520457325e-07
important O 0 2.7845697303519046e-08
because O 0 2.4154306998980246e-08
it O 0 3.441076401600185e-08
is O 0 9.704630876683495e-09
one O 0 3.813043658595916e-09
of O 0 7.658169098867518e-10
the O 0 7.56537321677797e-09
few O 0 3.671490844681102e-08
directly O 0 1.0121784725924954e-06
treatable O 0 0.0026402059011161327
causes O 0 7.164940143411513e-07
of O 0 2.787001278647949e-07
cardiomyopathy B-Disease 1 0.9999997615814209
in O 0 3.189903509337455e-06
children O 0 1.7807470840125461e-06
. O 0 1.47571583397621e-07
. O 0 6.319987164715712e-07

Cloning O 0 5.8201560023007914e-05
of O 0 2.409403805359034e-07
a O 0 2.8821884257013153e-07
novel O 0 3.6075999787499313e-07
member O 0 6.788211237562791e-08
of O 0 3.8330965068666956e-09
the O 0 2.3316282238283748e-08
low O 0 7.309922125386947e-07
- O 0 1.492378578404896e-05
density O 0 7.206529630821024e-07
lipoprotein O 0 8.448743756162003e-06
receptor O 0 1.1898981711055967e-06
family O 0 1.6475095208079438e-06
. O 0 1.1556162462511566e-06

A O 0 3.536942813298083e-06
gene O 0 1.999655069084838e-06
encoding O 0 4.843799388254411e-07
a O 0 9.976110959541984e-08
novel O 0 2.7660590262712503e-07
transmembrane O 0 7.270473929565924e-07
protein O 0 6.2089696939438e-07
was O 0 3.0995914812592673e-07
identified O 0 4.6308539225492495e-08
by O 0 2.0835730918378204e-09
DNA O 0 5.211179043840275e-08
sequence O 0 1.477441546882119e-08
analysis O 0 1.4240431056578018e-08
within O 0 5.26350074636639e-09
the O 0 5.693820526175841e-08
insulin B-Disease 0 0.05179724842309952
- I-Disease 1 0.9758795499801636
dependent I-Disease 1 0.9999364614486694
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 5.285477527650073e-06
IDDM B-Disease 0 0.0004146189312450588
) O 0 2.1137176986485429e-07
locus O 0 4.8051424528239295e-06
IDDM4 O 0 9.68270906014368e-05
on O 0 7.925474164949264e-06
chromosome O 0 0.0002483610005583614
11q13 O 0 5.4449006711365655e-05
. O 0 3.2302857562171994e-06

Based O 0 1.8793889466905966e-05
on O 0 1.4196397160048946e-06
its O 0 1.2114219316572417e-06
chromosomal O 0 0.0023121575359255075
position O 0 9.931778549798764e-06
, O 0 2.672643795165186e-08
this O 0 1.5552201748647576e-09
gene O 0 5.1868248363007297e-08
is O 0 5.539930736375709e-09
a O 0 1.84526864899226e-08
candidate O 0 6.737594304695449e-08
for O 0 5.131950420178555e-09
conferring O 0 5.896598054278002e-07
susceptibility O 0 8.668808004586026e-05
to O 0 1.0950929208775051e-05
diabetes B-Disease 0 0.2408311814069748
. O 0 1.4564815273843124e-06

The O 0 6.776677423658839e-07
gene O 0 3.155107833663351e-06
, O 0 7.230976706296133e-08
termed O 0 5.719829800909793e-07
low O 0 7.016292897787935e-07
- O 0 7.145142717490671e-06
density O 0 5.167628387425793e-07
lipoprotein O 0 2.9312213882803917e-06
receptor O 0 2.2135458266347996e-07
related O 0 1.9923157879020437e-07
protein O 0 2.5269125103477563e-07
5 O 0 2.362168487479721e-07
( O 0 2.5718012608422214e-08
LRP5 O 0 9.379534276376944e-06
) O 0 1.5496453897867468e-08
, O 0 1.4097139011681747e-09
encodes O 0 2.6409624709344826e-08
a O 0 1.0913728587524929e-08
protein O 0 4.7946048908897865e-08
of O 0 3.6692771043789207e-09
1615 O 0 1.292423007726029e-06
amino O 0 1.215602765114454e-07
acids O 0 3.9243570171265674e-08
that O 0 1.1791503329305897e-09
contains O 0 1.1779859310223628e-09
conserved O 0 8.848967780750172e-09
modules O 0 2.5655399582547034e-08
which O 0 2.024035161696247e-08
are O 0 8.387767702622284e-10
characteristic O 0 1.3637569296065521e-08
of O 0 1.2456494724588651e-09
the O 0 1.83995449987151e-08
low O 0 1.6746066648920532e-06
- O 0 2.0804305677302182e-05
density O 0 2.0031134226883296e-06
lipoprotein O 0 5.224634151090868e-05
( O 0 7.94023321759596e-07
LDL O 0 6.392593786586076e-05
) O 0 1.1303595215395035e-07
receptor O 0 3.5284560340187454e-07
family O 0 9.034770869220665e-07
. O 0 7.808756663507666e-07

These O 0 1.1182281696164864e-06
modules O 0 1.2714675676761544e-06
include O 0 6.36159072087139e-08
a O 0 6.419794118528444e-08
putative O 0 6.176730380502704e-07
signal O 0 3.3667157595118624e-07
peptide O 0 3.55237368410144e-08
for O 0 2.4693163069855473e-09
protein O 0 2.1673265848676238e-08
export O 0 3.073537513387237e-08
, O 0 3.5491345418137143e-09
four O 0 1.0170191799829809e-08
epidermal O 0 1.8654451423572027e-06
growth O 0 1.937191882461775e-06
factor O 0 1.0378324333260025e-07
( O 0 4.275526777064442e-08
EGF O 0 1.214415647154965e-06
) O 0 2.621825068160888e-08
repeats O 0 2.499917854947853e-07
with O 0 6.242959926794356e-09
associated O 0 4.488737204155768e-08
spacer O 0 2.5957774596463423e-06
domains O 0 3.2149239359569037e-07
, O 0 1.4003218140601348e-08
three O 0 3.107395940560309e-08
LDL O 0 8.53704332257621e-05
- O 0 3.3599742891965434e-05
receptor O 0 8.134106224133575e-07
( O 0 8.040455412583469e-08
LDLR O 0 2.2395206542569213e-05
) O 0 2.680643795827109e-08
repeats O 0 5.181594247005705e-07
, O 0 3.935193060300435e-09
a O 0 5.671057401457347e-09
single O 0 9.608692863594115e-08
transmembrane O 0 3.316505114980828e-07
spanning O 0 1.565132521363921e-07
domain O 0 1.6350269049780763e-07
, O 0 2.0841941505977957e-08
and O 0 1.3633798090495475e-08
a O 0 7.945901359107665e-08
cytoplasmic O 0 7.467540399375139e-06
domain O 0 2.777216195681831e-06
. O 0 1.0230083944406942e-06

The O 0 3.304968174688838e-07
encoded O 0 4.981014285476704e-07
protein O 0 3.8555728565370373e-07
has O 0 3.037046170106805e-08
a O 0 1.0259971539028356e-08
unique O 0 1.3016857813852312e-08
organization O 0 2.226710549280142e-08
of O 0 1.1845610714544819e-08
EGF O 0 1.9799765595962526e-06
and O 0 3.5804779940917797e-07
LDLR O 0 9.74919312284328e-05
repeats O 0 1.182374035124667e-05
; O 0 3.1748299988976214e-08
therefore O 0 1.7278447117519136e-08
, O 0 1.1819566658743952e-08
LRP5 O 0 1.5351324691437185e-05
likely O 0 8.663744210934965e-08
represents O 0 7.975004656657347e-09
a O 0 8.779301730044153e-09
new O 0 3.9939344276263e-08
category O 0 7.432234383486502e-08
of O 0 7.936038493028263e-09
the O 0 1.8440375981754187e-07
LDLR O 0 0.00037370636709965765
family O 0 3.915747129212832e-06
. O 0 8.132764151014271e-07

Both O 0 4.492284006119007e-06
human O 0 1.1685539220707142e-06
and O 0 4.4663619291895884e-07
mouse O 0 1.661693568166811e-05
LRP5 O 0 0.00041900575160980225
cDNAs O 0 2.5085635570576414e-05
have O 0 1.5129258201795892e-07
been O 0 4.51694148750903e-08
isolated O 0 9.911776999160793e-08
and O 0 1.1224829066236452e-08
the O 0 2.3722737108045067e-09
encoded O 0 2.2024901014106035e-08
mature O 0 1.9311636734187232e-08
proteins O 0 3.1997533511685106e-09
are O 0 5.671498271020425e-10
95 O 0 3.797265613059153e-09
% O 0 6.232371507763901e-09
identical O 0 5.922353452092466e-08
, O 0 3.447225083164085e-08
indicating O 0 7.647841471225547e-08
a O 0 5.3933927546268023e-08
high O 0 1.2662265191920596e-07
degree O 0 5.139289882549747e-08
of O 0 7.002861401872451e-09
evolutionary O 0 4.0972594206323265e-07
conservation O 0 2.602000961360318e-07
. O 0 1.109702267854118e-07
. O 0 3.696457042678958e-07

The O 0 1.4220868251868524e-06
APC B-Disease 0 1.0986285815306474e-05
variants O 0 1.9002829958481016e-06
I1307K O 0 1.2258619790372904e-06
and O 0 3.6484056664676245e-08
E1317Q O 0 3.4908686075141304e-07
are O 0 2.3831411510855105e-08
associated O 0 1.6922615486691939e-06
with O 0 0.41583171486854553
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.781145874701906e-05
but O 0 1.541756802225791e-07
not O 0 1.4359130773300421e-08
always O 0 5.824008830757066e-09
with O 0 3.5233895800956816e-09
a O 0 4.345504009961587e-07
family O 0 1.8076189007842913e-06
history O 0 5.779569960395747e-07
. O 0 1.2571471188493888e-06

Classical O 1 0.5243701934814453
familial B-Disease 1 0.9999997615814209
adenomatous I-Disease 1 0.999998927116394
polyposis I-Disease 1 1.0
( O 0 0.02263331227004528
FAP B-Disease 0 0.0005452373879961669
) O 0 1.3983888038637815e-06
is O 0 2.2597580695560282e-08
a O 0 8.897239922589506e-08
high O 0 6.136667707323795e-06
- O 0 0.20715342462062836
penetrance O 0 0.31960371136665344
autosomal B-Disease 1 0.9934980869293213
dominant I-Disease 0 0.013998030684888363
disease I-Disease 0 0.031585998833179474
that O 0 4.7567940697490485e-08
predisposes O 0 7.592783504151157e-07
to O 0 2.1661282545437643e-08
hundreds O 0 1.1696935864335956e-08
or O 0 3.182718089078662e-08
thousands O 0 8.715105082046648e-08
of O 0 2.5173463654937223e-05
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.8956919312477112
carcinoma I-Disease 1 1.0
and O 0 1.1306899068586063e-05
that O 0 6.842287092467814e-08
results O 0 4.273101694707293e-07
from O 0 1.1206602756885786e-08
truncating O 0 2.5004712824738817e-06
mutations O 0 2.6952197913487907e-06
in O 0 9.561120783985189e-09
the O 0 2.7259288160053075e-08
APC B-Disease 0 7.956948138598818e-06
gene O 0 3.5413372643233743e-06
. O 0 8.154183888109401e-07

A O 0 7.499741968786111e-06
variant O 0 4.705036189989187e-05
of O 0 7.91129934896162e-07
FAP B-Disease 0 0.0002209340746048838
is O 0 2.5863435439532623e-05
attenuated B-Disease 0 0.48335903882980347
adenomatous I-Disease 1 0.9999997615814209
polyposis I-Disease 1 0.9999973773956299
coli I-Disease 1 0.9999998807907104
, O 0 5.018638603360159e-06
which O 0 2.2480396921764623e-07
results O 0 8.102232413875754e-07
from O 0 3.821316241214845e-08
germ O 0 5.2575556765077636e-05
- O 0 2.722793215070851e-05
line O 0 5.775312092737295e-05
mutations O 0 1.8419652860757196e-06
in O 0 6.821031295345392e-09
the O 0 8.633404213753693e-09
5 O 0 1.5958300991769647e-07
and O 0 3.344295507190509e-08
3 O 0 1.0476773582013266e-07
regions O 0 4.2790510690338124e-08
of O 0 4.953256915740667e-09
the O 0 6.018576925725938e-08
APC B-Disease 0 7.466201623174129e-06
gene O 0 2.0832183054153575e-06
. O 0 4.806728384210146e-07

Attenuated B-Disease 1 0.9997488856315613
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 0.9999994039535522
coli I-Disease 1 1.0
patients O 1 0.9492986798286438
have O 0 2.131262135662837e-06
" O 0 5.482410415424965e-06
multiple O 0 0.00032267419737763703
" O 1 0.9992558360099792
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.4587849313538754e-06
typically O 0 2.3600316012561962e-07
fewer O 0 3.370601930896555e-08
than O 0 9.802054279361982e-09
100 O 0 1.1049581694067001e-08
) O 0 4.116494700667772e-09
without O 0 3.502350853779035e-09
the O 0 1.3644671170709444e-08
florid O 0 2.7889558623428456e-05
phenotype O 0 1.0217037015536334e-05
of O 0 2.3866572718134194e-08
classical O 0 2.08272967938683e-06
FAP B-Disease 0 4.2576029954943806e-05
. O 0 2.088609107886441e-06

Another O 0 5.718009106203681e-06
group O 0 3.979072971560527e-06
of O 0 3.6723733387589164e-08
patients O 0 4.406949187796272e-07
with O 0 2.6784565676507555e-08
multiple O 0 8.600488399679307e-06
adenomas B-Disease 0 0.014292892999947071
has O 0 1.8925351241705357e-06
no O 0 8.781667304447183e-08
mutations O 0 4.138517226692784e-07
in O 0 6.075493885759897e-09
the O 0 1.2028848139777892e-08
APC B-Disease 0 7.459416337951552e-07
gene O 0 2.214960659330245e-07
, O 0 5.172950956477962e-09
and O 0 1.3004796350912784e-08
their O 0 1.1360722851350147e-07
phenotype O 0 3.183699300279841e-05
probably O 0 1.5182723700490897e-06
results O 0 3.155517731556756e-07
from O 0 5.804169589396224e-09
variation O 0 1.0794899196753249e-07
at O 0 2.9863309691791073e-07
a O 0 1.5045060308693792e-07
locus O 0 2.9608984277729178e-06
, O 0 5.911778799827516e-08
or O 0 4.256990138173933e-08
loci O 0 1.2953681505223358e-07
, O 0 1.4055612673757878e-08
elsewhere O 0 4.302711431591888e-08
in O 0 8.815528751426882e-09
the O 0 7.235860977061748e-08
genome O 0 3.772387344724848e-06
. O 0 1.0704596888899687e-06

Recently O 0 0.00019639974925667048
, O 0 2.5732592234817275e-07
however O 0 3.726052000274649e-08
, O 0 6.845821687306852e-09
a O 0 5.081207987700509e-08
missense O 0 5.611115284409607e-06
variant O 0 1.2679060091613792e-05
of O 0 1.2202082189105568e-07
APC B-Disease 0 3.00412666547345e-05
( O 0 9.723143534756673e-08
I1307K O 0 1.0466342246218119e-06
) O 0 6.44033733010474e-08
was O 0 1.0441428912599804e-06
described O 0 5.137055723025696e-07
that O 0 1.029902740867783e-08
confers O 0 3.9805872376064144e-08
an O 0 1.3147932520496397e-08
increased O 0 6.084228516556323e-07
risk O 0 3.3821590477600694e-05
of O 0 0.012180046178400517
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.9781343780778116e-06
including O 0 4.062048475361735e-08
multiple O 0 6.114690222602803e-06
adenomas B-Disease 0 0.024118931964039803
, O 0 3.351620421199186e-07
in O 0 3.6632235378419864e-07
Ashkenazim O 0 0.0004987907013855875
. O 0 5.842441623826744e-06

We O 0 7.654629371245392e-06
have O 0 9.539684242554358e-08
studied O 0 7.812155189412806e-08
a O 0 1.7842229027564827e-08
set O 0 6.17151272308547e-08
of O 0 7.231801379958824e-09
164 O 0 1.4477873264695518e-06
patients O 0 7.369657168965205e-07
with O 0 2.758835648819513e-07
multiple O 1 0.999006450176239
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.0029234744142740965
/ I-Disease 1 0.8927621245384216
or I-Disease 0 0.02679145149886608
carcinoma I-Disease 1 1.0
and O 0 1.1452569196990225e-05
analyzed O 0 1.3475054402078968e-05
codons O 0 1.2441738363122568e-05
1263 O 0 1.7492411643615924e-05
- O 0 4.1505485569359735e-05
1377 O 0 3.910297527909279e-05
( O 0 9.139102274957622e-08
exon O 0 2.0107024738535983e-06
15G O 0 1.6335275176970754e-06
) O 0 8.98204710608752e-09
of O 0 2.054246106553137e-09
the O 0 2.5821229598932405e-08
APC B-Disease 0 1.2587211131176446e-06
gene O 0 3.633444123352092e-07
for O 0 2.6764954697000576e-08
germ O 0 7.309608918149024e-05
- O 0 2.281150227645412e-05
line O 0 4.002111018053256e-05
variants O 0 9.571900591254234e-06
. O 0 5.17175010372739e-07

Three O 0 6.574093276867643e-06
patients O 0 6.352263881126419e-06
with O 0 1.104431390785976e-08
the O 0 1.648981751145584e-08
I1307K O 0 5.89264573136461e-07
allele O 0 1.2340223065621103e-06
were O 0 9.679955326191703e-08
detected O 0 5.420008619694272e-07
, O 0 4.8131933994000065e-09
each O 0 6.1621356906016445e-09
of O 0 2.8124324202849493e-08
Ashkenazi O 0 0.0007435043808072805
descent O 0 6.907926581334323e-05
. O 0 2.135383965651272e-06

Four O 0 2.9814569643349387e-05
patients O 0 5.7023298722924665e-05
had O 0 2.762576798431837e-07
a O 0 1.9643424309379043e-07
germ O 0 0.00015648156113456935
- O 0 2.1093403120175935e-05
line O 0 1.1369993444532156e-05
E1317Q O 0 1.0327767085982487e-06
missense O 0 2.4328817289642757e-06
variant O 0 1.831817257880175e-06
of O 0 1.82718284946759e-08
APC O 0 2.54441306424269e-06
that O 0 4.3284508421947976e-08
was O 0 2.6475805725567625e-07
not O 0 7.501146370714196e-09
present O 0 5.847762274413526e-09
in O 0 1.5075414694365463e-08
controls O 0 3.94942890125094e-06
; O 0 1.473222681624975e-07
one O 0 2.179460167894831e-08
of O 0 2.312728009101761e-09
these O 0 7.293026627053223e-09
individuals O 0 2.5003499271036844e-09
had O 0 8.838412668410456e-08
an O 0 8.293705278106245e-09
unusually O 0 4.98669336934654e-08
large O 0 9.773975406801583e-09
number O 0 2.7392768942036128e-08
of O 0 1.942534488819092e-08
metaplastic B-Disease 0 0.00010061445937026292
polyps I-Disease 0 1.409293690812774e-05
of I-Disease 0 6.296197785360391e-09
the I-Disease 0 8.045333288464462e-08
colorectum I-Disease 0 7.485692913178355e-05
. O 0 7.753628779028077e-07

There O 0 2.763996917565237e-06
is O 0 8.142203711258844e-08
increasing O 0 3.06528846749643e-08
evidence O 0 3.353263267058537e-08
that O 0 7.882483998855605e-09
there O 0 6.397788965273321e-09
exist O 0 4.9036827931558946e-08
germ O 0 1.055028860719176e-05
- O 0 1.963353270184598e-06
line O 0 2.182606749556726e-06
variants O 0 4.409707088370851e-08
of O 0 1.4259096126068016e-09
the O 0 7.503092369631759e-09
APC B-Disease 0 1.5277933584911807e-07
gene O 0 6.26062259811988e-08
that O 0 7.573659921433773e-09
predispose O 0 9.502147690909624e-08
to O 0 7.1306365256873505e-09
the O 0 3.7003204944596746e-09
development O 0 2.4514195118285897e-08
of O 0 2.7407671154833224e-07
multiple O 1 0.9954404830932617
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9376479387283325
carcinoma I-Disease 1 1.0
, O 0 2.468372031216859e-06
but O 0 3.053064290270413e-08
without O 0 4.3193106868955056e-09
the O 0 7.841725491175566e-09
florid O 0 1.1742976312234532e-05
phenotype O 0 5.308902018441586e-06
of O 0 5.688921778101985e-09
classical O 0 6.072971103776581e-08
FAP B-Disease 0 3.082549824284797e-07
, O 0 1.4852058249914535e-08
and O 0 4.564895572656269e-09
possibly O 0 9.553245305937708e-09
with O 0 2.593236736458948e-09
importance O 0 3.4910416957245616e-07
for O 1 0.9530462026596069
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 7.761264896544162e-06
in O 0 1.0593252497415051e-08
the O 0 2.0357857621888797e-08
general O 0 4.930524610813336e-08
population O 0 3.0183528565430606e-08
. O 0 4.21303987252486e-08
. O 0 5.37010123480286e-07

Genomic O 0 0.00020067747391294688
structure O 0 1.034693923429586e-05
of O 0 4.188530340343277e-07
the O 0 2.2446195089287357e-06
human O 0 0.006931374780833721
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999966621398926
diarrhea I-Disease 1 1.0
( O 0 5.742783105233684e-05
CLD B-Disease 0 0.03240659460425377
) O 0 7.236715759972867e-07
gene O 0 8.010763849597424e-06
. O 0 1.1132377721878584e-06

Congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999992847442627
diarrhea I-Disease 1 1.0
( O 0 0.008777639828622341
CLD B-Disease 1 0.9677388668060303
) O 0 7.6161595643498e-06
is O 0 2.375612666583038e-07
caused O 0 4.2827173274417873e-07
by O 0 2.2410949540585534e-08
mutations O 0 6.981298383834655e-07
in O 0 6.426235543699477e-09
a O 0 7.858648842784532e-08
gene O 0 5.216181762079941e-07
which O 0 1.0669256056416998e-07
encodes O 0 2.7969861093879445e-06
an O 0 2.0493805550358957e-06
intestinal O 0 0.0005489865434356034
anion O 0 4.158852607361041e-05
transporter O 0 0.0014519313117489219
. O 0 4.715992417914094e-06

We O 0 3.617769471020438e-05
report O 0 1.438737513126398e-06
here O 0 1.253926651401116e-08
the O 0 3.898415368297492e-09
complete O 0 4.170147960280701e-08
genomic O 0 2.912283321165887e-07
organization O 0 2.1287132057068447e-08
of O 0 3.5391973796095044e-09
the O 0 3.857028829656883e-08
human O 0 1.9208634682854608e-07
CLD B-Disease 0 2.449285784678068e-05
gene O 0 1.066103322955314e-06
which O 0 7.557545700365154e-08
spans O 0 4.993975153411156e-07
approximately O 0 1.936174669481261e-07
39kb O 0 6.817393114033621e-06
, O 0 3.11578176592775e-08
and O 0 1.9352048852283588e-08
comprises O 0 2.7274838387825184e-08
21 O 0 2.1530547655856935e-07
exons O 0 8.93700143933529e-06
. O 0 5.066189032731927e-07

All O 0 5.315178896125872e-06
exon O 0 9.028262866195291e-05
/ O 0 0.00021123886108398438
intron O 0 5.623401011689566e-05
boundaries O 0 3.368041632256791e-07
conform O 0 1.0887177950280602e-06
to O 0 4.440107304048979e-08
the O 0 5.9462362145268344e-08
GT O 0 0.0002834687475115061
/ O 0 0.0028904618229717016
AG O 1 0.9999904632568359
rule O 0 2.011937567658606e-06
. O 0 1.2258351489435881e-06

An O 0 1.6913435274545918e-06
analysis O 0 8.391237997784629e-07
of O 0 2.686217648317779e-08
the O 0 3.400512937901112e-08
putative O 0 3.053235786865116e-06
promoter O 0 1.0194689821219072e-05
region O 0 2.4745421001171053e-07
sequence O 0 4.851381163462065e-08
shows O 0 5.4274472915949445e-08
a O 0 4.905123418552648e-08
putative O 0 1.6573745824643993e-06
TATA O 0 0.00010453120921738446
box O 0 1.8764058040687814e-06
and O 0 1.6320171880579437e-07
predicts O 0 1.5780429976075538e-06
multiple O 0 4.420393295845315e-08
transcription O 0 2.634337477047666e-07
factor O 0 9.796114852633764e-08
binding O 0 2.789705604300252e-07
sites O 0 1.0561537919784314e-06
. O 0 7.663903147658857e-07

The O 0 1.152108097812743e-06
genomic O 0 5.334679372026585e-06
structure O 0 1.080327706404205e-06
was O 0 1.1933904033867293e-06
determined O 0 5.8920228696024424e-08
using O 0 2.069647919711315e-08
DNA O 0 5.34777882421622e-07
from O 0 6.7239329659685154e-09
several O 0 3.885076260701226e-09
sources O 0 3.287351546532591e-08
including O 0 2.475593063877568e-09
multiple O 0 3.052924668622836e-08
large O 0 1.0314148823908909e-07
- O 0 2.6078188966494054e-05
insert O 0 1.3666228369402234e-05
libaries O 0 4.504416210693307e-06
and O 0 1.278989802955266e-08
genomic O 0 9.422880253850963e-08
DNA O 0 1.2383749208311201e-06
from O 0 1.9531829309471505e-07
Finnish O 0 0.0008440847741439939
CLD B-Disease 0 0.33654487133026123
patients O 0 4.4899079512106255e-05
and O 0 1.3887414240798535e-07
controls O 0 2.51118417509133e-05
. O 0 3.5889777336706175e-06

Exon O 0 0.00011907443695235997
- O 0 2.0172299628029577e-05
specific O 0 1.0523376658966299e-07
primers O 0 3.6014921533933375e-06
developed O 0 4.163997004980047e-07
in O 0 2.3897410272866182e-08
this O 0 5.077988696200464e-09
study O 0 1.1801679633549611e-08
will O 0 8.879468715861094e-09
facilitate O 0 3.234725909351255e-08
mutation O 0 1.71772470025644e-07
screening O 0 7.568464610585579e-08
studies O 0 1.3886269023544173e-08
of O 0 4.732050307154623e-09
patients O 0 1.428976617035005e-07
with O 0 1.703348928572268e-08
the O 0 3.084466015934595e-06
disease O 0 0.0004545329138636589
. O 0 1.4639540495409165e-06

Genomic O 0 8.909562893677503e-05
sequencing O 0 1.4485147403320298e-05
of O 0 2.3421615935603768e-07
a O 0 6.607365889976791e-07
BAC O 0 0.0004913779557682574
clone O 0 0.0007246710592880845
H O 1 0.9999986886978149
_ O 0 7.260454708557518e-07
RG364P16 O 0 4.6990984969852434e-07
revealed O 0 4.6704957412657677e-07
the O 0 2.1239061620548227e-09
presence O 0 2.4948141330582985e-09
of O 0 8.325843903200791e-10
another O 0 2.9285750713370362e-08
, O 0 8.088550274010231e-09
highly O 0 6.269390784297002e-09
homologous O 0 3.078794463817758e-08
gene O 0 1.4206986520548526e-07
3 O 0 3.137177628786958e-08
of O 0 3.909219170594724e-09
the O 0 6.473786839933382e-08
CLD B-Disease 0 2.63834936049534e-05
gene O 0 4.6090184468994266e-07
, O 0 3.426240402504277e-09
with O 0 7.936246104733868e-10
a O 0 1.5860706525927526e-08
similar O 0 1.456234777208465e-08
genomic O 0 2.7358836973689904e-07
structure O 0 5.373830731514317e-07
, O 0 8.300434473085261e-08
recently O 0 3.326977946471743e-07
identified O 0 2.0343928497368324e-07
as O 0 4.947131770904889e-08
the O 0 5.1789688768622e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 4.852684651268646e-05
( O 0 2.6786383955368365e-07
PDS B-Disease 0 0.00019164077821187675
) O 0 8.04188147185414e-08
. O 0 4.6120344876499075e-08
. O 0 4.58239270528793e-07

The O 0 4.0183617784350645e-06
APCI1307K O 0 0.00019151017477270216
allele O 0 9.752541518537328e-05
and O 0 2.7861538910656236e-05
cancer B-Disease 0 0.0031401582527905703
risk O 0 1.4692773220303934e-06
in O 0 2.3127510573317522e-08
a O 0 2.6843846967494756e-07
community O 0 1.81603027726851e-07
- O 0 1.4701360669278074e-05
based O 0 2.8659808322117897e-06
study O 0 2.2057651705154058e-08
of O 0 2.8758178061139006e-08
Ashkenazi O 0 0.00010385985660832375
Jews O 0 4.457805971469497e-06
. O 0 1.475250087423774e-06

Mutations O 0 0.0015768619487062097
in O 0 1.970029870790313e-06
APC O 0 5.0675538659561425e-05
are O 0 1.8786228395129e-07
classically O 0 7.37203736207448e-05
associated O 0 1.577698094479274e-05
with O 0 7.590656605316326e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999998807907104
polyposis I-Disease 1 1.0
( O 0 0.0002034537319559604
FAP B-Disease 0 4.0336417441722006e-05
) O 0 2.0278999102174566e-07
, O 0 1.230626089920861e-08
a O 0 1.2402453819504444e-07
highly O 0 1.006213187793037e-05
penetrant O 1 0.9664126634597778
autosomal B-Disease 1 1.0
dominant I-Disease 1 0.99998939037323
disorder I-Disease 1 1.0
characterized O 0 6.175663293106481e-05
by O 0 4.298954650039377e-07
multiple O 0 0.0009922069730237126
intestinal O 1 0.9812865853309631
polyps B-Disease 0 0.16751207411289215
and O 0 1.0314164455849095e-06
, O 0 4.6788503738071086e-08
without O 0 2.6021067967008094e-08
surgical O 0 5.475429588841507e-06
intervention O 0 1.974457575215638e-08
, O 0 1.755337875053442e-09
the O 0 5.072451791932053e-09
development O 0 5.5384850838891e-07
of O 0 0.040819112211465836
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.8019944693369325e-06
CRC B-Disease 0 0.0003257838252466172
) O 0 3.0060525091357704e-07
. O 0 6.486882284661988e-07

APC B-Disease 0 0.0005423120455816388
is O 0 1.3158767160348361e-06
a O 0 2.858032758012996e-06
tumour O 1 0.999998927116394
- O 0 0.00033888069447129965
suppressor O 0 6.0780228523071855e-05
gene O 0 4.896364316664403e-06
, O 0 3.1664303179468334e-08
and O 0 2.7368171728880952e-08
somatic O 0 5.448634055937873e-06
loss O 0 2.1234238374745473e-05
occurs O 0 8.15981593405013e-07
in O 0 3.315851699881023e-06
tumours B-Disease 1 0.9999997615814209
. O 0 1.318050726695219e-05

The O 0 2.6776169761433266e-06
germline O 0 0.00019352068193256855
T O 0 0.0004651212366297841
- O 0 5.6674116422072984e-06
to O 0 1.4218289834388997e-07
- O 0 2.1333851236704504e-06
A O 0 2.6316658932046266e-06
transversion O 0 1.8115855709766038e-05
responsible O 0 6.21576532466861e-07
for O 0 8.796129158383792e-09
the O 0 1.639776492368128e-08
APC O 0 4.821221750717086e-07
I1307K O 0 8.28436483857331e-08
allele O 0 6.437647215307152e-08
converts O 0 4.3603527899449546e-08
the O 0 4.148852372765077e-09
wild O 0 3.29963896206209e-08
- O 0 6.110628874012036e-07
type O 0 7.036443605556997e-08
sequence O 0 3.856712282868102e-08
to O 0 2.4091823647154342e-08
a O 0 9.92518721432134e-07
homopolymer O 0 0.031483665108680725
tract O 0 0.03963178023695946
( O 0 7.768483101244783e-07
A8 O 0 0.15805396437644958
) O 0 1.3918625541009533e-07
that O 0 1.6450707462922765e-08
is O 0 6.811868047407188e-08
genetically O 0 2.0045958081027493e-05
unstable O 0 0.0003955261781811714
and O 0 9.8666089343169e-07
prone O 0 1.9522365619195625e-05
to O 0 2.7415879344516725e-07
somatic O 0 2.7958687496720813e-05
mutation O 0 3.2630956411594525e-05
. O 0 1.834630211305921e-06

The O 0 1.4841588154013152e-06
I1307K O 0 2.0572781068040058e-05
allele O 0 2.2671272745355964e-05
was O 0 3.7586337384709623e-06
found O 0 3.499234821902064e-07
in O 0 1.0190564125878154e-07
6 O 0 1.7777300627130899e-06
. O 0 1.0379615105193807e-06

1 O 0 8.31948909763014e-06
% O 0 4.582930444030353e-07
of O 0 4.5145039706540047e-08
unselected O 0 2.2432977857533842e-05
Ashkenazi O 0 0.00032072729663923383
Jews O 0 1.8108729591403971e-06
and O 0 1.3530284093121736e-07
higher O 0 1.0766398617079176e-07
proportions O 0 3.3384009157089167e-07
of O 0 2.0934054489885057e-08
Ashkenazim O 0 8.980696293292567e-06
with O 0 1.4406649029297114e-07
family O 0 1.4469397910943371e-06
or O 0 5.929508120061655e-07
personal O 0 2.3843517737986986e-06
histories O 0 4.362076651887037e-06
of O 0 6.096205424910295e-07
CRC B-Disease 0 0.018582705408334732
( O 0 4.6107589923849446e-07
ref O 0 3.403283335501328e-05
. O 0 8.656261485384675e-08
2 O 0 3.7900932170487067e-07
) O 0 2.068772460006585e-07
. O 0 6.450811724789673e-07

To O 0 2.3308427898882655e-06
evaluate O 0 1.3818494153383654e-06
the O 0 4.0663351796865754e-08
role O 0 5.2166388542218556e-08
of O 0 7.772453791687894e-09
I1307K O 0 1.2483150158004719e-06
in O 0 9.064156643034949e-07
cancer B-Disease 0 2.851734279829543e-05
, O 0 2.740703664017019e-08
we O 0 3.433110862260946e-08
genotyped O 0 3.2304706110153347e-06
5 O 0 1.2733735843539762e-07
, O 0 4.328459013436259e-08
081 O 0 3.4385352591925766e-06
Ashkenazi O 0 1.3949263120593969e-05
volunteers O 0 6.291518417356201e-08
in O 0 8.963905173686726e-09
a O 0 1.013143418049367e-07
community O 0 1.9853075627906946e-07
survey O 0 4.367537712823832e-06
. O 0 9.581768836142146e-07

Risk O 0 0.00019949044508393854
of O 0 5.561949478760653e-07
developing O 0 0.0003702972608152777
colorectal B-Disease 1 1.0
, I-Disease 0 7.003293285379186e-05
breast I-Disease 0 0.017567472532391548
and I-Disease 0 9.953889730240917e-07
other I-Disease 0 5.649052354783635e-07
cancers I-Disease 0 0.0022002551704645157
were O 0 9.43462339364487e-08
compared O 0 8.816407159883966e-08
between O 0 8.022666087015295e-09
genotyped O 0 5.187312126508914e-06
I1307K O 0 5.132756086823065e-07
carriers O 0 5.0827491548943726e-08
and O 0 1.2888687450640646e-08
non O 0 8.539778661997843e-08
- O 0 3.1740116810397012e-06
carriers O 0 1.2008931093987485e-07
and O 0 2.1369796598946778e-08
their O 0 2.3158190032290804e-08
first O 0 3.3829300605248136e-07
- O 0 1.4751172784599476e-05
degree O 0 1.5443040410900721e-06
relatives O 0 2.3322456854657503e-06
. O 0 1.1649876796582248e-06

Sperm O 0 0.00012393997167237103
DNA O 0 3.5939599911216646e-05
analysis O 0 1.234330738952849e-06
in O 0 1.251815859859562e-07
a O 0 6.1044997892167885e-06
Friedreich B-Disease 1 0.9984707236289978
ataxia I-Disease 1 0.9999322891235352
premutation O 0 0.006150371395051479
carrier O 0 2.3193670131149702e-05
suggests O 0 3.7016252463217825e-07
both O 0 1.2040370478416662e-08
meiotic O 0 1.9553986021492165e-06
and O 0 3.3132359078535956e-08
mitotic O 0 1.5122435570447124e-06
expansion O 0 3.1773717523719824e-07
in O 0 3.1577751968825396e-08
the O 0 5.887888576694422e-08
FRDA B-Disease 0 0.00011854874173877761
gene O 0 8.677403457113542e-06
. O 0 1.2319469533395022e-06

Friedreich B-Disease 1 0.9999607801437378
ataxia I-Disease 1 0.9999978542327881
is O 0 4.731412263936363e-05
usually O 0 2.934709300461691e-06
caused O 0 7.784220201756398e-07
by O 0 8.852445887441718e-09
an O 0 1.0454750842825433e-08
expansion O 0 7.543316371538822e-08
of O 0 9.812492152150298e-09
a O 0 7.136570729926461e-07
GAA O 0 3.8187721656868234e-05
trinucleotide O 0 4.777258072863333e-05
repeat O 0 2.6139891815546434e-06
in O 0 2.1032629859973895e-08
intron O 0 5.967168817733182e-06
1 O 0 5.2460737975934535e-08
of O 0 2.3429549411702055e-09
the O 0 4.1116475557601007e-08
FRDA B-Disease 0 6.758605741197243e-05
gene O 0 3.3831506698334124e-06
. O 0 4.183133341939538e-07

Occasionally O 0 2.4457705876557156e-05
, O 0 2.3213075905914593e-07
a O 0 4.274629716860545e-08
fully O 0 4.656264351865502e-08
expanded O 0 2.272443921924605e-08
allele O 0 4.0797598899189325e-07
has O 0 6.490440540574127e-08
been O 0 4.5953946425925096e-08
found O 0 3.70429766860525e-08
to O 0 2.1574402708779417e-08
arise O 0 3.103640366930449e-08
from O 0 3.1531874888912625e-09
a O 0 3.701628159546999e-08
premutation O 0 3.6713938698085258e-06
of O 0 3.422034655642392e-09
100 O 0 2.8812918273501964e-08
or O 0 1.3621585992495966e-07
less O 0 3.625389979333704e-07
triplet O 0 0.0004949302528984845
repeats O 0 9.580420737620443e-05
. O 0 9.60033617047884e-07

We O 0 1.3649685570271686e-05
have O 0 4.487508533657092e-07
examined O 0 2.5854797058855183e-07
the O 0 9.46820399860826e-09
sperm O 0 4.83721635191614e-07
DNA O 0 3.922097846498218e-07
of O 0 5.592728058445573e-09
a O 0 2.4680798560439143e-07
premutation O 0 9.399876580573618e-05
carrier O 0 1.2471246009226888e-05
. O 0 1.59144678946177e-06

This O 0 1.5615141819580458e-06
mans O 0 2.8153792300145142e-05
leucocyte O 0 5.9684214647859335e-05
DNA O 0 3.7746001908089966e-05
showed O 0 1.7240034821952577e-06
one O 0 3.45559847403365e-08
normal O 0 1.0637882752462247e-07
allele O 0 7.312515322155377e-07
and O 0 3.77493130088169e-08
one O 0 2.2241382069410065e-08
allele O 0 3.4276220617357467e-07
of O 0 1.5605131409301976e-08
approximately O 0 1.4561368288923404e-07
100 O 0 1.5881842330145446e-07
repeats O 0 1.1567813999135979e-05
. O 0 8.51843196869595e-07

His O 0 1.752071148075629e-05
sperm O 0 7.465774979209527e-05
showed O 0 1.7997321037910297e-06
an O 0 6.922939110864945e-09
expanded O 0 2.3767677603814263e-08
allele O 0 2.811810873026843e-07
in O 0 1.6926485102430888e-08
a O 0 8.734692613643347e-08
tight O 0 5.792554134131933e-07
range O 0 1.695130578127646e-07
centering O 0 1.596509093815257e-07
on O 0 2.2064853055780986e-07
a O 0 3.6726959251609514e-08
size O 0 6.0641731636224e-08
of O 0 1.957814710351613e-08
approximately O 0 3.8867759144523006e-07
320 O 0 2.5675108190625906e-06
trinucleotide O 0 0.00011230733070988208
repeats O 0 3.783357533393428e-05
. O 0 1.1821626912933425e-06

His O 0 0.0001519380894023925
affected O 0 7.73844585637562e-05
son O 0 7.392776024062186e-05
has O 0 6.496496780528105e-07
repeat O 0 1.6105118447740097e-06
sizes O 0 2.2690876733122423e-07
of O 0 2.924165798390277e-08
1040 O 0 8.301007255795412e-06
and O 0 4.466557754767564e-07
540 O 0 5.203052751312498e-06
. O 0 1.2145326309109805e-06

These O 0 1.6125804904731922e-06
data O 0 1.98492807612638e-06
suggest O 0 1.9145393537201016e-07
that O 0 1.25105987791585e-08
expansion O 0 4.9315779904191004e-08
occurs O 0 9.199610850885165e-09
in O 0 3.410865367925453e-09
two O 0 1.0681266537915235e-08
stages O 0 3.3436580793022586e-07
, O 0 1.06947002365132e-08
the O 0 3.57161233921488e-09
first O 0 4.297454125889999e-08
during O 0 1.9717255383966403e-08
meiosis O 0 2.5310841422765407e-08
followed O 0 5.605447217504889e-09
by O 0 8.604564838421425e-10
a O 0 9.036829951014624e-09
second O 0 1.889140150979074e-07
mitotic O 0 5.671131020790199e-06
expansion O 0 1.3913729617343051e-06
. O 0 1.0823117690961226e-06

We O 0 1.1480148714326788e-05
also O 0 3.1148019274951366e-07
show O 0 3.5579211044023396e-07
that O 0 8.267108775328325e-09
in O 0 4.093085426148946e-09
all O 0 2.7099762434090735e-09
informative O 0 2.424787908239523e-07
carrier O 0 1.6657095329719596e-06
father O 0 5.37551215984422e-07
to O 0 9.337092876648967e-08
affected O 0 2.917208803410176e-07
child O 0 1.0865996955544688e-06
transmissions O 0 1.0025436495197937e-05
, O 0 1.248071246351401e-08
with O 0 2.202136251128195e-09
the O 0 5.263239621910998e-09
notable O 0 7.593824236096225e-09
exception O 0 3.6082721255326078e-09
of O 0 1.365541790754321e-09
the O 0 2.3902334334025e-08
premutation O 0 6.727528216288192e-06
carrier O 0 3.389029927802767e-07
, O 0 2.2424622159178398e-09
the O 0 1.3752469163463843e-09
expansion O 0 2.52308289816483e-08
size O 0 2.24013845695481e-07
decreases O 0 8.744316346565029e-07
. O 0 4.7065256580935966e-08
. O 0 3.397362888790667e-07

The O 0 2.6159616481891135e-06
R496H O 0 1.4292630112322513e-05
mutation O 0 1.0099305654875934e-05
of O 0 8.120846217707367e-08
arylsulfatase O 0 1.665891795710195e-05
A O 0 3.191528548995848e-06
does O 0 1.5229680911943433e-06
not O 0 1.188349074254802e-06
cause O 0 5.2082326874369755e-05
metachromatic B-Disease 1 0.9999967813491821
leukodystrophy I-Disease 1 0.9999980926513672
. O 0 2.199808477598708e-05

Deficiency B-Disease 1 0.9992448091506958
of I-Disease 0 1.5125407344385167e-06
arylsulfatase I-Disease 0 0.00039186154026538134
A I-Disease 0 2.5820627342909575e-05
( O 0 1.2890280913779861e-06
ARSA O 0 0.00040292480844073
) O 0 1.9038479592836666e-07
enzyme O 0 1.926405275298748e-06
activity O 0 3.1391407446790254e-06
causes O 0 0.00022208134760148823
metachromatic B-Disease 1 0.9999997615814209
leukodystrophy I-Disease 1 1.0
( O 0 0.00014847728016320616
MLD B-Disease 1 0.9999864101409912
) O 0 1.7004020946842502e-06
. O 0 1.8062144135910785e-06

A O 0 2.624965873110341e-06
number O 0 1.242549245716873e-07
of O 0 8.644991567052784e-08
ARSA O 0 0.0010119890794157982
gene O 0 3.7593330489471555e-05
mutations O 0 5.751415665145032e-05
responsible O 0 1.1013644325430505e-05
for O 0 5.5362534112646244e-06
MLD B-Disease 1 0.9999996423721313
have O 0 5.551299636863405e-06
been O 0 9.757854968484025e-07
identified O 0 3.398536591703305e-06
. O 0 5.079890570414136e-07

Recently O 0 6.155885057523847e-05
, O 0 8.784648741766432e-08
the O 0 1.5867513525336108e-08
R496H O 0 2.7439369887360954e-07
mutation O 0 5.795106972072972e-07
of O 0 2.8512019412119116e-08
ARSA O 0 0.0006847887998446822
was O 0 2.8127733457949944e-06
proposed O 0 8.728081013487099e-08
to O 0 3.73575161916051e-08
be O 0 2.719811043050413e-08
a O 0 4.131017306008289e-07
cause O 0 3.8687471715093125e-06
of O 0 9.846605735219782e-07
MLD B-Disease 1 0.9999997615814209
( O 0 1.7467107227275847e-06
Draghia O 0 4.538513894658536e-05
et O 0 0.0002874868514481932
al O 0 1.6484904335811734e-05
. O 0 1.3903819251481764e-07
, O 0 5.8255114510075146e-08
1997 O 0 1.769606257084888e-07
) O 0 6.217271675268421e-08
. O 0 2.9660657219210407e-07

We O 0 8.436874850303866e-06
have O 0 1.0421308616059832e-07
investigated O 0 3.0752445923099003e-07
the O 0 1.0665305083534804e-08
R496H O 0 4.2104574049517396e-07
mutation O 0 6.237784759832721e-07
and O 0 3.738189136015535e-08
found O 0 3.241427037892208e-08
this O 0 2.7068249863759775e-09
mutation O 0 8.553878672046267e-08
at O 0 3.8178193051408016e-08
a O 0 1.9071075385568292e-08
relatively O 0 1.8978687066351085e-08
high O 0 2.3045165775670284e-08
frequency O 0 3.984986278737779e-07
in O 0 1.5055128699259512e-08
an O 0 2.6193559321541215e-08
African O 0 1.486886613832894e-08
American O 0 6.812310004988831e-08
population O 0 2.016767197687841e-08
( O 0 4.801676389831755e-09
f O 0 6.889777637297811e-07
= O 0 3.228556408885197e-07
0 O 0 6.802066110367377e-08
. O 0 1.555437734168663e-08
09 O 0 5.2918906590093684e-08
, O 0 1.600404786472609e-08
n O 0 1.1318541055516107e-06
= O 0 2.124431603078847e-06
61 O 0 9.486643648415338e-07
subjects O 0 2.175793269998394e-07
) O 0 9.675137846443249e-08
. O 0 4.816272394236876e-07

The O 0 6.757801202184055e-06
ARSA O 0 0.00035938681685365736
enzyme O 0 9.526403118798044e-06
activity O 0 5.180833113627159e-07
in O 0 4.139724296692293e-08
subjects O 0 4.606284775832137e-08
with O 0 1.0479387135831075e-08
and O 0 9.244627108273562e-08
without O 0 5.777143208263169e-09
the O 0 2.832819090414773e-09
R496H O 0 2.0215973961512645e-07
mutation O 0 4.663010031435988e-07
was O 0 4.011754697330616e-07
determined O 0 9.749643936629582e-08
and O 0 3.2551131567970515e-08
found O 0 5.842313299808666e-08
to O 0 1.821295469994766e-08
be O 0 5.295525440374149e-08
normal O 0 5.997057428430708e-07
. O 0 4.863211984229565e-07

It O 0 1.0413999007141683e-05
is O 0 2.6923325435745937e-07
therefore O 0 4.5604156895251435e-08
concluded O 0 8.310287569202046e-08
that O 0 3.6427922900372778e-09
the O 0 5.931609425857687e-09
R496H O 0 6.30678925972461e-07
mutation O 0 3.936472126042645e-07
of O 0 1.7167380406135635e-08
ARSA O 0 0.00029231718508526683
does O 0 4.5814621785211784e-07
not O 0 2.21492211238683e-08
negatively O 0 1.183938138638041e-07
influence O 0 2.039419655375241e-08
the O 0 7.731541629141248e-09
activity O 0 6.78412064303302e-08
of O 0 1.8914290578209147e-08
ARSA O 0 0.0003951817052438855
and O 0 3.1914538567434647e-07
is O 0 3.620690236516566e-08
not O 0 1.7397031371046978e-08
a O 0 4.308033112465637e-07
cause O 0 8.514131877745967e-06
of O 0 3.888591891154647e-06
MLD B-Disease 1 0.9999899864196777

Down O 0 0.00011488012387417257
- O 0 1.819598583097104e-05
regulation O 0 1.0403012993265293e-06
of O 0 1.0539687167465672e-07
transmembrane O 0 8.254274689534213e-06
carbonic O 0 3.988277239841409e-05
anhydrases O 0 5.569223139900714e-05
in O 0 3.341482397445361e-06
renal B-Disease 1 0.999883770942688
cell I-Disease 1 0.9999243021011353
carcinoma I-Disease 1 1.0
cell O 1 0.6786999106407166
lines O 0 3.179327177349478e-05
by O 0 6.08021437642492e-08
wild O 0 1.0532929763940047e-06
- O 0 0.00010647922317730263
type O 0 9.660952491685748e-05
von B-Disease 1 0.9896615743637085
Hippel I-Disease 1 0.946503758430481
- I-Disease 0 0.3219248652458191
Lindau I-Disease 1 0.92529296875
transgenes O 0 0.0015612741699442267
. O 0 1.1385073776182253e-05

To O 0 5.116284683026606e-06
discover O 0 7.869680302974302e-06
genes O 0 1.6758368701630388e-06
involved O 0 4.1487876956125547e-07
in O 0 8.0668274904383e-07
von B-Disease 1 0.9995502829551697
Hippel I-Disease 1 0.999930739402771
- I-Disease 1 0.999900221824646
Lindau I-Disease 1 0.999943733215332
( O 0 3.756970500035095e-06
VHL B-Disease 0 0.00014229257067199796
) O 0 3.2680841854926257e-07
- O 0 2.165167643397581e-05
mediated O 0 0.00014936280786059797
carcinogenesis O 0 0.0006491083186119795
, O 0 1.98450493371638e-07
we O 0 7.85956260074272e-08
used O 0 9.488539035373833e-06
renal B-Disease 1 0.9992302656173706
cell I-Disease 1 0.9998177886009216
carcinoma I-Disease 1 1.0
cell O 1 0.8241022229194641
lines O 0 0.0002221283211838454
stably O 0 0.00011748103133868426
transfected O 0 2.111856338160578e-05
with O 0 4.332572700604942e-08
wild O 0 9.379572247780743e-07
- O 0 5.675697684637271e-05
type O 0 2.0925404896843247e-05
VHL O 0 0.0002927997265942395
- O 0 4.843142596655525e-05
expressing O 0 4.268366865289863e-06
transgenes O 0 6.471020606113598e-05
. O 0 2.3407774278894067e-06

Large O 0 2.99151224680827e-06
- O 0 6.2991703089210205e-06
scale O 0 1.0721904573074426e-06
RNA O 0 5.190714205127733e-07
differential O 0 5.358878070182982e-07
display O 0 1.387909946970467e-07
technology O 0 2.0443273740511358e-07
applied O 0 4.0838155968003775e-08
to O 0 1.0627941193774859e-08
these O 0 1.6817608416985763e-09
cell O 0 4.222257302899379e-06
lines O 0 4.491148956731195e-06
identified O 0 3.982524390266917e-07
several O 0 4.538719178270867e-09
differentially O 0 2.404810288680892e-07
expressed O 0 1.511214975380426e-08
genes O 0 4.191926805674484e-08
, O 0 4.034680589626305e-09
including O 0 1.3913729057790647e-09
an O 0 1.8153752279204127e-08
alpha O 0 6.027216841175687e-07
carbonic O 0 8.789274033915717e-06
anhydrase O 0 6.941279480088269e-06
gene O 0 1.13255271116941e-06
, O 0 6.525868201379126e-08
termed O 0 4.237137545715086e-06
CA12 O 0 0.0004311086086090654
. O 0 2.5851247755781515e-06

The O 0 8.506709718858474e-07
deduced O 0 1.7196208546010894e-06
protein O 0 2.480359171386226e-07
sequence O 0 9.730991479273143e-08
was O 0 1.061105194821721e-07
classified O 0 1.3989767921884777e-07
as O 0 8.162662545885269e-09
a O 0 2.3904933144081042e-08
one O 0 1.0275074657783989e-07
- O 0 2.2444362912210636e-05
pass O 0 1.8326279587199679e-06
transmembrane O 0 9.41364123718813e-06
CA O 0 7.4731688073370606e-06
possessing O 0 1.955484805193919e-07
an O 0 1.7370703986330227e-08
apparently O 0 2.4546929466851e-07
intact O 0 7.606860208397848e-08
catalytic O 0 1.334019543719478e-07
domain O 0 7.517362377029713e-08
in O 0 2.100877516397759e-08
the O 0 3.5646245066800475e-08
extracellular O 0 1.3710865687244222e-06
CA O 0 3.3895179512910545e-05
module O 0 1.5449460988747887e-05
. O 0 8.354610940841667e-07

Reintroduced O 0 0.00011461018584668636
wild O 0 1.5882033039815724e-05
- O 0 0.00010070190182887018
type O 0 5.70161864743568e-06
VHL B-Disease 0 8.677980076754466e-05
strongly O 0 6.108694492468203e-07
inhibited O 0 3.633551841630833e-07
the O 0 1.7202813396011152e-08
overexpression O 0 2.423627165626385e-07
of O 0 2.355689865396471e-09
the O 0 1.5574622480585276e-08
CA12 O 0 4.820463345822645e-06
gene O 0 2.3383448422009678e-07
in O 0 7.778474753195042e-09
the O 0 1.0597480581964192e-07
parental O 0 3.0536546546500176e-05
renal B-Disease 1 0.9999663829803467
cell I-Disease 1 0.999991774559021
carcinoma I-Disease 1 1.0
cell O 1 0.8865458965301514
lines O 0 0.0005917263915762305
. O 0 4.0275740502693225e-06

Similar O 0 1.062144019670086e-05
results O 0 9.607786523702089e-06
were O 0 1.2446650998754194e-07
obtained O 0 8.57734008263833e-08
with O 0 7.370375243453964e-08
CA9 O 0 0.00015506749332416803
, O 0 1.7493592352479936e-08
encoding O 0 3.712573359848648e-08
another O 0 9.475072459963485e-08
transmembrane O 0 9.225125268130796e-07
CA O 0 2.1955461306788493e-06
with O 0 5.577505124421123e-09
an O 0 4.560589772495405e-08
intact O 0 7.202874030554085e-07
catalytic O 0 3.190010147591238e-06
domain O 0 2.0994068563595647e-06
. O 0 7.56735232698702e-07

Although O 0 1.5307832654798403e-06
both O 0 1.5423627530708472e-07
domains O 0 2.6910646511169034e-07
of O 0 1.1379868603000887e-08
the O 0 4.8512145411905294e-08
VHL B-Disease 0 6.053431206964888e-06
protein O 0 3.8388384382415097e-07
contribute O 0 1.79886860962597e-08
to O 0 1.0983518983209706e-08
regulation O 0 2.9715859994894345e-08
of O 0 5.873718844640052e-09
CA12 O 0 2.317783764738124e-05
expression O 0 8.797610462352168e-08
, O 0 7.524618261811611e-09
the O 0 4.750163817845987e-09
elongin O 0 8.665840596222552e-07
binding O 0 1.3380025620790548e-07
domain O 0 1.3225985640019644e-07
alone O 0 3.724354371570371e-07
could O 0 1.4678892057418125e-07
effectively O 0 6.088233703849255e-07
regulate O 0 7.585244475194486e-06
CA9 O 0 0.0006687941495329142
expression O 0 9.511098141956609e-06
. O 0 2.3791637886461103e-06

We O 0 8.991672984848265e-06
mapped O 0 5.456564394989982e-05
CA12 O 0 0.0007187890005297959
and O 0 3.065878445340786e-06
CA9 O 0 0.0005537457764148712
loci O 0 4.04243928642245e-06
to O 0 4.672197349009366e-07
chromosome O 0 2.8547709007398225e-05
bands O 0 1.0435674084874336e-06
15q22 O 0 4.208404334349325e-06
and O 0 3.2721885645514703e-07
17q21 O 0 1.4195235053193755e-05
. O 0 1.1501365406729747e-06

2 O 0 2.5976916731451638e-05
respectively O 0 6.896411832713056e-06
, O 0 1.8070088003696583e-07
regions O 0 6.869381081742176e-07
prone O 0 1.0828355698322412e-05
to O 0 1.9857392885569425e-07
amplification O 0 4.113258000870701e-06
in O 0 3.780118973395474e-08
some O 0 5.542913683598272e-08
human O 0 3.2694608762540156e-06
cancers B-Disease 0 0.0027509192004799843
. O 0 2.063314013867057e-06

Additional O 0 5.463682555273408e-06
experiments O 0 2.6563411665847525e-06
are O 0 3.675765114508067e-08
needed O 0 4.753955096248319e-08
to O 0 9.262183908731458e-09
define O 0 7.028649662288444e-08
the O 0 1.7858162948414247e-08
role O 0 1.4110307233750063e-07
of O 0 1.0664699345852569e-07
CA O 0 3.1372223020298406e-05
IX O 0 1.7556925740791485e-05
and O 0 5.409487584984163e-06
CA O 0 2.5045259462785907e-05
XII O 0 2.9865011583751766e-06
enzymes O 0 1.0687954699051261e-07
in O 0 3.5084481986302762e-09
the O 0 4.051778024205532e-09
regulation O 0 3.6984101114967416e-08
of O 0 6.022927490079155e-09
pH O 0 7.541841569036478e-07
in O 0 7.090572573531517e-09
the O 0 5.740664388298455e-09
extracellular O 0 9.454781491058384e-08
microenvironment O 0 7.318612915696576e-07
and O 0 1.990812847907364e-08
its O 0 8.237567783453414e-08
potential O 0 2.9687534208733268e-08
impact O 0 7.392718970322676e-08
on O 0 9.584432518749963e-06
cancer B-Disease 0 3.6602941690944135e-05
cell O 0 3.2509418815607205e-05
growth O 0 8.387010893784463e-06
. O 0 9.263987408303365e-07

A O 0 3.896030648320448e-06
gene O 0 2.9611583158839494e-06
encoding O 0 1.2651464658119949e-06
a O 0 2.6235366590299236e-07
transmembrane O 0 2.6489997253520414e-06
protein O 0 9.724346909933956e-07
is O 0 2.2972010071953264e-08
mutated O 0 8.62725755723659e-07
in O 0 3.0382426530195517e-07
patients O 0 1.4183083294483367e-05
with O 0 0.0003480133891571313
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 1 0.7976967692375183
optic B-Disease 1 1.0
atrophy I-Disease 1 0.999992847442627
( O 0 0.04917256161570549
Wolfram B-Disease 1 0.9999998807907104
syndrome I-Disease 1 1.0
) O 0 5.1036827244388405e-06
. O 0 2.0615752873709425e-06

Wolfram B-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 0.004730939399451017
WFS B-Disease 1 0.8677025437355042
; O 0 4.6888624638086185e-05
OMIM O 0 0.0057851094752550125
222300 O 0 4.378060839371756e-05
) O 0 1.9411663743085228e-07
is O 0 2.903441398416362e-08
an O 0 2.806742145367025e-07
autosomal B-Disease 1 0.999897837638855
recessive I-Disease 1 0.9999978542327881
neurodegenerative I-Disease 1 0.9999996423721313
disorder I-Disease 1 0.9996215105056763
defined O 0 3.0201433673937572e-06
by O 0 1.1774883290627258e-07
young O 0 4.6148852561600506e-07
- O 0 8.684751810505986e-05
onset O 0 0.00010652175842551515
non O 0 8.510056431987323e-06
- O 0 0.008219374343752861
immune O 0 0.00022649354650638998
insulin B-Disease 0 0.13320018351078033
- I-Disease 1 0.944476306438446
dependent I-Disease 1 0.999489426612854
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.00012797022645827383
progressive O 0 0.2251901477575302
optic B-Disease 1 0.999994158744812
atrophy I-Disease 0 0.3234734833240509
. O 0 3.473544438747922e-06

Linkage O 0 0.0002825125411618501
to O 0 3.849550921586342e-06
markers O 0 3.271961395512335e-05
on O 0 2.53217567660613e-05
chromosome O 0 0.019392287358641624
4p O 0 0.19086095690727234
was O 0 2.8563528758240864e-05
confirmed O 0 1.0895528248511255e-06
in O 0 1.0175158493552772e-08
five O 0 8.486875202606825e-08
families O 0 2.1660356708252948e-07
. O 0 7.116779556781694e-07

On O 0 1.6837119574120152e-06
the O 0 6.699982435520724e-08
basis O 0 6.313288736237155e-08
of O 0 2.3593242914898838e-08
meiotic O 0 3.446779737714678e-05
recombinants O 0 0.0019132739398628473
and O 0 3.3667354728095233e-05
disease O 0 0.00031230211607180536
- O 0 4.223830910632387e-05
associated O 0 6.761914846720174e-06
haplotypes O 0 2.601497180876322e-05
, O 0 1.0570872888138183e-07
the O 0 2.78077472160021e-08
WFS B-Disease 0 0.00010205393482465297
gene O 0 8.528454600309487e-07
was O 0 1.20399619163436e-07
localized O 0 1.9002580131655122e-07
to O 0 4.827492361414443e-08
a O 0 5.158066755939217e-07
BAC O 0 0.00018024697783403099
/ O 0 3.522506449371576e-05
P1 O 0 0.00016929303819779307
contig O 0 9.339261850982439e-06
of O 0 8.928805250718597e-09
less O 0 3.588733221704388e-08
than O 0 1.483631528742535e-08
250 O 0 8.201995171930321e-08
kb O 0 5.6027343816822395e-05
. O 0 8.031524885154795e-07

Mutations O 0 0.001084000221453607
in O 0 5.889157250749122e-07
a O 0 2.695790612960991e-07
novel O 0 2.6293605515093077e-06
gene O 0 8.361422260350082e-06
( O 0 1.1193618121296822e-07
WFS1 O 0 1.6449394024675712e-05
) O 0 1.635434720981266e-08
encoding O 0 3.165125761483978e-08
a O 0 3.91447407821488e-08
putative O 0 9.344404361399938e-07
transmembrane O 0 4.5813922611159796e-07
protein O 0 3.724780697211827e-07
were O 0 5.649198797641475e-08
found O 0 3.66333487988868e-08
in O 0 6.4586886949768996e-09
all O 0 9.818595714250478e-09
affected O 0 5.994849772150701e-08
individuals O 0 1.6942561797961275e-09
in O 0 8.169874554653234e-09
six O 0 1.927337223150971e-07
WFS B-Disease 0 6.540610775118694e-05
families O 0 5.971045879960002e-08
, O 0 1.334171795264183e-08
and O 0 1.0952515339113233e-08
these O 0 4.8507402539144095e-09
mutations O 0 6.61316505556897e-07
were O 0 2.0750514195810865e-08
associated O 0 3.313362384460561e-08
with O 0 2.1802460281605818e-08
the O 0 3.3451042327214964e-06
disease O 0 0.0019400431774556637
phenotype O 0 0.00016919909103307873
. O 0 2.7820510695164558e-06

WFS1 O 0 0.002193227643147111
appears O 0 8.590487595938612e-06
to O 0 1.0895055879700521e-07
function O 0 8.245632443504292e-08
in O 0 6.988546630282144e-08
survival O 0 2.8047106752637774e-06
of O 0 2.2238412000774588e-08
islet O 0 3.3801050449255854e-05
beta O 0 1.3964497611596016e-06
- O 0 1.2091842108929995e-05
cells O 0 4.385648026072886e-06
and O 0 1.5034444800221536e-07
neurons O 0 3.542036438375362e-06
. O 0 7.833970272486113e-08
. O 0 4.3670448235388903e-07

Stable O 0 8.955090015660971e-05
interaction O 0 5.809333174511266e-07
between O 0 4.843133893928098e-08
the O 0 1.5131300656889834e-08
products O 0 3.1167152769739914e-07
of O 0 2.72393707589913e-09
the O 0 5.046986473189463e-08
BRCA1 O 0 5.703428541892208e-05
and O 0 1.4923978142178385e-06
BRCA2 O 0 0.00025387885398231447
tumor B-Disease 0 1.3814982594340108e-05
suppressor O 0 4.179642473900458e-06
genes O 0 5.493408821166668e-07
in O 0 4.298159339555241e-08
mitotic O 0 2.8289059628150426e-05
and O 0 2.1900505089433864e-06
meiotic O 0 0.00023598747793585062
cells O 0 5.947876343270764e-05
. O 0 1.5801965673745144e-06

BRCA1 O 1 0.5839208960533142
and O 0 6.498905713669956e-05
BRCA2 O 0 0.0047399261966347694
account O 0 2.879413159462274e-06
for O 0 3.815540949858587e-08
most O 0 2.0444788972895367e-08
cases O 0 1.056476151006791e-08
of O 0 5.277021042360275e-09
familial O 0 1.2309204066696111e-05
, O 0 2.3466465393084945e-07
early O 0 3.0108749342616647e-06
onset O 0 0.00010921138164121658
breast B-Disease 0 0.02076452411711216
and I-Disease 0 2.1546562493313104e-05
/ I-Disease 1 0.9996286630630493
or I-Disease 1 0.9988071918487549
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
and O 0 6.408478014918728e-08
encode O 0 1.5361767680133198e-07
products O 0 7.908718657745339e-07
that O 0 3.9496534931515725e-09
each O 0 9.257168365195412e-09
interact O 0 2.7594662554975002e-08
with O 0 4.542255283013219e-08
hRAD51 O 0 4.4263382733333856e-05
. O 0 1.1444033134466736e-06

Results O 0 0.00010806984937516972
presented O 0 9.877369393507252e-07
here O 0 6.873916191807439e-08
show O 0 1.9448260957233288e-07
that O 0 2.334894766420348e-08
BRCA1 O 0 1.4982794709794689e-05
and O 0 6.713702305205516e-07
BRCA2 O 0 7.822604675311595e-05
coexist O 0 9.91688921203604e-07
in O 0 7.85942422254493e-09
a O 0 4.452548196809403e-08
biochemical O 0 4.816437808585761e-07
complex O 0 1.6195606633573334e-07
and O 0 2.7982267170045816e-07
colocalize O 0 1.653814069868531e-05
in O 0 6.012083275663826e-08
subnuclear O 0 9.050613698491361e-06
foci O 0 4.250963684171438e-06
in O 0 3.3910112051671604e-08
somatic O 0 8.958128887570638e-07
cells O 0 2.3634761419089045e-06
and O 0 2.7518764156297948e-08
on O 0 1.586833775490959e-07
the O 0 1.0714914289167154e-08
axial O 0 1.9903995962522458e-07
elements O 0 5.0158451614379373e-08
of O 0 7.9163244848246e-09
developing O 0 3.383775606380368e-07
synaptonemal O 0 1.4303880561783444e-05
complexes O 0 1.954680783455842e-06
. O 0 1.3506321465683868e-06

Like O 0 2.0230980226187967e-05
BRCA1 O 0 0.0013483235379680991
and O 0 4.842122052650666e-06
RAD51 O 0 0.0012329444289207458
, O 0 1.4991879879744374e-06
BRCA2 O 0 6.168541585793719e-05
relocates O 0 6.6305024120083544e-06
to O 0 1.8152650227420963e-07
PCNA O 0 1.8603339412948117e-05
+ O 0 6.71305542709888e-07
replication O 0 5.060732632955478e-07
sites O 0 9.049061588939367e-08
following O 0 5.890348475645624e-08
exposure O 0 5.064295578449673e-07
of O 0 1.0498332869701699e-08
S O 0 7.692109647905454e-05
phase O 0 5.12405563313223e-07
cells O 0 5.101387614558917e-07
to O 0 1.0393755189852527e-07
hydroxyurea O 0 1.3683207725989632e-05
or O 0 7.448184646818845e-07
UV O 0 6.2689752667211e-05
irradiation O 0 5.452527602756163e-06
. O 0 9.530641591481981e-07

Thus O 0 1.585137397341896e-05
, O 0 1.2878914503744454e-06
BRCA1 O 0 6.262969691306353e-05
and O 0 1.2378743576846318e-06
BRCA2 O 0 0.00010613900667522103
participate O 0 1.127560267377703e-07
, O 0 2.7086857201652492e-08
together O 0 3.8055254947266803e-08
, O 0 2.1496976643220478e-08
in O 0 5.719210882659809e-09
a O 0 1.4807118020598864e-07
pathway O 0 1.1217859992029844e-06
( O 0 7.053353101582616e-07
s O 0 0.00040015747072175145
) O 0 5.115778733966181e-08
associated O 0 1.8507673615886233e-08
with O 0 1.5850202261802337e-09
the O 0 7.433720305982661e-09
activation O 0 3.7947618380940185e-08
of O 0 2.466689519309284e-09
double O 0 1.3160749858798226e-06
- O 0 3.726842987816781e-05
strand O 0 0.019937144592404366
break O 0 6.901875167386606e-05
repair O 0 0.00015726088895462453
and O 0 1.5657252561140922e-06
/ O 0 1.6133333701873198e-05
or O 0 2.4786001517895784e-07
homologous O 0 3.049411816391512e-06
recombination O 0 1.0253573236695956e-05
. O 0 2.4049461444519693e-06

Dysfunction O 0 0.11790327727794647
of O 0 3.5326308989169775e-07
this O 0 6.55662262261103e-08
pathway O 0 6.12475332673057e-07
may O 0 3.961360562243499e-06
be O 0 1.6944152747555563e-08
a O 0 2.8890841718975935e-08
general O 0 1.5170950717902087e-08
phenomenon O 0 7.6795764414328e-08
in O 0 6.4711671576844765e-09
the O 0 4.4375649821404295e-09
majority O 0 1.0040112741194207e-08
of O 0 2.3689366024370884e-09
cases O 0 2.676740429308211e-08
of O 0 4.752758187009931e-08
hereditary B-Disease 1 0.9939407110214233
breast I-Disease 1 0.9667651653289795
and I-Disease 0 0.0006745067075826228
/ I-Disease 1 0.9999381303787231
or I-Disease 1 0.9998946189880371
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 1.312421034072031e-07
. O 0 2.922326700627309e-07

A O 0 4.829849785892293e-06
novel O 0 1.7749231346897432e-06
Arg362Ser O 0 8.736307790968567e-06
mutation O 0 2.1419125459942734e-06
in O 0 1.81647337171853e-08
the O 0 2.140492050273224e-08
sterol O 0 1.2596069609571714e-05
27 O 0 4.2733399823191576e-06
- O 0 2.9248936698422767e-05
hydroxylase O 0 0.00011227359937038273
gene O 0 3.95966844735085e-06
( O 0 1.1246542186427178e-07
CYP27 O 0 3.6887759051751345e-05
) O 0 3.3657581610668785e-08
: O 0 4.420273036487288e-09
its O 0 3.85983973671955e-08
effects O 0 1.6716533934868494e-07
on O 0 1.0605386790984994e-07
pre O 0 2.515721746476629e-07
- O 0 9.605082595953718e-08
mRNA O 0 5.2168875441793716e-08
splicing O 0 2.3801207760243415e-07
and O 0 1.997183396440505e-08
enzyme O 0 3.1867944016994443e-07
activity O 0 2.573045776443905e-07
. O 0 3.383808007129119e-07

A O 0 1.6729989511077292e-05
novel O 0 2.919167400250444e-06
C O 0 9.269057045457885e-06
to O 0 5.397457769618086e-08
A O 0 2.553920523951092e-07
mutation O 0 3.8051487649681803e-07
in O 0 7.077372021768724e-09
the O 0 1.898657941978854e-08
sterol O 0 1.338366655545542e-05
27 O 0 5.074116870673606e-06
- O 0 3.3286240068264306e-05
hydroxylase O 0 8.540137787349522e-05
gene O 0 5.551183676288929e-06
( O 0 7.388828038301654e-08
CYP27 O 0 3.0173339837347157e-05
) O 0 4.818247845150836e-08
was O 0 2.149816964447382e-07
identified O 0 4.79455906088333e-08
by O 0 4.600865022297285e-09
sequencing O 0 1.870890002919623e-07
amplified O 0 5.153007691660605e-07
CYP27 O 0 4.660267677536467e-06
gene O 0 2.8421192155292374e-07
products O 0 1.477104092373338e-07
from O 0 6.872392432910601e-09
a O 0 2.6374044637123006e-07
patient O 0 6.06871435593348e-06
with O 0 1.814107008613064e-06
cerebrotendinous B-Disease 1 0.9999998807907104
xanthomatosis I-Disease 1 0.9999997615814209
( O 0 5.5713476285745855e-06
CTX B-Disease 0 0.0008202032186090946
) O 0 7.56184761030454e-07
. O 0 7.921075280137302e-07

The O 0 9.363789104099851e-07
mutation O 0 3.179370878569898e-06
changed O 0 3.1536407618659723e-07
the O 0 1.9309426946279018e-08
adrenodoxin O 0 1.548349132463045e-06
cofactor O 0 5.918558940720686e-07
binding O 0 3.021215775333985e-07
residue O 0 5.58427700525499e-07
362Arg O 0 2.5505814846837893e-06
to O 0 1.704818828329735e-07
362Ser O 0 9.144609066424891e-06
( O 0 1.329486849499517e-07
CGT O 0 1.7932434275280684e-05
362Arg O 0 3.1789918466529343e-06
to O 0 1.394019903955268e-07
AGT O 0 3.395690873730928e-05
362Ser O 0 4.69090991828125e-06
) O 0 5.1341071838351127e-08
, O 0 1.5709474610048346e-08
and O 0 3.6277203463441765e-08
was O 0 2.7302066882839426e-06
responsible O 0 1.5643297501810594e-06
for O 0 8.318563686771085e-07
deficiency O 0 2.254890750919003e-05
in O 0 1.2224474765787363e-08
the O 0 3.595523168087311e-08
sterol O 0 1.6634832718409598e-05
27 O 0 1.966101990547031e-06
- O 0 4.241770966473268e-06
hydroxylase O 0 1.1857062418130226e-05
activity O 0 1.3607602511456207e-07
, O 0 7.60604379479446e-09
as O 0 1.0868484778825405e-08
confirmed O 0 9.349015073212286e-08
by O 0 1.4683890769973118e-09
expression O 0 8.404474449719146e-09
of O 0 1.950709149767249e-09
mutant O 0 1.8426909775826061e-07
cDNA O 0 2.3384208702736942e-07
into O 0 1.532673366000381e-07
COS O 0 0.00026671934756450355
- O 0 4.9169070734933484e-06
1 O 0 9.258687896362972e-07
cells O 0 2.612132448120974e-06
. O 0 4.3746729261329165e-07

Quantitative O 0 7.347683276748285e-05
analysis O 0 4.328279374021804e-06
showed O 0 2.799454478008556e-06
that O 0 1.7622324932631273e-08
the O 0 4.116110119412042e-09
expression O 0 1.507035563008685e-08
of O 0 3.7203480296454927e-09
CYP27 O 0 2.4045953068707604e-06
gene O 0 8.009734386860146e-08
mRNA O 0 9.228577368958213e-08
in O 0 1.0209801004634755e-08
the O 0 2.4174772406126976e-08
patient O 0 5.37874257133808e-07
represented O 0 5.956100324056024e-08
52 O 0 1.0805389365486917e-06
. O 0 4.852620918427419e-07

5 O 0 7.2106327024812344e-06
% O 0 2.044444471493989e-07
of O 0 9.548946522386359e-09
the O 0 2.4765624218048288e-08
normal O 0 6.029125643181033e-07
level O 0 4.795386985279038e-07
. O 0 1.1641291166597512e-06

As O 0 7.263778911692498e-07
the O 0 8.398645690022022e-08
mutation O 0 1.1598925766520551e-06
occurred O 0 4.3019895201723557e-07
at O 0 3.25611893003952e-08
the O 0 3.1083187135294565e-09
penultimate O 0 3.755083071155241e-07
nucleotide O 0 1.1399772148479315e-07
of O 0 3.192912823024585e-09
exon O 0 4.466489542664931e-07
6 O 0 3.218810888938606e-07
( O 0 4.950508447620905e-09
- O 0 1.4193497577252856e-07
2 O 0 1.5777825979057525e-07
position O 0 1.791278521068307e-07
of O 0 4.721583568567667e-09
exon O 0 1.1306350415907218e-06
6 O 0 3.396390866328147e-07
- O 0 2.4978401143016526e-06
intron O 0 1.165089361165883e-05
6 O 0 1.963698110785117e-07
splice O 0 7.800608727848157e-06
site O 0 8.692442747815221e-07
) O 0 3.980304530415424e-09
of O 0 3.0942270967670993e-10
the O 0 5.890839815947402e-09
gene O 0 3.222183124762523e-07
, O 0 2.25718199686753e-08
we O 0 1.2976104635242791e-08
hypothesized O 0 6.852787493016876e-08
that O 0 6.925593432072219e-09
the O 0 3.4774640056411954e-08
mutation O 0 3.9871565604698844e-06
may O 0 9.582116717865574e-07
partially O 0 1.0375588317401707e-06
affect O 0 2.9451671323954542e-08
the O 0 2.9175568627692883e-09
normal O 0 3.202862686180197e-08
splicing O 0 2.3369983637167024e-07
efficiency O 0 7.464355888942009e-08
in O 0 1.9214931867850282e-08
exon O 0 1.2661034816119354e-06
6 O 0 3.9956492514647834e-07
and O 0 2.554801881160529e-08
cause O 0 2.5134045955610418e-08
alternative O 0 2.2205606242664544e-08
splicing O 0 8.720024879949051e-07
elsewhere O 0 9.263226843359007e-07
, O 0 1.0981005438281954e-08
which O 0 1.2555037898209775e-08
resulted O 0 4.224997951496334e-08
in O 0 3.250974600632617e-08
decreased O 0 2.4569815195718547e-06
transcript O 0 1.8988275769515894e-05
in O 0 6.652764028558522e-08
the O 0 1.6453100215585437e-07
patient O 0 5.863233582203975e-06
. O 0 4.619447508957819e-07

Transfection O 0 0.001192247262224555
of O 0 1.3061371646472253e-06
constructed O 0 4.45443174612592e-06
minigenes O 0 0.0001402860216330737
, O 0 8.591339195618275e-08
with O 0 4.313029489111386e-09
or O 0 2.7055669704623142e-08
without O 0 5.556438864573465e-09
the O 0 5.2478026368874e-09
mutation O 0 1.7418321363038558e-07
, O 0 6.827839182932394e-09
into O 0 2.111084107525585e-08
COS O 0 0.0005017859512008727
- O 0 5.8890614127449226e-06
1 O 0 6.907140459588845e-07
cells O 0 4.0479881135979667e-07
confirmed O 0 3.353171109665709e-07
that O 0 1.8394835654689246e-09
the O 0 3.1214368867438225e-09
mutant O 0 2.255659126149112e-07
minigene O 0 5.329111445462331e-06
was O 0 7.625518492204719e-07
responsible O 0 3.148933558350109e-08
for O 0 1.2029438556382388e-09
a O 0 8.286004771207445e-09
mRNA O 0 8.843016274795445e-08
species O 0 1.9650464366804954e-08
alternatively O 0 8.089062220051346e-08
spliced O 0 1.890104977064766e-05
at O 0 6.786565904803865e-07
an O 0 4.3663948900984906e-08
activated O 0 8.871031695889542e-07
cryptic O 0 1.8479067875887267e-06
5 O 0 6.993987256009859e-08
splice O 0 1.0067017683468293e-05
site O 0 2.5735046165209496e-06
88 O 0 2.9720715133407793e-07
bp O 0 5.133704235049663e-06
upstream O 0 1.3653594521656487e-07
from O 0 5.433524297160375e-09
the O 0 4.749411530724501e-09
3 O 0 7.927130951657091e-08
end O 0 1.0492190938293788e-07
of O 0 1.6713530115453068e-08
exon O 0 7.070856554491911e-06
6 O 0 9.399101941198751e-07
. O 0 5.61415390620823e-07

Our O 0 1.1596256626944523e-05
data O 0 2.985572791658342e-06
suggest O 0 1.8116435285264743e-07
that O 0 6.948828179531574e-09
the O 0 1.1061896287856143e-08
C O 0 9.868481356534176e-07
to O 0 2.1752864398649763e-08
A O 0 2.847740745437477e-07
mutation O 0 3.499298486531188e-07
at O 0 4.737363212825585e-08
the O 0 4.9006976254872825e-09
penultimate O 0 3.7142635278542e-07
nucleotide O 0 1.2045347830280662e-07
of O 0 4.882876769585209e-09
exon O 0 2.2655588338693633e-07
6 O 0 2.4056101111114003e-08
of O 0 9.084384355872999e-10
the O 0 9.98939775342933e-09
CYP27 O 0 7.990179256012198e-06
gene O 0 3.699419721669983e-07
not O 0 1.5629796124017048e-08
only O 0 1.0325640786845725e-08
causes O 0 1.2642115621019911e-07
the O 0 3.547925757629855e-07
deficiency B-Disease 0 2.5390163500560448e-05
in I-Disease 0 6.0247660194079344e-09
the I-Disease 0 3.191952657743968e-08
sterol I-Disease 0 2.1402573111117817e-05
27 I-Disease 0 1.37529957555671e-06
- I-Disease 0 4.636051471607061e-06
hydroxylase I-Disease 0 1.712205084913876e-05
activity I-Disease 0 1.4748097498795687e-07
, O 0 2.3361241829888968e-08
but O 0 1.3470642379331821e-08
also O 0 7.076619112922344e-08
partially O 0 7.644129027539748e-07
leads O 0 6.084634662784083e-08
to O 0 8.758894942673123e-09
alternative O 0 4.313829649049694e-08
pre O 0 3.513996205128933e-07
- O 0 1.0861173649345801e-07
mRNA O 0 8.42624388042168e-08
splicing O 0 2.0255998833818012e-07
of O 0 3.6509166800868798e-09
the O 0 4.058431812836716e-08
gene O 0 1.909427737700753e-06
. O 0 3.7457692769748974e-07

To O 0 4.163125595368911e-06
our O 0 3.578836071937985e-07
knowledge O 0 6.352545511845165e-08
, O 0 3.511710389147993e-08
this O 0 4.3137453609176646e-09
is O 0 6.853490663871753e-09
the O 0 1.518536763001066e-08
first O 0 6.010948823131912e-07
report O 0 7.070755714266852e-07
regarding O 0 2.5181167373489188e-08
effects O 0 1.1902393737273087e-07
on O 0 1.4992379249179066e-07
pre O 0 8.16806903003453e-07
- O 0 2.330744166556542e-07
mRNA O 0 3.9654842964864656e-08
splicing O 0 9.870819184243373e-08
of O 0 1.0981670017784495e-09
a O 0 1.8779127586299182e-08
mutation O 0 1.0880228984433415e-07
at O 0 4.942359765891524e-08
the O 0 1.4448305662995153e-08
- O 0 1.6399350215579034e-06
2 O 0 4.6827608457533643e-07
position O 0 7.807135204984661e-08
of O 0 1.777513469747305e-09
a O 0 6.173561217792667e-08
5 O 0 1.1616278783321832e-07
splice O 0 9.358235547551885e-05
site O 0 2.0838855562033132e-05
. O 0 7.440460763064038e-07

ATM O 0 0.005650675855576992
germline O 0 0.008290132507681847
mutations O 0 0.0006149868713691831
in O 0 3.955599822802469e-06
classical O 0 0.0009111770777963102
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
patients O 1 0.6256058216094971
in O 0 1.5653580476282514e-07
the O 0 1.0397780414450608e-07
Dutch O 0 8.568410703446716e-05
population O 0 6.126751372903527e-07
. O 0 1.0789850648507127e-06

Germline O 0 0.02090642787516117
mutations O 0 0.0015682964585721493
in O 0 3.618005166572402e-07
the O 0 3.223633271431936e-08
ATM O 0 5.4980475397314876e-05
gene O 0 1.7890743038151413e-06
are O 0 1.0733998578871251e-08
responsible O 0 2.9450501415340113e-07
for O 0 1.24961644587529e-07
the O 0 0.004989773500710726
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.006985274609178305
A B-Disease 1 0.9999983310699463
- I-Disease 1 0.9999958276748657
T I-Disease 1 1.0
) O 0 3.3504682050988777e-06
. O 0 1.418301280864398e-06

In O 0 5.601694283541292e-06
our O 0 1.132625015998201e-06
study O 0 9.319229832271958e-08
, O 0 2.3335726240247823e-08
we O 0 1.011841366249655e-08
have O 0 4.44227321594326e-09
determined O 0 9.78020420205894e-09
the O 0 3.5580678403590582e-09
ATM O 0 1.3660012882610317e-05
mutation O 0 3.2064116339824977e-07
spectrum O 0 4.6581646984122926e-08
in O 0 1.4317151020293295e-08
19 O 0 6.115350714708256e-08
classical O 0 1.9881893820183905e-07
A B-Disease 1 0.9999943971633911
- I-Disease 1 0.9999994039535522
T I-Disease 1 1.0
patients O 0 2.4335909984074533e-05
, O 0 3.758606315074076e-09
including O 0 8.428229225643236e-10
some O 0 1.8031066639778714e-09
immigrant O 0 2.74079866358079e-07
populations O 0 6.26178078277917e-08
, O 0 1.0265139849252591e-08
as O 0 6.503127369938966e-09
well O 0 4.539827624938653e-09
as O 0 1.457813247895956e-08
12 O 0 7.947368096949958e-09
of O 0 2.4810244969586392e-09
Dutch O 0 4.1649282138678245e-06
ethnic O 0 5.153606821295398e-07
origin O 0 6.821417741775804e-07
. O 0 8.306196832563728e-07

Both O 0 1.6768343584772083e-06
the O 0 1.7862872425666865e-07
protein O 0 5.569120276049944e-07
truncation O 0 9.394287189934403e-06
test O 0 2.5782385364436777e-06
( O 0 8.888538616247388e-08
PTT O 0 2.3367863832390867e-05
) O 0 1.2033161134183956e-08
and O 0 5.827264004665267e-09
the O 0 6.547085096286764e-09
restriction O 0 4.224586902523697e-08
endonuclease O 0 2.060392034763936e-06
fingerprinting O 0 1.3684825717064086e-05
( O 0 1.0790287774398166e-07
REF O 0 1.2892498489236459e-05
) O 0 5.723401308443954e-09
method O 0 2.2249528441875555e-08
were O 0 1.1358703311259433e-08
used O 0 6.700685872829126e-08
and O 0 6.41827639924486e-08
compared O 0 6.162184718050412e-08
for O 0 1.3653334018925989e-09
their O 0 4.509363993321358e-09
detection O 0 4.0965787206914683e-08
efficiency O 0 6.107633510055166e-08
, O 0 7.261075296582931e-09
identifying O 0 4.5876880960804556e-08
76 O 0 2.5590301433453533e-08
% O 0 5.259727320350294e-09
and O 0 6.019688747471719e-09
60 O 0 1.763752344174918e-08
% O 0 4.287316279771858e-09
of O 0 8.193121736610465e-10
the O 0 3.4206529164748645e-08
mutations O 0 9.85308906820137e-06
, O 0 7.541979130110121e-08
respectively O 0 5.397765789894038e-07
. O 0 4.611858628322807e-07

Most O 0 1.0185430255660322e-05
patients O 0 2.4719749490031973e-05
were O 0 9.08158597212605e-08
found O 0 5.954657211759695e-08
to O 0 2.268706289498823e-08
be O 0 4.1688913654525095e-08
compound O 0 1.846279246819904e-06
heterozygote O 0 2.2832002287032083e-05
. O 0 1.1197007552254945e-06

Seventeen O 0 6.496575952041894e-05
mutations O 0 8.898540545487776e-05
were O 0 2.8955255970686267e-07
distinct O 0 1.2550613348594197e-07
, O 0 4.461618985374116e-08
of O 0 3.559466277280876e-09
which O 0 1.935142677211843e-07
10 O 0 1.3987660452130513e-07
were O 0 9.088239494303707e-08
not O 0 8.025470776829025e-08
reported O 0 5.603661065833876e-06
previously O 0 1.3969198562335805e-06
. O 0 6.114849497862451e-07

Mutations O 0 0.0016383357578888535
are O 0 3.137926398721902e-07
small O 0 1.8275596858075005e-07
deletions O 0 1.2643788977584336e-05
or O 0 1.7374104572809301e-06
point O 0 3.147861434626975e-06
mutations O 0 3.061416282434948e-05
frequently O 0 1.0718204066506587e-06
affecting O 0 2.11621772905346e-06
splice O 0 0.000908694404643029
sites O 0 1.9503420844557695e-05
. O 0 3.302669483673526e-06

Moreover O 0 3.264284896431491e-05
, O 0 5.554570634558331e-07
a O 0 4.4757126715921913e-07
16 O 0 1.082195240087458e-06
. O 0 7.542927846770908e-07

7 O 0 0.0001358894514851272
- O 0 0.00010243416909361258
kb O 0 0.00016256053640972823
genomic O 0 3.268762384323054e-06
deletion O 0 3.257524895161623e-06
of O 0 7.161631287999626e-09
the O 0 1.2369327784256257e-08
3 O 0 1.0691297802623012e-07
end O 0 7.325316886408473e-08
of O 0 1.3148302446808202e-09
the O 0 9.126661204561515e-09
gene O 0 2.4131978193508985e-07
, O 0 1.493739887337142e-08
most O 0 4.654885366051076e-09
likely O 0 2.5040641560281074e-08
a O 0 1.7421005082951524e-08
result O 0 1.315257325273933e-08
of O 0 1.6480534714702344e-09
recombination O 0 3.751882360347736e-08
between O 0 1.50539243293224e-08
two O 0 6.003546104693669e-08
LINE O 0 2.0816551113966852e-05
elements O 0 4.667815005632292e-07
, O 0 2.083024526200461e-07
was O 0 1.1961900554524618e-06
identified O 0 1.485652774135815e-06
. O 0 3.9993435052565474e-07

The O 0 6.276243311731378e-07
most O 0 1.712366497486073e-07
frequently O 0 3.573658773348143e-07
found O 0 4.221558356221067e-07
mutation O 0 8.620406788395485e-07
, O 0 3.8636628119093075e-08
identified O 0 1.7723661471791274e-07
in O 0 9.797605393657705e-09
three O 0 3.4577940510871485e-08
unrelated O 0 3.867050963890506e-07
Turkish O 0 1.2790577557098004e-06
A B-Disease 1 0.9999902248382568
- I-Disease 1 0.9999831914901733
T I-Disease 1 1.0
individuals O 0 3.236750671931077e-07
, O 0 1.0550830609190598e-07
was O 0 1.746061229823681e-06
previously O 0 4.5224416567180015e-07
described O 0 4.981266101822257e-07
to O 0 1.652763614856667e-08
be O 0 5.2572399766859235e-09
a O 0 3.196997511167865e-08
Turkish O 0 1.7826160956246895e-06
A B-Disease 1 0.9999464750289917
- I-Disease 1 0.999833345413208
T I-Disease 1 0.9999998807907104
founder O 0 0.0001850044063758105
mutation O 0 1.162302760349121e-05
. O 0 6.03737589699449e-07

The O 0 3.469693297120102e-07
presence O 0 1.4107885704106593e-07
of O 0 6.104498684322834e-09
a O 0 1.0032861297304407e-07
founder O 0 3.2544137411605334e-06
mutation O 0 4.943924523104215e-07
among O 0 3.338825438348181e-09
relatively O 0 1.946301564359487e-09
small O 0 2.074824756448379e-09
ethnic O 0 5.1568072478858085e-08
population O 0 1.2939624483010448e-08
groups O 0 1.6328035590262857e-09
in O 0 5.351837195632925e-09
Western O 0 9.26390129052379e-08
Europe O 0 2.8508377454272704e-06
could O 0 2.5330842845505686e-07
indicate O 0 3.2135471172978214e-08
a O 0 1.804421856377303e-08
high O 0 7.362885412476317e-08
carrier O 0 2.991747010128165e-07
frequency O 0 4.017137200662546e-07
in O 0 1.6563674876124423e-08
such O 0 6.887877379568863e-09
communities O 0 2.2015142064901738e-07
. O 0 5.820158435199119e-07

In O 0 3.1784660677658394e-05
patients O 0 2.9284099582582712e-05
of O 0 4.831536415395021e-08
Dutch O 0 8.860235539032146e-06
ethnic O 0 2.0456067773011455e-07
origin O 0 1.8705100046645384e-07
, O 0 5.977450001637408e-08
however O 0 3.619343758032301e-08
, O 0 6.152224063527001e-09
no O 0 6.902002080977354e-09
significant O 0 1.5494858729425687e-08
founder O 0 2.1451753582368838e-06
effect O 0 3.0846555887364957e-07
could O 0 3.803537822477665e-07
be O 0 1.2719499409286072e-07
identified O 0 2.517913571864483e-06
. O 0 4.428917179666314e-07

The O 0 3.5071502679784317e-06
observed O 0 7.15883879820467e-06
genetic O 0 6.916012353030965e-06
heterogeneity O 0 2.2319206891552312e-06
including O 0 3.5192872616107707e-08
the O 0 1.6993316975799644e-08
relative O 0 8.586686561784518e-08
high O 0 1.1977705582921772e-07
percentage O 0 3.5002230447389593e-07
of O 0 4.1859724575488144e-09
splice O 0 0.0004939043428748846
- O 0 0.0004091121081728488
site O 0 3.9535301766591147e-05
mutations O 0 2.8279995603952557e-05
had O 0 4.403987077239435e-07
no O 0 1.5316791390773687e-08
reflection O 0 7.57398126438602e-08
on O 0 3.9233285065165546e-07
the O 0 2.823036879817664e-07
phenotype O 0 5.7836670748656616e-05
. O 0 9.102305966735003e-07

All O 0 3.804854486588738e-06
patients O 0 1.235153558809543e-05
manifested O 0 1.2912057627545437e-06
classical O 0 2.258527274534572e-06
A B-Disease 1 0.999777615070343
- I-Disease 1 0.9998290538787842
T I-Disease 1 0.9999998807907104
and O 0 6.981571232245187e-07
increased O 0 1.1221129625482718e-07
cellular O 0 1.7632178241910879e-06
radioresistant O 0 2.2938006623007823e-06
DNA O 0 2.319334498679382e-06
synthesis O 0 3.5978944197267992e-06
. O 0 1.0001867849496193e-06

Determination O 0 2.3937749574542977e-05
of O 0 1.3860845626822993e-07
the O 0 5.022134530463518e-08
genomic O 0 5.830257805428118e-07
structure O 0 1.5484495463624626e-07
of O 0 1.0176711917608827e-08
the O 0 3.954042071541153e-08
COL4A4 O 0 2.0283216144889593e-05
gene O 0 2.5135682335530873e-07
and O 0 5.495476518291298e-09
of O 0 4.44197700844029e-09
novel O 0 3.6918738715030486e-06
mutations O 0 0.001386212301440537
causing O 0 0.005784687120467424
autosomal B-Disease 1 0.9999737739562988
recessive I-Disease 1 0.9999986886978149
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
. O 0 4.388602974358946e-05

Autosomal B-Disease 1 0.9999984502792358
recessive I-Disease 1 0.9999997615814209
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 1.6831285392981954e-05
a O 0 6.562566795764724e-06
progressive O 0 0.012505765073001385
hematuric B-Disease 1 0.9849415421485901
glomerulonephritis I-Disease 1 0.9999997615814209
characterized O 0 0.00018018923583440483
by O 0 2.4547841803723713e-07
glomerular B-Disease 0 0.001058660913258791
basement I-Disease 0 0.06448406726121902
membrane I-Disease 0 0.002675370080396533
abnormalities I-Disease 1 0.9776185154914856
and O 0 5.148473292138078e-07
associated O 0 2.3742219923406083e-07
with O 0 4.2120834820025266e-08
mutations O 0 4.060049377585528e-06
in O 0 3.7537578378987746e-08
either O 0 4.589972490975924e-08
the O 0 3.1871099537283953e-08
COL4A3 O 0 3.387676042621024e-05
or O 0 4.712139300977469e-08
the O 0 1.0430570185349097e-08
COL4A4 O 0 8.948089089244604e-06
gene O 0 2.0444092285742954e-07
, O 0 2.718632430287471e-09
which O 0 1.3674471555091827e-09
encode O 0 2.3067727283887507e-08
the O 0 1.3600838677518823e-08
alpha3 O 0 8.872140824678354e-06
and O 0 1.4620187016589625e-07
alpha4 O 0 1.6437319573014975e-05
type O 0 2.8689644295809558e-06
IV O 0 0.002442825585603714
collagen O 0 4.303378227632493e-05
chains O 0 2.5690424081403762e-05
, O 0 1.0900127023205641e-07
respectively O 0 1.2899897683382733e-06
. O 0 6.551753131134319e-07

To O 0 3.077616611335543e-06
date O 0 1.7326714214505046e-06
, O 0 5.602510810831518e-08
mutation O 0 1.1520561571387589e-07
screening O 0 6.485466030881071e-08
in O 0 6.796240903383932e-09
the O 0 4.085278337839782e-09
two O 0 2.3967707818428607e-08
genes O 0 4.030845275337924e-07
has O 0 4.6533119757441455e-07
been O 0 2.775662153453595e-07
hampered O 0 1.4986904943725676e-06
by O 0 6.348170433767564e-09
the O 0 5.6319175989472114e-09
lack O 0 1.2743097244083401e-08
of O 0 4.102456596655202e-09
genomic O 0 4.3616091716103256e-07
structure O 0 1.4187369288265472e-06
information O 0 1.0361131899117026e-06
. O 0 9.103678166866302e-07

We O 0 2.925284206867218e-05
report O 0 2.121463467119611e-06
here O 0 1.6036070249469958e-08
the O 0 3.5288167943292592e-09
complete O 0 8.398566109235617e-08
characterization O 0 4.4468029614108673e-07
of O 0 4.414408838471218e-09
the O 0 1.942890293094024e-08
48 O 0 5.18589473585962e-08
exons O 0 1.7020344955653854e-07
of O 0 2.6746058701121456e-09
the O 0 9.043105819728225e-09
COL4A4 O 0 5.8379860092827585e-06
gene O 0 1.9780920013090508e-07
, O 0 5.516543222228165e-09
a O 0 5.768961752750101e-09
comprehensive O 0 7.712750971222704e-08
gene O 0 4.447396406703774e-07
screen O 0 1.2438230214684154e-06
, O 0 4.9941370150463626e-08
and O 0 2.476019389519024e-08
the O 0 8.245251592597924e-09
subsequent O 0 1.4168229256483755e-08
detection O 0 5.29990096254096e-08
of O 0 4.22940615862899e-09
10 O 0 4.267965536541851e-08
novel O 0 1.681258936514496e-07
mutations O 0 1.1762799658754375e-06
in O 0 2.0610603002069183e-08
eight O 0 4.313819317758316e-06
patients O 0 6.762977864127606e-05
diagnosed O 0 0.001160015701316297
with O 0 5.33026013727067e-06
autosomal B-Disease 1 0.9999978542327881
recessive I-Disease 1 0.9999992847442627
Alport I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999998807907104
. O 0 5.977353430353105e-05

Furthermore O 0 5.262120612314902e-05
, O 0 5.650868502016237e-07
we O 0 5.172302408595897e-08
identified O 0 5.656120549701882e-08
a O 0 2.037017132749952e-08
glycine O 0 1.6451654119009618e-06
to O 0 3.088746325374814e-08
alanine O 0 1.73792940927342e-07
substitution O 0 1.6503065580764087e-08
in O 0 5.514922740701422e-09
the O 0 8.356649594531973e-09
collagenous O 0 6.75642877467908e-06
domain O 0 1.229029180649377e-07
that O 0 2.5984963514247283e-08
is O 0 1.7716386579991195e-08
apparently O 0 3.2630640589559334e-07
silent O 0 7.103557209120481e-08
in O 0 1.7297364651724934e-09
the O 0 4.392320285262485e-09
heterozygous O 0 2.0402217160153668e-07
carriers O 0 6.458863310854213e-08
, O 0 1.5545005283001956e-08
in O 0 3.0098675551926135e-08
11 O 0 5.269560574561183e-07
. O 0 6.479926355495991e-07

5 O 0 7.858370736357756e-06
% O 0 2.390550832842564e-07
of O 0 9.431975200868692e-09
all O 0 7.61886553846125e-09
control O 0 3.482160479961749e-07
individuals O 0 1.2809526772628033e-08
, O 0 2.5308427353820662e-08
and O 0 4.5319225705497956e-08
in O 0 1.8810244029054957e-08
one O 0 5.19730214421088e-08
control O 0 7.303623306142981e-08
individual O 0 1.1356234175252666e-08
homozygous O 0 2.713120181851991e-07
for O 0 5.706984662623427e-09
this O 0 1.3915646412954175e-08
glycine O 0 2.4665932869538665e-06
substitution O 0 1.0189460226683877e-06
. O 0 5.918186616327148e-07

There O 0 1.2926392628287431e-05
has O 0 4.96178927278379e-07
been O 0 1.0399466532362567e-07
no O 0 1.6481296327697237e-08
previous O 0 4.462410529981753e-08
finding O 0 1.2915165825688746e-08
of O 0 1.452190034889611e-09
a O 0 2.7311175543331956e-08
glycine O 0 1.414386929354805e-06
substitution O 0 2.9873842066763245e-08
that O 0 1.50144661148488e-08
is O 0 1.5976048928223463e-08
not O 0 8.194359857327527e-09
associated O 0 1.3685801825147337e-08
with O 0 6.852131750889612e-09
any O 0 8.885097457778102e-08
obvious O 0 4.782165774486202e-07
phenotype O 0 1.008230265142629e-05
in O 0 1.656919579318128e-07
homozygous O 0 1.73904682014836e-05
individuals O 0 3.839896862700698e-07
. O 0 1.0637816103553632e-06

Founder O 0 0.0007569598965346813
BRCA1 O 0 0.0038608284667134285
and O 0 1.0475017006683629e-05
BRCA2 O 0 0.0008905890863388777
mutations O 0 7.513276068493724e-05
in O 0 2.45600176640437e-07
French O 0 4.68583675683476e-05
Canadian O 0 0.0010461475467309356
breast B-Disease 1 0.9995684027671814
and I-Disease 1 0.9910047054290771
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999992847442627
families O 0 4.040299700136529e-06
. O 0 1.8518248907639645e-06

We O 0 6.293088517850265e-06
have O 0 9.509018639164424e-08
identified O 0 1.451368945026843e-07
four O 0 2.1409613637501934e-08
mutations O 0 2.923575550539681e-07
in O 0 3.1215439122433963e-09
each O 0 3.306857676577124e-09
of O 0 4.391482288923498e-09
the O 0 2.5252625164284837e-06
breast B-Disease 1 0.6932376623153687
cancer I-Disease 0 0.0002650889800861478
- O 0 2.3938959202496335e-05
susceptibility O 0 2.7771400709752925e-05
genes O 0 1.6097179695861996e-06
, O 0 8.193582345938921e-08
BRCA1 O 0 2.4902312361518852e-05
and O 0 5.40411122074147e-07
BRCA2 O 0 0.00010170457971980795
, O 0 3.089972366865368e-08
in O 0 1.536020732828547e-08
French O 0 9.377512469654903e-06
Canadian O 0 7.59826143621467e-05
breast B-Disease 1 0.8359325528144836
cancer I-Disease 0 0.08211099356412888
and O 0 0.0012175586307421327
breast B-Disease 1 0.9999983310699463
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999998807907104
families O 0 9.197725603371509e-07
from O 0 2.5073003939724003e-07
Quebec O 0 1.9930634152842686e-05
. O 0 1.714917289064033e-06

To O 0 5.5234281717275735e-06
identify O 0 6.864390798000386e-06
founder O 0 2.504349140508566e-05
effects O 0 4.212094154354418e-06
, O 0 6.221850412657659e-08
we O 0 4.471654690973992e-08
examined O 0 3.128531886886776e-07
independently O 0 6.133960255283455e-07
ascertained O 0 6.7053533712169155e-06
French O 0 9.771658369572833e-06
Canadian O 0 8.962231731857173e-06
cancer B-Disease 0 1.595063804415986e-05
families O 0 1.1667568244888571e-08
for O 0 8.854962096904728e-09
the O 0 7.406801394438389e-09
distribution O 0 1.0664292204864978e-07
of O 0 6.225528093040111e-09
these O 0 1.2510312785707356e-08
eight O 0 6.265436240937561e-07
mutations O 0 2.5717732569319196e-05
. O 0 6.171430868562311e-07

Mutations O 0 0.0021392155904322863
were O 0 2.5548661142238416e-06
found O 0 1.8789292255405599e-07
in O 0 2.731815484935396e-08
41 O 0 9.654509369738662e-08
of O 0 6.797200136077208e-09
97 O 0 2.0075874829217355e-07
families O 0 1.6221545706684992e-07
. O 0 6.081653509681928e-07

Six O 0 3.107051497863722e-06
of O 0 8.650055605130547e-08
eight O 0 2.5473286768828984e-07
mutations O 0 3.780223778448999e-06
were O 0 9.512792331634046e-08
observed O 0 1.8950333924294682e-07
at O 0 1.34236088911166e-07
least O 0 8.89047058194592e-08
twice O 0 1.8572617364043253e-06
. O 0 8.958513717516325e-07

The O 0 3.3597855235711904e-06
BRCA1 O 0 0.0002011310716625303
C4446T O 0 2.093408693326637e-05
mutation O 0 2.9255295885377564e-05
was O 0 5.5472122539868e-07
the O 0 5.21243892492862e-09
most O 0 5.81668180288375e-09
common O 0 5.844765738061142e-08
mutation O 0 9.489873491475009e-07
found O 0 1.3145003663339594e-07
, O 0 8.998920719704984e-09
followed O 0 1.104511415661591e-08
by O 0 2.355402317633093e-09
the O 0 1.1712635483718259e-07
BRCA2 O 0 0.0002425450657028705
8765delAG O 0 2.54770911851665e-05
mutation O 0 1.2896765838377178e-05
. O 0 7.156492642934609e-07

Together O 0 5.686820713890484e-06
, O 0 2.0760971608524414e-07
these O 0 8.279448238113218e-09
mutations O 0 7.647651045772363e-07
were O 0 8.570831511178767e-08
found O 0 5.436294969740629e-08
in O 0 1.9113608473730892e-08
28 O 0 7.879962282686392e-08
of O 0 2.7572444327716994e-09
41 O 0 2.802152323511109e-07
families O 0 2.0073265716291644e-08
identified O 0 3.3424370826651284e-07
to O 0 2.3247896052680517e-08
have O 0 1.7999530754764237e-08
a O 0 3.9276520169551077e-07
mutation O 0 1.0858188943529967e-05
. O 0 6.86286568907235e-07

The O 0 2.3103452804207336e-06
odds O 0 7.126707259885734e-06
of O 0 1.577818053988267e-08
detection O 0 2.2538571897712245e-07
of O 0 4.499071781793873e-09
any O 0 6.389325513111999e-09
of O 0 3.084817956633401e-09
the O 0 2.3827228190498317e-08
four O 0 6.458013785959338e-07
BRCA1 O 0 0.0003452736127655953
mutations O 0 1.4261070646170992e-05
was O 0 5.627345558423258e-07
18 O 0 1.635970647839713e-07
. O 0 2.251966435551367e-07

7x O 0 0.0029510704334825277
greater O 0 5.6773487813188694e-06
if O 0 2.6930464969154855e-07
one O 0 1.9193247879911723e-08
or O 0 1.9475056234341537e-08
more O 0 9.556270441635206e-09
cases O 0 2.0960908386769006e-07
of O 0 8.31353390822187e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 7.134869406399957e-07
also O 0 1.1179707115616111e-07
present O 0 1.665570614761691e-08
in O 0 8.422544439667945e-09
the O 0 4.631428041079744e-08
family O 0 1.739917593113205e-06
. O 0 1.1822811529782484e-06

The O 0 2.1614971501549007e-06
odds O 0 5.0076955631084275e-06
of O 0 1.5717686707716894e-08
detection O 0 3.047648249321355e-07
of O 0 6.834771415498153e-09
any O 0 7.407140234505505e-09
of O 0 2.918981722999092e-09
the O 0 4.6571699385822285e-08
four O 0 1.1428808193159057e-06
BRCA2 O 0 0.0029760568868368864
mutations O 0 4.076526965945959e-05
was O 0 1.082596668311453e-06
5 O 0 4.3540867977753805e-07
. O 0 5.581455297942739e-07

3x O 0 0.006725963205099106
greater O 0 5.865481853106758e-06
if O 0 2.3151305583724024e-07
there O 0 1.9324605915471693e-08
were O 0 4.536930120480065e-08
at O 0 5.126298674440477e-08
least O 0 7.1133841039738854e-09
five O 0 1.7873428959092053e-08
cases O 0 2.341173654940576e-08
of O 0 1.445327342253222e-07
breast B-Disease 1 0.7510361075401306
cancer I-Disease 0 0.00020645653421524912
in O 0 2.665511722454994e-08
the O 0 1.4758087729660474e-07
family O 0 1.0771554116217885e-05
. O 0 2.1900962110521505e-06

Interestingly O 0 8.734709990676492e-05
, O 0 1.5993617807907867e-07
the O 0 7.55432782995058e-09
presence O 0 1.6229554589131112e-08
of O 0 7.962115411430659e-09
a O 0 1.927081757457927e-05
breast B-Disease 1 0.9458826184272766
cancer I-Disease 0 0.0002917305682785809
case O 0 3.194541591255984e-07
< O 0 2.756584365215531e-07
36 O 0 1.9593917954807694e-07
years O 0 2.2428569224075545e-08
of O 0 3.697082417986053e-09
age O 0 5.5227470596719286e-08
was O 0 4.546541561012418e-07
strongly O 0 4.874253534126183e-08
predictive O 0 9.607446571635592e-08
of O 0 2.346326910540597e-09
the O 0 3.942570714343674e-09
presence O 0 3.0774838233327273e-09
of O 0 9.89144766094796e-10
any O 0 1.885513523092186e-09
of O 0 1.755555589788571e-09
the O 0 2.61962096459456e-08
eight O 0 2.4941741116890626e-07
mutations O 0 7.432357506331755e-06
screened O 0 4.4228067963558715e-06
. O 0 6.318504688351823e-07

Carriers O 0 7.597096100653289e-06
of O 0 7.652977984662357e-08
the O 0 2.2479190064927934e-08
same O 0 3.3578587022020656e-08
mutation O 0 2.8183669087411545e-07
, O 0 6.324808676794191e-09
from O 0 2.1564603436274865e-09
different O 0 2.606973970031845e-09
families O 0 1.2153705597484077e-08
, O 0 7.573891736001315e-09
shared O 0 2.3225602774346044e-08
similar O 0 3.347422250499221e-08
haplotypes O 0 5.348846570996102e-06
, O 0 5.442976913627717e-08
indicating O 0 1.2606440691342868e-07
that O 0 4.30537738793646e-09
the O 0 5.2514672610470825e-09
mutant O 0 1.3113150032495469e-07
alleles O 0 1.4777944556954026e-07
were O 0 8.53824744240228e-08
likely O 0 5.998006713525683e-08
to O 0 1.098620039385878e-08
be O 0 1.1205448124940176e-08
identical O 0 9.312459781085636e-08
by O 0 1.0799672267580718e-08
descent O 0 1.0980282922901097e-06
for O 0 1.67806089024225e-08
a O 0 7.421511583061147e-08
mutation O 0 6.961871008570597e-07
in O 0 1.5145017684403683e-08
the O 0 2.1837086805476247e-08
founder O 0 1.7907055735122412e-05
population O 0 2.233712734778237e-07
. O 0 2.399561651600379e-07

The O 0 4.4515763875097036e-07
identification O 0 4.5951142624289787e-07
of O 0 3.177525798037095e-08
common O 0 5.87462352541479e-07
BRCA1 O 0 0.00030588210211135447
and O 0 2.824608827722841e-06
BRCA2 O 0 0.00027785554993897676
mutations O 0 5.761603460996412e-06
will O 0 2.1050970744340702e-08
facilitate O 0 3.2684887685263675e-08
carrier O 0 2.9014606184318836e-07
detection O 0 3.6925248991792614e-07
in O 0 4.617377058480088e-08
French O 0 6.670089987892425e-06
Canadian O 0 3.910566010745242e-05
breast B-Disease 0 0.28451550006866455
cancer I-Disease 0 0.015227984637022018
and O 0 0.0001650912599870935
breast B-Disease 1 0.9999977350234985
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 0.9999994039535522
families O 0 1.2369373507681303e-06
. O 0 9.395329243488959e-07

Are O 0 3.490952849460882e-06
Dp71 O 0 6.017673877067864e-05
and O 0 1.0650372814779985e-06
Dp140 O 0 3.0380997486645356e-05
brain O 0 0.00013413449050858617
dystrophin O 0 1.93825107999146e-05
isoforms O 0 4.64849608761142e-06
related O 0 9.27096834857366e-07
to O 0 6.225773745427432e-07
cognitive B-Disease 0 0.00016539769421797246
impairment I-Disease 0 0.03590122610330582
in O 0 3.1974432204151526e-05
Duchenne B-Disease 1 0.9999963045120239
muscular I-Disease 1 0.9998792409896851
dystrophy I-Disease 1 0.9999573230743408
? O 0 0.00042678945465013385

Molecular O 0 0.0002697691088542342
study O 0 4.594221081788419e-06
and O 0 4.942039595334791e-07
neuropsychological O 0 4.82569294035784e-06
analysis O 0 1.88732855121998e-07
were O 0 4.570917866431046e-08
performed O 0 5.3421612022930276e-08
concurrently O 0 3.233665069046765e-08
on O 0 3.8618287589997635e-07
49 O 0 3.9428773561667185e-06
patients O 0 3.5339451187610393e-07
with O 0 7.374262054327119e-07
Duchenne B-Disease 1 0.9999995231628418
muscular I-Disease 1 0.9999974966049194
dystrophy I-Disease 1 0.9999995231628418
( O 0 0.00011552154319360852
DMD B-Disease 1 1.0
) O 0 4.7158661686808045e-07
in O 0 2.829045975261124e-08
order O 0 1.212911193704258e-08
to O 0 3.200536369263318e-08
find O 0 4.765757211089294e-08
a O 0 4.5745466081825725e-08
molecular O 0 7.085735092005052e-07
explanation O 0 7.169821003571997e-08
for O 0 1.1529657228948054e-08
the O 0 2.0770319508756074e-07
cognitive B-Disease 0 3.363885480212048e-05
impairment I-Disease 0 2.7868900360772386e-05
observed O 0 7.148709642024187e-07
in O 0 1.0976883402236126e-07
most O 0 5.561792022490408e-06
DMD B-Disease 1 1.0
patients O 0 0.00030994758708402514
. O 0 1.5063435512274737e-06

Complete O 0 6.7138889789930545e-06
analysis O 0 2.63023565594267e-07
of O 0 8.385229399721084e-09
the O 0 3.6113032564344394e-08
dystrophin O 0 2.7832534215121996e-06
gene O 0 1.2371638149488717e-06
was O 0 2.5119388169514423e-07
performed O 0 1.3613430382974911e-07
to O 0 9.674119283431537e-09
define O 0 4.2533866206895254e-08
the O 0 9.485864538305577e-09
localization O 0 2.925659146058024e-07
of O 0 8.269300799668144e-09
deletions O 0 1.312456561208819e-06
and O 0 1.006062788633244e-07
duplications O 0 1.4707184163853526e-06
in O 0 2.274707355809369e-08
relation O 0 1.1864122484439577e-07
to O 0 1.1597925464457148e-07
the O 0 1.732078658278624e-07
different O 0 1.4900982705512433e-06
DMD B-Disease 1 0.9999986886978149
promoters O 0 0.0003478015714790672
. O 0 1.8843605857910006e-06

Qualitative O 0 6.094796844990924e-05
analysis O 0 9.229225952367415e-07
of O 0 1.248059255942735e-08
the O 0 4.1161591468608094e-08
Dp71 O 0 1.3877070159651339e-05
transcript O 0 2.313466575287748e-05
and O 0 5.9280381492499146e-08
testing O 0 1.4821438298895373e-08
for O 0 1.0952531104280183e-09
the O 0 2.116231190285589e-09
specific O 0 3.2779332581611698e-09
first O 0 3.069893494966891e-08
exon O 0 4.561233595268277e-07
of O 0 6.650034745092626e-09
Dp140 O 0 5.133196623319236e-07
were O 0 5.377984280130477e-08
also O 0 4.4473623006524576e-08
carried O 0 1.06413729383803e-07
out O 0 1.83940599640664e-07
. O 0 4.038171255160705e-07

Neuropsychological O 0 0.004146251827478409
analysis O 0 1.652300670684781e-05
assessed O 0 1.3749056051892694e-05
verbal O 0 5.290954959491501e-06
and O 0 1.4219784816305037e-06
visuospatial O 0 0.0002237608568975702
intelligence O 0 6.1118216763134114e-06
, O 0 2.1210173883901007e-07
verbal O 0 5.330547878656944e-07
memory O 0 1.911420258693397e-05
, O 0 1.9731518818844052e-07
and O 0 1.0689707607980381e-07
reading O 0 1.188698206533445e-06
skills O 0 6.343046834444976e-07
. O 0 6.452829666159232e-07

Comparison O 0 3.922182713722577e-06
of O 0 1.0256277249709456e-07
molecular O 0 1.690680619503837e-06
and O 0 4.3609023236967914e-07
psychometric O 0 1.6656233128742315e-05
findings O 0 2.4198450319090625e-06
demonstrated O 0 2.1823851170665876e-07
that O 0 1.2657780601443847e-08
deletions O 0 4.4319679659565736e-07
and O 0 1.0649880266555556e-07
duplications O 0 1.6537275087102898e-06
that O 0 3.843215523602339e-08
were O 0 2.001072552104688e-08
localized O 0 1.500894626360605e-07
in O 0 1.495390478112313e-08
the O 0 2.545196053915788e-08
distal O 0 1.608734964975156e-05
part O 0 1.5753830950870906e-07
of O 0 6.257659279640393e-09
the O 0 2.1270857075705862e-08
gene O 0 4.061185165937786e-07
seemed O 0 8.585081445744436e-08
to O 0 1.0687257301356112e-08
be O 0 1.3719412272905629e-08
preferentially O 0 2.5228621325368294e-07
associated O 0 1.6548240466818243e-07
with O 0 2.2745561523151991e-07
cognitive B-Disease 0 0.00021863881556782871
impairment I-Disease 0 0.0006085446220822632
. O 0 3.001297045557294e-06

Two O 0 2.3860191049607238e-06
altered O 0 2.3403166778734885e-05
Dp71 O 0 5.7822224334813654e-05
transcripts O 0 3.7818538203282515e-06
and O 0 2.7038128180834065e-08
two O 0 1.0649246817706626e-08
deleted O 0 3.179448242462968e-07
Dp140 O 0 1.4937606351850263e-07
DNA O 0 2.0636925057715416e-07
sequences O 0 2.4783581409337785e-08
were O 0 1.4575185502962995e-08
found O 0 2.084528105683603e-08
in O 0 5.126520985498928e-09
four O 0 1.5440051015502831e-07
patients O 0 1.3697326721739955e-06
with O 0 6.372368375195947e-07
severe O 0 0.16049782931804657
cerebral B-Disease 1 0.7973049283027649
dysfunction I-Disease 0 0.026790384203195572
. O 0 3.9744195419189055e-06

These O 0 3.183567059750203e-06
findings O 0 2.6621360120770987e-06
suggest O 0 1.7465396240368136e-07
that O 0 3.2938396454795793e-09
some O 0 9.218611429773205e-10
sequences O 0 4.093913208436106e-09
located O 0 1.5814064724395394e-08
in O 0 7.385668521209254e-09
the O 0 1.4639937262472813e-08
distal O 0 2.6209961561107775e-06
part O 0 6.635327309822969e-08
of O 0 2.4392818875895728e-09
the O 0 1.4008374016327707e-08
gene O 0 2.075079663654833e-07
and O 0 6.797630192068027e-08
, O 0 8.543179497166875e-09
in O 0 2.557204004105529e-09
particular O 0 2.2263833443503245e-08
, O 0 3.874998455444256e-08
some O 0 2.4319897207192298e-08
DMD B-Disease 1 0.9997559189796448
isoforms O 0 2.902024789364077e-07
expressed O 0 2.2597838267301995e-08
in O 0 1.1225984586360482e-08
the O 0 1.534618689902345e-07
brain O 0 0.0020860873628407717
may O 0 3.854348506138194e-06
be O 0 2.0374834264202946e-08
related O 0 2.1470956568236943e-08
to O 0 5.5355602768258905e-08
the O 0 4.641186421849852e-07
cognitive B-Disease 0 5.7655390264699236e-05
impairment I-Disease 0 5.7923272834159434e-05
associated O 0 4.507010373799858e-07
with O 0 1.4124216249911115e-06
DMD B-Disease 1 1.0
. O 0 1.9388976397749502e-06
. O 0 1.3396667100096238e-06

I1307K O 0 0.00040661400998942554
APC O 0 0.00020911682804580778
and O 0 4.6730531266803155e-07
hMLH1 O 0 2.9875379823351977e-06
mutations O 0 2.58369527728064e-06
in O 0 1.9357473846071116e-08
a O 0 6.769501936787492e-08
non O 0 5.906447313464014e-07
- O 0 7.391614872176433e-06
Jewish O 0 3.1139900329435477e-06
family O 0 9.615106364435633e-07
with O 0 3.0272724416136043e-07
hereditary B-Disease 1 0.9413602352142334
non I-Disease 0 0.4380883574485779
- I-Disease 1 0.9999995231628418
polyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.6310154023813084e-05

We O 0 2.1714372451242525e-06
describe O 0 1.2793553878509556e-06
a O 0 1.652578305311181e-07
French O 0 1.1013265975634567e-05
Canadian O 0 7.497610567952506e-06
hereditary B-Disease 0 0.28258785605430603
non I-Disease 0 0.17948350310325623
- I-Disease 1 0.9999997615814209
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 0.0004662639112211764
HNPCC B-Disease 1 0.9589974880218506
) O 0 2.363446583331097e-06
kindred O 0 3.9794325857656077e-05
which O 0 2.6657028229237767e-07
carries O 0 4.128079353904468e-07
a O 0 1.387033989885822e-07
novel O 0 8.338595876011823e-07
truncating O 0 2.143533856724389e-05
mutation O 0 1.1890805581060704e-05
in O 0 2.986857907671947e-07
hMLH1 O 0 5.3599171224050224e-05
. O 0 2.832528934959555e-06

Interestingly O 0 7.061691576382145e-05
, O 0 4.2999880633942666e-07
the O 0 3.7978537648086785e-08
I1307K O 0 1.2927977195431595e-06
APC O 0 2.0621712337742792e-06
polymorphism O 0 1.4954823654989013e-06
, O 0 3.7663873797555425e-08
associated O 0 2.9473588014639063e-08
with O 0 2.72334466089319e-09
an O 0 5.1508894927110305e-08
increased O 0 2.769252660073107e-06
risk O 0 4.0726099541643634e-05
of O 0 0.013326890766620636
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 8.463773042421963e-07
is O 0 5.7444903944769976e-08
also O 0 1.8289563286089106e-07
present O 0 1.390917159227456e-08
in O 0 1.621928014117202e-08
this O 0 3.476329979434922e-08
family O 0 1.594661625858862e-06
. O 0 9.53120547819708e-07

The O 0 1.3127619240549393e-06
I1307K O 0 6.656808182015084e-06
polymorphism O 0 1.1178144632140175e-05
has O 0 3.2548405215493403e-07
previously O 0 2.511732759558072e-07
only O 0 1.645149083628894e-08
been O 0 5.064633512574801e-08
identified O 0 1.4214236898624222e-07
in O 0 8.511348958961662e-09
individuals O 0 1.4002169423932287e-09
of O 0 4.977967371644354e-09
self O 0 8.357022124982905e-06
- O 0 0.010985326953232288
reported O 0 0.00580998370423913
Ashkenazi O 0 6.658908387180418e-05
Jewish O 0 1.6128972220030846e-06
origins O 0 7.18324690751615e-06
. O 0 1.4676024875370786e-06

In O 0 1.2954610610904638e-06
addition O 0 1.0747789502829619e-07
, O 0 6.059895696353124e-08
in O 0 1.9025151232199278e-08
this O 0 2.4332702963647534e-08
family O 0 4.0166241888073273e-07
, O 0 1.0442897746543167e-07
there O 0 1.537193128342551e-08
appears O 0 1.6712405681573728e-07
to O 0 3.27372369213208e-08
be O 0 1.497608437261988e-08
no O 0 7.794083600742852e-09
relationship O 0 1.2585894992866997e-08
between O 0 6.147508724296813e-09
the O 0 1.6136091574026068e-08
I1307K O 0 3.929225727006269e-07
polymorphism O 0 3.767878808957903e-07
and O 0 3.0773971815278856e-08
the O 0 8.701381837283861e-09
presence O 0 2.219629102739873e-08
or O 0 7.228480569665408e-08
absence O 0 3.802949422038182e-08
of O 0 4.198255965093267e-08
cancer B-Disease 0 1.4547305909218267e-05
. O 0 6.197085866688212e-08
. O 0 5.770768893853528e-07

Identification O 0 4.509212431003107e-06
of O 0 9.13990376716356e-08
a O 0 1.6600623098383949e-07
novel O 0 4.390680885535403e-07
mutation O 0 1.07440655483515e-06
of O 0 1.4507843815181332e-08
the O 0 1.08646965202297e-07
CPO O 0 6.30375652690418e-05
gene O 0 1.5401609232412738e-07
in O 0 2.2963062562553205e-09
a O 0 7.024375037190111e-08
Japanese O 0 1.7930233298102394e-06
hereditary B-Disease 0 0.0004353391705080867
coproporphyria I-Disease 0 0.00021999426826369017
family O 0 8.856822205416393e-06
. O 0 1.4867384834360564e-06

Hereditary B-Disease 1 0.9999094009399414
coproporphyria I-Disease 1 0.9797734618186951
( O 0 0.0001359108428005129
HCP B-Disease 0 0.022208495065569878
) O 0 3.858309582938091e-07
is O 0 2.6997314606092004e-08
an O 0 2.0367652098229883e-07
autosomal B-Disease 1 0.9934844374656677
dominant I-Disease 1 0.9210264086723328
disease I-Disease 1 0.7924180030822754
characterized O 0 2.797965180434403e-06
by O 0 1.0531207550457111e-07
a O 0 2.2759088096790947e-05
deficiency B-Disease 0 0.003548423293977976
of I-Disease 0 5.097107802498613e-08
coproporphyrinogen I-Disease 0 0.0008822536328807473
oxidase I-Disease 0 4.4498527131509036e-05
( O 0 1.2231224673087127e-06
CPO O 0 0.0006392538780346513
) O 0 3.1465802408092713e-08
caused O 0 4.6858342983568946e-08
by O 0 1.6847563344413174e-09
a O 0 8.39046450096248e-08
mutation O 0 9.342167572867766e-07
in O 0 3.29649338937088e-08
the O 0 1.9450895649697486e-07
CPO O 0 0.0005921699339523911
gene O 0 3.7855411392229144e-06
. O 0 4.862358764512464e-07

Only O 0 1.638145249671652e-06
11 O 0 8.424329394074448e-07
mutations O 0 8.680968903718167e-07
of O 0 7.927203782287506e-09
the O 0 2.593109371673563e-08
gene O 0 2.0138841136940755e-06
have O 0 1.8144567093258956e-07
been O 0 4.066583585426997e-07
reported O 0 1.0934096280834638e-05
in O 0 6.47857916646899e-07
HCP B-Disease 0 0.3165924847126007
patients O 0 2.41241814364912e-05
. O 0 5.719300588680198e-07

We O 0 1.6674208382028155e-05
report O 0 5.495384129972081e-07
another O 0 3.4029785211942e-08
mutation O 0 1.9229932490816282e-07
in O 0 8.33725710691624e-09
a O 0 6.268999186431756e-08
Japanese O 0 1.367370373372978e-06
family O 0 1.4079848824621877e-06
. O 0 1.1597277307373588e-06

Polymerase O 0 0.00021619291510432959
chain O 0 7.313820242416114e-05
reaction O 0 1.6682340628904058e-06
- O 0 1.9992125999124255e-06
single O 0 5.097156758893107e-07
strand O 0 2.8521095373434946e-05
conformational O 0 4.2736107275231916e-07
polymorphism O 0 4.865299843004323e-07
and O 0 2.1139166861416925e-08
direct O 0 4.3055681686610114e-08
sequence O 0 1.6065527574937732e-07
analyses O 0 2.3754812161769223e-07
demonstrated O 0 5.10567019773589e-08
a O 0 5.173190587015597e-08
C O 0 7.582638659187069e-07
to O 0 2.9533858025843074e-08
T O 0 1.962497663043905e-06
substitution O 0 9.480184637311595e-09
in O 0 2.6881896708630393e-09
exon O 0 1.3239437635093054e-07
1 O 0 1.2680204442006016e-08
of O 0 9.658331912021367e-10
the O 0 1.5285971599610093e-08
CPO O 0 6.0649072111118585e-06
gene O 0 3.1424601587559664e-08
at O 0 1.3183566238694766e-08
nucleotide O 0 8.659167605173934e-08
position O 0 2.8003972829537815e-07
85 O 0 4.157139699145773e-08
, O 0 1.9980520349349717e-08
which O 0 2.9709173787750842e-08
lies O 0 2.7098337795905536e-07
in O 0 1.59319260006896e-08
the O 0 1.755050860197116e-08
putative O 0 1.2060088465659646e-06
presequence O 0 2.2438939595303964e-06
for O 0 1.1889568440892617e-08
targeting O 0 4.197599423605425e-07
to O 0 1.7046043865320826e-07
mitochondria O 0 7.260929578478681e-06
. O 0 1.2355756098259008e-06

This O 0 9.546179171593394e-07
mutation O 0 3.252548822274548e-06
changes O 0 1.0669175054545121e-07
the O 0 1.1129533739051567e-08
codon O 0 2.8163813681203465e-07
for O 0 6.388765072529168e-09
glutamine O 0 1.0604719591356115e-07
to O 0 9.48736644801329e-09
a O 0 3.3979326019561995e-08
termination O 0 3.334588996040111e-07
codon O 0 3.517818356613134e-07
at O 0 7.271015078913479e-08
amino O 0 1.799013205072697e-07
acid O 0 1.2932243862451287e-06
position O 0 6.376344003911072e-07
29 O 0 1.1622378224274144e-06
. O 0 4.109135431917821e-07

MaeI O 0 0.00023211889492813498
restriction O 0 3.553618171281414e-06
analysis O 0 1.2918338825329556e-06
showed O 0 4.906063963971974e-07
two O 0 4.319788526885304e-09
other O 0 3.216580779508149e-09
carriers O 0 2.656913267173877e-08
in O 0 1.0883295153973904e-08
the O 0 2.7492427889797e-08
family O 0 1.7138055454779533e-06
. O 0 1.4892133322064183e-06

The O 0 2.191161911468953e-06
C O 0 0.0002631028473842889
- O 0 0.0029390344861894846
T O 0 0.00576643506065011
mutation O 0 1.8016401099885115e-06
is O 0 6.615017866806738e-09
located O 0 1.5235848138672736e-08
within O 0 2.117919173372229e-09
a O 0 7.730173479103541e-08
recently O 0 5.551801223191433e-07
proposed O 0 6.924393858298572e-08
putative O 0 2.9725390504609095e-07
alternative O 0 5.574264605456847e-08
translation O 0 1.6271033587145212e-07
initiation O 0 7.234922350107809e-08
codon O 0 1.529039650449704e-06
( O 0 7.741741825384452e-08
TIC O 0 8.66876871441491e-06
- O 0 1.9912570223823423e-06
1 O 0 4.372137141217536e-07
) O 0 1.1431993129917828e-08
, O 0 4.704332923211041e-09
supporting O 0 6.275300723501687e-09
that O 0 2.1168782282643406e-08
TIC O 0 6.063924047339242e-06
- O 0 1.1087180382673978e-06
1 O 0 2.396063223386591e-07
is O 0 1.525731008200637e-08
the O 0 4.490653182642745e-09
real O 0 3.3866652415781573e-07
TIC O 0 5.238087851466844e-06
rather O 0 2.3294724371680786e-08
than O 0 2.4081808547293804e-08
TIC O 0 3.7609568153129658e-06
- O 0 8.12778637282463e-07
2 O 0 2.874233757665934e-07
. O 0 4.855509772028199e-08
. O 0 1.677581593639843e-07

Human B-Disease 0 1.3266982932691462e-05
complement I-Disease 0 1.3970644431537949e-05
factor I-Disease 0 0.00014131469652056694
H I-Disease 1 1.0
deficiency I-Disease 1 0.9971219897270203
associated O 0 2.309505180164706e-05
with O 0 8.199716830858961e-05
hemolytic B-Disease 1 0.9999995231628418
uremic I-Disease 1 1.0
syndrome I-Disease 1 0.9999998807907104
. O 0 6.34751413599588e-05

This O 0 1.3182393558963668e-06
study O 0 4.038856502575072e-07
reports O 0 2.871458377740055e-07
on O 0 1.2377580560496426e-07
six O 0 9.231746389559703e-08
cases O 0 8.832565612237886e-08
of O 0 1.1333063554275213e-07
deficiency B-Disease 0 9.250189032172784e-05
in I-Disease 0 1.98392910988332e-08
the I-Disease 0 1.3274655152883952e-08
human I-Disease 0 1.4936714975988252e-08
complement I-Disease 0 4.578282286615831e-08
regulatory I-Disease 0 1.0246207438058264e-07
protein I-Disease 0 3.559930519259069e-07
Factor I-Disease 0 2.917442429861694e-07
H I-Disease 1 0.9999998807907104
( O 0 1.5057792097650236e-06
FH O 0 9.418576519237831e-05
) O 0 5.4719220266008506e-09
in O 0 1.5977503764474932e-09
the O 0 3.346910082413501e-09
context O 0 2.4749757798758765e-08
of O 0 3.076376131616598e-08
an O 0 8.590982906753197e-05
acute B-Disease 1 0.9992913007736206
renal I-Disease 1 1.0
disease I-Disease 1 0.9999998807907104
. O 0 7.082896900101332e-06

Five O 0 1.4651104720542207e-06
of O 0 5.4153694861724944e-08
the O 0 3.285283156628793e-08
cases O 0 6.82180214539585e-08
were O 0 7.284132408358346e-08
observed O 0 2.0179413695586845e-07
in O 0 4.2311430803465555e-08
children O 0 1.4664732361779897e-07
presenting O 0 1.5399757558043348e-06
with O 0 3.9285598177229986e-05
idiopathic O 1 0.9999996423721313
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.0017191587248817086
HUS B-Disease 1 0.9999986886978149
) O 0 1.1366241778887343e-05
. O 0 2.6209711450064788e-06

Two O 0 6.870913580314664e-07
of O 0 2.8819677311275882e-08
the O 0 5.1949434975995246e-08
children O 0 2.9172949211897503e-07
exhibited O 0 1.3095472013446852e-06
a O 0 6.1077198552084155e-06
homozygous O 0 0.054694317281246185
deficiency O 0 0.012288656085729599
characterized O 0 6.896701165715058e-07
by O 0 1.7697844967301535e-08
the O 0 3.340228360571018e-08
absence O 0 2.238540375287812e-08
of O 0 1.2486182088267128e-09
the O 0 8.137417850662132e-09
150 O 0 1.7172128607967352e-08
- O 0 6.787640813854523e-07
kD O 0 4.4010064925714687e-07
form O 0 1.3704294588023913e-08
of O 0 2.9897542219714524e-09
Factor O 0 6.868123847425522e-08
H O 1 0.9999978542327881
and O 0 2.222364088311224e-07
the O 0 8.780573601541164e-09
presence O 0 1.0255550186855089e-08
, O 0 5.226785226852826e-09
upon O 0 1.720247611025627e-09
immunoblotting O 0 1.8410364077681152e-07
, O 0 1.859052245478665e-09
of O 0 4.092310657011211e-10
the O 0 3.6455864993456544e-09
42 O 0 5.3840089719869866e-08
- O 0 2.982810087814869e-07
kD O 0 1.2456856666176463e-06
Factor O 0 6.338300551078646e-08
H O 1 0.9973032474517822
- O 0 1.3901303645980079e-06
like O 0 1.4709351070507637e-08
protein O 0 6.704392774281587e-08
1 O 0 9.540175227584768e-08
( O 0 1.8030318571504722e-08
FHL O 0 9.800213547350722e-07
- O 0 1.7349830159218982e-06
1 O 0 1.456046589964899e-07
) O 0 2.88224644151569e-09
and O 0 7.941367563546464e-09
other O 0 2.8456549117095165e-08
FH O 0 0.0004594892088789493
- O 0 1.0034495062427595e-05
related O 0 6.628761752835999e-07
protein O 0 9.525653581476945e-07
( O 0 4.439234757569466e-08
FHR O 0 1.2325614989094902e-05
) O 0 4.606530978890078e-08
bands O 0 6.248960744414944e-07
. O 0 4.69297617655684e-07

Southern O 0 5.697051892639138e-05
blot O 0 0.0014037578366696835
and O 0 4.505248512032267e-07
PCR O 0 1.1578733847272815e-06
analysis O 0 4.865837510692472e-08
of O 0 3.2971712027318745e-09
DNA O 0 2.1204066058544413e-07
of O 0 5.120921020562719e-09
one O 0 1.9684493679505977e-07
patient O 0 8.661882020533085e-07
with O 0 2.05387564733428e-07
homozygous O 0 0.007454886566847563
deficiency O 0 0.00631481921300292
ruled O 0 4.1926307403628016e-07
out O 0 2.6950599973929457e-08
the O 0 6.941039298880014e-09
presence O 0 7.234228771579865e-09
of O 0 6.535453844769279e-10
a O 0 1.5118896357080303e-08
large O 0 2.8614060454401624e-08
deletion O 0 6.647874215559568e-07
of O 0 3.8745682218177535e-09
the O 0 4.021621791139296e-08
FH O 0 7.483880472136661e-05
gene O 0 2.2665098242669046e-07
as O 0 6.922014517130037e-09
the O 0 1.7518233974556097e-08
underlying O 0 8.351348697033245e-06
defect O 0 1.2559940842038486e-05
for O 0 7.033719384708093e-08
the O 0 2.9746422569587594e-06
deficiency O 0 0.0015032864175736904
. O 0 1.2075279300916009e-06

The O 0 3.0022189889677975e-07
other O 0 2.147505107075176e-08
four O 0 2.429782597346275e-08
children O 0 4.9254580858359986e-08
presented O 0 9.029355396705796e-08
with O 0 2.444530764478259e-07
heterozygous O 0 0.00020439986838027835
deficiency O 0 0.00571821304038167
and O 0 1.2607259236574464e-07
exhibited O 0 6.514793540191022e-07
a O 0 6.116096784580805e-08
normal O 0 6.50946503810701e-07
immunoblotting O 0 5.654196229443187e-06
pattern O 0 5.846772523909749e-07
of O 0 4.357523675224684e-09
proteins O 0 1.9088687963630946e-08
of O 0 7.3346533291385185e-09
the O 0 5.791515604869346e-07
FH O 0 0.04350346326828003
family O 0 7.359511982940603e-06
. O 0 1.247592535946751e-06

Factor B-Disease 0 0.00225865188986063
H I-Disease 1 1.0
deficiency I-Disease 1 0.9868605732917786
is O 0 8.409963214717209e-08
the O 0 1.9286311214727903e-08
only O 0 4.7180930096146767e-07
complement B-Disease 1 0.9999210834503174
deficiency I-Disease 1 0.9999996423721313
associated O 0 1.7159348999484791e-06
with O 0 8.827173587633297e-07
HUS B-Disease 1 0.9999767541885376
. O 0 1.3206087714934256e-05

These O 0 1.3296088354763924e-06
observations O 0 4.7114299377426505e-06
suggest O 0 2.7129391355629195e-07
a O 0 7.220074849101366e-08
role O 0 1.8622405661972152e-07
for O 0 2.917576011896017e-07
FH O 0 0.007862834259867668
and O 0 4.994255505152978e-06
/ O 0 0.00010619134263833985
or O 0 1.4322880588224507e-06
FH O 0 0.0001434903679182753
receptors O 0 1.649776919521173e-07
in O 0 7.739583196553212e-09
the O 0 7.376421962135282e-08
pathogenesis O 0 6.230272265383974e-05
of O 0 2.867312787202536e-07
idiopathic O 1 0.7776498794555664
HUS B-Disease 1 0.9999805688858032
. O 0 2.1666360225935932e-06
. O 0 1.2234595487825572e-06

Further O 0 2.6429008812556276e-06
evidence O 0 1.9013005214674195e-07
for O 0 6.02297323126777e-09
a O 0 3.1051797577674733e-08
major O 0 9.191703753685943e-08
ancient O 0 6.999158017606533e-07
mutation O 0 0.010320153087377548
underlying O 1 0.5391947627067566
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 7.517070571338991e-06
linkage O 0 0.00017114328511524945
disequilibrium O 0 0.0004126454587094486
studies O 0 3.1020633173284295e-07
in O 0 7.400276835767272e-09
the O 0 2.831756162890997e-08
Japanese O 0 1.339832806479535e-06
population O 0 4.986151793673343e-07
. O 0 1.001089458441129e-06

The O 0 0.010685396380722523
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9810264706611633
DM B-Disease 1 1.0
) O 0 1.1862987776112277e-05
mutation O 0 1.0983865649905056e-05
is O 0 1.249920273949101e-07
an O 0 2.687735332074226e-07
unstable O 0 0.02537958323955536
( O 0 8.516759066878876e-07
CTG O 0 3.2511557947145775e-05
) O 0 5.124568147607533e-08
n O 0 2.2082797386246966e-06
repeat O 0 2.2862789137434447e-06
, O 0 1.423820439327983e-08
present O 0 5.905216760027088e-09
at O 0 1.9735992395908397e-08
a O 0 8.475111279437897e-09
copy O 0 3.869456293159601e-07
number O 0 4.731084857212409e-09
of O 0 1.043657604782311e-09
5 O 0 2.184092409152072e-07
- O 0 3.708844360517105e-06
37 O 0 6.400037477760634e-07
repeats O 0 7.543258675468678e-07
on O 0 2.3669015547511663e-07
normal O 0 9.908411868764233e-08
chromosomes O 0 1.1134740418583533e-07
but O 0 1.2733378795815042e-08
amplified O 0 1.355311667339265e-07
to O 0 9.287498770049751e-09
50 O 0 9.644383069939977e-09
- O 0 3.198178148977604e-07
3000 O 0 2.0211616913456965e-07
copies O 0 1.8374913679508609e-06
on O 0 4.147014988120645e-05
DM B-Disease 1 0.9999995231628418
chromosomes O 0 5.543186125578359e-05
. O 0 1.3260606692711008e-06

Previous O 0 2.9489327062037773e-05
findings O 0 5.342361873772461e-06
in O 0 1.1564371504846349e-07
Caucasian O 0 1.3237876373750623e-05
populations O 0 3.124807506083016e-07
of O 0 3.183239982718078e-08
a O 0 1.8147167793358676e-05
DM B-Disease 1 1.0
founder O 0 0.0005299485055729747
chromosome O 0 5.237549703451805e-05
raise O 0 1.7448448375034786e-07
a O 0 1.1708836922252885e-07
question O 0 3.227158273944042e-08
about O 0 1.067295762879894e-08
the O 0 9.594771199772367e-09
molecular O 0 4.5484497945835756e-07
events O 0 3.4424548545075595e-08
involved O 0 1.978834696103604e-08
in O 0 7.896900910964177e-09
the O 0 1.1304108760157305e-08
expansion O 0 7.523723866142973e-07
mutation O 0 7.925647878437303e-06
. O 0 3.9260157791431993e-07

To O 0 5.533197509066667e-06
investigate O 0 3.190542656739126e-06
whether O 0 2.026519609898969e-07
a O 0 9.828248437315779e-08
founder O 0 7.3668361437739804e-06
chromosome O 0 3.1608680728822947e-05
for O 0 1.1962660551034787e-07
the O 0 1.2677419363171794e-06
DM B-Disease 1 1.0
mutation O 0 8.967489520728122e-06
exists O 0 9.973443404476257e-09
in O 0 1.9913701798657257e-09
the O 0 2.332788184844503e-09
Japanese O 0 1.1681733980140052e-07
population O 0 9.945557266632932e-09
, O 0 6.740715541297959e-09
we O 0 6.650529016383189e-09
genotyped O 0 2.5433672590224887e-07
families O 0 3.534320169862326e-09
using O 0 3.669936887717995e-08
polymorphic O 0 2.1031321466580266e-06
markers O 0 8.076780432020314e-06
near O 0 7.886554158176295e-06
the O 0 2.744900200468692e-07
( O 0 3.058316053738963e-07
CTG O 0 3.168158946209587e-05
) O 0 5.835687133526335e-08
n O 0 4.030805484944722e-06
repeat O 0 3.5549333006201778e-06
region O 0 1.0364135505369632e-06
and O 0 1.0268472294683306e-07
constructed O 0 7.798853403073736e-06
haplotypes O 0 0.0001321162999374792
. O 0 1.511415916866099e-06

Six O 0 2.5293500129919266e-06
different O 0 1.9848646104492218e-07
haplotypes O 0 1.785363201634027e-05
were O 0 6.951594286874752e-07
found O 0 1.4153935126159922e-06
and O 0 9.46706404647557e-06
DM B-Disease 1 1.0
alleles O 0 7.517106496379711e-06
were O 0 2.2807991229001345e-07
always O 0 1.9060642841850495e-07
haplotype O 0 2.0811885406146757e-05
A O 0 4.737950348498998e-06
. O 0 1.975787199626211e-06

To O 0 4.090562015335308e-06
find O 0 4.3233066548964416e-07
an O 0 3.9703127896473234e-08
origin O 0 3.9333340140501605e-08
of O 0 9.249932375610115e-09
the O 0 1.6703164362752432e-07
( O 0 2.60116706840563e-07
CTG O 0 1.5639372577425092e-05
) O 0 2.6143148090795876e-08
n O 0 1.3003094636587775e-06
repeat O 0 1.425412051503372e-06
mutation O 0 4.904464390165231e-07
and O 0 3.963533501405436e-08
to O 0 2.09406838536097e-08
investigate O 0 4.3655539627707185e-08
the O 0 2.7648647815681215e-09
mechanism O 0 4.096912142870224e-09
of O 0 6.48249176560256e-10
the O 0 2.8405398033726215e-09
expansion O 0 5.234370092921381e-08
mutation O 0 1.4007630966261786e-07
in O 0 1.797437532147228e-09
the O 0 2.306419721875841e-09
Japanese O 0 5.078882736597734e-08
population O 0 6.110905559353341e-09
we O 0 2.4127679854046846e-09
have O 0 1.2977334762354076e-09
studied O 0 1.2279532057846154e-08
90 O 0 1.9341568346931126e-08
Japanese O 0 7.4117713211308e-07
DM B-Disease 1 0.9999992847442627
families O 0 3.9371400362142595e-08
comprising O 0 6.469056845759269e-09
190 O 0 2.398298271089061e-08
affected O 0 5.559028082302575e-08
and O 0 3.5013837162978234e-08
130 O 0 1.065209502826292e-07
unaffected O 0 8.714779369256576e-07
members O 0 6.609786140643337e-08
. O 0 2.2366673135820747e-07

The O 0 4.954609721607994e-06
results O 0 7.1477129495178815e-06
suggest O 0 1.0592044930035627e-07
that O 0 2.49158071952138e-09
a O 0 5.988824991476349e-09
few O 0 3.655376001887589e-09
common O 0 1.0544670026035874e-08
ancestral O 0 5.55617589270696e-07
mutations O 0 5.663007868861314e-06
in O 0 1.4755913824160416e-08
both O 0 2.3149709704739507e-08
Caucasian O 0 4.9110631152871065e-06
and O 0 1.0341313583239753e-07
Japanese O 0 1.2221775591569894e-07
populations O 0 2.45153177758084e-08
have O 0 2.252158015636496e-09
originated O 0 5.630531596523269e-09
by O 0 1.0411405071408808e-09
expansion O 0 8.64170690562105e-09
of O 0 1.4375372003883058e-09
an O 0 1.334843791056528e-08
ancestral O 0 6.617770509365073e-07
n O 0 1.222798164235428e-05
= O 0 7.048329848657886e-07
5 O 0 6.002882457778469e-08
repeat O 0 6.512780714729161e-07
to O 0 3.205827070473788e-08
n O 0 8.164665246113145e-07
= O 0 8.29568421067961e-07
19 O 0 1.7616653735785803e-07
- O 0 1.0180980325458222e-06
37 O 0 2.2897017970535671e-07
copies O 0 1.7613892850931734e-06
. O 0 6.058352823856694e-07

These O 0 7.530061907345953e-07
data O 0 4.0276944446304697e-07
support O 0 2.4834781342519818e-08
multistep O 0 4.487085334403673e-07
models O 0 3.3484386108284525e-07
of O 0 2.1898483026916438e-08
triplet O 0 9.671118459664285e-05
repeat O 0 9.35055322770495e-06
expansion O 0 1.764893937661327e-07
that O 0 2.8928390349847177e-08
have O 0 9.482409524252944e-09
been O 0 6.982534550559194e-09
proposed O 0 1.6076862507929945e-08
for O 0 3.8222857767777896e-08
both O 0 1.8177853462475468e-06
DM B-Disease 1 1.0
and O 0 2.8465388822951354e-05
Friedreichs B-Disease 0 0.011195098049938679
ataxia I-Disease 1 0.7853809595108032
. O 0 3.7339816572057316e-07
. O 0 6.798109666306118e-07

The O 0 9.620206355975824e-07
molecular O 0 4.75079150419333e-06
basis O 0 1.5132505950532504e-06
of O 0 8.15210569271585e-06
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 4.3589727738435613e-07
the O 0 2.953526490045988e-08
western O 0 4.869403369411884e-07
Cape O 0 1.9692145087901736e-06
, O 0 3.406056237054145e-08
South O 0 7.066665119737081e-08
Africa O 0 1.548682746488339e-07
. O 0 3.048750158995972e-07

Deficiency B-Disease 1 0.9953567385673523
of I-Disease 0 2.1283909745761775e-07
the I-Disease 0 6.194544965865134e-08
sixth I-Disease 0 1.4136829804556328e-06
component I-Disease 0 1.9250043692409236e-07
of I-Disease 0 1.0023944341241986e-08
human I-Disease 0 6.758303783271913e-08
complement I-Disease 0 2.5331087272206787e-07
( O 0 1.2563283746658271e-07
C6 O 0 0.0002698596799746156
) O 0 2.1376811787376937e-07
has O 0 9.752340446311791e-08
been O 0 1.7124611417784763e-07
reported O 0 1.7737791040417505e-06
in O 0 3.1852427362366598e-09
a O 0 1.0538095729373254e-08
number O 0 6.449037748268438e-09
of O 0 1.9975785470194296e-09
families O 0 8.296616726966022e-09
from O 0 7.769400234280965e-09
the O 0 1.2006429628286241e-08
western O 0 1.5186995483418286e-07
Cape O 0 6.342085043797852e-07
, O 0 2.1011659967484775e-08
South O 0 4.654319241126359e-08
Africa O 0 2.1799304761316307e-07
. O 0 2.6945619424623146e-07

Meningococcal B-Disease 1 0.9990149736404419
disease I-Disease 1 0.9953827261924744
is O 0 1.8184302916779416e-06
endemic O 0 2.1956864202365978e-06
in O 0 1.705794687723028e-07
the O 0 1.2441594776646525e-07
Cape O 0 3.0178057386365253e-06
and O 0 6.577590738743311e-08
almost O 0 1.429033247291045e-08
all O 0 2.0014381263422365e-09
pedigrees O 0 1.9126632366806007e-07
of O 0 4.934673469847439e-08
total O 0 0.0038342587649822235
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 6.214331165210751e-07
C6Q0 O 0 9.490882803220302e-05
) O 0 5.9029900967288995e-08
have O 0 2.833695944559622e-08
been O 0 9.889757990322323e-08
ascertained O 0 1.8355366364630754e-06
because O 0 3.315328100939041e-08
of O 0 9.696660185909423e-08
recurrent O 0 0.24141345918178558
disease O 0 0.01141242403537035
. O 0 1.8824979406417697e-06

We O 0 3.376040922375978e-06
have O 0 1.401530056455158e-07
sequenced O 0 6.28241707545385e-07
the O 0 1.5280432918984843e-08
expressed O 0 1.8790917266642282e-08
exons O 0 4.994647042622091e-07
of O 0 8.925638006473946e-09
the O 0 2.755658279340878e-08
C6 O 0 2.479052091075573e-05
gene O 0 3.5470222314870625e-07
from O 0 1.1027937674157329e-08
selected O 0 1.9591819722108994e-08
cases O 0 5.395149216269601e-09
and O 0 2.4070008208809668e-08
have O 0 1.7840154242776407e-08
found O 0 4.20295123149117e-08
three O 0 8.272096607697677e-08
molecular O 0 3.5656386899063364e-05
defects O 0 0.1114974319934845
leading O 0 1.0219599744232255e-06
to O 0 4.932942374580307e-07
total O 0 3.9885057958599646e-06
deficiency O 0 8.486134902341291e-05
879delG O 0 2.4860007670213236e-06
, O 0 6.216784953494425e-08
which O 0 1.596764143130258e-08
is O 0 5.617037945881975e-09
the O 0 4.515836593554923e-09
common O 0 3.4141288551836624e-07
defect O 0 2.881643695218372e-06
in O 0 2.051932668223344e-08
the O 0 2.3293035056326516e-08
Cape O 0 3.856941077629017e-07
and O 0 4.0260808020775585e-08
hitherto O 0 4.6996362357276666e-07
unreported O 0 2.610488820664614e-07
, O 0 1.9402460083028927e-08
and O 0 2.0641762077389103e-08
1195delC O 0 7.270764399436302e-07
and O 0 9.307274950742794e-08
1936delG O 0 1.2721613984467695e-06
, O 0 3.6300043859682773e-08
which O 0 4.640898509933322e-08
have O 0 2.2508835684220685e-08
been O 0 9.114295806966766e-08
previously O 0 6.720267720083939e-07
reported O 0 1.9952128695877036e-06
in O 0 1.062094945325498e-08
African O 0 3.1895059038333784e-08
- O 0 2.5749213818926364e-06
Americans O 0 5.95599772168498e-07
. O 0 4.89291551275528e-07

We O 0 6.240597485884791e-06
also O 0 1.9458315136944293e-07
show O 0 1.8444457339228393e-07
that O 0 5.704721139920821e-09
the O 0 4.5900310219337825e-09
879delG O 0 2.158660436180071e-06
and O 0 4.0323448047274724e-07
1195delC O 0 6.249218131415546e-05
defects O 0 0.013718629255890846
are O 0 5.0726645106635715e-09
associated O 0 2.9602151840890656e-08
with O 0 3.162380224353001e-08
characteristic O 0 0.0001454116718377918
C6 O 1 0.9921227097511292
/ O 0 0.011607128195464611
C7 O 0 0.0006426383624784648
region O 0 4.338528469816083e-06
DNA O 0 6.697001026623184e-06
marker O 0 1.679186766523344e-06
haplotypes O 0 7.38003518563346e-06
, O 0 1.8382463551347428e-08
although O 0 5.5828692779869016e-09
small O 0 1.3671713539054053e-08
variations O 0 1.5933223949105013e-06
were O 0 2.171465069977785e-07
observed O 0 1.1557838206499582e-06
. O 0 5.474419140227837e-07

The O 0 2.7901098746951902e-06
1936delG O 0 9.407391917193308e-05
defect O 0 0.0005575626855716109
was O 0 7.068011655064765e-06
observed O 0 2.445706002163206e-07
only O 0 1.0069992839589759e-08
once O 0 3.945740090216532e-08
in O 0 8.866860135015031e-09
the O 0 1.238006763770727e-08
Cape O 0 5.221312449066318e-07
, O 0 1.7506476268636106e-08
but O 0 5.591511698099794e-09
its O 0 1.1670098132299245e-07
associated O 0 3.8077149611126515e-07
haplotype O 0 2.4986047719721682e-05
could O 0 7.601013862768013e-07
be O 0 7.005148461303179e-08
deduced O 0 1.8429809642839245e-06
. O 0 3.789540130583191e-07

The O 0 1.598109975020634e-06
data O 0 2.083023673549178e-06
from O 0 5.912173151045863e-08
the O 0 2.2436870139586063e-08
haplotypes O 0 8.398873433179688e-06
indicate O 0 7.391321901195624e-07
that O 0 8.162724718374648e-09
these O 0 1.2537131333090201e-09
three O 0 3.3253407139000046e-08
molecular O 0 3.892624590662308e-05
defects O 0 0.3355579078197479
account O 0 1.191624278362724e-06
for O 0 1.2343961941496673e-07
the O 0 6.130293286332744e-07
defects O 0 0.05361189320683479
in O 0 1.615521583175905e-08
all O 0 2.1977639708126162e-09
the O 0 1.886982481380528e-08
38 O 0 1.219224117221529e-07
unrelated O 0 1.688795521204156e-07
C6Q0 O 0 2.3710959794698283e-05
individuals O 0 1.5085884541576888e-08
we O 0 2.048737535176315e-08
have O 0 1.3299668921717966e-08
studied O 0 8.948278207299154e-08
from O 0 1.3648628005569208e-08
the O 0 4.754426541353496e-08
Cape O 0 2.712017703743186e-06
. O 0 1.0024976972999866e-06

We O 0 1.5054265531944111e-05
have O 0 1.4508208323604777e-07
also O 0 6.220687964741956e-08
observed O 0 5.8803799163342774e-08
the O 0 7.503808241438037e-09
879delG O 0 3.3751166483853012e-06
defect O 0 2.5862368602247443e-06
in O 0 1.4299766704084504e-08
two O 0 2.659646725078346e-07
Dutch O 0 0.2058711051940918
C6 B-Disease 1 1.0
- I-Disease 1 0.9999786615371704
deficient I-Disease 1 0.9999990463256836
kindreds O 0 4.615903162630275e-05
, O 0 7.374902821766227e-08
but O 0 3.2708382669000002e-09
the O 0 5.222021925987974e-09
879delG O 0 2.152530214516446e-06
defect O 0 3.0804562811681535e-06
in O 0 1.7237924865298737e-08
the O 0 2.3043892127816434e-08
Cape O 0 2.3980571768333903e-06
probably O 0 4.5863757236475067e-07
did O 0 8.25356281097811e-08
not O 0 7.1573436066785234e-09
come O 0 5.418559378966847e-09
from O 0 2.7570132843379724e-09
The O 0 7.909623178647962e-09
Netherlands O 0 2.9995114800840383e-06
. O 0 8.480176205694079e-08
. O 0 3.418951166622719e-07

Complement B-Disease 0 0.13019922375679016
C7 I-Disease 1 0.9999998807907104
deficiency I-Disease 1 1.0
: O 0 2.410964953014627e-06
seven O 0 1.439483838794331e-07
further O 0 1.2208099064991984e-07
molecular O 0 3.994542930740863e-05
defects O 0 0.4233849346637726
and O 0 2.695050511647423e-07
their O 0 2.4352209493372357e-07
associated O 0 2.266104274895042e-06
marker O 0 3.7273548514349386e-05
haplotypes O 0 0.00023303563648369163
. O 0 2.9714724405494053e-06

Seven O 0 7.693598490732256e-06
further O 0 1.2547135384011199e-06
molecular O 0 3.7348936530179344e-06
bases O 0 2.8730985377478646e-06
of O 0 1.694502316240687e-05
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 6.496695732494118e-07
described O 0 7.438768534484552e-06
. O 0 1.3577092659033951e-06

All O 0 1.592780165537988e-07
these O 0 1.9888316771243808e-08
new O 0 1.048706934625443e-07
molecular O 0 1.4872070096316747e-05
defects O 0 0.002408401807770133
involve O 0 4.8364139360046465e-08
single O 0 7.994881343620364e-07
- O 0 6.050199317542138e-06
nucleotide O 0 1.3590539538199664e-06
events O 0 5.2305772157978936e-08
, O 0 1.7436230237422023e-08
deletions O 0 2.1741297473454324e-07
and O 0 3.1561313562633586e-08
substitutions O 0 8.077022073393891e-08
, O 0 5.482693410385764e-09
some O 0 5.939508329610987e-10
of O 0 7.424902359609575e-10
which O 0 9.332801909067712e-08
alter O 0 6.138458957138937e-06
splice O 0 4.517433626460843e-05
sites O 0 6.211486720530957e-07
, O 0 1.9010860441426303e-08
and O 0 5.4962654871815175e-08
others O 0 2.875462143947516e-07
codons O 0 5.222007530392148e-06
. O 0 6.368219374053297e-07

They O 0 2.133092039002804e-06
are O 0 1.3531002096556222e-08
distributed O 0 1.1237146324560854e-08
along O 0 1.2866041565473552e-08
the O 0 2.243361585385628e-08
C7 O 0 7.765302871121094e-05
gene O 0 1.2029155413983972e-06
, O 0 8.423219455266917e-09
but O 0 2.158443646038677e-09
predominantly O 0 3.1698543789815403e-09
towards O 0 5.524124269129516e-09
the O 0 1.3456825875834966e-08
3 O 0 3.824123950835201e-07
end O 0 1.5631159158147057e-06
. O 0 7.312111165447277e-07

All O 0 1.0608598586259177e-06
were O 0 3.593614223973418e-07
found O 0 6.023171295055363e-08
in O 0 1.3355975880813276e-08
compound O 0 1.448560738026572e-06
heterozygous O 0 3.7123513720871415e-06
individuals O 0 1.3566798884312448e-07
. O 0 8.226261343224905e-07

The O 0 1.5812087440281175e-05
C6 O 0 0.35783812403678894
/ O 0 0.0587758831679821
C7 O 0 0.0020183653105050325
marker O 0 5.3359170124167576e-05
haplotypes O 0 7.751090015517548e-05
associated O 0 6.623895956181514e-07
with O 0 1.1544162958898596e-07
most O 0 3.478768803688581e-06
C7 B-Disease 1 0.9997811913490295
defects I-Disease 1 0.9986369013786316
are O 0 9.43971798506027e-08
tabulated O 0 2.2342740066960687e-06
. O 0 8.679340623984899e-08
. O 0 5.804643024021061e-07

A O 0 1.4794792150496505e-05
genome O 0 1.3975481124361977e-05
- O 0 4.148010248172795e-06
wide O 0 9.76961871401727e-08
search O 0 1.3275622734454373e-07
for O 0 4.081642757114423e-08
chromosomal O 0 0.00013120008225087076
loci O 0 3.857908268400934e-06
linked O 0 0.00024588117958046496
to O 0 1.1336623174429405e-05
mental O 0 0.0003168121329508722
health O 0 1.4723140111527755e-06
wellness O 0 2.781215471259202e-06
in O 0 1.677476006989309e-07
relatives O 0 4.580885217819741e-07
at O 0 6.617682402065839e-07
high O 0 4.303862624510657e-06
risk O 0 1.4443436157307588e-05
for O 0 7.248019301187014e-06
bipolar B-Disease 1 0.9999984502792358
affective I-Disease 1 0.999984622001648
disorder I-Disease 1 0.8750274181365967
among O 0 4.334771119829384e-08
the O 0 1.6151302517641852e-08
Old O 0 1.1298126310066436e-06
Order O 0 2.3331459431119583e-07
Amish O 0 2.6490239179111086e-05
. O 0 1.4039557072464959e-06

Bipolar B-Disease 1 0.9999994039535522
affective I-Disease 1 0.9999971389770508
disorder I-Disease 1 0.9999980926513672
( O 0 0.0004709188942797482
BPAD B-Disease 1 0.9999998807907104
; O 0 0.07393509149551392
manic B-Disease 1 0.9999984502792358
- I-Disease 1 0.9999996423721313
depressive I-Disease 1 1.0
illness I-Disease 1 0.998675525188446
) O 0 4.929960368826869e-07
is O 0 5.29051789044388e-08
characterized O 0 2.7182457529306703e-07
by O 0 3.259555114709656e-08
episodes O 0 6.411375466086611e-07
of O 0 4.781171369927506e-08
mania B-Disease 0 0.00035285213380120695
and O 0 3.006264250871027e-06
/ O 0 0.0012966236099600792
or O 0 1.156968210125342e-06
hypomania B-Disease 0 0.00013678242976311594
interspersed O 0 5.350523792913009e-07
with O 0 1.8761801001687672e-08
periods O 0 1.600448200633764e-07
of O 0 9.56068575419522e-08
depression B-Disease 0 1.6458998288726434e-05
. O 0 7.806150961187086e-07

Compelling O 0 4.3080344767076895e-05
evidence O 0 2.278821284562582e-06
supports O 0 2.76855843139856e-07
a O 0 6.59407106695653e-08
significant O 0 5.1237083908972636e-08
genetic O 0 5.52359949779202e-07
component O 0 2.156346567971923e-07
in O 0 1.9746156709743445e-08
the O 0 2.768005913367233e-08
susceptibility O 0 8.233331755036488e-06
to O 0 4.499014210068708e-07
develop O 0 1.111294659494888e-05
BPAD B-Disease 1 0.9999963045120239
. O 0 7.259219273691997e-06

To O 0 4.641723080567317e-06
date O 0 2.646484745127964e-06
, O 0 1.005324250513695e-07
however O 0 1.931531912191531e-08
, O 0 8.605816503859387e-09
linkage O 0 1.6116549659273005e-06
studies O 0 1.0446682807696561e-07
have O 0 2.6446421941273002e-08
attempted O 0 7.592407200718299e-07
only O 0 1.0784316550882522e-08
to O 0 1.802846050225071e-08
identify O 0 8.390445600525709e-07
chromosomal O 0 6.228691927390173e-05
loci O 0 1.306246758758789e-06
that O 0 2.6655223450688936e-07
cause O 0 6.19976901816699e-07
or O 0 7.966448833940376e-08
increase O 0 2.2192062942849589e-07
the O 0 1.1776320718581701e-07
risk O 0 1.1389746532586287e-06
of O 0 3.48823228080164e-08
developing O 0 8.856957720126957e-06
BPAD B-Disease 1 0.9999957084655762
. O 0 1.1294870091660414e-05

To O 0 3.498010983093991e-06
determine O 0 8.729793421480281e-07
whether O 0 8.474209778341901e-08
there O 0 1.79973334013539e-08
could O 0 5.5094481865580747e-08
be O 0 8.395407036232427e-09
protective O 0 3.57151854757376e-08
alleles O 0 6.37186374774501e-08
that O 0 1.0759127810899827e-08
prevent O 0 7.972361970587372e-08
or O 0 1.7595060342046054e-07
reduce O 0 9.003952072816901e-07
the O 0 7.181947836443214e-08
risk O 0 2.6056238766614115e-07
of O 0 7.819083158722151e-09
developing O 0 1.714904215077695e-06
BPAD B-Disease 1 0.9999991655349731
, O 0 2.1301150354702258e-07
similar O 0 1.0970161667955836e-08
to O 0 2.2749807371269526e-08
what O 0 6.63624888375125e-09
is O 0 9.9263406383443e-09
observed O 0 5.0040537047379985e-08
in O 0 2.931771980740905e-08
other O 0 2.5793033273657784e-06
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.8625495101787237e-07
we O 0 1.0085143031801636e-07
used O 0 8.75234491104493e-06
mental O 0 0.0002119215059792623
health O 0 1.9241283553128596e-06
wellness O 0 1.2931990568176843e-05
( O 0 6.684295073000612e-08
absence O 0 8.491117853282049e-08
of O 0 3.3618572814475556e-08
any O 0 7.95892901805928e-06
psychiatric B-Disease 1 0.9344823360443115
disorder I-Disease 0 0.011327629908919334
) O 0 2.0186915250519633e-08
as O 0 2.18275086893982e-08
the O 0 2.8767777493499125e-08
phenotype O 0 2.873219273169525e-06
in O 0 2.4824457156569224e-08
our O 0 9.661767563784451e-08
genome O 0 9.193963705911301e-07
- O 0 3.0117796541162534e-06
wide O 0 2.1202266964337468e-07
linkage O 0 7.143766652006889e-06
scan O 0 2.1560725144809112e-05
of O 0 2.9408209201164937e-09
several O 0 3.3760181317177285e-09
large O 0 2.122490094791374e-08
multigeneration O 0 5.829007022839505e-06
Old O 0 2.2508714891955606e-07
Order O 0 9.788545973776763e-09
Amish O 0 5.257157908999943e-07
pedigrees O 0 1.110953462557518e-06
exhibiting O 0 5.152024868948502e-07
an O 0 2.455734104955809e-08
extremely O 0 2.0973627101739112e-07
high O 0 1.011435415421147e-06
incidence O 0 5.7265086070401594e-05
of O 0 8.800326440905337e-07
BPAD B-Disease 1 0.9999990463256836
. O 0 1.4476531760010403e-05

We O 0 1.0514069799683057e-05
have O 0 2.1714609488299175e-07
found O 0 7.815329183813446e-08
strong O 0 2.9603846485315444e-08
evidence O 0 3.0607608891841664e-08
for O 0 8.739171164506843e-09
a O 0 8.302366438783793e-08
locus O 0 2.251061232527718e-06
on O 0 1.2988955859327689e-05
chromosome O 0 0.0005348018603399396
4p O 0 0.0003371488128323108
at O 0 6.27063116098725e-07
D4S2949 O 0 6.422513365578197e-07
( O 0 1.3800931064622546e-08
maximum O 0 4.431299771567865e-08
GENEHUNTER O 0 1.2970153875357937e-05
- O 0 5.789020178781357e-06
PLUS O 0 1.2974801393283997e-06
nonparametric O 0 1.2056224250045489e-06
linkage O 0 6.715213203278836e-07
score O 0 1.0087585877727179e-07
= O 0 3.432054427321418e-07
4 O 0 8.879218427182423e-08
. O 0 2.4988541014181465e-08
05 O 0 3.3274793054260954e-07
, O 0 2.2752152162297534e-08
P O 0 1.1258898666710593e-05
= O 0 2.8656015160777315e-07
5 O 0 4.1025369768021847e-08
. O 0 5.206328257401083e-09
22 O 0 1.645993563670345e-08
x O 0 7.211679076135624e-07
10 O 0 4.778919659997882e-08
( O 0 1.4432442796419309e-08
- O 0 1.8068294593831524e-06
4 O 0 3.8931790413698764e-07
) O 0 1.5450707380182394e-08
; O 0 1.0367398495247926e-08
SIBPAL O 0 1.0973111557177617e-06
Pempirical O 0 4.249259291100316e-07
value O 0 2.3541099736235083e-08
< O 0 3.239875567828676e-08
3 O 0 3.3998254878042644e-08
x O 0 2.5054839625227032e-06
10 O 0 1.9109477022993815e-07
( O 0 2.675505328397776e-08
- O 0 3.583160150810727e-06
5 O 0 1.2534266033981112e-06
) O 0 2.9585276450916353e-08
) O 0 1.3782621266500428e-08
and O 0 8.47109120627465e-08
suggestive O 0 2.792772193060955e-06
evidence O 0 3.612447230239013e-08
for O 0 5.756156884473285e-09
a O 0 1.300247163271706e-07
locus O 0 5.850035449839197e-06
on O 0 7.363731856457889e-05
chromosome O 1 0.542448878288269
4q O 1 0.9954278469085693
at O 0 4.088179139216663e-06
D4S397 O 0 1.6268160152321798e-06
( O 0 3.02202813884378e-08
maximum O 0 7.317623129665662e-08
GENEHUNTER O 0 1.3809344636683818e-05
- O 0 4.0531358536100015e-06
PLUS O 0 7.401409334306663e-07
nonparametric O 0 8.669427984386857e-07
linkage O 0 1.3177065056879655e-06
score O 0 1.552435833218624e-07
= O 0 2.98707732326875e-07
3 O 0 7.788959521803918e-08
. O 0 1.559489604119335e-08
29 O 0 1.2335100052496273e-07
, O 0 1.2144389494039842e-08
P O 0 1.427500228601275e-05
= O 0 2.5701689310153597e-07
2 O 0 4.2435974734189585e-08
. O 0 1.0207854117538773e-08
57 O 0 7.144634395217508e-08
x O 0 7.987580374901881e-07
10 O 0 1.3676961430064694e-07
( O 0 1.362054202758145e-08
- O 0 9.950899766408838e-07
3 O 0 6.933128702257818e-07
) O 0 1.729869225641778e-08
; O 0 1.2449898001420934e-08
SIBPAL O 0 1.7361616073685582e-06
Pempirical O 0 6.936938348189869e-07
value O 0 2.1009856965292784e-08
< O 0 2.220653883000523e-08
1 O 0 2.8382773464841193e-08
x O 0 2.5226077013940085e-06
10 O 0 1.4890696320435381e-07
( O 0 2.913398944315304e-08
- O 0 3.4266358852619305e-06
3 O 0 2.5986157652369e-06
) O 0 6.363580951074255e-08
) O 0 4.6629899941308395e-09
that O 0 9.600445771695831e-09
are O 0 8.47359160616179e-09
linked O 0 1.0721070793806575e-05
to O 0 7.604445727338316e-06
mental O 0 0.00010337244748370722
health O 0 1.9982405774499057e-06
wellness O 0 1.0235665286018047e-05
. O 0 9.596117251930991e-07

These O 0 3.652301984402584e-06
findings O 0 1.7260351796721807e-06
are O 0 1.5392291885518716e-08
consistent O 0 8.053854116951698e-08
with O 0 9.144381252212952e-09
the O 0 2.082807348813276e-08
hypothesis O 0 1.5418096666053316e-07
that O 0 4.260675812162162e-09
certain O 0 3.4100784418455987e-09
alleles O 0 9.831379088609538e-08
could O 0 1.336094896942086e-07
prevent O 0 9.424066149676946e-08
or O 0 1.3108024177199695e-07
modify O 0 1.7901119235830265e-06
the O 0 1.2314060882090416e-07
clinical O 0 5.016639761379338e-07
manifestations O 0 4.0458343164573307e-07
of O 0 1.2379587133182213e-07
BPAD B-Disease 1 0.9999998807907104
and O 0 7.480381327695795e-07
perhaps O 0 6.590261136807385e-08
other O 0 7.429485293641847e-08
related O 0 2.0214316464262083e-05
affective B-Disease 1 0.9988839030265808
disorders I-Disease 1 0.9647195339202881
. O 0 3.0372311812243424e-06

Segregation O 0 0.0013039960758760571
distortion O 0 0.2355215698480606
in O 0 0.0005367519916035235
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
. O 0 0.00016541678633075207

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999761164188385
DM B-Disease 1 1.0
) O 0 2.9931114113423973e-05
is O 0 1.4996183494986326e-07
an O 0 2.819399185227667e-07
autosomal B-Disease 1 0.8731433153152466
dominant I-Disease 1 0.6895453333854675
disease I-Disease 1 0.9502336978912354
which O 0 5.218664114181593e-07
, O 0 2.7660794543749034e-08
in O 0 9.393232858201372e-09
the O 0 1.709304875419093e-08
typical O 0 5.15913939125312e-07
pedigree O 0 4.216250090394169e-06
, O 0 3.5381461316319474e-08
shows O 0 1.8671695301009095e-08
a O 0 8.22630674690572e-09
three O 0 1.8961175740628278e-08
generation O 0 2.517536188406666e-07
anticipation O 0 4.045726313961495e-07
cascade O 0 9.819188562687486e-06
. O 0 1.1791834140240098e-06

This O 0 2.7572125418373616e-06
results O 0 1.1636480849119835e-05
in O 0 5.788412636320572e-06
infertility B-Disease 1 0.9994484782218933
and O 1 0.9277858138084412
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 4.938900747220032e-05
CDM B-Disease 0 0.0001625061413506046
) O 0 1.4038309359420964e-07
with O 0 1.6471460639877478e-08
the O 0 1.0879481493475396e-07
disappearance O 0 4.844279101234861e-05
of O 0 6.819914801781124e-07
DM B-Disease 1 1.0
in O 0 2.059755388472695e-06
that O 0 2.1679473150015838e-07
pedigree O 0 1.682870242802892e-05
. O 0 1.7090185338020092e-06

The O 0 6.411871140699077e-07
concept O 0 3.411674640574347e-07
of O 0 2.7173273409175636e-08
segregation O 0 1.534324496788031e-06
distortion O 0 8.567470649722964e-05
, O 0 6.663787388561104e-08
where O 0 1.5536498310098068e-08
there O 0 2.051767200583754e-09
is O 0 3.5700526979098868e-09
preferential O 0 8.711847954145924e-08
transmission O 0 8.769311534706503e-07
of O 0 1.0282770190883639e-09
the O 0 4.939699316253154e-09
larger O 0 2.4319989577747947e-08
allele O 0 6.222402362254797e-07
at O 0 5.136977279107668e-07
the O 0 1.679531010267965e-06
DM B-Disease 1 1.0
locus O 0 4.153256304562092e-05
, O 0 1.4165263451104693e-07
has O 0 3.5991391200695944e-08
been O 0 2.2059293058873664e-08
put O 0 4.446692258852636e-08
forward O 0 2.6687573040362622e-08
to O 0 3.3867191717718015e-08
explain O 0 1.5997675006929057e-07
partially O 0 8.015202865863102e-07
the O 0 2.3180019681490194e-08
maintenance O 0 3.3737264857336413e-06
of O 0 3.68579122778101e-07
DM B-Disease 1 1.0
in O 0 5.074733735455084e-07
the O 0 1.0736540900779801e-07
population O 0 4.914263058708457e-07
. O 0 7.306185807465226e-07

In O 0 1.4890911188558675e-06
a O 0 1.079217668120691e-06
survey O 0 9.35860771278385e-06
of O 0 1.6613167019841057e-07
DM B-Disease 1 1.0
in O 0 2.472018877597293e-06
Northern O 0 4.249026005709311e-06
Ireland O 0 8.109251211863011e-06
, O 0 1.2340007060629432e-07
59 O 0 2.702297763335082e-07
pedigrees O 0 1.0721392982304678e-06
were O 0 3.491161635338358e-07
ascertained O 0 9.400183444085997e-06
. O 0 8.750832307669043e-07

Sibships O 0 0.000387887324905023
where O 0 1.1624018725342466e-06
the O 0 1.8833507198223742e-08
status O 0 1.3857746949952343e-08
of O 0 2.3070005905623248e-09
all O 0 4.412573861856117e-09
the O 0 1.3317717595384693e-08
members O 0 1.4370693079968078e-08
had O 0 1.6569875072036666e-07
been O 0 3.9946886687403094e-08
identified O 0 1.8068054430386837e-07
were O 0 2.658296871516086e-08
examined O 0 6.700582844132441e-08
to O 0 1.804208338285207e-08
determine O 0 2.9314588090301186e-08
the O 0 7.529528112115713e-09
transmission O 0 1.2566151781356893e-06
of O 0 6.028122001566771e-09
the O 0 3.9207213831105037e-07
DM B-Disease 1 0.9999997615814209
expansion O 0 1.5711325431766454e-06
from O 0 1.751486848888817e-07
affected O 0 1.3205264792759408e-07
parents O 0 2.2073011862744352e-08
to O 0 2.608328131259441e-08
their O 0 1.6304754524298914e-07
offspring O 0 4.050918050779728e-06
. O 0 6.689741098853119e-07

Where O 0 2.3113634597393684e-06
the O 0 1.9249895899520197e-07
transmitting O 0 0.00010528620623517781
parent O 0 1.591121508681681e-05
was O 0 1.496145728197007e-06
male O 0 3.6585103657671425e-07
, O 0 6.730722645897913e-08
58 O 0 7.160205655054597e-07
. O 0 5.157864961802261e-07

3 O 0 5.965529908280587e-06
% O 0 1.1093234775216843e-07
of O 0 5.396384228362194e-09
the O 0 3.5566039002787875e-08
offspring O 0 1.2350407132544206e-06
were O 0 2.4763127726146195e-07
affected O 0 7.998070827852644e-08
, O 0 2.135728749408372e-08
and O 0 2.866163661963128e-08
in O 0 5.553503878985566e-09
the O 0 1.105725555561321e-08
case O 0 3.710336571316475e-08
of O 0 1.0844376507890274e-09
a O 0 1.298873826272029e-07
female O 0 1.5862798363741604e-06
transmitting O 0 7.379549060715362e-05
parent O 0 3.6153330711385934e-06
, O 0 1.0007976669612617e-07
68 O 0 1.1137740330013912e-06
. O 0 5.226937105362595e-07

7 O 0 7.49790997360833e-05
% O 0 3.7207373679848388e-06
were O 0 6.900687594679766e-07
affected O 0 2.2840190467832144e-06
. O 0 1.4000100918565295e-06

Studies O 0 1.62608121172525e-05
on O 0 1.1868676210724516e-06
meiotic O 0 3.7751295167254284e-05
drive O 0 2.3553784558316693e-05
in O 0 2.4254146410385147e-05
DM B-Disease 1 1.0
have O 0 2.0821498765144497e-06
shown O 0 9.699028424847711e-08
increased O 0 3.353097000058369e-08
transmission O 0 5.00577186812734e-07
of O 0 1.5625792881834855e-09
the O 0 4.514751683615259e-09
larger O 0 4.1334910605428377e-08
allele O 0 5.209033133724006e-07
at O 0 3.41978591222869e-07
the O 0 5.275755370348634e-07
DM B-Disease 1 0.9999998807907104
locus O 0 9.665408470027614e-06
in O 0 1.5163074351676187e-07
non O 0 9.149126526608597e-06
- O 1 0.570183277130127
DM O 1 0.9999998807907104
heterozygotes O 0 6.325120921246707e-05
for O 0 2.4447567170682305e-07
CTGn O 0 6.960575410630554e-05
. O 0 1.60771753598965e-06

This O 0 9.539526217849925e-07
study O 0 1.8661054923541087e-07
provides O 0 3.103119539105137e-08
further O 0 2.5366952982608382e-08
evidence O 0 2.878633154068666e-08
that O 0 1.928940207562846e-08
the O 0 2.295397365514873e-07
DM B-Disease 1 0.9999997615814209
expansion O 0 9.308657240580942e-07
tends O 0 3.0568523357032973e-07
to O 0 2.155922551594358e-08
be O 0 3.662608349941365e-08
transmitted O 0 4.236341737851035e-06
preferentially O 0 3.023795215995051e-06
. O 0 1.0378714705439052e-06

Diagnosis O 1 0.9756640195846558
of O 0 4.256470128893852e-05
hemochromatosis B-Disease 1 0.9999994039535522
. O 0 0.00013044934894423932

If O 0 0.00010985508561134338
untreated O 0 0.30508753657341003
, O 0 4.438346149981953e-05
hemochromatosis B-Disease 1 1.0
can O 0 0.0008018852677196264
cause O 0 0.00032538865343667567
serious O 0 0.0001804152998374775
illness O 0 0.0014891924802213907
and O 0 6.148848683551478e-07
early B-Disease 0 5.706187948817387e-06
death I-Disease 0 5.1756264838331845e-06
, O 0 4.471475989475948e-08
but O 0 1.7332908441858308e-08
the O 0 5.286533522053105e-08
disease O 0 8.738425094634295e-06
is O 0 2.3390267500644768e-08
still O 0 1.1492337392837726e-07
substantially O 0 3.3453818559792126e-06
under O 0 3.28636161839313e-07
- O 0 0.16574257612228394
diagnosed O 0 0.45547574758529663
. O 0 1.111629671868286e-06

The O 0 1.1506159580676467e-06
cornerstone O 0 2.8283959636610234e-06
of O 0 4.611304404988914e-08
screening O 0 3.138234774269222e-07
and O 0 6.639555749643478e-08
case O 0 6.041118894017927e-08
detection O 0 1.8685364011616912e-07
is O 0 1.1791262188864948e-08
the O 0 9.036209114299254e-09
measurement O 0 1.0198920108450693e-06
of O 0 1.9580088661541595e-08
serum O 0 9.369290978611389e-07
transferrin O 0 9.075505431610509e-07
saturation O 0 2.503155087651976e-07
and O 0 2.0770865916119874e-08
the O 0 3.399812342763653e-08
serum O 0 6.111899324423575e-07
ferritin O 0 2.795660748233786e-06
level O 0 4.6616494842055545e-07
. O 0 7.733490861028258e-07

Once O 0 9.751792276802007e-06
the O 0 4.899616214970592e-07
diagnosis O 0 0.00042888495954684913
is O 0 1.5008630782631371e-07
suspected O 0 1.6180265447474085e-05
, O 0 4.632930199477414e-07
physicians O 0 1.0264359673328727e-07
must O 0 1.156147888536907e-08
use O 0 4.525115926412582e-08
serum O 0 6.295702519309998e-07
ferritin O 0 4.020363121526316e-06
levels O 0 1.8242459987050097e-07
and O 0 1.433633940450818e-07
hepatic O 0 0.00021938532881904393
iron O 0 3.2446361728943884e-05
stores O 0 3.319599272799678e-05
on O 0 1.5928535503917374e-05
liver O 0 0.0009254968608729541
biopsy O 0 0.02107624150812626
specimens O 0 3.297481327990681e-07
to O 0 3.227306706321542e-07
assess O 0 3.721407892953721e-06
patients O 0 3.4115413427571184e-07
for O 0 2.3361810264077576e-09
the O 0 9.132337552841818e-09
presence O 0 4.6186279689663934e-08
of O 0 5.353616217007584e-08
iron B-Disease 0 0.0020212295930832624
overload I-Disease 0 0.0004579320957418531
. O 0 1.3174714013075572e-06

Liver O 1 0.9999027252197266
biopsy O 1 0.9995368719100952
is O 0 1.6117132872750517e-06
also O 0 8.71419132408846e-08
used O 0 2.714674884884971e-08
to O 0 1.4164095674118471e-08
establish O 0 2.4080797800252185e-08
the O 0 1.1182347492422196e-08
presence O 0 2.9687930336308455e-08
or O 0 5.328606178522932e-08
absence O 0 2.816318911413873e-08
of O 0 3.571464191054474e-08
cirrhosis B-Disease 0 0.0027156539727002382
, O 0 1.747722535583307e-07
which O 0 3.3556534617673606e-07
can O 0 6.687636187052703e-07
affect O 0 8.9805589595926e-06
prognosis O 0 0.0006741827819496393
and O 0 5.844898964824097e-07
management O 0 4.85819600726245e-06
. O 0 4.5160712147662707e-07

A O 0 7.297353931789985e-06
DNA O 0 1.1501648259581998e-05
- O 0 1.5238792002492119e-05
based O 0 5.584548716797144e-07
test O 0 2.944987542718991e-08
for O 0 2.8076392322162746e-09
the O 0 7.150152470103421e-09
HFE O 0 3.5662067148223286e-06
gene O 0 1.8581373240067478e-07
is O 0 3.920883617780646e-09
commercially O 0 5.440890404884158e-08
available O 0 5.1566768632937965e-09
, O 0 2.827696077289943e-09
but O 0 2.615291094798522e-09
its O 0 9.914836063273924e-09
place O 0 6.473231195514018e-08
in O 0 3.041625618038779e-08
the O 0 1.8501326337627688e-07
diagnosis O 0 0.0004825807991437614
of O 0 5.505088438439998e-07
hemochromatosis B-Disease 1 1.0
is O 0 9.139272151514888e-06
still O 0 9.258828299607558e-07
being O 0 3.702878359490569e-07
evaluated O 0 8.300132208205468e-07
. O 0 3.631992626651481e-07

Currently O 0 6.7873183979827445e-06
, O 0 1.5325682056754886e-07
the O 0 9.646223375625596e-09
most O 0 3.8784868650054705e-09
useful O 0 1.7510418004462736e-08
role O 0 2.7638066057988908e-08
for O 0 2.1765066193779603e-08
this O 0 8.630769876560862e-09
test O 0 1.4215789434501858e-08
is O 0 3.305583806678669e-09
in O 0 1.4799226288886302e-09
the O 0 5.647557976828921e-09
detection O 0 6.896812578816025e-07
of O 0 2.0590177030044288e-07
hemochromatosis B-Disease 1 0.9999998807907104
in O 0 1.0407965191916446e-06
the O 0 3.156920058700052e-08
family O 0 1.5025730704110174e-07
members O 0 6.306366095998328e-09
of O 0 7.008981395273395e-09
patients O 0 5.5754977523747584e-08
with O 0 2.906409557468237e-09
a O 0 9.074622084881412e-07
proven O 0 5.271714599075494e-06
case O 0 9.225672670254426e-08
of O 0 1.2214732336701672e-08
the O 0 1.4275003650254803e-06
disease O 0 0.0001752235257299617
. O 0 7.512087449867977e-07

It O 0 2.071205926768016e-06
is O 0 1.2164679219495156e-07
crucial O 0 5.867204322385078e-07
to O 0 3.46187039212964e-06
diagnose O 1 0.9997746348381042
hemochromatosis B-Disease 1 1.0
before O 0 0.040172185748815536
hepatic B-Disease 1 0.9999890327453613
cirrhosis I-Disease 1 0.9992029070854187
develops O 0 0.00019456532027106732
because O 0 1.3404053333943011e-06
phlebotomy O 0 0.0005423925467766821
therapy O 0 4.453086876310408e-05
can O 0 1.8093728613166604e-06
avert O 0 0.0059390137903392315
serious O 0 0.3525940477848053
chronic O 1 0.9999842643737793
disease O 1 0.5829161405563354
and O 0 7.541258923993155e-07
can O 0 1.6815828018934553e-07
even O 0 1.243504641479376e-07
lead O 0 9.97102006294881e-07
to O 0 1.374749842852907e-07
normal O 0 7.286674872375443e-07
life O 0 5.408421657193685e-07
expectancy O 0 3.5990271953778574e-06
. O 0 6.370235894337384e-08
. O 0 4.2188014504063176e-07

Prevalence O 0 0.002685064449906349
of O 0 5.493639605447243e-07
the O 0 2.0176219095446868e-07
I1307K O 0 4.150653694523498e-06
APC B-Disease 0 5.95231176703237e-06
gene O 0 1.3908144183005788e-06
variant O 0 4.0114045987138525e-06
in O 0 3.5117974306331234e-08
Israeli O 0 4.867684992859722e-07
Jews O 0 2.4242191898338206e-07
of O 0 4.392554764365286e-09
differing O 0 7.131278323413426e-08
ethnic O 0 2.2163298751820548e-07
origin O 0 7.040295599836099e-07
and O 0 2.4642372409289237e-06
risk O 0 6.177819886943325e-05
for O 0 0.01365196704864502
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 7.624226327607175e-06

BACKGROUND O 0 0.00041153214988298714
& O 0 0.00020616812980733812
AIMS O 0 9.235996003553737e-06
Israeli O 0 2.3466068341804203e-06
Jews O 0 2.3678813931837794e-07
of O 0 2.627467132754191e-08
European O 0 1.8009494624493527e-06
birth O 0 4.251073278283002e-06
, O 0 8.674226847915634e-08
i O 0 1.0283800122579123e-07
. O 0 6.064136748307192e-09
e O 0 7.642709221045152e-08
. O 0 3.339920784384276e-09
, O 0 9.931984124023074e-09
Ashkenazim O 0 9.186373972625006e-07
, O 0 9.100517672777642e-09
have O 0 5.006246528438396e-09
the O 0 1.6268705849142862e-07
highest O 1 0.9835031032562256
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 7.64546130085364e-05
of O 0 6.581339917488549e-09
any O 0 2.7164153593162155e-08
Israeli O 0 4.750628249894362e-06
ethnic O 0 2.4888590814953204e-06
group O 0 1.993318073800765e-05
. O 0 1.2797922863683198e-06

The O 0 2.4707958345970837e-06
I1307K O 0 2.0288012819946744e-05
APC B-Disease 0 2.0806230168091133e-05
gene O 0 3.130551476715482e-06
variant O 0 8.278011591755785e-06
was O 0 2.7010401026927866e-06
found O 0 1.8216053376818309e-07
in O 0 6.342073533005532e-08
6 O 0 1.579303216203698e-06
. O 0 1.1786909226429998e-06

1 O 0 7.1034260145097505e-06
% O 0 1.6439908279153315e-07
of O 0 8.358657765938915e-09
American O 0 8.388511929524611e-08
Jews O 0 2.9880800411774544e-07
, O 0 3.056239705756525e-08
28 O 0 2.9244333177302906e-08
% O 0 3.745760146500743e-09
of O 0 3.57050189414565e-09
their O 0 3.351291888975538e-05
familial O 1 0.9999998807907104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 4.040461590193445e-06
, O 0 3.956856176046131e-08
but O 0 1.1276802602822045e-08
not O 0 4.394867580970185e-09
in O 0 5.809253078581378e-09
non O 0 1.539417837648216e-07
- O 0 8.297683052660432e-06
Jews O 0 1.0742275662778411e-05
. O 0 1.5686890719734947e-06

We O 0 3.3769713354558917e-06
assessed O 0 1.2548856602734304e-06
the O 0 5.3241564046402345e-08
I1307K O 0 1.4684229654449155e-06
prevalence O 0 9.108792255574372e-06
in O 0 2.1240937897459844e-08
Israeli O 0 4.811663529835641e-07
Jews O 0 9.760994146290614e-08
of O 0 3.627580236198469e-09
differing O 0 1.7152030906686377e-08
ethnic O 0 6.898556392798127e-08
origin O 0 1.9394252603888162e-07
and O 0 1.3969080328024575e-06
risk O 0 4.331986929173581e-05
for O 0 0.005173716228455305
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 6.532377028634073e-06

METHODS O 0 2.1149340682313778e-05
DNA O 0 1.239569337485591e-05
samples O 0 1.2144757874921197e-06
from O 0 4.713460910465983e-08
500 O 0 4.538643949558718e-08
unrelated O 0 6.877326086396351e-08
Jews O 0 6.091148918585532e-08
of O 0 2.391039144455931e-09
European O 0 3.7542631048381736e-07
or O 0 2.0016878465867194e-07
non O 0 2.5642785317359085e-07
- O 0 2.0490404040174326e-06
European O 0 3.9197678347591136e-07
origin O 0 6.865726476235068e-08
, O 0 1.018428363863677e-08
with O 0 2.49030751575674e-09
or O 0 9.734259265314904e-08
without O 0 1.4087685684671669e-08
a O 0 6.894176607374902e-08
personal O 0 2.0539982870104723e-06
and O 0 3.0236913062253734e-06
/ O 0 0.0003780298284254968
or O 0 6.118944497757184e-07
family O 0 2.1905130154209473e-07
history O 0 2.9605823570477696e-08
of O 0 2.5934854264164642e-08
neoplasia B-Disease 0 9.162277274299413e-05
, O 0 2.428097047868505e-07
were O 0 6.198587243488873e-08
examined O 0 8.159832987075788e-08
for O 0 2.4911006590855322e-09
the O 0 2.8387634465332212e-09
I1307K O 0 8.337642753986074e-08
variant O 0 3.454699708527187e-07
by O 0 5.100567079807661e-09
the O 0 7.931286738482868e-09
allele O 0 7.162084330047946e-07
- O 0 5.8978575907531194e-06
specific O 0 2.1448694553782843e-07
oligonucleotide O 0 5.057164889876731e-05
( O 0 2.1753741918928426e-07
ASO O 0 5.537009201361798e-05
) O 0 3.825888938990829e-08
method O 0 5.797566586807079e-07
. O 0 4.963057449458574e-07

RESULTS O 0 0.00019109247659798712
In O 0 2.120811046779636e-07
persons O 0 5.832404426087123e-08
at O 0 2.674919130640774e-07
average O 0 4.452940629562363e-06
risk O 0 4.3401902075856924e-05
for O 0 0.13367325067520142
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 7.958685728226556e-07
I1307K O 0 2.306173882971052e-06
was O 0 1.5891234852460911e-06
found O 0 9.333246708820297e-08
in O 0 2.614873473305579e-08
5 O 0 4.0554840552431415e-07
. O 0 7.571886158075358e-07

0 O 0 2.0273855625418946e-05
% O 0 9.11584095319995e-07
of O 0 1.8582094085672907e-08
120 O 0 6.357357307251732e-08
European O 0 5.042334692006989e-07
and O 0 3.388994400665979e-07
1 O 0 9.480836524744518e-07
. O 0 7.808071700310393e-07

6 O 0 8.28211796033429e-06
% O 0 1.9402170892135473e-07
of O 0 8.860756572914852e-09
188 O 0 7.821234504490349e-08
non O 0 3.158905315103766e-07
- O 0 5.070552106190007e-06
European O 0 3.1704660159448395e-06
Jews O 0 2.0493805550358957e-06
( O 0 6.164065524671969e-08
P O 0 4.220400296617299e-05
= O 0 9.037890436047746e-07
0 O 0 9.4889259116826e-08
. O 0 2.9975556259387304e-08
08 O 0 2.0245587961653655e-07
) O 0 7.532590728942523e-08
. O 0 2.4686588062650117e-07

It O 0 2.698648131627124e-06
occurred O 0 2.596005060695461e-06
in O 0 2.328295920506207e-07
15 O 0 5.778969125458389e-07
. O 0 1.0212108918494778e-06

4 O 0 5.779719685961027e-06
% O 0 3.304501774437085e-07
of O 0 2.393627696051226e-08
52 O 0 1.1019022849723115e-06
Ashkenazi O 0 2.956315438495949e-05
Israelis O 0 1.922263800224755e-05
with O 0 3.274125674579409e-06
familial O 1 0.9226618409156799
cancer B-Disease 1 0.8368670344352722
( O 0 7.171324227783771e-07
P O 0 0.004512268118560314
= O 0 4.062663720105775e-06
0 O 0 2.2135753852126072e-07
. O 0 6.707360000746121e-08
02 O 0 1.8752074026906485e-07
) O 0 9.708167603150741e-09
and O 0 2.4238396179043775e-08
was O 0 6.288135523391247e-07
not O 0 2.7111253686484815e-08
detected O 0 1.6272242930881475e-07
in O 0 4.872977132919232e-09
51 O 0 1.7144319031103805e-07
non O 0 5.0694271891416065e-08
- O 0 6.475886493717553e-07
European O 0 4.7092643740143103e-07
Jews O 0 9.594368748366833e-07
at O 0 6.827502829764853e-07
increased O 0 3.4896013403340476e-06
cancer B-Disease 0 8.110356429824606e-05
risk O 0 2.277908606629353e-06
. O 0 1.3455731959766126e-06

Colorectal B-Disease 1 0.9998722076416016
neoplasia I-Disease 0 0.27586716413497925
occurred O 0 0.000383728533051908
personally O 0 4.566664210869931e-05
or O 0 5.38537449301657e-07
in O 0 1.8489185293901755e-08
the O 0 8.786136262983746e-09
families O 0 8.158397513113869e-09
of O 0 4.660518193588814e-09
13 O 0 7.297454374111112e-08
of O 0 6.8457826074563854e-09
20 O 0 1.1057449711415757e-07
Ashkenazi O 0 5.3497137741942424e-06
I1307K O 0 2.542193442423013e-07
carriers O 0 2.3448158970040822e-08
, O 0 5.778002520884229e-09
8 O 0 2.75296319074414e-08
of O 0 5.273157466234579e-09
whom O 0 5.818748149977182e-07
also O 0 8.058784715103684e-07
had O 0 1.1868190767927445e-06
a O 0 2.1365909219639434e-07
personal O 0 8.224128009715059e-07
or O 0 1.1403766393414116e-06
family O 0 2.6380783424428955e-07
history O 0 3.6453521090606955e-08
of O 0 1.3857091119007237e-07
noncolonic O 0 0.0011330421548336744
neoplasia B-Disease 0 0.000675572024192661
. O 0 2.4415235202468466e-06

CONCLUSIONS O 0 9.386075544171035e-05
The O 0 4.602293870448193e-07
I1307K O 0 1.1405373697925825e-05
APC O 0 3.310358079033904e-05
variant O 0 3.0484081435133703e-05
may O 0 1.4168574580253335e-06
represent O 0 1.839463337205416e-08
a O 0 8.290592745652248e-08
susceptibility O 0 1.0043570910056587e-05
gene O 0 6.109491096140118e-06
for O 0 1.5610314221703447e-05
colorectal B-Disease 1 1.0
, I-Disease 0 9.58466671363567e-07
or I-Disease 0 1.60377908287046e-07
other I-Disease 0 3.1307877179642674e-08
, I-Disease 0 5.544573014049092e-07
cancers I-Disease 0 0.00022121949587017298
in O 0 7.27609261730322e-08
Ashkenazi O 0 0.00023268749646376818
Jews O 0 2.741598336797324e-06
, O 0 1.6411947001415683e-07
and O 0 7.509036947794812e-08
partially O 0 4.385451575217303e-06
explains O 0 2.792431246234628e-07
the O 0 1.072102673305153e-08
higher O 0 8.087672540568747e-07
incidence O 0 0.0017194498796015978
of O 0 0.01106650847941637
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.237017942112288e-07
European O 0 5.248688921710709e-06
Israelis O 0 0.00019049723050557077
. O 0 3.2134357752511278e-06

Systematic O 0 4.456150054465979e-05
analysis O 0 1.8088794604409486e-06
of O 0 9.225339425711354e-08
coproporphyrinogen O 0 8.39737695059739e-05
oxidase O 0 3.889659637934528e-05
gene O 0 0.0003951285616494715
defects O 1 0.909915566444397
in O 0 6.263757654778601e-07
hereditary B-Disease 1 0.7223471999168396
coproporphyria I-Disease 0 0.006642144173383713
and O 0 1.411540893059282e-06
mutation O 0 1.0503967132535763e-05
update O 0 2.5493787688901648e-05
. O 0 9.012937880470417e-07

Hereditary B-Disease 1 0.9999176263809204
coproporphyria I-Disease 1 0.9887027740478516
( O 0 0.00018302803800906986
HC B-Disease 1 0.9103396534919739
) O 0 4.676674052461749e-06
is O 0 2.516864014978637e-07
an O 0 7.244502285175258e-06
acute O 1 0.6805986166000366
hepatic B-Disease 1 0.9999927282333374
porphyria I-Disease 1 0.999998927116394
with O 0 3.269758963142522e-05
autosomal O 1 0.9989604949951172
dominant O 0 0.0038624019362032413
inheritance O 0 0.019238706678152084
caused O 0 0.0002077344834106043
by O 0 2.669893035545101e-07
deficient B-Disease 0 6.839175330242142e-05
activity I-Disease 0 1.540105074582243e-07
of I-Disease 0 5.3783431042120355e-08
coproporphyrinogen I-Disease 0 0.0004767489735968411
III I-Disease 0 0.0014527388848364353
oxidase I-Disease 0 2.7119453079649247e-05
( O 0 6.582196192539413e-07
CPO O 0 0.00010486527025932446
) O 0 1.8622334607698576e-07
. O 0 4.52804727046896e-07

Clinical O 0 0.0007627287996001542
manifestations O 0 3.2067688152892515e-05
of O 0 1.7081062253510026e-07
the O 0 1.3491362551576458e-06
disease O 0 0.003123339731246233
are O 0 2.929301423648667e-08
characterized O 0 1.3775756997347344e-06
by O 0 3.059763287183159e-07
acute O 0 5.3485411626752466e-05
attacks O 0 4.288040508981794e-05
of O 0 3.2974326131807175e-06
neurological B-Disease 1 0.9993568062782288
dysfunction I-Disease 0 0.01556943915784359
often O 0 1.0191531600867165e-06
precipitated O 0 4.1293533286079764e-06
by O 0 3.231192735597688e-08
drugs O 0 1.2013330774607311e-07
, O 0 2.7017508230642306e-08
fasting O 0 7.519484483964334e-07
, O 0 1.677194489957401e-07
cyclical O 0 0.00010478411422809586
hormonal O 0 2.930494156316854e-05
changes O 0 1.7343664637792244e-07
, O 0 4.7328654773082235e-08
or O 0 6.1891760196886025e-06
infectious B-Disease 0 0.0003298513183835894
diseases I-Disease 0 0.0009874466340988874
. O 0 2.5151607587758917e-06

Skin O 1 0.9999841451644897
photosensitivity O 1 0.999812662601471
may O 0 0.0025085420347750187
also O 0 6.628963546972955e-07
be O 0 6.80937404240467e-08
present O 0 1.474626856179384e-07
. O 0 6.30342810836737e-07

The O 0 2.644468850121484e-06
seven O 0 7.497829983549309e-07
exons O 0 6.097023288020864e-06
, O 0 2.4621831684612516e-08
the O 0 1.248252079477652e-08
exon O 0 6.645422672590939e-06
/ O 0 1.768746915331576e-05
intron O 0 9.602162208466325e-06
boundaries O 0 1.5646922690848442e-07
and O 0 9.830310432334954e-08
part O 0 2.0965462255162493e-08
of O 0 3.4265150716805692e-09
3 O 0 5.107764522449543e-08
noncoding O 0 1.267619609279791e-07
sequence O 0 1.1556164913884004e-08
of O 0 1.3421291855664208e-09
the O 0 2.1109512360339977e-08
CPO O 0 1.6936073734541424e-05
gene O 0 9.181226090504424e-08
were O 0 7.722359640638388e-09
systematically O 0 3.93116721397746e-07
analyzed O 0 4.5646277868627294e-08
by O 0 8.857203859236051e-10
an O 0 4.137748810251196e-09
exon O 0 8.423236863563943e-07
- O 0 6.521252089441987e-07
by O 0 3.168007012277485e-08
- O 0 6.386492259480292e-06
exon O 0 3.222772284061648e-05
denaturing O 0 3.0229963158490136e-05
gradient O 0 2.1767447833553888e-05
gel O 0 7.558543438790366e-05
electrophoresis O 0 5.498648079083068e-06
( O 0 3.596462860855354e-08
DGGE O 0 3.3057733617170015e-06
) O 0 6.9564531912647e-09
strategy O 0 2.4556310762591238e-08
followed O 0 4.217837634712396e-09
by O 0 1.4040036910856202e-09
direct O 0 1.445337804995006e-08
sequencing O 0 2.0774837139470037e-07
in O 0 2.339156246478069e-08
seven O 0 4.45417924765934e-08
unrelated O 0 4.3389982806729677e-07
heterozygous O 0 1.1539246997926966e-06
HC B-Disease 0 0.00864008441567421
patients O 0 1.2353420970612206e-05
from O 0 7.515183853001872e-08
France O 0 2.4872453650459647e-05
, O 0 3.302636457647168e-07
Holland O 0 3.1593372114002705e-05
, O 0 1.5257955965353176e-07
and O 0 1.8734343143478327e-07
Czech O 0 1.2115849131077994e-05
Republic O 0 2.7451433197711594e-06
. O 0 1.7361219306621933e-06

Seven O 0 6.789228336856468e-06
novel O 0 2.8878171178803314e-06
mutations O 0 9.059637704922352e-06
and O 0 4.9651113442905626e-08
two O 0 2.3629000978075965e-08
new O 0 2.7827016424453177e-07
polymorphisms O 0 4.5382628741208464e-05
were O 0 6.743971425748896e-07
detected O 0 9.098434929910582e-06
. O 0 4.6418458055086376e-07

Among O 0 1.6119254269142402e-06
these O 0 5.448596240853476e-08
mutations O 0 1.4842903510725591e-06
two O 0 5.8283788462176744e-08
are O 0 4.3434027929833974e-08
missense O 0 1.4557048416463658e-05
( O 0 1.145919839018461e-07
G197W O 0 8.649723213238758e-07
, O 0 7.397768087002987e-08
W427R O 0 3.169085971421737e-07
) O 0 1.3168437007493594e-08
, O 0 8.96602525557455e-09
two O 0 1.5727582791669192e-08
are O 0 1.8679212843153437e-08
nonsense O 0 4.35822585131973e-06
( O 0 4.271337061823033e-08
Q306X O 0 2.3941214521983056e-07
, O 0 3.887761579335347e-08
Q385X O 0 1.3018575373280328e-07
) O 0 9.14255071648995e-09
, O 0 1.6944758929327008e-09
two O 0 1.5532785058169907e-09
are O 0 2.308030433439967e-09
small O 0 2.184441783015245e-08
deletions O 0 4.264806193532422e-06
( O 0 2.2427242285516513e-08
662de14bp O 0 1.7168567012504354e-07
; O 0 1.6360463206410714e-08
1168del3bp O 0 4.338162682415714e-07
removing O 0 4.4234631957351667e-08
a O 0 6.680242137235837e-08
glycine O 0 6.282229151111096e-06
at O 0 8.912489875001484e-07
position O 0 2.937790384294203e-07
390 O 0 2.762813835488487e-07
) O 0 2.6910329964380253e-08
, O 0 9.051492000367034e-09
and O 0 8.506237492156288e-09
one O 0 1.8858383299402703e-08
is O 0 5.077504638961727e-09
a O 0 1.618081135745797e-08
splicing O 0 1.0028668839368038e-05
mutation O 0 4.251283826306462e-06
( O 0 2.542124732940465e-08
IVS1 O 0 1.1090522093581967e-05
- O 0 4.392428763821954e-06
15c O 0 1.0109146160175442e-06
- O 0 5.8915611589327455e-06
- O 0 2.4219221813837066e-05
> O 0 8.799805755188572e-07
g O 0 7.990658559720032e-06
) O 0 1.1765000529351255e-08
which O 0 8.651470650988813e-09
creates O 0 1.4619789823200335e-08
a O 0 1.4077263799094908e-08
new O 0 6.662872209517445e-08
acceptor O 0 8.603693117947842e-07
splice O 0 0.00013557495549321175
site O 0 9.39143865252845e-06
. O 0 1.3353858321352163e-06

The O 0 1.954725348696229e-06
pathological O 0 1.2544487617560662e-05
significance O 0 3.707047824264009e-07
of O 0 2.0583653892458642e-08
the O 0 4.9373472421621045e-08
point O 0 1.6762107861723052e-06
mutations O 0 2.5061171982088126e-06
G197W O 0 4.4032609025634883e-07
, O 0 2.0923076604617563e-08
W427R O 0 6.874139302226467e-08
, O 0 1.3110445173936114e-08
and O 0 6.765743076897479e-09
the O 0 5.394398261415745e-09
in O 0 2.1523725024508167e-08
- O 0 6.008213858876843e-06
frame O 0 5.158978819963522e-05
deletion O 0 1.5703995813964866e-05
390delGly O 0 1.8527717884353478e-06
were O 0 5.16966913721717e-08
assessed O 0 6.044092515367083e-08
by O 0 2.4281552324367794e-09
their O 0 1.0823592688780082e-08
respective O 0 2.1624707358114392e-08
expression O 0 4.0593839401026344e-08
in O 0 2.877786231536561e-09
a O 0 1.0908650871499503e-08
prokaryotic O 0 1.9841976950374374e-08
system O 0 2.3093832623999333e-08
using O 0 9.60433155228202e-08
site O 0 2.7206988306716084e-06
- O 0 9.776953447726555e-06
directed O 0 1.1666966202028561e-06
mutagenesis O 0 3.753114287974313e-05
. O 0 2.793579142235103e-06

These O 0 1.2602189372046269e-06
mutations O 0 2.217535256932024e-05
resulted O 0 3.709629652348667e-07
in O 0 2.50357690134706e-08
the O 0 2.7318677098264743e-08
absence O 0 6.516241057852312e-08
or O 0 2.1990103959979024e-08
a O 0 7.13159096221716e-08
dramatic O 0 2.1420844404929085e-06
decrease O 0 2.196199602622073e-06
of O 0 2.7665914004160186e-08
CPO O 0 0.00016891927225515246
activity O 0 5.815131203235069e-07
. O 0 5.749558908973995e-07

The O 0 1.5718429722255678e-06
two O 0 3.088364053382975e-07
polymorphisms O 0 2.4298780772369355e-05
were O 0 2.2432725188537006e-07
localized O 0 5.901470103708562e-07
in O 0 5.517861367820842e-08
noncoding O 0 9.62560307016247e-07
part O 0 2.1036040465105543e-08
of O 0 2.1148998108344585e-09
the O 0 7.330345663802973e-09
gene O 0 1.003703360424879e-07
1 O 0 4.3458395992956866e-08
) O 0 4.873813796990589e-09
a O 0 7.432078774627371e-08
C O 0 1.2414196135068778e-05
/ O 0 1.4109128642303403e-05
G O 0 1.3909265362599399e-05
polymorphism O 0 2.4970680101432663e-07
in O 0 1.5323189828109207e-08
the O 0 6.195454460566907e-08
promotor O 0 2.4943859898485243e-05
region O 0 1.316657630923146e-06
, O 0 1.9364268410981822e-08
142 O 0 6.725589685174782e-08
bp O 0 4.995860763301607e-06
upstream O 0 1.1228966201315416e-07
from O 0 4.348059245984359e-09
the O 0 3.873710685553533e-09
transcriptional O 0 6.696737386846507e-08
initiation O 0 3.838080431251001e-08
site O 0 6.000576036058192e-07
( O 0 4.225642413757669e-08
- O 0 2.9881534828746226e-06
142C O 0 3.300028083685902e-06
/ O 0 9.97708866634639e-06
G O 0 1.5216892279568128e-05
) O 0 1.4441308593404756e-08
, O 0 7.571840043851807e-09
and O 0 1.3320258673843455e-08
2 O 0 6.933036900136358e-08
) O 0 7.62692042854951e-09
a O 0 4.667334252417277e-08
6 O 0 9.340812994196313e-07
bp O 0 4.8860019887797534e-05
deletion O 0 5.564570528804325e-07
polymorphism O 0 1.648010936605715e-07
in O 0 9.963633473830669e-09
the O 0 9.102027576091132e-09
3 O 0 1.2426060891357338e-07
noncoding O 0 1.9809010609606048e-07
part O 0 1.2088602119320058e-08
of O 0 1.6630240518011874e-09
the O 0 3.365540024447e-08
CPO O 0 2.3617238184669986e-05
gene O 0 8.024674258422237e-08
, O 0 6.3703673447434994e-09
574 O 0 7.410789493178527e-08
bp O 0 8.36123126646271e-06
downstream O 0 2.0916736787057744e-07
of O 0 2.4570916412613997e-09
the O 0 1.2317861397548313e-08
last O 0 3.066087117531424e-07
base O 0 2.588770442457644e-08
of O 0 7.311574679036426e-10
the O 0 8.369857695811334e-09
normal O 0 3.9638780435780063e-07
termination O 0 3.5671894238475943e-07
codon O 0 7.532576091762166e-07
( O 0 3.634632506077651e-08
+ O 0 6.265012757467048e-07
574 O 0 4.995584959033295e-07
delATTCTT O 0 2.6421073471283307e-06
) O 0 1.5593816726777732e-07
. O 0 3.7248801731948333e-07

Five O 0 5.486333066073712e-06
intragenic O 0 0.00012315760250203311
dimorphisms O 0 0.00010271900100633502
are O 0 1.421091582187728e-07
now O 0 5.478744213860409e-08
well O 0 2.1901533031609688e-08
characterized O 0 2.0658724508848536e-07
and O 0 4.182486890158543e-08
the O 0 1.6800624891288862e-08
high O 0 1.509242508745956e-07
degree O 0 4.564749644941912e-08
of O 0 7.933132373239005e-09
allelic O 0 1.999410869757412e-06
heterogeneity O 0 6.3373004195455e-06
in O 0 5.567675316342502e-07
HC B-Disease 0 0.0056613171473145485
is O 0 4.096141879017523e-07
demonstrated O 0 6.385283768395311e-08
with O 0 1.9541204210327123e-09
seven O 0 7.340825280977015e-09
new O 0 1.2962202866617645e-08
different O 0 2.472817950405215e-09
mutations O 0 1.4852119534225494e-07
making O 0 6.278617181720847e-09
a O 0 1.3355058392505725e-08
total O 0 7.147453295885953e-09
of O 0 4.897109384671694e-09
nineteen O 0 1.8450630250299582e-06
CPO O 0 0.0013707398902624846
gene B-Disease 0 6.247514829738066e-05
defects I-Disease 0 0.48324763774871826
reported O 0 1.1902264304808341e-05
so O 0 5.975351768938708e-08
far O 0 5.64437314665156e-08
. O 0 6.35869170650949e-08
. O 0 4.204378569738765e-07

Coincidence O 0 1.7885686247609556e-05
of O 0 7.256301870484094e-08
two O 0 6.002058228204987e-08
novel O 0 5.51121331682225e-07
arylsulfatase O 0 9.175349077850115e-06
A O 0 9.997567076425184e-07
alleles O 0 6.053819561202545e-07
and O 0 1.755175560447242e-07
mutation O 0 1.689923124104098e-06
459 O 0 7.300391189346556e-07
+ O 0 3.7194317883404437e-06
1G O 0 2.9394337616395205e-05
> O 0 2.455367393849883e-07
A O 0 1.2675471339207434e-07
within O 0 1.0262085403667243e-08
a O 0 1.9019968533484644e-07
family O 0 3.5378807297092862e-06
with O 0 6.675174518022686e-06
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 0.9999991655349731
: O 0 1.6667074476117705e-07
molecular O 0 3.6695419680654595e-07
basis O 0 8.114110983115097e-08
of O 0 2.8545429131554556e-08
phenotypic O 0 1.7849581126938574e-05
heterogeneity O 0 0.0001043802039930597
. O 0 4.593922767526237e-06

In O 0 6.049403054930735e-06
a O 0 7.235825592033507e-07
family O 0 6.804505119362148e-07
with O 0 6.770186189442029e-08
three O 0 3.301515789644327e-07
siblings O 0 1.4910775689713773e-06
, O 0 9.629310682157666e-09
one O 0 6.3313865261704905e-09
developed O 0 7.971252102834114e-08
classical O 0 9.106995548791019e-07
late O 0 9.259181388188154e-05
infantile O 1 0.9953240752220154
metachromatic B-Disease 1 0.9999998807907104
leukodystrophy I-Disease 1 1.0
( O 0 0.00013775573461316526
MLD B-Disease 1 0.9999974966049194
) O 0 9.313487794315733e-07
, O 0 1.4559911676315096e-07
fatal O 0 0.00016088003758341074
at O 0 2.295750391567708e-06
age O 0 1.0396531280321142e-07
5 O 0 1.0082642631914496e-07
years O 0 7.844870708595408e-08
, O 0 1.6681585890410133e-08
with O 0 8.533753970141333e-08
deficient O 0 9.226913971360773e-05
arylsulfatase O 0 3.3020849514286965e-05
A O 0 1.0402078260085545e-05
( O 0 2.5813358206505654e-07
ARSA O 0 9.025534382089972e-05
) O 0 2.7029775750975205e-08
activity O 0 3.597567399538093e-08
and O 0 3.935825887424471e-08
increased O 0 5.534166120924056e-07
galactosylsulfatide O 0 0.0002921659033745527
( O 0 1.849230670813995e-06
GS O 1 0.9999803304672241
) O 0 6.725281878061651e-07
excretion O 0 3.819614903477486e-06
. O 0 5.626835672956076e-07

The O 0 3.114810454007966e-07
two O 0 8.850829402717864e-08
other O 0 2.562869383382349e-08
siblings O 0 8.140104341691767e-07
, O 0 5.5640882123952906e-08
apparently O 0 6.721665499753726e-07
healthy O 0 2.1656205717590638e-07
at O 0 2.4832610279190703e-07
12 O 0 2.203310032200534e-07
( O 0 1.3129038300974116e-08
1 O 0 2.5252646196349815e-07
/ O 0 1.0156176358577795e-05
2 O 0 6.195519972607144e-07
) O 0 1.7642435068410123e-08
and O 0 4.488086347009812e-08
15 O 0 9.674251799651756e-08
years O 0 3.9642969795750105e-08
, O 0 1.1887119732989504e-08
respectively O 0 1.977267771735569e-07
, O 0 1.8405268420451648e-08
and O 0 1.8967613257814264e-08
their O 0 7.281062153197126e-08
father O 0 9.433612717657525e-07
, O 0 6.045544864718977e-08
apparently O 0 4.808342168871604e-07
healthy O 0 2.5458755104068587e-08
as O 0 6.3904836977712876e-09
well O 0 1.4078713306275858e-08
, O 0 6.34405807886651e-08
presented O 0 2.9817093150086293e-07
ARSA O 0 0.00011605481995502487
and O 0 2.2238853034650674e-06
GS O 1 0.9999572038650513
values O 0 2.0830583480346831e-07
within O 0 4.99865171477154e-09
the O 0 7.528393908273756e-09
range O 0 4.0661223010829417e-07
of O 0 4.0415153534922865e-07
MLD B-Disease 1 0.999997615814209
patients O 0 4.461371645447798e-05
. O 0 6.896424338265206e-07

Mutation O 0 4.5757311454508454e-05
screening O 0 1.737985485306126e-06
and O 0 1.444734749611598e-07
sequence O 0 1.6692986548605404e-07
analysis O 0 1.7629039916755573e-07
disclosed O 0 6.468019819294568e-06
the O 0 2.553691125228852e-08
involvement O 0 7.445643035453031e-08
of O 0 2.069449722696959e-09
three O 0 8.654326144608149e-09
different O 0 2.282295419320235e-08
ARSA O 0 0.00017129283514805138
mutations O 0 2.6193818030151306e-06
being O 0 1.4966774486424583e-08
the O 0 3.4987117647489185e-09
molecular O 0 1.2914406966046954e-07
basis O 0 6.036649580209996e-08
of O 0 1.706542285262458e-08
intrafamilial O 0 5.741912536905147e-05
phenotypic O 0 2.2756572434445843e-05
heterogeneity O 0 3.759483661269769e-05
. O 0 2.0087281882297248e-06

The O 0 4.403757884574588e-06
late O 0 1.378965680487454e-05
infantile O 0 0.08653658628463745
patient O 0 0.0013064786326140165
inherited O 0 0.0010614580241963267
from O 0 8.631923833490873e-07
his O 0 2.288953737661359e-06
mother O 0 9.07062531041447e-06
the O 0 1.8276637092640158e-08
frequent O 0 4.951398864250223e-07
0 O 0 1.1183219612576067e-06
- O 0 1.359080670226831e-05
type O 0 3.4244176276843064e-06
mutation O 0 2.5329034087917535e-06
459 O 0 3.354773525643395e-07
+ O 0 5.751209641857713e-07
1G O 0 6.549162662849994e-06
> O 0 1.2091742007669382e-07
A O 0 4.5521252900471154e-07
, O 0 6.672308927591075e-08
and O 0 7.870573881518794e-08
from O 0 3.374191237526247e-08
his O 0 1.4119422075964394e-06
father O 0 1.7143073591796565e-06
a O 0 2.0686975688022358e-07
novel O 0 2.8649975547523354e-07
, O 0 4.14742196142015e-08
single O 0 1.0877925404884081e-07
basepair O 0 2.720732481975574e-06
microdeletion O 0 6.142026336419804e-07
of O 0 3.5678402454664138e-09
guanine O 0 5.077196973957143e-08
at O 0 2.20918821014493e-08
nucleotide O 0 1.545690508919506e-07
7 O 0 1.266604527927484e-07
in O 0 1.8788014699566702e-08
exon O 0 2.147420900655561e-06
1 O 0 1.1675001587718725e-06
( O 0 7.497602183548224e-08
7delG O 0 3.712503485076013e-06
) O 0 1.8231972376270278e-07
. O 0 7.551074645562039e-07

The O 0 1.9872597931680502e-06
two O 0 1.748919089550327e-06
clinically O 0 0.000709592248313129
unaffected O 0 2.614113691379316e-05
siblings O 0 5.169805717741838e-06
carried O 0 3.4274947324774985e-07
the O 0 9.396533329208978e-08
maternal O 0 5.721309207729064e-06
mutation O 0 2.792082113955985e-06
459 O 0 8.406095730606467e-07
+ O 0 2.5067938622669317e-06
1G O 0 3.2285919587593526e-05
> O 0 3.572146169972257e-07
A O 0 4.5340539145399816e-07
and O 0 1.493572483468597e-07
, O 0 3.047223628982465e-08
on O 0 1.573920513919802e-07
their O 0 6.633214155726819e-08
paternal O 0 8.775234050517611e-07
allele O 0 6.65085451601044e-07
, O 0 1.332142751664378e-08
a O 0 2.3873175436506244e-08
novel O 0 1.1261514032412379e-07
cytosine O 0 3.303014466382592e-07
to O 0 1.5484102888763118e-08
thymidine O 0 1.3195449355407618e-06
transition O 0 2.3479178423713165e-07
at O 0 6.219264037099492e-08
nucleotide O 0 3.263325538682693e-07
2435 O 0 1.0703331554395845e-06
in O 0 5.338972997037672e-08
exon O 0 1.7350030248053372e-06
8 O 0 1.825183915116213e-07
, O 0 6.162747201443608e-09
resulting O 0 7.404964641466449e-09
in O 0 3.0096189984618604e-09
substitution O 0 1.437409213878027e-08
of O 0 1.3016907551843815e-08
alanine O 0 1.2025303476548288e-05
464 O 0 1.1707602425303776e-06
by O 0 2.7416768944021896e-07
valine O 0 0.0032904590480029583
( O 0 4.07752708042608e-07
A464V O 0 3.889460003847489e-06
) O 0 3.505129768655024e-07
. O 0 8.904673904908122e-07

The O 0 4.893526238447521e-06
fathers O 0 1.2966233953193296e-05
genotype O 0 0.0001088548669940792
thus O 0 1.9119258922728477e-06
was O 0 1.6007350041036261e-06
7delG O 0 2.6434996470925398e-05
/ O 0 9.846565808402374e-05
A464V O 0 2.1167052182136104e-05
. O 0 2.7740845780499512e-06

Mutation O 0 0.00042780369403772056
A464V O 0 6.841797585366294e-05
was O 0 1.4564463526767213e-05
not O 0 4.741195880342275e-08
found O 0 7.490112352570577e-08
in O 0 6.177577915877919e-08
18 O 0 6.575470479219803e-07
unrelated O 0 2.0379115085233934e-05
MLD B-Disease 1 0.9999996423721313
patients O 0 5.1489325414877385e-05
and O 0 5.3682793321740974e-08
50 O 0 8.619405633680799e-08
controls O 0 1.06393645182834e-05
. O 0 2.5668402940937085e-06

A464V O 0 0.00038064003456383944
, O 0 2.7224143650528276e-06
although O 0 4.795437575921824e-07
clearly O 0 1.358884219371248e-06
modifying O 0 4.988904947822448e-06
ARSA O 0 0.003733789548277855
and O 0 3.1690655305283144e-05
GS O 1 0.999998927116394
levels O 0 7.065855243126862e-06
, O 0 4.9525418432949664e-08
apparently O 0 2.1839299790826772e-07
bears O 0 1.2227907575379504e-07
little O 0 2.562869383382349e-08
significance O 0 2.76628533413259e-08
for O 0 4.6059685843147236e-08
clinical O 0 5.058146257397311e-07
manifestation O 0 1.150305479313829e-06
of O 0 4.299241709304624e-07
MLD B-Disease 1 0.9999964237213135
, O 0 8.669370004099619e-07
mimicking O 0 5.73755369259743e-06
the O 0 1.0403969952221814e-07
frequent O 0 1.2383522516756784e-05
ARSA O 0 0.0026301611214876175
pseudodeficiency O 0 0.0001439993066014722
allele O 0 3.517719596857205e-05
. O 0 2.6558952868072083e-06

Our O 0 2.6651090593077242e-05
results O 0 6.3128040892479476e-06
demonstrate O 0 2.638984426539537e-07
that O 0 1.161250828829452e-08
in O 0 9.290812563733652e-09
certain O 0 2.176913405094183e-08
genetic O 0 3.0248706025304273e-05
conditions O 0 0.0002384561812505126
MLD B-Disease 1 0.999998927116394
- O 0 0.0002990835055243224
like O 0 1.0425478649267461e-06
ARSA O 0 0.000393932918086648
and O 0 2.2707943116984097e-06
GS O 1 0.9998912811279297
values O 0 1.7404803998033458e-07
need O 0 1.2305743979368344e-08
not O 0 3.0431908104588956e-09
be O 0 2.3172226359946535e-09
paralleled O 0 2.6979822109751694e-07
by O 0 1.360938028938108e-07
clinical O 0 6.29839541943511e-06
disease O 0 2.4330709493369795e-05
, O 0 1.0457144483666525e-08
a O 0 3.997127606680806e-08
finding O 0 4.637987416344913e-08
with O 0 5.940250957792159e-08
serious O 0 3.448140660111676e-06
diagnostic O 0 1.744262408465147e-05
and O 0 6.726006631652126e-07
prognostic O 0 0.0006936123827472329
implications O 0 9.599305485608056e-06
. O 0 2.4281000605697045e-06

Moreover O 0 3.844762977678329e-05
, O 0 9.346774731966434e-07
further O 0 5.219803824729752e-07
ARSA O 0 0.0004342933534644544
alleles O 0 5.261654223431833e-06
functionally O 0 4.920781520922901e-06
similar O 0 6.382799710991094e-08
to O 0 5.096680055771685e-08
A464V O 0 1.8770947463053744e-06
might O 0 2.544012431826559e-07
exist O 0 3.321486374829874e-08
which O 0 2.1439404918055516e-08
, O 0 6.503523941603362e-09
together O 0 5.9501927829330725e-09
with O 0 1.015970241269315e-08
0 O 0 7.303824531845748e-07
- O 0 2.8662609111052006e-05
type O 0 1.6670392142259516e-05
mutations O 0 4.8809168220032007e-05
, O 0 2.932891618456779e-07
may O 0 4.6797076720395125e-06
cause O 0 9.644659257901367e-07
pathological O 0 1.7175398170365952e-05
ARSA O 0 0.009640305303037167
and O 0 1.4155206372379325e-05
GS O 1 0.9999997615814209
levels O 0 3.606345217121998e-06
, O 0 2.3500277279708826e-08
but O 0 1.463345888907952e-08
not O 0 2.9023119907378714e-08
clinical O 0 1.3639213136684702e-07
outbreak O 0 6.806712349316513e-08
of O 0 4.8676080943721445e-09
the O 0 1.305494492953585e-06
disease O 0 0.00017321581253781915
. O 0 8.381187655004396e-08
. O 0 7.187153983068129e-07

Human O 0 0.0029045867267996073
MLH1 O 1 0.9980320334434509
deficiency O 1 0.9991135001182556
predisposes O 0 0.00045017394586466253
to O 0 8.682801308168564e-06
hematological B-Disease 1 0.7180838584899902
malignancy I-Disease 1 0.9577777981758118
and O 0 3.5077369830105454e-05
neurofibromatosis B-Disease 1 0.9104201197624207
type I-Disease 0 3.098090019193478e-05
1 I-Disease 0 9.620292985346168e-06
. O 0 2.4500461677234853e-06

Heterozygous O 0 0.0004503638483583927
germ O 0 0.0009842367144301534
- O 0 0.0001518666831543669
line O 0 1.7094218492275104e-05
mutations O 0 3.943756837543333e-06
in O 0 2.925839304168676e-08
the O 0 6.000982466503046e-08
DNA O 0 2.0571682398440316e-05
mismatch O 0 5.440281529445201e-05
repair O 0 0.0001376159198116511
genes O 0 3.05745197692886e-06
lead O 0 7.260264737851685e-06
to O 0 1.313682605541544e-05
hereditary B-Disease 1 0.9999865293502808
nonpolyposis I-Disease 1 0.9999997615814209
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.0200057406327687e-05

The O 0 4.136260395171121e-05
disease O 0 0.027138901874423027
susceptibility O 0 0.00021033643861301243
of O 0 3.2928869586612564e-07
individuals O 0 3.443643947775854e-07
who O 0 7.4329959716123994e-06
constitutionally O 0 1.0062582987302449e-05
lack O 0 8.140852258975428e-08
both O 0 8.858711986192702e-09
wild O 0 3.048784833481477e-07
- O 0 1.7665168343228288e-05
type O 0 2.8346041744953254e-06
alleles O 0 8.25938741400023e-07
is O 0 1.412665255884349e-07
unknown O 0 2.2779042865295196e-06
. O 0 9.831395573201007e-07

We O 0 1.2112142030673567e-05
have O 0 1.3435339951684e-07
identified O 0 1.8955429936795554e-07
three O 0 1.9887673730067945e-08
offspring O 0 3.8019240378162067e-07
in O 0 2.8684551622859544e-08
a O 0 1.0650633157638367e-05
hereditary B-Disease 1 0.9999970197677612
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 3.155639205942862e-05
who O 0 4.061284471390536e-06
developed O 0 3.6073083720111754e-06
hematological B-Disease 0 0.0017885069828480482
malignancy I-Disease 0 0.0008748193504288793
at O 0 8.269902309621102e-07
a O 0 1.1485938955502206e-07
very O 0 9.30132983967269e-08
early O 0 1.0039385642812704e-06
age O 0 1.4452557195454574e-07
, O 0 2.501381501929245e-08
and O 0 4.1705295217298044e-08
at O 0 2.5846441076282645e-07
least O 0 5.923333379342921e-09
two O 0 3.0238773707225164e-09
of O 0 7.627556364298016e-10
them O 0 4.3214698486337966e-09
displayed O 0 1.1078285666599186e-07
signs O 0 3.9731048673274927e-07
of O 0 4.878290127408036e-08
neurofibromatosis B-Disease 0 0.016141880303621292
type I-Disease 0 3.8426805986091495e-06
1 I-Disease 0 5.077558853372466e-06
( O 0 3.471417642231245e-07
NF1 B-Disease 0 4.1021561628440395e-05
) O 0 1.5034474643016438e-07
. O 0 4.0418547087028855e-07

DNA O 0 2.8548281989060342e-05
sequence O 0 1.0387467455075239e-06
analysis O 0 2.783123420613265e-07
and O 0 1.9981129639745632e-08
allele O 0 5.15567649017612e-07
- O 0 1.0882122296607122e-06
specific O 0 4.712732604161829e-08
amplification O 0 8.811378506834444e-07
in O 0 1.3427751355266082e-08
two O 0 2.7759366361124194e-08
siblings O 0 1.589541739122069e-06
revealed O 0 2.9677200927835656e-06
a O 0 5.154963673703605e-07
homozygous O 0 1.1908781743841246e-05
MLH1 O 0 0.00019511186110321432
mutation O 0 6.5331369114574045e-06
( O 0 6.267779895097192e-08
C676T O 0 2.3068380414770218e-06
- O 0 3.9756738260621205e-05
- O 0 0.00022005951905157417
> O 0 4.765084668179043e-06
Arg226Stop O 0 3.0489141863654368e-05
) O 0 2.1752869372448913e-07
. O 0 4.6174568524293136e-07

Thus O 0 2.5319927772216033e-06
, O 0 1.4511198287436855e-07
a O 0 2.5421013560844585e-07
homozygous O 0 1.0969984941766597e-05
germ O 0 0.00012995187717024237
- O 0 9.300409874413162e-05
line O 0 0.00011791403085226193
MLH1 O 0 0.0008576378459110856
mutation O 0 3.5986446164315566e-05
and O 0 4.179145776106452e-07
consequent O 0 5.015089482185431e-05
mismatch O 0 0.1503368616104126
repair O 1 0.9999181032180786
deficiency O 1 0.9980666041374207
results O 0 7.704810741415713e-06
in O 0 6.268675889486985e-08
a O 0 1.6441317711723968e-06
mutator O 0 0.00488350261002779
phenotype O 0 0.0008584088645875454
characterized O 0 6.724897957610665e-06
by O 0 8.189494451471546e-07
leukemia B-Disease 1 0.7482103109359741
and O 0 2.8037775336997584e-05
/ O 1 0.9990307092666626
or O 1 0.9091362357139587
lymphoma B-Disease 1 1.0
associated O 0 3.0225059163058177e-05
with O 0 4.828137321055692e-07
neurofibromatosis B-Disease 1 0.7172755599021912
type I-Disease 0 6.540343747474253e-06
1 I-Disease 0 1.133360910898773e-06
. O 0 1.5999934532828775e-07
. O 0 4.372349451386981e-07

Missense O 0 0.009658797644078732
mutations O 0 0.002797601977363229
in O 0 3.667099974791199e-07
the O 0 1.4056979580345796e-08
most O 0 5.865278041028432e-09
ancient O 0 1.1133526101048119e-08
residues O 0 4.643302418116946e-07
of O 0 3.456724018136015e-09
the O 0 2.313240798912375e-08
PAX6 O 0 1.0810309504449833e-05
paired O 0 9.208802680404915e-07
domain O 0 2.6117487550436636e-07
underlie O 0 1.995071897908929e-06
a O 0 1.3224369865838526e-07
spectrum O 0 1.651675347602577e-06
of O 0 7.641148158654687e-07
human O 0 0.0037343057338148355
congenital B-Disease 1 0.9999998807907104
eye I-Disease 1 0.9999920129776001
malformations I-Disease 1 0.999966025352478
. O 0 5.039645475335419e-05

Mutations O 0 0.000850039767101407
of O 0 2.678329451555328e-07
the O 0 2.274087620435239e-07
human O 0 9.529006206321355e-07
PAX6 O 0 0.0015430834610015154
gene O 0 0.0014541202690452337
underlie O 1 0.8193725943565369
aniridia B-Disease 1 1.0
( O 0 0.040813934057950974
congenital B-Disease 1 0.9999994039535522
absence I-Disease 0 8.025927854760084e-06
of I-Disease 0 9.721511418092632e-08
the I-Disease 0 1.5245520899043186e-06
iris I-Disease 1 0.8794634938240051
) O 0 3.8050978901083e-07
, O 0 1.7095461046778837e-08
a O 0 6.585636924683058e-08
rare O 0 1.3129034641679027e-06
dominant O 0 0.0005923552671447396
malformation B-Disease 1 0.8596465587615967
of I-Disease 0 1.0058919741595673e-07
the I-Disease 0 1.1112713309557876e-06
eye I-Disease 0 0.1045641303062439
. O 0 6.291245881584473e-06

The O 0 1.358615918434225e-06
spectrum O 0 3.0469236662611365e-06
of O 0 1.1478448413981823e-07
PAX6 O 0 0.0002807803393807262
mutations O 0 0.00023849259014241397
in O 0 3.30388229485834e-06
aniridia B-Disease 1 0.9999998807907104
patients O 0 0.0015879141865298152
is O 0 1.2779662483808352e-07
highly O 0 1.464633783143654e-07
biased O 0 5.72136877963203e-06
, O 0 3.0023503683196395e-08
with O 0 8.029263476316828e-09
92 O 0 8.209914881263103e-08
% O 0 4.933879971247279e-09
of O 0 1.90253235388127e-09
all O 0 1.8946279212173067e-08
reported O 0 2.6329076717956923e-05
mutations O 0 3.69524491361517e-06
leading O 0 3.324732347209647e-07
to O 0 3.331156221975107e-07
premature O 0 1.845006750045286e-06
truncation O 0 8.908139079721877e-07
of O 0 5.535642166876187e-09
the O 0 3.623882349756968e-08
protein O 0 2.0316140307841124e-06
( O 0 4.359038996426534e-08
nonsense O 0 4.5201130660643685e-07
, O 0 4.288870592006333e-09
splicing O 0 2.1232800406778551e-07
, O 0 8.883771052126122e-09
insertions O 0 2.3719542241451563e-07
and O 0 1.0928876292837231e-07
deletions O 0 9.512870633443526e-07
) O 0 2.191026560183218e-08
and O 0 4.532795472300677e-08
just O 0 4.671083431162515e-08
2 O 0 1.2543434024792077e-07
% O 0 1.2230119139644557e-08
leading O 0 1.187252784973225e-08
to O 0 1.1658441989581547e-09
substitution O 0 2.133276666427264e-09
of O 0 6.184504020012582e-10
one O 0 5.4854756292854745e-09
amino O 0 4.8174022992952814e-08
acid O 0 1.6086255527625326e-07
by O 0 6.216960724003684e-09
another O 0 1.1106933328619562e-07
( O 0 1.1219739093348835e-07
missense O 0 8.419377991231158e-06
) O 0 2.1720076404108113e-07
. O 0 6.990331939960015e-07

The O 0 1.6533458619960584e-06
extraordinary O 0 6.607894533772196e-07
conservation O 0 1.1660898735499359e-07
of O 0 6.392495421891908e-09
the O 0 1.3594847025899526e-08
PAX6 O 0 1.658805672377639e-06
protein O 0 2.03313803126548e-07
at O 0 1.3779204444119841e-08
the O 0 3.2718618925287046e-09
amino O 0 4.9630475729145473e-08
acid O 0 2.486765993126028e-07
level O 0 8.830118858327296e-09
amongst O 0 1.3397257525582518e-08
vertebrates O 0 6.743393043961987e-08
predicts O 0 4.466734026209451e-06
that O 0 3.765633138641533e-08
pathological O 0 3.753754981516977e-06
missense O 0 5.50042386748828e-05
mutations O 0 3.652490704553202e-05
should O 0 7.865081386171369e-08
in O 0 2.0045947124458507e-08
fact O 0 3.3581468272814163e-08
be O 0 2.7598556329166968e-08
common O 0 6.552209441679224e-08
even O 0 8.991614919295898e-08
though O 0 3.12643173572269e-08
they O 0 9.713612136863503e-09
are O 0 6.698190890830347e-09
hardly O 0 5.906267475097593e-08
ever O 0 5.953362958166508e-08
seen O 0 7.106307293724967e-07
in O 0 3.778285133648751e-07
aniridia B-Disease 1 0.9999990463256836
patients O 0 2.16780390474014e-05
. O 0 4.983536996405746e-07

This O 0 1.2518197536337539e-06
indicates O 0 1.1665407555483398e-06
that O 0 3.1095655828039526e-08
there O 0 6.258817464299682e-09
is O 0 5.2358850588518635e-09
a O 0 9.554123892030475e-08
heavy O 0 2.5173319954774342e-05
ascertainment O 0 6.693114846711978e-05
bias O 0 4.834642822970636e-06
in O 0 8.880417290413334e-09
the O 0 4.387698204766366e-09
selection O 0 4.900211347802497e-09
of O 0 3.4107092705681907e-09
patients O 0 3.815169691279152e-08
for O 0 4.99447727619895e-09
PAX6 O 0 6.576062332896981e-06
mutation O 0 1.9205792796128662e-06
analysis O 0 6.630077109548438e-08
and O 0 3.037022722196525e-08
that O 0 1.17062208815355e-08
the O 0 3.8442564687102276e-08
missing O 0 3.2754685435065767e-06
PAX6 O 0 0.00022740667918697
missense O 0 0.00020327688253019005
mutations O 0 9.765932918526232e-05
frequently O 0 3.500136926959385e-06
may O 0 4.4086195885029156e-06
underlie O 0 2.3697484721196815e-05
phenotypes O 0 1.590370447956957e-05
distinct O 0 2.12508211916429e-06
from O 0 8.534686912753386e-07
textbook O 0 0.00012475218682084233
aniridia B-Disease 1 0.9999960660934448
. O 0 1.1464699127827771e-05

Here O 0 2.766085344774183e-06
we O 0 1.186470015568375e-07
present O 0 2.2569407676087394e-08
four O 0 2.179955060910288e-08
novel O 0 3.4789837854987127e-07
PAX6 O 0 3.124064824078232e-05
missense O 0 0.00013986155681777745
mutations O 0 6.961093458812684e-05
, O 0 1.0113729587146736e-07
two O 0 1.7583813516353075e-08
in O 0 6.644420125212491e-08
association O 0 3.42760841931522e-08
with O 0 1.9949522922502183e-08
atypical O 0 1.0604901945043821e-05
phenotypes O 0 4.0026796341408044e-05
ectopia B-Disease 0 0.0004409289686009288
pupillae I-Disease 0 0.0005168215138837695
( O 0 2.6611434122969513e-07
displaced B-Disease 0 1.1517522580106743e-06
pupils I-Disease 0 1.7113065950979944e-06
) O 0 9.259747457690537e-07
and O 0 0.00010237157403025776
congenital B-Disease 1 0.9999994039535522
nystagmus I-Disease 0 0.3609188497066498
( O 0 4.976342324880534e-07
searching B-Disease 0 2.4965636384877143e-06
gaze I-Disease 0 6.37342527625151e-05
) O 0 1.0832623331680225e-07
, O 0 1.6466026764305752e-08
and O 0 1.3248652841468811e-08
two O 0 3.899904399418119e-08
in O 0 1.0122780480514848e-07
association O 0 1.3193930392674247e-08
with O 0 7.473127894286336e-09
more O 0 6.044265177251873e-08
recognizable O 0 0.00010964503599097952
aniridia B-Disease 1 0.9999587535858154
phenotypes O 0 6.493719411082566e-05
. O 0 1.4670064274469041e-06

Strikingly O 0 0.00026583459111861885
, O 0 5.422061235549336e-07
all O 0 1.0620686552442749e-08
four O 0 2.6469637148807124e-08
mutations O 0 9.715317901282106e-07
are O 0 3.903608547517479e-09
located O 0 3.0119405636241936e-08
within O 0 6.74808697809226e-09
the O 0 3.51500730744192e-08
PAX6 O 0 4.996737516194116e-06
paired O 0 1.8498256793009205e-07
domain O 0 6.70961242121848e-08
and O 0 2.1931755966875244e-08
affect O 0 4.578422263534776e-08
amino O 0 3.832644779322436e-08
acids O 0 5.836065852804495e-08
which O 0 9.052614657889535e-09
are O 0 8.050314859175955e-10
highly O 0 3.4299152407157862e-09
conserved O 0 1.4427928185511973e-08
in O 0 6.5340111099487785e-09
all O 0 1.5095491523453575e-09
known O 0 1.6862392371308488e-08
paired O 0 1.3776502783002798e-07
domain O 0 2.0692243651865283e-07
proteins O 0 2.6375050765636843e-07
. O 0 5.751840603807068e-07

Our O 0 1.1624733815551735e-05
results O 0 4.59825378129608e-06
support O 0 1.612563238495568e-08
the O 0 8.458444611392224e-09
hypothesis O 0 8.229370962453686e-08
that O 0 3.9186405231816934e-09
the O 0 2.4625717021109494e-09
under O 0 4.2524592736015165e-09
- O 0 1.7078455982755258e-07
representation O 0 5.1706745551882705e-08
of O 0 1.2120001002813297e-08
missense O 0 4.342509055277333e-05
mutations O 0 2.507833778508939e-05
is O 0 7.790965383946968e-08
caused O 0 2.8383487915562e-07
by O 0 2.5352102639430996e-08
ascertainment O 0 2.626547939144075e-05
bias O 0 1.8332924810238183e-05
and O 0 1.3907373386246036e-07
suggest O 0 6.200431812430907e-08
that O 0 3.1996800764488853e-09
a O 0 1.9566277487115258e-08
substantial O 0 1.4878857257372147e-07
burden O 0 4.107955930976459e-07
of O 0 2.5453125829244527e-08
PAX6 B-Disease 0 0.0012870070058852434
- I-Disease 0 0.1218118667602539
related I-Disease 0 0.0004515505279414356
disease I-Disease 0 0.00446296576410532
remains O 0 1.4204888429958373e-06
to O 0 1.8587593331176322e-07
be O 0 1.1657317600111128e-07
uncovered O 0 5.8131849982601125e-06
. O 0 1.548707899701185e-07
. O 0 3.6600670227926457e-07

The O 0 1.8926182292489102e-06
chromosomal O 0 0.0003227726847399026
order O 0 2.784034052183415e-07
of O 0 2.405922039372399e-08
genes O 0 6.004131023473747e-07
controlling O 0 3.4547003906482132e-06
the O 0 6.67872654958046e-08
major O 0 1.1517419551410057e-07
histocompatibility O 0 1.1161462225572905e-06
complex O 0 2.7257712531536527e-07
, O 0 4.636191874851647e-08
properdin O 0 1.2467719443520764e-06
factor O 0 4.768239136865304e-08
B O 0 9.373492275699391e-07
, O 0 6.645915817671266e-08
and O 0 2.256718516946421e-06
deficiency B-Disease 0 1.6940886780503206e-05
of I-Disease 0 9.868194039697187e-10
the I-Disease 0 1.2768351709269155e-08
second I-Disease 0 3.643614547854668e-07
component I-Disease 0 1.317663276267922e-07
of I-Disease 0 9.18472498057099e-09
complement I-Disease 0 4.045297998800379e-07
. O 0 7.099493473106122e-07

The O 0 5.053951213085384e-07
relationship O 0 4.4520305664264015e-07
of O 0 1.4157369498946082e-08
the O 0 1.3859226655199564e-08
genes O 0 1.5541245090844313e-07
coding O 0 2.0247318843757967e-06
for O 0 8.219377889417956e-08
HLA O 0 1.2542692275019363e-05
to O 0 6.838633481720535e-08
those O 0 5.094500377111899e-09
coding O 0 2.3473315025057673e-07
for O 0 1.3856795710864844e-08
properdin O 0 1.5835305475775385e-06
Factor O 0 5.129369640144432e-08
B O 0 3.599616604788025e-07
allotypes O 0 2.1269331682560733e-06
and O 0 2.141423465218395e-07
for O 0 5.206033506510721e-07
deficiency B-Disease 0 8.105795131996274e-06
of I-Disease 0 1.1895029405906143e-09
the I-Disease 0 5.988310736171343e-09
second I-Disease 0 2.9978301085975545e-07
component I-Disease 0 8.087612712870396e-08
of I-Disease 0 2.6411373088564005e-09
complement I-Disease 0 1.5753771265281102e-07
( O 0 8.33261921684425e-08
C2 O 0 1.0616568943078164e-05
) O 0 3.6979869832975965e-08
was O 0 1.964237554830106e-07
studied O 0 2.603725235417187e-08
in O 0 5.605981900913548e-09
families O 0 5.9834928123336795e-09
of O 0 1.4941388570832714e-08
patients O 0 1.1252780041104415e-06
with O 0 3.8718374639756803e-07
connective O 1 0.9613989591598511
tissue O 1 0.9992377758026123
disorders O 1 0.9502867460250854
. O 0 4.198210262984503e-06

Patients O 0 0.007559640798717737
were O 0 2.1178532279009232e-06
selected O 0 9.841285475431505e-08
because O 0 1.7085486803125605e-08
they O 0 1.14768017311917e-08
were O 0 1.0633049996044974e-08
heterozygous O 0 2.7172271188646846e-07
or O 0 3.578556118100096e-07
homozygous O 0 2.724806108744815e-05
for O 0 4.4488257117336616e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
. O 0 6.656053301412612e-06

12 O 0 8.289955076179467e-06
families O 0 8.583138537687773e-07
with O 0 7.679180669128982e-08
15 O 0 3.594261954731337e-07
matings O 0 1.5857785911066458e-05
informative O 0 1.8510430891183205e-05
for O 0 0.00014782507787458599
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 2.3106053959054407e-06
found O 0 1.6623815781713347e-06
. O 0 8.939065310187289e-07

Of O 0 1.536768650112208e-06
57 O 0 2.1765788460470503e-06
informative O 0 2.0305951693444513e-06
meioses O 0 2.1537667635129765e-05
, O 0 4.959820643080093e-08
two O 0 4.478788451223181e-09
crossovers O 0 3.454047146078665e-07
were O 0 2.28551471082028e-08
noted O 0 2.390789610728916e-08
between O 0 2.772676843676436e-08
the O 0 1.8087059288518503e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999979734420776
gene O 0 7.118069333955646e-07
and O 0 3.73873128012292e-08
the O 0 1.5097082695092467e-08
HLA O 0 3.718777225003578e-05
- O 0 9.334097740065772e-06
B O 0 7.763565577079135e-07
gene O 0 5.124568147607533e-08
, O 0 8.532313189313356e-10
with O 0 5.343531728208006e-10
a O 0 1.4833485550980186e-08
recombinant O 0 3.988422747625009e-08
fraction O 0 4.460402536210495e-08
of O 0 8.421099373379093e-09
0 O 0 4.842422640649602e-07
. O 0 9.338639870293264e-07

035 O 0 0.024280525743961334
. O 0 0.000152781285578385

A O 0 0.00010146531712962314
lod O 0 0.018999025225639343
score O 0 2.4465298338327557e-06
of O 0 6.0154327741202e-08
13 O 0 5.123527557771013e-07
was O 0 3.272637911777565e-07
calculated O 0 2.2589010484352912e-07
for O 0 1.6833887173106632e-08
linkage O 0 4.607160735758953e-05
between O 0 0.0002979675482492894
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.396625634697557e-06
HLA O 0 3.091066537308507e-05
- O 0 4.907612037641229e-06
B O 0 1.5345704014180228e-06
at O 0 2.8288843267887387e-08
a O 0 1.4813609894304136e-08
maximum O 0 3.103131263060277e-08
likelihood O 0 3.274148241416697e-08
value O 0 4.308285284082558e-09
of O 0 7.044493877117475e-10
the O 0 3.976297957564157e-09
recombinant O 0 4.741385595252723e-08
fraction O 0 4.852889290418716e-08
of O 0 1.643233105141917e-08
0 O 0 8.315454920193588e-07
. O 0 1.1923142437808565e-06

04 O 0 0.007247453089803457
. O 0 9.927761129802093e-05

18 O 0 1.3270335330162197e-05
families O 0 2.827034961683239e-07
with O 0 3.921662994343933e-08
21 O 0 2.0731275185426057e-07
informative O 0 3.026891590707237e-07
matings O 0 2.8174795261293184e-06
for O 0 4.297708144918033e-08
both O 0 2.845253277428128e-08
properdin O 0 5.879129275854211e-06
Factor O 0 1.3073069737856713e-07
B O 0 4.15286109500812e-07
allotype O 0 3.185395371474442e-06
and O 0 1.5104981798685913e-07
HLA O 0 5.270381734590046e-05
- O 0 1.7069391105906107e-05
B O 0 3.483316959318472e-06
were O 0 7.060548057324922e-08
found O 0 1.6866741248122707e-07
. O 0 3.2928934956544254e-07

Of O 0 1.9242513644712744e-06
72 O 0 6.737126113876002e-06
informative O 0 3.996383384219371e-06
meioses O 0 5.239507299847901e-05
, O 0 1.8414682756429102e-07
three O 0 3.278222493463545e-08
recombinants O 0 1.3401763681031298e-05
were O 0 1.9803287898412236e-07
found O 0 7.727726369921584e-08
, O 0 2.3527442216675354e-09
giving O 0 3.360381084505093e-09
a O 0 6.999562707221685e-09
recombinant O 0 5.683046921944879e-08
fraction O 0 4.736270042826618e-08
of O 0 2.1590871313037496e-08
0 O 0 1.2635330222110497e-06
. O 0 1.036606363413739e-06

042 O 0 0.00836188904941082
. O 0 0.00016936696192715317

A O 0 5.6764012697385624e-05
lod O 0 0.001956637715920806
score O 0 1.1955377203776152e-06
of O 0 1.289498197110106e-08
16 O 0 4.9091386955524285e-08
between O 0 1.9218708402490847e-08
HLA O 0 2.4523824322386645e-05
- O 0 5.524486823560437e-06
B O 0 6.969423793634633e-07
and O 0 1.0987080578672703e-08
Factor O 0 1.1960580081904482e-08
B O 0 1.4908486889453343e-07
allotypes O 0 1.1512382798173348e-06
was O 0 2.9381544663920067e-07
calculated O 0 1.53095243149437e-07
at O 0 1.8467614992800918e-08
a O 0 9.869628669889607e-09
maximum O 0 1.9899434988701614e-08
likelihood O 0 3.228888445505618e-08
value O 0 4.341611958835756e-09
of O 0 7.533373924673015e-10
the O 0 4.682294107993812e-09
recombinant O 0 6.20036075815733e-08
fraction O 0 5.9327213364213094e-08
of O 0 9.902684006135587e-09
0 O 0 4.883014526058105e-07
. O 0 1.2869056718045613e-06

04 O 0 0.005244475789368153
. O 0 3.9964023017091677e-05

A O 0 4.359647846285952e-06
crossover O 0 1.0180962817685213e-05
was O 0 8.872885700839106e-06
shown O 0 1.8831215697900916e-07
to O 0 1.52272487952132e-08
have O 0 9.485955132504387e-09
occurred O 0 2.856078928914485e-08
between O 0 3.0687792307304562e-09
genes O 0 3.829656236575829e-08
for O 0 5.502315048033779e-09
Factor O 0 1.629089929622296e-08
B O 0 2.839388457687164e-07
and O 0 1.0618604306955604e-07
HLA O 0 3.063784970436245e-05
- O 0 4.951492155669257e-05
D O 0 7.625487342011184e-05
, O 0 1.6977441674725924e-08
in O 0 3.5935057152158834e-09
which O 0 2.5937038117263e-07
HLA O 0 3.4055494325002655e-05
- O 0 1.7942524209502153e-05
D O 0 5.4306816309690475e-05
segregared O 0 2.656457809280255e-06
with O 0 2.5052488084043034e-08
HLA O 0 2.3122556740418077e-05
- O 0 2.8413624022505246e-06
A O 0 1.5582354535581544e-06
and O 0 5.160275691196148e-07
B O 0 3.285332013547304e-06
. O 0 7.900012519712618e-07

These O 0 1.0424483889437397e-06
studies O 0 4.198452359105431e-07
suggest O 0 9.181716364992099e-08
that O 0 2.8533821971876705e-09
the O 0 2.720759173513443e-09
genes O 0 2.5140709070115008e-08
for O 0 6.194648793922397e-09
Factor O 0 1.1366098107146172e-07
B O 0 2.4511666197213344e-05
and O 0 0.0013022547354921699
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999998807907104
are O 0 1.6025184734758113e-08
located O 0 1.694386320139074e-08
outside O 0 1.244315583903699e-08
those O 0 5.982614403876596e-09
for O 0 1.9444918564204272e-08
HLA O 0 1.1067235391237773e-05
, O 0 2.8310648048091025e-08
that O 0 3.283965765987773e-09
the O 0 1.1852655523725275e-09
order O 0 2.0581993886992223e-09
of O 0 2.362155360202678e-09
genese O 0 2.0462107386265416e-06
is O 0 2.6123062824012777e-08
HLA O 0 1.2886101785625215e-06
- O 0 3.2347386991204985e-07
A O 0 1.13724013317551e-06
, O 0 5.389937385302801e-08
- O 0 9.354131975669588e-07
B O 0 6.838320132374065e-07
, O 0 1.905529245505022e-08
- O 0 1.222302671521902e-06
D O 0 8.041763976507355e-06
, O 0 8.840213006067188e-09
Factor O 0 1.3151117528309442e-08
B O 0 1.8584509575703123e-07
allotype O 0 1.8869930499931797e-05
, O 0 2.146934093616437e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999995231628418
, O 0 1.6752721876400756e-08
that O 0 1.5578625056633655e-09
the O 0 2.1106441039364654e-09
genes O 0 1.0564019703451777e-07
coding O 0 3.614617162384093e-05
for O 0 3.607306280173361e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999997615814209
and O 0 1.5777165174313268e-07
Factor O 0 2.6928711704954367e-08
B O 0 1.2716492392428336e-07
allotypes O 0 2.7732542662306514e-07
are O 0 2.1733195243456294e-09
approximately O 0 5.559279703248876e-09
3 O 0 4.786737406448083e-08
- O 0 8.300955300910573e-07
- O 0 2.9243080916785402e-06
5 O 0 1.0196474420354207e-07
centimorgans O 0 2.5376976964253117e-07
from O 0 2.7932387514084667e-09
the O 0 4.319244961692448e-09
HLA O 0 3.4077861528203357e-06
- O 0 5.426638836070197e-07
A O 0 1.108020455831138e-06
and O 0 2.3487959310841688e-07
HLA O 0 1.6556319678784348e-05
- O 0 2.6977400011674035e-06
B O 0 5.08273956256744e-07
loci O 0 3.619067712179458e-08
, O 0 8.667705664322511e-09
and O 0 7.732117168757213e-09
that O 0 5.009093140273535e-09
the O 0 2.166748025445031e-08
apparent O 0 6.20505716142361e-07
lack O 0 2.2427242285516513e-08
of O 0 3.709980767041543e-09
recombinants O 0 1.4769943845749367e-06
between O 0 9.786082166840515e-09
the O 0 7.769400234280965e-09
Factor O 0 2.9746596297286487e-08
B O 0 6.556559242199e-07
gene O 0 2.1525713691517012e-06
and O 0 4.5734104787698016e-05
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999996423721313
gene O 0 2.469959326845128e-06
suggests O 0 1.4804830072989716e-07
that O 0 2.5449518048503705e-09
these O 0 5.566895278086292e-10
two O 0 5.999789554067547e-09
genes O 0 1.6381829937017756e-07
lie O 0 1.930219241330633e-06
in O 0 4.542818743402677e-08
close O 0 2.2449459891049628e-07
proximity O 0 2.2648329434105108e-07
to O 0 1.6059921392752585e-07
one O 0 9.667943601243678e-08
another O 0 3.8425710613410047e-07
. O 0 8.004448091014638e-07

Distribution O 0 7.219507551781135e-06
of O 0 1.993537921407551e-07
emerin O 0 8.470345346722752e-05
and O 0 1.2683683507930255e-06
lamins O 0 2.1322000975487754e-05
in O 0 1.6052693752044433e-07
the O 0 1.1281518652594968e-07
heart O 0 1.0084158930112608e-05
and O 0 2.437242301311926e-07
implications O 0 2.448375653330004e-07
for O 0 3.773420473862643e-07
Emery B-Disease 1 0.913156270980835
- I-Disease 1 0.997275173664093
Dreifuss I-Disease 1 0.9999687671661377
muscular I-Disease 1 0.9981628060340881
dystrophy I-Disease 1 0.998392641544342
. O 0 6.439971457439242e-06

Emerin O 0 0.0005248840316198766
is O 0 6.54097163987899e-07
a O 0 1.664586761762621e-07
nuclear O 0 1.140862877946347e-06
membrane O 0 2.168503669963684e-07
protein O 0 4.5607291099258873e-07
which O 0 4.1701081698874987e-08
is O 0 2.4900332462607366e-08
missing O 0 1.099792470427019e-07
or O 0 1.2792709469522379e-07
defective O 0 1.758990401867777e-05
in O 0 5.714595090466901e-07
Emery B-Disease 1 0.9439795017242432
- I-Disease 1 0.9998358488082886
Dreifuss I-Disease 1 0.9999973773956299
muscular I-Disease 1 0.9999817609786987
dystrophy I-Disease 1 0.9999940395355225
( O 0 2.317273356311489e-05
EDMD B-Disease 1 0.9999986886978149
) O 0 3.4263450743310386e-06
. O 0 1.5032569535833318e-06

It O 0 3.6671840462076943e-06
is O 0 9.835674319447207e-08
one O 0 2.2622721473908314e-08
member O 0 1.973441143832133e-08
of O 0 1.5148158283295743e-09
a O 0 1.0657744553554949e-07
family O 0 4.2478006889723474e-07
of O 0 4.4551732969466684e-08
lamina O 0 1.8150787582271732e-05
- O 0 1.308640912611736e-05
associated O 0 3.657310401194991e-07
proteins O 0 1.7624206094524197e-08
which O 0 1.2014264250126416e-08
includes O 0 1.0492987811971943e-08
LAP1 O 0 8.911060831451323e-06
, O 0 3.0654756955073026e-08
LAP2 O 0 8.03535476734396e-06
and O 0 2.1630035007547121e-07
lamin O 0 4.737950803246349e-05
B O 0 4.251749942341121e-06
receptor O 0 1.5213364576993627e-06
( O 0 6.777136718483234e-07
LBR O 0 5.55102524231188e-05
) O 0 2.6681217946133984e-07
. O 0 9.389829642714176e-07

A O 0 1.6439827959402464e-05
panel O 0 3.709102429638733e-06
of O 0 4.679126774931319e-08
16 O 0 1.8808833601724473e-07
monoclonal O 0 4.426434543347568e-07
antibodies O 0 4.2724494164758653e-07
( O 0 1.3918811703206302e-07
mAbs O 0 1.2552197858894942e-06
) O 0 6.105361904928941e-08
has O 0 7.307956906288382e-08
been O 0 7.726252704287617e-08
mapped O 0 1.4996526260802057e-06
to O 0 3.1198073457971986e-08
six O 0 8.33852986659167e-09
specific O 0 2.4233388629113506e-09
sites O 0 6.709392152970395e-09
throughout O 0 5.417112980410366e-09
the O 0 2.5173085838048337e-09
emerin O 0 1.7625626469452982e-07
molecule O 0 1.3346350691278985e-08
using O 0 1.50539243293224e-08
phage O 0 5.327051511017089e-08
- O 0 7.072692653764534e-08
displayed O 0 1.524887238701922e-08
peptide O 0 6.222204085304384e-09
libraries O 0 2.543200094962117e-09
and O 0 4.6496411165719564e-09
has O 0 1.6418983506127915e-08
been O 0 6.875644498194333e-09
used O 0 2.015905664620732e-08
to O 0 3.6045733509126876e-08
localize O 0 5.756302925874479e-06
emerin O 0 1.5882835214142688e-05
in O 0 5.449739504115314e-08
human O 0 6.205542746329229e-08
and O 0 3.9483717273469665e-07
rabbit O 0 0.0017510525649413466
heart O 0 0.00025948265101760626
. O 0 2.7333173875376815e-06

Several O 0 5.756132850365248e-06
mAbs O 0 3.0221401175367646e-05
against O 0 1.9764024727919605e-07
different O 0 1.0899336899683476e-07
emerin O 0 1.4910441677784547e-05
epitopes O 0 9.751708603289444e-06
did O 0 8.42147812818439e-07
not O 0 3.15154764507497e-08
recognize O 0 4.712714840593435e-08
intercalated O 0 2.3262229831289005e-07
discs O 0 1.2867784789705183e-05
in O 0 1.48304934555199e-07
the O 0 1.0459003618734641e-07
heart O 0 1.3634829883812927e-05
, O 0 5.976195183166055e-08
though O 0 1.1854561776658556e-08
they O 0 6.815803921256247e-09
recognized O 0 7.971932447503605e-09
cardiomyocyte O 0 4.874262913290295e-07
nuclei O 0 2.2995251924839977e-07
strongly O 0 6.584770773088167e-08
, O 0 4.424203670083671e-09
both O 0 2.8227653547929776e-09
at O 0 9.849604509781784e-08
the O 0 1.630109380812428e-08
rim O 0 1.429408825970313e-06
and O 0 9.537209422205706e-08
in O 0 1.2141796013054318e-08
intranuclear O 0 2.3864379272708902e-06
spots O 0 9.097776683120173e-07
or O 0 1.9971609788171918e-07
channels O 0 2.216800112364581e-06
. O 0 7.215786013148318e-07

A O 0 3.240752266719937e-05
polyclonal O 0 0.0003090214158874005
rabbit O 0 0.0002740412892308086
antiserum O 0 5.126816176925786e-05
against O 0 6.871254640827829e-07
emerin O 0 4.687293039751239e-05
did O 0 8.025667170841189e-07
recognize O 0 9.048284965729181e-08
both O 0 1.717625508490528e-08
nuclear O 0 5.257854240880988e-07
membrane O 0 8.821705677064529e-08
and O 0 2.7324512430482173e-08
intercalated O 0 9.330274508556613e-08
discs O 0 6.65487232254236e-06
but O 0 2.185058711745569e-08
, O 0 2.0132533418149023e-09
after O 0 4.320711344263373e-09
affinity O 0 6.752541636956266e-09
purification O 0 2.1999879251666243e-08
against O 0 2.5616804233408175e-09
a O 0 2.463333892421815e-08
pure O 0 3.4801718129529036e-07
- O 0 8.630469892523251e-06
emerin O 0 1.005503236228833e-05
band O 0 5.439571850729408e-07
on O 0 4.89864433461662e-08
a O 0 4.5393452552389135e-08
western O 0 4.929048031954153e-07
blot O 0 0.00015313760377466679
, O 0 1.3206008020461013e-07
it O 0 7.548915448296611e-08
stained O 0 3.414663524381467e-06
only O 0 1.1225085749799746e-08
the O 0 2.4015895050411018e-08
nuclear O 0 4.216844899929129e-06
membrane O 0 2.8232327622390585e-06
. O 0 8.311268402394489e-07

These O 0 3.3203198199771577e-06
results O 0 2.7821279218187556e-06
would O 0 8.380052207712652e-08
not O 0 1.7075320712933717e-08
be O 0 1.2855003284073518e-08
expected O 0 8.691815622796639e-08
if O 0 2.172259883082006e-08
immunostaining O 0 1.8449011349730426e-06
at O 0 7.52530979752919e-08
intercalated O 0 5.5307268098658824e-08
discs O 0 5.248914021649398e-06
were O 0 9.045955806641359e-08
due O 0 3.6424466998141725e-08
to O 0 4.684366228246972e-09
a O 0 1.3491830763712187e-08
product O 0 6.687980658171e-08
of O 0 2.0748405216153287e-09
the O 0 2.693128031694414e-08
emerin O 0 4.946504304825794e-06
gene O 0 7.798404908498924e-07
and O 0 1.2925299586186156e-07
, O 0 1.8265417622842506e-08
therefore O 0 1.670591132096888e-08
, O 0 6.888718928621529e-09
cast O 0 2.6200456915148607e-08
some O 0 2.197835247130797e-09
doubt O 0 9.863832417522644e-09
upon O 0 5.915520517874029e-09
the O 0 1.5413355924920324e-08
hypothesis O 0 1.440672008357069e-06
that O 0 1.147958073488553e-06
cardiac B-Disease 0 0.357085645198822
defects I-Disease 1 0.8382526636123657
in O 0 3.0582657473132713e-06
EDMD B-Disease 1 1.0
are O 0 2.474047278155922e-06
caused O 0 1.4960671705921413e-06
by O 0 2.8937495955005943e-08
absence O 0 5.6102312129269194e-08
of O 0 1.455701603703119e-08
emerin O 0 2.9181675927247852e-05
from O 0 1.1738466554334082e-07
intercalated O 0 1.3289889011502964e-06
discs O 0 6.478103750851005e-05
. O 0 1.246673264176934e-06

Although O 0 6.327909432002343e-06
emerin O 0 5.824047912028618e-05
was O 0 8.999702458822867e-07
abundant O 0 5.5001244447794306e-08
in O 0 1.606784927332683e-08
the O 0 9.8043724250374e-09
membranes O 0 1.395626725297916e-07
of O 0 9.133853673404246e-09
cardiomyocyte O 0 1.0853862477233633e-05
nuclei O 0 1.415760721101833e-06
, O 0 6.252126638628397e-08
it O 0 3.6421827331878376e-08
was O 0 3.4105036661458143e-07
absent O 0 3.499033951470665e-08
from O 0 2.8496291992752276e-09
many O 0 1.929733928207611e-09
non O 0 1.9022145636427013e-07
- O 0 1.0266616300214082e-05
myocyte O 0 3.983309579780325e-05
cells O 0 2.063347437797347e-06
in O 0 2.5702220796119946e-08
the O 0 2.10128874300608e-07
heart O 0 2.6064908524858765e-05
. O 0 1.448820398763928e-06

This O 0 5.694352580576378e-07
distribution O 0 3.824452221579122e-07
of O 0 4.21050927457145e-08
emerin O 0 4.1543851693859324e-05
was O 0 1.64296250204643e-06
similar O 0 1.330682497524549e-08
to O 0 1.4661676317473393e-08
that O 0 8.527631045751605e-09
of O 0 4.254528285230208e-09
lamin O 0 6.649720944551518e-06
A O 0 8.762097536418878e-07
, O 0 2.3899598744492323e-08
a O 0 3.77113877902957e-08
candidate O 0 1.1225453988572553e-07
gene O 0 9.262859634873166e-08
for O 0 9.445981774547363e-09
an O 0 8.371585380473334e-08
autosomal O 0 0.0002734331937972456
form O 0 1.6677472558512818e-06
of O 0 1.3243557077657897e-06
EDMD B-Disease 1 0.9999996423721313
. O 0 1.0974808901664801e-05

In O 0 2.988504093082156e-06
contrast O 0 3.608027327572927e-06
, O 0 8.431305786871235e-07
lamin O 0 0.0004378165758680552
B1 O 0 0.0009387548780068755
was O 0 3.6448695936996955e-06
absent O 0 1.8658208489341632e-07
from O 0 2.1243772962975527e-08
cardiomyocyte O 0 2.091497208311921e-06
nuclei O 0 1.2962296978002996e-06
, O 0 8.77284449529725e-08
showing O 0 5.364349249248335e-07
that O 0 1.6373363109778438e-07
lamin O 0 9.393462096340954e-05
B1 O 0 9.231666626874357e-05
is O 0 3.668313297566783e-08
not O 0 5.648355116960602e-09
essential O 0 5.889435605865856e-09
for O 0 4.058011704444198e-09
localization O 0 1.0774184744377635e-07
of O 0 4.202035164269091e-09
emerin O 0 3.1217800824379083e-06
to O 0 5.8890343268558354e-08
the O 0 9.347089502398376e-08
nuclear O 0 2.9788221581839025e-05
lamina O 0 4.9096353905042633e-05
. O 0 1.3233229765319265e-06

Lamin O 1 0.9206410646438599
B1 O 1 0.7858954668045044
is O 0 3.13430041387619e-06
also O 0 3.8836711269141233e-07
almost O 0 1.5144560450153222e-07
completely O 0 2.0567285901051946e-06
absent O 0 6.943371886336536e-07
from O 0 9.850036519765126e-08
skeletal O 0 0.00012010028149234131
muscle O 0 3.443602327024564e-05
nuclei O 0 6.108657544245943e-05
. O 0 2.1555952116614208e-06

In O 0 4.600917236530222e-05
EDMD B-Disease 1 0.9999912977218628
, O 0 8.580101962252229e-07
the O 0 1.6583811657255865e-08
additional O 0 2.3444984620368814e-08
absence O 0 5.415793324914375e-08
of O 0 2.4398604026032444e-08
lamin O 0 0.00024668354308232665
B1 O 0 0.0004789348167832941
from O 0 5.722034188693215e-07
heart O 0 2.9515345886466093e-05
and O 0 1.2785773151335889e-06
skeletal O 0 0.0003891433880198747
muscle O 0 1.3399284398474265e-05
nuclei O 0 4.3973368519800715e-06
which O 0 3.9346704738818516e-07
already O 0 2.863246493234328e-07
lack O 0 3.2336462396642673e-08
emerin O 0 1.0974861652357504e-05
may O 0 3.19193162567899e-07
offer O 0 1.0664023442075177e-08
an O 0 2.750143668350802e-09
alternative O 0 3.8552780523559704e-08
explanation O 0 3.149774840949249e-08
of O 0 2.423153899755448e-09
why O 0 2.5648548174217467e-08
these O 0 5.224900956335432e-09
tissues O 0 3.122519842690963e-07
are O 0 1.325380871719517e-08
particularly O 0 7.741416396811474e-08
affected O 0 1.8754793984498974e-07
. O 0 6.774203598070017e-08
. O 0 4.775156412506476e-07

Genetic O 0 0.00026550987968221307
mapping O 0 2.088758446916472e-05
of O 0 2.1359450386171375e-07
the O 0 5.588049134530593e-07
copper B-Disease 0 0.00039425899740308523
toxicosis I-Disease 0 0.0010024922667071223
locus O 0 1.242701182491146e-05
in O 0 3.0703884590366215e-07
Bedlington O 0 6.309584568953142e-05
terriers O 0 0.00034583359956741333
to O 0 2.709817636059597e-06
dog O 0 9.093323023989797e-05
chromosome O 0 0.000373067770851776
10 O 0 3.342545369378058e-07
, O 0 1.513655512042078e-08
in O 0 6.3346234924210876e-09
a O 0 9.938961653688239e-08
region O 0 5.67891356695327e-06
syntenic O 0 5.6442255299771205e-05
to O 0 1.757798742119121e-07
human O 0 1.0740002664988424e-07
chromosome O 0 4.8819729272508994e-05
region O 0 4.814789463125635e-06
2p13 O 0 6.548332294187276e-06
- O 0 1.1820030522358138e-05
p16 O 0 2.0282597688492388e-05
. O 0 1.603792611604149e-06

Abnormal O 1 0.9964367151260376
hepatic B-Disease 1 0.9999364614486694
copper I-Disease 0 0.06201256811618805
accumulation I-Disease 0 6.921272142790258e-05
is O 0 1.5326851610097947e-07
recognized O 0 6.852408773738716e-08
as O 0 2.134189855951263e-07
an O 0 2.9024426112300716e-05
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 2.8162089620309416e-06
man O 0 6.236556509975344e-05
, O 0 4.275217122540198e-07
mouse O 0 7.089181508490583e-06
, O 0 2.5366693989781197e-07
rat O 0 0.0003871484659612179
and O 0 2.0736172245960915e-06
dog O 0 0.00021902543085161597
. O 0 3.2241980534308823e-06

The O 0 2.1234875475784065e-06
major O 0 1.5034131592983613e-06
cause O 0 2.5851099962892476e-06
of O 0 1.926749177982856e-07
hepatic B-Disease 1 0.9369156956672668
copper I-Disease 0 0.04210803285241127
accumulation I-Disease 0 1.0457728421897627e-05
in O 0 1.529802489130816e-07
man O 0 1.4054587609280134e-06
is O 0 2.340821048107955e-08
a O 0 1.0819944407103321e-07
dysfunctional O 0 4.994279152015224e-06
ATP7B O 0 5.98009537498001e-05
gene O 0 4.1608391256886534e-06
, O 0 2.475982228133944e-07
causing O 0 4.763955803355202e-05
Wilson B-Disease 0 0.0005350267165340483
disease I-Disease 0 0.015491186641156673
( O 0 1.4299419035523897e-06
WD B-Disease 0 0.09820328652858734
) O 0 1.0465264494996518e-06
. O 0 1.3338762983039487e-06

Mutations O 0 0.0005902851698920131
in O 0 3.7875605585213634e-07
the O 0 7.21437629636057e-08
ATP7B O 0 8.06418465799652e-05
genes O 0 2.8885056053695735e-06
have O 0 1.2628642309664428e-07
also O 0 9.439249026854668e-08
been O 0 4.717337276360922e-08
demonstrated O 0 7.359361831049682e-08
in O 0 2.0131315281446405e-08
mouse O 0 6.289656539593125e-06
and O 0 1.5529999473073985e-06
rat O 0 0.0065588937141001225
. O 0 3.094808562309481e-06

The O 0 2.8521321837615687e-06
ATP7B O 0 0.00019465864170342684
gene O 0 2.07936955121113e-05
has O 0 4.919411935588869e-07
been O 0 1.0980632225709996e-07
excluded O 0 1.4118167257493042e-07
in O 0 6.925764850507221e-09
the O 0 5.9960716392026825e-09
much O 0 5.7756256666152694e-08
rarer O 0 3.706415327542345e-06
human O 0 1.043644033416058e-06
copper B-Disease 0 0.0053761801682412624
overload I-Disease 0 0.0005935508524999022
disease O 0 6.856722029624507e-05
non B-Disease 0 4.3314076947353897e-07
- I-Disease 0 1.3909490007790737e-05
Indian I-Disease 0 5.807084448861133e-07
childhood I-Disease 0 4.154361522523686e-05
cirrhosis I-Disease 0 0.0013776780106127262
, O 0 1.2493292445014959e-07
indicating O 0 2.0630307062674547e-06
genetic O 0 2.726370803429745e-05
heterogeneity O 0 7.133570034056902e-05
. O 0 4.424654889589874e-06

By O 0 2.090980615321314e-06
investigating O 0 1.4591159924748354e-06
the O 0 7.345716568352145e-08
common O 0 5.653980224451516e-06
autosomal O 1 0.9946261048316956
recessive O 1 0.9994574189186096
copper B-Disease 1 0.9732627272605896
toxicosis I-Disease 1 0.998082160949707
( O 0 9.103929187403992e-06
CT B-Disease 1 0.9590440988540649
) O 0 1.581582012022409e-07
in O 0 7.932620604833573e-08
Bedlington O 0 0.0001413811551174149
terriers O 0 0.0023961106780916452
, O 0 5.099587383483595e-07
we O 0 1.1652177889232007e-08
have O 0 3.890237465498103e-09
identified O 0 3.0611460033469484e-08
a O 0 8.291681119487748e-09
new O 0 5.514168677223097e-08
locus O 0 8.779252311796881e-07
involved O 0 1.927844692772851e-07
in O 0 3.421401515879552e-06
progressive O 1 0.9935111403465271
liver B-Disease 1 1.0
disease I-Disease 1 0.9999996423721313
. O 0 5.884671281819465e-06

We O 0 1.0316827683709562e-05
examined O 0 2.98965005640639e-06
whether O 0 2.138764045866992e-07
the O 0 8.240522930691441e-08
WD B-Disease 0 0.0010323893511667848
gene O 0 4.094059022463625e-06
ATP7B O 0 3.538964665494859e-05
was O 0 4.5375790591606346e-07
also O 0 3.294620398719417e-08
causative O 0 2.4106907403620426e-07
for O 0 6.188203371948475e-08
CT B-Disease 1 0.500496506690979
by O 0 4.572383005552183e-08
investigating O 0 2.553396996063384e-07
the O 0 5.545092207626112e-08
chromosomal O 0 0.0011611056979745626
co O 0 4.927088230033405e-05
- O 0 6.136293450254016e-06
localization O 0 1.178579736915708e-06
of O 0 1.2104637292509324e-08
ATP7B O 0 2.1426283637993038e-05
and O 0 3.938273707149165e-08
C04107 O 0 6.566071419911168e-08
, O 0 1.9957808738979566e-09
using O 0 7.3822321589034345e-09
fluorescence O 0 7.438361393496962e-08
in O 0 4.31984830129295e-08
situ O 0 1.7518922277304227e-06
hybridization O 0 6.618995485041523e-07
( O 0 5.315683893059031e-08
FISH O 0 8.305643177664024e-07
) O 0 1.4808333048677014e-07
. O 0 6.006833928040578e-07

C04107 O 0 0.00029981863917782903
is O 0 9.127480780080077e-07
an O 0 9.794993616196734e-08
anonymous O 0 9.245117666978331e-07
microsatellite O 0 1.7919697711477056e-05
marker O 0 2.616704659885727e-05
closely O 0 5.987690656183986e-06
linked O 0 4.9197024054592475e-05
to O 0 2.9133934731362388e-06
CT B-Disease 1 0.9904823303222656
. O 0 7.246726909215795e-06

However O 0 9.681460142019205e-06
, O 0 7.182748049672227e-07
BAC O 0 2.7026791940443218e-05
clones O 0 7.959452887007501e-06
containing O 0 2.3151613959271344e-07
ATP7B O 0 4.1216051613446325e-05
and O 0 1.677837673241811e-07
C04107 O 0 8.522795837961894e-07
mapped O 0 3.967140855820617e-06
to O 0 5.2341999179361665e-08
the O 0 4.6784126794818803e-08
canine O 0 1.1796753824455664e-05
chromosome O 0 0.0002259876928292215
regions O 0 1.9205901935492875e-06
CFA22q11 O 0 2.259106986457482e-05
and O 0 2.0003024303605343e-07
CFA10q26 O 0 6.965530701563694e-06
, O 0 5.670670688573409e-08
respectively O 0 9.573204096113841e-08
, O 0 7.0582966138488246e-09
demonstrating O 0 3.2798798343947055e-08
that O 0 3.168659645780281e-08
WD B-Disease 0 0.001667279633693397
cannot O 0 3.064470774916117e-07
be O 0 1.4201264164626082e-08
homologous O 0 1.5946464770877355e-07
to O 0 5.381041319196811e-07
CT B-Disease 1 0.8935500979423523
. O 0 2.0582906472554896e-06

The O 0 8.128150511765853e-06
copper O 0 4.813439954887144e-05
transport O 0 3.019936002601753e-06
genes O 0 1.6353060345863923e-06
CTR1 O 0 5.2965915529057384e-05
and O 0 6.333388000712148e-07
CTR2 O 0 0.00012377263919916004
were O 0 2.0696762703664717e-07
also O 0 6.092008675295801e-08
excluded O 0 5.6125859515532284e-08
as O 0 8.78337136356322e-09
candidate O 0 6.76832740964528e-08
genes O 0 5.197857433358877e-08
for O 0 6.766455129536553e-08
CT B-Disease 1 0.9744846820831299
since O 0 6.232243094927981e-07
they O 0 1.0513742765283496e-08
both O 0 8.785750793549596e-09
mapped O 0 2.1101518541399855e-06
to O 0 2.1212764522715588e-07
canine O 0 6.693554314551875e-05
chromosome O 0 0.0005383967654779553
region O 0 1.9456738300505094e-05
CFA11q22 O 0 0.00023398698249366134
. O 0 1.4659854059573263e-06

2 O 0 5.977148248348385e-05
- O 0 0.00011109975457657129
22 O 0 4.911344149149954e-06
. O 0 1.3699195733352099e-06

5 O 0 0.00015576356963720173
. O 0 4.0264239942189306e-05

A O 0 6.576024588866858e-06
transcribed O 0 1.624501783226151e-05
sequence O 0 1.0539612276261323e-06
identified O 0 1.3082139957987238e-06
from O 0 1.753816114558049e-08
the O 0 2.039404023435054e-08
C04107 O 0 8.864325309332344e-07
- O 0 2.653601541169337e-06
containing O 0 4.786285785485234e-07
BAC O 0 1.2412254363880493e-05
was O 0 5.464227115226095e-07
found O 0 1.5933323993522208e-08
to O 0 2.5701425432345104e-09
be O 0 1.3248140362520644e-09
homologous O 0 8.187049260754975e-09
to O 0 1.0267567240873632e-08
a O 0 3.0386683391725455e-08
gene O 0 1.532616380472973e-07
expressed O 0 7.951462599464776e-09
from O 0 6.077696124151544e-09
human O 0 3.330571018977935e-08
chromosome O 0 1.9969214918091893e-05
2p13 O 0 2.6067423277709167e-06
- O 0 8.144296771206427e-06
p16 O 0 5.052226015322958e-07
, O 0 9.730227290560833e-09
a O 0 2.2539467181559303e-08
region O 0 4.201572494366701e-07
devoid O 0 1.739667396805089e-07
of O 0 8.499555725904884e-09
any O 0 1.829581997014884e-08
positional O 0 2.0796176158910384e-06
candidate O 0 4.361710580269573e-06
genes O 0 2.602489757919102e-06
. O 0 1.0875493217099574e-06

Molecular O 0 6.519059388665482e-05
analysis O 0 2.2344358967529843e-06
of O 0 3.513747515171417e-08
the O 0 4.165743661133092e-08
APC B-Disease 0 2.9551379157055635e-06
gene O 0 4.527921930730372e-07
in O 0 1.3791035868848667e-08
205 O 0 6.249824480164534e-08
families O 0 5.493163257597189e-08
: O 0 1.6032032590374e-08
extended O 0 2.268274243988344e-07
genotype O 0 7.000342884566635e-05
- O 0 9.901138400891796e-05
phenotype O 0 8.621422603027895e-05
correlations O 0 4.220369191898499e-06
in O 0 1.7255894135814742e-07
FAP B-Disease 0 9.762956096892594e-07
and O 0 1.0141429385157608e-07
evidence O 0 1.1018181922395343e-08
for O 0 2.1037873665363804e-09
the O 0 3.699706541127057e-09
role O 0 2.1326675536670336e-08
of O 0 3.969099715561697e-09
APC B-Disease 0 5.999803533995873e-07
amino O 0 1.3204055449023144e-07
acid O 0 9.154958888757392e-07
changes O 0 5.156610995982192e-07
in O 0 0.00019806613272521645
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.008181894198060036
. O 0 5.434539616544498e-06

BACKGROUND O 0 0.00014069542521610856
/ O 0 0.000290209281956777
AIMS O 0 1.4928817790860194e-06
The O 0 3.064914366746052e-08
development O 0 2.0396808508849062e-07
of O 0 0.00013892448623664677
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.8308392668586748e-07
a O 0 9.317363947047852e-08
variable O 0 1.6610804323136108e-06
range O 0 2.739319597822032e-07
of O 0 5.840374939225512e-08
extracolonic O 0 0.0003035979170817882
manifestations O 0 0.00010949917486868799
in O 0 6.589071563212201e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 0.9999996423721313
polyposis I-Disease 1 1.0
( O 0 9.200993372360244e-05
FAP B-Disease 0 2.1937794372206554e-05
) O 0 1.5677812825742876e-07
is O 0 1.393609849742461e-08
the O 0 8.345722335434402e-09
result O 0 3.310595175776143e-08
of O 0 2.3267623383560476e-09
the O 0 4.254660623814743e-08
dominant O 0 2.9693605029024184e-05
inheritance O 0 0.0003431020595598966
of O 0 5.5829688790254295e-05
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.999998927116394
coli I-Disease 1 0.9999998807907104
( O 0 7.337010174524039e-06
APC B-Disease 0 4.5632121327798814e-05
) O 0 4.256750969489076e-07
gene O 0 7.3753349170146976e-06
mutations O 0 6.143422797322273e-05
. O 0 1.115546069740958e-06

In O 0 1.6531913615835947e-06
this O 0 6.112738049068867e-08
study O 0 4.784920548672744e-08
, O 0 6.866732071841852e-09
direct O 0 1.8391686396057594e-08
mutation O 0 2.6217259119221126e-07
analysis O 0 2.2614395689402045e-08
of O 0 3.1180926729490466e-09
the O 0 3.917880064818746e-08
APC B-Disease 0 9.269925271837565e-07
gene O 0 3.249047040299047e-07
was O 0 2.648125985160732e-07
performed O 0 7.861181927637517e-08
to O 0 1.718510489467917e-08
determine O 0 2.576677502474922e-07
genotype O 0 3.8737529393984005e-05
- O 0 5.4872838518349454e-05
phenotype O 0 5.310130654834211e-05
correlations O 0 1.6729512708479888e-06
for O 0 2.8155239917282415e-08
nine O 0 1.7770830140761973e-07
extracolonic O 0 9.549125024932437e-06
manifestations O 0 6.722101488776389e-07
and O 0 3.1258231558695115e-08
to O 0 3.9232190829352476e-08
investigate O 0 1.1271452393657455e-07
the O 0 3.071931686804419e-08
incidence O 0 6.3580887399439234e-06
of O 0 9.076178919542599e-09
APC B-Disease 0 4.06267145081074e-06
mutations O 0 1.6095567616503104e-06
in O 0 5.109528089519699e-08
non O 0 2.622388092277106e-05
- O 1 0.9984361529350281
FAP O 1 0.999901294708252
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999997615814209
. O 0 1.0553267202340066e-05

METHODS O 0 1.1867638022522442e-05
The O 0 3.596003637085232e-07
APC B-Disease 0 6.735931037837872e-06
gene O 0 1.1797166052929242e-06
was O 0 3.792924303525069e-07
analysed O 0 3.458982007487066e-07
in O 0 1.369645641347006e-08
190 O 0 7.935889811960806e-08
unrelated O 0 2.8727211542900477e-07
FAP B-Disease 0 7.539806574641261e-07
and O 0 5.510783296358568e-08
15 O 0 1.2036518626246107e-07
non O 0 4.7020216698001605e-06
- O 1 0.9952274560928345
FAP O 1 0.9999037981033325
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 4.7910398279782385e-06
using O 0 2.0091580665848596e-07
denaturing O 0 6.046274575055577e-05
gradient O 0 5.444194175652228e-05
gel O 0 0.0001250615023309365
electrophoresis O 0 2.6390548555355053e-06
, O 0 1.6808604286211448e-08
the O 0 3.9696370635056155e-09
protein O 0 7.108124577825947e-08
truncation O 0 1.7432876120437868e-06
test O 0 1.083855494243835e-07
, O 0 7.355135167586013e-09
and O 0 6.5253180636659636e-09
direct O 0 1.6003123448626866e-07
sequencing O 0 5.064081506134244e-06
. O 0 1.1292739827695186e-06

RESULTS O 0 0.0005555916577577591
Chain O 0 6.305776332737878e-05
terminating O 0 6.478051091107773e-06
signals O 0 2.5633125915192068e-06
were O 0 4.036984435629165e-08
only O 0 4.862216851364565e-09
identified O 0 2.3751324818022113e-07
in O 0 7.30589420072647e-08
patients O 0 1.4623812205627473e-07
belonging O 0 5.992038154545298e-08
to O 0 6.901925786451102e-08
the O 0 6.156228948839271e-08
FAP B-Disease 0 1.6209404520850512e-06
group O 0 4.606760285241762e-06
( O 0 3.332998588234659e-08
105 O 0 2.585430820545298e-07
patients O 0 1.1042154710594332e-06
) O 0 1.2105542168683314e-07
. O 0 5.101504143567581e-07

Amino O 0 2.860002678062301e-05
acid O 0 1.0670772098819725e-05
changes O 0 1.016734429981625e-07
were O 0 2.5501233125169165e-08
identified O 0 1.1476587502556868e-07
in O 0 1.1292816459729238e-08
four O 0 1.3854105418431573e-07
patients O 0 2.5843311846074357e-07
, O 0 4.7377581857688256e-09
three O 0 4.45222347877916e-09
of O 0 3.614250898564819e-09
whom O 0 2.605054874038615e-07
belonged O 0 1.9331986322868033e-07
to O 0 7.177220595622202e-09
the O 0 7.131343515709432e-09
non O 0 2.903702522871754e-07
- O 0 1.0100066901941318e-05
FAP O 0 2.5417477900191443e-06
group O 0 2.8784668756998144e-05
of O 0 8.878139487933367e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.00011663727491395548
. O 0 1.4614180372518604e-06

Genotype O 0 0.22972483932971954
- O 0 0.02267060987651348
phenotype O 0 0.0025624108966439962
correlations O 0 5.107336619403213e-05
identified O 0 1.790335045370739e-05
significant O 0 3.081773911617347e-07
differences O 0 4.3200711274948844e-07
in O 0 1.0391931937192567e-07
the O 0 3.798484016215298e-08
nature O 0 1.1194877913567325e-07
of O 0 9.530496392073928e-09
certain O 0 2.0668982969596073e-08
extracolonic O 0 2.0302413759054616e-05
manifestations O 0 1.051548679242842e-06
in O 0 4.476578752132809e-08
FAP B-Disease 0 3.3306396289844997e-06
patients O 0 6.754076480319782e-07
belonging O 0 7.548267433321598e-08
to O 0 2.7498932908542884e-08
three O 0 1.2701728735464712e-07
mutation O 0 1.5767865988891572e-05
subgroups O 0 1.0340843800804578e-05
. O 0 2.1318312519724714e-06

CONCLUSIONS O 0 0.00012088387302355841
Extended O 0 9.892123671306763e-06
genotype O 0 0.00031763382139615715
- O 0 0.0003013885871041566
phenotype O 0 9.645901445765048e-05
correlations O 0 3.5523780752555467e-06
made O 0 1.4321800279049057e-07
in O 0 4.73857397764732e-08
this O 0 4.7713779594005246e-08
study O 0 2.020834131144511e-07
may O 0 1.0342837413190864e-06
have O 0 6.606153402088921e-09
the O 0 4.034734768509907e-09
potential O 0 1.8795182299413682e-08
to O 0 1.322910847534331e-08
determine O 0 9.519595778328949e-09
the O 0 2.4514883456561165e-09
most O 0 1.4893920541325656e-09
appropriate O 0 4.1439172093760135e-09
surveillance O 0 1.0548194495640928e-07
and O 0 3.669670789463453e-08
prophylactic O 0 8.48015815790859e-07
treatment O 0 4.19843246390883e-07
regimens O 0 1.0759337953913928e-07
for O 0 1.2445767971769328e-08
those O 0 2.3773480961608584e-08
patients O 0 7.187168193922844e-08
with O 0 1.3163062639875989e-08
mutations O 0 7.5500552156881895e-06
associated O 0 2.456219760915701e-07
with O 0 1.2323812370595988e-07
life O 0 2.456183392496314e-05
threatening O 0 0.0037067350931465626
conditions O 0 3.752663542400114e-05
. O 0 1.2797984254575567e-06

This O 0 1.8102892909155344e-06
study O 0 5.371356337491306e-07
also O 0 1.5352480886576814e-07
provided O 0 2.247893249318622e-08
evidence O 0 2.9285976310688966e-08
for O 0 6.66489130551895e-09
the O 0 2.1832089913687014e-08
pathological O 0 2.2276187792158453e-06
nature O 0 3.412630888988133e-08
of O 0 2.4972184320404267e-09
amino O 0 1.459758891542151e-07
acid O 0 4.2703192093540565e-07
changes O 0 1.8507813948076546e-08
in O 0 1.1466518401448411e-08
APC O 0 5.669502343152999e-07
associated O 0 1.1001676014643635e-08
with O 0 1.8579817684383215e-09
both O 0 1.1126902954572415e-08
FAP B-Disease 0 3.711915894655249e-07
and O 0 6.500451377178251e-08
non O 0 1.0879354704229627e-05
- O 1 0.9977970123291016
FAP O 1 0.99991774559021
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 7.96668537077494e-05
. O 0 1.533421993826778e-07
. O 0 1.2977908454558928e-06

Inherited B-Disease 1 0.9999969005584717
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999946355819702
and O 0 0.3920753300189972
cancer B-Disease 1 0.9798521995544434
risk O 0 1.0990518603648525e-05
of O 0 4.1488696922442614e-08
the O 0 2.2521382447848737e-07
APC O 0 5.594336107606068e-05
I1307K O 0 1.876874375739135e-05
polymorphism O 0 3.8348360249074176e-05
. O 0 1.7115139598899987e-06

Germ O 0 0.008251302875578403
- O 0 0.00022775970865041018
line O 0 1.1824608918686863e-05
and O 0 7.404106838748703e-08
somatic O 0 6.618086558773939e-07
truncating O 0 3.1639356166124344e-06
mutations O 0 3.14363433062681e-06
of O 0 4.7891637322550196e-09
the O 0 1.6213341780257906e-08
APC B-Disease 0 1.668803633947391e-06
gene O 0 2.0004435441478563e-07
are O 0 1.3404637400071806e-09
thought O 0 1.672054317225502e-08
to O 0 1.5473128200937936e-07
initiate O 0 0.00010665857553249225
colorectal B-Disease 1 1.0
tumor I-Disease 0 0.03048599511384964
formation O 0 2.388423126831185e-05
in O 0 8.906479342840612e-05
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 0.00043831064249388874
sporadic O 1 0.6605415344238281
colorectal O 1 1.0
carcinogenesis O 1 0.9943190217018127
, O 0 1.20409558803658e-05
respectively O 0 2.0195433535263874e-05
. O 0 1.915990878842422e-06

Recently O 0 5.6028518883977085e-05
, O 0 3.345339223415067e-07
an O 0 1.0835206154524712e-07
isoleucine O 0 0.0016151467571035028
- O 0 0.0001767065259627998
- O 0 8.34824240882881e-05
> O 0 1.2502415529525024e-06
lysine O 0 2.557714469730854e-05
polymorphism O 0 3.196975512764766e-06
at O 0 5.138996357345604e-07
codon O 0 2.759848484856775e-06
1307 O 0 3.3618689485592768e-06
( O 0 2.194255088738828e-08
I1307K O 0 9.567545333766247e-08
) O 0 2.699138024198078e-09
of O 0 8.691690145390396e-10
the O 0 1.9352084379420376e-08
APC B-Disease 0 1.7137581380666234e-06
gene O 0 3.6912152268087084e-07
has O 0 5.479465414737206e-08
been O 0 2.229085893645788e-08
identified O 0 7.886291797376543e-08
in O 0 3.2533920002464356e-09
6 O 0 6.137318564469751e-08
% O 0 1.0944872563811714e-08
- O 0 6.047079637028219e-07
7 O 0 4.1690034890962124e-07
% O 0 7.957591030560707e-09
of O 0 1.4412792070928049e-09
the O 0 4.732603642310096e-08
Ashkenazi O 0 7.816863217158243e-05
Jewish O 0 1.9604531189543195e-06
population O 0 5.008230914427259e-07
. O 0 6.418717362066673e-07

To O 0 5.584635800914839e-06
assess O 0 5.4864271987753455e-06
the O 0 1.4702737871630234e-07
risk O 0 4.728570388579101e-07
of O 0 5.097241295715094e-09
this O 0 1.133448535028947e-08
common O 0 2.626520938520116e-07
APC B-Disease 0 3.441139824644779e-06
allelic O 0 1.3945958698968752e-06
variant O 0 5.491895353770815e-05
in O 0 1.845342922024429e-05
colorectal O 1 1.0
carcinogenesis O 0 0.1312863528728485
, O 0 8.088690606200544e-07
we O 0 3.9710322141672805e-08
have O 0 3.978239959678831e-09
analyzed O 0 3.108302593091139e-08
a O 0 8.14139156091187e-09
large O 0 1.396915294549217e-08
cohort O 0 1.480240285900436e-07
of O 0 1.244196923266827e-08
unselected O 0 6.510844741569599e-06
Ashkenazi O 0 3.242192542529665e-05
Jewish O 0 4.49075798769627e-07
subjects O 0 2.7301339855512197e-07
with O 0 1.4662215619409835e-07
adenomatous B-Disease 0 0.0011537403333932161
polyps I-Disease 0 0.004914977587759495
and O 0 2.885094545490574e-06
. O 0 3.70728480447724e-06
or O 1 0.9906772375106812
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 1.8826258951776254e-07
for O 0 1.1215883333193233e-08
the O 0 4.216786209099155e-08
APC O 0 1.2196327588753775e-05
I1307K O 0 4.230028025631327e-06
polymorphism O 0 5.611206688627135e-06
. O 0 1.147974444393185e-06

The O 0 2.8398833364917664e-06
APC O 0 1.8369748431723565e-05
I1307K O 0 4.92101162308245e-06
allele O 0 5.8339564930065535e-06
was O 0 2.0784655134775676e-06
identified O 0 3.020138592546573e-07
in O 0 4.2691052470900104e-08
48 O 0 1.684015700220698e-07
( O 0 8.223859815359447e-09
10 O 0 1.5184904000875576e-08
. O 0 4.370441786250012e-09
1 O 0 5.098089772559433e-08
% O 0 1.3640924834135149e-08
) O 0 2.8901352422394666e-09
of O 0 5.871725328177035e-09
476 O 0 1.8087811213263194e-06
patients O 0 2.873972789529944e-06
. O 0 4.795254540113092e-07

Compared O 0 1.3967633094580378e-05
with O 0 5.172558914523506e-08
the O 0 2.365001350312923e-08
frequency O 0 4.0058631611827877e-07
in O 0 1.0108614389991999e-08
two O 0 4.438605927248318e-09
separate O 0 1.0121333104962105e-07
population O 0 2.293129952590789e-08
control O 0 2.8449441913380724e-08
groups O 0 5.0356088188152626e-09
, O 0 3.881935661809166e-09
the O 0 3.5575655754627178e-09
APC O 0 2.2594915094487078e-07
I1307K O 0 9.091013453144114e-08
allele O 0 1.9442660459390027e-07
is O 0 8.857377942206313e-09
associated O 0 1.572998442611606e-08
with O 0 3.3065987725677815e-09
an O 0 9.633355801952348e-08
estimated O 0 2.69801262220426e-06
relative O 0 3.9313320598921564e-07
risk O 0 3.846897698167595e-07
of O 0 1.1332821792109371e-08
1 O 0 2.2765555058867903e-06
. O 0 2.2104920844867593e-06

5 O 0 2.102115104207769e-05
- O 0 3.775446384679526e-05
1 O 0 2.673679546205676e-06
. O 0 3.3826829621830257e-06

7 O 0 0.0006638361955992877
for O 0 0.00012096803402528167
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.2913084328174591
( O 0 2.3491011234000325e-06
both O 0 4.302194724914443e-07
P O 0 0.05688336119055748
= O 0 2.1724335965700448e-05
. O 0 2.6476965331312385e-07
01 O 0 2.0917284473398468e-06
) O 0 1.802984286314313e-07
. O 0 4.3289463746987167e-07

Furthermore O 0 3.311538966954686e-05
, O 0 4.4744706428900827e-07
compared O 0 4.066987173700909e-07
with O 0 3.899182843269955e-08
noncarriers O 0 4.8912796046352014e-05
, O 0 1.9039205767512613e-07
APC O 0 1.0133613841389888e-06
I1307K O 0 3.211598880170641e-07
carriers O 0 6.128147589379296e-08
had O 0 4.0177880578085023e-08
increased O 0 1.6236706201766538e-08
numbers O 0 3.04321581268141e-08
of O 0 3.652186464364604e-08
adenomas B-Disease 0 0.02331649698317051
and O 0 0.012111267074942589
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9951660633087158
per O 0 3.462992754066363e-05
patient O 0 1.826343941502273e-05
( O 0 1.070880912834582e-07
P O 0 0.0007050546701066196
= O 0 7.63251318858238e-06
. O 0 1.794811339550506e-07
03 O 0 3.054491912735102e-07
) O 0 6.358652271387655e-09
, O 0 3.4763745215826702e-09
as O 0 4.830151834056551e-09
well O 0 5.748630016455536e-09
as O 0 1.2117873815498115e-08
a O 0 5.532013958031712e-08
younger O 0 2.3786867586750304e-07
age O 0 5.3038142766581586e-08
at O 0 4.7143731762844254e-07
diagnosis O 0 0.00013999071961734444
. O 0 1.4333594435811392e-06

We O 0 9.20255024539074e-06
conclude O 0 4.220003120281035e-06
that O 0 2.721004399575122e-08
the O 0 1.6628058929768486e-08
APC O 0 1.7573740933585213e-06
I1307K O 0 5.776913667432382e-07
variant O 0 1.5254100844686036e-06
leads O 0 3.9702226217741554e-07
to O 0 1.5114204643396079e-07
increased O 0 2.0011352717119735e-06
adenoma B-Disease 1 0.9999980926513672
formation O 0 1.8839887161448132e-06
and O 0 7.946992752749793e-08
directly O 0 2.3068080778898548e-08
contributes O 0 6.714169842325646e-08
to O 0 1.1000542698980098e-08
3 O 0 2.6589816570776748e-08
% O 0 7.27890725471525e-09
- O 0 1.6749311271269107e-07
4 O 0 1.6116783285724523e-07
% O 0 6.706053046201532e-09
of O 0 2.0038140036149343e-09
all O 0 6.118162332313659e-08
Ashkenazi O 0 0.2521650791168213
Jewish O 1 0.9912539124488831
colorectal B-Disease 1 1.0
cancer I-Disease 1 0.9999995231628418
. O 0 4.738158622785704e-06

The O 0 9.656016572989756e-07
estimated O 0 1.0798116818477865e-06
relative O 0 4.17379681039165e-07
risk O 0 5.26068333783769e-07
for O 0 2.971483858971169e-08
carriers O 0 2.6990525725523185e-07
may O 0 4.1640845438450924e-07
justify O 0 6.170593991328133e-08
specific O 0 1.1595642668282835e-08
clinical O 0 5.565223659687035e-08
screening O 0 2.6838975486498384e-08
for O 0 5.59205615147107e-09
the O 0 6.5973768670346544e-09
360 O 0 3.3560630186002527e-07
, O 0 1.1930321619502138e-08
000 O 0 9.530968902993209e-09
Americans O 0 8.44177971970339e-09
expected O 0 4.665304942363946e-08
to O 0 2.0657948240909718e-08
harbor O 0 7.308667022698501e-07
this O 0 4.795379648925291e-09
allele O 0 1.234032396268958e-07
, O 0 1.0567380748227606e-08
and O 0 1.3009610277947559e-08
genetic O 0 1.5862012503475853e-07
testing O 0 2.838266688343083e-08
in O 0 2.4764477135619245e-09
the O 0 4.221894389644376e-09
setting O 0 4.7143867476506784e-08
of O 0 6.33203889321976e-09
long O 0 2.123630338246585e-07
- O 0 5.825955213367706e-06
term O 0 2.494807404218591e-06
- O 0 5.00621945320745e-06
outcome O 0 9.170460089080734e-07
studies O 0 4.0135372358918175e-08
may O 0 1.3026250655912008e-07
impact O 0 1.0555157814451377e-07
significantly O 0 2.1027868569944985e-05
on O 1 0.9993975162506104
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 3.376858558112872e-06
in O 0 2.3312058061719654e-08
this O 0 2.565437107193702e-08
population O 0 2.2685813405587396e-07
. O 0 6.055672656657407e-07

Localization O 0 0.00011684946366585791
of O 0 1.1769600405386882e-06
human O 0 6.46360774680943e-07
BRCA1 O 0 0.00011638530850177631
and O 0 4.806091169484716e-07
its O 0 7.066670946187514e-07
loss O 0 2.780669092317112e-06
in O 0 2.5132605330213664e-08
high O 0 2.0016686619328539e-07
- O 0 5.012258043279871e-06
grade O 0 1.8958878627017839e-06
, O 0 7.755604514159131e-08
non B-Disease 0 3.9579617805429734e-06
- I-Disease 0 0.2114548236131668
inherited I-Disease 1 0.9871528744697571
breast I-Disease 1 0.9995114803314209
carcinomas I-Disease 1 0.9999998807907104
. O 0 1.3586517525254749e-05

Although O 0 2.5362753603985766e-06
the O 0 9.473265549786447e-08
link O 0 1.6724058014006005e-06
between O 0 1.4526484903853998e-07
the O 0 1.0163685146835633e-06
BRCA1 O 1 0.5470142364501953
tumour B-Disease 1 0.9999998807907104
- O 0 0.00013109541032463312
suppressor O 0 5.2438757847994566e-05
gene O 0 9.429777492186986e-06
and O 0 2.5373906282766256e-06
hereditary B-Disease 1 0.9995594620704651
breast I-Disease 1 0.9999977350234985
and I-Disease 1 0.9999202489852905
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 1.2830145124098635e-07
established O 0 2.0635383179978817e-08
, O 0 1.0489745960740038e-08
the O 0 4.699454159151628e-09
role O 0 5.4019789530457274e-08
, O 0 2.9003029311525097e-08
if O 0 3.72642716683913e-09
any O 0 2.392668063677661e-09
, O 0 6.041267042178333e-09
of O 0 1.0487700707884073e-09
BRCA1 O 0 7.469221145584015e-06
in O 0 6.891454518154205e-08
non B-Disease 0 4.188373168290127e-06
- I-Disease 0 0.03690144047141075
familial I-Disease 1 0.8246814012527466
cancers I-Disease 1 0.9847737550735474
is O 0 4.4581318547898263e-07
unclear O 0 2.3808479454601184e-06
. O 0 7.228169920381333e-07

BRCA1 O 0 0.311349481344223
mutations O 0 0.002031751675531268
are O 0 2.0843302195316937e-07
rare O 0 1.9761725411626685e-07
in O 0 8.52683825769418e-08
sporadic B-Disease 0 6.637188926106319e-05
cancers I-Disease 1 0.6991209387779236
, O 0 2.320360295016144e-07
but O 0 1.2720082054329396e-07
loss O 0 6.635237923546811e-07
of O 0 1.9318745714258512e-08
BRCA1 O 0 0.00014823087258264422
resulting O 0 9.260214710593573e-07
from O 0 5.31142738680046e-08
reduced O 0 5.163347509551386e-07
expression O 0 9.327374783651976e-08
or O 0 7.52569846440565e-08
incorrect O 0 5.310839696903713e-07
subcellular O 0 1.5538370234935428e-06
localization O 0 1.46471381867741e-06
is O 0 3.0114467364228403e-08
postulated O 0 1.7206856739448995e-07
to O 0 1.1296134694305238e-08
be O 0 2.9229372255912267e-09
important O 0 1.7992245471276647e-09
in O 0 1.3146152610943318e-08
non B-Disease 0 1.995817910938058e-06
- I-Disease 0 0.10597945004701614
familial I-Disease 1 0.9903740882873535
breast I-Disease 1 0.9999945163726807
and I-Disease 1 0.9953043460845947
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 7.752099918434396e-06

Epigenetic O 0 0.008436527103185654
loss O 0 0.13152407109737396
, O 0 1.7357509705107077e-06
however O 0 2.424915237497771e-07
, O 0 4.75400021571204e-08
has O 0 7.670280410820851e-08
not O 0 1.2458355236333318e-08
received O 0 1.2254543158007891e-08
general O 0 6.370002303413003e-09
acceptance O 0 9.384693555603008e-08
due O 0 8.554695085649655e-08
to O 0 3.6472297182399416e-08
controversy O 0 3.793509861793609e-08
regarding O 0 2.0447400217449285e-08
the O 0 9.125407984811318e-09
subcellular O 0 1.0927193443421857e-06
localization O 0 6.407133810171217e-07
of O 0 2.4666343634294208e-08
BRCA1 O 0 1.752510797814466e-05
proteins O 0 1.787901169336692e-07
, O 0 4.027808842010927e-08
reports O 0 4.906480199906582e-08
of O 0 1.4171762652281927e-09
which O 0 1.2259411619197635e-07
have O 0 2.9753744357208234e-08
ranged O 0 9.285430024874586e-08
from O 0 2.3617949818088846e-09
exclusively O 0 1.4354804456218062e-08
nuclear O 0 6.260347618081141e-07
, O 0 8.849306176728078e-09
to O 0 1.4241762436029148e-08
conditionally O 0 1.7437115502616507e-06
nuclear O 0 1.0305708428859361e-06
, O 0 9.284505608775362e-09
to O 0 8.58827142735663e-09
the O 0 3.921206825907575e-08
ER O 0 0.00013361619494389743
/ O 0 1.301582688029157e-05
golgi O 0 5.383471943787299e-06
, O 0 3.099061984812579e-08
to O 0 1.8421740577423407e-08
cytoplasmic O 0 7.44354736070818e-07
invaginations O 0 3.175352958351141e-06
into O 0 2.9936874312852524e-08
the O 0 3.428203143585051e-08
nucleus O 0 1.1908267651961069e-06
. O 0 7.564199222542811e-07

In O 0 5.46762339581619e-06
an O 0 2.041038982270038e-07
attempt O 0 8.532302331332176e-07
to O 0 1.0981197107184926e-07
resolve O 0 7.076347969814378e-07
this O 0 2.5337939746350457e-08
issue O 0 8.146817265242134e-08
, O 0 4.591872482251347e-08
we O 0 2.855708380877786e-08
have O 0 2.7812946612471023e-08
comprehensively O 0 1.1019706107617822e-05
characterized O 0 9.301876957579225e-07
19 O 0 2.6462120672476885e-07
anti O 0 6.835575163677277e-07
- O 0 9.454480459680781e-05
BRCA1 O 0 0.0002839301887433976
antibodies O 0 2.008410319831455e-06
. O 0 5.582168682849442e-07

These O 0 6.739252285115072e-07
reagents O 0 2.2551073470822303e-06
detect O 0 2.2790907223679824e-06
a O 0 5.2834490560371705e-08
220 O 0 8.651144156601731e-08
- O 0 1.8420918195261038e-06
kD O 0 1.6024625892896438e-06
protein O 0 2.0337256501079537e-07
localized O 0 1.8069157192712737e-07
in O 0 1.0332003697044456e-08
discrete O 0 1.2999122134260688e-07
nuclear O 0 2.4888354346330743e-06
foci O 0 3.976015705120517e-06
in O 0 3.035088624869786e-08
all O 0 8.695260511615288e-09
epithelial O 0 1.6680573935445864e-06
cell O 0 5.0438768084859475e-05
lines O 0 1.536075615149457e-05
, O 0 4.2235878794372184e-08
including O 0 3.259193137594707e-09
those O 0 3.2502909252940526e-09
derived O 0 9.046248550248492e-08
from O 0 5.241113285592292e-07
breast B-Disease 0 0.000916379620321095
malignancies I-Disease 0 9.951399260899052e-05
. O 0 2.9712343803112162e-06

Immunohistochemical O 0 0.0006558856694027781
staining O 0 0.0003875056572724134
of O 0 1.63214610893192e-06
human O 0 1.894262823043391e-05
breast O 0 0.0032736172433942556
specimens O 0 2.6633015295374207e-06
also O 0 1.7772214278011234e-06
revealed O 0 1.085487656382611e-05
BRCA1 O 0 6.752949411747977e-05
nuclear O 0 9.944165867636912e-06
foci O 0 4.558701766654849e-05
in O 0 8.843755949783372e-07
benign O 0 0.018455870449543
breast O 0 0.020981591194868088
, O 0 1.955696916411398e-06
invasive B-Disease 0 0.004446732811629772
lobular I-Disease 1 0.9981471300125122
cancers I-Disease 1 0.9979896545410156
and O 0 1.0059051192001789e-06
low B-Disease 0 1.4172888768371195e-05
- I-Disease 0 0.037265364080667496
grade I-Disease 0 0.01301481667906046
ductal I-Disease 1 0.9984521865844727
carcinomas I-Disease 1 0.9999997615814209
. O 0 2.5561761503922753e-05

Conversely O 0 0.0001138332809205167
, O 0 2.565445129221189e-06
BRCA1 O 0 6.524376658489928e-05
expression O 0 9.73466512732557e-07
was O 0 2.0528759705484845e-06
reduced O 0 3.0568816100640106e-07
or O 0 1.2612562727554177e-07
undetectable O 0 4.838702238885162e-07
in O 0 3.5389002839281147e-09
the O 0 2.548711908190171e-09
majority O 0 6.07904082627897e-09
of O 0 2.9696127779033077e-09
high O 0 2.45352481442751e-07
- O 0 1.4915576684870757e-05
grade O 0 2.05065753107192e-05
, O 0 1.4193445849741693e-06
ductal B-Disease 0 0.142207071185112
carcinomas I-Disease 1 1.0
, O 0 8.596778684477613e-07
suggesting O 0 3.6622597576752014e-07
that O 0 1.5032719957730478e-08
absence O 0 1.8852125194257496e-08
of O 0 1.2046664110698657e-08
BRCA1 O 0 0.00020886336278636009
may O 0 4.028268904221477e-06
contribute O 0 1.5552952703501433e-08
to O 0 1.3540502052933334e-08
the O 0 3.861585184949945e-08
pathogenesis O 0 3.54280996361922e-06
of O 0 1.9314794208469266e-09
a O 0 6.849938927189214e-08
significant O 0 8.038921350816963e-08
percentage O 0 1.0226854101347271e-06
of O 0 5.5244324670411515e-08
sporadic B-Disease 0 0.00032691602245904505
breast I-Disease 1 0.9642441868782043
cancers I-Disease 1 0.5063591003417969
. O 0 3.8043503991502803e-07
. O 0 1.065081960405223e-06

